臨床腫瘍学 CLINICAL ONCOLOGY I・II Second edition (日本臨床腫瘍研究会編)

出版社： 癌と化学療法社
著者：
発行日： 1999-02-26
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784906225361
電子書籍版： 1999-02-26 （改訂第1版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

16,500 円(税込)

購入する

商品紹介

今回のsecond editionでは、全体をカバーするよう注意し、編集した。(序文より)

目次

  • 表紙
  • 序文
  • 執筆者一覧
  • レビュアー一覧
  • 目次
  • I. Principles of oncology
  • 1. 臨床腫瘍医学からみたがん ( 細胞 ) の特性
  • 2. がんの分子生物学
  • 3. 発がん機構
  • 4. 発がん因子
  • 1. ウイルス
  • 2. 化学因子
  • 3. 物理因子
  • 4. ホルモン
  • 5. がん遺伝子
  • 1. がん遺伝子・がん抑制遺伝子
  • 2. DNA複製および損傷修復と発がん
  • 6. 染色体異常
  • 7. 細胞がん化のシグナル伝達
  • 8. アポトーシス
  • 9. 細胞周期
  • 10. 血管新生
  • 11. 転移
  • 12. がん細胞の分化誘導と核内レチノイン酸レセプター
  • 13. 疫学
  • 14. がん遺伝学
  • 15. 腫瘍免疫
  • 16. 分子病理学
  • 17. がん予防
  • 1. 喫煙とがん
  • 2. がんと食餌, がんとホルモン, がん予防薬 etc
  • 18. 腫瘍診断学
  • 1-1. 内視鏡診断学 ( 消化器 )
  • 1-2. 内視鏡診断学 ( 呼吸器 )
  • 2. 画像診断 ( X線, CT, MRI, 超音波 )
  • 3. 腫瘍マーカー
  • 4. がんの病理診断の実際
  • 5. 腫瘍と外科病理
  • 19. がん検診
  • 20. 外科療法
  • 21. 放射線療法
  • 22. Interventional radiology
  • 23. がん化学療法
  • 24. がんの内分泌療法
  • 25. がんに対するBRM療法
  • 26. 抗がん剤開発
  • ( 基礎 ) ヒト培養がん細胞パネルによるスクリーニングを中心に
  • ( 臨床 )
  • 27. 抗がん剤と薬理動態
  • a) PK / PD
  • b) アルキル化剤
  • c) プラチナ誘導体の薬物動態
  • d) 代謝拮抗剤
  • e) トポイソメラーゼ阻害剤
  • f) 微小管阻害剤
  • g) 分化誘導剤
  • h) その他 ( 新しい抗がん剤を含む )
  • 28. 薬剤耐性
  • 29. 臨床試験
  • 30. がん治療におけるインフォームド・コンセント - 臨床試験でのインフォームド・コンセントの在り方 -
  • 31. 新GCPについて
  • 32. がん医療の経済
  • 33. 腫瘍学における情報伝達
  • 34. がん診療と報道 - 近藤理論に対するマスコミの立場を中心に -
  • 35. がん診療と倫理 - 臨床研究におけるプラシーボ対照の倫理性について - アメリカ医師会の指針案をもとに考える
  • 36. 臨床試験研究とその研究体制の在り方
  • 37. 新しいがん治療
  • 1. 重イオン・陽子線治療
  • 2. レーザー光化学治療
  • 3. 術中照射
  • 4. 遺伝子治療
  • 5. 内視鏡治療
  • 消化器
  • 呼吸器
  • 表紙
  • 目次
  • II. Practice of oncology
  • 38. 頭頸部がん
  • 39. 肺癌
  • 1. 小細胞肺癌
  • 2. 非小細胞肺癌
  • 40. 縦隔腫瘍
  • 41. 食道癌
  • 内科領域
  • 外科領域
  • 42. 乳癌
  • 43. 胃癌
  • 内科
  • 外科
  • 44. 結腸・直腸癌
  • 45. 肝癌
  • 46. 膵癌
  • 内科
  • 外科
  • 47. 胆道系がん
  • 48. 腎・尿路上皮癌
  • 1. 腎細胞癌
  • 2. 尿路上皮癌
  • 49. 前立腺癌
  • 50. 精巣腫瘍
  • 51. 子宮頸癌・外陰癌
  • 1. 子宮頸癌
  • 2. 外陰癌
  • 52. 子宮体癌
  • 53. 卵巣腫瘍・絨毛癌
  • 54. 悪性骨軟部腫瘍の治療
  • 55. 皮膚癌
  • 1. 悪性黒色腫
  • 2. 皮膚癌
  • 56. 脳腫瘍
  • 57. 内分泌系腫瘍
  • 58. ( 性腺外 ) 胚細胞腫瘍
  • 59. 小児固形がん
  • 60. 小児白血病・リンパ腫
  • 61. 白血病と類縁疾患
  • 62. 悪性リンパ腫
  • 1. ホジキン病
  • 2. 非ホジキンリンパ腫
  • 63. 多発性骨髄腫
  • 64. 原発不明がん
  • 65. HIV感染とがん
  • 66. 腫瘍随伴症候群
  • 67. がん性漿膜水
  • 1. 悪性胸水
  • 2. 心嚢炎
  • 3. がん性腹膜炎・がん性腹水
  • 68. 転移がんの治療
  • 1. 肺転移
  • 2. 肝転移外科治療
  • 3. 骨転移
  • 4. 脳転移
  • 69. 腫瘍関連緊急対策
  • 1. 上大静脈症候群
  • 2. 悪性腫瘍に伴う高カルシウム血症
  • 3. 脊髄損傷
  • 4. 消化管悪性腫瘍に対する緊急手術
  • 5. 泌尿器科的対策
  • 6. がん関連感染症
  • 70. 支持療法
  • 1. 造血幹細胞移植
  • 2. 化学療法薬物有害反応の対策
  • 3. 栄養対策
  • 4. がん性疼痛対策
  • 5. 外科手術と機能温存 ( QOLも含む )
  • 71. がん看護学
  • 1. 総論
  • 2. がん患者のリハビリテーション発声
  • 3. ストーマレハビリテーション
  • 72. サイコオンコロジー
  • 73. がん緩和医療学
  • 74. がん治療とQuality of Life
  • 付 : Revised Common Toxicity Criterias ( CTC )
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

P.12 掲載の参考文献
1) Gunthert U, Hofman M, Rudy W, et al: A new variant of glycoprotein CD 44 confer metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
 
2) Hayward WS, Neel BG, Astrin SM: Activation of cellular oncogene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290: 475-480, 1981.
 
3) Rabbits TH: Chromosomal translocations in human cancer. Nature 372: 143-149, 1994.
 
4) Chesi M, Nardini E, Brents LA, et al: Frequent translocation t (4;14) (p 16. 3;q32. 3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16: 260-264, 1997.
 
5) Iida S, Rao PH, Nallasivam P, et al: The (9;14) (p 13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 88: 4110-4117, 1996.
 
6) Iida S, Rao PH, Butler M, et al: Deregulation of MUM 1/IRF 4 by chromosomal translocation in multiple myeloma. Nat. Genet. 17: 226-230, 1997.
 
7) Veldman T, Vignon C, Schrock E, et al: Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat. Genet. 15: 406-410, 1997.
PubMed
8) Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313: 1111-1116, 1985.
 
9) Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
PubMed
10) Ogawa O, Eccles MR, Szeto J, et al: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilm 's tumour. Nature 362: 749-751, 1993.
 
11) Rainier S, Johnson LA, Dobry CJ, et al: Relaxation of imprinted genes in human cancer. Nature 362: 747-749, 1993.
PubMed
12) Suzuki H, Ueda R, Takahashi T, et al: Altered imprinting in lung cancer. Nat. Genet. 6: 332-333, 1994.
PubMed
13) Laird PN, Jackson-Grusby L, Fazeli A, et al: Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81: 197-205, 1995.
 
14) Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p 53 at 1 p 36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997.
 
15) Finlay CA, Hinds PW, Levine AT: The p 53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
 
16) Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p 53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878, 1994.
 
17) Kamb A, Gruis NA, Weaver-Feldhaus J, et al: Acell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
 
18) Fearon ER, Vogelstein B: Agenetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
 
19) Kawajiri K, Eguchi H, Nakachi K, et al: Association of CYP 1 A 1 germ line polymorphisms with mutations of the p 53 gene in lung cancer. Cancer Res. 56: 72-76, 1996.
 
20) Vinies P, Bartsch H, Caporaso N, et al: Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369: 154-156, 1994.
PubMed
21) Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acut promyelocyticleukemia. Blood 72: 567-572, 1988.
 
22) Kakizuka A, Miller WH, Umesono K, et al: Chromosomal translocation t (15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative tanscription factor, PML. Cell 66: 663-674, 1991.
 
23) Tobita T, Takeshita A, Kitamura K, et al: Treatment with a new synthetic retinoid, Am 80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90: 967-973, 1997.
PubMed
24) Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
PubMed
25) Arnord A, Kim HG, Gaz RD, et al: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J. Clin. Invest. 83: 2034-2040, 1989.
 
26) Seto M, Yamamoto K, Iida S, et al: Gene rearrangement and overexpression of PRAD in lymphoid malignancy with t (11;14) (q 13;q32) translocation. Oncogene 7: 1401-1406, 1992.
 
27) Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK 4. Nature 366: 704-707, 1993.
 
28) Nagata S, Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
PubMed
29) Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
PubMed
30) Yin XM, Oltvai ZN, Korsmyer SJ: BH 1 and BH 2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369: 321-323, 1994.
 
31) Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157, 1993.
 
32) Jost CA, Marin MC, Kaelin Jr WG: P73 is a human p 53-related protein that can induce apoptosis. Nature 389: 191-194, 1997.
 
33) Gross L: Intradermal immunization of C 3 H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3: 326-333, 1943.
 
34) Foley EJ: Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13: 835-837, 1953.
PubMed
35) Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18: 769-778, 1957.
PubMed
36) Itoh K, Platsoucas CD, Balch CM: Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and the involvement of the T cell receptor. J Exp. Med. 168: 1419-1441, 1988.
 
37) van der Gruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
 
38) Eura M, Ogi K, Chikamatsu K, et al: Expression of MAGE gene family by human head and neck squamous cell carcinomas. Int. J. Cancer 64: 304-308, 1995.
PubMed
39) Inoue H, Li J, Honda M, et al: Expression of MAGE-1, -2, -3 mRNA in gastric carcinoma. Med. Sci, Res. 22: 793-794, 1994.
 
40) Shichijo S, Tsunosue R, Imai Y: Preferential expression of MAGE gene family oll human lymphocytic leukemias. Cancer Immunol. Immunother. 1995. (in press)
 
41) van der Bruggen P, Szikora J-P, Boel P, et al: Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw 1601. Eur. J. Immunol. 24: 2134-2140, 1994.
PubMed
42) Skipper J, Stauss HJ: Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J. Exp. Med. 177: 11493-1498, 1993.
 
43) Ionannides C, Fisk B, Fan D: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol. 151: 225-245, 1993.
 
44) Udono H, Srivastava PK: Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178: 11391-1396, 1993.
 
45) Zitvogel L, Mayordomo JI, Tjandrawan T, et al: Therapy of murine tumors with tumor peptide-pulsed dendric cells: dependence on T cells, B 7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183: 87-97, 1996.
 
46) Kim NM, Piatyszek MA, Prouse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
 
47) Meyerson M, Counter CM, Eaton EN, et al: hEST 2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795, 1997.
 
48) Bryan TM, Englezou A, Dalla-Pozza L, et al: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 3: 1271-1274, 1997.
PubMed
49) Lynch HT, Krush AJ: Cancer family "G" revised: 1985-1970. Cancer 27: 1505-1511, 1971.
 
50) Mara G, Richard-Boland C: Hereditary nonpolyposis colorectal cancer: the syndrome, the gene, and historical perspectives. J. Natl. Cancer Inst. 87: 1114-1125, 1995.
 
51) Markowitz S, Wang J, Myeroff L, et al: Inactivation of the Type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995.
 
52) Rampino N, Yamamoto H, Ionov Y, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969, 1997.
PubMed
53) Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
PubMed
54) O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the supression of metastases by a Lewis lung carcinoma. Cell 79: 314-328, 1994.
 
55) Boehm T, Folkman J, Browder T, et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
 
56) Chin KV, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR 1 gene by Ras and p53. Science 255: 459-462, 1992.
 
57) Kimura Y, Furuhata T, Hirata K, et al: Genomic structure and chromosomal localization of GML (GPIanchored molecule-like protein) , agene induced by p 53. Genomics 41: 477-480, 1997.
 
58) Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur. J. Cancer 33: 787-791, 1997.
PubMed
P.25 掲載の参考文献
1) 豊島久真男, 黒木登志夫 (編集代表) : (がんのバイオサイエンス1～5巻) , 東大出版会, 1991.
 
1) Tooze J (ed) : "Molecular Biology of Tumor Virus", Cold Spring Habor Laboratories, 1973.
 
2) Weiss R, Teichi N, Varmus H, et al (eds) : "Molecular Biology of Tumor Virus", 2nd editon, RNA Tumor Viruses", 1982;Supplements and Appendixes, Cold Spring Harbor Laboratories, 1985.
 
2) 豊島久真男・他 (編) : 癌解明への新しいアプローチ, 最近医学, 1993年増刊.
 
3) Poiesz BJ, Ruscetti FW, Gazdar AF, et al: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc. Natl. Acad. Sci. USA 77: 7415-7419, 1980.
PubMed
4) Hinuma Y, Nagata K, Misaka M, et al: Adult T cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen inhuman sera. Proc. Natl. Acad. Sci. USA 78: 6476-6480, 1981.
 
5) Yohsida M, Seiki M : Recent advances in the molecular biology of HTLV-1 : trans-activation of viral and cellular genes. Annu. Rev. Immunol. 5 : 541-559, 1987.
 
6) Witkowski JA : The inherited character of cancer-a historical survey. Cancer Cell 2 : 229-257, 1990.
 
7) Benedict WF, Xu H-J, Hu S-X, et al : Role of the retinoblastoma gene in the initiation and progression of human cancer. J. Clin. Invest. 85 : 988-993, 1990.
 
8) Fearon ER, Vogelstein B : A genetic model for colorectal tumorigenesis. Cell 61 : 759-767, 1990.
PubMed
9) Knudson AG, Stanbridge EJ, Sugimura T, et al(eds) : “Genetic Basis for Carcinogenesis；Tumor Suppressor Genes and Oncogenes”, Japan Scientific Societies Press, 1989.
 
10) Nishizuka Y I The role of protein kinase C in cellular signal transduction. Nature 308: 693-698, 1984.
PubMed
11) Itai A, Kato Y, Tomioka N, et al: Areceptor model for tumor promoters: Rational superposition of teleocidins and phorbol esters. Proc. Natl. Acad. Sci. USA 85: 3688-3692, 1988.
 
12) Hunter T, Sefton BM: Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA 77: 1311-1315, 1980.
PubMed
13) Hunter T, Pines J: Cyclins and Cancer II: Cyclin D and CDK Inhibitors Come of Age. Cell 79: 573-582, 1994.
PubMed
P.35 掲載の参考文献
1) Berenblum I, Shubik P: The role of croton oil applications associated with a single painting of a carcinogen in tumour induction in the mouse 's skin. Br. J. Cancer 1: 379-383, 1947.
 
2) Quintanilla M, Brown K, Ramsden M, et al: Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80, 1986.
PubMed
3) Ames B, Durston WE, Yamasaki E, et al: Carcinogens are mutagens: asimple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. USA 70: 2281-2285, 1973.
 
4) Sugimura T: Multistep carcinogenesis: A1992 Perspective. Science 258: 603-607, 1992.
PubMed
5) 林 慎一, 川尻 要: P450遺伝子の多型と発癌感受性. 代謝 28 (増刊号癌'91) : 11-19, 1991.
 
6) 真木寿治: 自然突然変異とDNA修復. 実験医学 15: 1932-1937, 1997.
Medical*Online
7) Sloane DL, Goodman MF, Echols H: The fidelity of base selection by the polymerase subunit of DNA polymer- ase III holoenzyme. Nucleic Acids Res. 1616465-6475, 1988.
 
8) Brenowitz SB, Kwack S, Goodman MF, et al: Specificity and enzymatic mechanism of the editing exonuclease of Escherichia coli DNA polymerase III. J. Biol. Chem. 266: 7888-7892, 1991.
 
9) Zarbl H, Sukumar S, Arthur AV, et al: Direct mutagenesis of Ha-ras-10ncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315: 382-385, 1985.
 
10) Ames BN, Gold LS: Endogenous mutagens and the causes of aging and cancer. Mutat. Res. 250: 3-16, 1991.
PubMed
11) Iwakuma T, Sakumi K, Nakatsuru Y, et al : High incidence of nitrosamine-induced tumorigenesis in mice lacking DNA repair methyltransferase. Carcinogenesis l8: 1631-1635, 1997.
 
12) Fishel R, Lescoe MK, Rao MRS, et al: The human mutator gene homolog MSH 2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027-1038, 1993.
 
13) Papadopoulos N, Nicolaides NC, Wei YE, et al: Mutation of a mutL homolog in hereditary colon cancer. Science 263: 1625-1629, 1994.
 
14) Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
PubMed
15) Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeat sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558-561, 1993.
 
16) 益谷央豪, 菅澤 薫, 花岡文雄: 真核細胞のヌクレオチド除去修復. 細胞工学 13: 40-49, 1994.
 
17) van Gool, van der Horst GTJ, Citterio E, et al: Cockayne syndrome: defective repair of transcription. EMBO J. 16: 4155-4162, 1997.
 
18) Sands AT, Abuin A, Sanchez A, et al: High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 377: 162-165, 1995. .
PubMed
19) Alani E, Padmore R, Kleckner N: Analysis of wild-type and rad 50 mutants of yeast suggests an intimate relationship between meiotic chromosome synapsis and recombination. Cell 61: 419-436, 1990.
 
20) Fujiki H, Sueoka E, Komori A, et al: Tumor promotion and TNF-αgene expression by the okadaic acid class tumor promoters. Environ. Carcino. &Ecotox Revs. C 15 (1) : 40, 1997.
 
21) Ito N, Tsuda H, Tatematsu M, et al: Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rat: An approach for a new medium-term bioassay system. Carcinogenesis 9: 387-394, 1988.
PubMed
22) Tatematsu M, Furihata C, Katsuyama T, et al: Immunohistochemical demonstration of pyloric gland-type cells with low-pepsinogen isozyme l in preneoplastic and neoplastic tissues of rat stomachs treated with N-methyl-N '-nitro-N-nitrosoguanidine. J. Natl. Cancer Inst. 78: 771-777, 1987.
 
23) Tatematsu M, Nagamine Y, Farber E: Redifferentiation as a bases for remodeling of carcinogen-induced hepatocyte nodules to normal appearing liver. Cancer Res. 43: 5049-5058, 1983.
 
24) Imai T, Masui T, Ichinose M, et al : Reduction of glutathione S-transferase P-form mRNA expression in remodeling nodules in rat liver revealed by in situ hybridization. Carcinogenesis 18: 545-551, 1997.
PubMed
25) Fujimitsu Y, Nakanishi H, Inada K, et al: Development of aberrant crypt foci involves a fission mechanism as revealed by isolation of aberrant crypts. Jpn. J. Cancer Res. 87: 1199-1203, 1996.
PubMed
26) Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596-602, 1983.
PubMed
27) Sinn E, Muller W, Pattengale P, et al: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc gene in transgenic mice: synergistic action of oncogenes in vivo. Cell 49: 465-475, 1987.
PubMed
28) Donehower LA, Harvey M, Slagle BL, et al: Mice deficient for p 53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221, 1992.
 
29) Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet. 9: 138-141, 1993.
PubMed
30) Mulligan LM, Kwok JB, Healey CS, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2 A. Nature 363: 458-460, 1993.
PubMed
31) Nishisho I, Nakamura Y, Miyoshi Y, et al: Mutations of chromosome 5 q 21 genes in FAP and colorectal cancer patients. Science 253: 665-669, 1991.
 
32) Kinzler KW, Nilbert MC, Su LK, et al: Identification of FAP locus genes from chromosome 5 q 21. Science 253: 661-665, 1991.
 
33) Lee WH, Bookstein R, Hong F, et al: Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235: 1394-1399, 1987.
PubMed
34) Haber DA, Buckler AJ, Glaser T, et al: An internal deletion within an ll p 13 zinc finger genecontributes to the development of Wilms 'tumor. Cell 61: 1257-1269, 1990.
 
35) Malkin D, Li FP, Strong LC, et al: Germ line p 53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990.
 
36) Wallace MR, Marchuk DA, Andersen LB, et al: Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF 1 patients. Science 249: 181-186, 1990.
 
37) Rouleau GA, Merel P, Lutchman M, et al: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363: 515-521, 1993.
 
38) Knudson AG: Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol. 122: 135-140, 1996.
PubMed
39) Farber E, Cameron C: The sequential analysis of cancer development. Adv. Cancer Res. 31: 125-225, 1980.
 
40) Tanooka H: Monoclonal growth of cancer cells: Experimental evidence. Jpn. J. Cancer Res. (Gann) 79: 657-665, 1988.
PubMed
41) Tatematsu M, Fukami H, Yamamoto M, et al: Clonal analysis of glandular stomach carcinogenesis in C 3 H/HeN H BALB/c chimeric mice treated with N-methyl-N-nitrosourea. Cancer Lett. 83: 37-42, 1994.
 
42) Tatematsu M, Masui T, Fukami H, et al: Monoclonal development of squamous cell carcinomas from polyclonal papillary or nodular hyperplasias in the forestomach of C 3 H/HeN H BALB/c chimeric mice treated with N-methyl-N-nitrosourea or diethylnitrosamine. Carcinogenesis 17: 1365-1371, 1996.
PubMed
43) Tatematsu M, Masui T, Fukami H, et al: Primary monoclonal and secondary polyclonal growth of colon neoplastic lesions in C 3 H/HeN H BALB/c chimeric mice treated with 1, 2-dimethylhidrazine: immunohistochemical detection of C 3 H strain-specific antigen and simple sequence length polymorphism analysis of DNA. Int. J. Cancer 66: 234-238, 1996.
 
44) Hibi K, Takahashi T, Yamakawa K, et al: Three distinct regions involved in 3 p deletion in human lung cancer. Oncogene 7: 445-449, 1992.
 
45) Suzuki H, Takahashi T, Kuroishi T, et al: p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 52: 734-736, 1992.
PubMed
46) Slaughter DF, Southwich HW, Smkejkal W: "Field cancerization" in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 6: 963-968, 1953.
 
47) Kanjilal S, Strom SS, Clayman GL, et al: p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res. 5513604-3609, 1995.
PubMed
P.45 掲載の参考文献
1) Beasley RP, Hwang LY, Lin CC, et al: Hepatocellular carcinoma and hepatitis B virus. Lancet ii: 1129-1133, 1981.
 
2) Takada S, Koike K: Trans-activation function of 3 'truncated X gene-cell fusion product from integrated hepatitis B virus DNA in chronic hepatitis tissues. Proc. Natl. Acad. Sci. USA 87: 5628-5632, 1990.
PubMed
3) Yang W, Mason WS, Summers J: Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J. ViroL 70: 4567-4575, 1996.
 
4) Finlay YT, Hinds PW, Levine AJ: The p 53 proteooncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
 
5) Kobayashi M, Koike K: Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene 30: 227-232, 1984.
PubMed
6) Koike K, Shirakata Y, Yaginuma K, et al: Oncogenic potential of hepatitis B virus. Mol. Biol. Med. 6: 15H60, 1989.
PubMed
7) Wang GH, Seeger C: The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71: 663-670, 1992.
 
8) Spandau DF, Lee C: Trans-Activation of viral enhancers by the hepatitis B virus X protein. J. Virol. 62: 427-434, 1988.
PubMed
9) Twu JS, Schloemer RH: Transcriptional trans-activating function of hepatitis B virus. J. Virol. 61: 3448-3453, 1987.
PubMed
10) Seto E, Yen TSB, Peterlin BM, et al: Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc. Nat1. Acad, Sci. USA 85: 8286-8290, 1988.
 
11) Shirakata Y, Kawada M, Koike K, et al: The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH 3 T 3 cells. Jpn. J. Cancer Res. 80: 617-621, 1989.
 
12) Hohne M, Schaefer S, Scifer M, et al: Malignant transformation of immortalized transgenic hepatocyte after transfection with hepatitis B virus. DNA 9: 1137-1145, 1990.
 
13) Kim C, Koike K, Saito I, et al: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351: 317-320, 1991.
PubMed
14) Wang XW, Forrestar K, Harris CC, et al: Hepatitis B virus X protein inhibits p 53 sequence-specific DNA binding, transcriptional activity, and association with transcriptional factor ERCC 3: Proc. Natl. Acad. Sci. USA 91: 2230-2234, 1994.
 
15) Takada S, Koike K: Hepatitis B virus X gene expression is activated by X protein but repressed by p 53 tumor suppressor gene product in the transient expression system. Virology 216: 80-89, 1996.
 
16) Siddiqui A, Gaynor R, Srinivasan A, et al: Trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology 169: 479-484, 1989.
PubMed
17) Faktor O, Shaul Y: The identification of hepatitis B virus X gene responsive elements reveals functional similarity of X and HTLV-1 tax. Oncogene 5: 867-872, 1990.
PubMed
18) Maguire HF et al: HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interaction. Science 252: 842-844, 1991.
 
19) 鈴木健之, 吉田光昭: ヒトT細胞白血病ウイルス(HTLV) の制御因子Tax. 現代化学33 (増刊) : 175-181, 1997.
 
20) Cheong J-H, Yi M-K, Murakami S: Human RPB 5, a subunit shared by eukaryotic nuclear polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J 14: 143-150, 1995.
 
21) Takada S, Kido H, Koike K, et al: Interaction of hepatitis B virus X protein with a serine protease, tryptase TL 2, as an inhibitor. Oncogene 9: 341-348, 1994.
PubMed
22) Takada S, Tsuchida N, Koike K, et al: Disruption of the function of tumor-suppressor gene p 53 by the hepatitis B virus X protein and hepatocarcinogenesis. J. Cancer Res. Clin. Oncol. 121: 593-601, 1995.
 
23) Takada S, Kaneniwa N, Koike K, et al: Cytoplasmic retention of the p 53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 15: 1997. (in press)
 
24) 高田等子, 小池克郎: B型肝炎ウイルスと肝発癌. 蛋白質核酸酵素 35: 2089-2099, 1990.
 
25) Wollersheim M, Debelka U, Hofschneider PH: Atransactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 3: 545-552, 1988.
PubMed
26) Brechot C, Hadchonuel M, Scotto J, et al: Detection of hepatitis B virus DNA in liver and serum: adirect appraisal of the chronic carrier state. Lancet ii: 765-768, 1981.
 
27) Chisari FV, et al: Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59: 1145-1156, 1989.
PubMed
28) Moriaty AM, Alexander H, Lerner RA, et al: Antibodies to peptides detect new hepatitis B antigen: Serological correlation with hepatocellular carcinoma. Science 227: 429-432, 1985.
 
29) Caselmann WH, et al: Atrans-activator function is generated by integration of hepatitis B virus pre S/S sequences in human hepatocellular carcinoma DNA. Proc. Natl. Acad. Sci. USA 87: 2970-2974, 1990.
 
30) Geller SA, Nichols WS, Kim S, et al: Hepatocellular carcinogenesis is the sequel to hepatitis in Z＃2a1- antitrypsin transgenic mice: Histopathological and DNA ploidy studies. Hepatology l9: 389-397, 1994.
 
31) Seto E, Usheva A, Zambetti GP, et al: Wild-type p 53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89: 12028-12032, 1992.
 
32) Thut CJ, Chen JL, Tjian R, et al: P53 transcriptional activation mediated by co-activator TAFII 40 and TAFII 60. Science 267: 100-104, 1995.
 
33) EL-Deiry W, et al: Definitions of a consensus binding site for p 53. Nat. Genet. 1: 45-49, 1992.
 
34) Scheffner M, Werness BA, Howley P, et al: The E 60ncoprotein encoded by human papilloma virus type 16 and 18promotes the degradations of p 53. Cell 63: 1129-1136, 1990.
 
35) Hsu IC, et al: Mutational hot spot in the p 53 gene in human hepatocellular carcinoma. Nature 350: 427-428, 1991.
 
36) Bressae B, et al: Abnormal structure and expression of p 53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 87: 1973-1977, 1990.
 
37) Koike K, Takada S: Biochemistry and functions of hepatitis B virus X protein. Intervirology 38, 89-99, 1995.
PubMed
38) Dcria M, et al: The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J. 14: 4747-4757, 1995.
 
39) Dyson N, Howley P, Munger K, et al: The human papillomavirus-16 E 70ncoprotein is able to bind the retinoblastoma gene product. Science 243: 934-937, 1989.
 
P.56 掲載の参考文献
1) Doll R, Peto R: The causes of cancer: Quantitative estimates of avoidable risk of cancer in the United States today. Oxford Univ. Press, New York, 1981.
 
2) Perera FP, Weinstein IB: Molecular epidemiology and carcinogen-DNA adduct detection: New approaches to studies of human cancer causation. J. Chronic. Dis. 35: 581-600, 1982.
PubMed
3) Tomatis L, Aitio A, Wilbourn J, et al: Human carcinogens so far identified. Jpn. J. Cancer Res. 78: 887-898, 1987.
 
4) Cook JW, Hewett CL, Hieger I: The isolation of cancer-producing hydrocarbon from coaltar. Parts I, II and III. J. Chem. Soc. 395-405, 1933.
 
5) Knudson A: Two hits times 25 years. J. Natl. Cancer Inst. 89: 470-472, 1997.
 
6) Perera FP: Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J. Natl. Cancer Inst. 88: 496-509, 1996.
PubMed
7) Sugimura T: Overview of carcinogenic heterocyclic amines. Mutat. Res. 376: 211-219, 1997.
PubMed
8) Hecht SS, Hoffmann D: Tobacco specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 9: 875-884, 1988.
PubMed
9) Hecht SS, Adams JD, Numoro S, et al: Induction of respiratory tract tumors in Syrian golden hamsters by a single dose of 4- (methylnitrosoamine) -1- (3-pyridyl) -1-butanone (NNK) and the effect of smoke inhalation. Carcinogenesis 4: 1287-1290, 1983.
PubMed
10) Yamamoto K, Nakajima A, Eimoto H, et al: Carcinogenic activity of endogenously synthesized N-nitrosobis (2-hydroxypropyl) amine in rats administered bis (2-hydroxypropyl) amine and sodium nitrite. Carcinogenesis 10: 1607-1611, 1989.
PubMed
11) Metzler M, Degen GH: Sex hormones and neoplasia: Liver tumors in rodents. Arch. Toxicol. 10 (Suppl.) : 251-263, 1987.
PubMed
12) Taper HS: The effect of estradial-17-phenylpropionate and estradiol benzoate on N-nitrosomorpholine-induced liver carcinogenesis in oviariectomized rats. Cancer 42: 462-467, 1978.
 
13) Nakae D, Yoshiji H, Mizumoto Y, et al: High incidences of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res. 52: 5042-5045. 1992
PubMed
14) Nakae D, Yoshiji H, Maruyama H, et al: Production of both 8-hydroxydeoxyguanosine in liver DNA and α-glutamyltransferase-positive hepatocellular lesions in rats given a choline-deficient, L-amino acid-defined diet. Jpn. J. Cancer Res. 81: 1081-1084, 1990.
 
15) Cheng KC, Cahill DS, Kasai H, et al: 8-Hydroxyguanine, un abandunt from of oxidative DNA damage, causes G→Tand A→Csubsitutions. J. Biol. Chem. 267: 166-172, 1992.
 
16) International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Overall evaluation of carcinogenicity: An updating of IARC monographs vol. 1-42 (suppl. 7) , IARC, Lyon, France, 1987, pp. 297-308.
 
17) Kohler SW, Provast GS, Kretz PL, et al: Development of a short-term, in vivo mutagenesis assay: The effects of methylation on the recovery of a lambda phage shuttle vector from transgenic mice. Nucleic Acids Res. 18: 3007-3013, 1990.
 
18) Dycaico MJ, Provost GS, Kretz PL, et al: The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat. Res. 307: 461-478, 1994.
PubMed
19) Gossen JA, de Leeuw WJ, Tan CH, et al: Efficient rescue of integrated shuttle vectors from transgenic mice: Amodel for studying mutations in vivo. Proc. Natl. Acad. Sci. USA 86: 7971-7975, 1989.
 
20) Tennant RW, French JE, Spalding JW: Identifying chemical carcinogens and assessing potential risk in shortterm bioassays using transgenic mouse models. Environ. Health Perspect. 103: 942-950, 1995.
 
21) Storer RD, Cartwright ME, Cook WO, et al: Short-term carcinogenesis bioassay of genotoxic procarcinogenesis in PIM transgenic mice. Carcinogenesis 16: 285-293, 1995.
 
22) Saitho A, Kimura M, Takahashi R, et al: Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5: 1195-1200, 1990.
 
23) Yamamoto S, Mitsumori K, Kodama Y, et al: Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis 17: 2455-2461, 1996.
PubMed
24) Ito N, Tsuda H, Tatematsu M, et al: Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rat: An approach for a new medium-term bioassay system. Carcinogenesis 9: 387-394, 1988.
PubMed
25) Ito N, Imaida K, Tsuda H, et al: Wide-spectrum initiation models: Possible applications to medium-term multiple organ bioassays for carcinogenesis modifiers. Jpn. J. Cancer Res. 79: 413-417, 1988.
PubMed
26) Park HS, Goodlad RA, Wright NA: The incidence of aberrant crypt foci and colonic carcinoma in dimethylhydrazine-treated rats varies in a site-specific manner and depends on tumor histology. Cancer Res. 57: 4507-4510,
 
27) Mizumoto K, Tsutsumi M, Denda A, et al: Rapid production of pancreatic carcinoma initiated with Nnitrosobis (2-oxopropyl) amine and repeated augmentation pressure in hamsters. J. Natl. Cancer Inst. 80: 1564-1567, 1988.
 
28) Mizumoto K, Kitazawa S, Ito S, et al: Cycles of repeated augmentation pressure in rapid production of pancreatic and cholangiocellular carcinomas in hamsters initiated with N-nitrosobis (2-oxopropyl) amine. Carcinogenesis 10: 1457-1459, 1989.
 
29) Sugimura T: Multistep carcinogenesis: A1992 perspective. Science 258: 603-607, 1992.
PubMed
30) Sporn MB: The war on cancer. Lancet 347: 1377-1381, 1996.
PubMed
31) Sporn MB: Chemoprevention of cancer. Lancet 342: 1211-1213, 1993.
PubMed
32) Ames B, Gold LS: The causes and prevention of cancer: Gaining perspective. Environ. Health Perspect. 105 (Suppl. 4) : 865-873, 1997.
 
P.61 掲載の参考文献
1) Thomassen MJ, Buoen LC, Brand I, et al: Foreign-body tumorigenesis in mice: DNA synthesis in surface-attached cells during preneoplasia. J. Natl. Cancer Inst. 61: 359-363, 1978.
PubMed
2) Moizhessb TG, Vasiliev JM: Early and late stages of foreign-body carcinogenesis can be induced by implants of different shapes. Int. J. Cancer 44: 449-453, 1989.
 
3) Kane AB: Mechanisms of mineral fibre carcinogenesis. Mechanisms of fibre carcinogenesis. IARC Scientific Publications No. 140, IARC, Lyon, 1996, pp. 11-33.
 
4) Brand KG, Johnson KH, Buoen LC: Foreign body tumorigenesis. CRC Critical Rev. Toxicol. 4: 353-394, 1976,
 
5) Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, et al: Risk factors for squamous cell carcinoma of the oesophagus. Br. J. Surg. 83: 1174-1185, 1996.
PubMed
6) Uetsuji S, Okuda Y, Kwon AH, et al: Gallbladder cancer with a low junction of the cystic duct or an anomalous pancreaticobiliary junction. Eur. J. Gastroenterol. Hepatol. 8: 1213-1217, 1996.
PubMed
7) Beyersman, D: Interactions in metal carcinogenicity. Toxicol. Lett. 72: 333-338, 1994.
 
8) Yamamoto S, Wanibuchi H, Hori T, et al: Possible carcinogenic potential of dimethylarsinic acid as assessed in rat in vivo models: areview. Mut. Res. 386: 353-361, 1997.
 
9) IARC. IARC Monographs on the evaluation of carcinogenic risk of the chemicals to humans, some metals and metallic compounds. vol. 23, IARC, Lyon, 1980.
 
10) IARC. IARC Monographs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Chromium, nickel and welding. vo1. 49, IARC, Lyon, 1990.
 
11) Toyokuni S, Sagripanti JL: Increased 8-hydroxydeoxyguanosine in kidney and liver of rats continuously exposed to copper. Toxicol. Appl. Pharmacol. 126: 91-97, 1994.
PubMed
12) IARC. IARC Monographs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Asbestos. vol. 14, IARC, Lyon, 1977.
 
13) IARC. IARC Monographs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Silica and silicates. vol. 42, IARC, Lyon, 1987.
 
14) IARC. IARC Monographs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Man-made mineral fibres and radon. vol. 43, IARC, Lyon, 1988.
 
15) Clayson DB, Pringle JA: The influence of a foreign body on the induction of tumours in the bladder epithelium of the mouse. Br. J. Cancer 20: 564-568, 1966.
PubMed
16) IARC. IARC Monographs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Silica, some silicates, coal dusts and para-aramid fibrils. vol. 68, IARC, Lyon, 1997.
 
17) IARC. IARC Monographs on the Evaluation of Carcinogenic Risk of the Chemicals to Humans, Wood dust and formaldehyde. voL 62, IARC, Lyon, 1995.
 
18) Tsukahara Y, Fukamatsu Y, Hirabayashi T, et al: Adenocarcinoma of the endometrium following prolonged use of an intrauterine device. Nippon sanka fujinka gakkai zasshi (Acta Obstetrica et Gynaecologica Japonica) 35: 339-343, 1983.
PubMed
19) Baba N, Von Haam E: Squamous cell carcinoma of the rat endometrium produced by insertion of strings coated with paraffin and polymer. J. Natl. Cancer Inst. 47: 675-685, 1971.
PubMed
20) Van Natta BW, Thurston JB, Moore TS: Silicone breast implants Is there cause for concern? Indiana Medicine 83: 184-185, 1990.
PubMed
21) Brand KG: Do implanted medical devices cause cancer? (95 Refs) . J. Biomater. Appl. 8: 325-343, 1994.
 
22) Dewan PA: Is injected polytetrafluoroethylene (Polytef) carcinogenic? [see comments]. Br. J. Urol. 69: 29-33, 1992.
 
23) Dunn KW, Hall PN, Khoo CT: Breast implant materials: sense and safety[see comments]. Br. J. Plast. Surg. 45: 315-321, 1992.
 
24) Fukushima S, Tanaka H, Asakawa E, et al: Carcinogenicity of uracil, a nogenotoxic chemical, in rats and mice and its rationale. Cancer Res. 52: 3789-3794, 1989.
 
25) Ishii A, Matsuoka H, Aji T, et al: Parasite infection and cancer: with special emphasis on Scistosoma japoonicum infections (Trematoda) . Areview. Mut. Res. 305: 273-281, 1994.
 
26) Cohen SM, Cano M, Garland EM, et al: Urinary and urothelial effects of sodium salts in male rats. Carcinogenesis 16: 343-348, 1995.
PubMed
27) Kuwashima Y, Nemoto N, Ishikawa T: Expression of proto-oncogenes and cytoskeletal actin gene in foreign body-induced murine sarcomas. In Vivo 7: 139-142, 1993.
PubMed
P.71 掲載の参考文献
1) Weinberg DS, Ruggeri B, Barber MT, et al: Cholecystokinin A and B Receptors Are Differintially Expressed in Normal Pancreas and Pancreatic Adenocarcinoma. J. Clin. Invest. 100 (3) : 597-603, 1997.
 
2) Howell A, Dodwell DJ, Anderson H, et al: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann. Oncol. 3: 611-617, 1992.
PubMed
3) Teixeira C, Pratt MAC: CDK Is a Target for Retinoic Acid-Mediated Growth Inhibition in MCF-7 Human Breast Cancer Cells. Mol. Endocrinol. 11 (9) : 1191-1202, 1997.
 
4) Anzick SL, Kononen J, Walker RL, et al: AIB 1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer. Science 277: 965-968, 1997.
 
5) Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al: Comparison of the Effects of a Pure Steroid Antiestrogen with Those of Tamoxifen in a Model of Human Breast Cancer. J. Natl. Cancer Inst. 87 (10) : 746-750, 1995
 
6) Zajchowski DA, Sager R, Webster L: Estrogen Inhibits the Growth of Estrogen Receptor-negative, but not Estrogen Receptor-positive, Human Mammary Epithelial Cells Expressing a Recombinant Estrogen Receptor. Cancer Res. 53: 5004-5011, 1993.
 
7) Klein KA, Reiter RE, Redula J, et al: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 3 (4) : 402-408, 1997.
PubMed
8) Brzozowski AM, Pike ACW, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758, 1997.
 
9) Spencer TE, Jenster G, Burcin MM, et al: Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389: 194-198, 1997.
PubMed
10) Jackson, TA, Richer JK, Bain DL, et al: The Partial Agonist Activity of Antagonist-Occupied Steroid Receptors Is Controlled by a Novel Hinge Domain-Binding Coactivator L 7/SPA and the Corepressors N-CoR or SMRT. Mol. Endocrinol. 11 (6) : 693-705, 1997.
PubMed
11) Kato S, Endoh H, Masuhiro Y, et al: Activation of the Estrogen Receptor Though Phosphorylation by Mitogen- Activated Protein Kinase. Science 270: 1491-1494, 1995.
 
12) Zwijsen RML, Wientjens E, Klompmaker R, et al: CDK-Independent Activation of Estrogen Receptor by Cyclin D1. Cell 88: 405-415, 1997.
 
13) Montano MM, Katzenellenbogen BS: The quinone reductase gene: Aunique estrogen receptor-regulated gene that is activated by antiestrogens. Proc. NatL Acad. Sci. USA 94: 2581-2586, 1997.
 
14) Paech K, Webb P, Kuiper GGJM, et al: Differential Ligand Activation of Estrogen Receptors ERαand ERβ at AP l Sites. Science 277: 1508-1510, 1997.
 
P.83 掲載の参考文献
1) Bishop JM: The molecular genetics of cancer. Science 235: 305-311, 1987.
PubMed
2) Ponder B: Gene losses in human tumours. Nature 335: 400-402, 1988.
PubMed
3) Kinzer KW, Vogelstein B: Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761, 1997.
 
4) Bos JL: Ras oncogenes in human cancer;areview. Cancer Res. 49: 4672-4689, 1989.
 
5) James GL, Goldstein JL, Brown MS, et al: Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 260: 1937-1942, 1993.
PubMed
6) Kohl NE, Mosser SD, deSolms J, et al: Selective inhibition of ras-dependent transformation by a farnesyltrans ferase inhibitor. Science 260: 1934-1937, 1993.
 
7) Blackwell TK, Kretzner L, Blackwood EM, et al: Sequence-specific DNA binding by the c-myc protein. Science 250: 1149-1151, 1990.
 
8) Blackwood EM, Eisenman RN: Max: ahelix-loop-helix zipper protein that forms a sequence-specific DNAbinding complex with myc. Science 251: 1211-1217, 1991.
 
9) Schwab M, Amler LC: Amplification of cellular oncogenes: apredictor of clinical outcome in human cancer. Genes Chromsom. Cancer 1: 181-193, 1990.
 
10) Plowman GD, Green JM, Culouscou J, et al: Heregulin induces tyrosine phosphorylation of HER 4/P 180 erbB 4. Nature 366: 473-475, 1993.
 
11) van Heyningen V: One gene-four syndromes. Nature 367: 319-320, 1994.
PubMed
12) Lugo TG, Pendergast AM, Muller AJ, et al: Tyrosine kinase activity and transformation by the BCR/abl oncogene products. Science 247: 1079-1082, 1990.
PubMed
13) Benedict WF, Xu H, Hu S, et al: Role of the retinoblastoma gene in the initiation and progression of human cancer. J. Clin. Invest. 85: 988-993, 1990.
 
14) Helin K, Lees JA, Vidal M, et al: AcDNA encoding a pRB-binding protein with properties of the transcription factor E 2 F Cell 70: 337-350, 1992.
 
15) Kaelin WG, Krek W, Sellers WR, et al: Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E 2 F-like properties. Cell 70: 351-364, 1992.
 
16) Kamb A: Cyclin-dependent kinase inhibitors and human cancer. Curr. Top. Microbiol. Immunol. 227: 139-148, 1998.
PubMed
17) Merlo A, Herman JG, Mao L, et al: 5CpG island methylation is associated with transcriptional silencing of the tumour suppressor p 16/CDKN 2/MTS l in human cancers. Nat. Med. 1: 686-692, 1995.
 
18) Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
PubMed
19) Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p 53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878, 1994.
 
20) Szabo CI, King MC: Population genetics of BRCA I and BRCA 2. Am. J Hum. Genet. 60: 1013-1020, 1997.
 
21) Gowen LC, Avrutskaya AV, Latour AM, et al: BRCA I required for transcription-coupled repair of oxidative DNA damage. Science 281: 1009-1012, 1998.
 
22) Rubinfeld B, Souza B, Albert I, et al: Association of the APC gene product withβ-catenin. Science 262: 1731-1734, 1993.
 
23) Su L, Vogelstein B, Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 262: 1734-1737, 1993.
PubMed
24) Matsumine A, Ogai A, Senda T, et al: Biding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science 272: 1020-1023, 1996.
 
25) Powell SM, Zilz N, Beazer-Barclay Y, et al: APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237, 1992.
PubMed
26) Heldin CH, Miyazono K, ten Dijke P: TGF-βsignalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471, 1997.
 
27) Drummond IA, Madden SL, Rohwer-Nutter P, et al: Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT 1. Science 257: 674-678, 1992.
 
28) Ohta M, Inoue H, Cotticelli MG, et al: The FHIT gene, spanning the chromosome 3 p 14. 2fragile site and renal carcinoma-associated (3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597, 1996.
 
29) Modrich P: Mismatch repair, genetic stability, and cancer. Science 26611959-1960, 1994.
PubMed
30) Parsons R, Li G, Longley MJ, et al: Hypermutability and mismatch repair deficiency in RER+tumor cells. Cell 75: 1227-1236, 1993.
PubMed
31) Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF-βreceptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995.
 
P.95 掲載の参考文献
1) Bell SP, Stillman B: ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex. Nature 357: 128-134, 1992.
PubMed
2) Seki M, Khoda T, Yano T, et al: Characterization of DNA synthesis and DNA dependent ATPase activity at arestrictive temperature in temperature-sensitive tsFT 848 cells with thermolabile DNA helicase. Mol. Cell. Biol. 15: 165-172, 1995.
 
3) Suzuki M, Savoysky E, Izuta S, et al: RNA priming coupled with DNA synthesis on natural template by calf thymus DNA polymerase α-primase. Biochemistry 32: 12782-12792, 1993.
 
4) Collins K, Kobayashi R, Greider W: Purification of tetrahymana telomerase and cloning of genes encoding the two protein components of the enzyme. Cell 81: 677-686, 1995.
 
5) Waga S, Stillman B: Anatomy of DNA replication for revealed by reconstrution of SV 40 DNA replication in vitro. N ature 369: 207-212, 1994.
 
6) Araki H, Ropp DA, Jhonson AL, et al: DNA polymerase II, the probable homolog of mammalian DNA polymerase epsilon replicates chromosomal DNA in the yeast Saccha rollmyces cerevisie. EMBO J. 11: 733-740, 1992.
 
7) Savoysky E, Suzuki M, Simbulan C, et al: Immunopurified Rb protein inhibits SV 40 T-antigen dependent stimulation of DNA polymeraseα. Oncogene 8: 319-325, 1993.
 
8) Simbulan CMG, Suzuki M, Izuta S, et al: Poly (ADP) ribose stimulates DNA polymeraseαby physical association. J. Biol. Chem. 268: 93-99, 1993.
 
9) Murakami H, Okayama H: Akinase from fission yeast responsible for bloking mitosis in S phase. Nature 374: 817-819, 1995.
 
10) Navas TA, Zhou Z, Elledge SJ: DNA polymerase epsilon links the DNA replication machinary to the S phase check point. Cell 80: 29-39, 1995.
 
11) 松影昭夫: DNA複製とその調節. 東京大学出版会, 東京, 1995.
 
12) Kornberg A, Baker D: DNA replication (Second Ed.) . Freeman and Co, New York, 1991.
 
13) Wang TS-F: Cellular DNA polymerases. In: DNA Replication in Eukaryotic cells (ed. by DePamphilis ML) , Cold Spring Harbor Laboratory Press, New York, 1996, pp. 495-524.
 
14) Greider CW, Collins K, Autexier: DNA telomerases. In: DNA Replication in Eukaryotic cells (ed. by DePam- philis ML) , Cold Spring Harbor Laboratory Press, New York, 1996, pp. 619-638.
 
15) 久保田弓子, 滝沢温彦: S期誘導シグナルとDNA複製開始. DNA複製・修復と発癌 (松影昭夫編) , 羊土社, 東京, 1996, pp. 44-56.
 
16) 釣本敏樹: 複製開始領域の構成とその活性化機構. DNA複製・修復と発癌 (松影昭夫編) , 1996, 羊土社, 東京, pp. 57-68.
 
17) 吉田松年: 複製酵素の機能と制御. DNA複製・修復と発癌 (松影昭夫編) , 1996, pp. 81-89.
 
18) 中津可道, 田中亀代治: 除去修復機構とその欠損症, DNA複製・修復と発癌 (松影昭夫編) , 1996, 羊土社, 東京, pp. 131-139.
 
19) 池島三与子, 島田 隆: ミスマッチ修復の分子機構と発癌. DNA複製・修復と発癌 (松影昭夫編) , 羊土社, 東京, 1996, pp. 143-153.
 
20) Carothers AM: DNA damage, mutation, and repair. In: Encyclopedia of Cancer (ed. by Bertino JR) , Academic Press, New York and London, 1996, pp. 484-450.
 
21) Friedberg E, Walker G, Siede W: DNA repair and Mutagenesis. ASM Press, Washington, D. C., 1996.
 
22) Loeb L: A mutator phonotype may be required for multistage carcinogenesis. Cancer Res. 51: 3075-3079, 1991.
 
23) Sancar A: DNA repair in humans. Annu. Rev. Genet. 29: 69-106, 1996.
 
P.114 掲載の参考文献
1) Mitelman F, Kaneko Y, Berger R: Report of the committee on chromosome changes in neoplasia. In: HumanGene Mapping 1993, A Compendium (eds by Cuticchia AJ, Pearson PL) , Johns Hopkins Univ Press, Baltimore, 1994, pp. 773-812.
 
2) Rabbitts TH: Chromosomal translocations in human cancer. Nature 372: 143-149, 1994.
PubMed
3) Karp JE, Broder S: Molecular foundations of cancer. New targets for intervention. Nat. Med. 1: 309-320, 1995.
PubMed
4) Chen Z, Chen S-J, Wang Z-Y: Retinoic acid and acute promyelocytic leukemia: amodel of targetting treat- ment for human cancer. CR Acad. Sci. sciences de la vie 317: 1135-1141, 1994.
 
5) 阿部達生, 鎌田七男, 桜井雅温 (編) : 腫瘍染色体アトラス, 南江堂, 東京, 1986, pp. 27-51.
 
6) Dutrillaux R: New chromosome techniques. In: Molecular Structure of Human Chromosomes (ed by Yunis JJ) , Academic Press, New York, 1977, pp. 233-265.
 
7) Holmquist GP: Chromosome bands, their chromatin flavors, and their functional features. Am. J. Hum Genet. 1: 17-37, 1992.
PubMed
8) Saccone S, De Sario A, Della Valle G, et al: The highest gene concentrations in the human genome are intelomeric bands of metaphase chromosomes. Proc. Natl. Acad. Sci. USA 89: 4913-4917, 1992.
PubMed
9) Langlois TG, Yu, LC, Gray JW, et al: Quantitative karyotyping of human chromosomes by dual beam flow. Proc. Natl. Acad. Sci. USA 79: 7876-7880, 1982.
 
10) Antequera F, Bird A: Number of CpG islands and genes in human and mouse. Proc. Natl. Acad. Sci. USA 90:
PubMed
11) Saitoh Y, Laemmli K: Metaphase chromosome structure. Bands arise from a differential fold path of the highly AT-rich scaffold. Cell 76: 609-622, 1994.
 
12) Nagele R, Freeman T, Mcmorrow L, et al: Precise spartial positioning of chromosomes during prometaphase levidence for chromosomal order. Science 270: 1831-1835, 1995.
 
13) Strissel-Broeker PL, Super HG, Thirman MJ, et al: Distribution of llq23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachement regions and topoisomerase II consensus binding sites. Blood 87: 1912-1922, 1996.
 
14) Cimino G, Rapanotti MC, Biondi A, et al: Infant acute leukemias show the same biased distribution of ALL lgene breaks as topoisomerase II related secondary acute leukemias. Cancer Res. 57: 2879-2883, 1997.
 
15) Taniwaki M, Nishida K, Takashima T, et al: Nonrandon chromosomal rearrangements of 14q32. 3 and 19p13. 3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84: 2283-2290, 1994.
 
16) 阿部達生 (編) : 造血器腫瘍アトラス. 形態, 免疫, 染色体と遺伝子, 日本医事新報社, 東京, 1991, pp. 1-162.
 
17) Mitelman F, Mertens F, Johansson B: Abreakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat. Genet. 15: 417-474, 1997.
PubMed
18) Yokota S, Hansen-Hagge TE, Ludwig WD, et al: Use of polymerase chain reaction to monitor minimal residual disease in acute lymphoblastic leukemia. Blood 77: 331-339, 1991.
PubMed
19) Inoue K, Sugiyama H, Ogawa H, et al: WTI as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-3079, 1994.
 
20) Okuda T, van Deursen J, Hiebert SW, et al: AML-1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 321-330, 1996.
 
21) Nowell PC: Chromosome changes and the clonal evolution of cancer. In: Chromosome and Cancer (ed by German J) , John Wiley&Sons, New York, 1974, pp. 267-285.
 
22) de Grouchy J, Turleau C: Clonal evolution in the myeloid leukemias. In: Chromosome and Cancer (ed by German J) , John Wiley&Sons, New York, 1974, pp. 287-311.
 
23) Nakai H, Misawa S, Toguchida J, et al: Frequent p53 gene mutations in blast crisis of chronic myelogeneous leukemia, especially in myeloid crisis harvoring loss of a chromosome 17p. Cancer Res. 52: 6588-6593, 1992.
 
24) Mitani K, Ogawa S, Tanaka T, et al: Generation of the AML 1-EVI-1 fusion gene in the t (3;21) (q26;q22) causes blastic crisis in chronic myelogeneous leukemia. EMBO J. 13: 504-510, 1994.
 
25) Yokota S, Kiyoi H, Nakao M, et al: Internal tandem duplication of the FLT 3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on alarge series of patients and cell lines. Leukemia 11: 1605-1609, 1997.
 
26) Takashima T, Itoh M, Ueda Y, et al: Detection of l4q32. 33 translocation and t (11;14) in interphase nuclei of chronic B-cell leukemia/lymphomas by in silza hybridization. Int. J. Cancer 72: 31-38, 1997.
 
27) Guan X-Y, Melzter PS, Dalton WS, et al: Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. Nat. Genet. 8: 155-161, 1994.
 
28) Monni O, Joensuu H, Franssila K, et al: BCL 20verexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 90: 1168-1174, 1997.
PubMed
29) Visakorpi T, Hyytinen E, Koivisto P et al: In vitro amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9: 401-406, 1995.
PubMed
30) Quesnel B, Preudhomme C, Philippe N, et al: p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 85: 657-663, 1995.
PubMed
31) Johansson B, Mertens F, Mitelman F: Cytogenetic deletion maps of hematologic neoplasms: circumstancial evidence for tumor suppressor loci. Genes Chromsom. Cancer 8: 205-218, 1993.
 
32) Saltman DL, Dolganov GM, Warrington JA, et al: A physical map of 15 loci on human chromosome 5 q 23-q 33 by two-color fluorescence in situ hybridization. Genomics 16: 726-732, 1993.
 
33) Le Beau MM, Espinosa R, Neuman WL, et al: Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc. Natl. Acad. Sci. USA 90: 5484-5488, 1993.
PubMed
34) Fairman J, Wang RY, Liang H, et al: Translocations and deletions of 5q13. 1 in myelodysplasia and acute myelogenous leukemia. Evidence for a novel critical locus. Blood 88: 2259-2266, 1996.
PubMed
35) Neuman WL, Rubin C, Rios R, et al: Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders. Blood 79: 1501-1510, 1992.
PubMed
36) Johnson EJ, Scherer SW, Soborne L, et al: Molecular definition of a narrow interval at 7q22. lassociated with myelodysplasia. Blood 87: 3579-3586, 1996.
 
37) Le Beau MM, Espinosa III R, Davis EM, et al: Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 88: 1930-1935, 1996.
 
38) Vorechovsky I, Luo L, Dyer MJS, et al: Clustering of missense mutations in the ataxia-telangiectasia gene in asporadic T-cell leukemia. Nat. Genet. 17: 96-99, 1997.
 
39) Povirk LF, Shuker DE: DNA damage and mutagenesis induced by nitrogen mustards. Mutat. Res. 318: 205-226, 1994.
PubMed
40) Asimakopoulos FA, White NJ, Nacheva E, et al: Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 84: 3086-3094, 1994.
PubMed
41) Dohner H, Stilgenbauer S, James MR, et al: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89: 2516-2522, 1997.
PubMed
42) Brown Ag, Ross FM, Dunne EM, et al: Evidence for a new tumor suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. Nat. Genet. 3: 67-72, 1993.
 
43) Taniwaki M, Matsuda F, Jauch A, et al: Detection of 14q32 translocations in B-cell malignancies by in situ hybridization with yeast artificial chromosome clones containing the lgH gene locus. Blood 83: 2962-2969, 1994.
 
44) Nishida K, Tamura A, Nakazawa N, et al: The immunoglobulin heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90: 526-534, 1997.
PubMed
45) Chesi M, Nardin E, Brents LA, et al: Frequent translocations t (4;14) (p16. 3;q32. 3) in multiple myeloma is associated with increased expression and activating mutations of fibroblasts growth factor receptor 3. Nat. Genet. 16: 260-264, 1997.
 
46) Iida S, Rao PH, Butler M, et al: Deregulation of MUM 1/IRF 4 by chromosomal translocation in multiple myeloma. Nat. Genet. 17: 226-230, 1997.
 
47) Schrock E, du Manoir S, Veldman T, et al: Multicolor spectral karyotyping of human chromosomes. Science 273: 494-497, 1996.
PubMed
48) Speicher MR, Ballard SG, Ward DC: Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat. Genet. 12: 368-375, 1996.
 
49) Veldman T, Vignon C, Schrock E, et al: Hidden chromosomal abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat. Genet. 15: 406-410, 1997.
PubMed
50) Knutsen T, Veldman T, Padilla-Nash H, et al: Spectral karyotyping: Chromosomes in color. Applied Cytogenetics 23: 26-32, 1997.
 
51) Jenkins RB, Le Beau MM, Kraker WJ, et al: Fluorescence in situ hybridization: Asensitive method for trisomy 8 detection in bone marrow specimens. Blood 79: 3307-3315, 1992.
 
52) Tkachuk DC, Westbrook CA, Andreef M, et al: Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 250: 559-562, 1990.
 
53) Taniwaki M, Silverman GA, Nishida K, et al: Translocations and amplification of the BCL 2 gene are detected in interphase nuclei of non-Hodgkin 's lymphoma by in situ hybridization with yeast artificial chromosome clones. Blood 86: 1481-1486, 1995.
 
54) Kearney L, Watkins PC, Young BD, et al: DNA sequences of a chromosome 21 specific YAC detect the t (8;21) breakpoint of acute myelogeneous leukemia. Cancer Genet. Cytogenet. 57: 109-119, 1991.
 
55) Kearney L, Bower M, Gibbons B, et al: Chromosome 11q23 translocations in both infant and adult acute leukemias are detected by in situ hybridization with yeast artificial chromosome. Blood 80: 1659-1665, 1992.
PubMed
56) Taniwaki M, Nishida K, Ueda Y, et al: Interphase and metaphase detection of the breakpoint of 14 q 32translocations in B-cell malignancies by double-color fluorescence in situ hybridization. Blood 85: 3223-3228, 1995.
 
57) Lengauer C, Riethman HC, Speicher MR, et al: Metaphase and interphase cytogenetics with Alu-PCR-amplified yeast artificial chromosome clones containing the BCR gene and the protooncogenes c-raf-1, c-fms, and c-erbB-2. Cancer Res. 52: 2590-2596, 1990.
 
58) Stilgenbauer S, Doehner H, Bulgay-Moerschel M, et al: High frequency of monoallelic retinoblastoma gene deletion in B-cell chronic lymphoid leukemia shown by interphase cytogenetics. Blood 81: 2118-2124, 1993.
 
59) Doenher H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580-1589, 1995.
 
60) van den Engh G, Sachs R, Trasak BJ: Estimating genomic distance from DNA sequence location in cell nuclei by a random walk model. Science 257: 1410-1412, 1992.
 
61) Delattre O, Zucmans J, Plougastel B, et al: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165, 1992.
 
62) Sorensen PHB, Lessnick SL, Lopez-Terrada D, et al: Asecond Ewing 's sarcoma translocation, t (21;22) , fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 6: 146-151, 1994.
 
63) Zucman J, Delattre O, Desmaze C, et al: EWS and ATF-1 gene fusion induced by t (12;22) translocation in malignant melanoma of soft parts. Nat. Genet. 4: 341-345, 1993.
 
64) Crozat A, Aman P, Mandahl N, et al: Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363: 640-644, 1993.
PubMed
65) Clark J, Rocques PJ, Crew AJ, et al: Identification of novel genes, SYT and SSX, involved in the t (X;18) (P11. 2;q112) translocation found in human synovial sarcoma. Nat. Genet. 7: 502-508, 1994.
 
66) Galili N, Davis RJ, Fredericks WJ, et al: Fusion of a fork head domain gene to PAX 3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 5: 230-235, 1993.
 
67) Knudson AG Jr: Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 45: 1437-1443, 1985.
PubMed
68) Friend SH, Bernards R, Rogelj S, et al: Ahuman DNA segment with properties of the gene that predisposes to retino-blastoma and osteosarcoma. Nature 323: 643-646, 1986.
 
69) Call KM, Glaser T, Itto CY, et al: Isolation and characterization of a zinc finger polypeptide gene at human chromosome 11 Wilms tumor locus. Cell 60: 509-520, 1990.
 
70) Kinzler KW, Nibert MC, Su LK, et al: Identification of FAP locus genes from chromosome 5 q 21. Science 253: 661-665, 1991.
 
71) Cawthon RM, Weiss R, Xu G, et al: Amajor segment of the neurofibromatosis type I: cDNA sequence, genomic structure and point mutations. Cell 62: 193-201, 1990.
 
72) Trofatter JA, MacCollin MM, Rutter JL, et al: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72: 791-800, 1993.
PubMed
73) Miki Y, Swensen J, Ahsttuck-Eidens D, et al: Astrong candidate for the breast and ovarian cancer susceptibility gene BRCA 1. Science 266: 66-71, 1994.
 
74) Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276: 404-407, 1997.
PubMed
75) Collins F: Positional cloning moves from perditional to traditional. Nat. Genet. 9: 347-350, 1995.
PubMed
76) Kaghad M, Bonnet H, Young A, et al: Moneallelicaly expressed gene related to p 53 at 1 p 36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997.
 
77) Jost CA, Marin MC, Kaelin WJ Jr: P73 is a human P53-related protein that can induce apoptosis. Nature 389: 191-194, 1997.
 
78) Tanaka K, Miura N, Satokata I, et al: Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain. Nature 348: 73-76, 1990.
 
79) Legerski R, Peterson C: Expression cloning of a human DNA repair gene involved in xeroderma pigmentosum group C. Nature 359: 70-73, 1992.
 
80) Flejter WL, McDaniel LD, Johns D, et al: Correction of xeroderma pigmentosum complementation group Dmutant cell phenotypes by chromosome and gene transfer: Involvement of the human ERCC 2 DNA repair gene. Proc. Natl. Acad. Sci. USA 89: 261-265, 1992.
 
81) Scherly D, Nouspickel T, Corlet J, et al: Complementation of the DNA repair defect in xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD 2. Nature 363: 182-185, 1993.
 
82) Gibson RA, Buchwald M, Roberts RG, et al: Characterization of the exon structure of the Fanconi anaemia group C gene by vectorette PCR. Hum. Mol. Genet. 2: 35-38, 1993.
 
83) Savitsky K, Bar-Shira A, Gilad S, et al: Asingle ataxia telangiectasia gene with a product similar to PI-3kinase. Science 268: 1749-1753, 1995.
 
84) Ellis NA, Gorden J, Ye T-Z, et al: The Bloom 's syndrome gene product is homologous to RecQ helicase. Cell83: 655-666, 1995.
 
85) Yu C-E, Oshima J, Fu YH, et al: Positional cloning of the Werner 's syndrome gene. Science 272: 258-272, 1996.
 
86) Hashimoto N, Ichikawa D, Arakawa Y, et al: Frequent deletion of material from chromosome arm lp in oligodendroglial tumors revealed by double-target fluorescence in situ hybridization and microsatellite analysis. Genes Chromosom. Cancer 14: 295-300, 1995.
 
87) Ichikawa D, Hashimoto N, Hoshima M, et al: Analysis of numerical aberrations in specific chromosomes by fluorescence in situ hybridization (FISH) as a diagnostic tool in breast cancer. Cancer 77: 2065-2069, 1996.
 
P.129 掲載の参考文献
1) Weinberg RA: How cancer arises. Sci. Am. 275: 62-70, 1996.
PubMed
2) Vogelstein B, Kinzler K: The multistep nature of cancer. Trends Genet. 9: 138-141, 1993.
PubMed
3) Pawson T: Protein modules and signalling networks. Nature 373: 573-580, 1995.
PubMed
4) Hill CS, Treisman R: Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80: 199-211, 1995.
PubMed
5) Marshall CJ: MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. 4: 82-89, 1994.
PubMed
6) Cowley S, Paterson H, Kemp P, et al: Activation of MAP kinase kinase is necessary and sufficient for PC 12 differentiation and for transformation of NIH 3 T 3 cells. Cell 77: 841-852, 1994.
 
7) Mansour SJ, Matten WT, Hermann AS, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 2651966-970, 1994.
PubMed
8) Hsuan J, Tan S: Growth factor-dependent phosphoinositide signalling. Int. J. Biochem. Cell Biol. 29: 415-435, 1997.
PubMed
9) Kapeller R, Cantley L: Phosphatidylinositol 3-kinase. Bioessays 16: 565-576, 1994.
PubMed
10) Klippel A, Kavanaugh W, Pot D, et al: Aspecific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol, Cell. Biol. 17: 338-44, 1997.
 
11) Twamley-Stein G, Pepperkok R, Ansorge W, et al: The Src family tyrosine kinases are required for plateletderived growth factor-mediated signal transduction in NIH 3 T 3 cells. Proc. Natl. Acad. Sci. USA 90: 7696-7700, 1993.
 
12) Flynn D, Leu T, Reynolds A, et al: Identification and sequence analysis of cDNAs encoding a 110-kilodalton actin filament-associated pp 60 src substrate. Mol. Cell. Biol. 13: 7892-7900, 1993.
 
13) Shual K, Ziemiecki A, Wilks A, et al: Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 366: 580-583, 1993.
 
14) Chin YE, Kitagawa M, Su WC, et al: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p 21 WAF l/CIP l mediated by STAT 1. Science 272: 719-722, 1996.
 
15) Mansbridge JN, Ausserer WA, Knapp MA, et al: Adaptation of EGF receptor signal transduction to threedimensional culture conditions: changes in surface receptor expression and protein tyrosine phosphorylation. J. Cell Physiol. 161: 374-382, 1994.
 
16) Tzahar E, Waterman H, Chen X, et al: Ahierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16: 5276-5287, 1996.
 
17) Sawyers C, Denny C: Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell 77: 171-173, 1994.
 
18) Golub TR, Barker GF, Lovett M, et al: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t (5;12) chromosomal translocation. Cell 77: 307-316, 1994.
 
19) Golub TR, Goga A, Barker GF, et al: Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mo1, Cell. Biol. 16: 4107-4116, 1996.
 
20) Takahashi M: Oncogenic activation of the ret protooncogene in thyroid cancer. Crit. Rev. Oncog. 6: 35-46, 1995.
PubMed
21) Bos J: ras oncogenes in human cancer: areview (published erratum appears in Cancer Res. 1990 Feb 15;50 (4) : 1352) . Cancer Res. 49: 4682-4689, 1989.
 
22) Lowy D, Willumsen B: Function and regulation of ras. Annu. Rev. Biochem. 62: 851-891, 1993.
PubMed
23) Van Aelst LaDS-S C: Rho GTPases and signaling networks. Genes Dev. 11: 2295-2322, 1997.
 
24) Nobes C, Hall A: Rho, rac, and cdc 42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81: 53-62, 1995.
 
25) Kimura K, Ito M, Amano M, et al: Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rhokinase) (see comments) . Science 273: 245-248, 1996.
 
26) Amano M, Chihara K, Kimura K, et al: Formation of actin stress fibers and focal adhesions enhanced by Rhokinase. Science 275: 1308-1311, 1997.
 
27) Khosravi-Far R, Solski PA, Clark GJ, et al: Activation of Rac 1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell. Biol. 15: 6443-453, 1995
PubMed
28) Qiu RG, Chen J, Kirn D, et al: An essential role for Rac in Ras transformation. Nature 374: 457-459, 1995.
PubMed
29) Nakamura Y: Cleaning up on beta-catenin (news) . Nat. Med. 3: 499-500, 1997.
PubMed
30) Meredith JE Jr, Fazeli B, Schwartz MA: The extracellular matrix as a cell survival factor. Mol. Biol. Cell 4: 953-961, 1993.
PubMed
31) Bohmer R, Scharf E, Assoian R: Cytoskeletal integrity is required throughout the mitogen stimulation phase of the cell cycle and mediates the anchorage-dependent expression of cyclin D l. Mol. BioL Cell 7: 101-111, 1996.
 
32) Zhu X, Ohtsubo M, Bohmer R, et al: Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol. 1331391-403, 1996.
PubMed
33) Bottazzi MEaA RK: The extracellular matrix and mitogenic growth factors control G 1 phase cyclins and cyclin-dependent kinase inhibitors. Trends in Cell Biology 7: 348-352, 1997.
 
34) Steeg P, Abrams J: Cancer prognostics: past, present and p 27 (news;comment) . Nat. Med. 3: 152-154, 1997.
 
35) Kawada M, Yamagoe S, Murakami Y, et al: Induction of p 27 Kip 1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15: 629-637, 1997.
 
36) Hunter T: Oncoprotein networks. Cell 88: 333-346, 1997.
PubMed
P.147 掲載の参考文献
1) Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26: 239-257, 1972.
PubMed
2) Dini L, Coppola S, Ruzittu MT, et al: Multiple pathways for apoptotic nuclear fragmentation. Exp. Cell Res. 223: 340-347, 1996.
PubMed
3) Leist M, Single B, Kunstle G, et al: Apoptosis in the absence of poly- (ADP-ribose) polymerase. Biochem. Biophys. Res. Commun. 233: 518-522, 1997.
PubMed
4) Miura M, Zhu H, Rotello R, et al: Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75: 653-660, 1993.
 
5) Harvey NL, Butt AJ, Kumar S: Functional activation of Nedd2/ICH-1 (caspase-2) is an early process inapoptosis. J. Biol. Chem. 272: 13134-13139, 1997.
PubMed
6) Li H, Bergeron L, Cryns V, et al: Activation of caspase-2 in apoptosis. J. Biol. Chem. 272: 21010-21017, 1997.
PubMed
7) Keane RW, Srinivasan A, Foster LM, et al: Activation of CPP32 during apoptosis of neurons and astrocytes. J. Neurosci. Res. 48: 168-180, 1997.
PubMed
8) 杭田慶介: Caspaseとアポトーシス. 日癌会56回総会記: 22, 1997.
 
9) Kamada S, Washida M, Hasegawa J, et al: Involvement of caspase-4 (-like) protease in Fas-mediated apoptotic pathway. Oncogene 15: 285-290, 1997.
PubMed
10) Faleiro L, Kobayashi R, Fearnhead H, et al: Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J. 16: 2271-2281, 1997.
PubMed
11) Juan TS, McNiece IK, Argento JM, et al: Identification and mapping of Casp7, a cysteine protease resembling CPP32 beta, interleukin-1 beta converting enzyme, and CED-3. Genomics 40: 86-93, 1997.
PubMed
12) Muzio M, Chinnaiyan AM, Kischkel F, et al: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827, 1996.
PubMed
13) Cohen GM: Caspases: the executioners of apoptosis. Biochem. J. 32: 1-16, 1997.
 
14) Hu S, Vincenz C, Ni J, et al: 1-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD-g5-induced apoptosis. J. Biol. Chem. 272: 17255-17257, 1997.
 
15) Goltsev YV, Kovalenko AV, Arnold E, et al: CASH, a novel caspase homologue with death effector domains. J. Biol. Chem. 272: 19641-19644, 1997.
 
16) Inohara N, Koseki T, Hu Y, et al: CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc. Natl. Acad. Sci. USA 94: 10717-10722, 1997.
PubMed
17) Zou H, Henzel WJ, Liu X, et al: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413, 1997.
 
18) Didenko VV, Hornsby PJ: Presence of double-strand breaks with single-base 3 'overhangs in cells undergoing apoptosis but not necrosis. J. Cell Biol. 135: 1369-1376, 1996.
 
19) Gottlieb RA, Nordberg J, Skowronski E, et al: Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc. Natl. Acad. Sci. USA 93: 654-658, 1996.
PubMed
20) Khodarev NN, Ashwell JD: An inducible lymphocyte nuclear Ca2+/Mg2+-dependent endonuclease associated with apoptosis. J. Immunol. 156: 922-931, 1996.
PubMed
21) Shiokawa D, Ohyama H, Yamada T, et al: Purification and properties of DNase gamma from apoptotic rat thymocytes. Biochem. J. 326: 675-681, 1997.
PubMed
22) Khodarev NN, Ashwell JD: An inducible lymphocyte nuclear Ca2+/Mg (2+) -dependent endonuclease associated with apoptosis. J. Immunol. 156: 922-931, 1996.
PubMed
23) Sakahira H, Enari M, Magata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391: 96-99, 1998.
 
24) Perry DK, Smyth MJ, Stennicke HR, et al: Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J. BioL Chem. 272: 18530-18533, 1997.
PubMed
25) Schlegel J, Peters I, Orrenius S, et al: CPP32/apopain is a key interleukin 1 beta converting enzyme-like protease involved in Fas-mediated apoptosis. J. Biol. Chem. 271: 1841-1844, 1996.
PubMed
26) Yoon YS, Kim JW, Kang KW, et al: Poly (ADP-ribosyl) ation of histone HI correlates with internucleosomal DNA fragmentation during apoptosis. J. Biol. Chem. 271: 9129-9134, 1996.
 
27) Takahashi A, Musy PY, Martins LM, et al: CrmA/SPI-2 inhibition of an endogenous ICE-related protease responsible for lamin A cleavage and apoptotic nuclear fragmentation. J. Biol. Chem. 271: 32487-32490, 1996.
PubMed
28) Rao L, Perez D, White E: Lamin proteolysis facilitates nuclear events during apoptosis. J. Cell Biol. 135: 1441-1455, 1996.
PubMed
29) Takahashi A, Alnemri ES, Lazebnik YA, et al: Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recongnition properties are active in apoptosis. Proc. Natl. Acad. Sci. USA 93: 8395-8400, 1996.
PubMed
30) Orth K, Chinnaiyan AM, Garg M, et al: The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J. Biol. Chem. 271: 16443-16446, 1996.
PubMed
31) Weaver VM, Carson CE, Walker PR, et al: Degradation of nuclear matrix and DNA cleavage in apoptotic thymocytes. J. Cell Sci. 109: 45-56, 1996.
PubMed
32) Paddenberg R, Wulf S, Weber A, et al: Internucleosomal DNA fragmentation in cultured cells under conditions reported to induce apoptosis may be caused by mycoplasma endonucleases. Eur. J Cell Biol. 71: 105-119, 1996.
PubMed
33) Suda T, Nagata S: Purification and characterization of the Fas-ligand that induces apoptosis J. Exp. Med. 179: 873-879, 1994.
PubMed
34) Khan AA, Soloski MJ, Sharp AH, et al: Lymphocyte apoptosis: mediation by increased type 3 inositol 1, 4, 5-trisphosphate receptor. Science 273: 503-507, 1996.
PubMed
35) Vito P, Lacana E, D 'Adamio L: Interfering with apoptosis: Ca (2+) -binding protein ALG-2 and Alzheimer 's disease gene ALG-3. Science 271: 521-525, 1996.
 
36) Squier MK, Miller AC, Malkinson AM, et al: Calpain activation in apoptosis. J. Cell Physiol. 159: 229-237, 1994.
PubMed
37) Vincenz C, Dixit VM: Fas-associated death domain protein interleukin-1 beta Converting enzyme 2 (FLICE2) , an ICE/Ced-3 homologue, is proximally involved in CD95-and p55-mediated death signaling. J. Biol. Chem. 272: 6578-6583, 1997.
 
38) Bodmer JL, Burns K, Schneider P, et al: TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (Apo-1/CD95) . Immunity 6: 79-88, 1997.
PubMed
39) Kitson J, Raven T, Jiang YP, et al: Adeath-domain-containing receptor that mediated apoptosis. Nature 384: 372-375, 1996.
 
40) Screaton GR, Mongkolsapaya J, Xu XN, et al: TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7: 693-696, 1997.
PubMed
41) Ahmad M, Srinivasula SM, Wang L, et al: CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. Cancer Res. 57: 615-619, 1997.
PubMed
42) Irmler M, Thome M, Hahne M, et al: Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195, 1997.
PubMed
43) Thome M, Schneider P, Hofmann K, et al: Viral FHCE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386: 517-521, 1997.
 
44) Srinivasula SM, Ahmad M, Ottilie S, et al: FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J. Biol. Chem. 272: 18542-18545, 1997.
PubMed
45) Darmon AJ, Nicholson DW, Bleackley RC: Activation of the apoptotic protease CPP32 by cytotoxic T-cell-) derived granzyme B. Nature 377: 446-448, 1995
PubMed
46) Verheij M, Bose R, Lin XH: Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380: 75-79, 1996.
PubMed
47) Suntana P, Penal LA, Haimovitz-Friedman A, et al: Acid sphingomyelinase-deficient human lymphoblastosis and mice are defective in radiation-induced apoptosis. Cell 86: 189-199, 1996.
 
48) Chen X, Ko LJ, Jayarman L, et al: p53 levels, functional doma｛ns, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10: 2438-2451, 1996.
 
49) Bonfoco E, Krainc D, Ankarcrona M, et al: Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc. Natl. Acad. Sci. USA 92: 7162-7166, 1995.
PubMed
50) Saini KS, Thompson C, Winterford CM, et al: Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic beta cell line, INS-1. Biochem. Mol. Biol. Int. 39: 1229-1236, 1996.
 
51) Polyak K, Xia Y, Zweier JL, et al: Amodel for p53-induced apoptosis. Nature 389: 300-305, 1997.
 
52) Gorospe M, Cirielli C, Wang X, et al: p21 (Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14: 929-935, 1997.
PubMed
53) Sheikh MS, Chen YQ, Smith ML, et al: Role of p21 Wafl/Cip1/Sdil in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. Oncogene 14: 1875-1882, 1997.
 
54) Gomez-Manzano C, Fueyo J, Kyritsis AP, et al: Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J. Natl. Cancer Inst. 89: 1036-1044, 1997.
PubMed
55) Ohashi K, Nemoto T, Eishi Y, et al: Expression of the cyclin dependent kinase inhibitor p21 WAF1/CIPI in oesophageal squamous cell carcinomas. Virchows Arch. 430: 389-395, 1997.
 
56) Li WW, Fan J, Hochhauser D, et al: Overexpression of p21 wafl leads to increased inhibition of E2Pl phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res. 57: 2193-2199, 1997.
 
57) Englert C, Maheswaran S, Garvin AJ, et al: Induction of p21 by the Wilms 'tumor suppressor gene WT1. Cancer Res. 57: 1429-1434, 1997.
PubMed
58) Lill NL, Grossman SR, Ginsberg D, et al: Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-627, 1997.
PubMed
59) Jost CA, Marin MC, Kaelin WG: p73 is a human p53-related protein that can induce apoptosis. Nature 389: 191-194, 1997.
PubMed
60) Kimura Y, Furuhata T, Urano T, et al: Genomic structure and chromosomal localization of GML (GPIanchored molecule-like protein) , agene induced by p53. Genomics 41: 477-480, 1997.
 
61) Kimura Y, Furuhata T, Shiratsuchi T, et al: GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene 1511369-1374, 1997.
PubMed
62) Teoh G, Urashima M, Ogata A, et al: MDM2 protein overexpression promotes proliferation and survival ofmultiple myeloma cells. Blood 90: 1982-1992, 1997.
 
63) Chen L, Marechal V, Moreau J, et al: Proteolytic cleavage of the mdm20ncoprotein during apoptosis. J. Biol. Chem. 272: 22966-22973, 1997.
PubMed
64) Spengler D, Villalba M, Hoffmann A, et al: Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J. 16: 2814-2825, 1997.
PubMed
65) Liu X, Kim CN, Yang J, et al: Induction of apoptotic program in cell-tree extracts: requirement for dATP and cytochrome c. Cell 86: 147-157, 1996.
 
66) Li P, Nijhawan D, Budihardjo I, et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex inities an apoptotic protease cascade. Cell 91: 479-489, 1997.
 
67) Wang X, Studzinski GP: Antiapoptotic action of 1, 25-dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c. Exp. Cell Res. 235: 210-217, 1997.
PubMed
68) Hannun YA: Functions of ceramide in coordinating cellular responses to stress. Science 274: 1855-1859, 1997.
 
69) Susin SA, Zamzami N, Castedo M, et al: The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95 and ceramide-induced apoptosis. J. Exp. Med. 186: 25-37, 1997.
PubMed
70) Geley S, Hartmann BL, Kofler R: Ceramides induce a form of apoptosis in human acute lymphoblastic leukemia cells that is inhibited by Bcl-2, but not by CrmA. FEBS Lett. 400: 15-18, 1997.
 
71) Brenner B, Koppenhoefer U, Weinstock C, et al: Fas-or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of jun N-terminal Kinase/p38 kinases and GADD153. J. BioL Chem. 272: 22173-2281, 1997.
PubMed
72) De Maria R, Lenti L, Malisan F, et al: Requirement for GD3 ganglioside in CD95-and ceramide-induced apoptosis. Science 277: 1652-1655, 1997.
PubMed
73) Shirakabe K, Yamaguchi K, Shibuya H, et al: TAKI Mediates the Ceramide Signaling to Stress-activated Protein Kinase/c-Jun N-terminal Kinase. J. Biol. Chem. 272: 8141-8144, 1997.
 
74) Sawai H, Okazaki T, Takeda Y, et al: Ceramide-induced translocation of protein kinase C-delta and-epsilon to the cytosol. Implications in apoptosis. J. Biol. Chem. 272: 2452-2458, 1997.
PubMed
75) Mosser DD, Caron AW, Bourget L, et al: Role of the human heat shock protein hsp70 in protection against stressinduced apoptosis. Mol. Cell Biol. 17: 5317-5327, 1997.
 
76) Michael JM, Lavin MF, Watters DJ: Resistance to radiation-induced apoptosis in Burkitt 's lymphoma cells is associated with defective ceramide signaling. Cancer Res. 57: 3600-3605, 1997.
 
77) Chmura SJ, Nodzenski E, Beckett MA, et al: Loss of ceramide production confers resistance to radiationinduced apoptosis. Cancer Res. 57: 1270-1275, 1997.
 
78) Franke TF, Cantley LC: ABad Kinase makes good. Science 390: 116-117, 1997.
 
79) Cheng EH-Y, Kirsch DG, Clem RJ, et al: Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278: 1966-1968, 1997.
 
80) Hanada M, Aime Sempe C, Sato T, et al: Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J. Biol. Chem. 270: 11962-11969, 1995.
 
81) Reed JC, Zha H, Aime-Sempe C, et al: Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv. Exp. Med. Biol. 406: 99-112, 1996.
PubMed
82) Wang K, Yin XM, Chao DT, et al: BID: anovel BH3 domain-only death agonist. Genes Dev. 10: 2859-2869, 1996.
 
83) Hunter JJ, Parslow TG: Apeptide sequence from Bax that converts Bcl-2 into an activator of apoptosis. J. Bio1. Chem. 271: 8521-8524, 1996.
 
84) Kharbanda S, Pandey P, Schofield L, et al : Role for bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc. Natl. Acad. Sci. USA 94: 6939-6942, 1997.
PubMed
85) Kluck RM, Bossy-Wetzel E, Green DR, et al: The release of cytochrome c from mitochondria: aprimary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
 
86) Adachi S, Cross AR, Babior BM, et al: Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during fas-mediated apoptosis. J. Biol. Chem. 272: 21878-21882, 1997.
PubMed
87) Minn AJ, Velez P, Schendel SL, et al: Bcl-x (L) forms an ion channel in synthetic lipid membranes. Nature 385: 353-357, 1997.
PubMed
88) Schendel SL, Xie Z, Montal MO, et al: Channel formation by antiapoptotic protein Bcl-2. Proc. Natl. Acad. Sci. USA 94: 5113-5118, 1997.
PubMed
89) Antonsson B, Conti F, Ciavatta A, et al: Inhibition of Bax channel-forming activity by Bcl-2. Science 277: 370-372, 1997.
PubMed
90) Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
PubMed
91) Gura T: How TRAIL kills cancer cells, but not normal cells. Science 277: 768, 1997.
 
92) Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807- 810, 1994.
 
93) Aas T, Borrensen A-L, Geisler S, et al: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2: 811-814, 1996.
 
94) Suzuki A, Kato M: Chemotherapeutic agent CPT-11 induces the new expression of the apoptosis initiator to the cytoplasm. Exp. Cell Res. 227: 154-159, 1996.
PubMed
95) Shibata Y, Takiguchi H, Tamura K, et al: Stimulation of interleukin-1 beta-converting enzyme activity during growth inhibition by CPT-11 in the human myeloid leukemia ce田ine K562. Biochem. Mol. Med. 57: 25-30, 1996.
 
96) Seimiya H, Mashima T, Toho M, et al: c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J. Biol. Chem. 272: 4631-4636, 1997.
PubMed
97) Goldwasser F, Bae I, Fornace AJ Jr, et al: Differential GADD45, P21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Oncol. Res. 8: 317-323, 1996.
PubMed
98) Adjei PN, Kaufmann SH, Leung WY, et al: Selective induction of apoptosis in Hep 3B cells by topoisomerase Iinhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32. J. Clin. Invest. 98: 2588-2596, 1996.
 
99) Shimizu T, Pommier Y: Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia 11: 1238-1244, 1997.
PubMed
100) Suzuki A, Iwasaki M, Kato M, et al: Sequential operation of ceramide synthesis and ICE cascade in CPT-11-initiated apoptotic death signaling. Exp. Cell Res. 233: 41-47, 1997.
PubMed
101) Yoshida A, Takauji R, Inuzuka M, et al: Role of serine and ICE-like proteases in induction of apoptosis by etoposide in human leukemia HL-60 cells. Leukemia 10: 821-824, 1996.
PubMed
102) Martins LM, Kottke T, Mesner PW, et al: Activation of multiple interleukin-1 beta converting enzyme homologues in cytosol and nuclei of CL-60 cells during etoposide-induced apoptosis. J. Biol. Chem. 272: 7421-7430, 1997.
 
103) Chresta CM, Masters JR, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio. Cancer Res. 56: 1834-1841, 1996.
 
104) Skladanowski A, Larsen AK: Expression of wild-type p53 increases etoposide cytotoxicity in MI myeloidleukemia cells by facilitated G2 to M transition: implications for gene therapy. Cancer Res. 57: 818-823, 1997.
 
105) Sebestyen A, Mihalik R, Petak I, et al: Modulation of apoptosis signaling in etoposide-treated lymphoma cells. Anticancer Res. 17: 2609-2614, 1997.
PubMed
106) Kawamura K, Grabowski D, Krivacic K, et al: Cellular events involved in the sensitization of etoposideresistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem. Pharmacol. 52: 1903-1909, 1996.
PubMed
107) Huang TS, Shu CH, Shih YL, et al: Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett. 110: 77-85, 1996.
PubMed
108) Ibrado AM, Huang Y, Fang G, et al: Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ. 7: 1087-1094, 1996.
PubMed
109) Trielli MO, Andreassen PR, Lacroix FB, et al: Differential Taxol-dependent arrest of transformed and nontransformed cells in the Gl Phase of the cell cycle, and specific-related mortality of transformed cells. J. Cell Biol. 135: 689-700, 1996.
 
110) Blagosklonny MV, Schulte T, Nguyen P, et al: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56: 1851-1854, 1996.
 
111) Huang TS, Shu CH, Yang WK, et al: Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res. 57: 2974-2978, 1997.
PubMed
112) Lanni JS, Lowe SW, Licitra EJ, et al: P53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. USA 94: 9679-9683, 1997.
PubMed
113) Wahl AF, Donaldson KL, Fairchild C, et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2: 72-79, 1996.
PubMed
114) Zhang J, Alter N, Reed JC, et al: Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc. Natl. Acad. Sci. USA 93: 5325-5328, 1996.
PubMed
115) Arora AS, Jones BJ, Patel TC, et al: Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology 25: 958-963, 1997.
PubMed
116) Yu R, Shtil AA, Tan TH, et al: Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. Cancer Lett. 107: 73-81, 1996.
 
117) Cai Z, Stancou R, Korner M, et al: Impairment of Fas-antigen expression in adriamycin-resistant but not TNFresistant MCF7 tumor cells. Int. J. Cancer 68: 535-546, 1996.
 
118) Del Bufalo D, Biroccio A, Soddu S, et al: Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J. Clin. Invest. 98: 1165-1173, 1996.
PubMed
119) Datta R, Banach D, Kojima H, et al: Activation of the CPP32 protease in apoptosis induced by 1-beta-Darabinofuranosylcytosine and other DNA-damaging agents. Blood 88: 1936-1943, 1996.
 
120) Kim CN, Wang X, Huang Y, et al: Overexpression of Bcl-X (L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res. 57: 3115-3120, 1997.
PubMed
121) Enokido Y, Araki T, Aizawa S, et al: p53 involves cytosine arabinoside-induced apoptosis in cultured cerebellar granule neurons. Neurosci. Lett. 203: 1-4, 1996.
PubMed
122) Yoshida A, Ueda T: The mechanism of apoptosis induced by anticancer agents in human leukemia cells. Nippon Rinsho 54: 1822-1827, 1996.
PubMed
123) Guedez L, Suresh A, Tung F, et al: Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2. Eur. J. Haematol. 57: 149-156, 1996.
PubMed
124) Bullock G, Ray S, Reed JC, et al: Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein. Leukemia 10: 1731-1740, 1996.
PubMed
125) Dong J, Naito M, Tsurou T: c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells. Oncogene 15: 639-647, 1997.
 
126) Gallagher WM, Cairney M, Schott B, et al: Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14: 185-193, 1997.
PubMed
127) Vikhanskaya F, Clerico L, Valenti M, et al: Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53. Int. J. Cancer 72: 155-159, 1997.
 
128) Dixit M, Yang JL, Poirier MC, et al: Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J. Natl. Cancer Inst. 89: 365-373, 1997.
PubMed
129) Micheau O, Solary E, Hammann A, et al: Sensitization of cancer cells treated with cytotoxic drugs to fasmediated cytotoxicity. J. Natl. Cancer Inst. 89: 783-789, 1997.
 
130) Kalechman Y, Shani A, Dovrat S, et al: The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. J. Immunol. 156: 1101-1109, 1996.
 
131) Friesen C, Herr I, Krammer PH, et al: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in druginduced apoptosis in leukemia cells. Nat. Med. 2: 574-577, 1996.
 
132) Kawamura KI, Grabowski D, Weizer K, et al: Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. Br. J. Cancer 73: 183-188, 1996.
PubMed
133) Kinzler KW, Vogelstein B: Life (and death) in a malignant tumour. Nature 379: 19-20, 1996.
 
134) Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
PubMed
135) Shirai T, Shibata M, Takahashi S, et al: Differences in cell proliferation and apoptosis between reversible and irreversible mucosal lesions associated with uracil-induced urolithiasis in N-bytyl-N- (4-hydroxybutyl) nitrosamine-pretreated. Carcinogenesis 16: 501-505, 1995.
 
P.159 掲載の参考文献
1) Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344: 503-508, 1990.
PubMed
2) King RW, Jackson PK, Kirschner MW: Mitosis in transition. Cell 79: 563-571, 1994.
PubMed
3) Sherr C: Mammalian GI cyclins. Cell 73: 1059-1065, 1993.
 
4) Hunter T: Braking the cycle. Cell 75: 839-841, 1993.
PubMed
5) Sherr CJ: GI phase progression: Cycling on cue. Cell 79: 551-555, 1994.
 
6) Hunter T, Pines J: Cyclins and Cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
PubMed
7) De Bondt HL, Rosenblatt J, Jancarik J, et al: Crystal structure of cyclin-dependent kinase 2. Nature: 595-602, 1993.
PubMed
8) Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
PubMed
9) Nevins JR: E2F: alink between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429, 1992.
 
10) DePinho RA: The cancer-chromatin connection. Nature 391: 533-526, 1998.
PubMed
11) Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
PubMed
12) Prives C: How loops, b-sheets and a helices help us to understand p53. Cell 78: 839-841, 1994.
 
P.177 掲載の参考文献
1) Hanahan D, Folkman J: Patterns and everging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
PubMed
2) Fantanini G, Vignati S, Bigini D, et al: Neoangiogenesis: aputative marker of malignancy in non-small-cell lung cancer (NSCLC) development. Int. J. Cancer 67: 615-619, 1996.
 
3) Rac J, Filmus J, Kerbel RS: Reciprocal paracrine interactions between tumour cells and endothelial cells: the angiogenesis progression hypothesis. Eur. J. Cancer 14. 2438-2450, 1996.
 
4) Folkman J, Klagsburn M: Angiogenic factors. Science 235: 442-447, 1987.
 
5) Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84: 1875-1887, 1992.
PubMed
6) Polverini PJ, Leibovich SJ: Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophage. Lab. Invest. 51: 635-642, 1984.
PubMed
7) Shweiki D, Itin A, Soffer D, et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
PubMed
8) Forsythe JA, Jiang B, Lyer NN, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16: 4604-4613, 1996.
 
9) Ryuto M, Ono M, Izumi H, et al: Inducition of vascular endothelial growth factor by tumor necrosis factor a in human glioma cells. J. Biol. Chem. 271: 28220-28228, 1996.
 
10) Yoshida S, Ono M, Shono T, et al: Involvement of interleukin-8, vascular endothelial growth factor and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol. 17: 4015-4023, 1997.
PubMed
11) White FC, Carroll SM, Kamps MP: VEGFmRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors 12: 289-301, 1995.
 
12) Alon T, Hemo I, Itin A: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 18: 1024-1028, 1995.
 
13) Ferara N, Cavver-Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivaition of VEGF gene. Nature 380: 439-442, 1996.
 
14) Shalaby F, Rosant J, Yamaguchi TP, et al: Failure of blood-island formation and vasculogenesis in FIK-1 deficient mice. Nature 376: 62-66, 1995.
 
15) Fong GH, Rossant J, Gertsenstein M, et al: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995.
PubMed
16) Hori A, Sasada R, Matsutani E, et al: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 51: 6180-618, 1991.
PubMed
17) Czlbayko F, Smith RV, Chung HC, et al: Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factor. J. Biol. Chem. 269: 28243-28248, 1994.
 
18) Okamura K, Morimoto A, Hamanaka R, et al: Amodel system for tumor angiogenesis: involvement of transforming growth factor-α in tube formation of human microvascular endothelial cells induced by esophageal cancer cells. Biochem. Biophys. Res. Commun. 186: 1471-1479, 1992.
 
19) Cozzolino F, Torcia M, Aldinucci D, et al: Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc. Natl. Acad. Sci. USA 87: 6487-6491, 1990.
PubMed
20) Cozzolino F, Torcia M, Lucibello M, et al: Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J. Clin. Invest. 91: 2504-2512, 1993.
PubMed
21) Fukushi J, Morisaki T, Shono T, et al: Novel biological functions of interleukin-4: Formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo. Biochem. Biophys. Res. Commun. 250: 444-448, 1998.
PubMed
22) Shono T, Ono M, Izumi H, et al: Involvement of the transcription factor NF-πB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol. Cell. Biol. 16: 4231-4239, 1996.
 
23) Huang S, Xie K, Bucana CD, et al: Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin. Cancer Res. 2: 1969-1979, 1996.
PubMed
24) Sgadari C, Angiolillo AL, Tosato G: Inhibition of angiogenesis by interleukin-12 is mediated by the inerferoninducible protein 10. Blood 87: 3877-3882, 1996.
PubMed
25) Angiolillo AL, Kanegane H, Sgadari C, et al: Interleukin-15 promotes angiogenesis in vivo. Biochem. Biophys. Res. Commun. 233: 231-237, 1997.
PubMed
26) Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-inducedvascular responses. Cancer Res. 47: 5155-5161, 1987.
PubMed
27) Ezekoqitz RA, Mulliken JB, Folkman J: Interferon alfa-2 a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326: 1456-1463, 1992.
 
28) Yang EY, Moses HL: Transforming growth factor beta-l induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol. 111: 731-741, 1990.
 
29) Angiolillo AL, Sgadari C, Taub DD, et al: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182: 155-162, 1995.
PubMed
30) Gupta SK, Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 invovles a unique action on Sphase progression. J. Cell Biol. 127: 1121-1127, 1994.
 
31) Suri C, Jones PF, Pastan S, et al: Requisite role of angiopoietin-1, a ligand for the TIE 2 receptor, during embryonic angiogenesis. Cell 87: 1153-1155, 1996.
 
32) Davis S, Aldrich TH, Jones PF, et al: Isolation of angiopoietin-1, a ligand for the TIE 2 receptor, by secretiontrap exprssion cloning. Cell 87: 1153-1155, 1996.
 
33) Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie 2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
PubMed
34) Yeo T-K, Dvorac HF: Tumor-stroma. Diagnostic Immunopathology (ed. by Colvin RB, et al) , Raven Press. New York, 1995.
 
35) Castellani P, Viale G, Dorcaratto A, et al: The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59: 612-618, 1994.
PubMed
36) Zagzag D, Friedlander DG, Miller DC, et al: Tenascin expression in astorocytoma correlates with angiogenesis. Cancer Res. 55: 907-914, 1995.
 
37) Rogers SA, Padanilam BJ, Hruska KA, et al: Metanephric osteopontin regulates nephrogenesis in vitro. Am. J. Pathol. 272: 469-476, 1997.
 
38) Schwartz MA, Ingber D: Review: Integrating with integrins. Mol. Biol. Cell 5: 389-393, 1994.
PubMed
39) Brooks PC, Montgomery AM, Rosenfeld M, et al: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994.
PubMed
40) Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571, 1994.
PubMed
41) Liotta LA, Steeg PS, William G, et al: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
 
42) Ueno H, Nakamura H, Inove M, et al: Expression and tissue localization of membrane-types 1, 2 and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 57: 32055-2060, 1997.
 
43) Millauer D, Coughi MP, Plate KH, et al: Dominan-negative inhibition of Flk-1 suppress the growth of many tumor type in vivo. Cancer Res. 56: 1615-1620, 1996.
 
44) Strawn LM, Mcmahon G, App H, et al: Flk-1 as a target for tumor growth inhibitor. Cancer Res. 56: 3540-3545, 1996.
PubMed
45) Kendall RL, Wang G, Thomas KA, et al: Identification of a natural soluble form of the vascular endothelial growth factor receptor, Flt-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226: 324-338, 1996.
PubMed
46) Beigelman L, MsSwiggen JA, Draper KG, et al: Chemical modification of hummerhead ribozymes. J. Biol. Chem. 270: 25702-25708, 1995.
 
47) Czubayko F, L-Coopman EDE, Aigner A, et al: Asecreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat. Med. 3: 1137-1140, 1997.
 
48) O' Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: anovel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell79: 315-328, 1994.
 
49) Gately S, Twardowski P, Stack MS, et al: Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56: 4887-4890, 1996.
PubMed
50) Dong Z, Kumar R, Yang X, et al: Macrophage-derived metalloelastase is responsible for the generation of angiogenesis in Lewis lung carcinoma. Cell 88: 801-810, 1997.
 
51) O' Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogeneous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
 
52) Henrik Sandvad Rasmussen: Preclinical and early clinical data with batimastat and marimastat, two novel matrix metalloproteinase inhibitors. Proc. Angiogenesis Antagonists, 1996.
 
53) Maucer HJ, Hanna NN, Beckett MA et al: Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394: 287-291, 1998.
 
54) D ' Amato RJ, Loughman MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Aacd. Sci. USA 91: 4082-4085, 1994.
 
55) Klausner JD, Freedman VH, Kaplan G: Thalidomide as an anti-TNF-a inhibitor: implicaitions for clinical use. Clin. Immunol. Immunopathol. 81: 219-2234, 1996.
PubMed
56) Fine HA, Loeffler JS, Kyritsis A et al: Aphase I trial of the anti-angiogenic agent, thalidomide, in androgen independent prostate cancer. Proc. Am. Soc. Clin. Oncol. 16: 385 a, 1997.
 
57) AACR meeting Abst. ＃2721, 1996.
 
58) Liu S, Widom J, Kepm CW et al: Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282: 1324-1327, 1998.
 
59) Gutheil J, Campbell TN, Pierce PR et al: Phase l study of vitaxin, an anti-angiogenic humanized monoclonal antibody to vascular integrin｛alpha｝｛nu｝｛beta｝3. Proc. Am. Soc. Oncol. 17: 215 a, 1998.
 
60) Ezekowits A, Mulliken J, Folkman J: Additional corrections: interferon for hemangiomas of infancy. N. Engl. J. Med. 333: 595-596, 1995.
PubMed
61) Kohn EC, Reed E, Sarosy E, et al: Aclinical investigation of a cytotoxic calcium influx inhibitor in patients with refractory cancers. Cancer Res. 56: 569-573, 1996.
 
62) Voest EE, Kenyon BM, O'Reilly MS, et al: Angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87: 581-586, 1995.
 
63) Quinn TE, Thurman GB, Sundell AK, et al: CM 101, a polysaccharide antitumor agent does not inhibit wound healing in murine models. J. Cacner Res. Clin. Oncol. 121: 253-256, 1995.
PubMed
64) Taraboletti G, Garofalo A, Belotti D, et al: Inhibition of angiogenesis and murine hemangioma growth bybatimastat, a synthetic inhibitor of matrix metaloproteases. J. Natl. Cancer Inst. 87: 293-298, 1995.
 
65) Johnston MR, Mullen JBM, Pagura M et al: AG 3340, a novel metalloproteinase (MMP) inhibitor, decreases growth and metastases of orthotopic human lung cancer in a nude rat preclinical model system. Proc. Am. Ass. Cancer Res. 39: 302, 1998.
 
P.194 掲載の参考文献
1) Fidler IJ: Selection of successive tumor line for metastasis. Nature (New Biol.) 242: 148-149, 1973.
PubMed
2) Tsuruo T, Yamori T, Naganuma K, et al: Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma. Cancer Res. 43: 5437-5442, 1983.
PubMed
3) Morikawa K, Walker SM, Jessup JM, et al: ln vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res. 48: 1943-1948, 1988.
 
4) 入村達郎: 癌転移の分子機構-序論. 実験医学 7: 525-526, 1989.
 
5) Hart I, Fidler IJ: An in vitro quantitative assay for tumor cell invasion. Cancer Res. 38: 3218-3224, 1978.
 
6) Nicolson GL: Metastatic tumor cell attachment and invasion assay utilizing vascular endothelial cell monolayers. J. Ilistochem. Cytochem. 30: 214-220, 1982.
 
7) Kramer RH, Bensch KK, Wong J: Invasion of reconstituted basement-membrane matrix by metastatic tumor cells. Cancer Res. 46: 1080-1089, 1986.
 
8) Akedo H, Shinkai K, Mukai M, et al: Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: Amodel for tumor invasion, Cancer Res. 46: 2416-2422, 1986.
 
9) del Regata JA: Pathways of metastatic spread of malignant tumors. Semin. Oncol. 4: 33-38, 1977.
 
10) Fisher B, Fisher ER: The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg. Gyneco1. Obstet. 122: 791-798, 1966.
PubMed
11) Harmanek P, Sobin LH: TNM Classification of Malignant Tumors. 4th Ed, Springer-Verlag, Berlin, 1987.
 
12) Ewing J: A Treatise on Tumors. 3rd Ed, WB Saunders, Philadelphia, 1920.
 
13) Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573, 1989.
 
14) Zeidman I, Buss JM: Experimental studies on the spread of cancer in the lymphatic system: effectiveness of the lymph node as a barrier to the passage of emnonic tumor cells. Cancer Res. 14: 403-410, 1954.
PubMed
15) Berg JW, Huvos AG, Axtell LM, et al: Anew sign of favorable prognosis in mammary cancer: hyperplastic reactive lymph nodes in the apex of the axilla. Ann. Surg. 177: 8-15, 1973.
 
16) Hill RP: Metastasis. In The Basic Science of Oncology (ed by Tannock IF, Hill RP) , Pergamon Press, New York, 1987, pp. 160-175.
 
17) Tarin D, Price JE: Influence of microenvironment and vascular anatomy on "metastatic" colonization potential of mammary tumors. Cancer Res. 41: 3604-3609, 1981.
PubMed
18) Hart IR, Fidler IJ: Role of organ selectivity in the determination of metastasis pattern of B 16 melanoma. Cancer Res. 41: 1282-1287, 1981.
 
19) Nicolson GL: Organ specificity of tumor metastasis: role of preferential adhesion, invasion, and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev. 7: 143-188, 1988.
PubMed
20) Hujanen ES, Terranova VP: Migration of tumor cells to organ-derived chemoattractants. Cancer Res. 45: 3517-3521, 1985.
PubMed
21) Yamori T, Iida H, Tsukagoshi S, et al: Growth stimulating activity of lung extract on lung-extract on lungcolonization clone 26 clones and its partial-characterization. Clin. Exp. Metastasis 6: 131-139, 1992.
 
22) Sugarbaker EV: Patterns of metastasis in human malignancy. Cancer Biol. Rev. 2: 235-278, 1981.
 
23) Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893-895, 1977.
PubMed
24) Glaves D: Correlation between circulating cancer cells and incidence of metastasis. Br. J. Cancer 48: 665-673, 1983.
PubMed
25) Glaves D, Huben RP, Weiss L: Haematogenous dissemination of cells from human renal adenocarcinomas. Br. J. Cancer 57: 32-35, 1988.
PubMed
26) Fialkow PJ: The origin and development of human tumors studied with cell markers. N. Engl. J. Med. 291: 26-35, 1974.
PubMed
27) Vogelstein B, Fearon ER, Hamilton SR, et al: Clonal analysis using recombinant DNA probes from the Xchromosome. Cancer Res. 47: 4806-4813, 1987.
 
28) Nowell PC: Mechanisms of tumor progression. Cancer Res. 48: 2203-2207, 1988.
 
29) Nicolson GL: Tumor cell instability, diversification, and progression to the metastatic phenotype: From oncogene to oncofetal expression. Cancer Res. 47: 1473-1487, 1987.
PubMed
30) Feron ER, Vogelstein B: Agenetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
 
31) Dear TN, Kefford RF: Molecular oncogenetics of metastasis. Mol. Aspects Med. 11: 243-324, 1990.
PubMed
32) Dear TN, Ramshow JA, Kefford RF: Differential expression of a novel gene, WDNM 1, in nonmetastatic rat mammary adenocarcinoma cells. Cancer Res. 48: 5203-5209, 1989.
 
33) Dear TN, McDonald DA, Kefford RF: Transcriptional down-regulation of a rat gene, WDNM 2, in metastatic DNMBA-8 cells. Cancer Res. 49: 5323-5328, 1989.
 
34) Phillips SM, Bendal AJ, Ramshow IA: Isolation of gene associated with high metastatic potential in rat mammary adenocarcinoma. J. Natl. Cancer Inst. 82: 199-203, 1990.
 
35) Sharp MGF, Adama SM, Elvin P, et al: Asequence previously identified as metastasis-related encodes an acidic ribosomal phosphoprotein, P 2. Br. J. Cancer 61: 83-88, 1990.
 
36) Tulchinsky EM, Grigorian MS, Ebralidze AK, et al: Stracture of gene mts 1, transcribed in metastatic mouse tumor cells. Gene 87: 219-225, 1990.
 
37) Pencil SD, Toh Y, Nicolson GL: Candidate metastasis-associated genes of the rat 1376 NF mammary adenocarcinoma. Breast Cancer Res. Treat. 25: 165-174, 1993.
 
38) Toh Y, Pencil SD, Nicolson GL: Anovel candidate metastasis-associated gene, mtα 1, differentially expressed in highly metastatic mammary adenocarcinoma cell line. J. Biol. Chem. 268: 22958-22967, 1994.
 
39) Habets GGM, Scholtes EHM, Zuydeest D, et al: Identification of an invasive-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for rho-like protein. Cell 77: 537-546, 1994.
 
40) Steeg PS, Bevilacqua G, Kopper L, et al: Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Cancer Inst. 80: 200-204, 1988.
PubMed
41) Dong JT, Lamb PW, Rinker-Schaeffer CW, et al: KAI I, a metastases suppressor gene for prostate cancer on human chromosome ll p 11. 2. Science 268: 884-886, 1995.
 
42) Fidler IJ: Critical factors in the biology of human cancer metastasis. Cancer Res. 50: 6130-6138, 1990.
PubMed
43) Morikawa K, Walker SM, Nakajima M, et al: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res. 48: 6863-6871, 1988.
PubMed
44) Nicolson GL: Cancer progression and growth: Relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp. Cell Res. 202: 171-180, 1993.
 
45) Liotta LA, Steeg PS, Stetler-Stevenson GW: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
 
46) Weidner N, Semple Jp, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in breast carcinoma. N. Engl. J. Med. 324: 1-8, 1991.
PubMed
47) Weidner LA, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143: 401-409, 1993.
 
48) Maeda K, Chung Y, Takatsuka S, et al: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J. Clin. Oncol. 13: 477-481, 1995.
PubMed
49) Weiss L, Ward PM: Cell detachment and rnetastasis. Cancer Metastasis Rev. 2: 111-127, 1983.
PubMed
50) Behrens J, Mareel MM, Van Roy FM, et al: Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J. Cell Biol. 108: 2435-2447, 1989.
PubMed
51) Frixen UH, Behrens J, Sachs M, et al: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. 113: 173-185, 1991.
 
52) Vleminckx K, Vakaet L, Mareel M, et al: Genetic manupulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor. Cell 66: 107-119, 1991.
 
53) Shimoyama Y, Nagafuchi A, Fujita S, et al: Cadherin dysfunction in a human cancer cell line: Possible involvement of loss ofα-catenin expression in reduced cell-cell adhesiveness. Cancer Res. 52: 5770-5774, 1992.
 
54) Hirano S, Kimoto N, Shimoyama Y, et al : Identification of a neural α-catenin as a key regulator of cadherin function and multicellular organization. Cell 70: 293-301, 1992.
 
55) Anderssen AM, Moran N, Gaardavoll H, et al: Characterization of NCAM expression and function in BT 4 C and BTCn glioma cells. Int. J. Cancer 47: 124-129, 1991.
 
56) Eghbali B, Kessler JA, Reid LM, et al: Involvement of gap junctions in tumorigenesis: Transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc. Natl. Acad. Sci. USA 88: 10701-10705, 1991.
PubMed
57) Bechimal S, Fuks A, Jothy S: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57: 327-334, 1989.
PubMed
58) Inohara H, Raz A: Functional evidence that cell surface Galectin-3 mediates homotipic cell adhesion. Cancer Res. 55: 3267-3271, 1995.
 
59) Ligtenberg MJL, Buijs F, Vos HL, et al: Suppression of cellular aggregation by high levels of episialin. Cancer Res. 52: 2318-2324, 1992.
 
60) Shimoyama Y, Hirohashi S: Expression of E-and P-cadherin in gastric carcinomas. Cancer Res. 51: 2185-2192, 1991.
 
61) Shiozaki H, Tahara H, Oka H, et al: Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am. J. Pathol. 139: 17-23, 1991.
PubMed
62) Schipper JH, Frixen UH, Behrens J, et al: E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res. 51: 6328-6337, 1991.
PubMed
63) Umbas R, Isaacs WB, Aalders TW, et al: Decreased expression of E-cadherin in high grade prostate cancer. Cancer Res. 52: 5104-5108, 1992.
PubMed
64) Rasbridge SA, Gillet CE, Sampson SA, et al: Epithelial (E-) add placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J. Pathol. 169: 245-250, 1993.
 
65) Bringuier PP, Umbas R, Schaafama HE, et al: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 53: 3241-3245, 1993.
 
66) Mattijssen V, Peters HM, Schalkwijk L, et al: E-cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int. J. Cancer 55: 580-585, 1993.
PubMed
67) Shiozaki H, Iihara K, Oka H, et al: Immunohistochemical detection ofα-catenin expression in human cancer. Am. J. Pathol. 144: 1-8, 1994.
 
68) Jessup JM, Homas P: Carcinoembryonic antigen: function in metastasis by human colorectal carcinoma. Cancer Metastasis Rev. 8: 263-280, 1989.
 
69) Zotter S, Philomena CH, Lossnitzer A, et al: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev. 11-2: 55-101, 1988.
 
70) Nakamori S, Ota DM, Cleary KR, et al: MUC l mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106: 353-361, 1994.
 
71) Liotta LA: Tumor invasion and metastases-Role of the extracellular matrix. Cancer Res. 46: 1-7, 1986.
 
72) Fidler IJ: Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iod-2'-deoxyuridine. J. Natl. Cancer Inst. 45: 773-782, 1970.
 
73) Hill RP, Young SD, Cillo D, et al: Metastatic cell phenotypes: Quantitative studies using the experimental metastasis assay. Cancer Rev. 5: 118-151, 1986.
 
74) Hilgard P: Anticoagulants and tumor growth: Pharmacological consideration. In: Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects (ed by Nicolson GL, Milas L) , Raven Press, New York, 1984, pp. 353-360.
 
75) Gasic GJ: Role of plasma, platelets and endothelial cells and incidence of metastasis. Cancer Metastasis Rev. 3: 665-673, 1983.
 
76) Tsuruo T, Kawabata H, Iida H, et al: Tumor-induced platelet aggregation and growth promoting factors as determinants for successful tumor metastasis. Clin. Exp. Metastasis 4: 25-33, 1986.
PubMed
77) Handa K, Nudelman E, Striud MR, et al: Selectin GMP-140 (CD 62 ; PADGEM) binds to sialosyl-Lex and sialosyl-Lea, and sulfated glycans modulate this binding. Biochem. Biophys. Res. Commun. 181: 1223-1230, 1991.
 
78) Magnani JL, Nilsson BO, Brockhaus M, et al: Amonoclonal antibody-defined antigen associated with gastrointestinal cancer in aganglioside containing sialylated lacto-N-fucopentaose II. J. Biol. Chem. 257: 14365-14369, 1982.
 
79) Fukishima K, Hirota M, Terasaki PI, et al: Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer Res. 44: 5279-5285, 1984.
 
80) Ruoslahti E, Gianocotti FG: Integrins and tumor cell dissemination. Cancer Cells 1: 119-126, 1989.
 
81) Haynes BF, Liao HX, Patton KL: The transmembrane hyaluronate receptor (CD 44) : Multiple functions, multiple forms. Cancer Cells 3: 347-350, 1991.
 
82) Hanna N: Role of natural killer cells in host defense against cancer metastasis. In Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects (ed by Nicolson GL, Milas L) , Raven Press, New York, 1984, pp. 309-319.
 
83) Springer TA, Laskey LA: Sticky sugars for selectins. Nature 349: 196-197, 1991.
 
84) Kramer RH, Nicolson GL: Interactions of tumor cells with vascular endothelial cell monolayers: Amodel for metastatic invasion. Proc. Natl. Acad. Sci. USA 76: 5704-5708, 1979.
 
85) Springer TA: Adhesion receptor of immune system. Nature 346: 425-434, 1990.
 
86) Lawrence MB, Springer TA: Leukocytes roll on a selectin at physiologic flow rates: Distinct from and prerequisite for adhesion through integrins. Cell 65: 859-873, 1991.
 
87) Stetler-Stevenson WG, Aznavvrian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9: 541-573, 1993.
 
88) Skinner MP, Lucas CM, Burns GF, et al: GMP-140 binding to neutrophils is inhibited by sulfated glycans. J. Biol. Chem. 266: 5371-5374, 1991.
PubMed
89) Hynes RO: Integrins: Afamily of cell surface receptors. Cell 48: 549-554, 1987.
 
90) Hynes RO: Integrins: Versatility, modulation, signaling in cell adhesion. Cell 69: 11-25, 1992.
PubMed
91) Rice GE, Bevilacqua MP: An inducible endothelial cell surface glucoprotein mediates melanoma adhesion. Science 246: 1303-1306, 1989.
 
92) Takada A, Ohmori K, Yoneda Y, et al: Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 53: 354-361, 1993.
 
93) Izumi Y, Taniuchi Y, Tsuji T, et al: Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: Liver colonization and adhesion to vascular endothelial cells. Exp. Cell Res. 216: 215-221, 1995.
PubMed
94) Sacchi A, Falcioni R, Kennel SJ, et al: Ligand-induced phosphorylation of murine tumor surface protein (TSP-1) associated with metastasis phenotype. Cancer Res. 49: 2615-2620, 1989.
 
95) Chan BM, Matsuura N, Hemler ME, et al: ln vitro and in vivoconsequences of VLA-2 expression on rabdomyosarcomas cells. Science 251: 1600-1602, 1991.
 
96) Humphries MJ, Olden K, Yamada KM: A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma. Science 233: 467-470, 1986.
PubMed
97) Nakamori S, Kameyama M, Imaoka S, et al: Increased expression of sialyl lewisxantigen correlates with poor survival in patients with colorectal carcinoma: Clinicopathological and immunohistochemical study. Cancer Res. 53: 3632-3637, 1993.
 
98) Nakayama T, Watanabe M, Katsumata T, et al: Expression of sialyl Lewisa as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 75: 2051-2056, 1995.
 
99) Nakamori S, Furukawa H, Hiratsuka M, et al: Expression of carbohydrate antigen sialyl Lea: Anew functional prognostic factor in gastric cancer. J. Clin. Oncol. 15: 816-825, 1997.
 
100) Narita T, Funahashi H, Satoh Y, et al: Association of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer 71: 3044-3049, 1993.
PubMed
101) Kawai T, Suzuki M, Kase K, et al: Expression of carbohydrate antigens in human pulmonary adenocarcinoma. Cancer 72: 1581-1587, 1993.
PubMed
102) Albelda SM, Mette SA, Buck CA, et al: Integrin distribution in malignant melanoma: association of theβ3 subunit with tumor progression. Cancer Res. 50: 6757-6764, 1990.
 
103) Kramer RH, Vu M, Cheng YF, et al: Integrin expression in malignant melanoma. Cancer Metastasis Rev. 10: 115-128, 1991.
 
104) Tomita Y, Saito T, Saito K, et al: Possible significance of VLA-4 (α4β1) for hematogenous metastasis of renal-cell cancer. Int. J. Cancer 60: 753-758, 1995.
 
105) Fujita S, Watanabe M, Kubota T, et al: Alteration of expression in integrin p 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett. 91: 145-149, 1995.
PubMed
106) Jalkanen S, Bargatze RF, de los Toyos J, et al: Homing receptors and the control of lymphocyte recognition. Immunol. Rev. 91: 39-60, 1986.
 
107) Aruffo A, Stamenkovic I, Melnick M, et al: CD 44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313, 1990.
 
108) Heider K-H, Hofmann M, Hors E, et al: AHuman homologue of the rat-metastasis-associated variant of CD 44 is expressed in colorectal carcinomas and adenomatous polyps. J. Cell Biol. 120: 227-233, 1993.
 
109) Hofmann M, Rudy W, Zoller M, et al: CD 44 splice variant of glycoprotein confer metastatic behavior in rat. Cancer Res. 51: 5292-5297, 1991.
 
110) Gunthert U, Hofman M, Rudy W, et al: Anew variant of glycoprotein CD 44 confer metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
 
111) Rudy W, Hofmann M, Scfwartz-Albeyz R, et al: The two major CD 44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res. 53: 1262-1268, 1993.
 
112) Matsumura Y, Tarin D: Significance of CD 44 gene products for cancer diagnosis and disease evaluation. Lancet 340: 1053-1058, 1992.
 
113) Tanabe KT, Ellis LM, Daya H: Expression of CD 44 R 1 adhesion molecule in colon carcinoma and metastasis. Lancet 341: 725-726, 1993.
 
114) Mayer B, Jauch KW, Gunthert U, et al: De-novo expression of CD 44 and survival in gastric cancer. Lancet 342: 1019-1022, 1993.
 
115) Mackay CR, Terpe HJ, Stauder R, et al: Expression and modulation of CD 44 variant isoforms in humans. J. Cell Biol. 124: 71-72, 1994.
 
116) Raz A, Lotan R: Endogenous galactoside-binding lectins: anew class of functional cell surface molecules related to metastasis. Cancer Metastasis Rev. 6: 433-452, 1987.
 
117) Senger DR, Galli SJ, Dvorak AM, et al: Tumor cell secrete a vascular permeability factor that promote accumulation of ascites fluid. Science 219: 983-985, 1983.
 
118) Honn KV, Tang DG, Grossi I, et al: Tumor cell-derived 12 (S) -hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Res. 54: 565-574, 1994.
PubMed
119) Stoolman LM: Adhesion molecules controlling lymphocyte migration. Cell 56: 907-910, 1989.
PubMed
120) Khokha R, Denhardt DT: Matrix metalloproteinases and tissue inhibitor of metalloproteinases: areview of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9: 391-405, 1989.
 
121) Nakajima M, Chop AM: Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin. Cancer Biol. 2: 115-127, 1991.
PubMed
122) Sato H, Takino T, Okada Y, et al: Amatrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65, 1994.
 
123) Khokha R, Waterhouse P, Yagel S, et al: Anti-sense RNA-induced reduction in murine TIMP leveles confers oncogenicity in Swiss 3 T 3 cells. Science 243: 947-950, 1989.
 
124) Lah TT, Kokalj-Kunovar M, Strukelj B, et al: Stefins and lysosomal cathepsins B, L, and D in human breast carcinoma. Int. J. Cancer 50: 36-44, 1992.
 
125) Zucker S, Lysik RM, Zarrabi MH, et al: Mr 92, 000 collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 53: 140-146, 1993.
 
126) Shuja S, Sheehan K, Murnane MJ: Cystein endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int. J. Cancer 49: 341-346, 1991.
 
127) Nomura H, Sato H, Seiki M, et al: Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55: 3263-3266, 1995.
PubMed
128) Tandon AK, Clark GM, Chamness GC, et al: Cathepsin D and prognosis in breast cancer. N. Engl. J. Med. 322: 297-302, 1990.
PubMed
129) Fabra A, Nakajima M, Bucana CD, et al: Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice. Differentiation 52: 101-110, 1992.
 
130) Kolega J: Effects of mechanical tension on protrusive activity and microfilament and intermediate filament organization in an epidermal epithelium moving in culture. J. Cell Biol. 102: 1400-1411, 1986.
 
131) Aznavoorian SA, Stracke ML, Krutzsch H, et al: Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J. Cell Biol. 110: 1427-1438, 1990.
 
132) McCarthy JB, Hager SJ, Furcht LTF: Human fibronectin contains distinct adhesion-and motility promoting domains for metastatic melanoma cells. J. Cell Biol. 102: 179-188, 1986.
 
133) Mensing H, Albini A, Krieg T, et al: Enhanced chemotaxis of tumor-derived and virus-transformed cells to fibronectin and fibroblast conditioned medium. Int. J. Cancer 33: 43-48, 1985.
 
134) McCarthy JB, Basara ML, Palm SL, et al: The role of cell adhesion proteins laminin and fibronectin in the movement of malignant and metastatic cells. Cancer Metastasis Rev. 4: 125-152, 1985.
PubMed
135) Stoker M, Gherardi E: Regulation of cell movement: The mitogenic cytokines. Biochem. Biophys. Acta 1072: 81-102, 1991.
 
136) Liotta LA, Mandler R, Murano G, et al: Tumor cell autocrine motility factor. Proc. Natl. Acad. Sci. USA 83: 3302-3306, 1986.
PubMed
137) Grey AM, Schor AM, Rushton G, et al: Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts. Proc, Natl. Acad. Sci. USA 86: 2438-2422, 1989.
PubMed
138) Weidner KM, Arakaki N, Hartmann G, et al: Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. USA 88: 7001-7005, 1991.
PubMed
139) Stracke ML, Krutzsch HC, Unsworth EJ, et al: Identification, purification, and partial sequence analysis of Autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267: 2524-2529, 1992.
 
140) Wang M, Stearns M: Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S. C. I. D. mice. Differentiation 48: 115-121, 1991.
 
141) Watanabe H, Carmi P, Hogan V, et al: Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J. Biol. Chem. 266: 13442-13448, 1991.
PubMed
142) Wang M, Steans M, Stearns ME: Identification of the receptor for a novel Mr 78, 000“lnvasion stimulating factor”from metastatic human prostatic PC-3 ML clones. Cancer Res. 54: 2492-2495, 1994.
 
143) Guiruis R, Schiffman E, Liu B, et al: Detection of autocrine motility factor in urine as a marker of bladder cancer. J. Natl. Cancer Inst. 12: 1203-1211, 1988.
 
144) Picard M, Schor S, Grey AM, et al: Migration-stimulating activity in serum of breast cancer patients. Lancet 337: 130-133, 1991.
 
145) Otto T, Birchmeier W, Schmit U, et al: Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinoma. Cancer Res. 54: 3120-3123, 1994.
 
146) Nakamori S, Watanabe H, Kameyama M, et al: Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer 74: 1855-1862, 1994.
PubMed
147) Hamada J, Cavanaugh PG, Lotan O, et al: Separable growth and migration factors for large Cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br. J. Cancer 66: 349-353, 1992.
PubMed
148) Isoai A, Giga-Hama Y, Shinkai K, et al: Purification and characterization of tumor invasion-inhibiting factors. Jpn. J. Cancer Res. 81: 909-914, 1990.
PubMed
149) Cerra RF, Nathanson SD: Organ-specific chemotactic factors present in lung extracellular matrix. J. Surg. Res. 46: 422-426, 1989.
PubMed
150) Miyake M, Hakomori S: A specific cell surface glycoconjugate controlling cell motility: Evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry 340: 3328-3334, 1991.
 
151) Schaller MD, Borgman CA, Cobb BS, et al: pp 125 FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc. Natl. Acad. Sci. USA 89: 5192-5196, 1992.
 
152) Hanks SK, Calalb MB, Harper MC, et al: Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc. Natl. Acad. Sci. USA 89: 8487-8491, 1992.
PubMed
153) Guan JL, Shalloway D: Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature 358: 690-692, 1992.
PubMed
154) Weiner TM, Liu ET, Craven R, et al: Expression of focal adhesion kinase gene and invasive cancer. Lancet 342: 1024-1025, 1993.
PubMed
155) Nobes CD, Hall A: Rho, Rac, and cdc 42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81: 53-62, 1995.
 
156) Nakamori S, Yoshioka K, Kameyama M, et al: Increased expression of RHOAp 21 protein is involved in progression and metastasis of colorectal carcinoma. In: Recent Advances in Gastroenterological Carcinogenesis I (ed by Tahara E, Sugimachi K, Oohara T) , Monduzzi Editore, Bologna, 1996, pp. 901-904.
 
157) Schabel FM: Concepts for systemic treatment of micrometastasis. Cancer 35: 15-24, 1975
 
158) Fidler IJ: The evolution of biological heterogeneity in metastatic neoplasms. In: Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects (ed by Nicolson GL, Milas L) , Raven Press, New York, 1984, pp. 5-30.
 
159) Nicolson GL: Cancer metastasis ; Tumor cell and host organ properties important in metastasis to specific secondary sites. Biochem. Biophys. Acta 948: 175-224, 1988.
PubMed
160) Yamori T, Iizuka Y, Takayama Y, et al: Insulin-like growth factor I induces tyrosine phosphorylation of a Mr 150, 000and Mr 160, 000 protein in highly metastatic mouse colon carcinoma 26 NL-17 cells. Cancer Res. 51: 5859-5865, 1991.
 
161) Folkman J: Tumor angiogenesis: Apossible control point in tumor growth. Ann. Intern. Med. 82: 96-100, 1975.
 
162) Holmgren L, Michael SO, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1: 149-153, 1995.
 
163) Noguchi S, Aihara T, Nakamori S, et al: The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 74: 1595-1600, 1994.
PubMed
164) Schoenfeld A, Luqmani Y, Smith D, et al: Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 54: 2986-2990, 1994.
PubMed
165) Hayashi N, Arakawa H, Nagase H, et al: Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res. 54: 3853-3856, 1994.
PubMed
166) Mori M, Mimorti K, Inoue H, et al: Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res. 55: 3417-3420, 1995.
 
167) Sasaki A, Boyce BF, Story B, et al: Bisphonate risedrate reduces metastatic human breast cancer in bone in nude mice. Cancer Res. 55: 355-3557, 1995.
 
168) Yamaoka M, Yamamoto T, Sudo K, et al: Inhibition of tumor growth and metastasis of rodent tumor by the angiogenesis inhibitor O- (choroacetyl-carbamoyl) fumagillol (TNP-470 ; AGM-1470) . Cancer Res. 53: 4262-4267, 1993.
 
169) Tanaka T, Konno H, Baba S, et al: Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res. 55: 836-839, 1995.
PubMed
170) Iishi H, Tatsuta M, Baba M, et al: Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Int. J. Cancer 63: 716-719, 1995.
PubMed
P.213 掲載の参考文献
1) 首藤紘一, 橋本祐一 (編) : 発癌と制癌の化学. 広川書店, 東京, 1990.
 
2) 穂積本男, 高久史麿 (編) : 癌細胞の分化誘導と制癌. ソフトサイエンス社, 東京, 1985.
 
3) 穂積本男, 斉藤政樹, 佐藤光信 (編) : 癌細胞の分化誘導とアポトーシス. 共立出版, 東京, 1995.
 
4) Collins K, Jacks T, Pavletich NP: The cell cycle and cancer. Proc. Natl. Acad. Sci. USA 94: 2776-2778, 1997.
PubMed
5) Maeda M, Ichikawa Y: Spontaneous development of macrophage-like cells in aculture ofof myeloid leukemia cells. Gann 64: 265-271, 1970.
 
6) Ichikawa Y: Differentiation of acell line of myeloid leukemia. J Cell Physiol. 74: 223-234, 1969.
 
7) Lotem J, Sachs L: Induction of specific changes in the surface membrane of myeloid leukemic cells by steroid hormones. Int. J. Cancer 15: 731-740, 1975.
PubMed
8) Friend C, Scher JG, Holland, JG et al: Hemoglobin synthesis in murine virus induced leukemic cells in vitro: Stimulation of erythroid differentiation by dimethyl sulfoxide. Proc. Natl. Acad. Sci. USA 68: 378-382, 1971.
 
9) Wessely O, Deiner EM, Beug H, et al : The glucocorticoid receptor is a key regulator of the decision between self-renewal and differentiation in erythroid progenitors. EMBO J. 16: 267-280, 1997.
PubMed
10) Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334, 1975.
PubMed
11) Nakajima O, Kagechika H, Shudo K, et al: Possible involvement of retinoid-like cofactor in serum in hemin/protoporphyrin IX-induced differentiation of human leukemia K 562 cells. Biochem. Biophys. Res. Commum. 206: 1003-1010, 1995.
 
12) Collins SJ, Gallo RC, Gallagher RE: Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature 270: 347-349, 1977.
 
13) Koeffler HP, Golde DW: Acute myelogenous leukemia: ahuman cell line responsive to colony-stimulating activity. Science 200: 1153-1154, 1978.
 
14) Collins SJ, Ruscetti FW, Gallagher RE, et al: Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc. Natl. Acad. Sci. USA 75: 2458-2462, 1978.
PubMed
15) Breitman TR, Selonick SE, Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) , by retinoic acid. Proc. Natl. Acad. Sci. USA 77: 2936-2940, 1980.
PubMed
16) Heberman E, Callaham MF: Induction of terminal differentiation in human promyelocytic leukemia cells bytumor-promoting agents. Proc. Natl. Acad. Sci. USA 76: 1293-1297, 1979.
 
17) Miyaura C, Abe E, Kuribayashi T, et al: 1α, 25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commum. 101: 1131-1138, 1981.
 
18) Ball ED, Guyre PM, Shen L, et al: Gamma interferon induces monocytoid differentiation in the HL-60 cell line. J. Clin. Invest. 73: 1072-1077, 1984.
 
19) Strickland S, Mahdavi V: The induction of differentiation in teratocarcinomas stem cells by retinoic acid. Cell 15: 393-403, 1978.
PubMed
20) "The Retinoids", 2nd ed,. eds. Sporn MB, Roberts AB, Goodman DS, Raven Press l994.
 
21) 首藤紘一 (編) : 「レチノイド」. 橋本祐一, 講談社サイエンティフィク, 1992.
 
22) Huang M, Ye Y, Chen S, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
PubMed
23) Evans RM l The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1988.
 
24) Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 83: 841-850, 1996.
 
25) Weihua X, Kolla V, Kalvakolanu DV: Modulation of interferon action by retinoid. J. Biol. Chem. 272: 9742-9748, 1997.
PubMed
26) Cippitelli M, Ye J, Viggiano V, et al: Retinoic acid-induced transcriptional modulation of the human interferon-γpromoter. J. Biol. Chem. 271: 26783-26793, 1996.
 
27) Stoecklin E, Wissler M, Gouilleux F, et al: Functional interactions between STAT 5 and the glucocorticoid receptor. Nature 383: 726-728, 1996.
 
28) Verma A, Nye JS, Snyder SH: Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc. Natl. Acad. Sci. USA 84: 2256-2260, 1987.
PubMed
29) Nakajima O, Hashimoto Y, Iwasaki S: Possible involvement of peripheral-type benzodiazepine receptor inerythroid differentiation of human leukemia cell line, K 562. Biol. Pharm. Bull. 18: 903-906, 1995.
 
30) Weiss B, Sachs L: Indirect induction of differentiation in myeloid leukemic cells by lipid A. Proc. Natl. Acad. Sci. USA 75: 1374-1378, 1978.
PubMed
31) Imashuku S, Fossett MC III., Green AA: Characterization of adenosine cyclic 3 ': 5 '-monophosphate-binding proteins in human neuroblastoma. Cancer Res. 39: 3006-3013, 1979.
 
32) Hsie AW, Puck TT: Morphological transformation of chinese hamster cells by adenosine cyclic 3 ': 51-monophosphate and testosterone. Proc. NatL Acad. Sci. USA 68: 358-361, 1971.
 
33) Itoh T, Miura K, Miki H, et al: β-Tubulin binds Src homology 2 domains through a region different from the thyrosine-phosphorylated protein-recognizing site. J. Biol. Chem. 271: 27931-27935, 1996.
 
34) Nakajima O, Sugishita Y, Hashimoto Y, et al: Increase in the chemically induced differentiation of human leukemia cell lines by tubulin disruptors. Biol. Pharm. Bull. 17: 742-744, 1994.
PubMed
35) Honma Y, Kasukabe T, Hozumi M: lnhibition of differentiation of cultured mouse myeloid leukemia cells by nonsteroidal antiinflammatory agents and counteraction of the inhibition by prostaglandin E. Cancer Res. 39: 2190-2194, 1979.
 
36) riffin J, Munroe D, Major P, et al: Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp. Hematol. 10: 774-781, 1982.
 
37) Lotem J, Sachs L: Regulation of normal differentiaion in mouse and human myeloid leukemia cells by phorbol esters and the mechanism of tumor promotion. Proc. Natl. Acad. Sci. USA 76: 5158-5162, 1979.
 
38) Tomida M, Yamamoto Y, Hozumi M: Induction by synthetic polyribonucleotide poly (1) of differentiation of cultured mouse myeloid leukemic cells. Cell Differ. 7: 305-312, 1978.
 
39) Okabe J, Hayashi M, Honma Y, et al: Induction of differentiation of cultured mouse myeloid leukemic cells by arginase. Biochem. Biophys. Res. Commum. 89: 879-884, 1979.
 
40) Okabe-Kado J, Honma Y, Hayashi M, et al: Effects of histone fractions on induction of differentiation of cultured mouse myeloid leukemia cells. Cancer Lett. 41: 1997-2002, 1981.
 
41) Mizoguchi H, Fukasawa H, Steuernagel A, et al: Specific binding of 12-O-tetra-decanoylphorbol-13-acetate to histone H 1. Biol. Pharm. Bull. 17: 1114-1117, 1994.
 
42) Schults TF, Spiker S, Quatrano RS: Histone H l enhances the DNA binding activity of transcription factor EmBP-1. J. Biol. Chem. 271: 25742-25745, 1996.
 
43) Liu Y, Lee MO, Wang HG, et al: Retinoic acid receptor 6 mediates the grwoth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 16: 1138-1149, 1996.
 
44) Lopez-Boado YS, Klaus M, Dawson M, et al: Retinoic acid-induced expression of apolipoprotein D andconcomitant growth arrest in human breast cancer cells are mediated through a retinoic acid receptor RAR α-dependent signaling pathway. J. Biol. Chem. 271: 32106-32111, 1996.
 
45) Wu Q, Li Y, Liu R, et al: Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur 77 and COUP-TF and their heterodimerization. EMBO J. 16: 1656-1669, 1997.
 
46) O'Malley B: The steroid receptor superfamily: More excitement predicted for the future. Mol. Endocrino1. 4: 363-369, 1990.
 
47) Hashimoto Y, Shudo K: Retinoids and their nuclear receptors. Cell Biol. Rev. 25: 209-230, 1991.
 
48) Forman BM, Samuels HH: Interactions among a subfamily of nuclear hormone receptors: The regulatory zipper model. Mol. Endocrinol. 4: 1293-1301, 1990.
PubMed
49) Kurokawa R, Soederstroem M, Hoerlein A, et al: Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377: 451-454, 1995.
 
50) Hoerlein AJ, Naar AM, Heizel T, et al: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear co-repressor. Nature 377: 397-404, 1995.
 
51) Chen AD, Evans RM: Atranscriptional co-repressor that interacts with nuclear hormone receptors. Nature377: 454-457, 1995.
 
52) Dawson MI, Elstner E, Kizaki M, et al: Myeloid differentiation mediated through retinoic acid receptor/retinoid
PubMed
53) Xreceptor (RXR) not RXR/RXR pathway. Blood 84: 446-452, 1994. Boltling J, Castro DS, Oeberg F, et al: Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation. J. Biol. Chem. 272: 9443-9449, 1997.
 
54) Tontonoz P, Singer S, Forman BM, et al: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activatied receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 94: 237-241, 1997.
 
55) Magy L, Kao HY, Chakracatri D, et al: Nuclear receptor repression mediated by a complex containing SMRT, mSin 3 A, and histone deacetylase. Cell 89: 373-380, 1997.
 
56) Torchia J, Rose DW, Inostroza J, et al: The transcriptional co-activator p/CIP binds CBP and mediated nuclearreceptor function. Nature 387: 677-684, 1997.
 
57) Heery M, Kalkhoven E, Hoare S, et al: Asignature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 3871733-736, 1997.
 
58) Bourguet W, Ruff W, Chambon P, et al: Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375: 377-382, 1995.
 
59) Renaud JP, Rochel N, Ruff M, et al: Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378: 681-689, 1995.
 
60) Gu W, Shi X, Roeder RG: Synergistic activation of transcription by CBP and p 53. Nature 387: 819-823, 1997.
 
61) Lill NL, Grossman SR, Gonsberg D, et al: Binding and modulation of p 53 by p 300/CBP coactivators. Nature 387: 823-827, 1997.
 
62) Houle B, Leduc F, Bradley WEC: Implication of RARB in epidermoid (squamous) lung cancer. Genes Chromosom. Cancer 3: 358-366, 1991.
 
63) de The H, Chomienne C, Lanotte M, et al: The t (15: 17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptorαgene to a novel transcribed locus. Nature 347: 558-561, 1990.
 
64) Brown D, Kogan S, Lagasse E, et al: APMLRARαtransgene initiate murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94: 2552-2556, 1997.
 
65) 橋本祐一, 首藤紘一: PML-RARαの機能. 血液・腫瘍科 30: 74-78, 1995.
 
66) Dyck JA, Maul GG, Miller WH Jr, et al: Anovel macromolecular structure is a target of the promyelocyteretinoic acid receptor oncoprotein. Cell 76: 333-347, 1994.
 
67) Everett RD, Meredith M, Orr A, et al: Anovel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16: 1519-1530, 1997.
 
68) Abe E, Miyaura C, Sakagami H, et al: Differentiation of mouse erythroid leukemia cells by 1 a, 25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 78: 4990-4994, 1981.
 
69) Metcalf D, Moore MAS, Warner NL: Colony formation in vitro by myelomonocytic leukemia cells. J. Natl. Cancer Inst. 43: 983-997, 1969.
 
70) Metcalf D: Clonal analysis of the action of GM-CSF on the proliferation and differentiation of myelomonocytic leukemia cells. Int. J. Cancer 24: 616-623, 1979.
PubMed
71) Moore MAS, Gabrilove J, Sheridan AP: Myeloid leukemic cell differentiation induced by human postendotoxin serum and vitamin analogues. Haematol. Bluttansfus. 28: 327-337, 1983.
 
72) Cooper PC, Metcalf D, Burgess A: Biochemical and functional characterization of mature progeny purified from amyelomonocytic leukemia cell line. Leukemia Res. 6: 313-327, 1982.
PubMed
73) Gamba-Vitalo C, Blair OC, Tritton TR, et al: Cytotoxicity and differentiating actions of adriamycin in WEHI-3BD+leukemia cells. Leukemia 1: 188-197, 1987.
 
74) Marks P, Rifkind RA: Erythroleukemic differentiation. Ann. Rev. Biochem. 47: 419-448, 1978.
PubMed
75) Clarke GD, Ryan PJ: Tranquillizers can block mitogenesis in 3 T 3 cells and induce differentiation of Friend cells. Nature 287: 160-161, 1980.
 
76) Hozumi M: Fundamentals of chemotherapy of myeloid leukemia by induction of leukemia cell differentiation. Adv. Cancer Res. 38: 111: 169, 1983.
 
77) Andersson LC, Jokinen M, Gahmberg CG: Induction of erythroid differentiation in the human leukaemia cell line K 562. Nature 278: 364-365, 1979.
 
78) Hozumi M: Anew approach to chemotherapy of myeloid leukemia cells by inducer of normal differentiation. Cancer Biol. Rev. 3: 153-211, 1982.
 
79) Koeffler HP, Bar-Eli M, Territo MC: Phorbol ester effect on differentiation of human myeloid leukemia cell lines blocked at different stages of maturation. Cancer Res. 41: 919-926, 1981.
PubMed
80) Gianni AM, Presta M, Polli E, et al: In "Advances in Red Blood Cell Biology", Raven Press, 1982, pp. 279-287.
 
81) Minowada J: In "Human Lymphocyte Differentiation", INSERM SYMP No. 8, eds. Serrou B, Rosenfeld C, Elsevier Press, 1978, pp. 337-344.
 
82) Sundstroem C, Nilsson K: Establishment and characterization of ahuman histocytic lymphoma cell line (U-937) . Int. J. Cancer 17: 565-577, 1976.
 
83) Olsson IL, Breitman TR: Induction of differentiation of the human histocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3 ': 5 '-monophosphate-inducing agents. Cancer Res. 42: 3924-3927, 1982.
 
84) Olsson I, Gullberg U, Ivhed I, et al: Induction of differentiation of the human histiocytic lymphoma cell line U-937by 1α, 25-dihydroxycholcalciferol. Cancer Res. 43: 5862-5867, 1983.
 
85) Tsuchiya S, Yamabe M, Yamaguchi Y, et al: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1) . Int. J. Cancer 26: 171-176, 1980.
PubMed
86) Ohta M, Furukawa Y, Ide C, et al: Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-1, -S, -M and-K) with capabilities of monocyte-macrophage lineage differentiation and constitutive production of interleukin 1. Cancer Res. 46: 3067-3074, 1986.
 
87) Artzt K, Dubois P, Bennett D, et al: Surface antigens common to mouse cleavage embryos and primitive teratocarcinoma cells in culture. Proc. Natl. Acad. Sci. USA 70: 2988-2992, 1973.
PubMed
88) Hu F, Lesney PF: The isolation and cytology of two pigment cell strains from B 16 mouse melanomas. Cancer Res. 24: 1634-1643, 1964.
 
89) Oikawa A, Nakayasu M: Stimulation of melanogenesis in cultured melanoma cells by calciferols. FEBS Lett. 42: 32-35, 1974.
PubMed
90) Green H, Kehinde O: Sublines of mouse 3T3 cells that accumulate lipid. Cell 1: 113-116, 1974.
 
91) Rubin CS, Hirsch A, Fung C, et al: Development of hormone receptors and hormonal responsiveness in vitro: Insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-LI cells. J. Biol. Chem. 253: 7570-7578, 1978.
 
92) Sudo H, Kodama H, Amagai Y, et al: In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J. Cell Biol. 96: 191-198, 1983.
 
93) Sidell N: Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J. Natl. Inst. 68: 589-596, 1981.
 
94) Pahlman S, Odelstad L, Larsson E, et al: Phenotypic changes of human neuroblastoma cells in culture induced by 12-0-tetradecanoylphorbol-13-acetate. Int. J. Cancer 28: 583-589, 1981.
 
95) Littauer UZ, Palfrey C, Kimhi Y, et al: Induction of differentiation in mouse neuroblastoma cells. Natl. Cancer Inst. Monogr. 48: 333-337, 1978.
PubMed
96) Ishii DN, Maniatis GM: Haemin promotes rapid neurite outgrowth in cultured mouse neuroblastoma cells. Nature 274: 372-374, 1978.
PubMed
97) Sandquist D, Williams TH, Sahu SK, et al: Morphological differentiation of a murine neuroblastoma clone in monolayer culture induced by dexamethasone. Exp. Cell Res. 113: 375-381, 1978.
PubMed
98) Prasad KN: Differentiation of neuroblastoma cells in culture. Biol. Rev. 50: 129-265, 1975.
PubMed
99) Rizzino A, Crowley C: Growth and differentiation of embryonal carcinoma cell line F 9 in defined media. Proc. atl. Acad. Sci. USA 77: 457-461, 1980.
 
P.232 掲載の参考文献
1) Parkin DM, Whelan SL, Ferlay J, et al (eds) : Cancer Incidence in Five Continents, Vol. VII. IAR Scientific Publication No. 143, IARC, Lyon, 1997.
 
2) 花井 彩, 藤本伊三郎: 日本のがん罹患率とその推移. がん・統計白書-罹患/死亡/予後-1993 (富永祐民, 青木國雄, 花井 彩・他編) , 篠原出版, 東京, 1993, pp. 107-144.
 
3) 北川貴子, 津熊秀明, 大島 明・他: 1992年 (平成4年) 全国がん罹患数, 罹患率の推定. 地域がん登録の精度向上と活用に関する研究平成8年度研究班報告書 (大島明編) , 1997, pp. 32-44.
 
4) 黒石哲生, 広瀬加緒瑠, 田島和雄・他: 日本におけるがん死亡 (1950-1990) . がん・統計白書-罹患/死亡/予後-1993 (富永祐民, 青木國雄, 花井 彩・他編) , 篠原出版, 東京, 1993, pp. 1-105.
 
5) 厚生統計協会 (編) : 国民衛生の動向. 臨時増刊44 (9) : 50-59, 1997.
 
6) 北川貴子, 津熊秀明, 花井 彩・他: 1975-89年の全国罹患率 (推計値) に基づくがん罹患の将来推計. 厚生の指標43: 10-18, 1996.
 
7) Parkin DM, Muir CS, Whelan SL, et al (eds) : Cancer Incidence in Five Continents, Vol. VI. IARC Scientific Publication No. 120, IARC, Lyon, 1992.
 
8) 津熊秀明, 村上良介, 花井 彩・他: わが国における大腸癌の疫学. 外科57: 1-7, 1995.
 
9) 津熊秀明, 花井 彩, 北川貴子・他: 乳がん罹患の動向. CRC 2: 618-625, 1993.
 
10) Shimizu H, Mack TM, Ross RK, et al: Cancer of the gastrointestinal tract among Japanese and white immigrants in Los Angeles County. J. Natl. Cancer. Inst. 78: 223-228, 1987.
 
11) 藤本伊三郎, 花井 彩, 日山與彦・他 (編) : 大阪府におけるがんの罹患と死亡1963-1989. 篠原出版, 東京, 1993.
 
12) Fraumeni Jr JF, Devesa SS, Hoover RN, et al: Epidemiology of Cancer. Cancer, Principles&Practice of Oncology (ed by DeVita Jr VT, Hellman S, Rosenberg ST) , 4th Ed, Lippincott Company, Philadelphia, 1993, pp. 150-181.
 
13) Higgison J, Muir CS, Munoz N: Human Cancer: Epidemiology and Environmental Causes. Cambridge Monographs on Cancer Research. Cambridge University Press, New York, 1992.
 
14) 大島 明, 津熊秀明, 味木和喜子・他 (編) : 大阪府におけるがん患者の生存率の動向1975-89年. 篠原出版, 東京, 1998.
 
15) Hennekens CH, Buring JE: Epidemiology in Medicine. Little, Brown and Company, Boston, 1987.
 
16) Rothman KJ, Greenland S: Modern Epidemiology. Lippincott-Raven, Philadelphia, 1998.
 
17) Monson RR: Occupational Epidemiology. CRC Press, Florida, 1980, pp. 93-103.
 
P.242 掲載の参考文献
1) Knudson AG: Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68: 820-823, 1971.
PubMed
2) 山本 雅: がん遺伝子とがん抑制遺伝子. 南江堂, 東京, 1996.
 
3) Akiyama Y, Sato H, Yamada T, et al: Germline mutation of the hMSH 6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 5713920-3923, 1997.
 
4) Palombo F, Iaccarino I, Nakajima E, et al: hMutSβ, a heterodimer of hMSH 2 and hMSH 3, binds to insertion/deletion loops in DNA. Curr. Biol. 6: 1181-1184, 1996.
 
5) Oto M, Miyake S, Yuasa Y: Optimization of nonradioisotopic single strand conformation polymorphism analysis with a convention minislab gel electrophoresis apparatus. Anal. Biochem. 213: 19-22, 1993.
 
6) Akiyama Y, Iwanaga R, Saitoh K, et al: Transforming growth factor-βtype II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer patients. Gastroenterology 112: 33-39, 1997.
 
7) Fodde R, Luijt RVD, Wijnen J, et al: Eight novel inactivating getm line mutations at the APC gene identified by denaturing gradient gel electrophoresis. Genomics 13: 1162-1168, 1992.
 
8) Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J. Clin. Oncol. 14: 1730-1736, 1996.
 
9) Lu S-L, Akiyama Y, Nagasaki H, et al: Loss or somatic mutations of hMSH 20ccur in hereditary nonpolyposis colorectal cancers with hMSH 2 germline mutations. Jpn. J. Cancer Res. 87: 279-287, 1996.
PubMed
10) Konishi M, Kikuchi-Yanoshita R, Tanaka K, et al: Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 111: 307-317, 1996.
PubMed
P.252 掲載の参考文献
1) Old LJ: Cancer immunology: The search for specificity-G. H. A. Clowes memorial lecture. Cancer Res. 41: 361-375, 1981.
 
2) Lloyd KO, Old LJ: Iluman monoclonal antibodies to glycolipids and other carbohydrate antigens: Dissection of the human immune response in cancer patients. Cancer Res. 49: 3445-3451, 1989.
PubMed
3) Itoh K, Platsoucas CD, Balch CM: Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and the involvement of the T cell receptor. J. Exp. Med. 168: 1419-1441, 1988.
 
4) Knuth A, Wolfel T, Klehmann E, et al: Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of the antigens by immunoselection. Proc. Natl. Acad. Sci. USA 86: 2804-2808, 1989.
PubMed
5) Anichini A, Mazzocchi A, Fossati G, et al: Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and Mechanisms of interaction. J. ImmunoL 142: 3692-3701, 1989.
PubMed
6) Bjorkman PJ, Saper MA, Samraoui B, et al: Structure of the human class I histocompatibility antigen, HLAA2. Nature 329: 506-512, 1987.
 
7) Townsend ARM, Rothbard J, Gotch FM, et al: The epitopes of influenza nucleoprotein recognized by cytotoxic Tlymphocytes can be defined with short synthetic peptides. Cell 44: 959-968, 1986.
 
8) Cox ALJ, Skipper Y, Chen RA, et al: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716, 1994.
 
9) Van der Bruggen P, Traversari C, Chomez P, et al: Agene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1697, 1991.
 
10) Brichard VA, Van Pel T, Wolfel C, et al: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A 2 melanomas. J. Exp. Med. 178: 489, 1993.
 
11) Kawakami Y, Eliyahu S, Delgaldo CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91: 3515-3519, 1994.
 
12) Kawakami Y, Eliyahu S, Sakaguchi K, et al: Identification of the immunodominant peptides the MART-1 human melanoma antigen recognized by the maj ority of HLA-A 2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352, 1994.
 
13) Van den Eynde BJ, Van den Bruggen P: Tcell defined Tumor antigens. Curr. Opin. Immunol. 9: 684-693, 1997
 
14) Jung S, Schluesener HJ: Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J. Exp. Med. 173: 273-276, 1991.
 
15) Skipper J, Stauss HJ: Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J. Exp. Med. 177: 1493-1498, 1993.
PubMed
16) Fenton RG, Taub DD, Kwak LW, et al: Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras prote-oncogenes. J. Natl. Cancer. Inst. 85: 1294-1302, 1993.
 
17) Peace DJ, Smith JW, Chen W, et al: Lysis of ras oncogene-transformed cells by specific cytotoxic Tlymphocytes elicited by primary in vitro immunization with mutated ras peptide. J. Exp. Med. 179: 473-479, 1994.
 
18) Ioannides C, Fisk B, Fan D, et al: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell. Immunol. 151: 225-245, 1993.
PubMed
19) Yoshino I, Peoples GE, Goedegebuure PS, et al: Association of HER 2/neu expression with sensitivity to tumor specific CTL in human ovarian cancer. J. Immunol. 152: 2393-2399, 1994.
 
20) Fisk B, Blevins TL, Wharton JT, et al: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181: 2109-2117, 1995.
 
21) Carl HJ, Mahmood T, Hans W, Hakan M.: Rational use of biological response modifiers in hematological malignancies-A review of treatment with interferon, cytotoxic cells and antibodies. Leuk. Res. 13: 1039-1046, 1989.
 
22) 高橋利忠, 上田龍三: 15. 単クローン抗体の治療への応用. がんと生体防御 (徳永徹編) , 東京大学出版会, 東京, 1994, pp190-203.
 
23) Byers VS, Rodvien R, Grant K, et al: Phase I study monoclonal antibody-ricin a chain immunotoxin xomazyme-791 in patients with metastatic colon cancer. Cancer Res. 49: 6153-6160, 1989.
PubMed
24) Scott AM, Welts: Antibody-based immunological therapies. Curr. Opini. Immunol. 9: 717-722, 1997.
 
25) Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B 1 radio immunotherapy for B-cell lymphoma. J Clin. Oncol. 14: 1974-1981, 1996.
 
26) Caron PC, Jurcic JG, Scott AM, et al: APhase IB trial of humanized monoclonal antibody M 195 (anti-CD 33) in myeloid leukemia: specific targeting without immunogenicity. Blood 83: 1760-1768, 1994.
 
27) Rosenberg SA: The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10: 180-199, 1992.
 
28) Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologoustumor-infiltrating lymphocytes and interleukin 2. J. Nat1. Cancer Inst. 86: 1159-1166, 1994.
 
P.260 掲載の参考文献
1) 菊地浩吉: 序論. 新病理学総論 (菊地浩吉, 吉木敬編) , 南山堂, 東京, 1993, pp. 1-13.
 
2) 前田 盛: 分子病理学. 病理と臨床 5: 2, 1997.
 
3) Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal tumor development. N. Engl. J. Med. 319: 525-532, 1988.
PubMed
4) Yasui W, Yokozaki H, Tahara E: Molecular diagnosis of gastrointestinal cancer. In "Molecular Pathology of Gastroenterological Cancer: Application to Clinical Practice" (ed. by Tahara E) . Springer-Verlag, Tokyo, 1997, pp. 187-207.
 
5) Fujimori T, Satonaka K, Yamamura-Ideki Y, et al: Non-involvement of ras-mutations in flat colorectal adenomas and carcinomas. Int. J. Cancer 56: 1-5, 1994.
 
6) Shimamoto F, Tanaka S, Tahara E: Pathogenesis of serrated adenoma of the colorectum: Implication for malignant progression. In "Molecular Pathology of Gastroenterological Cancer: Application to Clinical Practice" (ed. by Tahara E) . Springer-Verlag, Tokyo, 1997, pp. 93-106.
 
7) 安井 弥, 田原榮一: 蛋白質解析 (ウェスタンブロット法, Immunohistochemistry) . 分子生物学的アプローチによる癌研究プロトコール (横田 淳, 山本 雅編) . 羊土社, 東京, 1995, pp. 108-115.
 
8) 渡辺慶一, 中根一穂: 酵素抗体法改訂3版, 学術企画, 東京, 1992.
 
9) 尾上 均, 山崎 大, 磯崎耕次・他: in situ hybridization法. 遺伝子工学実験法 (渋谷正史, 横田崇編) , 中外医学社, 東京, 1994, pp. 319-328.
 
10) Radinsky R, Bucana CD, Ellis LM, et al: Arapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res. 53: 937-943, 1993.
 
11) 安西春幸: EGF受容体のin situ hybridization法による検出. [続]がんの浸潤・転移研究マニュアル (がん転移研究会編) , 金芳堂, 京都, 1997, pp. 229-231.
 
12) 松原謙一, 吉川 寛 (監修) : FISH実験プロトコール (細胞工学別冊実験プロトコールシリーズ) . 秀潤社, 東京, 1994.
 
13) 稲澤譲治: ホルマリン固定標本や剥離細胞を試料にしたFISH法による染色体異常の検出. 分子生物学的アプローチ による癌研究プロトコール (横田 淳, 山本 雅編) , 羊土社, 東京, 1995, pp. 232-242.
 
14) Yasui W, Ito H, Tahara E: DNA analysis of archival material and its application to tumour pathology. In "Diagnostic Molecular Pathology: APractical Approach" (eds. by Herrington CS, McGee JO ' D) . OxfordUniversity Press, Oxford, 1992, pp. 193-206.
 
15) Shinata D, Hawes D, Li Z-H, et al: Specific genetic analysis of microscopic tissue after selective ultravioletradiation fractionation and the polymerase chain reaction. Am. J Pathol. 141: 539-543, 1992.
 
16) 川村眞智子, 林 健志: PCR-SSCP. 臨床DNA診断法 (古庄敏行, 井村裕夫監修) , 金原出版, 東京, 1995, pp. 90- 97.
 
17) Saiki RK, Gelfand DH, Stoffel S, et al: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487-491, 1988.
PubMed
18) Orita M, Iwahana H, Kanazawa H, et al: Detection of polymorphism of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad, Sci. USA 86: 2766-2770, 1989.
PubMed
19) Horii A, Han H-J, Shimada M, et al: Frequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers. Cancer Res. 54: 3373-3375, 1994.
PubMed
20) Fishel R, Lescoe MK, Rao MRS, et al: The human mutator gene MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027-1038, 1993.
 
21) Bronner CE, Baker SM, Morrison PT, et al: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colorectal cancer. Nature 368: 258-261, 1994.
PubMed
22) 中村祐輔: ヒトがんでの遺伝子異常と遺伝子診断: 概説. 「がんと遺伝子-機能から診断・治療まで-」. 蛋白質核酸酵素 (増刊) 42: 1771-1715, 1997.
 
23) 三好康雄, 中村祐輔: ヒトがんでの遺伝子異常と遺伝子診断: 遺伝性腫瘍. 「がんと遺伝子-機能から診断・治療まで-」. 蛋白質核酸酵素 (増刊) 42: 1776-1722, 1997.
 
24) Tahara E: Genetic alterations in human gastrointestinal cancers: The application to molecular diagnosis. Cancer 75 S: 1410-1417, 1995.
 
25) Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p 53 at 1 p 36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997.
 
P.270 掲載の参考文献
1) 渡辺 昌, 山口直人: 肺癌はどこまで増え続けるか・またその予後は? Medical Practice 8: 1673-1680, 1991.
 
2) 平山 雄: 予防がん学: その新しい展開. メディサイエンス社, 東京, 1987.
 
3) Tsugane S, Watanabe S, Sugimura H, et al: Recent trends in different histological types of lung cancer in Tokyo based on Pathological Autopsy Records. Jpn. J. Cancer Res. 78: 162-169, 1987.
PubMed
4) Wynder EL, Graham EA: Tobacco smoking as a possible etiologic factor in bronchogenic carcinoma. J. Am. Med. Assoc. 143: 329, 1950.
PubMed
5) Doll R, H川AB: Smoking and carcinoma of the lung. BMJ 2: 739, 1950.
 
6) 喫煙と健康, 喫煙と健康問題に関する報告書第2版. 厚生省 (編) , 東京, 健康体力づくり事業財団, 1993.
 
7) Mizuno S, Akiba S, Hirayama T: Lung cancer risk comparison among male smokers between the "Six-prefecture cohort"in Japan and the British physicians ' s cohort. Jpn. J. Cancer Res. 80: 1165-1170, 1989.
 
8) Watanabe S, Tsugane S, Arimoto H, et al: Trend of lung cancers in the National Cancer Center of Japan and comparison with that of Japanese Pathological Autopsy Records. Jpn. J. Cancer Res. 78: 460-466, 1987.
PubMed
9) Sugimura H, Watanabe S, Tsugane S, et al: Case-control study on histologically determined multiple primary lung cancer. J. Natl. Cancer Inst. 79: 435-441, 1987.
PubMed
10) Suzuki T, Sobue T, Fujimoto I, et al: Association of adenocarcinoma of the lung with cigarette smoking by grade of differentiation and subtype. Cancer Res. 50: 444-447, 1990.
PubMed
11) US Environmental Protection Agency: Respiratory Health Aspects of Passive Smoking. Lung Cancer and other Disorders. Washington, EPA, 1992.
 
12) Saracchi R: The interactions of tobacco smoking and other agents in cancer etiology. Epidemiol. Rev. 9: 175-193, 1987.
 
13) 中地 敬, 今井一枝: 喫煙と肺癌の遺伝的感受性. Pharma Med. 11: 103-108, 1994.
Medical*Online
14) Kobayashi Y, Arimoto H, Watanabe S: Occurrence of multiple primary cancer at the National Cancer Center Hospital, 1966-1990. Jpn. J. Clin. Oncol. 21: 233-251, 1991.
 
15) Unakami M, Hara M, Fukuchi S, et al: Cancer of the gastric cardia and the habit of smoking. Acta Pathol. Jpn. 39: 420-424, 1989.
PubMed
16) 渡辺 昌: 膵がんの疫学. 消化器科 10: 611-617, 1989.
 
17) Hartge P, Silverman D, Hoover R, et al: Changing cigarette habits and bladder cancer risk: Acase-control study. J. Natl. Cancer Inst. 78: 1119-1125, 1987.
 
18) Vecchia CL, Negri E, D ' Avanzo, et al: Smoking and renal cell carcinoma. Cancer Res. 50: 5233-5233, 1990.
 
19) Palmer JR, Rosenberg L: Cigarette smoking and the risk of breast cancer. Epidemiol. Rev. 15: 145-156, 1993
PubMed
20) Brownson RC, Chang JC, Davis JR: Cigarette smoking and risk of leukemia. Am. J. Epidemiol. 134: 938-941, 1991.
PubMed
21) Kinlen LJ: Leukemia and smoking habits among U. S. veterans. BMJ 297: 657-659, 1988.
PubMed
22) Severson RK: Cigarette smoking and leukemia. Cancer 60: 141-144, 1987.
PubMed
23) DeVesa SS, Blot W, Fraumeni Jr F: Declining lung cancer rates among young men and women in the United States: acohort analysis. J. Natl. Cancer Inst. 81: 1568-1571, 1989.
 
24) 山口直人, 渡辺 昌: CANSAVEによる肺癌の将来予測. CRC 1: 132-137, 1992.
 
25) 渡辺 昌: 海外におけるがんの薬物予防. CRC 1: 186-198, 1992.
 
26) The alpha-tocopherol, beta-carotene cancer prevention study group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330: 1029-1035, 1994.
 
27) 平山 雄: 喫煙と疾病, 大規模コホート研究の総括. Pharma Med. 11: 19-32, 1994.
Medical*Online
28) Goto K, Watanabe S: Social cost of smoking for the 21 st century. J. Epidemiol. 5: 113-116, 1995.
 
29) Goto K, Watanabe S: Economy and Diseconomy of Tobacco. Tob. Control. (in press)
 
30) 厚生省保健医療局健康増進栄養課 (監) : 喫煙対策Q&A. 保健同人社, 東京, 1994.
 
31) Fagerstrom KO, Tejding R, Westin A, et al: Aiding reduction of smoking with nicotine replacement medications : hope for the recalcitrant smoker? Tob. Control 6: 311-316, 1997.
PubMed
32) Jimenez-Ruiz C, Kunze M, Fagerstrom KO: Nicotine replacement: anew approach to reducing tobaccorelated harm. Eur. Respir. J. 11: 473-479, 1998.
 
33) Manley M, Lynn W, Epps RP, et al: The American Stop Intervention Study for cancer prevention: an overview. Tob. Control 6 (Suppl. 2) : S5-S 11, 1997.
 
34) Ockene JK, Lindsay EA, Hymowitz N, et al: Assist for the Community Intervention Trial for Smoking Cessation. Tob. Control 6 (Suppl. 2) : S49-56, 1997.
 
35) 中村正和: 母子保健の立場からみた喫煙問題. Pharma Med. 11: 81-88, 1994.
Medical*Online
36) Richmond R: Educating Medical Students about Tobacco: Planning and Implementation. International Union against Tuberculosis and Lung Diseases, Southwood Press Pry Ltd., NSW, 1996.
 
37) Shopland DR (Ed.) : Smoking and Tobacco Control Monogr 5, Tobacco and the Clinician, NIH, Bethesda, 1994.
 
38) Roemer R: Ligislative action to combat the world tobacco epidemic. WHO, Geneva, 1993.
 
39) 総務庁, 青少年と自動販売機に関する調査研究報告書, 平成7年3月, 総務庁.
 
P.281 掲載の参考文献
1) Sporn MB, Dunlop NM, Newton DL, et al: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) . Fed. Proc. 35: 1332-1338, 1976.
PubMed
2) Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323: 795-801, 1990.
PubMed
3) Thun MJ, Namboodiri MM, Heath Jr CW: Aspirin use and reduced risk of fetal colon cancer. N. Engl. J. Med. 325: 1593-1596, 1991.
 
4) 厚生省大臣官房統計情報部: 人口動態統計, 厚生省, 東京, 1995.
 
5) Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319: 525-532, 1988.
PubMed
6) Slaughter DP, Southwick HW, Smejkal W: "Field cancerization" in oral stratified squamous epithelium. Cancer 6: 963 968, 1953.
 
7) Lee JS, Lippman SM, Hong WK: Chemoprevention of aerodigestive tract carcinogenesis. In: Proceedings of the 7th Yousong Symposium Molecular&Cell Biology of Cancer (ed by Son K-S, Han M-H) . Yousong, Korea, 1993, pp. 106-111.
 
8) Hanai A, Kozono S, Fujimoto I: An estimate of cancer prevalence in Japan as of January 1, 1990. Jpn. J. Cancer Clin. 38: 419-427, 1992.
 
9) Wattenberg LW, Leong JL: Inhibition of the carcinogenic action of benzo (a) pyrene by flavones. Cancer Res. 30: 1922-1925, 1970.
PubMed
10) Troll W, Klassen A, Janoff A: Tumorigenesis in mouse skin: inhibition by synthetic inhibitors of proteases. Science 169: 1211-1213, 1970.
PubMed
11) O' Shaughnessy JA: Chemoprevention of breast cancer. JAMA 275: 1349-1353, 1996.
 
12) Costa A, Formelli F, Chiesa F, et al: Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 54: 2032 S-2037 S, 1994.
 
13) Sharma S, Stutzman JD, Kelloff GJ, et al: Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res. 54: 5848-5855, 1994.
PubMed
14) Arnold JT, Wilkinson BP, Sharma S, et al: Evaluation of chemopreventive agents in different mechanistic classes using a rat tracheal epithelial cell culture transformation assay. Cancer Res, 55: 537-543, 1995.
PubMed
15) Pezzuto JM: Bioassay-guided discovery of natural products for use as chemopreventive agenets. In: Proceedings of the 86 th Annual Meeting of American Association for Cancer Research. Toronto, Ontario, Canada, 1995 ' 36: 705-706, 1995.
 
16) Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived fromgrapes. Science 275: 218-220, 1997.
PubMed
17) Boone CW, Steele VE, Kelloff GJ: Screening for chemopreventive (anticarcinogeneic) compounds in rodents. Mutat. Res. 267: 251-255, 1992.
PubMed
18) Steele VE, Moon RC, Lubet CJ, et al: Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program. J. Cell. Biochem. 20 (suppl.) : 32-54, 1994.
 
19) Yuspa SH: The pathogenesis of squamous cell cancer: lesson learned from studies of skin carcinogenesis-thirtythird G. H. A. Clowes Memorial Award lecture. Cancer Res. 54: 1178-1189, 1994.
 
20) Muto Y, Ninomiya M, Fujiki H: Present status of research on cancer chemoprevention in Japan. Jpn. J. Clin. Oncol. 20: 219-223, 1990.
PubMed
21) Fujiki H, Suganuma M, Yoshizawa S, et al: Sarcophytol A and (-) -epigallocatechin gallate (EGCG) . nontoxic inhibitors of cancer development. In: Cancer Chemoprevention (ed by Wattenberg LW, Lipkin M, Boone CW, et al) . CRC, Boca Raton, 1992, pp. 393-405.
 
22) Komori A, Suganuma M, Okabe S, et al: Canventol inhibits tumor promotion in CD-1 mouse skin through inhibition of tumor necrosis factorαrelease and of protein isoprenylation. Cancer Res. 53: 3462-3464, 1993.
 
23) Kelloff GJ, Boone CW, Steele VE, et al: Progress in cancer chemoprevention: perspectives on agent selection and short-Term clinical intervention trials. Cancer Res. (Suppl.) 54: 2015-2024, 1994.
 
24) Kelloff GJ, Boone CW, Malone WF, et al: Chemoprevention clinical trials. Mutat. Res. 267: 291-295, 1992.
PubMed
25) DePalo G, Veronesi U, Camerini T, et al: Can fenretinide protect woman against ovarian cancer? . J. Natl. Cancer Inst. 87: 146-147, 1995.
 
26) Muto Y, Moriwaki H, Ninomiya T, et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N. Engl. J. Med. 334: 1561-1567, 1996.
 
27) The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330: 1029-1035, 1994.
 
28) Omenn GS, Goodman GE, Thornquist MD, et al: Risk factors for lung cancer and for intervention effect in CARET, the beta-carotene and retinol efficacy trial. J. Natl. Cancer Inst. 88: 1550-1559, 1996.
 
29) Komori A, Yatsunami J, Suganuma M, et al: Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res. 53: 1982-1985, 1993.
PubMed
30) Yoshizawa S, Horiuchi T, Fujiki H, et al: Antitumor promoting activity of (-) -epigallocatechin gallate, the main constituent of "tannin" in green tea. Phytother. Res. 1: 44-47, 1987.
 
31) Yamane T, Takahashi T, Kuwata K, et al: Inhibition of/V-methyl-1V '-nitro-N-nitrosoguanidine-induced carcinogenesis by (-) -epigallocatechin gallate in rat glandular stomach. Cancer Res. 55: 2081-2084, 1995.
 
32) Yamane T, Hagiwara N, Tateishi M, et al: Inhibition of Azoxymethane-induced colon carcinogenesis in rat by green tea polyphenol fraction. Jpn. J. Cancer Res. 82: 1336-1339, 1991.
PubMed
33) Narisawa T, Fukaura Y: Avery low dose of green tea polyphenols in drinking water prevents N-methyl-Nnitrosourea-induced colon carcinogenesis in F 344 rats. Jpn. J. Cancer Res. 84: 1007-1009, 1993.
 
34) Nishida H, Omori M, Fukutomi Y, et al: Inhibitory effects of (-) -epigallocatechin gallate on spontaneous hepatoma in C3H/HeNCrj mice and human hepatoma-derived PLC/PRF/5 cells. Jpn. J. Cancer Res. 85: 221-225, 1994.
PubMed
35) 武藤泰敏: 厚生省がん研究助成金による研究報告集. 厚生省, 東京, 1990, pp. 88-98.
 
36) Conney AH, Wang ZY, Huang MT, et al: Inhibitory effect of oral administration of green tea on tumorigenesis by ultraviolet light, 12-O-tetradecanoylphorbol-13-acetate and N-nitrosodiethylamine in mice. In: CancerChemoprevention (ed by Wattenberg LW, Lipkin M, Boone CW, et al) . CRC, Boca Raton, 1992, pp. 361-373.
 
37) Xu Y, Ho C-T, Arnin SG, et al: Inhibition of tobacco-specific nitrosoamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidantes. Cancer Res. 52: 3875-3879, 1992.
 
38) Imai K, Suga K, Nakachi K: Cancer preveutive effects of drinking green tea among a Japanese population. Prev. Med. 26: 769-775, 1997.
PubMed
P.300 掲載の参考文献
1) Shindler R: History of gastroscopy. In: GASTROSCOPY (2 nd ed.) . hafner Publishing Company, new York, 1950, pp. 1-13.
 
2) Hirshowitz BI, Curtis LE, Peters CW, et al: Demonstration of a new gastroscope, the "fiberscope". Gastroenterology 35: 50, 1958.
 
3) 吉田茂昭, 廣田映五: 進行癌の発育経過からみた早期胃癌診断の再検討. Gastroenterol. Endosc. 22: 1450-1453, 1980.
 
4) 吉田茂昭, 山口 肇, 斉藤大三・他: 内視鏡の読み方-胃炎像の鑑別診断. 臨床消化器内科 12: 1785-1792, 1988.
 
5) 渡辺七六, 吉田茂昭, 山口 肇・他: 肉眼所見との対比からみた内視鏡診断-殊に慢性胃炎像との鑑別困難な早期胃癌について. 胃と腸 26: 39-50, 1991.
 
6) Morson BC, Dawson IMP: The polyp-cancer sequence. In: GASTROINTESTINAL PATHOLOGY, Blackwell Scientific Publications, London, 1972, pp. 542-547.
 
7) 工藤進英, 林 俊一, 三浦宏二 ・他: 平坦・陥凹型早期大腸癌の内視鏡診断と治療. 胃と腸 24: 317-329, 1989.
 
8) 津田純郎, 八尾恒良, 松井敏幸・他: 内視鏡, X線からみた表面型大腸腫瘍-肉眼分類の問題点-. 胃と腸 27: 935- 947, 1992.
 
9) 吉田 操, 室井正彦, 門馬久美子・他: 食道m, sm 癌の質的診断ならびに鑑別診断-内視鏡の立場から-. 胃と腸 25: 1059-1066, 1990.
 
10) 吉田茂昭, 辻 靖, 斉藤大三・他: 臨床経過からみた胃生検の問題点-陥凹性病変を中心に-. 胃と腸 25: 959- 969, 1990.
 
11) 吉田茂昭, 秋谷正彦, 山口 肇・他: 胃の腺腫: 私はこう取り扱う-高危険群の内視鏡像とその臨床的取り扱い. 胃と腸 22: 693-700, 1987.
 
12) 小沢壮治, 安藤暢敏, 池田佳史・他: 遺伝子異常からみた食道癌の臨床特性. 日気食会報 46: 115-120, 1995.
 
13) Boku N, Chin K, Hosokawa K, et al: Biological markers as a predictor for response and prognosis of unresecta-ble gastric cancer patients treated with 5-fluorouracil and cis-platin. Clin. Cancer Res. 4: 1469-1474, 1998.
 
14) Ono H, Kondo H, Saito D, et al: Rapid diagnosis of gastric malignant lymphoma from biopsy specimens: detection of immunoglobulin heavy chain rearrangement by polymerase chain reaction. Jpn. J. Cancer Res. 84: 813-817, 1993.
PubMed
15) Kondo H, Sugano K, Fukayama N, et al: Detection of point mutations in the K-ras Oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 73: 1589-1594, 1994.
 
16) 工藤進英: 5拡大電子スコープ. 早期大腸癌: 平坦・陥凹型へのアプローチ, 医学書院, 東京, 1993, pp. 70-75.
 
17) 山口 肇, 吉田茂昭, 小黒八七郎: 電子スコープと画像処理. 消化器内視鏡 1: 445-451, 1989.
 
18) 吉田茂昭, 山口 肇, 勝 健一・他: TV内視鏡-電子内視鏡による計量診断. 臨床医 21: 45-49, 1995.
 
19) 山口 肇, 吉田茂昭, 小黒八七郎: ステレオ電子内視鏡立体計測システム. 画像情報 22: 1323-1327, 1990.
 
20) 小田紀彦, 野波徹夫, 山口雅浩・他: 単眼内視鏡を用いた被写体の表面形状推定. Med. Imag. Tech. 11: 399-400, 1993.
 
21) 小野良祐, 別府和重, 平野裕志・他: 肺癌の内視鏡放射線療法. KARKINOS 6: 949-955, 1993.
 
22) 土方 淳: 超音波内視鏡検査. 放射線医学大系 特別巻4B超音波診断II, (田坂 晧, 松浦啓一, 飯尾正広他: 編) 中山書店, 東京, 1988, pp. 212-216.
 
23) 吉本一哉, 恩田浩明, 小川 聡・他: 超音波内視鏡による大腸癌の深達度診断. 消化器内視鏡の進歩 35: 186-190, 1989.
 
24) 大村卓味, 土方 淳, 水口安則・他: 胃外性圧排の内視鏡診断. 消化器内視鏡の進歩 40: 183-188, 1992.
 
25) 吉本一哉, 岸 秀幸, 長谷川毅・他: 大腸における粘膜下腫瘤および壁外病変の内視鏡下超音波診断能の検討. 消化器内視鏡の進歩 40: 216-220, 1992.
 
26) Boku N, Yoshida S, Ohtsu A, et al: The differential diagnosis of malignant lymphoma and reactive lympho-recticular hyperplasia of the stomach using endoscopic ultrasonography. Dig. Endosc. 2: 163-169, 1994.
 
27) 土方 淳: 超音波内視鏡による胃癌の診断. 東邦医会誌 35: 406-422, 1989.
Medical*Online
28) 安田健治朗, 宇野耕治, 田中聖人・他: 超音波内視鏡による早期胃癌の鑑別 内視鏡治療を目的に. 胃と腸 27: 1167-1174, 1992.
 
29) 木田光広, 今泉 弘, 西山和男・他: ラジアル型内視鏡用超音波プローブによる上部消化管疾患の診断. 消化器内視鏡 5: 149-156, 1993.
 
30) 石塚俊一郎, 掛村忠義, 片桐耕吾・他: バルーン・シースを用いた細径超音波プローブによる内視鏡的超音波断層法の 基礎的および臨床的検討. 消化器内視鏡の進歩 45: 78-82, 1994.
 
31) 高田洋孝, 小林博之, 掛村忠義・他: 内視鏡的超音波断層法による深達度診断に及ぼす大腸粘膜ひだの影響. 消化器内 視鏡の進歩 41: 217-220, 1992.
 
32) 相部 剛, 藤村 寛, 沖田 極: 胃の超音波内視鏡検査 (III) -胃癌の壁深達度, リンパ節転移-. 臨床消化器内科 5 (5) : 703-712, 1990.
 
33) 大島郁也: 超音波内視鏡による食道癌, 胃癌のリンパ節転移診断の研究. Gastroenterol. Endosc. 32: 1059-1069, 1990.
 
34) 池田昌弘, 両角敦郎, 佐野主一・他: 超音波内視鏡による肝・胆道系癌の診断. 消化器内視鏡 1: 791-799, 1989.
 
35) 野口隆義, 秋山哲司, 播磨健三・他: 内視鏡的超音波検査. 胆と膵 14: 121-128, 1993.
 
36) 野田 裕, 藤田直孝, 小林 剛・他: 超音波内視鏡による胆管癌の進展度診断. 胆と膵 15: 1029-1035, 1994.
 
37) 有村文男, 松元 淳, 中塩一昭・他: 超音波内視鏡による肝外胆管癌の進展度診断. Gastroenterol. Endosc. 34: 1863- 1870, 1992.
 
38) 遠藤正章, 森田隆幸, 羽田隆吉・他: 超音波内視鏡による胆管癌の進展度診断-深達度, 水平浸潤, 他臓器浸潤の診断能の検討. Gastroenterol. Endosc. 33: 243-256, 1991.
 
39) 一瀬雅典, 神津照雄, 浅野武秀・他: ラジアル型細径超音波プローブによる肝外胆管癌の進展度診断. 胃と腸 29: 795- 801, 1994.
 
40) 乾 和郎, 中澤三郎, 吉野純治・他: 胆管内超音波検査による胆管癌の深達度診断. 胆と膵 15: 1037-1041, 1994.
 
41) 安田健治朗, 宇野耕治, 田中聖人・他: 膵癌診断における超音波内視鏡-ERCPと対比して-. 消化器内視鏡 3: 863- 871, 1991.
 
42) 三竹正弘, 内藤靖夫, 塚本純久・他: 超音波内視鏡による膵癌の術前進展度診断. 胆と膵 12: 625-631, 1991.
 
43) 真口宏介, 藤井常志, 西野徳之・他: 超音波内視鏡による小膵癌診断. 消化器内視鏡 7: 1119-1124, 1995.
 
44) 古川 剛, 内藤靖夫, 廣岡芳樹・他: 細径超音波プローブによる新たなる展開. 消化器内視鏡 7: 1127-1134, 1995.
 
45) Tajiri H, Kobayashi M, Niwa H, et al: Clinical application of an ultrathin pancreatoscope using a sequential video converter. Gastrointest. Endosc. 39: 371-374, 1993.
 
46) 田尻久雄, 小林正彦, 丹羽寛文: 経口的膵管内視鏡. 臨床消化器内科 10: 144-148, 1995.
 
47) 須賀俊博, 宮川宏之, 長川達哉・他: 経口的胆膵管鏡による膵疾患の診断. 消化器内視鏡 3: 879-884, 1991.
 
48) Izuishi K, Ryu M, Tajiri H, et al: Preoperative imaging for the location of intraductal pancreatic tumor and pancreatic duct using ERP-CT. Proc. World Congress Int. College Surgeon 15: 685-689, 1996.
 
49) 古川 剛, 内藤靖夫, 三竹正弘・他: Intravascular ultrasound catheterによる経胆管, 経膵管検査法. 日超医論文集59: 788-789, 1991.
 
P.314 掲載の参考文献
1) 厚生省大臣官房統計情報部編: 平成5年・人口動態統計. 1: 276-277, 1993.
 
2) 厚生統計情報部編: 国民衛生の動向・厚生の指標臨時増刊. 44: 433-434, 1997.
 
3) Cole P, Rodu B: Declining cancer mortality in the United States. Cancer 78: 2045-2048, 1996.
PubMed
4) Ikeda S, Tsuboi E, Ono R, et al: Flexible bronchofiberscope. Jpn. J. Clin. Oncol. 1: 55-65, 1971.
 
5) Landa JF: Indication for bronchoscopy. Chest 73: 686-690, 1978.
 
6) Radke JR, Conway WA, Eyler WR, et al: Diagnostic accuracy in peripheral lung lesions. Chest 76: 176-179, 1979.
PubMed
7) Shure D, Fedullo PF: Concise clinical study. Am. Rev. Respir. Dis. 128: 1090-1092, 1983.
 
8) Shure D: Fiberoptic bronchoscopy-Diagnostic applications. Clin. Chest Med. 8: H3, 1987.
 
9) 楠 洋子, 瀧藤伸英, 高田 実・他: 肺野孤立性陰影に対する気管支鏡検査の役割-経気管支的腫瘍生検 (TBTB) を中心に-. 気管支学 13: 92-97, 1991.
 
10) Shure D: Tissue procurement I Bronchoscopic techniques for lung cancer. Lung Cancer, Lippincott, Philadel-phia, 1996, pp. 471-479.
 
11) 日高 徹: 内視鏡画像診断支援システムの現況と問題点. 映像情報 (M) 26: 419-421, 1994.
 
12) 日本肺癌学会編: 肺癌取扱い規約. 改訂第4版, 金原出版, 東京, 1996, pp. 63-71.
 
13) 日本肺癌学会・気管支鏡所見分類委員会: 「肺癌取扱い規約」の一部改定 (案) について. 肺癌 36: 339-340, 1996.
 
14) 加藤治文, 小野寿太郎, 新妻雅行・他: 新しい吸引針による経気管支ファイバースコープ生検. 日胸疾患会誌 16: 774- 780, 1978.
 
15) Wang KP, Marsh BR, Summer WR, et al: Transbronchial needle aspiration for diagnosis of lung cancer. Chest 80: 48-50, 1981.
PubMed
16) Wang KP, Haponik EF, Britt EJ, et al: Transbronchial needle aspiration of peripheral pulmonary nodules. Chest 86: 819-823, 1984.
PubMed
17) Wang KP: Transbronchial needle aspiration. J. Bronchology 1: 63-68, 1994.
 
18) Wang KP: Flexible transbronchial needle aspiration biopsy for histologic specimens. Chest 88: 860-863, 1985.
PubMed
19) Wang KP, Terry PB, Marsh BR: Bronchoscopic needle aspiration biopsy of paratracheal tumors. Am. Rev. Respir. Dis. 118: 17-21, 1978.
 
20) Schrek R, Baker LA, Ballard GP, et al: Tabacco smoking as etiologic factor in disease. Cancer Res. 10: 49-58, 1950.
 
21) Mills CA, Porter MM: Tabacco smoking habits and cancer of mouth and respiratory system. Cancer Res. 10: 539-542, 1950.
 
22) Wynder EL, Graham EA: Tabacco smoking as possible etiologic factor in bronchogenic carcinoma: study of 684proved cases. JAMA 143: 329-336, 1950.
 
23) Doll R, Hill AB: Smoking and carcinoma of lung: preliminary report. BMJ 2: 739-748, 1950.
PubMed
24) Levin ML, Goldstein H, Gerhardt PR: Cancer and tabacco smoking: preliminary report. JAMA 143: 336-338, 1950.
 
25) Auerbach O, Gere JB, Forman JB, et al: Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N. Engl. J. Med. 256: 97-104, 1957.
PubMed
26) Edell ES, Cortese DA: Photodynamic therapy in the management of early supeficial squamous cell carcinoma as an alternative to surgical resection. Chest 102: 1319-1322, 1992.
 
27) Hayata Y, Kato H, Konaka C, et al: Photodynamic therapy (PDT) in early stage lung cancer. Lung Cancer 9: 287-294, 1993.
 
28) Furuse K, Fukuoka M, Kato H, et al: Aprospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. J. Clin. Oncol. 11: 1852-1857, 1993.
 
29) 楠 洋子, 梁 尚志, 高田 実・他: 特集「PDTの臨床」 肺癌に対するPDT. 日本レーザー医学会誌 15: 13-19, 1994.
 
30) Imamura S, Kusunoki Y, Takifuji N, et al: Photodynamic therapy and/or external beam radiation therapy for roentgenologically occult lung cancer. Cancer 73: 1608-1614, 1994.
PubMed
31) Fukutomi H, Kawakita I, Nakahara A, et al: Endoscopic diagnosis and treatment of gastric cancer by laser beam. Laser-Tokyo ' 81, Laser Endoscopy (II) , Tokyo 1981, pp. 26-29.
 
32) 川北 勲, 中原 朗, 祭 承喜・他: レーザー光の胃癌診断への応用-レーザー光励起蛍光観察-. Prog. Dig. Endosc. 20: 57-61, 1982.
 
33) Yang YL, Ye YM, Li FM, et al: Characteristic autofluorescence for cancer diagnosis and its origin. Laser Surg. Med. 7: 528-532, 1987.
PubMed
34) Profio AE, Doiron DR: A feasibility study of the use of fluorescence bronchoscopy for localization of small cell lung tumours. Phys. Med. Biol. 22: 949-957, 1977.
 
35) Profio AE, Doiron DR, King EG: Laser fluorescence bronchoscope for localization of occult lung tumors. Med. Phys. 6: 523-525, 1979.
PubMed
36) Doiron DR, Profio AE, Vincent RG, et al: Fluorescence bronchoscopy for detection of lung cancer. Chest 76: 27-32, 1979.
 
37) 加藤治文, 小中千守, 小野寿太郎・他: ヘマトポルフィリン誘導体, およびクリプトン・レーザー光線照射による犬肺癌の腫瘍局在の診断. 肺癌 21: 439-445, 1981.
 
38) Hayata Y, Kato H, Konaka C, et al: Fiberoptic bronchoscopic laser photoradiation for tumor localization in lung cancer. Chest 82: 10-14, 1982.
PubMed
39) Kato H, Aizawa K, Ono J, et al: Clinical measurement of tumor fluorescence using a new diagnostic system with hematoporphyrin derivative, laser photoradiation, and a spectroscope. Lasers Surg. Med. 4: 49-58, 1984.
 
40) Kato H, Cortese DA: Early detection of lung cancer by means of hematoporphyrin derivative fluorescence and laser photoradiation. Clin. Chest Med. 6: 237-253, 1985.
PubMed
41) 加藤治文, 会沢勝夫, 西宮克明・他: エキシマ・レーザーを用いた癌画像診断装置. 癌と化学療法 13: 1647-1652, 1986.
 
42) Kluftinger AM, Davis NL, Quenville NF, et al: Detection of squamous cell cancer and pre-cancerous lesions by imaging of autofluorescence in the hamster cheek pouch model. Surg. Oncol. 1: 183-188, 1992.
PubMed
43) Lam S, MacAulay C, Hung J: Detection of dysplasia and carcinoma in sitza with a lung imaging fluorescence endoscope device. J. Thorac. Cardiovasc. Surg. 105: 1035-1040, 1993.
PubMed
44) Lam S, MacAulay C, Leriche JC, et al: Early localization of bronchogenic carcinoma. Diagn. Ther. Endosc. 1: 75-78, 1994.
PubMed
45) Hung J, Lam S, LaRiche JC, et al: Autofluorescence of normal and malignant bronchial tissue. Lasers Surg. Med. 11: 99-105, 1991.
 
46) 古谷鉄夫, 池田徳彦, 岡田真也・他: 特集「Photodynamic diagnosis, PDT」気管支組織における自家蛍光. 日本レーザー医学会誌 17: 75-80, 1996.
 
47) Kato H, Okunaka T, Ikeda N, et al: Applicatiorl of simple imaging technique for fluorescence bronchoscope: Preliminary report. Diagn. Ther. Endosc. 1: 79-81, 1994.
 
48) 金 慶一, 池田徳彦, 奥中哲弥・他: 特集「Photodynamic diagnosis, PDT」気管支組織における自家蛍光. 日本レーザー医学会誌17: 81-85, 1996.
 
49) Baumgartner R, Huber RM, Schulz H, et al: Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. J. Photochem. Photobiol. B 36: 169-174, 1996.
PubMed
50) Douglas MC, Rodney AW: Transluminal ultrasound imaging development and devices. Intravascular Ultrasound Imaging, Raven Press, New York, 1993, pp. 31-44.
 
51) Pandian NG, Andreas K, Barbara B, et al: Ultrasound angioscopy: Real-time, two dimensional, intraluminal ultrasound imaging of blood vessels. Am. J. Cardiol. 62: 493-494, 1988.
 
52) Ono R, Suemasu K, Matsunaka T: Bronchoscopic ultrasonography in the diagnosis of lung cancer. Jpn J. Clin. Oncol. 23: 34-40, 1993.
 
53) Hurter TH, Hanrath P: Endobronchial sonography: feasibility and preliminary results. Thorax 47: 565-567, 1992.
 
54) Goldberg BB, Steiner RM, Liu JB, et al: US-assisted bronchoscopy with use of miniature transducer-containing catheters. Radiology 190: 233-237, 1994.
PubMed
55) 栗本典昭, 村山正毅, 小浜祥均・他: 気管, 気管支周囲病変に対する気管支腔内超音波検査の臨床応用. 臨床放射線 42: 143-150, 1997.
 
56) 廣岡健児: 細径高周波超音波プローブの現況と発展. 映像情報 (M) 29: 590-593, 1997.
 
57) 栗本典昭, 村山正毅, 別府 敬・他: 気管支扁平上皮癌の深達度診断に対する, 気管支腔内超音波検査の経験-臨床例と針刺し実験-. 呼吸 15: 561-567, 1996.
 
58) Martini N, Flehinger BJ: Surgical treatment of lung carcinoma. Surg. Clin. North Am. 67: 1037-1049, 1987.
 
59) Mountain CF, Dresler CM: Regional lymph node classification for lung cancer staging. Chest 111: 1718-1723, 1997.
PubMed
60) 厚生省末舛班: 澤村献児, 李 龍彦, 末舛恵一・他: R2-3縦隔郭清を施行したN2肺癌切除成績の検討. 肺癌 28: 1-9, 1988.
 
61) Rosell R, Gomez-Codina JG, Camps C, et al: Arandomized trial comparing Preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 330: 153-158, 1994.
 
62) Harrow EM, Wang KP: The staging of lung cancer by bronchoscopic transbronchial needle aspiration. Thorac. Endosc. 6: 223-235, 1996.
 
63) Rea HH, Shevland JE, House AJS: Accuracy of computed tomographic scanning in assessment of the mediastinum in bronchial carcinoma. J. Thorac. Cardiovasc. Surg. 81: 825-829, 1981.
 
64) Faling LJ, Pugatch RD, Jung-Legg Y, et al: Computed tomographic scanning of the mediastinum in the staging of bronchogenic carcinoma. Am. Rev. Respir. Dis. 124: 690-695, 1981.
PubMed
65) Martini N, Heelan R, Westcott J, et al: Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma. J. Thorac. Cardiovasc. Surg. 90: 639-648, 1985.
PubMed
66) 三谷惟章, 下高原哲郎, 山王邦博・他: 肺癌の縦隔リンパ節転移に対するCT診断-領域別廓清リンパ節とCT所見との対比検討-. 肺癌 26: 643-649, 1986.
 
67) Daly BDT, Faling LJ, Bite G, et al: Mediastinal lymph node evaluation by computed tomography in lung cancer. J. Thorac. Cardiovasc. Surg. 94: 664-672, 1987.
 
68) Carlens E: Mediastinoscopy: Amethod for inspection and tissue biopsy in the superior mediastinum. Dis. Chest 36: 343-352, 1959.
 
69) Coughlin M, Deslauriers J, Beaulieu M, et al: Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann. Thorac. Surg. 40: 556-560, 1985.
PubMed
70) Friedman PJ: Lung cancer: Update on staging classifications. AJR 150: 261-264, 1987.
 
71) Patterson GA, Ginsberg RJ, Poon PY, et al: Aprospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. J. Thorac. Cardiovasc. Surg. 94: 679-684, 1987.
 
72) 安光 勉, 大嶋仙哉, 中野 昇・他: 手術適応が考えられた肺癌症例に対する連続600例の縦隔鏡検査成績. 肺がん集学的治療の最前線. 癌と化学療法社, 東京, 1989, pp. 10-15.
 
73) 曽我浩之, 竹内龍三, 栗田 啓・他: 経食道的超音波検査: 肺癌の縦隔リンパ節転移診断-特に気管分岐部リンパ節について-. 臨床外科 42: 1405-1410, 1987.
 
74) Kondo D, Imaizumi M, Abe T, et al: Endoscopic ultrasound examination for mediastinal lymph node metastases of lung cancer. Chest 98: 586-593, 1990.
PubMed
75) Schuder G, Isringhaus H, Kubale B, et al: Endoscopic ultrasonography of the diagnosis of bronchial carcinoma. J. Thorac. Cardiovasc. Surg. 39: 299-303, 1991.
 
76) 加藤治文, 河手典彦, 松島 康・他: 肺針穿刺生検. 臨床病理 41: 95-109, 1980.
 
77) Wang KP, Marsh BR, Summer WR, et al: Transbronchial needle aspiration for diagnosis of lung cancer. Chest80: 48-50, 1981.
PubMed
78) Wang KP, Haponik EF, Gupta PK, et al: Flexible transbronchial needle aspiration: Technical considerations. Ann. Otol. Rhinol. Laryngol. 93: 233-236, 1984
PubMed
79) Wang KP, Haponik EF, Britt EJ, et al: Transbronchial needle aspiration of peripheral pulmonary nodules. Chest86: 819-823, 1984.
PubMed
80) Wang KP: Flexible transbronchial needle aspiration biopsy for histologic specimens. Chest 88: 860-863, 1985.
PubMed
81) Wang KP, Terry PB, Marsh BR: Bronchoscopic needle aspiration biopsy of paratracheal tumors. Am. Rev. Respir. Dis. 118: 17-21, 1978.
 
82) Harrow E, Halber M, Hardy S, et al: Bronchoscopic and roentgenographic correlates of a positive transbronchial needle aspiration in the staging of lung cancer. Chest 100: 1592-1596, 1991.
PubMed
83) Wang KP, Brower R, Haponik EF, et al: Flexible transbronchial needle aspiration for staging of bronchogenic carcinoma. Chest 84: 571-576, 1983.
PubMed
84) 楠 洋子, 福岡正博: 経気管支穿刺吸引法, 縦隔鏡検査の有用性と限界. Medicina 28: 426-428, 1991.
 
85) 石井正憲, 小中千守, 加藤治文: 原発性肺癌における経気管支針吸引細胞診 (Transbronchial aspiration cytology: TBAC) による縦隔リンパ節及び肺門リンパ節転移の術前質的診断の検討. 気管支学 15: 627-635, 1993.
Medical*Online
86) Schenk DA, Bower JH, Bryan CL, et al: Transbronchial needle aspiration staging of bronchogenic carcinoma. Am. Rev. Respir. Dis. 134: 146-148, 1986.
PubMed
87) Ihde DC, Cohen MH, Bernath AM, et al: Serial fiberoptic bronchoscopy during chemotherapy for small cell carcinoma of the lung. Chest 74: 531-537, 1978.
PubMed
88) Nakhosteen JA, Niederle N: Small cell lung cancer: Serial bronchofiberscopy and photographic documentation-The bridge sign. Chest 83: 12-16, 1983.
 
89) Tondini M, Rizzi A: Small-cell lung cancer: Importance of fiberoptic bronchoscopy in the evaluation ofcomplete remission. Tumori 75: 266-268, 1989.
 
90) Parrat E, Pujol JL, Gautier V, et al: Chest tumor response during lung cancer chemotherapy. Chest 103: 1495-1501, 1993.
PubMed
91) Osterlind K, Ihde D, Ettinger DS, et al: Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat. Rep. 67: 3-9, 1983.
PubMed
92) Tanio Y, Watanabe M, Inoue T, et al: Chemo-radioresistance of small cell lung cancer cell lines derived from untreated primary tumors obtained by diagnostic bronchofiberscopy. Jpn. J. Cancer Res. 81: 289-297, 1990.
PubMed
93) 村上 功, 檜山桂子, 奥崎 健・他: 経気管支鏡的採取標本における肺癌遺伝子異常の解析. 気管支学 17: 691-694, 1995.
Medical*Online
94) Clements NC, Nelson MA, Wymer JA, et al: Analysis of K-ras gene mutations in malignant and nonmalignant endobronchial tissue obtained by fiberoptic bronchoscopy. Am. J. Respir. Crit. Care Med. 152: 1374-1378, 1995.
PubMed
95) Sundaresan V, Ganly P, Hasleton P, et al: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 7: 1989-1997, 1992.
PubMed
96) 小宮武文, 平島智徳, 楠 洋子・他: 内視鏡的早期肺癌におけるp53遺伝子異常の検索. Jpn. J. Cancer. Res. 87 (suppl.) : 118, 1996.
 
97) Mitsudomi T, Lam S, Shirakusa T, et al: Detection and sequencing of p 53gene mutations in bronchial biopsy samples in patients with lung cancer. Chest 104: 362-365, 1993.
 
98) Thiberville L, Payne P, Vielkinds J, et al: Evidence of cumulative gene losses with progression of premalignantepithelial lesions to carcinoma of the bronchus. Cancer Res. 55: 5133-5139, 1995.
PubMed
99) Szabo E, Birrer MJ, Mulshine JL: Early detection of lung cancer. Semin. Oncol. 20: 374-382, 1993.
PubMed
P.329 掲載の参考文献
1) Jones K: Brain hemorrhage；Evaluation with fast spin-echo and conventional dual spin-echo images. Radiology 182: 53-58, 1992.
PubMed
2) 大松広伸, 柿沼龍太郎, 森山紀之・他: 癌検診の最前線. 癌治療, 今日と昨日 17 (3) : 25-28, 1995.
 
3) 柿沼龍太郎, 大松広伸, 金子昌弘・他: 末梢性微小肺がんをどう診断するか, 日本胸部臨床 56 (7) : 547-553, 1997.
 
4) Takayasu K, Muramatsu Y, Furukawa H, et al: Early Hepatocellular Carcinoma: Appearance at CT during Arterial Portography and CT Arteriography with Pathologic Correlation. Radiology 194: 101-105, 1995.
PubMed
5) 村上康二, 縄野 繁, 森山紀之・他: 膵充実性腫瘍の画像診断. 消化器外科 20: 1800-1809, 1997,
 
P.339 掲載の参考文献
1) ASCO Expert Panel T: Clinical practice guidelines for the use of tumor markers in breast and colorectalcancer: Report of the American Society of Clinical Oncology Expert Panel. J. Clin. Oncol. 14: 2843-2877, 1996.
 
2) Kramer BS, Gohagan J, Prorok P, et al: ANational Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71 (suppl.) : 589-593, 1993.
 
3) Hirai H, Nishi S, Watabe H, et al: Some chemical, experimental and clinical investigations on α-fetoprotein. In: Alpha-fetoprotein and hepatoma (eds. by Hirai H, Miyaji T) : Gann Monogr. 14: 19-34, 1973.
 
4) Tang Z: Screening and early treatment of primary liver cancer with special reference to the east part of China. Ann. Med. Singapore 9: 3-5, 1989.
 
5) Thomas P, Zamcheck N: Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA) . Dig. Dis. Sci. 28: 216-224, 1983.
PubMed
6) Kamata K, Uchida M, Takeushi Y, et al: Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction. NephroL Dial. Transplant. 11: 1267-70, 1996. Waldmann TA, Strober W: Metabolism of immunoglobulins. Prog. Allergy 13: 1-100, 1969.
 
7) Waldmann TA, Stober W:Metabolism of immunoglobulins. Prog. Allergy 13 : 1-200, 1969
 
8) Salmon SE, Smith BA: Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J. Clin. Invest. 49: 1114-1121, 1970.
PubMed
9) Princler GL, McIntire KR, Adamson RH: ln vitro alpha-feto-protein synthesis by monkey hepatocellular carcinoma. J. Natl. Cancer Inst. 60: 643-648, 1978.
 
10) Lopez LA, Del Villar V, Ulla M, et al: Prevalence of abnormal levels of serum tumor markers in elderly people. Age Ageing 25, 45-50, 1996.
PubMed
11) Kagan AR, Steckel RJ: Imaging cancer of unknown primary site. In: Cancer Medicine, 4th ed. (eds. by Holland JF, Bast Jr RC, Morton DL, et al) , Williams & Wilkins, Baltimore 1997, pp. 563-565.
 
12) Bergstrand CG, Czar B: Demonstration of a new protein fraction in serum from the human fetus. Scand J. Clin. Lab. Invest. 8: 174, 1956.
PubMed
13) Abelev GI, Perova SD, Khramkova NI, et al: Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation I: 174-180, 1963.
PubMed
14) Toner GC, Geller NC, Tan C, et al: Serum tumor marker half-life during chemotherapy aUows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res. 50: 5904-5910, 1990.
 
15) Lack EE, Neave C, Vawter GF: Hepatoblastoma: Aclinical and pathologic study of 54 cases. Am. J. Surg. Patho1. 6: 693-705, 1982.
 
16) 飯野四郎, 遠藤康夫: α-フェトプロテイン (AFP) . 日本臨牀 53: 696-698, 1995.
Medical*Online
17) Cappac S, Newlands ES, Dent J, et al: Problems of interpretation of serum concentrations of alpha-fetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumors. Br. J. Cancer 48: 335-340, 1982.
 
18) Ruther U, Luthgens M, Bader H, et al: Human chorionic gonadotropin in patients with pure seminoma. J. Tumor Marker Oncol. 4: 77-88, 1989.
 
19) Tabernero JM, Germa JR, Mora J, et al: Alpha-fetoprotein-concanavalin A binding as a maiker to discriminate between germ cell tumors and liver diseases. Proc. Am. Soc. Clin. Oncol. 14: 81, 1995.
 
20) Waldman TA, McIntire KR: Serm alpha-phetoprotein ievels in patients with ataxia-teleangiectasia. Lancet 2: 1112-1115, 1972.
 
21) Belanger L, Belanger M, Prive L, et al: Tyrosinemic hereditaire et alpha-1-fetoproteine: 1. interest clinique del 'alpha-fetoproteine dans la tyrosinemic hereditaire. Pathol. Biol. 21: 449-455, 1973.
 
22) 古川みどり, 中西敏己, 奥田博明・他: 肝細胞癌におけるPIUKA-IIのvitamin K 感受性に関する検討. 日消誌 85: 2583-2589, 1988.
 
23) van Tornout JM, Buckley JD, Quinn JJ, et al: Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: Areport from the Children 's Cancer Group. J. Clin. Oncol. 15: 1190-1197, 1997.
PubMed
24) Ruther U, Lathgens M, Bader H, et al: Human chorionic gonadotropin in patients with pure seminoma. J. Tumor Marker Oncol. 4: 77-88, 1989.
 
25) Saller B, Clara R, Spottl G, et al: Testicular cancer secretes intact human choriogonadotropin (hCG) and its freeβ-subunit: evidence that hCG (+hCG-β) assays are the most reliable in diagnosing and follow-up. Clin. Chem. 362: 234-239, 1990.
 
26) Bosl GJ, Geller NL, Cirrincione C, et al: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 43: 3403-3407, 1983.
PubMed
27) Nisselbaum JS, Bosl GJ, Golbey D, et al: Changes in serum alpha-fetoprotein and chorionic gonadotropin in response to cancer therapy. Ann. Clin. Lab. Sci. 14: 178-188, 1984.
 
28) Muggia FM, Rosen SW, Weintraub BD, et al: Ectopic placental proteins in nontrophoblastic tumors. Serial measurement following chemotherapy. Cancer 36: 1327-1337, 1975.
 
29) Toner GC, Geller NL, Tan C, et al: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res. 50: 5904-5910, 1990.
PubMed
30) Nishimura R, Ide K, Utsunomiya T, et al: Fragmentation of the β-subunit of human chorionic gonadotropin produced by choriocarcinoma. Endocrinology 123: 420-425, 1988.
 
31) Schutter EM, Mulder C, van Kamp GJ, et al: The beta-core fragment of human chorionic gonadotropin: biochemical background and clinical application. Anticancer Res. 17: 1255-1272, 1997.
PubMed
32) Bast RC Jr, Klug TL, St. John E, et al: Aradioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309: 883-887, 1983.
 
33) Davis HW, Zurawski VR, Bast RC, et al: Characterization of the CA 125 antigen associated with epithelial ovarian carcinomas. Cancer Res. 46: 6143, 1986.
 
34) Kabawat SE, Bast RC Jr, Welch WR, et al: Immunopathologic characterization of a monoclonal antibody that recognized common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am. J. Clin. Pathol. 79: 98-104, 1983.
 
35) NIH Consensus Development Panel on Ovarian Cancer: Ovarian Cancer, Screening, Treatment, and Follow-up. JAMA 273: 491-497, 1994.
 
36) 有吉 寛, 桑原正喜, 葛谷和夫: CA125. 日本臨牀 53 (増刊号) : 706-709, 1995.
 
37) McIntire KR, Waldmann TA, Moertel CG, et al: Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res. 35: 991-996, 1975.
PubMed
38) Kawahara M, Terasaki P, Chia P, et al: Use of four monoclonal antibodies to detect tumor markers. Cancer 581 2008-2012, 1986.
 
39) Purves LR, Branch WR, Geddes EW, et al: Serum alpha-fetoprotein VII. The range of apparent serum values in normal people, pregnant women and primary liver cancer high-risk populations. Cancer 31: 578-587, 1973.
 
40) Niloff JM, Bast RC Jr, Schaetzl EM, et al: Predictive value of CA125 antigen levels at second look procedures in ovarian cancer. Am. J. Obstet. Gynecol. 151: 982-986, 1985.
 
41) Bereck JS, Knapp RC, Malkasian GD, et al: CA125 serum levels correlate with second look operations among ovarian cancer patients. Obstet. Gynecol. 67: 685-689, 1986.
 
42) Grankvist K, Ljungberg B, Rasmuson T: Evaluation of five glycoprotein tumor markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int. J. Cancer 74: 233-236, 1997.
PubMed
43) Gold P, Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immuno tolerance and absorption techniques. J. Exp. Med. 121: 439-462, 1965.
 
44) Coligan JE, Henkart PA, Todd CW, et al: Heterogeneity of the carcinoembryonic antigen. Immunochemistry 10: 591-599, 1973.
PubMed
45) Thomas P, Toth CA, Saini KS, et al: The structure metabolism and function of the carcinoembryonic antigen gene family. Biochem. Biophys. Acta 1032: 177-189, 1990.
PubMed
46) Hass GM, Bolling TJ, Kinders JR, et al: Preparation of synthetic polypeptide domains of carcinoembryonic antigen and their use in epitope mapping. Cancer Res. 5111876-1882, 1991.
 
47) Fletcher RH: Carcinoembryonic antigen. Ann. Intern. Med. 104: 66-73, 1986.
PubMed
48) Myers RE, Sutherland DJ, Meakin JW, et al: Carcinoembryonic antigen in breast cancer. Cancer 42: 1520-1526, 1978.
PubMed
49) Sculier JP, Feld R, Evans WK, et al: Carcinoembryonic antigen: A useful prognostic marker in small-cell lung cancer. J. Clin. Oncol. 3: 1349-1354, 1985.
PubMed
50) Magnani JL, Steplewski Z, Koprowski H, et al: Identification of the gastro-intestinal and pancreatic cancerassociated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 43: 5489-5492, 1983.
 
51) Heptner G, Domschke S, Domschke W: Comparison of CA 72. 4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies. Scand. J. Gastroenterol. 24: 745-750, 1989.
PubMed
52) Tsuruta T, Ogawa A, Ishii K, et al: CA 19-9: apossible serum marker for embryonal carcinoma. Urol. Int. 58: 20-24, 1997.
 
53) 小田桐恵美: CA 19-9. 日本臨牀 53 (増刊号) : 719-722, 1995.
 
54) Satake K, Kanazawa G, Kho I, et al: Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Am. J. Gastroenterol. 80: 630-636, 1985.
PubMed
55) 広田正毅, 福島喜代康, 平谷一人・他: 嚢胞性線維症とびまん性汎細気管支炎の血清中CA 19-9. 医学のあゆみ143: 789-790, 1987.
 
56) Strom BL, Maislin G, West SL, et al: Serum CEA and CA 19-9: potential future diagnostic or secreening tests for gallbladder cancer? Int. J. Cancer 45: 821-824, 1990.
PubMed
57) Maeta M, Yoshioka H, Shimizu T, et al: Carbohydrate antigen 19-9 in tissue and sera from patients with gastric cancer. Oncology 47: 229-233, 1990.
PubMed
58) Richter JM, Christensen MR, Rustgi AK, et al: The clinical utility of the CA 19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss: acost-effectiveness analysis. Arch. Intern. Med. 149: 2292-2297, 1989.
 
59) Pleskow DK, Berger HJ, Gyves J, et al: Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann. Intern. Med. 110: 704-709, 1989.
 
60) Hilkens J, Hilgers J, Buijs F, et al: Monoclonal antibodies against human milk fat globule membranes useful in carcinoma research. In: Protides of Biological Fluids (ed. by Peeters H) , Vol. 31, Pergamon Press, New York, 1984, p. 1013.
 
61) Kufe D, Inghirami G, Abe M, et al: Differential reactivity of a monoclonal antibody (DF3) with humanmalignant versus benign breast tumors. Hybridoma 3: 223, 1984.
PubMed
62) Hayes DF, Zurawski VR, Jufe DW: Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J. Clin. Oncol. 4: 1542, 1986.
 
63) Hayes DF, Kiang DT, Korzun A, et al: CA l5-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 7: 38a, 1988.
 
64) Marangos pJ, Schmechel D, Parma AM, et al: Measurement of neuron-specific and non-neuronal isoenzymes of enolase in rat, monkey and human nervous tissue. J. Neurochem. 33: 319-329, 1979.
PubMed
65) Schmechel D, Marangos PJ, Zis PA, et al: Brain enolases as specific markers of neuronal and glial cells. Science 199: 313-315, 1978.
 
66) Carney DN, Marangos PJ, Ihde DC, et al: Serum neuron-specific enolase: amarker for disease extent and response to therapy of smal1-cell cancer. Lancet 1: 583-585, 1982.
 
67) Ishigura Y, Kato K, Shimizu A, et al: High levels of immunoreactive nervous system-specific enolase in sera of patients with neuroblastoma. Clin. Chem. Acta 121: 173.
 
68) Ebert W, Ryll R, Muley T, et al: Do neuron-specific enolase levels discriminate between small-cell lung cancer. Tumor Biol. 17: 362-368, 1996.
PubMed
69) Lippo KK, Terho T: Concomitant monitoring of serum neuron-specific enolase and creatinine kinase BB in small cell lung cancer. Acta Oncol. 30: 321-324, 1990.
 
70) Harding M, McAlister J, Hulks G, et al: Neuron specific enolase (NSE) in small cell lung cancer: atumor marker of prognostic significance? Br. J. Cancer 61: 605-607, 1990.
 
71) Ariyoshi Y, Kato K, Sugiura T, et al: Therapeutic significance of neuron-specific enolase (NSE) in lung cancer. Proc. Am. Soc. Clin. Oncol. 5: 23, 1986.
 
72) Nou E, Eteinholtz L, Bergh J, et al: Neuron-specific enolase as a follow-up marker in small cell bronchial carcinoma. Cancer 65: 1380-1385, 1990.
 
73) Burghuber OC, Worofka B, Schernthaner G, et al: Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 65: 1386-1390, 1990.
PubMed
74) 河原正明, 古瀬清行, 荒井六郎・他: 小細胞肺癌患者における血清Neuron-specific Enolase測定の意義-Carcinoem- bryonic antigenとの対比-. 癌と化学療法 14: 146-151, 1987.
 
75) Shaw E, Klee G, Grill J, et al: Utility of the serum tumor marker neuron specific enolase (NSE) in small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Onco1. 14: 81, 1995.
 
76) Jorgensen LGM, Osterlind K, Genolla J, et al: Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC) : acombined multivariable analysis on data from nine centers. Br. J. Cancer 74: 463-467, 1996.
 
77) Miyake Y, Kodama T, Yamaguchi K: Pro-gastrin-releasing peptide (31-98) is a specific tumor marker inpatients with small cell lung carcinoma. Cancer Res. 54: 2136-2140, 1994.
 
78) 児玉哲郎, 阿部庄作, 山口健・他: ELISA法による血清ProGRP測定の臨床的意義. 医学と薬学 32: 87-97, 1994.
 
79) Kato H, Torigoe T: Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 41: 1621-1628, 1977.
 
80) Kato H, Morioka H, Aramaki S, et al: Radioimmunoassay for tumor antigen of human cervical squamous cellcarcinoma. Cell Mol. Biol. 25: 51-56, 1979.
 
81) Kato H, Morioka H, Tsutsui H, et al: Value of tumor antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 50: 1294-1296, 1982.
PubMed
82) Maruo T, Shibata K, Kimura A, et al: Tumor associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Cancer 56: 302-308, 1985.
PubMed
83) Eibling DE, Johnson JT, Wagner RL, et al: SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Laryngoscope 99: 117-124, 1989.
 
84) Petrelli NJ, Shaw N, Bhargava A, et al: Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal. J. Clin. Oncol. 6: 782-785, 1988.
PubMed
85) 沼 文隆・他: 血中SCC抗原値が異常高値を示した乾癬患者の1例. 日癌治療会誌 28: 84-89, 1993.
 
86) Molina R, Filella X, Torres MD, et al: SCC antigen measured in malignant and nonmalignant diseases. Clin. Chem. 36: 251-254, 1990.
PubMed
87) 松原義人, 安田雄司, 塙健・他: 肺癌におけるSCC抗原. 日癌治療会誌 21: 1036-1048, 1986.
 
88) Kato H, Morioka H, Aramaki S, et al: Prognostic significance of the tumor antigen TA-4 in squamous cell carcinoma of the uterine cervix. Cancer 56: 302-308, 1985.
 
89) van der Gaast A, Schoenmakers CHH, Kok TC, et al: Evaluation of a new tumor marker in patients with nonsmall-cell lung cancer: Cyfra 21. I. Br. J. Cancer 69: 525-528, 1994.
 
90) Takada M, Masuda N, Matsuura E, et al: Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br. J. Cancer 71: 160-165, 1995.
PubMed
91) Hamzaoui A, Thomas P, Castelnau O, et al: Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring. Lung Cancer 16: 191-202, 1997.
PubMed
92) Stieber P, Dienemann H, Hasholzner U, et al: Comparison of cytokeratin fragment 19 (CYFRA 21-1) , tissue polypeptide antigen (TPA) as tumor markers in lung cancer. Eur. J. Clin. Chem. Clin. Biochem. 31: 689-694, 1993.
 
93) Huang MS, Jong SB, Tsai MS et al: Comparison of cytokeratin fragment 19 (CYFRA 21-1) , tissue specific antigen (TPA) and carcinoembryonic antigen (CEA) as tumor markers in bronchogenic carcinoma. Respir. Med. 91: 135-142, 1997.
 
94) Wollenberg B, Jan V, Schmit UM, et al: Cyfra 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res. 16: 3117-3124, 1996.
 
95) Pujol JL, Grenier J, Daures Jp, et al: Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1. Immunoradiometric Assay as a marker of lung cancer. Cancer Res. 53: 61-66, 1993.
 
96) Nakata B, Chung YS, Kato Y, et al: Clinical significance of serum CYFRA 21-1 in gastric cancer. Br. J. Cancer 73: 1529-1532, 1996.
PubMed
97) Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest. Urol. 17: 159-163, 1979.
PubMed
98) Hara M, Inoue T, Koyanagi Y, et al: Immunoelectrophoretic studies of the protein component in human seminal plasma (especially its specific component) . (Forensic immunological study of body fluid and secretions. VI) Jpn. J. Legal Med. 23: 117-122, 1969.
 
99) Richie Jp, Catalona WJ, Ahmann FR, et al: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 42: 365-374, 1993.
PubMed
100) Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324: 1156-1161, 1991.
PubMed
101) Lange PH: The nest era for prostate cancer. JAMA 269: 95-96, 1993. American College of Physicians. Clinical guideline: . part III. Screening for prostate cancer. Ann. Intern. Med. 126: 480-484, 1997.
 
102) American College of Physicians. Clinical guideline:part III. Screening for prostate cancer. Ann. Intern. Med. 126 : 480-484, 1997.
 
103) Labrie F, Dupont A, Candas B, et al: Decrease of prostate cancer death by screening: first data from the Quebec prospective and randomized study. Proc. Am. Soc. Clin. Oncol. 17: 2a, 1998.
 
104) Benson MC, Whang IS, Pantuck A, et al: Prostate specific antigen density: ameans of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol. 147: 815-816, 1992.
 
105) Partin AW, Carter HB, Chan DW, et al: Prostate-specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol. 143: 747, 1990.
PubMed
106) Vashi AR, Oesterling JE: Percent free prostate-specific antigen: Entering a new era in the detection of prostate cancer. Mayo Clin. Proc. 72: 337-344, 1997.
PubMed
107) Carter HB, Epstei JI, Chan DW, et al: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277: 1456-1460, 1997.
 
108) Catalona WJ, Smith DS, Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2. 6 to 4. 0ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277: 1452-1455, 1997.
 
109) Osterling JE, Chan DW, Epstein JI, et al: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139: 766-772, 1988.
 
110) Lange PH, Ercole CJ, Lightner DJ, et al: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 141: 873-879, 1989.
PubMed
111) Kabalin JN, Hodge KK, McNeal JE, et al: Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J. Urol. 142: 326-331, 1989.
PubMed
112) Ruckle HC, Klee GG, Oesterling JE: Prostate-specific antigen: Concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin. Proc. 69: 69-79, 1994.
PubMed
113) Boogerd W, Vroom TM, van Heerde PV, et al: CSF cytology versus immunocytochemistry in meningealcarcinomatosis. J. Neurol. Neurosurg. Psychiatry 51: 142-145, 1988.
 
114) Schold SC, Wasserstrom WR, Fleisher M, et al: Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann. Neurol. 8: 597, 1980.
PubMed
115) Posner JB: Leptomeningeal metastases. In: Neurologic complications of cancer. F. A. Davis Company, Philadelphia, 1995, pp. 143-171.
 
116) Dhillon DP, Spiro SG: Malignant pleural effusions. Br. J. Hosp. Med. 29: 506, 1983.
PubMed
117) Cascinu S, Del Ferro E, Barbanti I, et al: Tumor markers in the diagnosis of malignant serous effusions. Am. J. Clin. Oncol. 20: 247-250, 1997.
 
118) Villena V, Lopez-Encuentra A, Echave-Sustaeta J, et al: Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Cancer 78: 736-740, 1996.
PubMed
119) Gerbes AL, Hoermann R, Mann K, et al: Human chorionic gonadotropin-beta in the differentiation of malignancy-related and nonmalignant ascites. Digestion 57: 113-117, 1996.
PubMed
120) Ismail MA, Rotmensch J, Mercer LJ, et al: CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders. J. Reprod. Med. 39: 510-OOO, 1994.
PubMed
121) Kornek G, Schenk T, Raderer M, et al: Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br. J. Cancer 71: 182-185, 1995.
PubMed
122) Schwartz MK: Cancer markers (eds. by DeVita VT, Hollman S, Rosenberg SA) , 3rd ed., Lippincott Co, Philadelphia, 1993, pp. 531-542.
 
P.352 掲載の参考文献
1) 向井 清: 組織学的悪性度診断. 病理と臨床 7: 844-847, 1991.
 
2) 菅野晴夫: がんの組織病理学. がんの科学. I. がんの生物学 (太田邦夫, 山本 正, 杉村 隆・他編) 南江堂, 東京, 1980, pp. 16-42.
 
3) Minna JD, Pass H, Glatstein E, et al: Cancer of the lung. In Cancer. Principles & Practice of Oncology. (edited by Devita VT Jr, Hellman S, Rosenberg A) , 4th Ed, Lippincott, Philadelphia, 1989, pp. 591-705.
 
4) Takise A, Kodama T, Shimosato Y, et al: Histopathologic prognostic factors in adenocarcinoma of the periph- eral lung less than 2 cm in diameter. Cancer 61: 2083-2088, 1988.
 
5) 向井 清: 増殖細胞抗原. 病理と臨床 8 (臨時増刊) : 178-185, 1990.
 
6) Enzinger FM, Weiss SW: Soft Tissue Tumors. 3 rd Ed. Mosby, St. Louis, 1995, pp. 1-16.
 
7) Myhre-Jensen O, Kaae S, Madsen EH, et al: Histopathological grading in soft tissue tumours. Acta Pathol. Microbiol. Immunol. (A) 91: 145-150, 1983.
 
8) 下山正徳, 向井 清, 菊池昌弘・他: 専門病理医による非ポジキンリンパ腫の病理診断とホルマリン固定標本による TBマーカー免疫診断の一致率: LCPP (Lymphoma Clinico-pathology Panel) による共同研究. がんの臨床 39: 739 -765, 1993.
 
9) Cotran RS, Kumar V, Robbins SL: Robbins Pathologic Basis of Disease. 4th Ed, WB Saunders, Philadelphia, 1989, pp. 239-305.
 
10) Seidman JD, Berman JJ: Premalignant nonepithelial lesions: Abiological classification. Mod. Pathol. 6: 544- 554, 1993.
 
11) 向井 清: 腫瘍の病理診断に用いられる免疫組織化学マーカー. 癌と化学療法 18: 1383-1388, 1991.
Medical*Online
12) 町並陸生: 電子顕微鏡所見を病理組織診断にどう役立てるか. 病理と臨床 10 (臨時増刊) : 8-15, 1992
 
13) Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early breast carcinoma. Cancer 74 (suppL) : 381-400, 1994.
 
14) 加藤治文, 小中千守, 平野 隆・他: CAS 200システムを用いた予後因子の検討. 病理と臨床 12: 853-857, 1994.
 
15) Asamura H, Nakajima T, Mukai K, et al: Degree of malignancy in thymic epithelial tumors in terms of nuclear DNA content and nuclear area. Am. J. Pathol. 133: 615-622, 1988.
PubMed
P.357 掲載の参考文献
1) Byers RM, Bland KI, Borlase B, et al: The prognostic and therapeutic value of frozen section determinations in the surgical treatment of squamous carcinoma of the head and neck. Am. J. Surg. 136: 525-528, 1978.
PubMed
2) Ackerman LV, Ramirez GA: Indications for and limitations of frozen section diagnoses. Br. J. Surg. 46: 336-350, 1959.
PubMed
3) Nakazawa H, Rosen P, Lane N, et al: Frozen section experience in 3000 cases. Am. J. Clin. Pathol. 49: 41-51, 1968.
PubMed
4) Kurman RJ, Solomon D: The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Springer-Verlag, New York, 1994.
 
5) Page DL, Johnson JE, Dupont WD: Probabilistic approach to the reporting of fine-needle aspiration cytology of the breast. Cancer 81: 6-9, 1997.
PubMed
6) The Papanicolaou Society of Cytopathology: Guidelines of the Papanicolaou Society of Cytopathology for the examination of fine-needle aspiration specimens from thyroid nodules. Diagn. Cytopathol. 15: 84-89, 1996.
PubMed
7) Hermansen C, Poulsen HS, Jensen J, et al: Diagnostic reliability of combined physical examination, mammography, and fine-needle puncture ("triple test") in breast tumors. A prospective study. Cancer 60: 1866-1871, 1987.
 
8) Schuhmann R, Huebner F, Brose C, et al: Der Stellenwert der Aspirationszytologie im Rahmen der Tripel-Diagnostik tastbarer Mamma-Veraenderungen. Geburtsh. u. Fauenheilk. 55: 553-558, 1995.
 
9) 覚道健一, 中村靖司, 長沼 広・他: 特集-甲状腺癌オブザーバー・バリエーション. 病理と臨床 14: 580-582, 1996.
 
10) Mukai K, Abe M, Ohshima K, et al: Hodgkin 's disease: results of central pathology review for a protocol study (JGOG 890 G) in Japan. Mod. Pathol. 10: 130 A, 1997.
 
P.371 掲載の参考文献
1) Wilson JMG, Jungner G: Principles and Practice of Screening for Diseases. WHO, Geneva, 1968 (重松逸造, 福島一郎, 加藤孝之 (監訳) : 疾病スクリーニングの原理と方法. 日本公衆衛生協会, 東京, 1970, pp. 1-4) .
 
2) Cole P, Morrison AS: Basic issues in population screening for cancer. J. Nat1. Cancer Inst. 64: 1263-1272, 1980.
 
3) Miller AB: Principles of screening and the evaluation of screening programs. In: Screening for Cancer (ed by Miller AB) , Academic Press, Orlando, 1985, pp. 3-24.
 
4) Prorok PC, Miller AB (eds) : Screening for Cancer. UICC Technical Report Series Volume 78, UICC, Geneva, 1984, p. 4.
 
5) Greenwald P, Costlow R, Prorok P, et al: Screening in the context of cancer control. In: Screening for Cancer (ed by Miller AB) , Academic Press, Orlando, 1985, pp. 25-48.
 
6) 大島 明: 癌集団検診の評価手法の基本. 日医師会誌 107: 527-530, 1992.
 
7) Day NE: Estimating the sensitivity of a screening test. J. Epidemiol. Community Health 39: 364-366, 1985.
 
8) Hakama M, Chamberlain J, Day NE, et al: Evaluation of screening programmes for gynaecological cancer. Br. J. Cancer 52: 669-673, 1985.
PubMed
9) Fletcher SW, Black W, Harris R, et al: Report of the international workshop on screening for breast cancer. J. Natl. Cancer Inst. 85: 1644-1656, 1993.
PubMed
10) Kerlikowske K, Grady D, Rubin SM, et al: Efficacy of screening mammography, a meta-analysis. JAMA 273: 149-154, 1995.
PubMed
11) Smart CR, Hendrick RE, Rutlegdge JH III, et al: Benefit of mammography screening in women aged 40 to 49 years: current evidence from randomized controlled trials. Cancer 75: 1619-1626, 1995.
 
12) Shapiro S, Venet W, Strax P, et al: Periodic Screening for Breast Cancer: The Health Insurance Plan Project and Its Sequelae. The Johns Hopkins Univ. Press, Baltimore, 1988.
 
13) Fontana RS, Sanderson DR, Woolner LB, et al: Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 67: 1155-1164, 1991.
PubMed
14) Prorok PC: Screening studies. In: Cancer Prevention and Control (eds by Greenwald P, Kramer BS, Weed DL) , Marcel Dekker, New York, 1995, pp. 225-242.
 
15) Mandel JS, Bond JH, Timothy R, et al: Reducing mortality from colorectal cancer by screening for fecal occult blood. N. Engl. J. Med. 328: 1365-1371, 1993.
 
16) Hardcastle JD, Chamberlain JO, Robinson MHE, et al: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477, 1996.
 
17) Kronborg O, Fenger C, Olsen J, et al: Randomised study of screening for colorectal cancer with faecal-occultblood cancer. Lancet 348: 1467-1471, 1996.
 
18) Oshima A, Hirata N, Ubukata T, et al: Evaluation of a mass screening program for stomach cancer with a casecontrol study design. Int. J. Cancer 38: 829-833, 1986.
 
19) Fukao A, Tsubono Y, Tsuji I, et al: The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: apopulation-based case-control study. Int. J. Cancer 60: 45-48, 1995.
 
20) 阿部陽介, 光島 徹, 永谷京平・他: Case-control studyの手法を用いた胃癌死亡減少に対する胃集団検診の効果の疫学的評価. 日消病会誌 92: 836-845, 1995.
 
21) Sobue T, Suzuki T, Hashimoto S, et al: Acase-control study of the effectiveness of cervical cancer screening in Osaka, Japan. Jpn. J. Cancer Res. 79: 1269-1275, 1988.
 
22) Sobue T, Suzuk T, Naruke T, et al: Acase-Control study for evaluating lung-cancer screening in Japan. Int. J. Cancer 50: 230-237.
 
23) 久道 茂 (編) : 厚生省がん研究助成金による適正な大腸集団検診制度の確立と精度の向上に関する研究. 平成2年度 報告書, 東北大学医学部公衆衛生学教室, 仙台, 1991, p. 11.
 
24) Saito H, Soma Y, Koeda J, et al: Reduction in risk of mortality from colorectal cancer by fecal blood screening with immunochemical hemagglutination test. A case-control study. Int. J. Cancer 61: 465-469, 1995.
PubMed
25) Oshima A: Acritical review of cancer screening Programs in Japan. Int. J. Technol. Assess. Health Care 10: 348-358, 1994.
 
26) Hakama M, Miller AB, Day NE: Screening for Cancer of the Uterine Cervix. IARC Scientific Publication No. 76, IARC, Lyon, 1986.
 
27) U. S. Preventive Services Task Force: Guide to Clinical Preventive Services, 2nd ed., Williams & Wilkins, Baltimore, 1996, pp. 105-117.
 
28) Tsukuma H, Mishima T, Oshima A: Prospective study of "early" gastric cancer. Int. J. Cancer 31: 421-426, 1983.
PubMed
29) Oshima A: Acritical review of cancer screening Programs in Japan. Int. J. Technol. Assess. Health Care 10: 348-358, 1994.
 
30) Chamberlain J, Miller AB (eds) : Screening for Gastrointestinal Cancer. Hans Huber Publishers, Toronto, 1988, p. 63.
 
31) Nishi M, Miyake H, Takeda T, et al: Mass screening for neuroblastoma and mortality in birth cohorts. Int. J. Cancer 71: 552-555, 1997.
PubMed
32) Woods WG, Tuchman M, Robison LL, et al: Apopulation-based study of the usefulness of screening forneuroblastoma. Lancet 348: 1682-1687, 1996.
 
33) Ajiki W, Tsukuma H, Oshima A, et al: Effects of mass screening on incidence, mortality, and survival rates inOsaka, Japan. Cancer Causes and Control 1998 (in press) .
 
34) 厚生省統計情報部: 平成7年度老人保健事業報告, 厚生省統計情報部, 東京, 1997.
 
P.379 掲載の参考文献
1) Urban JA: Radical excision of the chest wall for mammary cancer. Cancer 4: 1263, 1951.
PubMed
2) Brock SR, Whytehead LL: Radical pneumonectomy for bronchial carcinoma. Br. J. Surg. 43: 8-24, 1955.
 
3) McNeer G, Sunderland DA, Mclnnes G, et al: Amore through operation for gastric cancer: Anatomical basis and description of technique. Cancer 4: 957, 1951.
 
4) Fortner JG: Regional resection of cancer of the pancreas. Surgery 73: 307-320, 1973.
PubMed
5) Veronesi U, Valagussa P: Inefficacy of internal mammary node dissection in breast cancer surgery. Cancer 47: 170, 1981.
PubMed
6) Ramsey HE, Cahan WG, Beattie EJ, et al: The importance of radical lobectomy in lung cancer. J. Thorac. Cardiovasc. Surg. 58: 225-230, 1969.
PubMed
7) McNeer G, Bowden L, Booher RJ, et al: Elective total gastrectomy for cancer of the stomach; Endresults. Ann. Surg. 180: 252-256, 1974.
 
8) Fortner JG: Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites; tumorstaging and results. Ann. Surg. 199: 418-425, 1984.
 
9) Sobin LH, Wittekind CH: TNM Classification of Malignant Tumours (Fifth Edition) , Wiley-Liss, New York, 1997, pp. 1-4.
 
10) Annual report of national cancer center hospital 1996. National cancer center hospital, Tokyo, 1996, pp. 34-57.
 
11) がんの統計編集委員会 (委員長: 垣添忠生) 編: がんの統計 '97. 財団法人がん研究振興財団, 東京, 1997.
 
12) Bonenkampf JJ, Songun I, Hermans J, et al: Randomized comparison of morbidity after D 1 and D 2 dissection for gastric cancer in 996 Dutch patients. Lancet 345: 745-748, 1995.
 
13) Cushieri A, Fayers P, Fielding J, et al: Postoperative morbidity and mortality after D 1 and D 2 resections for gastric cancer; preliminary results of the MRC randomized controlled surgical trial. Lancet 347: 995-999, 1996.
 
14) Sano T, Martin IG: Lymphadenectomy and pancreatico-splenectomy in gastric cancer surgery. Lancet 348: 195-196, 1996.
PubMed
15) Veronesi U, Saccozzi R, DelVecchio M, et al: Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N. Engl. J. Med. 305: 6-11, 1981.
 
16) Ziere HU, Muller JM, Jacobi CA, et al : Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the esophagus: aprospective randomized study. World J. Surg. 19: 444-449, 1995.
 
17) 後藤満一, 門田守人, 左近賢人・他: 膵癌における術中照射療法の評価. 日外会誌 94: 269-276, 1993.
 
18) Rosell R, Gomez-Codina J, Camps C, et al: Arandomized trial comparing preoperative chemotherapy plussurgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 330: 153-158, 1994.
 
19) Howell A, Bush H, George WD, et al: Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet ii (8398) : 307-311, 1984.
 
20) Spitz FR, Abbruzzese JL, Lee JE, et al: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J. Clin. Oncol. 15: 928-937, 1997.
PubMed
21) NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450, 1990.
PubMed
22) Bozzetti F, Audisio RA, Giardini R, et al: Role of surgery in patients with primary non-Hodgkin 's lymphoma of the stomach; an old problem revisited. Br. J. Surg. 80: 1101-1106, 1993.
PubMed
23) Tsuchiya R, Asamura H, Kondo H, et al: Extended resection of the left atrium, great vessels, or both for lung cancer. Ann. Thorac. Surg. 57: 960-965, 1994.
PubMed
24) 川原英之, 藤田博正, 小田桐重遠・他: 大動脈合併切除を伴う食道癌切除例の1例. 日外会誌 86: 1546-1551, 1985.
 
25) Yamaoka Y, Ozawa K, Kumada K, et al: Total vascular exclusion for hepatic resection in cirrhotic patients: application of venovenous bypass. Arch. Surg. 127: 276-280, 1992.
PubMed
26) Skinner DG, Pritchett TR, Lieskovsky G, et al : Vena caval involvement by renal cell carcinoma; surgical resection provides meaningful long-term survival. Ann. Surg. 210: 387-394, 1989.
PubMed
27) 広野達彦, 小池輝明, 滝沢恒世・他: 胸骨正中切開による両側縦隔リンパ節郭清とその意義. カレントテラピー 4: 1480-1483, 1986.
 
28) 大橋一郎, 高木国夫, 小西敏郎・他: 胃癌の大動脈リンパ節転移陽性の5年生存例について. 日消外会誌 9: 112-116, 1976.
 
29) 佐々木壽英, 梨本 篤, 筒井光広・他: 胃癌大動脈周囲リンパ節郭清の適応. 日消外会誌 22: 1749-1754, 1989.
 
30) Shimizu J, Oda M, Morita K, et al: Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination. J. Surg. Oncol. 61: 1-6, 1996.
PubMed
31) 米村 豊, 藤村 隆, 伏田幸夫・他: 腹膜播種性胃癌に対するsubtotal peritonectomy+温熱化学療法. 手術 49: 553-557, 1995.
 
32) Sugarbaker PH: Peritonectomy procedures. Ann. Surg. 221: 29-42, 1995.
PubMed
33) Nakagawa H, Kimura S, Kubo S, et al: Prognostic factors in patients surviving for more than 1 or 5 years after removal of metastatic brain tumors. Neurol. Med. Chir. 32: 947-951, 1992.
PubMed
34) Rusch VW: Pulmonary metasectomy. Chest 107: 322 s-331 s, 1995.
 
35) 山本順司, 小菅智男, 島田和明・他: 転移性肝癌の外科治療; 適応と治療成績. 消化器外科 18: 1655-1662, 1995.
 
36) 幕内博康, 町村貴郎, 杉原 隆・他: 食道粘膜癌の内視鏡的診断と治療. 消化器内視鏡 2: 447-452, 1990.
 
37) 平尾雅紀, 小林多加志, 長谷良高男・他: 胃の腫瘍性病変に対する内視鏡的切除法. Gastroenterol. Endosc. 25: 1942- 1953, 1983.
 
38) Kudo S, Kashida H, Nakajima T, et al: Endoscopic diagnosis and treatment of early colorectal cancer. World J. Surg. 21: 694-701, 1997.
PubMed
39) 金平永二 , 大村健二 , 渡辺洋宇: 特殊な直腸鏡を用いた直腸腫瘍の治療. 手術 48: 1465, 1994.
 
40) 三富利夫, 幕内博康: 早期食道癌に対する内視鏡的粘膜切除術. 消化器外科 19: 563-570, 1996.
 
41) 竹腰隆男, 藤井 彰, 馬場保昌・他: 早期胃癌に対する内視鏡切除の限界; 長期予後からみた限界と対策. 臨牀消化器 内科 8: 649-660, 1993.
 
42) Landreneau RJ, Mack MJ, Hazelrigg SR, et al: Video-assisted thoracic surgery: basic technical concepts and intercostal approach strategies. Ann. Thorac. Surg. 54: 800-807, 1992.
PubMed
43) 大橋秀一: 腹腔鏡下胃内手術. 手術 48: 333-337, 1994.
 
44) 大上正祐, 熊井浩一郎, 若林 剛・他: 早期胃癌に対する新しい治療法; lesion lifting法による腹腔鏡下胃局所切除術. 胃と腸 28: 1461-1468, 1993.
 
45) Gagner M, Rheault M, Dubuc J: Laparoscopic partial hepatectomy for liver tumor. Surg. Endosc. 6: 97, 1992.
 
46) Jacob M, Verdeja JC, Goldstein HS: Minimally invasive colon resection (laparoscopic colectomy) . Surg. Laparosc. Endosc. 1: 144-150, 1991.
 
47) Ono Y, Sahashi M, Yamada S, et al: Laparoscopic nephrectomy without morcellation for renal cell carcinoma; initial two cases. J. Urol. 150: 1222-1224, 1993.
 
48) Cushieri A: Endoscopic subtotal oesophagectomy for cancer using the right thoracoscopic approach. Surg. Oncol. 2: 3-11, 1993.
 
49) Watson DI, Devitt PG, Game PA: Laparoscopic Billroth II gastrectomy for early gastric cancer. Br. J. Surg. 82: 661-662, 1995.
PubMed
50) 小西文雄, 永井秀雄, 岡田真樹・他: 大腸癌に対する腹腔鏡下手術のcontroversy; 現時点で進行癌は適応となりうるか? JSES 1: 19, 1996.
 
51) Downey RJ, McCormack P, LoCicero J III: The video-assisted thoracic surgery study group. Dissemination of malignant tumors after video-assisted thoracic surgery; areport of twenty-one cases. J. Thorac. Cardiovasc. Surg. 111: 954-960, 1996.
 
52) Wexner SD, Cohen SM: Port site metastases after laparoscopic colorectal surgery for cure of malignancy. Br. J. Surg. 82: 295-298, 1995.
PubMed
53) 秋山 洋, 佐藤靖雄, 高橋文夫・他: 非開胸食道全摘出による一期的咽頭胃吻合術. 手術 27: 1-5, 1973.
 
54) 中野博重, 渡辺明彦, 澤田秀智・他: 胃癌に対する幽門保存胃切除術の適応と成績. 外科治療 68: 131-135, 1993.
 
55) Traverso LW, Longmire WP: Preservation of the pylorus in pancreaticoduodenectomy. Surg. Gynecol. Obstet. 146: 959-962, 1978.
PubMed
56) Starzl TE, Demetris AJ, VanThiel D: Medical progress. Liver transplantation (Second of two parts) . N. Engl. J. Med. 321: 1092, 1989.
 
57) Gane EJ, Portmann BC, Naoumov NV, et al: Long-term results of hepatitis C infection after liver transplantation. N. Engl. J Med. 334: 815-820, 1996.
PubMed
58) Mazzaferro V, Regaila E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334: 693-699, 1996.
 
59) 市田文弘, 谷川久一: 肝移植適応規準. 国際図書出版, 東京, 1991, pp. 38-41.
 
60) Starzl TE, Fung J, Tzakis A, et al: Baboon-to-human liver transplantation. Lancet 341: 65-71, 1993.
PubMed
61) Starzl TE, Todo S, Tzakis A, et al: Abdominal organ cluster transplantation for the treatment of upper abdominal malignancy. Ann. Surg. 210: 374-386, 1989.
PubMed
62) Satava RM: Lest we forget the future. J Am. Coll. Surg. 184: 519-520, 1997.
PubMed
P.399 掲載の参考文献
1) Hall EJ: Radiology for the radiologist, Fourth ed, Lippincott, Philadelphia, 1994.
 
2) Mivechi NF, Hofer KG, Hofer MG: Influence of hypoxia and acidity on thermal radiosensitization and direct heat-induced death of BP-8 sarcoma cells. Radiology 138: 465-471, 1981.
PubMed
3) Dewey WG, Hopewood LE, Sapareto SA, et al: Cellular responses to combinations of hyperthermia and radiation. Radiology 123: 463-474, 1977.
 
4) Phillips TL: Radiation-chemotherapy interaction. Lung Cancer (eds by Pass HI, et al) , Lippincott-Raven, New York, 1995, pp. 251-270.
 
5) Withers HR: Biologic basis for altered fractionation schemes. Cancer 55: 2086-2095, 1985.
PubMed
6) Fowler JF: What next in fractionated radiotherapy? Br. J. Cancer 49 (S) : 285-300, 1984.
 
7) Peters LJ, Ang KK, Thames HD: Accelerated fractionation in the radiation treatment of head and neck cancer: Acritical comparison of different strategies. Acta Oncol. 27: 185-194, 1988.
 
8) Withers HR, Taylor JMG, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27: 131-146, 1988.
 
9) Horiot JC, Fur RL, N 'Guyen T, et al: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy, Radiother. Oncol. 25: 231-241, 1992.
 
10) Pinto LHJ, Canary PCV, Araujo CMM, et al: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in Stages III and IV oropharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 21: 557-562, 1991.
 
11) Sanchiz F, Milla A, Torner J, et al: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 19: 1347-1350, 1990.
 
12) Datta NR, Choudhry AD, Gupta S, et al: Twice a day versus once a day radiation therapy in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 17: 132 (abst) , 1989.
 
13) Marcial V, Pajak T, Chang C, et al: Hyperfractionationed photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, and sinuses, using radiation therapy as the only planned modality. Preliminary report by the Radiation Therapy Oncology Group (RTOG) . Int. J. Radiat. Oncol. Biol. Phys. 13: 41-47, 1987.
PubMed
14) Jackson SM, Weir LM, Hay JH, et al: Arandomized trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 43: 39-46, 1997.
 
15) Saunders MI, Dische S, Barrett A, et al: Randomized multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small℃ell lung cancer: an interium report. Br. J. Cancer 73: 1455-462, 1996.
 
16) Schmidt-Ullrich RK, Johnson CR, Wazer DE, et al: Accelerated superfractionated irradiation for advanced carcinoma of the head and neck: concomitant boost technique. Int. J. Radiat. Oncol. Biol. Phys. 21: 563-568,
PubMed
17) Van den Bogaert W, Van der Bogaert E, Horiot J CI, et al: EORTC Cooperative Group of Radiotherapy: Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 12: 587-591, 1986.
 
18) Van den Bogaert W, Van der Schueren E, Horiot JC, et al: The EORTC randomized trial on three fractions per day and misonidazole (trial No. 22811) in advanced head and neck cancer: long term results and side effects. Radiother. Oncol. 35: 91-99, 1995.
PubMed
19) Crino L, Latini P, Meacci M, et al: Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-smal-cell lung cancer. Ann. Onco1. 4: 847-851, 1993.
 
20) Arriagada R, Chevalier TL, Quoix E, et al: ASTRO Prenary: Effect of chemotherapy on localy advanced nonsmall cell lung carcinoma: Arandomized study of 353 patients. Int. J. Radiat. Oncol. Biol. Phys. 20: 1183-1190, 1991.
 
21) Mira JG, Miller TP, Crowley J: Chest irradiation (RT) vs. chemotherapy+/-Prophylactic brain RT in localizednon-small-cell lung cancer: ASouthwest Oncology Group randomize study. Int. J. Radiat. Oncol. Biol. Phys. Proceeding of the ASTRO 33 th annual meeting: 145, 1991.
 
22) Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: seven year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J. Natl. Cancer Inst. 88: 1210-1215, 1996.
 
23) Mattson K, Holsti LR, Holsti P, et al: Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur. J. Cancer Clin. Oncol. 24: 477-482, 1988.
PubMed
24) Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann. Intern. Med. 115: 681-686, 1991.
PubMed
25) Trovo MG, Minatel E, Veronesi A, et al: Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma ': Arandomized study. Cancer 65: 400-404, 1990.
 
26) Lewin F, Damber L, Jonsson H, et al: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: arandomized phase III study. Radiother. Oncol. 43: 23-28, 1997.
 
27) Eschwege F, Gueddari BE, Wierzbiki R, et al: Randomized multicentric international phase III trial of neoad-adjuvant chemotherapy (NACT) with bleomycin (B) , epirubicin (E) , cisplatin (C) followed by radiotherapy versus radiotherapy alone in undifferentiated carcinoma of nasopharyngeal type (UCNT) : Preliminary results. Int. J. Radiat. Oncol. Biol. Phys. 32: 192 (abst) , 1995.
 
28) Martin M, Hazan A, Vergnes L, et al: Randomized study of 5-fluorouracil and cisplatin as neoadjuvant therapy in head and neck cancer: Apreliminary report. Int. J, Radiat. Oncol. Biol. Phys. 191973-975, 1990.
 
29) Brunin F, Rodriguez J, Jaulerry C, et al: Induction chemotherapy in advanced head and neck cancer: Preliminary results of a randomized study. Acta Oncol. 28: 61-65, 1989.
PubMed
30) Arcangeli G, Nervi C, Righini RE, et al: Combined radiation and drugs: The effect of intra-arterial chemotherapy followed by radiotherapy in head and neck cancer. Radiother. Oncol. 1: 101: 107, 1983.
 
31) Petrovich Z, Block J, Kuish H, et al: Arandomized comparison of radiotherapy with a radiotherapy-chemotherapy combination in Stage IV carcinoma of the head and neck. Cancer 47: 2259-2264, 1981.
 
32) Fazekas JT, Sommer C, Kramer S: Adjuvant intravenous methotrexate or definitive radiotherapy alone foradvanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx. Int. J. Radiat. Oncol. Biol. Phys. 6: 533-541, 1980.
PubMed
33) Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N. Engl. J. Med. 326: 524-530, 1992.
PubMed
34) Trovo MG, Minatel E, Franchin G, et al: Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 24: 11-15, 1992.
PubMed
35) Soresi E, Clerici M, Grilli R, et al: Arandomized clinical trial comparing radiation therapy v radiation therapy plus cis-Dichlorodiammine plainum (II) in the treatment of locally advanced non-srnall cell lung cancer. Semin. Oncol. 15: 20-25, 1988.
 
36) Johnson DH, Einhorn LH, Bartolucci A, et al: Thoracic radiotherapy dose not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann. Intern. Med. 113: 33-38, 1990.
PubMed
37) Furuse K, Fukuoka M, Takada Y, et al: Arandomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin C (M) , vindesine (V) , and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC) : Preliminary analysis. ASCO proceedings: 459 a, 1997.
 
38) Herskovic A, Martz K, Al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326: 1593-1598, 1992.
PubMed
39) Araujo CMM, Souhami L, Gil RA, et al: Arandomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 67: 2258-2261, 1991.
 
40) Earle JD, Gelber RD, Moertel CG, et al: Acontrolled evaluation of combined radiation and bleomycin therapy for squamous cell carcinoma of the esophagus. Int. J. Radiat. Oncol, Biol. Phys. 6: 821-826, 1989.
 
41) Jeremic B, Shibamoto Y, Stanisavljevic B, et al: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: aprospective randomized trial. Radiother. Oncol. 43: 29-37, 1997.
 
42) Weissberg JB, Son YH, Papac RJ, et al: Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 17: 3-9, 1989.
PubMed
43) Gupta NK, Pointon RCS, Wilkinson PM: Arandomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin. Radiol. 38: 575-581, 1987.
 
44) Fu KK, Phillips TL, Silverberg IJ, et al: Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: Update of a Northern California Oncology Group Randomized Trial. J. Clin. Oncol. 5: 1410-1418, 1987.
 
45) Vermund H, Kaalhus O, Winther F, et al: Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: Aphase III clinical trial. lnt. J. Radiat. Oncol. Biol. Phys. 11: 1877-1886, 1985.
 
46) Shanta V, Krishnamurthi S: Combined bleomycin and radiotherapy in oral cancer. Clin. Radiol. 31: 617-620, 1980.
PubMed
47) Merlano M, Benasso M, Corvo R, et al: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J. Natl. Caner Inst. 88: 583-589, 1996.
 
48) Shields TW: Preoperative radiation therapy in the treatment of bronchial carcinoma. Cancer 30: 1388-1393, 1972.
PubMed
49) Acollaborative study: Preoperative irradiation of cancer of the lung: Final report of a therapeutic triaL Cancer 36: 914-925, 1975.
 
50) Arnott SJ, Duncan W, Kerr GR, et al: Low dose preoperative radiotherapy for carcinoma of the esophagus: results of a randomized clinical trial. Radiother. OncoL 24: 108-113, 1992.
PubMed
51) Gignoux M, Roussel A, Paillot B, et al: The value of preoperative radiotherapy in esophageal cancer: Results of a study of the EORTC. World J. Surg. 11: 426-432, 1987.
 
52) Nygaard K, Hagen S, Hansen HS, et al: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: Arandomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J. Surg. 16: 1104-1110, 1992.
 
53) Wang M, Gu X-Z, Yin W, et al: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int. J. Radiat. Oncol. Biol. Phys. 16: 325-327, 1989.
PubMed
54) Launois B, Delarue D, Campion JP, et al: Preoperative radiotherapy for carcinoma of the esophagus. Surg. Gynecol. Obstet. 153: 690-692, 1981.
PubMed
55) Stockholm Rectal Cancer Study Group: Preoperative short-term radiation therapy in operable rectal carcinoma. Cancer 66: 49-55, 1990.
 
56) Gerard A, Buyse M, Nordlinger B, et al: Preoperative radiotherapy as adjuvant treatment in rectal cancer: Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) . Ann. Surg. 208: 606-614, 1988.
PubMed
57) Higgins GA, Humphrey EW, Dwight, RW: Preoperative radiation and surgery for cancer of the rectum: Veterans Administration Surgical Oncology Group Trial II. Cancer 58: 352-359, 1986.
PubMed
58) Roswit B, Higgins GA, Keehn RJ: Preoperative irradiation for carcinoma of the rectum and rectosigmoid colon: Report of a National Veterans Administration randomized study. Cancer 35: 1597-1602, 1975.
PubMed
59) Higgins GA, Conn JH, Jordan PH, et al: Preoperative radiotherapy for colorectal cancer. Ann. Surg. 181: 624- 631, 1975.
 
60) Stearns MW, Deddish MR, Quan SHQ, et al: Preoperative roentgen therapy for cancer of the rectum and rectosigmoid. Surg. Gynecol. Obstet. 138: 584-586, 1974.
 
61) Fletcher GH: Subclinical disease. Cancer 53: 1274-1284, 1984.
PubMed
62) Fletcher GH: Irradiation of subclinical disease in the draining lymphatics. Int. J. Radiat. Oncol. Biol. Phys. 10: 939-942, 1984.
PubMed
63) Vikram B, Strong EW, Sha JP, et al: Failure in the neck following multimodality treatment for advanced head and neck cancer. Head Neck Surg. 6: 724-729, 1984.
 
64) The Lung Cancer Study Group: Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N. Engl. J. Med. 315: 1377-1381, 1986.
 
65) Van Houtte P, Rocmans P, Smets P, et al: Postoperative radiation therapy in lung cancer: Acontrolled trial after resection of curative design. Int. J. Radiat. Oncol. Biol. Phys. 6: 983-986, 1980.
 
66) Fok M, Sham JST, Choy D, et al: Postoperative radiotherapy for carcinoma of the esophagus: aprospective, randomized controlled study. Surgery 113: 138-147, 1993.
 
67) Teniere P, Hay J-M, Fingerhut A, et al: Postoperative radiation therapy dose not increase survival after resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. Surg. Gynecol. Obstet. 173: 123-130, 1991.
 
68) Gastrointestinal Tumor Study Group: Prolongation of the disease free interval in surgically treated rectal carcinoma. N. Engl. J. Med. 312: 1465-1472, 1985.
 
69) Balslev I, Pedersen M, Teglbjaerg PS, et al: Postoperative radiotherapy in Dukes 'Band C carcinoma of the rectum and rectosigmoid. Cancer 58: 22-28, 1986.
 
70) Tupchong L, Scott CB, Blitzer PH, et al: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int. J. Radiat. Oncol. Biol. Phys. 20: 21-28, 1991.
PubMed
71) Pahlman L, Glimelius B: Pre-or postoperative radiotherapy in rectal and rectosigmoid carcinoma: report from arandomized multicenter trial. Ann. Surg. 211: 187-192, 1990.
 
72) Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324: 709-715, 1991.
PubMed
73) Laramore GE, Scott CB, Al-Sarraf M, et al: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup study OO34. Int. J. Radiat. Oncol. Biol. Phys. 23: 705-713, 1992.
PubMed
74) Haffty BG, Son YH, Sasaki CT, et al: Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 27: 241-250, 1993.
PubMed
75) Bachaud JM, Cohen-Jonathan E, Alzieu C, et al: Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 36: 999-1004, 1996.
PubMed
76) Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically resected rectal cancer. N. Engl. J. Med. 312: 1465-1472, 1985.
 
77) Fisher B, Wolmark N, Rockette H, et al: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP R-01. J. Natl. Cancer Inst. 80: 21-29, 1988.
 
78) Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for thetreatment of patients with surgical adjuvant adenocarcinoma of the rectum. J. Clin. Oncol. 10: 549-557, 1992.
 
79) O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med. 331: 502-507, 1994.
 
80) Overgaard J, Gonzalez DG, Hulshof MCCM, et al: Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 345: 540-543, 1995.
PubMed
81) Valdagni R, Amichetti M: Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymphnodes in stage IV head and neck patients. Int. J. Radiat. Oncol. Biol. Phys. 28: 163-169, 1993.
 
82) Perez CA, Gillespie B, Pajak T, et al: Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: Areport by the Radiation Therapy Oncology Group. Int. J Radiat. Oncol. Biol. Phys. 16: 551-558, 1989.
 
83) Perez C, Pajak T, Emami B, et al: Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Am. J. Clin. Oncol. 14: 133-141, 1991.
PubMed
84) Egawa S, Tsukiyama I, Watanabe S, et al: Arandomized clinical trial of hyperthermia and radiation versus radiation alone for superficially located cancers. J. Jpn. Soc. Ther. Radiol. Oncol. 1: 135-140, 1989.
 
85) Ernami B, Scott C, Perez CA, et al: Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors: Aprospectively controlled randomized study by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 34: 1097-1104, 1996.
 
86) Vernon CC, Hand JW, Field SB, et al: Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. Int. J. Radiat. Oncol. Biol. Phys. 35: 731-744, 1996.
PubMed
P.420 掲載の参考文献
1) Margulis AR: Interventional Diagnostic radiology-A subspeciality. AJR 99: 761-762, 1967.
 
2) Wallace S: Interventional radiology. Cancer 37: 517-531, 1976.
PubMed
3) Martin HE, Ellis EB: Biopsy by needle and aspiration. Ann. Surg. 92: 169-181, 1930.
PubMed
4) Lindblom K: Percutaneous puncture of renal cyctes and tumors. Acta Radiol. 27: 66, 1946.
PubMed
5) McFadzean AJS, Chang KPS, Wong CC: Solitary pyogenic abscess of liver treated by closed aspiration and antibiotics: Areport of 14 consecutive cases with recovery. Br. J. Surg. 41: 141, 1953.
 
6) Wiechel KL: Percutaneous transhepatic cholangiogrophy: technique and application. Acta Chir. Scand. (SuppL) 330: 1, 1964.
 
7) Dotter CT, Judkins MP: Transluminal treatment of arteriosclerotic obstruction. Description of a technique and apreliminary report of application. Circulation 30: 654-670, 1964.
 
8) Adam A, Hemingway AP: Interventional radiology. In: Oxford Textbook of Palliative Medicine (2 nd edition) (eds. by Doyle D, Hanks GWC, MacDonald N) . Oxford University Press, Oxford, New York, Tokyo, 1998, pp. 239-248.
 
9) Collins J: Pharmacologic rationale for regional drug delivery. J. Clin. Oncol. 2: 498-504, 1984.
PubMed
10) Lang EK: Superselective arterial catheterization as a vehicle for delivering radioactive infarct particles to tumors. Radiology 98: 391-399, 1974.
 
11) Yamada R, Sato M, Nakatsuka H, et al: Hepatic arterial embolization in 120 patients with unresectable hepatoma. Radiology 148: 397-401, 1983.
PubMed
12) Nakamura H, Hashimoto T, Oi H, et al: Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 17: 783-786, 1989.
PubMed
13) Konno T, Maeda H, Iwai K, et al: Effect of arterial administration of high-molecular weight anticancer agent SMANCS with lopid lymphographic agent on hepatoma. A preliminary report. Eur. J. Cancer Clin. Oncol. 191 1053-1065, 1983.
 
14) 田口鐵男, 斎藤達雄, 太田 潤・他: YM 881 (ジノスタチンスチマラマー) 懸濁液の肝動注における第II相試験. 癌と化学療法 18: 1665-1675, 1991.
 
15) Nakamura H, Hashimoto T, Oi H, et al: Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin in oil emulsion with overflow to segmental portal veins. Acta Radiol. 31: 347-349, 1990.
PubMed
16) Uchida H, Ohisi H, Matsuo N, et al: Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with anticancer drug and gelfoam particles for hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 13: 140-145, 1990.
 
17) Uchida H, Matsuo N, Sakaguchi H, et al: Segmental embolotherapy for hepatic cancer: Keys to success. Cardiovasc. Intervent. Radiol. 16: 67-71, 1993.
PubMed
18) 第9回全国原発性肝癌追跡調査報告 (1986-1987) , 日本肝癌研究会, 1990.
 
19) 西村幸洋, 打田日出夫, 郭 啓勇・他: 肝細胞1075例に対する肝動脈塞栓術-特に累積生存率と3年以上生存9例からみた抗癌剤混入リピオドール併用の評価-. 日癌治療会誌 26: 2279-2289, 1991.
 
20) Ikeda K, Kumada H, Saitoh S, et al: Effect of repeated transcatheter arterial embolization of the survival time in patients with hepatocellular carcinoma. Cancer 68: 2150-2154, 1991.
PubMed
21) Yamamoto K, Masuzawa M, Kato M, et al: Analysis of prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Cancer Chemother. Pharmacol. 31 (Suppl.) : S 77-S81, 1992.
 
22) 高田恵二: 原発性肝癌に対する経カテーテル治療の適応と選択に関する研究. 肝臓 35: 496-508, 1992
 
23) 畑中義美, 山下康行, 荒川昭彦・他: 1. 進行肝細胞癌に対するIVR (2) 切除不能肝細胞癌の肝動脈塞栓療法における予後因子. IVR 10: 253-256, 1995.
 
24) Yodono H, Sasaki T, Tarusawa K, et al: Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. Cancer Chemother. Pharmacol. 31 (Suppl.) : S89-S 92, 1992.
 
25) 高安幸生, 小竹正昌, 楢崎勝弘・他: 1. 進行肝細胞癌に対するIVR (4) リザーバーによる動注化学療法. IVR 10: 263-267, 1995.
 
26) Patt YZ: Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: The controversy continues. J. Clin. Oncol. 11: 815-819, 1991.
 
27) Begos DG, Ballantyne GH: Regional chemotherapy for colorectal liver metastases: Thirty years without patient benefit. J. Surg. Oncol. 56: 139-144, 1994.
PubMed
28) Hohn DC, Stagg RJ, Friedman MA, et al: Arandomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J. Clin. Oncol. 7: 1646-1654, 1989.
 
29) Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann. Intern. Med. 107: 459-465, 1987.
PubMed
30) Martin JK, O'Connel MJ, Wieand HS, et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch. Surg. 125: 1022-1027, 1990.
 
31) Chang AE, Schneider PD, Sugarbaker PH, et al: Aprospective randomized trial of regional versus systemic continuous 5 FU-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann. Surg. 206: 685-693, 1987.
 
32) Kemeny MM, Goldberg D, Beatty JD, et al: Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal cancer. Cancer 57: 492-498, 1986.
PubMed
33) Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of prospective randomized trial. J. Clin. Oncol. 10: 1112 1118, 1992.
 
34) Allen Mersh TG, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260, 1994.
PubMed
35) Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J. NatL Cancer Inst. 881252-258, 1996.
PubMed
36) 荒井保明: IVRにおける肝動注化学療法の基本手技. 臨床放射線 12: 1497-1508, 1993.
 
37) Arai Y, Inaba Y, Takeuchi Y: Interventional techniques for hepatic infusion chemotherapy. In: Interventional Radiology (Third Edition) (ed. by Casterfieda-Zuniga WD) . Williams & Wilkins, Baltimore, Philadelphia, London, Paris, Bangkok, Buenos Aires, Hong Kong, Munich, Sydney, Tokyo, Wroclaw, 1997, pp. 192-206.
 
38) Durand-Zaleski I, Roche B, Buyse M, et al: Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J. Natl. Cancer Inst. 89: 790-795, 1997.
PubMed
39) 荒井保明: II. 転移性肝癌に対する動注化学療法3. 血流改変術. IVR 8: 42-46, 1993.
 
40) 荒井保明, 木戸長一郎, 有吉 寛: 大腸癌肝転移の治療-間歇的大量5FU肝動注化学療法. カレントテラピー 12: 94-99, 1994.
 
41) Arai Y, Inaba Y, Takeuchi Y., et al: Intermittent hepatic arterial infusion of high-dose 5 FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother. Pharmacol. 40: 526-530, 1997.
PubMed
42) Arai Y, Sone Y, Inaba Y, et al: Hepatic arterial infusion chemotherapy for liver metastases from breast cancer. Cancer Chemother. Pharmacol. 33 (Suppl.) : S142-S 144, 1994.
 
43) 荒井保明, 富田和美, 大橋計彦・他: 動注化学療法とQOL. 癌治療と宿主 6: 267-272, 1994.
 
44) 荒井保明: 大腸癌肝転移に対する動注化学療法の現況と研究戦略. 癌と化学療法 20: 2467-2471, 1993.
Medical*Online
45) Seldinger SI: Catheter replacement of the needle in percutaneous arteriography. A new technique. Acta Radiol. 39: 368-376, 1953,
PubMed
46) 荒井保明, 澤田 敏, 中島康雄・他: Non-vascular IVR-画像診断手技の治療への応用- (木戸長一郎監) , 癌と化学療法社, 東京, 1991, pp. 143-151.
 
47) 蘆田 浩: IV 膿瘍ドレナージ. 放射線医学大系 特別巻 1 インターベンショナルラジオロジー (編集代表 田坂晧) , 中山書店, 東京, 1986, pp. 288-299.
 
48) 荒井保明: 8-26 Interventional radiologyの手技を用いた治療法の有効性についての研究. 厚生省がん研究助成金による研究報告書 平成8年度, 国立がんセンター, 東京, 1996, pp. 422-426.
 
49) Wright KC, Wallace S, Charnsangavej C, et al: Percutaneous endovascular stents: an experimental evaluation. Radiology 156: 69-72, 1985.
PubMed
50) Palmaz JC, Sibbitt PP, Reuter SR, et al: Expandable intraluminal graft: apreliminary study. Radiology 156: 73-77, 1985.
 
51) Rousseau H, Peul J, Joffre F, et al: Self-expanding endovascular prosthesis: an experimental study. Radiology 164: 709-714, 1987.
 
52) Uchida BT, Putman JS, Rosch J: Modification of Gianturco wire stents. AJR 150: 185-187, 1988.
 
53) 前田宗宏, 玉田俊明, 幕谷士郎・他: 消化管のステント. 画像診断 13: 309-314, 1993.
 
54) Sawada S, Fujiwara Y, Koyama T, et al: Application of expandable metallic stent to the venous system. Acta Radiol. 33: 156-159, 1992.
PubMed
55) Frui S, Sawada S, Irie T, et al: Hepatic inferior vena obstruction; treatment of two types with Gianturco expandable metallic stents. Radiology 176: 665-670, 1990.
 
56) 澤田 敏: ステントの機能とその適応. 映像情報 (M) 27: 1159-1163, 1995.
 
57) 岸 和史, 光実 淳, 園村哲朗・他: 門脈腫瘍栓に対するstent治療法の開発-dacron sheet covered self expandable metallic stentによる経皮経肝門脈形成術-. 日医放会誌 52: 1192-1194, 1992.
 
58) 荒井保明: 6-30 Interventional Radiologyの手技を用いた治療法の有効性に関する研究. 厚生省がん研究助成金による研究報告集 平成7年度, 国立がんセンター, 東京, 1995, pp. 242-247.
 
59) Sawada S, Tanigawa N, Kobayashi M, et al: Malignant tracheobronchial obstructive lesions: Treatment with Gianturco expandable metallic stents. Radiology 188: 205-208, 1993.
PubMed
60) Maeda M, Timmermans HA, Uchida B, et al: In vitro comparison of the spiral Z stent and the Gianturco Z stent. JVIR 3: 565-569, 1992.
PubMed
61) Yoshioka T, Sakaguchi H, Yoshimura H, et al: Expandable metallic biliary endoprostheses: Preliminary clinical evaluation. Radiology 177: 253-257, 1990. Coons H: Metallic stents for the treatment of biliary obstruction: A report of 100 cases. Cardiovasc. Intervent. Radiol. 15: 367-374, 1992.
 
62) Uchida H, Yoshioka T, Maeda M, et al: Use of original, modified, and spiral Z stents in the biliary system.
 
63) Stents-state of the art and future development (ed. by Liermann DD) . Polyscience Publication lnc, 1995, pp. 202-207.
 
64) 齋藤博哉, 桜井康雄, 高 明夫・他: メタリックステントによる悪性胆道狭窄の治療. 胆と膵 16: 931-938, 1995.
Medical*Online
65) Cwikiel W: Esophageal nitinol stents: long-term results-state of the art and future development. (ed. by Liermann DD) . Polyscience Publication Inc, 1995, pp. 218-221.
 
66) Song HY, Choi KC, Kwon HC, et al: Esophageal strictures: treatment with a new design of a modifiedGianturco stent. Radiology 184: 729-734, 1992.
PubMed
67) Schaer J, Katon RM, Ivancev K, et al: Treatment of malignant esophageal obstruction with silicone-coated metallic self-expanding stent. Gastrointest. Endosc. 38: 7-11, 1992.
PubMed
68) 藤原義夫, 澤田 敏, 田辺芳雄・他: Metallic stentの気管, 食道, 尿道への応用-動物実験を中心として-. 臨床放射線 35: 557-562, 1990.
 
69) 青木貴徳, 齋藤博哉, 高 明夫・他: 悪性食道気管支瘻に対するGore-Tex covered expandable metallic stentによる治療. Gastroenterol. Endosc. 37: 827-832, 1995.
 
70) 冨田 優, 廣田省三, 松本真一・他: 連結部を持たない両面被覆covered stentの検討. IVR 10: 381-384, 1995.
 
71) Watokinson A, Ellul J, Entwisle K, et al: Plastic covered metallic endoprostheses in the management of oesophageal perforation in patients with oesophageal carcinoma. Clin. Radiol. 50: 304-309, 1995.
PubMed
72) Knyrim K, Wagner HJ, Bethge N, et al: Acontrolled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N. Engl. J. Med. 329: 1302-1307, 1993.
 
73) 荒井保明: 8-26 Interventional radiologyの手技を用いた治療法の有効性についての研究. 厚生省がん研究助成金による研究報告書 平成9年度. 国立がんセンター, 東京, 1996. (印刷中)
 
74) 栗林幸夫, 大滝 誠, 岩田美郎・他: 消化管出血. 画像診断 11 (別冊) : 111-125, 1992.
 
75) Toyoda H, Nakano S, Takeda I, et al: Transcatheter arterial embolization for massive bleeding from duodenal ulcers not controlled by endoscopic hemostasis. Endoscopy 27: 304-307, 1995.
PubMed
76) 関 竜夫, 白土桃子: 消化管出血に対するIVR (2) 腫瘍性出血. IVR 10: 18, 1995.
 
77) 石川 徹: Interventional radiologyの歴史と展望. Non-vascular Interventional Radiology 手技と考え方 (石川徹編) , 中外医学社, 東京, 1993, pp. 1-8.
 
78) Smith EH: Complications of percutaneous abdominal fine-needle biopsy. Radiology 128: 253-258, 1991.
 
79) 中島康雄: 3. 胸部 I. 生検 1. 経皮的穿刺-A. 肺. Non-vascular Interventional Radiology 手技と考え方 (石川徹編) , 中外医学社, 東京, 1993, pp. 17-23.
 
80) 荒井保明: 3. 胸部 I. 生検 1. 乳房および胸壁. Non-vascular Interventional Radiology 手技と考え方 (石川徹編) , 中外医学社, 東京, 1993, pp. 44-48.
 
81) 林 信成: 4. 腹部 I. 生検 1. 腫瘤. Non-vascular Interventional Radiology 手技と考え方 (石川徹編) , 中外医学社, 東京, 1993, pp. 72-79.
 
82) 荒井保明: 6-30 Interventional Radiologyの手技を用いた治療法の有効性に関する研究. 厚生省がん研究助成金による研究報告集 平成6年度, 国立がんセンター, 東京, 1994, pp. 459-463.
 
83) Ebara M, Ohto M, Sugiura N, et al: Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. Gastroenterol. Hepatol. 5: 616-626, 1990.
PubMed
84) Honda N, Guo Q, Uchida H, et al: Percutaneous hot saline injection therapy for hepatic tumors: An alternative to percutaneous ethanol injection therapy. Radiology 190: 53-57, 1994.
PubMed
85) Dedrick CG, Olson RR, Athanasoulis CA: Transcatheter embolization of the spleen. In: Interventional Radiology (eds. by Athanasoulis CA, Pfister RC, Greene RE, Roberson GH) . WB. Saunders, Philadelphia, 1982, pp. 223-227.
 
86) Nakao N, Miura K, Takahashi H, et al: Hepatocellular carcinoma: combined hepatic, arterial, and portalvenous embolization. Radiology 161: 303-307, 1986.
 
87) Rosch J, Uchida BT, Putnam JS: Experimental intrahepatic portacaval anastomosis: Use of expandable Gianturco stents. Radiology 162: 481, 1987.
PubMed
88) 吉川公彦, 打田日出夫, 坂口 浩・他: TIPS最新レヴュー;門脈圧亢進症, 食道・胃静脈瘤治療におけるTIPSの位置付け. 日医放会誌 54: 22-24, 1994.
 
P.453 掲載の参考文献
1) MarshaU EK Jr: Historical perspectives in chemotherapy. In Advances in chemotherapy Vol. 1 (eds. dy Goldin A, Howking 1F) , Academic Press, New York, 1964, pp. 1-8.
 
2) De Vita VT Jr: Principles of chemotherapy. In: Cancer: Principles and Practice of Oncology (eds. by De Vita VTJr, Hellman S, Rosenberg SA) . 4th Edition, J B, Lippincott Co., Philadelphia, 1993, pp. 276-292.
 
3) 西條長宏: 癌化学療法の変貌. Current review: 癌化学療法93-94 (鶴尾 隆, 西條長宏編) , 中外医学社, 東京, 1993, pp. 4-10.
 
4) 西條長宏: 進歩する化学療法. 図説臨床「癌」シリーズ癌化学療法の進歩 (末舛恵一, 西條長宏編) (新版) , メジカルビュー社, 東京, 1993, pp. 6-11.
 
5) 西條長宏: 癌の分子治療の展開. (西條長宏編) , 医薬ジャーナル社, 大阪, 1995, pp. 9-28.
 
6) 石田智之, 西條長宏: 抗癌剤における薬物動態および薬剤耐性の最新情報. 先端医療 12: 77-79, 1995.
 
7) 石田智之, 西條長宏: 新しい抗癌剤の動向. 医学と薬学 32: 407-414, 1994.
Medical*Online
8) 有岡 仁, 西條長宏: Biochemical modulationの考え方. 癌治療とbiomodulation (漆崎一朗編) . 医薬ジャーナル社, 大阪, 1995, pp. 93-118.
 
9) 赤沢修吾, 大和朋子: Biomodulation. Oncology Frontier (太田和雄, 塚越 茂, 西條長宏・編) . 先端医学社, 東京, 1996, pp. 40-47.
 
10) Fossella FV, Lippman SM, shin DM, et al: maximum to lerated dose defined for single agent gemcitabine-a phase Idose escalation study in chemotherapy naive patients with advanced non-small cell lung cancer. J. Clin. Oncol. 15: 310-316, 1997.
 
11) Burris III HA, Mooke MJ, Andersen JA, et al: Improvements in survival and clinical benefit with gemcitabine as first line chemotherapy for patients with advanced pancreas cancer. J. Clin. Oncol. 15: 2403-2413, 1997.
 
12) WHO Handbook for reporting results of cancer treatment. WHO, Geneva, 1979.
 
13) Grading of toxicity: In Manual of Oncologic Therapeutics 1991/1992 (ed. by Wittes WE) , Lippincott, Philadel-phia, 1991, pp. 448-455.
 
14) Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? . J. Clin. Oncol. 11: 1866-1872, 1993.
PubMed
15) Pignon JP, Orriagoda R, Ihde DC, et al: Ametaanalysis of thoracic radiotherapy for small cell lung cancer. N. Engl. J. Med. 327: 1618-1624, 1992.
 
16) Pass HL, Pogrebniak HW, Steinberg SM, et al: Randomized trial of neoadjuvant therapy or lung cancer: interim analysis. Ann. Thorac. Surg. 53: 922-998, 1992.
 
17) Martini N, Kris MG, Flehinger BJ, et al: Preoperative chemotherapy for stage IIIA (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg. 55: 1365-1374, 1993.
PubMed
18) Goldie JH, Coldman AJ: Role of mathematical modeling in protocol for mutation in cancer chemotherapy. Cancer Treat. Rep. 63: 1041-1045, 1985.
 
19) Nathanson L, Hall TC, Schilling AC, et al: Concurrent combination chemotherapy of human solid tumors: Experience with three-drug regimen and review of the literature. Cancer Res. 29: 419-425, 1969.
 
20) Potter VR: Sequential blocking of metabolic pathways in vivo. Proc. Soc. Exp. Biol. Med. 76: 41-46, 1951.
PubMed
21) Elion GB, Singer S, Hitchings GH, et al: Antagonists of nucleic acid derivatives: VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208: 477-488, 1954.
PubMed
22) Sartorelli AC: Approaches to the combination chemotherapy of transplantable neoplasms. Prog. Ext. Tumor Res. 6: 228-288, 1965.
 
23) De Vita VT, Schein PS: The use of drugs in combination for the treatment of cancer: Rationale and results. N. Engl. J. Med. 288: 988-1006, 1973.
 
24) Freireich EJ, Karon M, Frei E: Quadruple combined chemotherapy (VAMP) for acute lymphocytic leukemia in children. Proc. Am. Assoc. Cancer Res. 5: 20, 1964.
 
25) Pinke D, Hermoulex K, Borella L, et al: Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 27: 247-256, 1971.
 
26) De Vita VT Jr, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin 's disease. Ann. Intern. Med. 73: 881-895, 1970.
 
27) Campbell L, Souza LM, Morstyn G, et al: Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxin chemotherapy. Lancet 1: 667-672, 1988.
 
28) Antman KS, Griffin JD, Karen S, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy induced myelosuppression. N. Engl. J. Med. 318: 593-598, 1988.
 
29) Gabrilove J, Jakubowski A, Howard S, et al: Granulocyte colony-stimulating factor reduces neutropenia and associated morbidity of chemotherapy for transitional cell carcinoma of the urothelium. N. Engl. J. Med. 318: 1414-1422, 1988.
 
30) John AT, Douglas JL, Pamela K, et al: Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplagia syndrome: Toxicity, pharmacokinetics and hematological effects. J. Clin. Oncol. 7: 629-637, 1989.
 
31) Champlin RE, Nimer SD, Irekand P, et al: Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 73: 694-699, 1989.
PubMed
32) Hesketh PJ, Gandara DR: Serotonin antagonists: anew class of antiemetic agents. J. Natl. Cancer Inst. 83: 613-620, 1991.
 
33) Currow DC, Noble PC, Cooney NJ, et al: The clinical use of ondansetron: New-South Wales TherapeuticAssessment Group. Med. J. Aust. 162: 145-149, 1995.
 
34) Van Belle S, Bleiberg H, Canon JL, et al: Optimal combination therapy with tropisetron in 445 patients with subtotal control of chemotherapy-induced nausea and emesis. Proc. Am. Soc. Clin. Oncol. 13: 430, 1994.
 
35) Johnsonbaugh RE, Mason BA, Friedman CJ, et al: Oral granisetron is an effective anti-emetic in patients receiving moderatory emetogenic chemotherapy. Proc. Am. Soc. Clin. Oncol. 13: 437, 1994.
 
36) Rittenberg CN, Gralla RJ, Lettow LA, et al: New approaches in preventing delayed emesis: Altering the time of regimen initiation and use of combination therapy in a 109 patients trial. Proc. Am. Soc. Clin. Oncol. 14: 526, 1995.
 
37) Latreille J, Johnston D, Stewart D, et al: Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP) . Astudy by the National Institute of Canada Clinical Trial Group (NCIC CTG) . Proc. Am. Soc. Clin. Oncol. 14: 529, 1995.
 
38) Jones AL, Lee GJ, Bosanquet N, et al: The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur. J. Cancer 29A: 51-56, 1993.
 
39) De Vita VT Jr: Dose response is alive and welL J. Clin, Oncol. 4: 1157-1159, 1986.
 
40) Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin 's lymphoma. N. Engl. J. Med. 328: 1022-1006, 1993.
 
41) Cooper IA, Wolf MM, Robertson TI, et al: Randomized comparison of MACOP-B with CHOP in patients with intermediate grade non-Hodgkin 's lymphoma. J. Clin. Oncol. 12: 769-778, 1994.
PubMed
42) Shimoyama M, Ohta K, Kikuchi M, et al: Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin 's lymphoma treated with VEPA and VEPA-M. J. Clin. Oncol. 6: 128-141, 1988.
 
43) Ihde DC: Chemotherapy for lung cancer N. Engl. J. Med. 327: 1434, 1992.
PubMed
44) Jackson DV, Casse LD, Zekkan P J, et al: Improvement of long term surviral in extensive small cell lung cancer. J. Clin. Oncol. 6: 1161-1169, 1988.
 
45) Fukuoka M, Furuse K, Saijo N, et al: Randomized Trial of CPA, ADM, VCR, versus CDDP and etoposide versus alterating of these regimens in small cell lung cancer. J. Natl. Cancer Inst. 83: 855-861, 1991.
 
46) Saijo N: Combined modality therapy for small cell lung Cancer. Oncology 49: 2-10, 1992.
PubMed
47) McGwire WP, Kloskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334: 1-6, 1996.
 
48) Capri G, Tarengi E, Fulfago F, et al: The role of taxanes in the treatment of breast cancer. Semin. Oncol. 23: 68-75, 1996.
 
49) 末舛恵一, 西條長宏・編: 化学療法の進歩. 図説臨床 [癌]シリーズno. 1, メジカルビュー社, 東京, 1993, pp. 79-84.
 
50) 大塚貞明, 馬場秀夫, 杉町圭蔵: 感受性テスト. current review癌化学療法1993-94 (鶴尾隆, 西條長宏, 編) , 中外医学社, 東京, 1993, pp. 103-109.
 
51) Weisenthal LM, Marsden JA, Dill PL, et al: A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 43: 749-757, 1983.
PubMed
52) Funa K, Dawson N, Jewett PB, et al: Automated fluorescent analysis for drug-induced cytotoxicity assays. Cancer Treat. Rep. 70: 1147-1151, 1986.
PubMed
53) Bickis IJ, Henderson IWD, Quastel JH, et al: Biochemical studies of human tumors II. In vitro estimation of individual tumor sensitivity to anti-cancer agents. Cancer 19: 103-113, 1966.
 
54) 東 弘, 伊藤英太郎, 森 武貞・他: 制癌剤感受性テストの理論と実際-とくに核酸合成阻害を指標とする方法 (INSA法) について. 綜合臨床 20: 1360-1367, 1971.
 
55) 東 弘: 癌化学療法の問題点-制癌剤感受性試験 (INAS法の臨床経験) . 癌の臨床 25: 761-764, 1979.
 
56) 近藤達平: 制癌剤の適応-感受性試験. 最新医学 19: 2304-2311, 1964.
 
57) 市橋秀仁, 津荷龍生, 近藤達平・他: ATPを指標とする制癌剤感受性試験. 日癌治療会誌 22: 1090, 1987.
 
58) Rotman B, Papermaster BW: Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. Proc. Natl. Acad. Sci. USA 55: 134-141, 1966.
PubMed
59) 楠本宏記, 前原喜彦, 杉町圭蔵: 抗癌剤感受性試験の意義と問題点-SDI法を中心として図説臨床「癌」シリーズno. 1 癌化学療法の進歩, 末舛恵一, 西條長宏・編, メジカルビュー社, 東京, 1993, pp. 79-84.
 
60) Skehan P, Storeng R, Scudiero O, et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82: 1107-1112, 1990.
 
61) Hamburger A, Salmon SE: Primary bioassay of human stern cells. Science 197: 461-463, 1977.
 
62) Tanigawa N, Kern DH, Hikasa Y, et al: Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res. 42: 2159-2164, 1982.
PubMed
63) Kern DH, Drogemuller CR, Kennedy MC, et al: Development of a miniaturized improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumor. Cancer Res. 45: 5436-5441, 1985.
PubMed
64) Freeman AE, Hoffman RM: In vivo-like growth of human tumors in vitro. Proc. Natl. Acad. Sci. USA 83: 2694-2698, 1986.
PubMed
65) Vescio RA, Redfern CH, Nelson TJ, et al: . ln vivo-like drug response of human tumors growing in three-dimensional gel-supported primary culture. Proc. Natl. Acad. Sci. USA 84: 5029-5033, 1987.
 
66) Perrapato SD, Slocum HK, Huben RP, et al : Assessment of human genitourinary tumors and chemosensitivity testing in 3-dimensional collagen gel culture. J. Urol. 14311041-1045, 1990.
PubMed
67) Kanzawa F, Nishio K, Fukuoka K, et al: Evaluation of synergism by a novel three dimensional model for the combined action of cisplatin and etoposide on the growth of a human small cell lung cancer cell line, SBL-3. Int. J. Cances 71: 311-319, 1997.
 
68) Rygaard J, Povlsen CO: Heterotransplantation of a human malignant tumor to "Nude"mice. Acta. Pathol. Microbiol. Scand. 77: 758-760, 1969.
PubMed
69) 藤田昌英, 大嶋一徳, 薄金真雄・他: ヌードマウス移植-消化器癌および乳癌株の特徴-とくにそのCEA産生性と抗癌剤感受性について. 日外会誌 83: 457-467, 1982.
 
70) Bogden AE: Arapid screening method for testing chemotherapeutic agents against human tumor xenografts. Symposium on the Use of Athymic (nude) mice in Cancer Research, Gustav Fischer Inc, New York, 1978, pp. 231-250.
 
71) Bogden AE, Haskell PM, LePage DJ: Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Expl. Cell Biol. 47: 281-293, 1979.
 
72) Bogden AE, Cobb WR, LePage DJ: Chemotherapy responsiveness of human tumor as first transplant generation xenografts in the normal mouse: Six-day subrenal capsule assay. Cancer 48: 10-20, 1981.
PubMed
73) Edelstein MB, Fiebig HH, Smink T, et al: Comparison between macroscopic and microscopic evaluation of tumor responsiveness using the subrenal capsule assay. Eur. J. Cancer Clin. Oncol. 19: 995-1009, 1983.
 
74) Levi FA, Blum JP, Lemaigre G, et al: Afour-day subrenal capsule assay for testing the effectiveness of anticancer drugs against human tumors. Cancer Res. 44: 2660-2667, 1984.
 
75) Aamdal S, Fodstad O, Pihl A: Human tumor xenografts transplanted under the renal capsule of conventional mouse: Growth rates and host immune response. Int. J. Cancer 34: 725-730, 1984.
PubMed
76) Edelstein MB, Smink T, Ruiter DJ, et al: Improvements and limitations of the subrenal capsule assay for determining tumour sensitivity to cytostatic drugs. Eur. J. Cancer Clin. Oncol. 20: 1549-1556, 1984.
PubMed
77) Fingert HJ, Treiman A, Pardee AB: Transplantation of human or rodent tumors into cyclosporin-treated mice: afeasible model for studies of tumor biology and chemotherapy. Proc. Natl. Acad. Sci. USA 81: 7927-7931, 1984.
PubMed
78) Bosma GC, Custer RP, Bosma MJ, et al: A severe combined immunodeficiency mutation in the mouse. Nature 301: 527-530, 1983.
PubMed
79) Rubinstein LV, Shoemaker RH, Paull KD, et al: Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82: 1113-1118, 1990.
PubMed
80) Aas T, Borresen AL, Geisler S, et al: Specific P 53 mutations are associated with de novo resistance to doxorubicin in breast cances patients., Nat. Med. 2: 811-814, 1997.
 
81) Debernardis D, Sire EG, Eeudis PD, et al: P53 status does not effect sensitivity of human ovarian cancer cell line to paclitaxel. Cancer Res. 57: 870-874, 1997.
PubMed
82) Cole SPC, Bhardway G, Garlach JH, et al: Overexpression of a transporter gene in a multi-drug resistant human lung cancer line. Science 258: 1650-1654, 1992.
 
83) Niimi S, Nakagawa K, Saijo N: Relationship between sensitivity to anticancer agents and GSH content and GST activity. Jikei Med. J. 391395-407, 1992.
 
84) Siemann DW, Beyers KL: In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Br. J. Cancer 68: 1071-1079, 1993.
PubMed
85) Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53: 5433-5438, 1993.
PubMed
86) Niimi S, Nakagawa K, Sugimoto Y, et al: Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cell line selected by cisplatin. Cancer Res. 52: 328-333, 1992.
 
87) Sugimoto Y, Ohe Y, Nishio K, et al: In vitro enhancement of fluoropyridine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small cell lung carcinoma cell lines. Cancer
 
88) Chemother. Pharmacol. 30: 417-422, 1992. Sugimoto Y, Ohe Y, Nishio K, et al: Mechanisms of collateral sensitivity of fluorouracil of a cis-diamminedichloroplatinum (II) -resistant human non-small lung cancer cell line. Br. J. Cancer 65: 857-864, 1992.
 
89) Calson P, Salles B: Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother. Pharmacol. 32: 85-89, 1993.
 
90) Fujiwara Y, Kasahara K, Sugimoto Y, et al: Detection of proteins that recognize platinum-modified DNA using gel mobility shift assay. Jpn. J. Cancer Res. 81: 1210-1213, 1990.
PubMed
91) Kubo S, Matsunami M, Arioka H, et al: Participation of poly (ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines. J. Cancer Res. Clin. Oncol. 118: 244-248, 1992.
 
92) Nishio M, Nishio K, Arioka H, et al: Increase of HMG proteins in cis-DDP resistant cell lines. J. Cell Pharmacol. 1: 251-255, 1994.
 
93) Arends MJ, McGregor AH, Toft NJ, et al: Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br. J. Cancer 6S: 1127-1133, 1993.
 
94) Niimi S, Nakagawa K, Yokota J, et al: Resistance to anticancer drugs in NIH 3 T 3 cells transfected with cmyc and/or c-H-ras genes. Br. J. Cancer 63: 237-241, 1991.
PubMed
95) Brown R, Clugston C, Burns P, et al: Increased accumulation of P 53 protein in cisplatin resistant ovarian cell lines. Int. J. Cancer 55: 678-84, 1993.
 
96) Vendrik CPJ, Bergers JJ, DeJong WH, et al: Resistance to cytostatic drugs at the cellular level. Cancer Chemother. Pharmacol. 29: 413-429, 1992.
 
97) Andoh T, Yasui Y, Koiwai O, et al: Molecular basis of resistance to CPT-11. a specific inhibitor of DNA topoisomerase I. In: The mechanism and new approach on drug resistance of cancer cells (ed. by Miyazaki T, Takaku F and Sakurada K) . Elsevier Science Publishers, Amsterdam, 1993, pp. 95-101.
 
98) Fujiwara Y, Sugimoto Y, Kasahara K, et al: Determination of drug response in a cisplatin-resistant human cancer cell line. Jpn. J. Cancer Res. 81: 527-535, 1990.
 
99) Gately DP, Howel SB: Cellular accumulation of the anticancer agent cisplatin: Areview. Br. J. Cancer 67: 1171-1176, 1993.
 
100) Hamaguchi K, Godurin AK, Yakushiji M, et al: Cross resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 53: 5225-5232, 1993.
 
101) Ishikawa T: Glutathione S-conjugate export pump.: Structure and function of glutathione-S-transferase (ed. by Tew KD, Pickett CB, et al) , CRC press, Boca Raton, 1993, pp. 211-221.
 
102) Reed E, Parker RJ, Gill I, et al: Platinum-DNA adduct in leucocyte DNA of malignancies. Cancer Res. 53: 3694-3699, 1993.
PubMed
103) Saijo N, Lazo JS: "Metallothioneins in drug resistance" in Drug Resistance in Oncolgy (ed. by Teicher BA) , Marcel Dekker, New York, 1993, pp. 339-350.
 
104) Scanlon KJ, Kashani-Sabet M, Tone T, et al: Cisplatin resistance in human cancers. Pharmacol. Ther. 52: 385-406, 1991.
PubMed
105) Zhang B, Seki S, Akiyama K, et al: Detection and analysis by gel electrophoresis of cisplatin-mediated DNA damage. Acta. Med. Okayama 46: 427-434, 1992.
PubMed
106) Morikage T, Bungo M, Inomata M, et al: Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn, J. Cancer Res. 82: 747-751, 1991.
 
107) Morikage T, Ohmori T, Nishio K, et al: Modulation of cisplatin sensitivity and accumulation by amphotericin Bin cisplatin-resistant human lung cancer cell lines. Cancer Res. 53: 3302-3307, 1993.
 
108) Ohmori T, Morikage T, Sugimoto Y, et al: The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP) . Jpn. J. Cancer Res. 84: 83-92, 1993.
PubMed
109) Ohmori T, Nishio K, Ohta S, et al: Ouabain resistant non-small cell lung Cancer cell line shows collateral sensitivity to cis-diammine dichloroplatinum. Int. J. Cancer 57: 111-116, 1994.
PubMed
110) Kasahara K, Fujiwara Y, Nishio K, et al: Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 51: 3237-3242, 1991.
PubMed
111) Kurakawa H, Nishio K, Ishida T, et al: Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with theγGCS gene. Jpn. J. Cancer Res. 88: 108-110, 1997.
 
112) Suzuki T, Nishio K, Sasaki H, et al: CDNA cloning of a short type of multidrug resistant protein. Biochem. Biophys. Res. Commun. 238: 790-794, 1997.
 
113) Kubota N, Kanzawa F, Nishio K, et al: Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem, Biophys. Res. Commun. 188: 571-577, 1992.
PubMed
114) Kubota N, Nishio K, Takeda Y, et al: Characterization of an etoposide-resistant human ovarian cancer cell line. Cancer Chemother. Pharmacol. 34: 183-190, 1994.
PubMed
115) Mirski SEL, Evans CD, Almquist KC, et al: Alterd topoisomerase IIa in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res. 53: 4866-4873, 1993.
 
116) Kanzawa F, Sugimoto Y, Minato K, et al: Establishment of a camptothecin analogue (CPT-11) -resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 50: 5919-5924, 1990.
PubMed
117) Ogasawara H, Nishio K, Takeda Y, et al: KW-2189, a novel cyclopropylpyrroloindole, is activated by carboxyl esterase and induces DNA-strand breaks. Jpn. J. Cancer Res. 85: 418-425, 1994.
PubMed
118) Karato A, Sasaki Y, Shinkai T, et al: Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J. Clin. Oncol. 11: 2030-2035, 1993.
PubMed
119) Liebmann JE, Cook JA, Lipshultz CC, et al: Cytotoxic studies of paclitaxel (Taxo1) in human tumor cell lines. Br. J. Cancer 68: 1104-1109, 1993.
 
120) Akiyama T, Yasida T, Tsujita M, et al: GI phase accumulation induced by UCN-01 is associated with dephaphorylation of RB and cdk 2 proteins as well as induction of cak inhibitor P 21/Cip I/WAF l in P53-mediated human epidermoid carcinoma A 431 calls. Cancer Res. 57: 1495-1501, 1997.
 
121) Levitzki A, Gazit A: Tyrosine kinase inhibitors: An new approach to dnug development. Science 267: 1782-1788, 1995.
 
122) Weinstein JN, Myers TG, O'connor PM, et al: An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997.
 
123) Clark PI for the Medical Research Council Lung Cancer Working Party: Updated results of a randomized trial conformed that orad etoposide alone is inadequate palliative chemotherapy for small caH lung cancer. Proc. IASLC p 42, 1997.
 
124) Morita M, Sasaki Y, Saijo N: The antitumor activity of radiation therapy is reduced in patients with non-smallcell carcinoma of the lung refractory to chemotherapy. Ann. Oncol. 3: 273-276, 1992.
 
125) Oshita F, Fujiwara Y, Saijo N: Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin resistant cell line. J. Cancer Res. Clin. Oncol. 119: 28-34, 1992.
 
126) Green JA, Dawson AA, Fell LF, et al: Measurement of drug dosage intensity in MVPP therapy in Hodgkin 'sdisease. Br. J Clin. Pharmacol. 9: 511-514, 1980.
 
127) Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat. Rep. 66: 439-449, 1982.
PubMed
128) Goldie JH, Coldman AJ: Amathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63: 1727-1733, 1979.
PubMed
129) Coldman AJ, Goldie JH: Impact of dose intensive chemotherapy on the development of permanent drug resistance. Semin. Oncol. 14 (suppl. 4) : 29-33, 1987.
 
130) Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep. 61: 1307-1317, 1977.
PubMed
131) Hryniuk W, Bush H: The importance of dose intensity on chemotherapy of metastatic breast cancer. J. Clin. Oncol. 2: 1281-1288, 1984.
PubMed
132) Hryniuk WM, Levine MN: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin. Oncol. 14 (suppl. 4) : 3-11, 1987.
 
133) Klasa RJ, Murray N, Coldman AJ, et al: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J. Clin. Oncol. 9: 499-508, 1991.
PubMed
134) Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage smallcell lung cancer. J. Clin. Oncol. 9: 1632-1638, 1991.
 
135) Fukuoka M, Takada M, Masuda S, et al: Dose intensive weekly chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small-cell lung cancer. Proc. ASCO 11: 290, 1992.
 
136) Furuse K, Kubota K, Nishiwaki Y, et al: For the JCOG: Phase III study of dose intensive weekly chemotherapy with rh GCSF versus standard chemotherapy in ED-SCLC. Proc. Am. Soc. Clin. Oncol. 15: 375, 1996.
 
137) Murray N, Livingston R, Shepherd F, et al: Arandomized study of CODE plus thoracic irradiation versus alternating CAV/PE for extensive stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 16: 456, 1997.
 
138) De Vita VT Jr, Hubbard SM, Longo DL, et al: The chemotherapy of lymphomas: looking back, moving forward-the Richard and Hinda Rosental Foundation Award lecture. Cancer Res. 4715810-5824, 1987.
 
139) Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin 's lymphoma. N. Engl. J. Med. 328: 1002-1006, 1993.
PubMed
140) Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin 's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med. 327: 1478-1484, 1992.
PubMed
141) Gianni AM, Bregni M, Siena S, et al: Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol. Oncol. 7: 139-148, 1989.
PubMed
142) Armitage JO: New frontiers in cancer chemotherapy? J. Clin. Oncol. 4: 1577-1578, 1986.
PubMed
143) Shepherd FA, Evans WK, Blackstain ME, et al: Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J. Clin. Oncol. 5: 635-640, 1987,
 
144) Konno T: Targeting chemotherapy for hepatoma: Arterial administration of anticancer drugs dissolved in Lipiodol. Eur. J. Cancer 28: 403-409, 1992.
PubMed
145) Presant CA, Scolaro M, Kennedy P, et al: Lipiodomal daunorubicin treatment of HIV-associated Kaposi 's sarcoma. Lancet 341: 1242-1243, 1993.
 
146) Yamaguchi T, Tsurumi H, Kitamura K, et al: Production, binding and cytotoxicity of human/mouse chimetric monoclonal antibody-neocarzinostatin conjugate. Jpn. J. Cancer Res. 84: 1190-1194, 1993.
 
147) Baselga J, Tirpathy D, Mendelsohn J, et al: Phase II study of recombinant human anti-HER 2 monoclonal antibody (rhuMAb HER 2) in stage IV breast cancer (BC) : HER 2-shedding dependent pharmacokinetics and antitumor activity. Proc. ASCO l4: 103, 1995.
 
148) Pegram M, Lipton A, Pietras R, et al: Phase II study of intravenous recombinant humanized anti-p 185 HER 2 monoclonal antibody (rhuMAb HER 2) plus cisplatin in patients with HER-2/NEU overexpressing metastatic breast cancer. Proc. ASCO 14: 106, 1995.
 
149) 抗悪性腫瘍薬の臨床評価法に関するガイドライン. 新薬評価ガイドライン1991 (日本公定書協会編) , 薬事日報社, 東京, 1991.
 
150) GCPハンドブック. 厚生省薬務局審査第一課監修, 薬業時報社, 東京, 1990.
 
151) Collins JM, Zaharko DS, Dedrick RL, et al: Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep. 70: 73-80, 1986.
PubMed
152) EORTC Pharmacokinetics and Metabolism Group: Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur. J. Cancer Clin. Oncol. 23: 1083-1087, 1987.
PubMed
153) Fuse E, Kobayashi S, Inaba M, et al : Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J. NatL Cancer Inst. 86: 989-996, 1994.
PubMed
154) Smith DB, Ewen C, Mackintosh J, et al: Aphase I and pharmacokinetic study of amphetinile. Br. J. Cancer 57: 623-627, 1988.
 
155) Schwartsmann G, Dodion P, Vermorken JB, et al: Phase I study of brequinar sodium (NSC 368390) in patients with solid malignancies. Cancer Chemother. Pharmacol. 25: 345-351, 1990.
PubMed
156) Gianni L, Vigani L, Surbone A, et al: Pharmacology and clinical toxicity of 4 '-iodo-4 '-deoxydoxorubicin: An example of successful application of pharmacokinetics to dose escalation in phase I trials. J. Natl. Cancer Inst. 82: 469-477, 1990.
 
157) Foster BJ, Newell DR, Graham MA, et al: Phase I trial of the anthrapyrazole CI-941. Prospective evaluation of a pharmacokinetically guided dose escalation scheme. Eur. J. Cancer 28: 463-469, 1992.
PubMed
158) Allan SG, Cummings J, Evans S, et al: Phase I study of the anthrapyrazole biantazole: Clinical results and pharmacology. Cancer Chemother. Pharmacol. 28: 55-58, 1991.
PubMed
159) Ames MM, Loprinzi CL, Collins JM, et al: Phase I and clinical evaluation of piroxantron hydrochloride (oxantrazole) . Cancer Res. 50: 3905-3909, 1990.
PubMed
160) Hantel A, Donehower RC, Rowinsky EK, et al: Phase I study and pharmacodynamics of piroxantrone (NSC349174) , anew anthrapyrazole. Cancer Res. 50: 3284-3288, 1990.
 
161) Erlichman C, Moore M, Kerr IG, et al: Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole CI-937 (DuP 937) . Cancer Res. 51: 6317-6322, 1991.
PubMed
162) Graham MA, Bissett D, Setanoians A, et al: Preclinical and phase I studies with rhizoxin to appl a pharmacokinetically guided dose escalation scheme. J. Natl. Cancer Inst. 841494-500, 1992.
 
163) Donehower R, Grove W, Whitfield L, et al: Successful use of pharmacologically guided dose escalation (PGDE) in a phase I trial of CI-958. Proc, ASCO 12: 139, 1993.
 
164) Levantal BG, Wittes RE: Combination chemotherapy. In: Research Methods in Clinical Oncology (eds. by Levantal BG, Wittes RE) , Raven Pres, New York, 1988, p. 129.
 
165) Korn EL, Simon R: Using the tolerable-dose diagram in the design of phase 1 combination chemotherapy trials. J. Clin. Oncol. 11: 794-801, 1993.
PubMed
166) O'Quigley J, Pepe M, Fisher L, et al: Continual reassessment method: apractical design for phase I clinical trials in cancer. Biometrics 46: 33-48, 1990.
 
167) Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: acautionary note. Cancer Res. 49: 5870-5878, 1989.
PubMed
168) Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280, 1990.
PubMed
169) Nishio K, Fujiwara Y, Miyahara Y, et al: Cis-diamminedichloroplatinum (II) inhibits p 34cdc2 protein kinase in human lung-cancer cells. Int. J. Cancer 55: 616-622, 1993.
 
170) Fukuoka M, Niitani H, Suzuki A, et al: Aphase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer [see comments]. J. Clin. Oncol, 10: 16-20, 1992.
 
171) Masuda N, Fukuoka M, Kusunoki Y, et al: et alg cancer. J. Clin. Oncol. 10: 1225-1229, 1992.
 
172) Fujiwara Y, Yamakido M, Fukuoka M, et al: Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC) . Proc. ASCO 13: 335, 1994.
 
173) 古江 尚: 塩酸イリノテカン (CPT-11) . 癌と化学療法 21: 709-717, 1994.
Medical*Online
174) 太田和雄, 大野竜三, 白川 茂・他: 悪性リンパ腫・急性白血病に対する塩酸イリノテカン (CPT-11) の後期第II相臨床試験. 癌と化学療法 21: 1047-1055, 1994.
Medical*Online
175) 田口鐵男, 冨永 健, 小川一誠・他: 再発・進行乳癌に対するCPT-11 (塩酸イリノテカン) の後期第II相臨床試験. 癌と化学療法 21: 1017-1024, 1994.
Medical*Online
176) 二ツ木浩一, 涌井 昭, 中尾功・他: 再発・進行胃癌に対する塩酸イリノテカン (CPT-11) の後期第II相臨床試験. 癌と化学療法 21: 1033-1038, 1994.
Medical*Online
177) 坂田 優, 島田安博, 吉野正曠・他: 進行膵がんに対するCPT-11 (塩酸イリノテカン) の後期第II相臨床試験. 癌と化学療法 21: 1039-1045, 1994.
 
178) Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol. 11: 909-913, 1993.
 
179) Karato A, Sasaki Y, Shinkai T, et al: Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J. Clin. OncoL 11: 2030-2035, 1993.
PubMed
180) Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol. 10: 1775-1780, 1992.
PubMed
181) Kelland LR, Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 30: 444-450, 1992.
PubMed
182) McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: aunique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111: 273-279, 1989.
 
183) Thigpen T, Blessing J, Ball H, et al: Phase II trial as second line therapy for ovarian carcinoma. Proc. ASCO9: 156, 1990.
 
184) Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study of Taxol (T) in patients (Pts) with advanced ovarian cancer. Proc. AACR 31: 187, 1990.
 
185) Sarosy G, Kohn E, Stone DA, et al: Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol. 10: 1165-1170, 1992.
PubMed
186) Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. NatL Cancer Inst. 83: 1797-1805, 1991.
PubMed
187) Chang A, Kim K, Glick J, et al: Phase II study of taxol in patients with stage IV non-small cell lung cancer (NSCLC) . Proc. ASCO 11: 293, 1992.
 
188) Murphy WK, Winn RJ, Fossella FV, et al: A phase II study of taxol (NSC 125973) in patients (pts) with nonsmall cell lung cancer (NSCLC) . Proc. ASCO 11: 294, 1992.
 
189) Kanzawa F, Sugimoto Y, Minato K, et al: Establishment of a camptothecin analogue (CPT-11) -resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 50: 5919-5924, 1990.
PubMed
190) Kubota N, Kanzawa F, Nishio K, et al: Detection of topoisomerase I gene point mutation in CPT-II resistant lung cancer cell line. Biochem. Biophys. Res. Commun. 188: 571-577, 1992.
 
191) Andoh T, Ishii K, Susuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA 84: 5565-5569, 1987
 
192) Ohta S, Nishio K, Ohmori T, et al: A taxol resistant human small cell lung cancer cell line is partially dependent of taxol for its growth. Proc. AACR 34: 304, 1993.
 
193) Culver KW, Ram Z, Wallbridge S, et al: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors [see comments]. Science 256: 1550-1552, 1992.
 
194) Ram Z, Culver KW, Walbridge S, et al: In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53: 83-88, 1993.
PubMed
195) Ratajczak MZ, Kant JA, Luger SM, et al: ln vivo treatment of human leukemia in a scid mouse model with cmyb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 89: 11823-11827, 1992.
 
196) Georges RN, Mukhopadhyay T, Zhang Y, et al: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 53: 1743-1746, 1993.
PubMed
197) Kashani-Sabet M, Funato T, Tone T, et al: Reversal of the malignant phenotype by an ant卜燃ribozyme. Antisense Res. Dev. 2: 3-15, 1992.
 
198) Snyder DS, Wu Y, Wang JL, et al: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 821600-605, 1993.
 
199) Mercer WE, Shields MT, Lin D, et al: Growth suppression induced by wild-type p 53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. NatL Acad. Sci. USA 88: 1958-1962, 1991.
 
200) Leone A, Flatow U, King CR, et al: Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm 23-transfected melanoma cells. Cell 65: 25-35, 1991.
 
201) Huang HJ, Yee JK, Shew JY, et al: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242: 1563-1566, 1988.
PubMed
202) 小倉 剛: サイトカインの癌治療への応用. 免疫薬理 12: 356-359, 1994.
 
203) Chen L, Ashe S, Brady WA, et al: Costimulation of antitumor immunity by the B 7 counterreceptor for the T lymphocyte molecules CD 28 and CTLA-4. Cell 71: 1093-1102, 1992.
 
204) Heise C, Sampson-Johannes A, Williams A, et al: ONYX-015, an EIB gene attenuated adenovirus causes tumor specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3: 639-645, 1997.
 
205) Lok S, Kaushansky K, Holly RD, et al: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369: 565-568, 1995.
 
206) 高上洋一: 白血病に対する末梢血幹細胞移植. 今日の移植 4: 72-79, 1991.
 
207) clarlees, Boyerm；millwand M, Findlay M, et al: MTA (Ly 231514) An adive agent in advonced non-smallcall bewg Cancer. Proc. ASCO 17: 1793, 1998.
 
208) Matsuda A, Takenuki T, Tanaka M, et al: Synthescs of new broad spectwn antineopla§lic nudeobides., DMDC its denivatcves J. Med. Chem. 34: 1793, 1998. Tanaka M, Matsuda A, Feoao: Tetal Antitumor of a novel nucleotide. CNDAC against murine and
 
209) Tanaka M, Matsuda A, Feoao: Tetal Antitumor of a novel nucleotide. CNDAC against murine and human Twmcrs. Cancer Lett. 64: 67-74, 1992.
 
210) Clarke SJ, Jackman AL, Judson IR: The history of the development and clinical use of CB 3717 and ICI D 1694. Adv. Exp Med. Biol. 339: 277-287, 1993.
PubMed
211) Jackman AL, Gibson W, Brown M, et al: The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D 1694. [Review]. Adv. Exp. Med. Biol. 339: 265-276, 1993.
PubMed
P.471 掲載の参考文献
1) Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2: 104-107 (part I) , 162-165 (part 2) , 1894.
 
2) Huggins C, Hodges CL: Studies on prostatic cancer, 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1: 293-297, 1941.
 
3) Clark JH, Schrader WT, O'Malley BW: Mechanisms of action of steroid hormones. In: Williams Textbook of Endocrinology, 8th edition (eds. by Wilson JD, Foster DW) , W. B. Saunders Company, Philadelphia, 1992, pp. 35-90.
 
4) Elledge RM, Osborne CK: Oestrogen receptors and breast cancer. Br. Med. J. 314: 1843-1844, 1997.
 
5) Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcolne of breast cancer patients. Br. J. Cancer 74: 1445-1451, 1996.
PubMed
6) Henderson IC, Harris JR: Principles in the management of metastatic disease. In Breast Disease, 2nd ed. (eds. by Henderson IC, Harris JR) , Lippincott, New York, 1990, pp. 547-677.
 
7) Mouridsen H, Palshof T, Patterson J, et al: Tamoxifen in advanced breast cancer. Cancer Treat. Rev. 5: 131-141, 1978.
PubMed
8) Plotkin D, Lechner JJ, Jung WE, et al: Tamoxifen flare in advanced breast cancer. JAMA 240: 2644-2646, 1978.
PubMed
9) Clarysse A: Hormone-induced tumor flare. Eur. J. Cancer 21: 545-547, 1985.
 
10) Fisher B, Costanitino Jp, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86: 527, 1994.
 
11) Canney PA, Griffiths T, Latief TN, et al: Clinical significance of tamoxifen withdrawal response. Lancet 1: 36, 1987.
PubMed
12) Howell A, Dodwell DJ, Anderson H, et al: Response after withdrawal of tamoxifen and progestogens i advanced breast cancer. Ann. Oncol. 3: 611-617, 1992.
PubMed
13) Swain SM: Endocrine therapies of cancer. In Cancer chemotherapy and biotherapy principles and practice (eds. by Chabner BA, Longo DL) , Lppincott-Raven, Philadelphia, 1996, pp. 59-108.
 
14) Kangas L, Nieminen A-L, Blanco G, et al: Anew triphenylethylene compound, Fc-1157 a. II. antitumor effects. Cancer Chemother. Pharmacol. 17: 109-113, 1986.
 
15) Hard GC, Iatropoulos MJ, Jordan K, et al: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD (BR) Rats. Cancer Res. 53: 4534-4541, 1993.
PubMed
16) Watanabe T, Junzheng W, Morikawa K, et al: ln vitro sensitivity test of breast cancer cells to hormonal agents in a radionucleotide-incorporation assay. Jpn. J. Cancer Res. 81: 536-543, 1990.
 
17) DeGregorio MW, Ford JM, Benz CC, et al: Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J. Clin. Oncol. 7: 1359-1364, 1989.
PubMed
18) Buzdar AU, Hortobagyi GN: Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J. Clin. Oncol. 16: 348-353, 1998.
PubMed
19) 野村靖夫, 冨永 健, 阿部令彦・他: 進行・再発乳癌に対するNK 622 (クエン酸トレミフェン) の臨床評価-タモキシフェンとの二重盲検法による比較試験-. 癌と化学療法 20: 247-258, 1993.
 
20) 浅石和昭, 冨永 健, 阿部令彦・他: タモキシフェン療法耐性の乳癌症例に対する高用量NK 622 (クエン酸トレミフェン) の有効性と安全性. 癌と化学療法 20: 91-99, 1993.
Medical*Online
21) Wakeling AE: The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat. 25: 1-9, 1993.
PubMed
22) Howell A, DeFriend D, Robertson J, et al: Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29-30, 1995.
PubMed
23) Gregory EJ, Cohen SC, Oines DW, et al: Megestrol acetate therapy for advanced breast cancer. J. Clin. Oncol. 3: 155-160, 1985.
PubMed
24) Davila E, Vogel CL, East D, et al: Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer 61: 2161-2167, 1988.
PubMed
25) Becher R, Miller AA, Hoffken K, et al: High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen. Cancer 63: 1938-1943, 1989.
PubMed
26) Cavalli F, Goldhirsch A, Jungi F, et al: Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J. Clin. Oncol. 2: 414-419, 1984.
PubMed
27) Etienne MC, Milano G, Frenay M, et al: Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. J. Clin. Oncol. 10: 1176-1182, 1992.
PubMed
28) Hortobagyi GN, Buzdar AU, Frye D, et al: Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res. Treat. 5: 321-326, 1985.
PubMed
29) Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group: Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Jpn. J. Cancer Res. 84: 455-461, 1993.
 
30) Watanabe T, Adachi I, Tajima K, et al: Improving the quality of life during chemoendocrine therapy for metastatic breast cacner: arandomized comparison of tamoxifen (TAM) versus medroxyprogesterone acetate (MPA) in combination with doxorubicin (ADM) plus cyclophosphamide. Proc. Am. Soc. Clin. Oncol. 13: 90, 1994.
 
31) Kaufmann M, Jonat W, Kleeberg U, et al: Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J. Clin. Oncol. 7: 1113-1119, 1989.
 
32) Saphner T, Troxel AB, Tormey DC, et al: Phase II study of goserelin for patients with postmenopausal metastatic breast cancer. J. Clin. Oncol. 11: 1529-1535, 1993.
PubMed
33) Watanabe T, Adachi I, Taguchi T, et al: 144-SR (leuprorelin sustained release formulation) in premenopausal patients with metastatic breast cancer (MBC) . Breast Cancer Res. Treat. 37: 74, 1995.
 
34) Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J. Clin. Oncol. 16: 994-999, 1998.
PubMed
35) Lipton A, Harvey HA, Santen RJ, et al: Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 42: 3434 s-3436 s, 1982.
 
36) Goss PE, Gwyn KMEH: Current perspectives on aromatase inhibitors in breast cancer. J. Clin. Oncol. 12: 2460-2470, 1994.
PubMed
37) 青山英昭: 進行・再発乳癌に対するCGS 16949 Aの治療効果-多施設共同研究による後期第二相試験-. 癌と化学療法 21: 477, 1994.
 
38) The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N. Engl. J. Med. 311: 128H286, 1984.
 
39) Kaisary AV, Tyrrell CJ, Peeling WB, et al: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br. J. Urol. 67: 502-508, 1991.
PubMed
40) Thompson IM, Zeidman EJ, Rodriguez FR: Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate[see comments]. J. Urol. 144: 1479-1480, 1990.
 
41) Waxman J, Man A, Hendry WF, et al: Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br. Med. J. Clin. Res. 291: 1387-1388, 1985.
 
42) Cox RL, Crawford ED: Estrogens in the treatment of prostate cancer. J. Urol. 154: 1991-1998, 1995.
PubMed
43) Chang A, Yeap B, Davis T, et al: Double-blind, randomized study of primary hormonal treatment of stage D 2 prostate carcinoma: flutamide versus diethylstilbestrol. J. Clin. Oncol. 14: 2250-2257, 1996.
 
44) Iversen P, Tyrrell CJ, Kaisary AV, et al: Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51: 389-396, 1998.
 
45) Huggins C, Scott WW: Bilateral adrenalectomy in prostatic cancer. Clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann. Surg. 122: 1031-1041, 1993.
 
46) Labrie F, Dupont A, Belanger A, et al: New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4: 579-594, 1983.
PubMed
47) Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without furutamide in prostatic carcinoma. N. Engl. J. Med. 321: 419-424, 1989.
PubMed
48) Janknegt RA, Abbou CC, Bartoletti R, et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J. Urol. 149: 77-83, 1993.
PubMed
49) Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 11: 1566-1572, 1993.
PubMed
50) Nieh PT: Withdrawal phenomenon with the antiandrogen casodex. J. Urol. 153: 1070-1073, 1995.
PubMed
51) Akakura K, Akimoto S, Ohki T, et al: Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45: 700-705, 1995.
PubMed
52) Suzuki H, Sato N, Watabe Y, et al: Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol. 46: 759-765, 1993.
PubMed
53) Ehrlich CE, Young PC, Cleary RE: Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, nd carcinomatous endometria: therapeutic implications. Am. J. Obstet. Gynecol. 141: 539-546, 1981.
 
54) Gurpide E: Hormone receptors in endometrial cancer (Review) . Cancer 48: 638, 1981.
PubMed
55) Zaino RJ, Satyaswaroop PG, Mortel R: The relationship of histologic and histochemical parameters to proges. terone receptor status in endometrial adenocarcinomas. GynecoL Oncol. 16: 196-208, 1983.
 
56) Soper JT, Christensen CW: Steroid receptors and endometrial cancer. Clin. Obstet. Gynecol. 13: 825-842, 1986.
 
57) Kelley RM, Baker WH: Progestational agents in the treatment of carcinoma of the endometrium. N. Engl. J. Med. 264: 216, 1961.
PubMed
58) Santen RJ, Manni A, Harvey H, et al: Endocrine treatment of breast cancer in women (Review) . Endocr. Rev. 11: 221-265, 1990.
PubMed
59) ThigPen JT, Homesley HD: Arandomized study of medroxyprogesterone acetate (MPA) 200 mg versus 1000mg in the treatment of advanced, persistent or recurrent carcinoma of the endometrium. In : Gynecologic Oncology Group Statistical Report, p 177. Buffalo. Gynecologic Oncology Group, 1990.
 
60) ThigPen JT, Blessing J, DiSaia P: Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: Results of therapy and correlation with estrogen and progesterone levels. The gynecologic oncology experience. In: Endocrinology of Malignancy (eds. by baulieu EE, Slacobelli S, McGuire WL) , Park Ridge, NJ, Parthenon, 1986, p. 446.
 
61) Ehrlich CE, Young PC, Stehman FB, et al: Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am. J, Obstet. Gynecol. 158: 796-807, 1988.
PubMed
62) Kauppila A: Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature (Review) . Acta Oncol. 28: 561-566, 1989.
PubMed
63) Moore TD, Phillips PH, Nerenstone SR, et al : Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions (Review) . J. Clin. Oncol. 9: 1071-1088, 1991.
PubMed
64) Quinn MA, Campbell JJ, Murray R, et al: Tamoxifen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone. Aust. N. Z. J. Obstet. Gynaecol. 21: 226-229, 1981.
 
65) Tatman JL, Freedman RS, Scott W, et al: Treatment of advanced endometrial adenocarcinoma with cyclicsequential ethinyl estradiol and medroxyprogesterone acetate. Eur. J. Cancer Clin. Oncol. 25: 1619-1621, 1989.
PubMed
66) Kline RC, Freedman RS, Jones LA, et al: Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Cancer Treat. Rep. 71: 327-328, 1987.
PubMed
P.489 掲載の参考文献
1) 漆崎一朗, 塚越茂: 癌とBRM. サイエンスフォーラム, 東京, 1982.
 
2) 曽根三郎, 小倉 剛: 臨床免疫, 第XV腫瘍免疫: 担癌生体の免疫能. 日本臨牀 (増刊号) : 137-143, 1990.
 
3) Pisani RJ: Bronchogenic carcinoma: immunologic aspects. Mayo Clin. Proc. 68: 386-392, 1993.
PubMed
4) Oldham RK: Biological response modifiers. J. Natl. Cancer Inst. 70: 789-796, 1983.
PubMed
5) Foon KA: Biological response modifiers: anew immunotherapy. Cancer Res. 49: 1621-1639, 1989.
 
6) Stone NN, Droller MJ: Role of immunotherapy in the treatment of bladder and renal cell carcinoma. Semin. Surg. Oncol. 7: 239-243, 1991.
PubMed
7) Herberman RB: Design of clinical trials with biological response modifiers. Cancer Treat. Rep. 69: 1161-1164, 1985.
PubMed
8) Talmadge JE, Herberman RB: The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat. Rep. 70: 171-181, 1986.
PubMed
9) Arai K, Lee F, Miyajima A, et al: Cytokines: coordinators of immune and inflammatory responses. Annu. Rev. Biochem. 59: 783-836, 1990.
PubMed
10) Berke G: The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu. Rev. Immunol. 12: 735-773, 1994.
PubMed
11) Azuma M, Cayabyab M, Buck D, et al: CD 28 interaction with B 7 costimulates primary allogenic proliferative responses and cytotoxicity mediated by small resting T lymphocytes. J. Exp. Med. 175: 353-360, 1992.
 
12) Cui J, Shin T, Kawano T, et al: Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626, 1997.
 
13) Sone S, Yanagawa H, Nii A, et al: Induction of interleukin-2 activated killer effector activity and its regulatory mechanism. Gann Monogr. Cancer Res. 40: 81-93, 1993.
 
14) Strand S, Hofmann WJ, Hug H, et al: Lymphocyte apoptosis induced by CD 95 (Apo-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med. 2: 1361-1364, 1996.
 
15) Sone S: Role of alveolar macrophages in pulmonary neoplasias. Biochim. Biophys. Acta 823: 227-245, 1986.
PubMed
16) Old LJ: Tumor necrosis factor: In Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy (eds. by Bonavida B, Granger G) , Basel, Karger, 1990, pp. 1-30.
 
17) Grimm EA, Crump W III, Durett A, et al: Transforming growth factor (TGF-β) inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol. Immunother. 27: 53-58, 1988.
 
18) Itoh K, Tilden AB, Balch CM: Role of interleukin-2 and a serum suppressive factor on the induction of activated killer cell cytotoxicity for human melanoma cells. Cancer Res. 45: 3173-3178, 1985.
 
19) Sone S, Yanagawa H, Nii A, et al: Induction of interleukin 2-activated effector activity and its regulatory mechanisms (eds. by Ogura T, Takaku F) . Regulation of Human Cancer by Cytokines 40: 81-93, 1993.
 
20) Chan SH, Kobayashi M, Santoli D, et al: Mechanism of interferonγ production by natural killer cell stimulatory factor (NKSF/IL12) . Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J, Immunol. 148: 92-98, 1992.
 
21) Yamamura Y, Ogura T, Sakatani M, et al: Randomized controlled study of adjuvant immunotherapy with Nocardia rubra cell wall skeleton for inoperable lung cancer. Cancer Res. 43: 5575-5579, 1983.
PubMed
22) 桝野富弥, 岸本 進, 小倉 剛・他: 肺癌の癌性胸膜炎に対するLC 9018の治療効果-多施設によるphase III ran- domized controlled study. Biotherapy 4: 29-37, 1990.
 
23) 生越喬二: 細菌製剤および合成化合物による治療-BCG, OK-432, PSK, Lentinan, Bestatin, Levamisole, SPG, MDP, etc-. 癌と化学療法 12: 273-280, 1998.
 
24) Parkinson DR: Levamisole. In: Biological Therapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 795-801.
 
25) 赤座英之, 岩崎明郎: BCGと膀胱癌-その後の展開. Biotherapy 9: 737-745, 1995.
 
26) Herr HW: lnstillation therapy for bladder cancer. In: Biological Therapy of Cancer (ed. by DeVita, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 705-711.
 
27) Schlom J: Monoclonal antibodies in cancer therapy: basic principles. In: Biological Therapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, philadelphia, 1995, pp. 507-521.
 
28) Houghton AN, Chapman PB: Clinical applications of monoclonal antibodies in cancer. In: Biological Therapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 576-590.
 
29) Irie RF, Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD 2. Proc. Natl. Acad. Sci. USA 83: 8694-8698, 1986.
 
30) Oldham RK, Foon KA, Morgan AC, et al: Monoclonal antibody therapy of malignant melanoma: in vivo Iocalization in cutaneous metastasis after intravenous administration. J. Clin. Oncol. 2: 1235-1244, 1984.
 
31) Vadham-Raj S, Cordon C, Carswell EA, et al: Phase I trial of a mouse monoclonal antibody against GD 3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J. Clin. Oncol. 6: 1636-1648, 1988.
 
32) Cheung NV, Lazarus H, Miraldi FD, et al: Ganglioside GD 2 specific monoclonal antibody 3 F 8: Aphase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. 5: 1430-1440, 1987.
 
33) Caufield J, Barna B, Murthy S, et al: Phase-Ia-Ibtrial of an anti-GD 3 monoclonal antibody in combination with interferon-α in patients with malignant melanoma. J. Biol. Resp. Modif. 9: 319-328, 1990.
 
34) Alexander HR, Pass HI: Biologic therapy with TNF: systemic administration and isolation-perfusion. In: Biological Therapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 329-345.
 
35) Denardo SJ, O'Grady LF, Richman CM, et al: Radioimmunotherapy for advanced breast cancer using 1-131-ChL 6 antibody. Anticancer Res. 17: 1745-1751, 1997.
 
36) Pai LH, Pastan I: Monoclonal antibodies in cancer therapy: Immunotoxins and recombinant toxins. In: Biological Therapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 521-533.
 
37) Markman M, Reichman B, Ianotti N, et al: Phase I trial of recombinant tumor necrosis factor administered by the intraperitoneal route. Reg. Cancer Treat. 2: 174-177, 1989.
 
38) Raith U, Kaufmann M, Schmid H, et al: Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur. J. Cancer 27: 121-125, 1991.
 
39) Hardy J, Jones A, Gore ME, et al: Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor. Eur. J. Cancer 26: 771, 1990.
PubMed
40) Serretta V, Corselli G, Piazza B, et al: Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha: preliminary report of a phase I-II study. Eur. Urol. 22: 112-114, 1992.
PubMed
41) 早川正道: 腎細胞癌に対する免疫療法の現状と今後の課題. 日本医事新報 3499: 13-18, 1991.
Medical*Online
42) Savage PD, Muss HB: Biologic therapy with interferon-α and β: Renal cell cancer. In: Biological Therapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 373-387.
 
43) Minasian LM, Motzer RJ, Gluck L, et al: Interferon alfa-2 a in advanced renal cell carcinoma: treatment results and survival in l59 patients with long-term follow-up. J. Clin. Oncol. 11: 1368-1375, 1993.
 
44) Neidhart JA, Anderson SA, Harris JE, et al: Vinblastine fails to improve response of renal cancer to interferon alfa-n l l high response rate in patients with pulmonary metastases. J. Clin. Oncol. 9: 832-837, 1991.
 
45) Lotze MT, Chang AE, Seipp CA, et al: High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment morbidity, and histological findings. JAMA 25613117-3124, 1986.
 
46) Rosenberg SA, Yang JC, Topalian SL, et al: The treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose interleukin-2. JAMA 271: 907-913, 1994.
PubMed
47) Yang JC, Topalian SL, Parkinson D, et al: Arandomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma--an interin report. J. Clin. Oncol. 12: 1572-1576, 1994.
 
48) Marincola FM, Rosenberg SA: Biologic therapy with interleukin-2: clinical application, melanoma. In: Biological Therapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 250-262.
 
49) Weiss GR, Margolin KA, Aronson FR, et al: Arandomized phase II trial of continuous infusion interleukin-2 0r bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell cancer. J. Clin. Oncol. 10: 275-281, 1992.
 
50) Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alfa interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7: 1863-1874, 1989.
 
51) Ilson DH, Motzer RJ, Kradin RL, et al: Aphase-II trial of interleukin-2 and interferon alfa-2 a in patients with advanced renal cell carcinoma. J. Clin. Oncol. 10: 1124-1130, 1992.
 
52) Lipton A, Harvery H, Gibant E, et al: Interleukin-2 (IL-2) and interferon-2 a outpatient therapy for metastatic renal cell carcinoma. J. Immunother. 13: 122-129, 1993.
 
53) Yasumoto K, Ogura T: Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer: amulti-institutional cooperative study. Biotherapy 3: 345-349, 1991.
 
54) Tepper RI, Pattengale PK, Leder P: Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57: 503-512, 1989.
 
55) Margolin K, Aronson FR, Sznol M, et al: Phase II studies of recombinant human IL-4 in advanced renal cancer and malignant melanoma. J. Immunother. 15: 147-153, 1994.
 
56) Fujiki F, Mukaida N, Hirose K, et al: Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10gene transfer. Cancer Res. 57: 94-99, 1997.
 
57) Huhn RD, Radwanski E, O'Connel SM, et al: Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human Interleukin 10 in healthy volunteers. Blood 87: 699-705, 1996.
 
58) Atkins MB, Robertson MJ, Gordon M, et al: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3: 409-417, 1997.
PubMed
59) Atkins MB, Trehu EG, Mier JW: Combination cytokine theapy. In: Biological Therapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 443-466.
 
60) Rosenberg SA, Lotze MT, Muul LM, et al: Aprogress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-20r high-dose interleukin-2 alone. N. Engl. J. Med. 316: 889-897, 1987.
 
61) Rosenberg SA, Lotze MT, Aebersold PM, et al: Prospective randomized trial of high dose interleukin-2 alone or with lymphokine activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85: 622-632, 1993.
 
62) Keilholz U, Scheibenbogen C, Brado M, et al: Regional adoptive immunotherapy with interleukin-2 and lympho- kine-activated killer (LAK) cells for liver metastasis. Eur. J. Cancer 30 A: 103-105, 1994.
 
63) Merchant RE, Baldwin NG, Rice CD, et al: Adoptive immunotherapy of malignant glioma using tumor-sensi- tized T lymphocytes. Neurol. Res. 19: 145-152, 1997.
 
64) Rosenberg SA, Spiess P, Lafreniere R: Anew approach to the adoptive immunotherapy of cancer with tumor- infiltrating lymphocytes. Science 223: 1318: 321, 1986.
 
65) Rosenberg SA, Yannelli J, Yang JC, et al: Treatment of patients with metastatic melanoma using autologous tumor infiltrating lymphocytes. J. Natl. Cancer Inst. 86: 1159-1166, 1994.
PubMed
66) Chang AE, Sondak VK, Bishop DK, et al: Adoptive immunotherapy with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum. Gene Ther. 7: 773-792, 1996.
PubMed
67) Chang AE, Aruga A, Cameron MJ, et al: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD 3 and interleukin-2. J. Clin. Oncol, 15: 796-807, 1997.
 
68) Gerner FR, Moore GE: Feasibility study of immunotherapy in patients with solid tumors. Cancer 38: 131-143, 1976.
 
69) Laucius JF, Bodurtha AJ, Mastrangelo MJ, et al: Aphase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer 40: 2091-2093, 1977.
 
70) Hoover HC Jr, Brandhorst JS, Peters LC, et al: Adjuvant active specific immunotherapy for human colorectal cancer: 6. 5year median follow up of a phase III prospectively randomized trial. J. Clin. Oncol. 11: 390-399, 1993.
 
71) Dranof G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine GM- CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543, 1993
 
72) Jaffee EM, Hurwitz H, Pardoll DM: Gene therapy of cancer: gene modification of tumors. In: BiologicalTherapy of Cancer (ed. by DeVita VT, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, pp. 4774-4783.
 
73) Marchand M, Weymants P, Pankin E, et al: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63: 883-885, 1995.
 
74) Tjoa BA, Erickson SJ, Bowes VA, et al: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32: 272-278, 1997.
PubMed
75) Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332, 1998.
PubMed
76) Yano S, Nishioka Y, Nokihara H, et al: Macrophage colony-stimulating factor gene transduction into human lung cancer cells differentially regulates metastasis formations in various organ microenvironments of natural killer celLdepleted SCID mice. Cancer Res. 57: 784-790, 1997.
 
77) 川上正舒, 早田邦康: 癌悪液質とサイトカイン-TNFと代謝. Biotherapy 6: 1230-1237, 1992.
 
78) 漆崎一朗: サイトカインの神経, 内分泌, 免疫相関. Biotherapy 6: 1178-1187, 1992.
 
P.502 掲載の参考文献
1) 矢守隆夫, 上原至雅, 済木育夫・他: わが国における制がん剤候補物質のスクリーニング成績・第7報. 癌と化学療法 25 (Suppl. I) : 1998.
 
2) Boyd MR: Status of the NCI preclinical antitumor drug discovery screen. Principles & Practice of Oncology 3: 1-12, 1989.
 
3) Monks A, Scudiero D, Skehan P, et al: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83: 757-766, 1991.
PubMed
4) Weinstein JN, Myers TG, O'Connor PM, et al: An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997.
 
5) 矢守隆夫: ヒト培養がん細胞パネルによるスクリーニング. 癌と化学療法 24: 129-135, 1997.
 
6) Paull KD, Shoemaker RH, Hodes L, et al: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81: 1088-1092, 1989.
PubMed
P.509 掲載の参考文献
1) 世界医師会総会: ヘルシンキ宣言, ヘルシンキ, 1964, 東京, 1975, ベニス, 1983.
 
2) Silverman WA: Human experimentation: A Guided Step into the Unknown. Oxford University Press, New York, 1985.
 
3) Piantadosi S, Saijo N, Tamura T: Basic design considerations for clinical trials in oncology. Jpn. J. Cancer Res. 83: 547-558, 1992.
PubMed
4) 星野一正: 医療の倫理 (岩波新書201) . 岩波書店, 東京, 1991.
 
5) 厚生省令第28号平成9年3月27日: 医薬品の臨床試験の実施の基準に関する省令, 1997.
 
6) 中央薬事審議会答申平成9年3月13日: 医薬品の臨床試験の実施の基準 (GCP) の内容, 1997.
 
7) 厚生省薬務局新医薬品課長通知薬新薬第9号平成3年2月4日: 抗悪性腫瘍薬の臨床評価ガイドライン, 1991.
 
8) 厚生省医薬品安全局GCP研究会: 改訂GCPハンドブック. 薬業時報社, 東京, 1997.
 
9) 厚生省薬務局GCP研究会: 医師のための治験ハンドブック. 改訂第2版, ミクス, 東京, 1997.
 
10) ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuti- cals for Human Use) : Guideline for Good Clinical Practice. IFPMA, Geneva, 1996.
 
11) 日本臨床腫瘍研究会: 第9回日本臨床腫瘍研究会プログラム・抄録. 平成8年8月, 東京, 1997.
 
12) 下山正徳, 田島絹子, 恒松隆一郎・他: 厚生省がん研究助成金指定研究「固形がんの集学的治療の研究」班における臨 床試験計画 (プロトコール) の作成と実施, 並びに結果の統計解析とその評価に関するガイドライン (改訂第3版) 第1部プロトコールの作成に関する医学的並びに科学的事項とその審査. 癌の臨床 42: 197-229, 1996.
 
13) がん薬物療法研究会: がん臨床試験ガイド-よりよいがん治療を求めて-. Churchill Communications Japan, 東京, 1997.
 
P.572 掲載の参考文献
1) 藤井博文, 佐々木康綱: 薬理学的マーカーを用いたがん化学療法. 臨床医 21: 80-83, 1995.
 
2) 国兼浩嗣, 西條長宏: 癌化学療法の新しい標的. 化学療法の領域 9: 13-19, 1993.
 
3) 佐々木康綱: 抗癌剤の臨床薬理学-Oncological Pharmacology, 化学療法の進歩-新版. メジカルレビュー社, 東京, 1993, pp. 106-112.
 
4) Ratain MJ: Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin. Oncol. 19: 8-13, 1992.
 
5) Grochow LB, Baraldi C, et al: Is dose normalization to weight or body surface area useful in adults? JNatl. Cancer Inst. 82: 323-325, 1990.
PubMed
6) Ratain MJ: Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J. Clin. Oncol. 16: 2297-2298, 1998.
PubMed
7) 佐々木康綱: 抗癌剤の臨床薬理学. 図説臨床癌シリーズno. 1癌化学療法の進歩-新版-, メジカルレビュー社, 1993, pp. 106-122.
 
8) 高田寛治: 序. 薬物動態学. 基礎と応用, 薬業時報社, 東京, 1995, pp. 1-2.
 
9) Rowland M, Tozer T: Clinical pharmacokinetics concepts and applications (second edition) ,. Lea & Febiger, 1989.
 
10) 高田寛治: 薬物動態学的1-コンパートメント・モデル. 薬物動態学基礎と応用, 薬業時報社, 東京, 1995, pp. 3-50.
 
11) Gibaldi M, Perrier D: Pharmacokinetics. Marcel Dekker Inc, New York, 1975.
 
12) Akaike H: An information criterion (AIC) ,. Math. Sci. 14 (153) : 5-9, 1976.
 
13) Imbimbo BP, Martinelli P, et al: Efficiency of different criteria for selecting pharmacokinetic multiexponential equations. Biopharm. Drug Dispos. 12: 139-147, 1991.
PubMed
14) Kamikubo K, Murase H, et al: Microcomputer-based nonlinear regression analysis of ligand-binding data: application of Akaike 's information criterion. Jpn. J. Pharmacol. 40: 342-346, 1986.
 
15) Yamaoka K, Nakagawa T, et al: Application of Akaike 's information criterion (AIC) , in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6: 165-175, 1978.
 
16) Bischoff KB, Dedrick RL, et al: Methotrexate pharmacokinetics. J Pharm. Sci. 60: 1128-1133, 1971.
PubMed
17) 高田寛治: 薬物動態学的2-コンパートメント・モデル. 薬物動態学基礎と応用, 薬業時報社, 東京, 1995, pp. 51-78.
 
18) 山岡 清: マイコンによる薬物体内動態解析法. 南江堂, 東京, 1987.
 
19) 山岡 清, 谷川原祐介: マイコンによる薬物速度論入門. 南江堂, 東京, 1987.
 
20) Bourne DWA: MULTI-FORTE, a microcomputer program for modeling and simulation of pharmacokinetics data. Comput. Methods Programs Biomed. 23: 277-281, 1986.
 
21) 越前宏俊: TDM講習テキスト-TDMの考え方と臨床応用の基礎-. ダイナボット株式会社.
 
22) Yamaoka K, Tanigawara Y, et al: Apharmacokinet analysis program (MULTI) , for microcomputer. J. Pharmacobiodyn. 4: 879-885, 1981.
PubMed
23) Metzler CM, Elfring GL, et al: A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562, 1974.
 
24) 中川 徹, 小柳義夫: 最小2乗法による実験データ解析. 東京大学出版会, 東京, 1982.
 
25) Charter MK: The estimation of moments: Atechnical note. J. Pharmacokin et. Biopharm. 17: 203-208, 1989.
 
26) Dunne A, et al: Estimation of noncompartmental parameters: Atechnical note. J. Pharmacokinet. Biopharm. 17: 131-137, 1989.
PubMed
27) 高田寛治: ノンコンパートメント解析法. 薬物動態学基礎と応用. 薬業時報社, 東京, 1995, pp. 79-92.
 
28) Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6: 539-546, 1978.
PubMed
29) Wagner JG: Types of mean residence times. Biopharm. Drug Dispos. 9: 41-57, 1988.
PubMed
30) Wagner JG: Pharmacokinetics for the pharmaceutical scientist. Technomic, Lancaster, 1988.
 
31) 高田寛治: コンパートメント解析における非線形最小二乗法を用いる曲線あてはめ計算. 薬物動態学基礎と応用. 薬業時報社, 東京, 1995, pp. 153-155.
 
32) Nimmo WS: Drugs, disease and altered gastric emptying. Clin. Pharmacokinet. 1: 189-203, 1976.
PubMed
33) Pfeffer M, Nardella PA, et al: Etoposide (VP-16) ,. Academic Press Inc, Ltd, London, 1984.
 
34) Marzola M, Zucchetti M, et al: Low-dose oral etoposide in epithelial cancer of the ovary. Ann. Oncol. 4: 517-519, 1993.
PubMed
35) Hande KR, Krozely MG, et al: Bioavailability of low-dose oral etoposide. J. Clin. Oncol. 11: 374-377, 1993.
PubMed
36) Calvert AH, Lind MJ, et al: Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. Cancer Treat. Rev. 19 (Suppl. C) : 27-33, 1993.
 
37) Hande KR: Etoposide pharmacology. Semin. Oncol. 19 (6 Suppl. 13) : 3-9, 1992.
 
38) Waits TM, Johnson DH, et al: Prolonged administration of oral etoposide in non-small-cell lung cancer: aphase II trial. J. Clin. Oncol. 10: 292-296, 1992.
 
39) Clark PI: Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin. Oncol. 19 (2Suppl. 6) : 20-27, 1992.
 
40) Carney DN: The pharmacology of intravenous and oral etoposide. Cancer 67 (1 Suppl) : 299-302, 1991.
 
41) Miller AA, Herndon JE, et al: Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phaselllstudy of the Cancer and Leukemia Group. Br. J. Clin. Oncol. 13: 1871-1879, 1995.
 
42) Sonnichsen DS, Ribeiro RC, et al: Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clin. Pharmacol. Ther. 58: 99-107, 1995.
PubMed
43) Pinkerton CR, Dick G, et al: 24-hour plasma etoposide profile after oral and intravenous administration in children. Eur. J. Cancer 29 A (10) , 11479-1481, 1993.
 
44) Slevin ML: The clinical pharmacology of etoposide. Cancer 67 (1 SupPL) : 319-329, 1991.
 
45) Ohno R, Yamada K, et al: PhaseIlstudy: treatment of non-Hodgkin 's lymphoma with an oral antitumor derivative of bis (2, 6-dioxopiperazine) ,. J. Natl. Cancer Inst. 84: 435-438, 1992.
PubMed
46) Matthias M, Sohr R, et al: Bioavailability of cyclophosphamide following oral administration in high doses. Onkologie 7: 48-49, 1984.
PubMed
47) Zhou XJ, Bore P, et al: Pharmacokinetics of Navelbine after oral administration in cancer patients. Cancer Chemother. Pharmacol. 29: 66-70, 1991.
PubMed
48) Lucas S, Donehower R, et al: Absolute bioavailability (ABA) , liquid-filled soft geratin capsules at full therapeutic doses in patients with solid tumors. Ann. Oncol. 3 (supPl. 1) : 125, 1992.
 
49) 中島 創, 西條長宏: 臨床薬理学に基づく至適投与法の決定法. がん治療のState of the art-Medical Oncologistの育成を目指して-, 協和企画通信, No. 4, 1993.
 
50) Wan SH, Huffma DH, et aI: Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res. 34: 3487-3491, 1974.
 
51) Howell SB, Chu BBF, et al: Long-duration intracavity infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J. Clin. Invest. 67: 1161-1170, 1981.
 
52) Van Echo DA, Egorin MJ, et al: Phase I clinical and pharmacological trial of carboplatin daily for 5 days. Cancer Treat. Rep. 6811103-1114, 1984.
 
53) Shea TC, Flaherty M, et al: Aphase I clinical and pharmacokinetic study of carboplatin, autologous bone marrow support. J. Clin. Oncol. 7: 651-661, 1989.
 
54) 厚生省薬務局新医薬品課編: 新医薬品承認審査概要 (SBA) , No. 1「塩酸イリノテカン」. 日本公定書協会, 1994.
 
55) Goodman LS, Gilman A: The pharmacological basis of therapeutics. Macmillan Publishing Co, Inc, 1985.
 
56) Thyss A, Milano G, et al: Clinical and pharmacokinetic evidence of a life-threatening action between methotrexate and letoprofen. Lancet 1: 256-258, 1986.
 
57) Nierenberg DW: Competitive inhibition of methotrexate accumulation in rabbit kidney slices by nonsteroidal anti-inflamatory drugs. J. Pharmacol. Exp. Ther. 226: 1-6, 1983.
 
58) Zipser RD, Hoefs JC, et al: Prostaglandins: Modulations of renal function and pressor resistance in chronic liver disease. J. Clin. Endcrinol. Metab. 48: 895-900, 1979.
 
59) Pitman SW, Frei E: Weekly methotrexate-calcium leucovorin rescue: Effect of alkalinization on nephrotoxicity；Pharmacokinetics in the CNS；and use in CNS non-Hodgkin 's lymphoma. Cancer Treat. Rep. 611695-701, 1977.
 
60) Drobitch RK, Svensson CK: Therapeutic drug monitoring insaliva: An update. Clin. Pharmacokinet. 23: 365- 379, 1992.
 
61) 久保木芳徳, 藤沢隆一: 唾液の採取法と取り扱い. 臨床検査 30 (9) : 937-942, 1986.
 
62) 西原カズヨ: 唾液中の薬物濃度の測定. 臨床検査 30 (9) : 961-970, 1986.
 
63) Steele WH, Stuart JFB, et al: Serum, tear and salivary concentrations of methotrexate in man. Br. J. Clin. Pharmacol. 7: 207-211, 1979.
 
64) Schroder H, Jensen KB, et al: Lack of correlation between methotrexate concentrations in serum saliva and sweat after 24 h methotrexate infusions. Br. J. Clin. Pharmacol. 24: 537-541, 1987.
PubMed
65) Frauendienst-Egger G, Bartels H, et al: Methotrexate concentrations in serum and saliva in children treated with high doses of methotrexate. J. Clin. Chemistry Clin. Biochemistry 27: 228-229, 1989.
 
66) Gouyette A, Deniel A, et al: Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmaco- kinetic and metabolic studies. Eur. J. Cancer Clin. Oncol. 23: 1627-1632, 1987.
 
67) Takahashi T, Fujiwara Y, Sumiyoshi H, et al: Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Cancer Chemother. Pharmacol. 40: 449-452, 1997.
PubMed
68) Uematsu T, Kondo K, et al: Measurement of temafloxacin in human scalp hair as an index of drug exposure. J. Pharm. Sci. 83: 42-45, 1994.
PubMed
69) Miyazawa N, Uematsu T, et al: Ofloxacin in human hair determined by high performance liquid chromatography. Forensic Sci. Int. 51: 65-77, 1991.
PubMed
70) Sparreboom A, Huizing MT, et al: Isolation, purification, and biological activity of mono-and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother. Pharmacol. 36: 299-304, 1995.
PubMed
71) Catherine M, Martino M, et al: Uses and limitations of nuclear magnetic resonance (NMR) , spectroscopy in clinical pharmacokinetics. Clin. Pharmacokinet. 20 (5) : 337-349, 1991.
 
72) Evelhoch JL: In vivo 1gF nuclear magnetic resonance spectroscopy: apotential monitor of 5-fluorouracil pharmacokinetics and metabolism. Invest. New Drugs 7: 5-12, 1989.
 
73) Malet-Martino MC, Bernadou J, et al: 1gF NMR spectrometry evidence for bile acid conjugates of α-fluoro-β-alanine as the main biliary metabolisms of antineoplastic fluoropyrimidines in humans. Drug Metab. Dispos. 16: 78-84, 1988.
 
74) McSheehy PMJ, Griffiths JR, et al: 1gF NMR studies of fluoropyrimidine chemotherapy: areview. NMR Biomed. 2: 133-141, 1989.
 
75) Heidelberger C, Danenberg PV, et al: Fluorinated pyrimidines and their nucleosides. In: Advances in en- zymology and related areas of molecular biology (ed. by Meister) , John Wiley & Sons Inc., New York, 1983, pp. 57-121.
 
76) Pinedo HM, Peters GFJ: Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6: 1653-1664, 1988.
 
77) Bernadou J, Armand Jp, et al: Complete urinary profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance. Clin. Chem. 31: 864-848, 1985,
 
78) Hull WE, Port RE, et al: Metabolites of 5-fluorouracil in plasma and urine, as monitored by lgF nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res. 48: 1680-1688, 1988.
PubMed
79) Hull WE, Port RE, et al: in vitro 1gF-NMR study of 5-fluorouracil metabolism in liver and implanted tumors of the mouse. Proc. Soc. Magn. Reson. Med. 3: 594-595, 1986.
 
80) Malet-Martino MC, Armand Jp, et al: Evidence for the importance of 5 '-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry. Cancer Res. 46: 2105-2112, 1986.
PubMed
81) Semmler W, Bachert-Baumann P, et al: Realtime follow up of 5-fluorouracil metabolism in the liver of tumor patients by means of lg F MR spectroscopy. Radiology 174: 141-145, 1990.
 
82) Glaholm J, Leach MO, et al: Comparison of 5-fluorouracil pharmacokinetics following intraperitonear and intravenous administration using in vivo lgF magnetic resonance spectroscopy. Br. J. Radiology 63: 547-553, 1990.
 
83) Schlemmer HP, Bachert P, et al: Drug monitoring of 5-fluorouracil: in vivo lgF NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn. Reson. Imaging 12 (3) : 497-511, 1994.
 
84) DeForni M, Martino R, et al: Phosphorus-31 nuclear magnetic resonance spectroscopy (31P NMR) : asuitable technique for quantification of ifosfamide and its phosphorated metabolisms in human urine. In: Recent advances in chemotherapy, anticancer section (eds. by Rubinstein & Adam) , E. Lewin-Epstein Ltd, Jerusalem, 1989b, pp. 752. 1-752. 2.
 
85) Nicolay K, Aue WP, et al: Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 3iP-NMR and implications for adriamycin-induced cardiotoxicity. Biochim. Biophys. Acta 929: 5-13, 1987.
 
86) Tausch-Treml R, Kopf-Maier P, et al: 31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance. Br. J. Cancer 64: 485-493, 1991.
PubMed
87) Tofts PS, Wray S: A critical assessment of methods of measuring metabolite concentrations by NMR spectroscopy. NMR Biomed. 1: 1-10, 1988.
 
88) Goldstein DS, Coronado L, et al: 6-[Fluorine-18]fluorodopamine pharmacokinetics and dosimetry in humans. J. Nucl. Med. 35: 964-973, 1994.
PubMed
89) Herzog H, Seitz RJ, et al: Pharmacokinetics and radiation dose of oxygen-151abelled butanol in rCBF studies in humans. Eur. J. Nucl. Med. 21: 138-143, 1994.
PubMed
90) Ding YS, Fowler JS, et al: Synthesis and PET studies of fluorine-18-BMY 148021a potential antipsychotic drug. J. Nucl. Med. 34: 246-254, 1993.
PubMed
91) Fischman AJ, Livni E, et al: Pharmacokinetics of[18 F]fleroxacin in healthy human subjects studied by using positron emission tomography. Antimicrob. Agents Chemother. 37: 2144-2152, 1993.
 
92) Rubin RH, Livni E, et al: Pharmacokinetics of fleroxacin as studied by positron emission tomography and[18F]fleroxacin. Am. J. Med. 94: 31-37, 1993.
 
93) Tilsley DW, Harte RJ, et al: New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography. Cancer Surv. 17: 425-442, 1993.
PubMed
94) 近藤啓吾, 鈴木良彦・他: PET. 臨床画像 12: 174-180, 1995.
 
95) Hassan M, Oberg G, et al: In vivo distribution of[11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother. Pharmacol. 30: 81-85, 1992.
PubMed
96) Jones T, Tilsley DW, et al: Positron emission tomography for tumour assessment. NMR Biomed. 5: 265-269, 1992.
PubMed
97) Ponto LL, Ponto JA, Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II) ,. Clin. Pharmacokinet. 22 (4) : 274-283, 1992.
PubMed
98) Ponto LL, Ponto JA: Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part I) ,. Clin. Pharmacokinet. 22 (3) : 211-222, 1992.
PubMed
99) Schaaf LJ, Dobbs BR, et al: Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) , in colorectal cancer patients. Eur. J. Clin. Pharmacol. 32: 411-418, 1987.
PubMed
100) Gianni L, Kearns CM, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13: 180-190, 1995.
PubMed
101) Peece PA, Stafford I, et al: Nonlinear renal clearance of ultrafilterable platinum in patients treated with cisdichlorodiammine platinum (II) . Cancer Chemother. Pharmacol. 15: 295-299, 1985.
 
102) Shimoyama M: Cytocidal action of anticancer antigens: evaluation of the sensitivity of cultured animal and human cancer cells. Bibl. Haematologica 40: 711-722, 1975.
 
103) 杉山雄一, 稲葉 實: In vivo in vitro pharmacokinetics: In vitro殺細胞kineticsデータとpharmacokineticsデータを基にしたin vivo殺細胞効果の予測. Current review癌化学療法1990～91 (西條長宏, 鶴尾 隆, 編) . 中外医学社, 東京, 1990.
 
104) 杉山雄一, 稲葉 實: 前臨床から臨床へ薬理動態の基礎研究. 図説臨床(癌) シリーズNo. 1癌化学療法の進歩, メジカルビュー社, 東京, 1992.
 
105) Ratain MJ, Schilsky RL, et al: Pharmacodynamics in cancer therapy. J. Clin. Oncol. 8: 1739-1753, 1990.
PubMed
106) Egorin MJ, Echo DA, et al: Pharmacokinetics and dosage reduction of cis-diammine (1, 1-cyclobutanedicalboxylato) platinum in patients with impaired renal function. Cancer Res. 44: 5432-5438, 1984.
PubMed
107) Taguchi J, Saijo N, et al: Prediction of hematologic toxicity of carboplatin by creatinine cleatinine rate. Jpn. J. Cancer Res. 78: 977-982, 1987.
 
108) Newell DR, Siddik ZH, et al: Plasma free platinum pharmacokinetics in patients treated with high-dose carboplatin. Eur. J. Cancer Clin. Oncol. 23: 1399-1405, 1987.
PubMed
109) Sasaki Y, Amano T, et al: Phase I study and pharmacological analysis of cis-diammine (glycolato) platinum (254-S；NSC 375101 D) administered by 5-day continuous intravenous infusion. Cancer Res. 51: 1472-1477, 1991.
 
110) Ackland SP, Ratain MJ, et al: Pharmacokinetics and pharmacodynamics of long-term continuous infusion doxorubicin. Clin. Pharmacol. Ther. 45: 340-347, 1989.
PubMed
111) Minami H, Shimokata K, et al: Phase I clinical and pharmacokinetic study of a 14 day infusion of etoposide in patients with lung cancer. J. Clin. Oncol. 11: 1602-1608, 1993.
PubMed
112) Bennett CL, Sinkule JA, et al: Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res. 47: 1952-1956, 1987.
PubMed
113) Ratain MJ, Schilsky RL, et al: Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability. Clin. Pharmacol. Ther. 45: 226-233, 1989.
PubMed
114) Au JL-S, Rustum YM, et al: Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in the treatment of colorectal carcinoma. Cancer Res. 42: 2930-2937, 1982.
PubMed
115) Ratain MJ, Vogelzang NJ: Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res. 46: 4827-4830, 1986.
PubMed
116) Egorin MJ, Van Echo DA, et al: Human pharmacokinetics, excretion, and metabolism of anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res. 46: 1513-1520, 1986.
PubMed
117) Kerpel-Fronius S, Erdelyi-Toth V, et al: Relation 'between dose, plasmaconcentration and toxicity in phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG) . Cancer Chemother. Pharmacol. 16: 264-268, 1986.
 
118) Rowinsky EK, Ettinger DS, et al: Phase I and pharmacological study of hexamethylene bisacetamide in patients with advanced cancer. J. Clin. Oncol. 4: 1835-1844, 1986.
 
119) Egorin MJ, Sigman LM, et al: Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC95580) administered as a five-day continuous infusion. Cancer Res. 47: 617-623, 1987.
PubMed
120) Rowinsky EK, Ettinger DS, et al: Prolonged infusion of hexamethylene bisacetamide: Aphase I and pharmacological study. Cancer Res. 47: 5788-5795, 1987.
 
121) Pendyala L, Mdajewics S, et al: Effect of renal function impairment on iproplatin pharmacokinetics and relation to toxicity. Cancer Res. 45: 5936-5938, 1985. to toxicity. Cancer Res. 45: 5936-5938, 1985.
 
122) Schilsky RL, O'Laughlin K, et al: Phase I and pharmacological study of thymidine (NSC 21548) and cisdiam-minedichloroplatinum (II) in patients with advanced cancer. Cancer Res. 46: 4184-4188, 1986.
 
123) Gianni L, Kearns CM, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13: 180-190, 1995.
PubMed
124) Brown T, Havlin K, et al: Aphase I trial of taxol given by a 6-hour intravenous infusion. J. Clin. Oncol. 911261- 1267, 1991.
 
125) Ohtsu T, Sasaki Y, et al: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A3-hour infusion versus a 24-hour infusion. Clin. Cancer Res. 1: 599-606, 1995.
 
126) Extra JM, Rousseau F, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976；NSC 628503) given as a short intravenous infusion. Cancer Res. 53: 1037-1042, 1993.
PubMed
127) Pazdur R, Newman RA, et al: Phase I trials of Taxotere: Five-day schedule. J. Natl. Cancer Inst. 84: 1781-1788, 1992.
PubMed
128) Sasaki Y, Hakusui H, et al: Apharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn. J. Cancer Res. 86: 101-110, 1995.
PubMed
129) Schellens JHM, Eckardt JR, et al: Pharmacokinetics (PK) , clinical pharmacodynamics (PD) and safety of chronic cral topotecan (T) , in a phase I study. Proc. Am. Soc. Clin. Oncol. 14: 457, 1995.
 
130) Desai ZR, Van den Berg HW, et al: Can severe vincristine neurotoxicity by prevented? Cancer Chemother. Pharmacol. 8: 211-214, 1982.
PubMed
131) Reece PA, Stafford I, et al: Creatinine clearance as a predictor of ultrafilterable disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J. Clin. Oncol. 5: 304-309, 1987.
PubMed
132) Oshita F, Saijo N, et al: Correlation between total dose of cisplatin and vibratory perception threshold in chemotherapy induced peripheral neuropathy of cancer patients. Cancer J. 5: 165-169, 1992.
 
133) Grochow LB, Jones RJ, et al: Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 25: 55-61, 1990.
 
134) Hantel A, Rowinsky EK, et al: Clinical and pharmacologic reappraisal of dichloromethotrexate. J. Natl. Cancer Inst. 80: 1547-1553, 1988.
PubMed
135) Thyss A, Milano G, et al: Clinical pharmacokinetic study of 5-FU infusions for head and neck cancer. Cancer Chemother. Pharmacol. 16: 64-66, 1986.
PubMed
136) van Groeningen CJ, Pinedo HM, et al: Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on dose escalation schedule. Cancer Res. 48: 6956-6961, 1988.
PubMed
137) Ohe Y, Sasaki Y, et al: Phase I study and pharmacokinetics of CPT-11with 5-day continuous infusion. J. Natl. Cancer Inst. 84: 972-974, 1992.
 
138) 福岡正博: 化学療法. 肺癌 32: 605, 1992.
 
139) Rowinsky EK, Noe DA, et al: Clinical pharmacology of oral and i. v. N-methylformamide: Apharmacologic basis for lack of clinical antineoplastic activity. J. Natl. Cancer Inst. 80: 671-678, 1988.
 
140) Coleman CN, Halsey J, et al: Relationship between the neurotoxicity of hypoxic cell radiosensitixer SR 2508 and pharmacokinetic profile. Cancer Res. 43: 319-322, 1987.
 
141) Rowinsky EK, Chaudhry V, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol. 11: 2010-2020, 1993.
PubMed
142) Brenner DE, Wiernik PH, et al: Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer 53: 1042-1048, 1984.
PubMed
143) Legha SS, Benjamin RS, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 96: 133-139, 1982.
PubMed
144) Rodman JH, Abromowitch M, et al: Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial. J. Clin. Oncol. 5: 1007-1014, 1987.
 
145) La Rocca RV, Meer J, et al: Suramin-induced polyneuropathy. Neurology 40: 954-960, 1990.
PubMed
146) Scher HI: Suramin: Here to stay? J. Natl. Cancer Inst. 85: 594-597, 1993.
 
147) Penta JS, Rosner GL, et al: Choice of starting dose and escalation for phase I studies of anticancer agents. Cancer Chemother. Pharmacol. 31: 247-250, 1992.
PubMed
148) Evans WE, Crom WR, et al: Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med. 314: 471-477, 1986.
PubMed
149) Hayder S, Lafolie P, et al: 6-Mercaptopurine plasma levels in children with acute lymphoblastic leukemia: Relation to relapse risk and myelotoxicity. Ther. Drug Monit. 11: 617-622, 1989.
PubMed
150) Slevin ML, Clark PI, et al: Arandomized trial to evaluate the effect of schedule on the activity of etoposide insmall-cell lung cancer. J. Clin. Oncol. 7: 1333-1340, 1989.
 
151) Hillcoat BL, McCulloch PB, et al: Clinical response and plasma levels of 5-fluorouracil in patients with coloniccancer treated by drug infusion. Br. J. Cancer 38: 719-724, 1978.
PubMed
152) Lu K, Yap HY, et al: Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. Cancer Res. 43: 1405-1408, 1983.
PubMed
153) Stein CA, LaRocca RV, et al: Suramin: an anticancer drug with a unique mechanism of action. J. Clin. Oncol. 7: 499-508, 1989.
PubMed
154) Jodrell DI, Egorin MJ, et al: Relationships between carboplatin exposure and tumor response and toxicity inpatients with ovarian cancer. J. Clin. Oncol. 10: 520-528, 1992.
 
155) Etienne MC, Milano G, et al: Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. J. Clin. Oncol. 10: 1176-1182, 1992.
PubMed
156) Spears CP, Gustavsson BG, et al: Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res. 48: 5894-5900, 1988.
PubMed
157) Liliemark JO, Plunkett W, et al: Relationship of 1-B-D-arabinofuranosylcytosine in plasma to 1-B-Darabinofuranosylcytosine 5 '-triphosphate levels in leukemic cells during treatment with high dose 1-β-Darabinofuranosylcytosine. Cancer Res. 45: 5942-5957, 1985.
 
158) Heineman V, Estey E, et al: Patient specific dose rate for continuous infusion (CI) high-dose cytarabine (Ara-C) in relapsed acute myelogenous leukemia. J. Clin. Oncol. 7: 622-628, 1989.
 
159) Plunkett W, Iacoboni S, et al: Pharmacologically directed Ara-C therapy for refractory leukemia. Semin. Oncol. 12 (suppl. 3) : 20-30, 1985.
 
160) Gandhi V, Estey E, et al: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenousleukemia during therapy. J. Clin. Oncol. 11: 116-124, 1993.
 
161) Lennard L, Lilleyman JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J. Clin. Oncol. 7: 1816-1823, 1989.
PubMed
162) Abbruzzese JL, Grunewald R, et al: Aphase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 9: 491-498, 1991.
 
163) Balis FM: Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin. Pharmacokinet. 11: 223-235, 1986.
PubMed
164) Liliemark J, Peterson C: Pharmacokinetic optimisation of anticancer therapy. Clin. Pharmacokinet. 21: 213-231, 1991.
PubMed
165) Loadman PM, Bibby MC: Pharmacokinetic drug interactions with anticancer drugs. Clin. Pharmacokinet. 26: 486-500, 1994.
PubMed
166) Lane EA, Guthrie S, et al: Effects of ethanol on drug and metabolite pharmacokinetics. Clin. Pharmacokinet. 10: 228-247, 1985.
PubMed
167) Vokes EE: Interactions of chemotherapy and radiation. Semin. Oncol. 20: 70-79, 1993.
PubMed
168) Henriksson R, Rogo K, et al: Interaction between cytostatics and nutrients. Med. Oncol. Tumor Pharmacother. 8: 79-86, 1991.
PubMed
169) Bremnes RM, Smeland E, et al: The effect of vindesine on methotrexate hydroxylation in the rat. Biochem. Pharmacol. 42: 1561-1568, 1991.
PubMed
170) Bore P, Lena N, et al: Methotrexate-vindesine association in head and neck cancer: modification of methotrexate 's hydroxylation in presence of vindesine. Cancer Chemother. Pharmacol. 17: 171-176, 1986.
PubMed
171) Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol. 10: 896-903, 1992.
 
172) Grem JL, McAtee N, et al: Apilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J. Clin. Oncol. 9: 1811-1820, 1991.
 
173) Czeka MJ, Jager W, et al: Clinical pharmacokinetics of 5-fluorouracil. Influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Arzneimittelforschung 43: 387-390, 1993.
 
174) Danhauser LL, Freimann JH, et al: Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon-alfa-2 b in patients with advanced cancer. J. Clin. Oncol. 11: 751-761, 1993.
 
175) Trump DL, Egorin MJ, et al: Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J. Clin. Oncol. 9: 2027-2035, 1991.
PubMed
176) Okuda H, Nishiyama T, Ogura K, et al: Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug. Metab. Dispos. 25: 270-3, 1997.
 
177) Sasaki Y, Ohtsu Y, et al: Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J. Natl. Cancer Inst. 86: 1096-1098, 1994.
 
178) Saltz L, Kanowitz J, et al: Phase I trial of irinotecan (CPT-11) , 5-fluorouracil (FU) , and leucovorin (LV) inpatients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 14: 476, 1995.
 
179) Hill SR, Pollard LA, Bibby MC: Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma. Anticancer Res. 12: 2169-2175, 1992.
 
180) Hill SR, Bibby MC: 5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice. Cancer Chemother. Pharmacol. 34: 57-62, 1994.
PubMed
181) Taal BG, Bokkel HWW, et al: 5-fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results. Eur. J. Cancer 26: 856, 1990.
 
182) Bowen D, White JC, et al: A basis for fluoropyrimidine-induced antagonism to methotrexate in Ehrlich ascites tumor cells in vitro. Cancer Res. 38: 219-222, 1978.
PubMed
183) Bertino JR, Sawicki WL, et al: Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res. 37: 327-328, 1977.
PubMed
184) Cadman E, Hermer R, et al: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 205: 1135-1137, 1979.
 
185) Mulder JH, Smink T, et al: 5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling. Eur. J. Cancer Clin. Oncol. 17: 831-837, 1981.
PubMed
186) Cano JP, Aubert C, et al: Advantages and limitations of pharmacokinetic studies in the rationalization of anticancer therapy: methotrexate and 5-FU. Cancer Treat. Rep. 65: 33-42, 1981.
PubMed
187) Bastian G, Demarcq C, et al: Pharmacokinetics of 5-fluorouracil: effect of association with cis-platinum duringlong term infusion. Proc. Am. Soc. Clin. Oncol. 5: 55, 1986.
 
188) Balis FM, Holcenberg JS, et al: The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin. Pharmacol. Therapeutic 41: 384-387, 1987.
PubMed
189) Ataya K, Pydyn E, et al: The uptake and metabolism of cyclophosphamide by ovary. Select Cancer Ther. 6: 83. -91, 1990.
 
190) Lichman S, Ratain M, et al: Phase I trial of GM-CSF plus high dose cyclophosphamide in solid tumor. Proc. Am. Soc. Clin. Oncol. 9: 256, 1990.
 
191) Sladek NE, Powers JF, et al: Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Res. 47: 2723-2726, 1984.
 
192) Struct RF, Alberts DF, et al: Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in randomized, crossover trial. Cancer Res. 47: 2723-2726, 1987.
 
193) Hardy RW, Moore MJ, et al: Analysis of phosphoramide mustard by reversed-phase ion pair high pressure liquid chromatography. Ther. Drug Monit. 9: 221-226, 1987.
PubMed
194) Moore MJ: Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20: 194-208, 1991.
PubMed
195) Bagley CMJ, Bostick FW, et al: Clinical pharmacology of cyclophosphamide. Cancer Res. 33: 226-233, 1973.
 
196) Moore MJ, Hardy RW, et al: Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin. Pharmacol. Ther. 44: 622-628, 1988.
PubMed
197) Anthony LB, Long QC, et al: The effect of cimetidine on cyclophosphamide metabolism in rabbits. Cancer Chemother. Pharmacol. 27: 125-130, 1990.
PubMed
198) Dorr RT, Soble MJ, et al: Interaction of cimetidine but not ranitidine with cyclophosphalnide in mice. Cancer Res. 46: 1795-1799, 1986.
 
199) Witten JW, Frederiksen PL, et al: The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol. Acta Pharmacol. Toxicol. 46: 392-394, 1980.
 
200) Cagnoni PJ, Matthes S, et al: Ondansetron significantly reduces the area under the curve (AUC) of cyclophosphamide (CPA) and cisplatin (CDDP) . Proc. Am. Soc. Clin. Oncol. 14: 462, 1995.
 
201) Faber OK, Mouridsen HT, et al: The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol. Toxicol. 35: 195-200, 1974.
PubMed
202) Dodion P, Riggs Jr C, et al: Interactions between cyclophosphamide and adriamycin metabolism in rats. J. Pharmacol. Exp. Ther. 229: 51-57, 1984.
 
203) Bruno NA, Slate DL, et al: Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug-resistant cells. J. Natl. Cancer Inst. 82: 419-424, 1990.
 
204) Henriksson R, Grankvist K, et al: Interactions between anticancer drugs and other clinically used pharmaceuticals: areview. Acta Oncol. 28: 451-462, 1989.
 
205) Wilson WH, Jamis-Dow C, et al: Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J. Clin. Oncol, 13: 1985-1994, 1995.
PubMed
206) Erlichman C, Moore M, et al: Phase I pharmacokinetic study of cyclosporin-A combined with doxorubicin. Cancer Res. 53: 4837-4842, 1993.
PubMed
207) Goel R, Cleary SM, et al: Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J. Natl. Cancer Inst. 81: 1552-1560, 1989.
PubMed
208) Gouyette A, Daniel A, et al: Clinical pharmacology of high-dose etoposide associate with cisplatin. Pharmacokinetic and metabolic studies. Eur. J. Cancer Clin. Onco1. 23: 1627-1632, 1987.
 
209) Leone R, Fracasso ME, et al: Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother. Pharmacol. 29: 385-390, 1992.
PubMed
210) Cosolo W, Schwarz MA, et al: Interaction of cisplatin with other cytotoxic and non-steroidal anti-inflammatory drugs. Anticancer Drugs 2: 169-174, 1991.
PubMed
211) Rowinsky EK, Kaufmann SH, Baker SD, et al: Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol. 14: 3074-3084, 1996.
PubMed
212) Fedeli L, Mariantonietta C, et al: Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64: 1805-1811, 1989.
 
213) Leveque D, Jehl F, et al: Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J. Clin. Pharmacol. 32: 1096-1098, 1992.
PubMed
214) Clark PI, Slevin ML, et al: The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12: 223-252, 1987.
PubMed
215) Rodman JH, Murry DJ, et al: Pharmacokinetics of high-doses of etoposide and the influence of anticonvulsants in pediatric cancer-patients. Clin. Pharmacol. Ther. 51: 156, 1992.
 
216) Baker DK, Relling MV, et al: Increased teniposide clearance with concomitant anticonvulsant therapy. J. Clin. Oncol. 10: 311-315, 1992.
PubMed
217) Lum BL, Kaubisch S, et al: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10: 1635-1642, 1992.
 
218) Keller RP, Altermatt HJ, et al: Pharmacologic interactions between the resistance-modifying cyclosporin SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer 51: 433-438, 1992.
PubMed
219) Van Hoogenhuijze J, Lankelma J, et al: Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide. Eur. J. Cancer Clin. Oncol. 23: 807-811, 1987.
PubMed
220) Peros WP, Rodman JH, et al: Pharmacokinetics of continuous-infusion amsacrie and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. Cancer Chemother. Pharmacol. 27: 397-400, 1991.
 
221) Gianni L, Locatelli A, et al: Order of administration and pharmacokinetics of paclitaxel (P) by 3 h infusion and doxorubicin (D) by iv bolus. Proc. Am. Soc. Clin. Oncol. 14: 169, 1995.
 
222) Holmes FA, Madden T, Newman RA, et al: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 14: 2713-2721, 1996.
 
223) Rowinsky EK, Gibert MR, et al: Sequences of taxol and cisplatin: A phase I and pharmacologic study. J. Clin. Oncol. 9: 1692-1703, 1991.
 
224) Rowinsky EK, Citardi M, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin an antimicrotubule agents taxol and vincristine. J. Cancer Res. Clin. Oncol. 119: 727-722, 1993.
PubMed
225) Jekunen A, Christen R, et al: Synergistic interactions between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br. J. Cancer 69: 299-306, 1994.
 
226) Schellens JHM, Ma J, et al: Pharmacokinetics of cisplatin and taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence taxotere/cisplatin and cisplatin/taxotere in a phase I/IIstudy in solid tumor patients. Proc. Am. Soc. Clin. Oncol. 13: 132, 1994.
 
227) Weiss RB, Donehower RC, et al: Hypersensitivity reactions from taxol. J. Clin. Oncol. 8: 1263-1268, 1990.
PubMed
228) 山本 昇, 西條長宏: 癌化学療法の副作用対策. 臨床腫瘍研究最前線-Direction of Medical Oncology-No. 3, 協和企画通信, 東京, 1996.
 
229) Somogyi A, Muirhead M: Pharmacokinetic interactions of cimetidine. Clin. Pharmacokinet. 12: 1321, 1987.
 
230) Slichenmyer WJ, Donehower RC, et al: Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemother. Pharmacol. 36: 227-232, 1995.
PubMed
231) Cresteil T, Monserrat B, et al: Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 54: 386-392, 1994.
 
232) Harris JW, Rahman A, et al: Metabolism of taxol by human microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54: 4026-4035, 1994.
 
233) Calvert AH, Newell DR, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7: 1748-1756, 1989.
PubMed
234) Letrent SP, Brouwer KLR, et al: Carboplatin (CBDCA) pharmacokinetics and prediction of AUC after highdose CBDCA following high-dose paclitaxel. Proc. Am. Soc. Clin. Oncol. 14: 462, 1995.
 
235) Kearns CM, Belani CP, et al: Pharmacokinetics of paclitaxel and carboplatin in combination. Semin. Oncol. 22 (Suppl. 12) : 1-4, 1995.
 
236) Bruno R, Vivier N, et al: Lack of influence of dexamethasone premedication on docetaxel (Taxotere) pharmacokinetics. 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, Netherlands, 1996.
 
237) Chabner BA: Clinical strategies for cancer treatment: the role of drugs. In: Cancer chemotherapy (eds. by Chabner & Collins) , J. B. Lippincott Company, Philadelphia, 1990, pp. 1-15.
 
238) Kintzel PE, Dorr RT: Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat. Rev. 21: 33-64, 1995.
PubMed
239) Jacobs C, Kalman SM, et al: Renal handling of cis-diamminedichloroplatinum (II) . Cancer Treat Rep. 64: 1223-1226, 1980.
PubMed
240) Goren MP, Wright RK, et al: Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxocity by prior cis-diamminedichloroplatinum (2) therapy. Cancer Res. 47: 1457-1460, 1987.
 
241) Goren MP, Wrigut RK, et al: Enhancement of methotrexate nephrotoxicity after cisplatin therapy, Cancer 58: 2617-2621, 1986.
 
242) Egorin MJ, Van Echo DA, et al: Pharmacokinetics and dosage reduction of cis-diammine (1, 1-cyclobutanedicarboxylato) plutinum in patients with impaired renal function. Cancer Res. 44: 5432-5438, 1984.
PubMed
243) Calvert AH, Newell DR, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7: 1748-1756, 1989.
PubMed
244) Benjamin RS: A practical approach to adriamycin toxicity. Cancer Chemother. Rep. 6: 191-194, 1975.
 
245) Twelves CJ, Dobbs NA, et al: Clinical pharmacokinetics of epirubicin: Dose nomogram based on liver biochemistory test. Proc. Am. Soc. Clin. Oncol. 10: 99, 1991.
 
246) Stewart CF, Arbuck SG, et al: Changes in the clearance of total unbound etoposide in patients with liver dysfunction. J. Clin. Oncol. 8: 1874-1879, 1990.
PubMed
247) D 'Incalci M, Cosmo R, et al: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res. 46: 2566-2571, 1986.
 
248) Joel SP, Shah R, et al: Predicting etoposide toxicity: Relationship to organ function and protein binding. J. Clin. Oncol. 14: 257-267, 1996.
PubMed
249) Moore MJ: Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20: 194-208, 1991.
PubMed
250) Juma FD: Effect of liver function on the pharmacokinetics of cyclophosphamide. Eur. J. Clin. PharmacoL 26: 591-593, 1984.
PubMed
251) Bagley CM, Bostick FW, et al: Clinical pharmacology of cyclophosphamide. Cancer Res. 33: 226-235, 1973.
PubMed
252) Robieux I, Sorio I, et al: Pharmacokinetics of vinorelbine in breast cancer patients with liver metastasis. Proc. Am. Soc. Clin. Oncol. 14: 458, 1995.
 
253) Huizing MT, Vermorken JB, et al: Pharmacology of paclitaxel and three main metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3 hour paclitaxel infusion: A Europian Cancer Center (ECC) Trial. Proc. Am. Soc, Clin. Oncol. 14: 460, 1995.
 
254) Francis P, Bruno R, et al: Pharmacodynamics (PD) of docetaxel (Taxotere) in patients (pts) with liver metastasis (METS) . Proc. Am. Soc. Clin. Oncol. 13: 138, 1994.
 
255) Shinn AF, Rutkowski D, et al: Dosage modifications of cancer chemotherapeutic agents in renal failure. Drug Intell. Clin. Pharm. 11: 140-141, 1977.
 
256) Rochon PA, Gurwitz JH: Drug therapy. Lancet 346: 32-36, 1995.
PubMed
257) Greenblatt DJ, Sellers EM, et al: Drug disposition in old age. N. Engl. J. Med. 306: 1081-1088, 1982.
PubMed
258) Balducci L, Parker M, et al: Pharmacology of antineoplastic agents in the elderly patient. Semin. Oncol. 16: 76-84, 1989.
PubMed
259) Cohen JL: Pharmacokinetic changes in aging. Am. J. Med. 80: 31-38, 1986.
PubMed
260) Powis G: Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat. Rev. 9: 85-124, 1982.
PubMed
261) Moore MJ, Erlickman C: Therapeutic drug monitoring in oncology. Clin. Pharmacokinet. 13: 205-227, 1987.
 
262) Maloney AG, Schmucker DL, et al: The effects of aging on the hepatic microsomal mixed-function oxidase system of male and female monkeys. Hepatology 6: 282-287, 1986.
PubMed
263) Lamy PP: Comparative pharmacokinetic changes and drug therapy in an older population. J. Am. Geriatr. Soc. 30: 811-818, 1982.
 
264) Yamamoto N, Tamura T, et al: The influence of aging on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother. Pharmacol. 36: 102-106, 1995.
PubMed
265) Miya T, Sasaki Y, et al: Pharmacokinetic study of mitomycin C with emphasis on the influence of aging. Jpn. J. Cancer. Res 83: 1382-1385, 1992.
PubMed
266) Joel SP, Shah R, et al: Predicting etoposide toxicity: Relationship to orgar function and protein binding. J. Clin. Oncol. 14: 257-267, 1996.
 
267) Borkowski JM, Duerr M, et al: Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother. Pharmacol. 33: 493-496, 1994.
PubMed
268) 長島聖二, 西條長宏: 癌治療の臨床試験計画. 臨床腫瘍研究最前線-Direction of Medical Oncology-No. 1, 協和企画通信, 東京, 1995.
 
269) van Warmerdam LJC, ten BokkelHuinink WW, et al: Limited-sampling models for anticancer agents. J. CancerRes. Clin. Oncol. 120: 427-433, 1994.
 
270) Sasaki Y, Miya T, et al: Limited sampling strategy (LSS) for mitomycin C (MMC) pharmacokinetics. 肺癌 32: 785, 1992.
 
271) Egorin MJ, Forrest A, et al: A limited sampling strategy for cyclophosphamide pharmacokinesics. Cancer Res. 49: 3129-3133, 1989.
PubMed
272) Ratain MJ, Vogelzang NJ: Limited sampling model for vinblastine pharmacokinetics. Cancer Treat. Rep. 71: 935-939, 1987.
PubMed
273) Ratain MJ, Robert J, et al: Limited sampling model for doxorubicin pharmacokinetics. J. Clin. Oncol. 9: 871-876, 1991.
PubMed
274) Ackland SP, Choi KE, et al: Human plasma pharmacokinetics of thiotepa following administration of high-dosethiotepa and cyclophosphamide. J. Clin. Oncol. 6: 1192-1192, 1988.
PubMed
275) Miller AA, Tolley EA, et al: Pharmacodynamics of three daily infusions od etoposide in patients with extensivestage small-cell lung cancer. Cancer Chemother. Pharmacol. 31: 161-166, 1992.
 
276) Gentili D, Zucchetti M, et al: A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemother. Pharmacol. 32: 482-486, 1993.
PubMed
277) Joel SP, Heap L, et al: A limited sampling strategy for the calculator of etoposide pharmacokinetics. Proc. Am. Soc. Clin. Oncol. 9: 67, 1990.
 
278) Ratain MJ, Staubus AE, et al: Limited sampling models for Amonafide (NSC 308847) pharmacokinetics. Cancer Res. 48: 4127-4130, 1988.
PubMed
279) Sorensen BT, Stomgren A, et al: A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother. Pharmacol. 31: 324-327, 1993.
PubMed
280) Jakobsen P, Steiness E, et al: Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. Cancer Chemother. Pharmacol 28: 63-68, 1991.
PubMed
281) Sasaki Y, Mizuno S, et al: A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn. J. Cancer Res. 86: 117-123, 1995.
PubMed
282) Chabot GG: Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother. Pharmacol. 36: 463-472, 1995.
PubMed
283) Port RE, Edler L, et al: Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve. Ther. Drug Monit. 13: 96-102, 1991.
PubMed
284) Moore MJ, Bunting P, et al: Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther. Drug Monit. 15: 394-399, 1993.
PubMed
285) 大津智子, 佐々木康綱: 抗癌剤のPharmacodynamics. 癌と化学療法 20: 1741-1749, 1993.
Medical*Online
286) Sheiner LB, Grasela TH An introduction to mixed effect modelling: concepts, definitions and justification. J. Pharmacokinet. Biopharm. 19: 11 S-23 S, 1991.
 
287) Powers JD: Statistical considerations in pharmacokinetic study design. Clin. Pharmacokinet. 24 (5) : 380-387, 1993.
PubMed
288) 高田寛治: ポピュレーションファーマコキネティックス. 薬物動態学基礎と応用. 薬業時報社, 東京, 1995, pp. 163- 170.
 
289) Periclou AP, Avramis VI: Population pharmacokinetic (PPK) analysis of cytosine arabinoside (ara-C) following high dose (HDara-C) and continuous infusion (CI) in pediatric patients with leukemias. Proc. Am. Soc. Clin. Oncol. 14: 463, 1995.
 
290) Thomson AH, Whiting B: Bayesian parameter estimation and population pharmacokinetics. Clin. Pharmacokinet. 22: 447-467, 1992.
PubMed
291) Bruno R, Hille D, et al: Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere) in phase II studies. Proc. Am. Soc. Clin. Oncol. 14: 457, 1995.
 
292) Yamamoto N, Tamura T, et al: CPT-11: Population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn. J. Cancer Res. 85: 972-977, 1994.
PubMed
293) Evans WE, Crom WR, et al: Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med. 314: 471-477, 1986.
PubMed
294) Plunkett W, Iacoboni S, et al: Pharmacologically directed ara-C therapy for refractory leukemia. Semin. Oncol. 12 (2Suppl. 3) : 20-30, 1985.
 
295) Santini J, Milano G, et al: 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br. J. Cancer 59: 287-290, 1989.
 
296) Ratain MJ, Mick R, et al: Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J CIin. Oncol. 9: 1480-1486, 1991.
 
297) Slevin ML, Joel SP, et al: Therapeutic monitoring of infusional etoposide in previously untreated small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. 13: 133, 1994.
 
298) Rodman JH, Abromowitch M, et al: Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial. J Clin. Oncol. 5: 1007-1014, 1987.
 
299) Scher HI, Jodrell DI, et al: Use of adaptive control with feedback to individualize suramin dosing. Cancer Res. 52: 64-70, 1992.
PubMed
300) Jodr ell DI, Reyno LM, et al: Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J. Clin. Oncol. 12: 166-175, 1994.
 
301) Eisenberger MA, Reyno LM, et al: Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J. Natl. Cancer Inst. 85: 611-621, 1993.
 
302) Eisenberger MA, Sinibaldi VJ, et al: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J. Clin. Oncol. 13: 2174-2186, 1995.
PubMed
303) Minami H, Shimokata K, et al: Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J. Clin. Oncol. 11: 1602-1608, 1993.
PubMed
304) Kunitoh H, Watanabe K: Phase I/II and pharmacologic study of long-term continuous infusion etoposidecombined with cisplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 12: 83-89, 1994.
PubMed
305) Stein CA, LaRocca RV, et al: Suramin: An anticancer drug with a unique mechanism of action. J. Clin. Oncol. 7: 499-508, 1989.
PubMed
306) Scher HI: Suramin: Here to stay? J. Natl. Cancer Inst. 85: 594-597, 1993.
 
307) Kobayashi K, Vokes EE, et al: Phase I study of sramin given by intermittent infusion without adaptive control in patients with advanced cancer. J. Clin. Oncol. 13: 2196-2207, 1995.
 
308) Evans WE: Alternative approaches for phase I studies of anticancer drugs: Arole for therapeutic drug monitoring. Ther. Drug Monit. 15: 492-497, 1993.
 
309) Chabot GG: Factors involved in clinical pharmacology variability in oncology (review) . Anticancer Res. 14: 2269-2272, 1994.
PubMed
310) Shimada T, Yamazaki H, et al: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
PubMed
311) Flockhart DA: Drug interactions and the cytochrome P 450 system: The role of cytochrome P450 2C19. Clin. Pharmacokinet. 29: 45-52, 1995.
PubMed
312) Yoshida A: Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics 2: 139-147, 1992.
PubMed
313) Hadidi AFA, Coulter CEA, et al: Phemotypically deficient urinary elimination of carboxyphosphamode after cyclophosphamide administration to cancer patients. Cancer Res. 48: 5167-5171, 1988.
 
314) Boddy AV, Furtun Y, et al: Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J. Natl. Cancer Inst. 84: 1744-1748, 1992.
PubMed
315) Tuchman M, Stoeckeler JS, et al: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl. J. Med. 313: 245-249, 1985.
PubMed
316) Diasio RB, Beavers TL, et al: Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81: 47-51, 1988.
PubMed
317) Milano G, Etienne MC: Evolution from pharmacokinetics to pharmacogenetics. The example of 5-fluorouracil. Rev. Med. Interne 15: 287-291, 1994.
PubMed
318) Lennard L, Lilleyman JS, et al: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225-229, 1990.
PubMed
319) Szumlanski CL, Honchel R, et al: Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presense of isozymes. Pharmacogenetics 2: 148-159, 1992.
 
320) Allerheiligen S, Johnston R, et al: Gemcitabine pharmacokinetics are influenced by gender, body surface area and duration of infusion. Proc, Am. Soc. Clin. Oncol. 13: 136, 1994.
 
321) Ratain MJ, Mick R, et al: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin. Pharmacol. Ther. 50: 573-539, 1991.
PubMed
322) Ratain MJ, Mick R, et al: Phase I study of amonafide dosing based acetylator phenotype. Cancer Res. 53: 2304-2308, 1993.
PubMed
323) Bjorn L, Bernard B: Chronopharmacokinetics: Are they clinically relevant? Clin. Pharmacokinet. 26: 419-427, 1994.
 
324) Hrushesky WJM, Bjarnason GA: Circadian cancer therapy. J. Clin. Oncol. 11: 1403-1417, 1993.
 
325) Cardoso SS, Scheving LE, et al: Mortality of mice as influenced by the hour of the day of drug (ara-C) administration. Pharmacologist 12: 302, 1970.
 
326) Haus E, Halberg F, et al: Increased tolerance of mice to arabinosylcytosine given on schedule adjusted to circadian system. Science 177: 80-82, 1972.
PubMed
327) Levi FA, Hrushesky WJM: Cisplatin urinary pharmacokinetics and nephrotoxicity: Acommon circadian mechanism. Cancer Treat. Rep. 66: 1933-1938, 1982.
 
328) Levi FA, Hrushesky WJM: Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing, Cancer Res. 42: 950-955, 1982.
 
329) Sothern RB, Levi F, et al: Control of a murine plasmacytoma with doxorubicin-cisplatin l Dependence on circadian stage of treatment. J. Natl. Cancer Inst. 81: 135-145, 1989.
 
330) Hrushesky WJM: Circadian timing of cancer chemotherapy. Science 228: 73-75, 1985.
 
331) Petit E, Milano G, et al: Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 48: 1676-1679, 1988.
 
332) Harris B, Song R, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian var｛ation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50: 197-201, 1990.
 
333) Metzger G, Comisso C, et al: Difference in time course of plasma levels of 5-fluorouracil (5-FU) during constant or chronomodulated infusion in cancer patients. Proc. Am. Assoc. Cancer. Res. 33: 534, 1992.
 
334) Vassal G, Challine D, et al: Chronopharmacology of high-dose busulfan in children. Cancer Res. 53: 1534-1537, 1993.
PubMed
335) von Roemeling R, Hrushesky WJM: Circadian patterning of continuous floxuridine infusion reduces toxicityand allows higher dose intensity in patients with widespread cancer. J. Clin. Oncol. 7: 1710-1719, 1989.
 
336) Hrushesky WJM, von Roemeling R, et al: Circadian-shaped infusion of floxuridine for progressive metastaticrenal cell carcinoma. J CIin. Oncol. 8: 1504-1513, 1990.
 
337) Huben RP, Dragone N, et al: Continuous infusion FUDR chemotherapy in the treatment of metastatic renal cell carcinoma. J. Urol. A 413, 1990 (abstr) .
 
338) Damascelli B, Marchiano A, et al: Circadian continuous chemotherapy of renal cell carcinoma vvTith an implantable, programmable infusion pump. Cancer 66: 237-241, 1990.
PubMed
339) Dexeus FH, Logothetis CJ, et al: Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J. Urol. 146: 709-713, 1991.
PubMed
340) Hrushesky WJM, Bjarnason G, et al: Fluoropyrimidine circadian continuous infusion shape affects its toxicity profile. Proc. Am. Soc. Clin. Oncol. 12: 248, 1993.
 
341) Wasen C, Hrushesky WJM, et al: Circadian modification of intra-arteria15-fluoro-2 '-deoxyuridine infusion rate reduces its toxicity and perrnits higher dose intensity. J Infus. Chemorher. 2: 69-75, 1992.
 
342) Focan C, Levi F, et al: Chronotherapy of hepatic metastasis from colorectal cancer by local and general infusion. Proc. Am. Soc. Clin. Oncol. 11: 542, 1992.
 
343) Levi F, Soussan A, et al: Programmable-in time pumps for chronotherapy of patients with colorectal cancer with 5-day circadian-modulated venous infusion of 5-fluorouracil. Proc. Am. Soc. Clin. Oncol. 8: 429, 1989.
 
344) Bjarnason GA, Kerr I, et al: Phase I study of 5-fluorouracil (5-FU) and leucovorin (LV) by 14 day continuous infusion chronotherapy in patients with metastatic adenocarcinoma. Eur. J. Cancer 2: A528, 1991.
 
345) Levi F, Misset JL, et al: Achronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69: 893-900, 1992.
PubMed
346) Levi F, Brienza JL, et al: Circumvention of clinical resistance of metastatic colorectal cancer to 5-fluorouracil (5-FU) with circadian rhythm modulated chemotherapy. Proc. Am. Soc. Clin. Oncol. 11: A500, 1992.
 
347) Hrushesky WJM, von Roemeling R, et al: Circadian chronotherapy: From animal experiments to human cancer chemotherapy, In: Chronopharmacology Cellular and Biochemical Interactions (ed. by Lemmer B) , Decker, New York, 1989, pp. 439-473.
 
348) Barrett R, Blessing J, et al: Circadian timed combination doxorubicin cisplatin chemotherapy for advanced endometrial cancer. Gynecol. Oncol. 36: 285, 1990.
 
349) Caussanel Jp, Levi F, et al: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst. 82: 1046-1050, 1990.
 
350) Levi F, Benavides M, et al: Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: Arandomized phase II trial with an evaluation of circadian timing and dose-intensity. J. Clin. Oncol. 8: 705-714, 1990.
 
351) Kerr DJ, Lewis C, et al: The myelotoxicity of carboplatin is influenced by the time of its administration. Hematol. Oncol. 8: 59-63, 1990.
PubMed
352) Focan C : Chronotherapy in lung and ovarian cancer. J. Cancer Res. Clin. Oncol. 116 (suppl 2, part II abstr) : 16. 20, 24, 1990.
 
353) Brummer PD, Levi F, et al: Aphase I trial of 21-day continuous venous infusion ofα. -interferon at circadian rhythm modulated rate in cancer patients. J. ImmunoL 10: 440-447, 1991.
 
354) Rivard GE, Infante-Rivard C, et al: Maintenance chemotherapy for childhood acute lymphoblastic leukemia: Better in the evening. Lancet 2: 1264-1266, 1985.
PubMed
355) Collins JM, Zaharko DS, et al: Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep. 70: 73-80, 1986.
PubMed
356) EORTC Pharmacokinetics and Metabolism Group: Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur. J. Cancer Clin. Oncol. 23: 1083-1087, 1987.
PubMed
357) Fuse E, Fobayashi S, et al: Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J. Natl. Cancer Inst. 86: 989-996, 1994.
 
358) Smith DB, Ewen C, et al: Aphase I and pharmacokinetic study of amphetinile. Br. J. Cancer 57: 623-627, 1988.
 
359) Schwartsmann G, Dodion P, et al: Phase I study of brequinar sodium (NSC 368390) in patients with solid malignancies. Cancer Chemother. Pharmacol. 25: 345-351, 1990.
PubMed
360) Donehower R, Grove W, et al: Successful use of pharmacologically guided dose escalation (PGDE) in a phase Itrial of CI-958. Proc. Am. Soc. Clin. Oncol. 12: 139, 1993.
 
361) Foster BJ, Newell DR, et al: Phase I trial of the anthrapyrazole CI-941. Prospective evaluation of a pharmacokinetically guided dose escalation scheme. Eur. J. Cancer 28: 463-469, 1992.
PubMed
362) Allan SG, Cummungs J, et al: Phase I study of the anthrapyrazole biantazole: Clinical results and pharmacology. Cancer Chemother. Pharmacol. 28: 55-58, 1991.
 
363) Ames MM, Lopronzi CL, et al: Phase I and clinical evaluation of piroxantron hydrochloride (oxantrazole) . Cancer Res. 50: 3905-3909, 1990.
 
364) Hantel A, Donehower RC, et al: Phase I study and pharmacodynamics of piroxantrone (NSC 349174) , anewanthrapyrazole. Cancer Res. 50: 3284-3288, 1990.
PubMed
365) Erlichman C, Moore M, et al: Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole CI-937 (DuP 937) . Cancer Res. 51: 6317-6322, 1991.
PubMed
366) Gianni L, Vigani L, et al: Pharmacology and clinical toxicity of 4 '-iodo-4 '-deoxydoxorubicin: An example of successful application of pharmacokinetics to dose escalation in phase I trials. J. Natl. Cancer Inst. 82: 469-477, 1990.
 
367) Graham MA, Bissett D, et al: Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme. J. Natl. Cancer Inst. 84: 494-500, 1992.
PubMed
368) O'Quigley J, Pepe M, Fisher L: Continual reassessment method: apractical design for phase I clinical trials in cancer. Biometrics 46: 33-48, 1990.
 
369) Zervos PH, Faries D, Dorr FA, et al: Practical use of the modified continual reassessment method for dose escalation in a phase I trial with LY 231514. Proc. Am. Soc. Clin. Oncol. 14: 473, 1995.
 
370) Rinaldi D, Burris H, Dorr FA, et al: Aphase I evaluation of LY 231514 administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Proc. Am. Soc. Clin. Oncol. 14: 474, 1995.
 
371) Sinbald di V, Eisenburger M, Moore-Cooper S, et al: Phase I study of a pharmacologically derived, dairy×5, monthly schedule of suramin in patients with hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 14: 469, 1995.
 
372) 佐々木康綱: 抗がん剤の臨床薬理学. 臨床腫瘍学, 第1版, 癌と化学療法社, 東京, 1996, pp. 335-352.
 
128-a) Gupta EM, Lestingi T, et al: Metabolic fate of irinotecan in humans: Cor relation of glucuronidation with diarrhea. Cancer Res. 54: 3723-3725, 1994.
 
P.594 掲載の参考文献
1) Calabresi P, Parks RE: Alkylating agents, antimetabolites, hormones and other antiproliferative agents. In: The pharmacological bases of therapeutics (eds by Goodman LS, Gilman A) , Macmillan, New York, 1975, p. 1254.
 
2) Devita VT, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin 's disease. Ann. Intern. Med. 73: 881, 1970.
PubMed
3) 薬剤の添付文書による
 
4) Brock N: Oxazaphosphorine cytostatics: past present future. Cancer Res. 49: 1, 1989.
PubMed
5) Calvin M, Padgett CA, Fancily C: A biologically active metabolize of cyclophosphamide. Cancer Res. 33: 915, 1973.
 
6) 薬剤の添付文書による
 
7) 薬剤の添付文書による
 
8) Brook N, Hilgard P, Peukert M: Bases and new developments in the field of oxazaphosphorines. Cancer Invest. 6: 513, 1988.
 
9) 薬剤の添付文書による
 
10) Santos GW, Tutschka PJ, Brookmeyer R, et al: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med. 309: 1347, 1983.
PubMed
11) 薬剤の添付文書による
 
12) 薬剤の添付文書による
 
13) 薬剤の添付文書による
 
P.606 掲載の参考文献
1) Rosenberg B, Van Camp L, Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from aplatinum electrode. Nature 205: 698 699, 1965.
 
2) Sherman SE, Lippard SJ: Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev. 87: 1153 1181, 1987.
 
3) Demarcq C, Bunch RT, Creswell D, et al: The role of cell cycle progression in cisplatin induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ. 5: 983 993, 1994.
 
4) Blommaert FA, van Kijk Knijnenburg HCM, Dijt FJ, et al: Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34: 8474 8480, 1995.
 
5) Reed E, Ozols RF, Tarone R, et al: Platinum DNA adducts in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum based chemotherapy. Proc. Natl. Acad. Sci. USA 84: 5024 5028, 1987.
 
6) Schellens JHM, Ma J, Planting ASTL, et al: Relationship between the exposure to cisplatin, DNA adduct formation in leucocytes, and tumor response in patients with solid tumors. Br. J. Cancer 73: 1569 1575, 1996.
 
7) Johnsson A, Hoglund P, Grubb A, et al: Cisplatin pharmacokinetics and pharmacodynamics inpatients with squamous cell carcinoma of the head/neck or esophagus. Cancer Chemother. Pharmacol. 39: 25 33, 1996.
 
8) De Pooter CM, Van Oosterom AT, Scalliet PG, et al: Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. Biochem. Pharmacol. 51: 629 634, 1996.
 
9) Motzer RJ, Reed E, Perera F, et al: Platinum DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme linked immunosorbent assay. Cancer 73: 2843 2852, 1994.
 
10) Richon VM, Schulte N, Eastman A: Multiple mechanisms of resistance to cis diamrninedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res. 47: 2056 2061, 1987.
 
11) Teicher BA, Holden SA, Kelley MJ, et al: Characterization of a human squamous carcinoma cell line resistant to cis diamminedichloroplatinum (II) . Cancer Res. 47: 388 393, 1987.
 
12) Andrews PA, Mann SC, Velury S, et al: Cisplatin uptake mediated cisplatin resistance in human ovarian carcinoma cells. In: Platinum and other metal coordination compounds in cancer chemotherapy (ed. by Nicolini M) . Martinus Nijhoff, Boston, 1988, pp. 248 254.
 
13) Andrews PA, Velury S, Mann SC, et al: cis Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48: 68 73, 1988.
 
14) Gale GR, Morris CR, Atkins LM, et al: Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res. 33: 813 818, 1973.
 
15) Mann SC, Andrews PA, Howell SB: Short term cis diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 25: 236 240, 1990.
 
16) Gately DP, Howell SB: Cellular accumulation of the anticancer agent cisplatin: areview. Br. J. Cancer 67: 1171 1176, 1993.
 
17) Andrews PA, Albright KD: Role of membrane ion transport in cisplatin accumulation. In: Platinum and other metal coordination compounds in cancer chemotherapy (ed by Howell S) . Plenum Press, New York, 1991, pp. 151 159.
 
18) Andrews PA, Mann SC, Huynh HH, et al: Role of the Na+, K+ adenosine triphosphatase in the accumulation of cis diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res. 51: 3677 3681, 1991.
 
19) Mann SC, Andrews PA, Howell SB: Modulation of cis diamminedichloroplatinum (II) accumulation and sensitivity by forskolin and 3 isobutyl 1 methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J Cancer 48: 866 872, 1991.
 
20) Taniguchi K, Wada M, Kohno K, et al: Ahuman canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56: 4124 4129, 1996.
 
21) Kelley SL, Basu A, Teicher BA, et al: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813 1815, 1988.
 
22) Godwin AK, Meister A, O'Dwyer PJ, et al: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89: 3070 3074, 1992.
 
23) Hosking LK, Whelan RDH, Shellard SA, et al: An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines. Biochem. Pharmacol. 40: 1833 1842, 1990.
 
24) Sasada T, Iwata S, Sato N, et al: Redox control of resistance to cis diamminedichloroplatinum (II) (CDDP) : protective effect of human thioredoxin against CDDP induced cytotoxicity. J. Clin. Invest. 97: 2268 2276, 1996.
 
25) Ishikawa T, Ali Osman F: Glutathione associated cis diamminedichloroplatinum (II) metabolism and ATP dependent efflux from leukemia cells. J. Biol. Chem. 268: 20116 20125, 1993.
 
26) Masuda H, Ozols RF, Lai G M, et al: Increased DNA repair as a mechanism of acquired resistance to cis diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 48: 5713 5716, 1988.
 
27) Huang J C, Zamble DB, Reardon JT, et al: HMG domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA 91: 10394 10398, 1994.
 
28) Segal Bendirdjian E, Jacquemin Sablon A: Cisplatin resistance in a murine leukemia cell line is associated with adefective apoptotic process. Exp. Cell Res. 218: 201 212, 1995.
 
29) Hoffmann J S, Pillaire M J, Maga G, et al: DNA polymeraseβbypasses in vitro a single d (GpG) cisplatin adduct placed on codon 130f the HRAS gene. Proc. Natl. Acad. Sci. USA 92: 5356 5360, 1995.
 
30) Timmer Bosscha H, Mulder NH, de Vries EGE: Modulation of cis diamminedichloroplatinum (II) resistance: a review. Br. J. Cancer 66: 227 238, 1992.
 
31) Cheung Y W, Cradock JC, Rao Vishnuvajjala B, et al: Stability of cisplatin, iproplatin, carboplatin, andtetraplatin i commonly used intravenous solutions. Am. J. Hosp. Pharm. 44: 124 130, 1987.
 
32) Earhart RH: Instability of cis dichlorodiammineplatinum in dextrose solution. Cancer Treat. Rep. 62: 1105 1106, 1978.
 
33) Loehrer PJ, Einhorn LH: Drugs five years later, cisplatin. Ann. Intern. Med. 100: 704 713, 1984.
 
34) Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA, et al: Carboplatin versus cisplatin. Ann. Oncol. 4 (supple. 4) : 41 48, 1993.
 
35) Vermorken JB, van der Vijgh WJF, Klein I, et al: Pharmacokinetics of free and total platinum species after short term infusion of cisplatin. Cancer Treat. Rep. 68: 505 513, 1984.
 
36) Elferink F, van der Vijgh WJF, Klein I, et al: Pharmacokinetics of carboplatin after iv administration. Cancer Treat. Rep. 71: 1231 1237, 1987.
 
37) Sasaki Y, Tamura T, Eguchi K, et al: Pharmacokinetics of (glycolato O, O') diammine platinum (II) , anew platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother. Pharmacol. 23: 243 246, 1989.
 
38) Gormley PE, Bull JM, LeRoy AF, et al: Kinetics of cis dichlorodiammineplatinum. Clin. Pharm. Ther. 25: 351 357, 1979.
 
39) Forastiere AA, Belliveau JF, Goren MP, et al: Pharmacokinetic and toxicity evaluation of five day continuous infusion versus intermittent bolus cis diamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res. 48: 3869 3874, 1988.
 
40) Nagai N, Kinoshita M, Ogata H, et al: Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother. Pharmacol. 39: 131 137, 1996.
 
41) Gormley PE, Gangji D, Wood JH, et al: Pharmacokinetic study of cerebrospinal fluid penetration of cisdiamminedichloroplatinum (II) . Cancer Chemother. Pharmacol. 5: 257 260, 1981.
 
42) Berman IJ, Mann MP: Seizures and transient cortical blindness associated with cisplatinum (II) diamminedichloride (PDD) therapy in a thirty year old man. Cancer 45: 764 766, 1980.
 
43) Belt RJ, Himmelstein KJ, Patton TF, et al: Pharmacokinetics of non protein bound platinum species following administration of cis dichlorodiammineplatinum (II) . Cancer Treat. Rep. 63: 1515 1521, 1979.
 
44) Lokich JJ: Phase I study of cis diamminedichloroplatinum (II) administered as a constant 5 day infusion. Cancer Treat. Rep. 64: 905 908, 1980.
 
45) Reece PA, Stafford I, Russell J, et al: Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis dichlorodiammineplatinum (II) . Cancer Chemother. Pharmacol. 15: 295 299, 1985.
 
46) Reece PA, Stafford I, Russell J, et al: Creatinine clearance as a predictor of ultrafiltrable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafiltrable platinum plasma levels and nephrotoxicity. J. Clin. Oncol. 5: 304 309, 1987.
 
47) Belliveau JF, Posner MR, Ferrari L, et al: Cisplatin administered as a continuous 5 day infusion: plasma platinum levels and urine platinum excretion. Cancer Treat. Rep. 70: 1215 1217, 1986.
 
48) Reece PA, Stafford I, Davy M, et al: Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother. Pharmacol. 24: 256 260, 1989.
 
49) Vermorken JB, van der Vijgh WJF, Klein I, et al: Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin. Pharmacol. Ther. 39: 136 144, 1986.
 
50) Samson MK, Rivkin SE, Jones SE, et al: Dose response and dose survival advantage for high versus low dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 53: 1029 1035, 1984.
 
51) Kaye SB, Lewis CR, Paul J, et al: Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340: 329 333, 1992.
 
52) Kaye SB, Paul J, Cassidy J, et al: Mature results of a randomized trial of two doses of cisplatin for thetreatment of ovarian cancer. J. Clin. Oncol. 14: 2113 2119, 1996.
 
53) Ozols RF, Corden BJ, Jacob J, et al: High dose cisplatin in hypertonic saline. Ann. lntern. Med. 100: 19 24, 1984.
 
54) Aamdal S, Fodstadφ, Kaalhus O, et al: Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle. J. Natl. Cancer Inst. 73: 743 752, 1984.
 
55) Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor risk germ cell tumors: aSoutheastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol. 9: 1163 1172, 1991.
 
56) Rossof AH, Slayton RE, Perlia CP: Preliminary clinical experience with cis diamminedichloroplatinum (II) (NSC 119875, CACP) . Cancer 30: 1451 1456, 1972.
 
57) Hayes DM, Cvitkovic E, Golbey RB, et al: High dose cis platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372 1381, 1977.
 
58) Blachley JD, Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann. Intern. Med. 95: 628 632, 1981.
 
59) Al Sarraf M, Fletcher W, Oishi N, et al: Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: asouthwest oncology group study. Cancer Treat. Rep. 66: 31 35, 1982.
 
60) Belt RJ, Taylor S: Randomized trial of hydration and mannitol in preventing cis platinum induced nephrotoxicity. Proc. Am. Assoc. Cancer Res. and ASCO 201388, 1979.
 
61) Ostrow S, Egorin MJ, Hahn D, et al: High dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat. Rep. 65: 73 78, 1981.
 
62) Einhorn LH, Donohue J: Cis diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87: 293 298, 1977.
 
63) Daugaard G, Rossing N, Rorth M: Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high dose. Cancer Chemother. Pharmacol. 21: 163 167, 1988.
 
64) Schilsky RL, Anderson T: Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann. Intern. Med. 90: 929 931, 1979.
 
65) Salem P, Hall SW, Benjamin RS, et al: Clinical phase I II study of cis dichlorodiammine platinum (II) given by continuous iv infusion. Cancer Treat. Rep. 62: 1553 1555, 1978.
 
66) Marty M, Pouillart P, School S, et al: Comparison of the 5 hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032 F) with high dose metoclopramide in the control of cisplatin induced emesis. N. Engl. J. Med. 322: 816 821, 1990.
 
67) Sledge GW Jr, Einhorn L, Nagy C, et al: Phase III double blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple day cisplatin based chemotherapy. Cancer 70: 2524 2528, 1992.
 
68) Hesketh PJ, Harvey WH, Harker WG, et al: Arandomized, double blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high dose cisplatininduced emesis. J. Clin. Oncol. 12: 596 600, 1994.
 
69) Roila F, Tonato M, Cognetti F, et al: Prevention of cisplatin induced emesis: adouble blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J. Clin. Oncol. 9: 675 678, 1991.
 
70) Noble A, Bremer K, Goedhals L, et al: Adouble blind, randomized, crossover comparison of granisetron and ondansetron in 5 day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur. J. Cancer 30 A: 1083 1088, 1994.
 
71) Navari R, Gandara D, Hesketh P, et al: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin induced emesis. J. Clin. Oncol. 13: 1242 1248, 1995.
 
72) Navari RM, Madajewicz S, Anderson N, et al: Oral ondansetron for the control of cisplatin induced delayedemesis: alarge, multicenter, double blind, randomized comparative trial of ondansetron versus placebo. J. Clin. Oncol. 13: 2408 2416, 1995.
 
73) 01ver I, Paska W, Depierre A, et al: Amulticentre, double blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin induced delayed emesis. Ann. Oncol. 7: 945 952, 1996.
 
74) Kris MG, Gralla RJ, Tyson LB, et al: Controlling delayed vomiting: double blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J. Clin. Oncol. 7: 108 114, 1989.
 
75) Italian Group for Antiemetic Research: Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin induced delayed emesis. J. Clin. Oncol. 15: 124 130, 1997.
 
76) Goel R, Cleary SM, Horton C, et al: Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J. Natl. Cancer Inst. 8111552 1560, 1989.
 
77) Aamdal S, Fodstad O, Pihl A: Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis diamminedichloroplatin (II) in mice bearing murine and human tumors. Cancer Chemother. Pharmacol. 21: 129 133, 1988.
 
78) Howell SB, Pfeifle CE, Wung WE, et al: Intraperitoneal cis diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res. 43: 1426 1431, 1983.
 
79) Casper ES, Kelsen DP, Alcock NW, et al: Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat. Rep. 67: 235 238, 1983.
 
80) Elferink F, van der Vijgh WJF, Klein I, et al: Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol. 21: 57 60, 1988.
 
81) Howell SB, Pfeifle CL, Wung WE, et al: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97: 845 851, 1982,
 
82) Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335: 1950 1955, 1996.
 
83) Dedrick RL, Flessner MF: Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J. Natl. Cancer. Inst. 89: 480 487, 1997.
 
84) Markman M, Reichman B, Hakes T, et al: Responses to second line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J. Clin. Oncol. 9: 1801 1805, 1991.
 
85) Knox RJ, Friedlos F, Lydall DA, et al: Mechanism of cytotoxicity of anticancer platinum drugs l evidence that cis diamminedichloroplatinum (II) and cis diammine (1, 1 cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46: 1972 1979, 1986.
 
86) Repta AJ, Longo DF: Reactions of cisplatin with human plasma and plasma fractions. In: Cisplatin. Current status and new developments (eds. by Prestayko AW, Crooke ST, Carter SK) , Academic Press Inc, New York, 1980, pp. 285 304.
 
87) Harland SJ, Newell DR, Siddik ZH, et al: Pharmacokinetics of cis diammine 1, 1 cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res. 44: 1693 1697, 1984.
 
88) van der Vijgh WJF: Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 21: 242 261, 1991.
 
89) Gaver RC, Colombo N, Green MD, et al: The disposition of carboplatin in ovarian cancer patients. Cancer Chemother. Pharmacol. 22: 263 270, 1988.
 
90) Riccardi R, Riccardi A, Lasorella A, et al: Clinical pharmacokinetics of carboplatin in children. Cancer Chemother. Pharrnacol. 33: 477 483, 1994.
 
91) Murry DJ, Sandlund JT, Stricklin LM, et al: Pharmacokinetics and acute renal effects of continuously infused carboplatin. Clin. Pharmacol. Ther. 54: 374 380, 1993.
 
92) Shea TC, Flaherty M, Elias A, et al: Aphase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J. Clin. Oncol. 7: 651 661, 1989.
 
93) Egorin MJ, Van Echo DA, Olman EA, et al: Prospective validation of a pharmacologically based dosing scheme for the cis diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum (II) . Cancer Res. 45: 6502 6506, 1985.
 
94) Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7: 1748 1756, 1989.
 
95) Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol. 10: 520 528, 1992.
 
96) Newell DR, Pearson ADJ, Balmannno K, et al: Carboplatin pharmacokinetics in children: the development of apediatric dosing formula. J. Clin. Oncol. 11: 2314 2323, 1993.
 
97) Ando Y, Minami H, Saka H, et al: Adjustment of creatinine clearance improves accuracy of Calvert 's formula for carboplatin dosing. Br. J. Cancer 76: 1067 1071, 1997.
 
98) Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst. 87: 573 580, 1995.
 
99) Chatelut E, Boddy AV, Peng B, et al: Population pharmacokinetics of carboplatin in children. Clin. Pharmacol. Ther. 59: 436 443, 1996.
 
100) Minami H, Ando Y, Saka H et al: Re: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst. 89: 968 969, 1997.
 
101) van Warmerdam LJC, Rodenhuis S, van der Wall E, et al: Pharmacokinetics and pharmacodynamics of carboplatin administered in a high dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br. J. Cancer 73: 979 984, 1996.
 
102) Calvert AH, Harland SJ, Newell DR, et al: Early clinical studies with cis diammine 1, 1 cyclobutane dicarbox ylate platinum II. Cancer Chemother. Pharmacol. 9: 140 147, 1982.
 
103) Koeller JM, Trump DL, Tutsch KD, et al: Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30 minute infusion. Cancer 57: 222225, 1986.
 
104) Evans BD, Raju KS, Calvert AH, et al: Phase II study of JM 8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat. Rep. 67: 997 1000, 1983.
 
105) Mangioni C, Bolis G, Pecorelli S, et al: Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J. Natl. Cancer Inst. 81: 1464 1471, 1989.
 
106) Adams M, Kerby IJ, Rocker I, et al: Acomparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol. 28: 57 60, 1989.
 
107) Taylor AE, Wiltshaw E, Gore ME, et al: Long term follow up of the randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J. Clin. Oncol. 12: 2066 2070, 1994.
 
108) Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin cyclophosphamide versus carboplatin cyclophosphamide in advanced ovarian cancer: arandomized phase III study of the National Cancer Institute of Canada Clinical Trial Group. J. Clin. Oncol. 10: 718 726, 1992.
 
109) Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer. J. Clin. Oncol. 10: 706 717, 1992.
 
110) Canetta R, Bragman K, Smaldone L, et al: Carboplatin: current status and future prospects. Cancer Treat. Rev. 15 (supple. B) : 17 32, 1988.
 
111) Gurney H, Crowther D, Anderson H, et al: Five year follow up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Ann. Oncol. 1: 427 433, 1990.
PubMed
112) Horwich A, Sleijfer DT, Fossa SD, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J. Clin. Oncol. 15: 1844 1852, 1997.
 
113) Klastersky J, Sculier Jp, Lacroix H, et al: Arandomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol O7861. J. Clin. Oncol. 8: 1556 1562, 1990.
 
114) Los G, Verdegaal EME, Mutsaers PHA, et al: Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 28: 159 165, 1991.
 
115) Markman M, Reichman B, Hakes T, et al: Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small volume residual ovarian cancer. Gynecol. Oncol. 50: 100 104, 1993.
 
116) 古瀬清行, 福岡正博, 浅本 仁・他: 肺非小細胞癌に対する254-S・VDS療法とCDDP・VDS療法との比較臨床試験 成績. 癌と化学療法 19: 1019-1026, 1992.
Medical*Online
117) 堀内正敏, 三宅浩郷, 太田和雄: 254-S (Cis-diammine glycolato platinum) の聴力障害. 癌と化学療法 19: 1327- 1332, 1992.
 
118) Weiss RB, Christian MC: New cisplatin analogues in development: areview. Drugs 46: 360 377, 1993.
 
119) 平林光司, 岡田悦子, 尾熊隆嘉・他: 白金系抗腫瘍剤 cis-diammine (glycolato) platinum (254-S) の静脈内投与お よび腹腔内投与における体内動態. 癌と化学療法 17: 2221-2227, 1990.
Medical*Online
120) Sasaki Y, Amano T, Morita M, et al: Phase I study and pharmacological analysis of cis diammine (glycolato) platinum (254 S；NSC 375101D) administered by 5 day continuous intravenous infusion. Cancer Res. 51: 1472 1477, 1991.
 
121) Kidani Y, Noji M, Tashiro T: Antitumor activity of platinum (II) complexes of 1, 2 diaminocyclohexane isomers. Jpn. J. Cancer. Res. 71: 637 643, 1980.
 
122) Gamelin E, Le Bouil A, Boisdron Celle M, et al: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5 fluorouracil in colorectal cancer patients. Clin. Cancer Res. 3: 891 899, 1997.
 
123) Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25: 299 303, 1990.
 
124) Boughattas NA, L6vi F, Fournier C, et al: Circadian rhythm in toxicities and tissue uptake of 1, 2 diamminocyclohexane (trans 1) oxalatoplatinum (II) in mice. Cancer Res. 49: 3362 3368, 1989.
 
125) Caussanel J P, L6vi F, Brienza S, et al: Phase I trial of 5 day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J. Natl. Cancer Inst. 82: 1046 1050, 1990.
 
126) L6vi FA, Zidani R, Vannetzel J M, et al: Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: arandomized multi institutional trial. J. Natl. Cancer Inst. 86: 1608 1617, 1994.
 
127) L6vi F, Zidani R, Misset J L, et al: Randomized multicenter trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350: 681 686, 1997.
 
P.620 掲載の参考文献
1) 古江 尚, 太田和雄, 田口鐵男・他: 癌化学療法の基礎と臨床. 癌と化学療法社, 東京, 1986, pp. 155-188.
 
2) Faber S, Diamond LK, Mercer RD, et al: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4 aminopteroylglutamic acid (aminopterin) . N. Engl. J. Med. 238: 787 793, 1948.
 
3) Yang CH, Peterson RH, Sirotnak FM, et al: Folate analog transport by plasma membrane vesicles isolated from L 12101eukemia cells. J. Biol. Chem. 25411402 1407, 1979.
 
4) Mattews DA, Alden RA, Bolin JT, et al: Dihydrofolate reductase X ray structure of the binary complex with methotrexate. Science 197: 452 455, 1977.
 
5) Wiliams JW, Dugglerby RG, Cutler R, et al: The inhibition of dihydrofolate reductase by folate analogues: structural requirements for slow and tight binding inhibitors. Biochem. Pharmacol. 25: 2695 2702, 1978.
 
6) Rutman RJ, Cantarow A, Paschkis KE: Studies on 2 acethylaminofluorene carcinogenesis. III. The utilization of uracil 2 Ci4 by pre neoplastic rat liver. Cancer Res. 14: 119 126, 1954.
 
7) Heidelberger C, Chaudhari NK, Danenberg P, et al: Fluorinated pyrimidines. A new class of tumour inhibitory compounds. Nature 179: 663 666, 1957.
 
8) Sonmmer A, Santi DV: Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5 fluoro 2t deoxyuridylate and methylene tetrachloride. Bhiochem. Biophys. Res. Commun. 57: 689 696, 1974.
 
9) Kanamaru R, Kakuta H, Sato T, et al: The inhibitory effects of 5 fluorouracil on the metabolism of pre ribosomal and ribosomal RNA in 1210 in vitro. Cancer Chemother. Pharmacol. 17: 43 46, 1986.
 
10) Lu Z, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J. Biol. Chem. 267: 17102, 1992.
 
11) Diasio RB, Beavers TL, Carpenter T: Familial deficiency of dihydropyrimidine dehydrogenase: biological basis for familial pyrimidinemia and severe 5 fluorouracil induced toxicity. J. Clin. Invest. 81: 47, 1988.
 
12) Au JL, Sadee W: Activation of futrafur (R, S+tetrahydro 2 furanyl) 5 fluorouracil to 5 fluorouracil and butyrolactone. Cancer Res. 36: 2814 2819, 1980.
 
13) Fujii S, Ikenaka K, Fukushima M, et al: Effect of uracil and its derivatives on antitumor activity of 5 Fu and 1 (2 tetrahydrofuranyl) 5 fluorouracil. Jpn. J. Cancer Res. 69: 763, 1978.
 
14) Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol. 46: 333, 1988.
 
15) 藤田 浩: フッ化ピリミジン化合物抗癌剤の薬理動態. メディカルレビュー社, 東京, 1986, pp. 61-111.
 
16) Bollag W, Hartmann HR: Tumor inhibitory effects of a new fluorouracil derivative: 5 ' deoxy 5 fluorouridine. Eur. J. Cancer 16: 427 432, 1980.
 
17) Walwick ER, Robert WK, Dekker CA: Cyclization during the phosphorylation of uridine and cytidine polyphosphoric acid: anew route to the O 2 2 ' cyclonucleoside. Proc. Chem. Soc.: 84, 1959.
 
18) Townsend AJ, Cheng Y C: Sequence specific effects of ara 5 aza CTP and ara CTP on DNA synthesis by purified human DNA polymerase in vitro: visualization of chain elongation on a defined template. Mol. Pharmacol. 32: 330, 1987.
PubMed
19) Parker WB, Cheng Y C: Inhibition of DNA primase by nucleoside triphosphate and their arabinofuranosyl analogs. Mol. Pharmacol. 31: 146, 1987.
PubMed
20) Housset M, Daniel MT, Degos L et al: Small doses of ara C in the treatment of acute myeloid leukemia: differentiation of myeloid leukemia cells? Br. J. Haematol. 51: 125 129, 1982.
 
21) Yoshida Y, Yamada J, Watanabe T, et al: Participation of peroxisomalβ-Oxidation system in the chainshortening of PCA16, A metabolite of the cytosine arabinoside prodrug, YNKO 1, in rat liver. Biochem. Pharmacol. 39: 1505 1512, 1990.
 
22) Oh ishi J, Kataoka T, Tsukagoshi S, et al: Production of N succinyl 1-β-D arabinofuranosylcytosine, a novel metabolite of N4 behenoyl 1-β-D arabinofuranosylcytosine in mice and its biological significance. Cancer Res. 41: 2501, 1981.
 
23) Elison GB, Burgi E, Hitchings GH: Studies on condensed pyrimidine systems IX. The synthesis of some 6 substituted purines J. Am. Chem. Soc. 74: 411, 1952.
 
24) Burchenal JH, Murphy ML, EIIison RR, et al: Clinical evaluation of a new antimetabolite, 6 mercaptopurine, in the treatment of acute leukemia and allied diseases. Blood 8: 965, 1953.
 
25) Elison GB: Biochemistry and pharmacology of purine analogs. Fed. Proc. 26: 898, 1967.
 
26) Berns A, Rubenfeld S, Rymzo WT: Hazard of combining allopurinol and thiopurine. N. Engl. J. Med. 286: 730, 1972.
PubMed
27) Young CW, Hodas S: Hydroxyurea: inhibitory effect on DNA metabolism. Science 146: 1172 1174, 1964.
 
28) Bertino JR, Sawicki WL, Lindquist CA, et al: Schedule dependent antitumor effects of methotrexate and 5 fluorouracil. Cancer Res. 37: 327, 1977.
PubMed
29) Cadman EC, Heimer R, Davis L: Enhanced 5 fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 205: 1135, 1979.
 
30) Scanlon KJ, Newman EM, Lu Y, et al: Biochemical basis for cisplatin and 5 fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA 83: 8923, 1986.
PubMed
31) 佐治重豊, 相羽恵介, 荒木 浩・他: 低容量CDDPと5-FU療法の現状について. 癌と化学療法 24: 1892-1900, 1997.
 
32) Evans RM, Laskin JD, Hakala MT: Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthetase by 5 fluorouracil. Cancer Res. 41: 3288 3295, 1981.
 
33) Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma. J. Clin. Oncol. 7: 1419, 1989.
PubMed
34) Boarman DH, Allegra CJ: Intracellular metabolism of 5 formyltetrahydrofolate in human breast and colon celllines. Cancer Res. 52: 36 44, 1992.
 
35) Wadler S, Schwartz EL, Goldmanj M, et al: Fluorouracil and recombinant alpha 2 a interferon；an active regimen against advanced colorectal cancer. J. Clin. Oncol. 7: 1769, 1989.
 
36) Grem JL, van Groeningen CJ, Ismail AA, et al: The role of interferon-α as a modulator of fluorouracil and leucovorin. Eur. J. Cancer 31 A: 1316, 1995.
 
37) Elias L, Sandoval JM l Interferon effects upon fluorouracil metabolism by HL60 cells. Biochem. Biophys. Res. Commun. 163: 867, 1989.
 
38) Houghton JA, Morton CL, Adkins DA, et al: Locus of the interaction among 5 fluorouracil, leucovorin and interferon-α2 a in colon carcinoma cells. Cancer Res. 53: 4243, 1993.
 
39) Warren RD, Nichols AP, Bender RA: Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res. 38: 668 671, 1978.
 
40) Pinedo HM, Zaharko DS, Bull JM, et al: The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 36: 4418, 1976.
PubMed
P.632 掲載の参考文献
1) Gellert M: DNA topoisomerases. Ann. Rev. Biochem 50: 879 910, 1981.
 
2) Wang JC: DNA topoisomerases. Ann. Rev. Biochem. 54: 665 697, 1985.
 
3) Wang JC: Recent studies of DNA topoisomerases. Biochim. Biophys. Acta 909: 1 9, 1987.
 
4) Schneider E, Hsiang YH, Liu L: DNA topoisomerases as anticancer drug targets. Adv. Pharmacol. 21: 149 183, 1990.
 
5) Wang JC: DNA topoisomerases: why so many? J. Biol. Chem. 266: 6659 6662, 1991.
 
6) Roca J: The mechanisms of DNA topoisomerases. Trends Biol. Sci. 20: 156 160, 1995.
 
7) Chen AY, Liu LF: DAN topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol. 34: 191 218, 1994.
 
8) 安藤俊夫: DNA トポロジーの生物効果. 細胞工学 6: 830-838, 1987.
 
9) 安藤俊夫: DNA トポイソメラーゼの生物機能. 癌と化学療法 18: 1543-1649, 1991.
Medical*Online
10) Liu LF, Miller KG: Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from Hela cell nuclei. Proc. Natl. Acad. Sci. USA 78: 3487 3491, 1981.
 
11) Wall ME, Wani MC, Cook CE, et al: Plant antitumor agents. 1. The isolation and structure of camptothecin, anovel alkaloidal leukemia and tumor inhibitor from camptothecin acuminata. J. Am. Chem. Soc. 88: 3888 3890, 1966.
 
12) Li LH, Fraser TJ, Olin EJ, et al: Action of camptothecin on mammalian cells in culture. Cancer Res. 32: 2643-2650, 1972.
PubMed
13) Drewinko B, Freireich EJ, Gottlieb JA: Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res. 34: 747 750, 1974.
 
14) Gallo RC, Whang Peng J, Adamson RH: Studies on the antitumor activity mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 46: 789 795, 1971.
 
15) Gottlieb J, Guarino A, Call J, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880) . Cancer Chemother. Rep. 54: 461 470, 1970.
 
16) Moertel CG, Schutt AJ, Reitemeier RJ, et al: Phase II study of camptothecin (NSC100880) in the treatment of advanced gastrointestinal cancer. Cancer Treat. Rep. 56195 101, 1972.
 
17) Gottlieb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC 100880) . Cancer Chemother Rep. 56: 103 105, 1972.
 
18) Creaven PJ, Allen LM, Muggia FM: Plasma camptothecin (NSC 100880) levels during a 5 day course of treatment: relation to dose and toxicity. Cancer Chemother. Rep. 56: 573 578, 1972.
 
19) Muggia, FM, Creaven, PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880) lCorrelation with preclinical studies. Cancer Chemother. Rep. 56: 515 521, 1972.
 
20) Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873 14878, 1985.
 
21) Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7 ethyl 10 [4 (1 piperidino) 1 piperidino] carbonyloxy Camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res. 47: 5944 5947, 1987.
 
22) Furuta T, Yokokura T, Mutai M: Antitumor activity of CPT-11 against rat Walker carcinoma. Gan to Kagaku Ryoho 15: 2757 2760, 1988 (in Japanese) .
 
23) Bissery MC, Mathieu Boue A, Lavelle F: Experimental antitumor activity of CPT-11 in vitro and in vivo. In Proceedings of the Seventh NCI EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1992 p. 82 (Abstr.) .
 
24) Matsuzaki T, Yokokura T, Mutai M, et al : Inhibition of apontaneous and experimental metastasis by a new derivative of camptothecin, and camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol. 21: 308 312, 1988.
 
25) Kudoh S, Takada M, Masuda N, et al: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn. J. Cancer Res. 84: 203 207, 1993.
 
26) Tsuruo T, Matsuzaki T, Matsushita M, et al: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21: 71 74, 1988.
 
27) Kaneda N, Nagata H, Furuta T, et al: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50: 1715 1720, 1990.
 
28) Tsuji T, Kaneda N, Kado K, et al: CPT-11 converting enzyme from rat serum: Purification and some properties. J. Pharmacobiodyn. 14: 341 349, 1991.
 
29) Kawato Y, Aonuma M, Hirota Y, et al: Intracellular roles of SN 38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51: 4187 4191, 1991.
 
30) Furuta T, Yokokura T: Effect of administration schedule on the antitumor activity of CPT-11, a camptothecin derivative. Gan to Kagaku Ryoho 17: 121 130, 1990 (in Japanese) .
 
31) Atsumi R, Suzuki W, Hakusui H: Identification of the metabolites of irinotecan, a new derivative of camptoth ecin, in rat bile and its biliary excretion. Xenobiotica 21: 1159 1169, 1991.
 
32) Taguchi T, Wakui A, Hasegawa K, et al: Phase I clinical study of CPT-11. Gan to Kagaku Ryoho 17: 115 120, 1990 (in Japanese) .
 
33) Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 83: 1164 1168, 1991.
 
34) Abigerges D, Chabot G G, Armand J P, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 13: 210 221, 1995.
 
35) Rothenberg ML, Kuhn JG, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194 2204, 1993.
 
36) Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7 Cthyl 10 [4 (1 piperidino) 1 piperidino]carbonyloxycamptothecin (CPT-11) administered as aninety minute infusion every 3 weeks. Cancer Res. 54: 427 436, 1994.
 
37) Catimel G, Chabot GG, Guastalla JP, et al: Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann. Oncol. 6: 133 140, 1995.
 
38) de Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 54: 4347 4354, 1994.
 
39) Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5 day continuous infusion. J. Natl. Cancer Inst. 84: 972 974, 1992.
 
40) Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 11: 909 913, 1993.
 
41) Bugat R, Suc E, Rougier Ph, et al: CPT-11 (lrinotecan) as second line therapy in advanced colorectal cancer (CRC) : Preliminary results of a multicentric phase II study. Proc. Am. Soc. Clin. Oncol. 13: 200, 1994 (Abstr.) .
 
42) Rougier Ph, Culine S, Bugat R, et al: Multicentric phase II study of first line CPT-11 (Irinotecan) in advanced colorectal cancer (CRC) : Preliminary results. Proc. Am. Soc. Clin. Oncol. 13: 200, 1994 (Abstr.) .
 
43) Bugat R, Rougier P, Douilland JY, et al: Efficacy of Irinotecan HCI (CPT-11) in patients with metastatic colorectal cancer after progression while receiving a 5 FU based chemotherapy. Proc. Am. Soc. Clin. Oncol. 14: 222, 1995 (Abstr.) .
 
44) Conti JA, Kemeny N, Saltz L, et al: Irinotecan (CPT-11) is an active agent in untreated patients (pts) with metastatic colorectal cancer (CRC) . Proc. Am. Soc. Clin. Oncol. 13: 195, 1994 (Abstr.) .
 
45) Pitot HC, Wender D, O'Connell MJ, et al: Aphase II trial of CPT-11 (Irinotecan) in patients with metastatic colorectal carcinoma: ANorth Central Cancer Treatment Group (NCCTG) study. Proc. Am. Soc. Clin. Oncol. 13: 197, 1994 (Abstr.) .
 
46) Rothenberg ML, Eckardt JR, Burris III HA, et al: Irinotecan (CPT-11) as second line therapy for pts with 5 FU refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. 13: 198, 1994 (Abstr.) .
 
47) Takeuchi S, Takamizawa H, Takeda Y, et al: An early phase II study of CPT-11 for gynecologic cancers. Gan to Kagaku Ryoho 18: 579 584, 1991 (in Japanese) .
 
48) Takeuchi S, Dobashi K, Fujimoto S, et al: Alate phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Gan to Kagaku Ryoho 18: 1681 1689, 1991 (in Japanese) .
 
49) Takeuchi S, Noda K, Yakushiji M, CPT-11 Study Group on Gynecologic malignancy: Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma (CC) . Proc. Am. Soc. Clin. Oncol. 11: 224, 1992 (Abstr.) .
 
50) Kambe M, Wakui A, Nakao I, et al: Alate phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 12: 198, 1993 (Abstr.) .
 
51) Sakata Y, Wakui A, Nakao I, et al: Alate phase II study of irinotecan (CPT-11) , in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 12: 211, 1993 (Abstr.) .
 
52) Bonneterrre J, Pion JM, Adenis A, et al: Aphase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients. Proc. Am. Soc. Clin. Onco1. 12: 94, 1993 (Abstr.) .
 
53) Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: Anew derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8: 1907 1912, 1990.
 
54) Tsuda H, Takatsuki K, Ohno R, et al: Treatment of adult T cell leukemia lymphoma with irinotecan hydrochloride (CPT-11) . Br. J. Cancer 701771 774, 1994.
 
55) Nakai H, Fukuoka M, Furuse K, et al: An early phase II study of CPT-11 for primary lung cancer. Gan to Kagaku Ryoho 18: 607 612, 1991 (in Japanese) .
 
56) Fukuoka M, Niitani H, Suzuki A, et al: Aphase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 10: 16 20, 1992.
 
57) Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. 10: 241, 1991 (Abstr.) .
 
58) Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: Anew derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol. 10: 1225 1229, 1992.
 
59) Sasaki Y, Yoshida Y, Sudoh K, et al: Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN 38 in patients treated with CPT-11. Jpn. J. Cancer Res. 86: 111 116, 1995.
 
60) Chabot GG, Abigerges D, Gandia D, et al: Pharmacokinetic pharmacodynamic relationships in patients administered with CPT-11, a new camptothecin analogue. Proc. Am. Assoc. Cancer Res. 33: 266, 1992 (Abstr.) .
 
61) Masuda N, Kudoh S, Fukuoka M: Irinotecan (CPT-11) : Pharmacology and clinical applications. Crit. Rev. Oncol Hematol. 24: 3 26, 1996.
 
62) Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 54: 3723 3725, 1994.
 
63) Gupta E, Mick R, Ramirez J, et al: Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol. 15: 1502 1510, 1997.
 
64) Rivory LP, Haaz M C, Canal P, et al: Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin. Cancer Res. 3: 1261 1266, 1997.
 
65) Johnson RK, McCabe FL, Faucette LF, et al: SK & F 104864, a water soluble analog of camptothecin with broad spectrum activity in preclinical models. Proc. Am. Assoc. Cancer Res. 30: 623, 1989 (Abstr.) .
 
66) Hertzberg RP, Caranfa MJ, Holden KG, et al: Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32: 715 720, 1989.
 
67) Kingsbury WD, Boehm JC, Jakas DR, et al: Synthesis of water soluble (aminoalkyl) camptothecin analogues: I nhibition of topoisomerase I and antitumor activity. J. Med. Chem. 34: 98 107, 1991.
 
68) Burris HA III, Hanauske A R, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units in vitro. J. Natl. Cancer Inst. 84: 1816 1820, 1992.
 
69) Hendricks CB, Rowinsky EK, Grochow LB, et al: Effect of P glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK & F 104864) , anew camptothecin analogue. Cancer Res. 52: 2268 2278, 1992.
 
70) Wall JG, Burris HA, Von Hoff DD, et al: Aphase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK & F 104864) given as an intravenous bolus every twenty one days. Anticancer Drugs 3: 337 345, 1992.
 
71) Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: Anovel topoisomerase I inhibitor. J. Clin. Oncol. 10: 647 656, 1992.
 
72) Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of topotecan by 24 hour continuous infusion weekly. Cancer Res. 54: 1220 1226, 1994.
 
73) ten Bokkel Huinink WW, Rodenhius S, Beijnen J, et al: Phase I study of the topoisomerase I inhibitor topotecan (SK & F 104864 A) . Proc. Am. Soc. Clin. Oncol. 11: 110, 1992 (Abstr.) .
 
74) Eckardt J, Burris H, Kuhn J, et al: Phase I and pharmacokinetic trial of continuous infusion topotecan in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 11: 138, 1992 (Abstr.) .
 
75) Sirott MN, Saltz L, Young C, et al: Phase I and clinical pharmacologic study of intravenous topotecan (T) . Proc. Am. Soc. Clin. Oncol. 10: 104, 1991 (Abstr.) .
 
76) Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony stimulating factor. J. NatL Cancer Inst. 85: 1499 1507, 1993.
 
77) Rowinsky E, Sartorius S, Grochow L, et al: Phase I and pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony stimulating factor (G CSF) : toxicologic differences between concurrent and post treatment G CSF administration. Proc. Am. Soc. Clin. Oncol. 11: 116, 1992 (Abstr.) .
 
78) Schiller JH, Kim K, Huston P: Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group Tria1. J. Clin. Oncol. 14: 2345 2352, 1996.
 
79) Ardizzoni A, Hansen H, Dombernosky P, et al: Topotecan, a new active drug in the second line treatment of small cell lung cancer: Aphase II study in patients with refractory and sensitive disease. J. Clin. Oncol. 15: 2090 2096, 1997.
 
80) Beran M, Kantarjian H, O'Brien S, et al: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88: 2473 2479, 1996.
 
81) Creemers GL, Bolis G, Gore M, et al: Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of a large European phase II study. J. Clin. Oncol. 14: 3056 3061, 1996.
 
82) Kudelka AP, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14: 1552 1557, 1996.
 
83) Carmichael J, Gordon A, Malfetano J, et al: Topotecan, a new active drug, vs paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group Trial. Proc. Am. Soc. Clin. Oncol. 15: 283, 1996 (Abstr.) .
 
84) Gordon A, Bookman M, Malmstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial. Proc. Am. Soc. Clin. Oncol. 15: 282, 1996 (Abstr.) .
 
85) Lynch TJ Jr, Kalish L, Strauss G, et al: Phase II study of topotecan in metastatic non-small-cell lung cancer. J. Clin. Oncol. 12: 347 352, 1994.
 
86) Perez Soler R, Fossella FV, Glisson BS, et al: Phase II study of topotecan in patients with advanced non smallcell lung cancer previously untreated with chemotherapy. J. Clin. Oncol. 14: 503 513, 1996.
 
87) Takano H, Kohno K, Matsuo K, et al: DNA topoisomerase targeting antitumor agents and drug resistance. Anticancer Drugs 3: 323 330, 1992.
 
88) Bojanowski K, Lelievre S, Markovits J, et al: Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA 89: 3025 3029, 1992.
 
89) Wadler S, Fuks JZ, Wiernik PH: Phase I and II agents in cancer therapy: 1. Anthracyclines and related compounds. J. Clin. Pharmacol. 26: 491 509, 1986.
 
90) Potmesil M, Hsiang YH, Liu LF, et al: Resistance of human leukemic and normal lymphocytes to drug induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res. 48: 3537 3543, 1988.
 
91) Robert J: Clinical pharmacokinetics of idarubicin. Clin. Pharmacokinet. 24: 275 288, 1993.
 
92) Cersosimo RJ: Idarubicin: An anthracycline antineoplastic agent. Clin. Pharm. 11: 152 167, 1992.
 
93) Stewart CF, Ratain MJ: Topoisomerase interactive agents. In Cancer: Principles and Practice of Oncology (eds. by Devita VT Jr, Hellman S, Rosenberg SA.) , 5th Edition, JB Lippincott, Philadelphia, 1997, pp. 452 469.
 
94) Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin induced congestive heart failure. Ann. Intern. Med. 91: 710 717, 1979.
 
95) Praga C, Beretta G, Vigo PL, et al: Adriamycin cardiotoxicity: Asurvey of 1273 patients. Cancer Treat. Rep. 63: 827 834, 1979.
 
96) Bristow MR, Billingham ME, Mason JW, et al: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep. 6: 873 879, 1978.
 
97) Torti FM, Bristow MR, Howes AE, et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann. Intern. Med. 99: 745 749, 1983.
 
98) Weiss AJ, Metter GE, Fletcher WS: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep. 60: 813 822, 1976.
 
99) Lum BL, Svec JM, Torti FM: Doxorubicin: Alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell. Clin. Pharm. 19: 259 264, 1985.
 
100) Billingham ME, Bristow MR, Glatstein E, et al: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am. J. Surg. Pathol. 1: 17 23, 1977.
PubMed
101) Bristow MR, Mason JW, Billingham ME, et al: Doxorubicin cardiomyopathy: Evaluation by phonocaridography, endomyocardial biopsy, and cardiac catheterization. Ann. Intern. Med. 88: 168 175, 1978.
 
102) Minow RA, Benjamin RS, Lee ET, et al: Adriamycin cardiomyopathy Risk factors. Cancer 39: 1397 1402, 1977.
 
103) Goorin AM, Borow KM, Goldman A, et al: Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children. Cancer 47: 2810 2816, 1981.
 
104) Pratt CB, Ransom JL, Evans WE: Age related adriamycin cardiotoxicity in children. Cancer Treat. Rep. 62:
PubMed
105) 1381 1385, 1978.
 
106) Juret P, Heron JF, Couette JE, et al: Hydroxy 9 methyl 2 ellipticinium for osseous metastases from breast cancer: A5 year experience. Cancer Treat. Rep. 66: 1909 1916, 1982.
 
107) Rouesse JG, Le Chevalier T, Caile P, et al: Phase II study of elliptinium in advanced breast cancer. Cancer Treat. Rep. 69: 707 708, 1985.
 
108) Harvey VJ, Hardy JR, Smith S, et al : Phase II study of the amsacrine analogue CI 921 (NSC 343499) in nonsmall cell lung cancer. Eur. J. Cancer 26: 1617 1620, 1991. Sklarin NT, Wiernik PH, Grove WR, et al: A phase II trial of CI 921 in advanced malignancies. Invest. New Drugs 10: 309 312, 1992.
 
109) Grove WR, Fortner CL, Wiernik PH: Review of amsacrine, an investigational antineoplastic agent. Clin. Pharm. 1: 320 326, 1982.
 
110) Muggia FM, Burris HA: Clinical development of topoisomerase interactive drugs. Adv. Pharmacol. 29 B: 1 31, 1994.
 
111) Ratain MJ, Mick R, Berezin F, et al: Paradoxical relationship between acetylator and amonafide toxicity. Clin. Pharmacol. Ther. 50: 573 579, 1991.
 
112) Hainsworth JD, Greco FA: Etoposide: twenty years later. Ann. Oncol. 6: 325 341, 1995.
 
113) Sinha BK: Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49: 11 19, 1995.
 
114) Clark PI: Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin. Onco1. 19: 20 27, 1992 (Suppl.) .
 
115) Joel SP, Hall M, Gaver RC, et al: Complete recovery of radioactivity after administration of 14C etoposide in man. Proc. Am. Soc. Clin. Oncol. 14: 168, 1995 (Abstr.) .
 
116) Wolff SN, Grosh WW, Prater K, et al: In vitro pharmacodynamic evaluation of VP 16 213 and implications for chemotherapy. Cancer Chemother. Pharmacol. 19: 246 249, 1987.
 
117) Slevin ML, Clark PI, Joel SP, et al: Arandomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J. Clin. Oncol. 7: 1333 1340, 1989.
 
118) Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: Aphase II trial. J. Clin. Onco1. 8: 1613 1617, 1990.
PubMed
119) Hainsworth JD: Chronic administration of etoposide in the treatment of non Hodgkin 's lymphoma. Leuk. Lymphoma 10 (Suppl.) : 65 72, 1993.
 
120) Medical Research Council Lung Cancer Working Party: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: Astopped multicentre randomised trial. Lancet 348: 563 566, 1996.
 
121) Souhami RL, Spiro SG, Rudd RM, et al: Five day oral etoposide treatment for advanced small cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl. Cancer Inst. 89: 577 580, 1997.
 
122) Miller AA, Herndon JE, Hollis DR, et al: Schedule dependency of 21 day oral versus 3 day intravenous etoposide in combination with intravenous cisplatin in extensive stage small cell lung cancer: Arandomized phase III study of the Cancer and Leukemia Group B. J. Clin. Oncol. 13: 1871 1879, 1995.
 
P.650 掲載の参考文献
1) Raff EC: Genetics of microtubule systems. J. Cell Biol. 99: 1 10, 1984.
 
2) Margolis RL, Wilson L: Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell 13: 1 8, 1973.
 
3) Jackson DV, Bender RA: Cytotoxic thresholds of vincristine in a murine and human leukemia cell line in vitro. Cancer Res. 39: 4346 4349, 1979.
 
4) Chan SY, Worth R, Ochs S: Block of axoplasmic transport in vitro by vinca alkaloids. J. Neurobiol. 11: 251 264, 1980.
 
5) Iqbal Z, Ochs S: Uptake of vinca alkaloids into mammalian nerve and its subcellular components. J. Neurochem. 34: 59 68, 1980.
 
6) Houghton JA, Houghton PJ, Hazelton BJ, et al: In sitza selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res. 45: 2706 2712, 1985.
 
7) Minotti AM, Barlow SB, Cabral F: Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J. Biol. Chem. 266: 3987 3994, 1991.
 
8) Cabral FR, Barlow SB: Resistance to the antimitotic agents as genetic probes of microtubule structure and function. Pharmacol. Ther. 52: 159 171, 1991.
 
9) Johnson IS, Armstrong JG, Gorman M, et al: The vinca alkaloids: anew class of oncolytic agents. Cancer Res. 23: 1390 1427, 1963.
 
10) Nelson RL, Dyke RW, Root MA: Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat. Rev. 7 (suppl.) : 17 24, 1980.
 
11) Owellen RJ, Harte CA, Hains FO: Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res. 37: 2597 2602, 1977.
 
12) Owellen RJ, Root MA, Hains FO: Pharmacokinetics of vindesine and vincristine in humans. Cancer Res. 37: 2603 2607, 1977.
 
13) Rahmani R, Bruno R, 11iadis A, et al: Clinical pharmacokinetics of the antitumor drug navelbine (5 ' noranhydrovinblastine) . Cancer Res. 47: 5796 5799, 1987.
 
14) Sethi VS, Jackson DV Jr, White DR, et al: Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res. 41: 3551 3555, 1981.
 
15) Nelson RL: The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med. Pediatr. Onco1. 101-115 127, 1982.
 
16) Ohnuma T, Norton L, Andrejczuk A, et al: Pharmacokinetics of vindesine given as an intravenous bolus and 24 hour infusion in humans. Cancer Res. 45: 464 469, 1985.
 
17) Jackson DV Jr, Castle MC, Bender RA: Biliary excretion of vincristine. Clin. Pharmacol. Ther. 24: 101-107, 1978.
PubMed
18) Bender RA, Castle MC, Margileth DA, et al: The pharmacokinetics of[3 H] vincristine in man. Clin. Pharmacol. Ther. 22: 430-435, 1977.
 
19) Hande K, Gay J, Gober J, et al: Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusion. Cancer Treat. Rev. 7 (suppl.) : 25-30, 1980.
 
20) Bore P, Rahmani R, van Cantfort J, et al: Pharmacokinetics of a new anticancer drug, navelbine, in patients；Comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother. Pharmacol. 23: 247-251, 1989.
PubMed
21) Zhou Pan XR, Sere6 E, Zhou XJ, et al: Involvement of human liver cytochrome P 4503Ain vinblastine metabolism: drug interactions. Cancer Res. 53: 5121-5126, 1993.
PubMed
22) Van den Berg HW, Desai ZR, Wilson R, et al: The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose limiting elimination. Cancer Chemother. Pharmacol. 8: 215 219, 1982.
 
23) Desai ZR, van den Berg HW, Bridges JM, et al: Can severe vincristine neurotoxicity be prevented? Cancer Chemother. Pharmacol. 8: 211-214, 1982.
PubMed
24) Sulkes A, Collins JM: Reappraisal of some dosage adjustment guidelines. Cancer Treat. Rep. 71: 229-133, 1987.
PubMed
25) Owellen RJ, Hartke CA: The pharmacokinetics of 4 acetyl tritium vinblastine in two patients. Cancer Res. 35: 975 980, 1975.
 
26) Jackson DV Jr, Sethi VS, Long TR, et al: Pharmacokinetics of vindesine bolus and infusion. Cancer Chemother. Pharmacol. 13: 114 119, 1984.
 
27) Urien S, Bree F, Breillout F, et al: Vinorelbine high affinity binding to human platelet and lymphocytes: distribution in human blood. Cancer Chemother. Pharmacol. 32: 231 234, 1993.
 
28) Leveque D, Quoize E, Dumont P, et al: Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother. Pharmaco1. 33: 176 178, 1993.
 
29) Jehl F, Quoix E, Leveque D, et al: Pharmacokinetic and preliminary metabolic fate of navelbine I humans as determined by high performance liquid chromatography. Cancer Res. 51: 2073 2076, 1991.
 
30) Robieux I, Sorio R, Borsatti E, et al: Pharmacokinetics of vinorelbine in patients with liver metastases. Clin. Pharmacol. Ther. 59: 32 40, 1996.
 
31) Sorio R, Robieux I, Galligioni E, et al: Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur. J. Cancer 33: 301 303, 1997.
 
32) Jackson DV, Wells HB, Atkins JN, et al: Amelioration of vincristine neurotoxicity by glutamic acid. Am. J. Med. 84: 1016 1022, 1988.
 
33) Le Chevalier T, Brisgand D, Douillard J Y, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Onco1. 12: 360 367, 1994.
 
34) Dorr RT, Alberts DS: Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J. Natl. Cancer Inst. 74: 113 120, 1985.
 
35) Bellone JD: Treatment of vincristine extravasation. JAMA 245: 343, 1981.
PubMed
36) McLendon BF, Bron AJ: Corneal toxicity from vinblastine solution. Br. J. Ophthalmol. 62: 97 99, 1978.
 
37) McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N. Engl. J. Med. 334: 1 6, 1996.
 
38) Diaz JF, Andreu JM: Assembly of purified GDP tubulin into microtubules induced by RP 56976 and paclitaxel: reversibility, ligand stoichiometry and competition. Biochemistry 32: 2747 2755, 1993.
 
39) Donaldson KL, Gollsby G, Kiener PA, et al: Activation of p 34cdk2 coincident with Taxol induced apoptosis. Cell Growth Differ. 5: 1041 1050, 1994.
 
40) Bissery M G, Guenard D, Gueritte Vogelein F, et al: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503) , aTaxol analogue. Cancer Res. 51: 4845 4852, 1991.
 
41) Tishler RB, Schiff PB, Geard CR, et al: Taxol: anovel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys. 22: 613 617, 1992.
 
42) Chervinsky D, Brecher M, Hoelcle M: Cremophor EL enhances taxol efficacy in a multi drug resistant C 1300 neuroblastoma cell line. Anticancer Res. 13: 93 96, 1993.
 
43) Longnecker SM, Donehower RC, Cates AE, et al: High performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat. Rep. 71: 53 59, 1987.
 
44) Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 47: 2486 2493, 1987.
 
45) Brown T, Havlin K, Weiss G, et al: Aphase I trial of taxol given by a 6 hour intravenous infusion. J. Clin. Oncol. 9: 1261 1267, 1991.
 
46) Wiernik PA, Schwartz EL, Einzig A, et al: Phase I trial of taxol given as a 24 hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol. 5: 1232 1239, 1987.
 
47) Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J. Clin. Oncol. 11: 2127 2135, 1993.
 
48) Schiller JH, Storer B, Tutsch K, et al: Phase I trial of 3 hour infusion of paclitaxel with or without granulocyte colony stimulating factor in patients with advanced cancer. J. Clin. Oncol. 12: 241 248, 1994.
 
49) Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J. Clin. Oncol. 13: 180 190, 1995.
 
50) Sparreboom A, van Tellingen O, Nooijen WJ, et al: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 56: 2112 2115, 1996.
 
51) Jamis Dow CA, Klecker RW, Sarosy G, et al: Steady state plasma concentrations and effects of taxo1 for a 250 mg/m2 dose in combination with granulocyte colony stimulating factor in patients with ovarian cancer. Cancer Chemother. Pharmacol. 33148 52, 1993.
 
52) Harris JW, Rahman A, Kim BR, et al: Metabolism of taxol by human hepatic microzomes and liver slices participation of cytochrome P4503A4 and an unknown p 450 enzyme. Cancer Res. 54: 4026 4035, 1994.
 
53) Cresteil T, Monsarrat B, Alvinerie P, et al: Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 54: 386 392, 1994.
 
54) Rahman A, Korzekwa KR, Grogan J, et al: Selective biotransformation of taxol to 6 a hydroxytaxol by human cytochrome P4502C8. Cancer Res. 54: 5543 5546, 1994.
 
55) Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: aphase I and phar macologic study. J. Clin. Oncol. 9: 1692 1703, 1991.
 
56) Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J. Cancer Res. Clin. Oncol. 119: 727 733, 1993.
 
57) LeBlanc GA, Sundseth SS, Weber GF, et al: Platinum anticancer drugs modulate P 450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res. 52: 540-547, 1992.
PubMed
58) Huizing MT, Giaccone G, van Warmerdam LJC, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and dose sequencing study in patients with non-small-cell lung cancer. J. Clin. Oncol. 15: 317-329, 1997.
 
59) Holmes FA, Madden T, Newman RA, et al: Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 14: 2713-2721, 1996.
 
60) Gianni L, ViganδL, Locatelli A, et al: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol. 15: 1906-1915, 1997.
 
61) Berg SL, Cowan KH, Balis FM, et al: Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72 hour infusion. J. Natl. Cancer Inst. 86: 143-45, 1994.
PubMed
62) Mushlin PS, Cusack BK, Boucek RJ Jr, et al: Time related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br. J. Pharmacol. 110: 975 982, 1993.
 
63) Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3 hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer l high antitumor efficacy and cardiac effects in a dose finding and sequence findi study. J. Clin. Oncol. 13: 2688 2699, 1995.
 
64) Webster LK, Cosson EJ, Stokes KH, et al: Effect of the paclitaxel vehicle, Cremophor EL, on the pharmaco kinetics of doxorubicin and doxorubicinol in mice. Br. J. Cancer 73: 522 524, 1996.
 
65) Rischin D, Webster LK, Millward MJ, et al: Cremophor pharmacokinetics in patients receiving 3 , 6 , and 24 hour infusions of paclitaxel. J. Natl. Cancer Inst. 88: 1297 1301, 1996.
 
66) Fisherman JS, Cowan KH, Noone M, et al: Phase I/II study of 72 hour infusional paclitaxel and doxorubicin with granulocyte colony stimulating factor in patients with metastatic breast cancer. J. Clin. Oncol. 14: 774 782, 1996.
 
67) Kennedy MJ, Zahurak ML, Donehower RC, et al: Phase I and pharmacologic study of sequence of paclitaxel and cyclophosphamide supported by granulocyte colony stimulating factor in women with previously treated metastatic breast cancer. J. Clin. Oncol. 14: 783 791, 1996.
 
68) Slichenmyer W, Donehower R, Chen TL, et al: Pretreatment H2 receptor antagonists that differ in P 450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemother. Pharmacol. 36: 227 232, 1995.
 
69) Markman M, Rowinsky E, Hakes T, et al: Phase I trial of intraperitoneal taxol: aGynecologic Oncology Group study. J. Clin. Oncol. 10: 1485 1491, 1992.
 
70) Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of taxotere (RP 56976；NSC 628503) given as a short intravenous infusion. Cancer Res. 53: 1037 1042, 1993.
 
71) Burris H, Irvin R, Kuhn J, et al: Phase I clinical trial of taxotere administered as either a 2 hour or 6 hour intravenous infusion. J. Clin. Oncol. 11: 950 958, 1993.
PubMed
72) Bissett D, Setanoians A, Cassidy J, et al: Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24 hour infusion. Cancer Res. 53: 523 527, 1993.
 
73) De Valeriola D, Brassine C, Piccart M, et al: Study of excretion balance, metabolism and protein binding of C 14 radiolabelled taxotere (RP 56976, NSC 6285039) in cancer patients. Proc. Am. Assoc. Cancer Res. 34: 373, 1993.
 
74) Marre F, Sanderink GJ, de Sousa G, et al: Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP 3A subfamily in humans. Cancer Res. 56: 1296 1302, 1996.
 
75) Bruno R, Vivier N, Claude J, et al: Apopulation pharmacokinetic model for docetaxel (Taxotere(R)) : model building and validation. J. Pharmacokinet. Biopharm. 24: 153 172, 1996.
 
76) Francis P, Bruno R, Seidman A, et al: Pharmacodynamics of docetaxel (taxotere) in patients with liver metastases. Proc. Am. Soc. Clin. Oncol. 13: 138, 1994.
 
77) Pronk LC, Schellens JHM, Planting AST, et al: Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J. Clin. OncoL 15: 1071 1079, 1997.
 
78) Donehower RC, Rowinsky EK, Grochow LB, et al: Phase I trial of taxol in patients with advanced cancer. Cancer Treat. Rep. 71: 1171 1177, 1987.
 
79) Klaassen U, Wilke H, Strumberg D, et al: Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur. J. Cancer 32 A: 547 549, 1996.
 
80) Akerley W, Glantz M, Choy H, et al: Phase I trial of weekly paclitaxel in advanced Lund Cancer. J. Clin. Oncol. 16: 153 158, 1998.
 
81) Sarosy G, Kohn E, Stone DA, et al: Phase I study of taxol and granulocyte colony stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol. 10: 1165 1170, 1992.
 
82) Grem JL, Tutsch KD, Simon KJ, et al: Phase I study of taxol administered as a short iv infusion daily for 5 days. Cancer Treat. Rep. 71: 1179. 1184, 1987.
 
83) Legha SS, Tenney DM, Krakoff IR: Phase I study of taxol using a 5 day intermittent schedule. J. Clin. Oncol. 4: 762 766, 1986.
 
84) Ohtsu T, Sasaki Y, Tamura T, et al: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3 hour infusion versus a 24 hour infusion. Clin. Cancer Res. 1: 599 606, 1995.
 
85) Eisenhauer E, ten Bokkel Huinink WW, Swenerton KD, et al: European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J. Clin. Oncol. 12: 2654 2666, 1994.
 
86) Arbuck SG, Christian MC, Fisherman JS, et al: Clinical development of Taxol. Monogr. Natl. Cancer Inst. 15: 11 24, 1993.
 
87) Lubejko BG, Sartorius SE: Nursing considerations in paclitaxel (Taxol) administration. Semin. Oncol. 20 (suppl. 3) : 26 30, 1993.
 
88) McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: Aunique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111: 273 279, 1989.
 
89) Arbuck SG, Strauss H, Rowinsky E, et al: Areassessment of cardiac toxicity associated with taxol. Monogr. Natl. Cancer Inst. 15: 117 130, 1993.
 
90) Bicher A, Levenback C, Burke TW, et al: Infusion site soft tissue injury after paclitaxel administration. Cancer 76: 116 120, 1995.
 
91) Ajani JA, Dodd LG, Daugherty K, et al: Taxol induced soft tissue injury secondary to extravasation: characterization by histopathology and clinical course. JNCI 86: 51 53, 1994.
 
92) Shapiro J, Richardson CE: Paclitaxel induced racall soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J. Clin. Oncol. 12: 2237 2238, 1994.
 
93) Bertelli G, Cafferata MA, Ardizzoni A, et al: Skin ulceration potential of paclitaxel in a mouse skin model in vitro. Cancer 79: 2266 2268, 1997.
 
94) Aapro MS, Zulian G, Alberto P, et al: Phase I and pharmacokinetic study of RP 56976 in a new ethanol free formulation of Taxotere. Ann. Onco1. 3 (suppl. 5) : 53, 1992.
 
95) Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of docetaxel administered as a 1 hour intravenous infusion on a weekly basis. J. Clin. Oncol. 12: 1458 1467, 1994.
 
96) Hainsworth JD, Burris HA, III, Erland JB, et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. 16: 2164 2168, 1998.
 
97) Pazdur R, Newrnan RA, Newman BM, et al: Phase I trial of taxotere: five day schedule. J. Natl. Cancer Inst. 84: 1781 1788, 1992.
 
98) Piccart MJ, Klijn J, Paridaens R, et al: Corticosteroids significantly delay the onset of docetaxel induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J. Clin. Oncol. 15: 3149 3155, 1997.
 
99) Onetto N, Canetta R, Winograd B, et al: Overview of taxol safety. Monogr. Natl. Cancer Inst. 15: 131 139, 1993.
 
P.658 掲載の参考文献
1) Huang M, Ye Y, Chen S, et al: Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567 572, 1988.
 
2) Degos L, Dombret H, Chomienne C, et al: All trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85: 2643 2653, 1995.
 
3) Asou N, Adachi K, Tamura J, et al: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with al1 trans retinoic acid. J. Clin. Oncol. 1997, (in press) .
 
4) Takeshita A, Sakamaki H, Miyawaki S, et al: Significant reduction of medical costs by differentiation therapy with all trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytc lekemia. Cancer 76: 602 608, 1995.
 
5) Castaigne S, Lefebvre P, Chomienne C, et al: Effectiveness and pharmacokinetics of low dose all trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood 82: 3560 3563, 1993.
 
6) Conley BA, Egorin MJ, Sridhara R, et al: Phase I clinical trial of all trans retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol. 39: 291 299, 1997.
 
7) Muindi JR, Frankel SR, Huselton C, et al: Clinical pharmacology of oral all trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 52: 2138 2142, 1992.
 
8) Usuki K, Endo M, Osawa M, et al: Pharmacokinetics of all trans retinoic acid in Japanese patients with acute promyelocytic leukemia. Int. J. Hematol. 63: 19 23, 1996.
 
9) Adamson PC: Pharmacokinetics of all trans retinoic acid: Clinical implication in acute promyelocytic leukemia. Semin. HematoL 31: 14 17, 1994.
 
10) Lazzarion M, Regazzi MB, Corso A: Clinical relevance of all trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic Ieukemia. Leukemia Lymph. 23: 539 543, 1996.
 
11) Regazzi MB, Lacona I, Gervasutti C, et al: Clinical pharmacokinetics of tretinoin. Clin. Pharmacokinet. 32: 382 402, 1997.
 
12) Rigas JR, Francis PA, Muindi JR, et al: Constitutive variability in the pharmacokinetics of the natural retinoid, all trans retinoic acid and its modulation by ketoconazole. J. Natl. Cancer Inst. 85: 1921 1926, 1993.
 
13) Schwartz EL, Hallam S, Gallagher RE, et al: Inhibition of all trans retinoic acid metabolism by fluconazole invitro and in patients with acute promyelocytic leukemia. Biochem. Pharmacol. 50: 923 928, 1995.
 
14) Tobita T, Takeshita A, Kitamura K, et al: Treatment with a new synthetic retinoid, Am 80, of acute promyelocytic leukemia relapsed from complete remission induced by all trans retinoic acid. Blood 90: 967 973, 1997.
 
15) Adamson PC, Bailey J, Pluda J, et al: Pharmacokinetics of all trans retinoic acid administered on an intermittent schedule. J. Clin. Oncol. 13: 1238 1241, 1997.
 
16) Miller WH Jr, Jakubowski A, Tong WP, et al: 9 cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 85: 3021 3027, 1995.
PubMed
17) Kagechica H, Kawachi E, Hashimoto Y, et al: Retino benzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J. Med. Chem. 31: 2182-2192, 1988.
 
18) Hashimoto Y, Kagechica H, Kawachi E, et al: Correlation of differentiation inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. J. Cancer Res. Clin. Oncol. 121: 696-698, 1995.
 
P.667 掲載の参考文献
1) Kidd JG: Regression of transplanted lymphomas induced in vivo by measns of normal guniea pig serum: 1. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J. Exp. Med. 98: 565 582, 1953.
 
2) Broome JD: Evidence that L asparaginase of guinia pig serum is responsible for its antilymphoma effects: 1. Properties of the L asparaginase of gunia pig serum in relation to those of the antilymphoma substance. J. Exp. Med. 118: 99 120, 1963.
 
3) Eden OB, Shaw MP, Lilleyman JS, et al: Non randomised study comparing toxicity of Escherichia coli and Emoinia asparaginase in children with leukemia. Med. Pediatr. Oncol. 18: 497 502, 1990.
 
4) Cao SG, Zhao QY, Ding ZT, et al: Chemical modification of enzyme molecules to improve their characteristics. Ann. NY Acad. Sci. 613: 460 467, 1990.
 
5) Ohnama T, Holland JF, Meyer P: Erwinia carotovora asparaginase inpatients with prior anaphylaxis toasparaginase from E. Co li. Cancer 30: 376 381, 1972.
 
6) Tagami S, Matsuda K: An enzymatic method for the kinetic measurement of L asparaginase activity and Lasparagine with an ammonia gas sensing electrode. Chem. Pharm. Bul. (Tokyo) 38: 153 155, 1990.
 
7) Cheson BD: Miscellaneous chemotherapeutic agents. In: Cancer: Principles and Practice of Oncology (eds. by De Vita VT Jr, Hellman S, Rosenberg SA) . 5th Edition, JB Lippincott, Philadelphia, 1997, pp. 490 498.
 
8) Worton KS, Kerbel RS, Andrulis IL: Hypomethylation and reactivation of the asparagine synthetase gene induced by L asparaginase and ethyl methanesulfonate. Cancer Res. 51: 985 989, 1991.
 
9) Asselin BL, Whitin JC, CoPPola DJ, et al: Comparative pharmacokinetic studies of three asparaginase preparations. J. Clin. Oncol. 11: 1780 1786, 1993.
 
10) Ohnuma T, Holland JF, Sinks LF: Biochemical and pharmacological studies with L-asparaginase in man. Cancer Res. 30: 2297 2305, 1970.
 
11) 藤本孟男: 小児白血病・リンパ腫, 臨床腫瘍学 (日本臨床腫瘍研究会編) , 癌と化学療法, 東京, 1996, pp. 993-1012.
 
12) Oettgen HF, Stephenson PA, Schwartz MK, et al: Toxicity of E. coli L asparaginase in man. Cancer 25: 253 278, 1970.
 
13) Castaman G, Rodeghiero F, Dini E: Thrombotic complications during L asparaginase treatment for acute lymphocytic leukemia. Haematologica 75: 567 569, 1990.
 
14) Semeraro N, Montemurro P, Giordano P, et al: Unbalanced coagulation fibrinolysis potnatial during L asparaginase therapy in children with acute lymphoblastic leukaemia. Thromb. Haemost. 64: 38 40, 1990.
 
15) Feinberg WM, Swenson MR: Cerebrovascular complication of L asparaginase therapy. Neurology 38: 127 133, 1988.
 
16) Petering DH, Byrnes RW, Antholine WE, et al: The role of redox active metals in the mechanism of action of bleomycin. Chem. Biol. Interact. 73: 133 182, 1990.
 
17) Ciriolo MR, Magliozzo RS, Peisach J: Microsome stimulated activation of ferrous bleomycin in the presence of DNA. J. Biol. Chem. 262: 6290 6295, 1987.
 
18) Kozarich JW, Worth L Jr, Frank BL, et al: Sequence specific isotope effects on the cleavage of DNA by bleomycin. Science 245: 1396 1399, 1989.
 
19) Barlogie B, Drewinko B, Schumann J, et al: Pulse cytophotometric analysis of cell cycle perturbation with bleomycin in vitro. Cancer Res. 36: 1182 1187, 1976.
 
20) Chabner BA, Myers CE: Antitumor antibiotics. In: Cancer: Principles and Practice of Oncology (eds. by De Vita VT Jr, Hellman S, Rosenberg SA) . 4th Edition, JB Lippincott, Philadelphia, 1993, pp. 374 384.
 
21) Alberts DS, Chen HSG, Mayersohn M, et al: Bleomycin pharmacokinetics in man: II. Intracavitary administration. Cancer Chemother. Pharmacol. 2: 127 132, 1979.
 
22) Alberts DS, Chen HSG, Liu M, et al: Bleomycin pharmacokinetics in man: I. Intravenous administration. Cancer Chemother. Pharmacol. 1: 177 181, 1978.
 
23) Einhorn LH, Donohue JP: Improved chemotherapy ill disseminated testicular cancer. J. Uro1. 117: 65 69, 1979.
 
24) Willialns SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316: 1435 1440, 1987.
 
25) Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin 's disease with MOPP, ABVD, or MOPP altcrnating with ABVD. N. Engl. J. Med. 327: 1478 1484, 1992.
PubMed
26) Blum RH, Carter SK, Agre K: Aclinical review of bleomycin a new antineoplastic agent. Cancer 31: 903 914, 1973.
 
27) Goldiner PL, Carlon GC, Critkovic E, et al: Factors influencing post operative morbidity and mortality in patients treated with bleomycin. Br. Med. J.: 1664 1667, 1978.
 
28) Crooke ST, Bradner WT: Mitomycin C: areview. Cancer Treat. Rev. 3: 121 139, 1976.
 
29) Tomasz M, Chowdary D, Lipman R: Reaction of DNA with chemically or enzymatically activated mitomycinC: isolation and tructure of the major covalent adduct. Proc. Natl. Acad. Sci. USA 83: 6702 6706, 1986.
 
30) Teicher BA: Antitumor alkylating agents. In: Cancer: Principles and Practice of Oncology (eds. by De Vita VT Jr, Hellman S, Rosenberg SA) . 5th Edition, JB Lippincott, Philadelphia, 1997, pp. 405 418.
 
31) Keyes SR, Fracasso PM, Heimbrook DC, et al: Role of NADPH: cytochrome C reductase and DT disphorase in the biotransformation of mitomycin C. Cancer Res. 44: 5638 5643, 1984.
 
32) Iyengar BS, Remers WA: Acomparison of mechanism proposed for the conversion of mitomycins into mitosenes. J. Med. Chem. 28: 963 967, 1985.
 
33) Van Hazel GA, Scott M, Rubin J: Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat. Rep. 67: 805 810, 1983.
PubMed
34) Van Helsdingen PJRO, Rikken CHM, Sleeboom HP: Mitomycin C resorption following repeated intravesical installations using different installation times. Urol. Int. 43: 42 46, 1988.
 
35) Shinkai T, Eguchi K, Sasaki Y, et al: Arandomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small-cell lung cancer. Eur. J. Cancer 27: 571 575, 1991.
 
36) Maehara Y, Watanabe A, Kakeji Y, et al: Postgastrectomy prescription of mitomycin C and UFT for patients with stage IV gastric carcinoma. Am. J. Surg. 160: 242 244, 1990.
 
37) Verweij J, Boven E, Van Der Meulen J, et al: Recovery from mitomycin Cinduced haemolytic uraemic syndrome. Cancer 54: 2878 2881, 1984.
 
38) Valavaara R, Nordman E: Renal complication of mitomycin C therapy with special reference to the total dose. Cancer 55: 47 50, 1985.
 
39) Oswoll ES, Kiessling PJ, Patterson JR: Interstitial pneumonia from mitomycin. Ann. Intern. Med. 89: 352 355, 1978.
 
40) Luedke D, McLaughlin TT, Daughaday C, et al: Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression. Cancer 55: 542 545, 1985.
 
41) Erei E 3d: The clinical use of actinomycin. Cancer Chemother. Rep. 58: 49 54, 1974.
 
42) Reich E, Franklin RM, Shatkin AJ, et al: Action of actinomycin D on animal cells and viruses. Proc. Natl. Acad. Sci. USA 48: 1238 1245, 1962.
 
43) Ross WE, Glaubiger DL, Kohn KW: Quantitative and qualitative aspects of intercalator induced DNA damage. Biochim. Biophys. Acta. 562: 41 50, 1979.
 
44) Tattersall NHM, Sodergren JE, Segupta SK, et al: Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin. Pharmacol. Ther. 17: 701 708, 1975.
 
45) Stewart CF, Ratain MJ: Topoisomerase interactive agents. In: Cancer: Principles and Practice of Oncology (eds. by De Vita VT Jr, Hellman S, Rosenberg SA) . 5th Edition, JB Lippincott, Philadelphia, 1997, pp. 452 467.
 
46) Petrilli ES, Twiggs LB, Blessing JA, et al: Single dose actinomycin D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer 60: 2173 2176, 1987.
 
47) Chabner BA: Miscellaneous agents. In: Cancer: Principles and Practice of Oncology (eds. by De Vita VT Jr, Hellman S, Rosenberg SA) . 4th Edition, JB Lippincott, Philadelphia, 1993, pp. 385 389.
 
48) Costanzi JJ, Vaitkevicius VK, Quagliana JM, et al: Combination chemotherapy for disseminated malignant melanoma. Cancer 35: 342 346, 1975.
 
49) Wibur JR, Sutow WW, Sullivan MP, et al: Chemotherapy of sarcomas. Cancer 36: 765 769, 1975.
 
50) Elias A, Ryan L, Sulkes A, et al: Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J. Clin. Oncol. 7: 1208 1216, 1989.
PubMed
51) Yap BS, Baker LH, Sinkovic JG, et al: Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat. Rep. 64: 93 98, 1980.
 
52) Comis RL: DTIC (NSC 45388) in malignant melanoma: aperspective. Cancer Treat. Rep. 60: 165 176, 1976.
 
53) Feaux de Lacroix W, Runne U, Hauk H, et al: Acute liver dystrophy with thrombosis of hepatic veins: afatal complication of dacarbazine treatment. Cancer Treat. Rep. 67: 779 784, 1983.
 
54) Ceci G, Bella M, Melissari M, et al: Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 61: 1988 1991, 1988.
 
55) Smith PJ, Ekert H, Waters KD, et al: High incidence of cardiomyopathy in children treated with Adriamycin and DTIC i combination chemotherapy. Cancer Treat. Rep. 61: 1736 1738, 1977.
 
56) Weinkam RJ, Shiba DA: Metabolic activation of procarbazine. Life Sci. 22: 937 945, 1978.
 
57) Moloney SJ, Wiebkin P, Cummings SW, et al: Metabolic activation of the terminal N methyl group of Nisopropyl alpha ( methylhydrazino) p toluamide hydrochloride (procarbazine) . Carcinogenesis 6: 397 401, 1985.
 
58) Therman E: Chromosome breakage by 1 methyl 2 benzylhydrazine in mouse cancer cells. Cancer Res. 32: 1133 1136, 1972.
 
59) DeConti RC: Procarbazine in the management of late Hodgkin 's disease. JAMA 215: 927 930, 1971.
 
60) Chabner BA, Sponzo R, Hubbard S, et al: High dose intermittent intravenous infusion of procarbazine. Cancer Chemother. Rep. 57: 361 363, 1973.
 
61) Ortin TT, Shostak CA, Donaldson SS: Gonadal status and reproductive function following treatment for Hodgkin 's disease in childhood: the Stanford experience. Int. J. Radiat. Oncol. Biol. Phys. 19: 873 880, 1990.
 
62) Weiss RB: Introduction: new sources and new antitumor drugs in development. Semin. Oncol. 24: 153 155, 1997.
 
63) Christian MC, Pluda JM, Ho PTC, et al: Promising new agents under development by the division of cancer treatment, diagnosis, and centers of the National Cancer Institute. Semin. Oncol. 24: 219 240, 1997.
 
64) Pettit GR, Herald CL, Doubek DL, et al: Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 104: 6846 6848, 1982.
 
65) Hocevar BA, Fields AP: Selective translocation of beta II protein kinase C to the nucleus of human promyelocytic (HL 60) leukemia cells. J. Biol. Chem. 266: 28 33, 1991.
 
66) Levine BL, May WS, Tyler PG, et al: Response of Jurkat T cells to phorbol ester and bryostatin. Development of sublines with distinct functional responses and changes in protein kinase C activity. J. Immunol. 147: 3474 3481, 1991.
 
67) Prendiville J, Crowther D, Thatcher N, et al: Aphase I study of intravenous bryostatin l in patients with advanced cancer. Br. J. Cancer 68: 418 424, 1993.
 
68) Philip PA, Rea D, Thavasu P, et al: Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl, Cancer Inst. 85: 1812 1818, 1993.
 
69) Jayson GC, Crowther D, Prendiville J, et al: Aphase I trial of bryostatin l in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer 72: 461 468, 1995.
 
70) Takahashi I, Asano K, Kawamoto I, et al: UCN 01 and UCN 02, new selective inhibitors of protein kinase C. 1. Screening, producing organism and fermentation. J. Antibiot. (Tokyo) 42: 564 570, 1989.
 
71) Takahashi I, Saitoh Y, Yoshida M, et al: UCN 01 and UCN 02, new selective inhibitors of protein kinase C. II. Purification, physico chemical properties, structural determination and biological activities. J. Antibiot. (Tokyo) 42: 571 576, 1989.
 
72) Wang Q, Fan S, Eastman A, et al: UCN 011Apotent abrogater of G2 checkpoint function in cancer cells with distupted p 53. J. Natl. Cancer Inst. 88: 956 965, 1996.
 
73) Akinaga S, Gomi K, Morimoto M, et al: Antitumor activity of UCN 01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 51: 4888 4892, 1991.
 
74) Kaur G, Stetler Stevenson M, Seber S, et al: Growth inhibition with reversible cell cycle arrest of carcinomacell by flavone L86 8275. J. Natl. Cancer Inst. 84: 1736 1740, 1992.
 
75) Arguello F, Alexander M, Sterry JA, et al: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vito against human leukemia and lymphoma xenografts. Blood 91: 2482 2490, 1988.
 
76) Bible KC and Kaufmann SH.: Flavopiridol: acytotoxid flavone that induces cell death in noncycling A549human lung carcinoma cells. Cancer Res. 56: 4856 4861, 1996.
 
77) Carlson BA, Dubay MM, Sausville EA, et al.: Flavopiridol induces Gl arrest with inhibition of cyclin dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973 2978, 1996.
 
78) Worland PJ, Kaur G, Stetler Stevenson M, et al: Alteration of the phosphorylation state pf p34cdc2 kinase by the flavone L86 8275 in breast carcinoma cells. Biochem. Pharmacol. 46: 1831 1840, 1993.
 
79) Losiewics MD, carlson BA, Kaur G, et al: Potent inhibition of CDC2 kinase activity by the flavonoid L86 8275. Biochem. Biophys. Res. Comm. 201: 589 595, 1994.
 
80) Thomas J, Tutsch K, Arzoomanian R, et al: Phase I clinical and pharmacokinetic trial of the cyclin dependent kinase (CDK) inhibitor flavopiridol. Proc. Am. Soci. Clin. Oncol. 17: 209a, 1998.
 
81) Werner JL, Kelsen DP, Karpeh M, et al: The cyclin dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer. Proc. Am. Soci. Clin. Oncol. 17: 234a, 1998.
 
82) Schwartz GK, Werner JL, Maslak P, et al: Flavopiridol enhances the biological effects of paclitaxel: aphase Itrial in patients with advanced solid tumors. Proc. Am. Soci. Clin. Oncol. 17: 188a, 1998.
 
83) Ueda H, Nakajima H, Hori Y, et al: FR901228, a novel antitumor bicyclic depsipeptide produced byChromobacterium violaceum No. 968: Taxonomy, fermentation, isolation, physico chemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) 47: 301 310, 1994.
 
84) Ueda H, Nakajima H, Hori Y, et al: Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, 0n Ha ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 58: 1579 1583, 1994.
 
85) Ueda H, Manda T, Matsumoto S, et al: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968: IIL Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo) 47: 315 323, 1994.
 
86) Kohn EC, Liotta LA: L651582: Anovel antiproliferative and antimetastasis agent. J. Natl. Cancer Inst. 82: 54 60, 1990.
 
87) Kohn EC, Sandeen MA, Liotta LA: ln vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res. 52: 3208 3212, 1992.
 
88) Kohn EC, Alessandro R, Spoonster J, et al: Angiogenesis: role of calcium mediated signal transduction. Proc. Natl. Acad. Sci. USA 92: 1307 1311, 1995.
 
89) Figg WD, Cole KA, Reed E, et al: Pharmacokinetics of orally administered carboxyamidotiazole, an inhibitor of calcium mediated signal transduction. Clin. Cancer Res. 1: 797 803, 1995.
 
90) Kohn EC, Reed E, Sarosy G, et al: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. 56: 569 573, 1996.
 
91) Pluda JM: Tumor associated angiogenesis: mechanisms, clinica川mplications, and therapeutic strategies. Semin. Oncol. 24: 203 218, 1997.
 
92) Gore M, A 'Hern R, Stankiewicz M, et al: Tumour marker levels during marimastat therapy. Lancet 348: 263 264, 1996.
 
93) Wojtowicz Praga S, Torri J, Johnson M, et al: Phase I study of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 16: 2150 2156, 1998.
 
94) Adams M, Thomas H: Aphase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc. Am. Soc. Clin. Oncol. 17: 217a, 1998.
 
95) Carmichael J, Ledermann JA, Woll PJ, et al: Phase IB study of concurrent administration of marimastat and gemcitabine in non resectable pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 17: 232a, 1998.
 
96) Gradishar W, Sparano J, Cobeigh M, et al: Aphase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 17: 144a, 1998.
 
97) O'Reilly S, Mani S, Ratain MJ, et al: Schedules of 5FU and the matrix metalloproteinase inhibitor marimastat (MAR) : aphase I study. Proc. Am. Soc. Clin. Oncol. 17: 217a, 1998.
 
98) Ingber D, Fujita T, Kishimoto S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555 557, 1990.
 
99) Maione TE, Gray GS, Petro J, et al: Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides. Science 247: 77 79, 1990.
 
100) O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: anovel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315 328, 1994.
 
101) Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1: 149 153, 1995.
 
102) O'Reilly MS, Holmgren L, Chen C, et al: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2: 689 692, 1996.
 
103) Wu Z. O'Reilly MS, Folkman J, et al: Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Comm. 236: 651 654, 1997.
 
104) Sim BKL, O'Reilly MS, Liang H, et al: Arecombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57: 1329 1334, 1997.
 
105) O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277 285, 1997.
 
106) Boehm T, Folkman J, Browder T, et al: Antiangiogenic therapy of experimental cancer dose not induce acquired drug resistance, Nature 390: 404 407, 1997.
 
107) Brown JM.: SR4233 (Tirapazamine) : anew anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67: 1163 1170, 1993.
 
108) Dorie MJ and Brown JM.: Tumor specific, schedule dependent interaction between tirapazamine (SR4233) and cisplatin. Cancer Res. 53: 4633 4636, 1993.
 
109) Senan S, Rampling R, Graham MA, et al: Phase I and pharmacokinetic study of tirapazamine (SR4233) administered every three weeks. Clin. Cancer Res. 3: 31 38, 1997.
 
110) Johnson CA, Kilpatrick D, Von Roemeling R, et al: Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J. Clin. Oncol. 15: 773 780, 1997.
 
111) Curran WJ, Movsas B, Hancock S, et al: Phase I trial of oral TirazoneTM (tirapazamine, TPZ) shows good bioavailability and tolerance. Proc. Am. Soci. Clin. Oncol. 17: 208a, 1998.
 
112) Von Pawel J and Von Roemeling R.: Survival benefit from TirazoneTM (tirapazamine) and cisplatin in advanced non-small-cell lung cancer (NSCLC) patients: final results from the international phase III catapul I trial. Proc. Am. Soci. Clin. Oncol. 17: 454a, 1998.
 
113) Kim C, Pinto HA, Tate D, et al: Tirapazamine, cisplatin & fluorouracil as induction chemotherapy & simultaneous chemoradiotherapy for organ preservation in advanced head and neck cancer. Proc. Am. Soci. Clin. Oncol. 17: 395a, 1998.
 
114) Aghajanian C, Levenbeck C, Chen Y, et al: Amulti center phase II study of tirapazamine plus cisplatin in patients with metastatic or recurrent cervical cancer. Proc. Am, Soci. Clin. Oncol. 17: 353a, 1998.
 
115) Gatineau M, Rixe O, Fizazi L, et al : PhaseI study of tirapazamine cisplatin vinorelbine in patients with inoperable non-small-cell lung cancer (NSCLC) . Proc. Am. Soci. Clin. Oncol. 17: 485a, 1998.
 
116) Ho PTC, Parkinson DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol. 24: 187 202, 1997.
 
117) Stec WJ, Zon G, Egan W, et al: Automated solid phase synthesis, separation and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106: 6077 6079, 1984.
 
118) Bishop MR, Iversen PL, Bayever E, et al: Phase I trial of an antisense oligonucleotide OL (1) p53 in hematologic malignancies. J. Clin. Oncol. 14: 1320 1326, 1996.
 
119) Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53 deficient human tumor cells. Science 274: 373 376, 1996.
 
120) Heise C, Sampson Johannes A, Williams A, et al: ONYX 015, an EIB gene attenuated adenovirus, causes tumor specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3: 639 645, 1997.
 
121) Yew PR, Berk AJ: Inhibition of p53 transactivation required for transformation by adenovirus early IBprotein. Nature 357: 82 85, 1992.
 
122) Bergsland E, Mani S, Kirn D, et al: Intratumoral injection of ONYX 015 for gastrointestinal tumors metastatic to the liver: aphase I trial. Proc. Am. Soci. Clin. Oncol. 17: 211a, 1998.
 
123) Mulvihill SJ, Warren RS, Fell S, et al: Aphase I trial of intratumoral injection with an EIB attenuated adenovirus, ONYX 015, into unresectable carcinomas of the exocrine pancreas. Proc. Am. Soci. Clin. Oncol. 17: 211a, 1998.
 
124) Kirn D, Nemunaitis J, Ganly I, et al: Aphase II trial of intratumoral injection with an EIB deleted adenovirus, ONYX 015, in patients with recurrent, refractory head and neck cancer. Proc. Am. Soci. Clin. Oncol. 17: 391a, 1998.
 
P.687 掲載の参考文献
1) Young RC: Drug resistance: The clinical problem. In: Drug Resistance in Cancer Therapy (ed by Ozols RF) Kluwer Academic Publishers, Boston, 1989, pp. 1 12.
 
2) Dewhirst NW: Angiogenesis and blood flow in solid tumors. In: Drug resistance in oncology (ed by Teicher BA) . Marcel Dekker, New York, 1993, pp. 3 24.
 
3) Chen C J, Chin JE, Ueda K, Clark DP, et al: Internal duplication and homology with bacterial transport proteins in the MDR 1 (p glycoprotein) gene from multidrug resistant human cells. Cell 47: 381 389, 1986.
 
4) Gottesman MM, Hrycyna CA: Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 29: 607 649, 1995.
 
5) Ueda K, Okamura N, Tanigawa Y, et al: Human P glycoprotein transports cortisol, aldosterone, and dexameth asone but not progesterone. J. Biol. Chem. 267: 24248 24252, 1992.
 
6) Schinkel AH, Smit JJM, van Tellingen O, et al: Disruption of the mouse 7 a P glycoprotein gene leads to adeficiency in the blood brain barrier and to increased sensitivity to drug. Cell 77: 491 502, 1994.
 
7) Smit JJ, Schinkel AH, Oude Elferink PRJ, et al: Homozygous disruption of the murine mdr 2 P glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451 462, 1993.
 
8) van Helvoort A, Smit AJ, Sprong H, et al: MDR 1 P glycoprotein is a lipid translocase of broad specificity, while MDR 3 P glycoprotein specifically translocates phosphatidylcholin. Cell 87: 507 517, 1996.
 
9) Mizoguchi T, Yamada K, Akiyama S, et al: Expression of the MDR 1 gene in human gastric and colorectaI carcinomas. J. Natl. Cancer Inst. 82: 1679 1683, 1990.
 
10) Kuwazuru Y, Hanada S, Akiyama S, et al: Expression of P glycoprotein in adult T cell leukemia cells. Blood 76: 2065 2071, 1990.
 
11) Chin K V, Ueda K, Pastan I, et al: Modulation of the activity of the promoter of the human R 1 gene by Ras and p 53. Science 255: 459 426, 1992.
 
12) Mickley MA, Bates SE, Richert ND, et al: Modulation of the expression of a multidrug resistance gene by differentiating agents. J. Biol. Chem. 264: 18031 18040, 1989.
 
13) Tsuruo T, Iida H, Tsukagoshi S, et al: Overcoming of vincristine resistance in P 3881eukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41: 1967 1972, 1981.
 
14) Beck WT, Dalton WS: Mechanisms of drug resistance. In: Cancer: Principles & Practice of Oncology (eds by Devita Jr, Hellman S, Rosenberg SA) . 5th Edition, Lippincott Raven, Philadelphia, 1997, pp. 498 512.
 
15) Cole SPC, Bhardwaj G, Deeley RG, et al: Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 1650 1654, 1992.
 
16) Jedlitschky G, Leier I, Bucholz U, et al: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene encoded conjugate export pump. Cancer Res. 56: 988, 1996.
 
17) Loe DW, Almquist KC, Deeley RG, et al: Multidrug resistance protein (MRP) mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: demonstration of glutathione dependent vincristine transport. J. Biol. Chem. 271: 9675 9682, 1996.
 
18) Norris MD, Bordow SB, Haber M, et al: Association between high levels of expression of the multidrug resistance associated protein (MRP) and poor outcome in primary human neuroblastoma. N. Engl. J. Med. 334: 231 238, 1996.
 
19) Nooter K, Westerman AM, Flens MJ, et al: Expression of the multidrug resistance associated protein (MRP) gene in human cancers. Clin. Cancer Res. 1: 1301 1310, 1995.
 
20) Scheper RJ, Broxtermam HJ, Scheffer GL, et al: Overexpression of a Mr 110, 000 vesicular protein in non Pglycoprotein mediated multidrug resistance. Cancer Res. 53: 1475 1479, 1993.
 
21) Scheffer GL, Wijngaard PLT, Flens MJ, et al: The drug resistance related protein LRP is the human major vault protein. Nat. Med. 1: 578 582, 1995.
 
22) Kedersha N, Rome LH: Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J. Cell Biol. 103: 699 709, 1986.
 
23) Chugani DC, Rome LH, Kedersha NL: Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J. Cell Sci. 106: 23 29, 1993.
 
24) Izquierdo MA, Scheffer GL, Flens MJ, et al: Broad distribution of the multidrug resistance related vault lung resistance protein in normal human tissues and tumors. Am. J. Pathol. 148: 877 887, 1996.
 
25) Izquierdo MA, Shoemaker RH, Flens MJ, et al: 0verlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int. J. Cancer 65: 230 237, 1996.
 
26) Izquierdo MA, van Der Zee AGJ, Vermorken JB, et al: Drug resistance associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J. Natl. Cancer Inst. 87: 1230, 1995.
 
27) List AF, Spier CS, Grogan TM, et al: Overexpression of the major vault transporter protein LRP predicts treatment outcome in AML. Blood 87: 2464, 1996.
PubMed
28) 西條長宏: シスプラチン耐性. 薬剤耐性の分子機構 (鶴尾 隆編) , 羊土社, 東京, 1994, pp. 109-121.
 
29) Ishikawa T, Ali Osman F: Glutathione associated cis diamminedichloroplatinum (II) metabolism and ATPdependent efflux from leukemia cells: Molecular characterization of glutathione platinum complex and its biological significance. J. Biol. Chem. 268: 20116 20125, 1993.
 
30) Fujii R, Mutoh M, Sumizawa T, et al: Adenosine triphosphate dependent transport of leukotriene C. by membrane vesicles prepared from cisplatin resistant human epidermoid carcinoma tumor cells. J. Natl. Cancer Inst. 86: 1781 1784, 1994.
 
31) Taniguchi K, Wada M, Kohno K, et al: Ahuman canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56: 4124 4129, 1996.
 
32) Masuda H, Ozols RF, Lai G M, et al: Increased DNA repair as a mechanism of acquired resistance to cisdiamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 48: 5731, 1988.
 
33) Lai G M, Ozols RF, Young RF, et al: Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol. 37: 4597, 1988.
 
34) Masuda H, Tanaka T, Matsuda H, et al: Increased removal of DNA bound platinum in a human ovarian cancer cell line resistant to cis diamminedichloroplatinum (II) . Cancer Res. 50: 1863, 1990.
 
35) Parker RJ, Eastman A, Bostick Burton F, et al: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin DNA lesions and reduced drug accumulation. J. Clin. Invest. 87: 772, 1991.
 
36) Eastman A, Schulke N: Enhanced DNA repair as a mechanism of resistance to cis diamminedichloroplatinum (II) . Biochemistry 27: 4730, 1998.
 
37) Dabholkar M, Vionnet J, Bostrick Bruton F, et al: Messenger RNA levels of XPAC and ERCCI in ovarian cancer tissue correlate with response to platinum based chemothrapy. J. Clin. Invest. 94: 703, 1998.
 
38) Chu G, Chang E: Cisplatin resistant cells express increased levels of a factor that recognizes damaged DNA. Proc. Natl. Acad. Sci. USA 87: 3324, 1990.
PubMed
39) Chu G, Chang E: Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 242: 564, 1988.
 
40) Hughes EN, Engelsberg BN, Billings PC: Purification of nuclear factor that binds to cisplatin damaged DNA: identity with high mobility group proteins！and 2. J. Biol. Chem. 267: 13520, 1992.
 
41) Pil PM, Lippard SJ: Specific binding of chromosomal protein HMG 1 to DNA damaged by the anticancer drug cisplatin. Science 256: 234, 1988.
 
42) Johnson SW, Swiggard PA, Handel LM, et al: Relationship between platinum DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin sensitive and resistant human ovarian cancer cells. Cancer Res. 54: 5911, 1994.
PubMed
43) Hamaguchi K, Godwin AK, Yakushiji M, et al: Cross resistance to diverse drugs is associated with primary cisplatin resistance to ovarian cancer cell lines. Cancer Res. 54: 5911, 1994.
 
44) Kaufmann WK: Pathways of human cell post replication repair. Carcinogenesis 10: 1, 1989.
PubMed
45) Mamenta EL, Poma EE, Kaufmann WK, et al: Enhanced replicative bypass of platinum DNA adducts in cisplatin resistant human ovarian carcinoma cell lines. Cancer Res. 54: 3500, 1994.
PubMed
46) 秋山伸一: 抗がん剤のはたらき-課題と展望-. 共立出版, 東京, 1991.
 
47) Radparvar S, Houghton PJ, Houghton JA: Effect of polyglutamylation of 5, 10 methylene tetrahydrofolate on the binding of 5 fluoro 2 deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem. Pharmacol. 38: 335, 1989.
 
48) Wang F S, Aschele C, Sobrero A, et al: Decreased folypolyglutamate synthetase expression: anovel mechanism of fluorouracil resistance. Cancer Res. 53: 3677, 1993.
 
49) Berger SH, Jenh C H, Jonson LF, et al: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine resistant human cells. Mol. Pharmacol. 28: 461, 1985.
 
50) Barbour KW, Berger SH, Berger FG: Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol. Pharmacol. 37: 515, 1990.
PubMed
51) Chu E, Koeller DM, Casey JL, et al: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl. Acad. Sci. USA 88: 8977, 1991.
PubMed
P.719 掲載の参考文献
1) Leventhal BG, Wittes RE: Research Methods in Clinical Oncology. Raven Press, New York, 1986.
 
2) Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremity. N Engl. J. Med. 314: 1600 1606, 1986.
 
3) 西條長宏: がん治療の進歩と臨床試験. からだの科学 187: 74-78, 1996.
 
4) Kisner DL: Reporting treatment toxicities. In Cancer Clinical Trials: Methods and Practice, edited by ME Buyse, MJ Staquet, RJ Sylvester, Oxford University Press, Oxford, 1984, pp. 178 190.
 
5) Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5: 649 655, 1982.
 
6) Ajani JA, Welch SR, Raber MN, et al: Comprehensive criteria for assessing therapy induced toxicity. Cancer Invest 8: 147 159, 1990.
 
7) Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects solid cancer chemotherapy. J. Jpn. Soc. Cancer Ther. 28: 101 130, 1993.
 
8) Tobinai K, Kohno A, Shimada Y, et al: Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn. J. Clin. Oncol. 23: 250 257, 1993.
 
9) LENT SOMA scales for all anatomic sites. Int. J. Radiat. Oncol. Biol. Phys. 31: 1049 1091, 1995.
 
10) Kaplan EL, Meier P: Nonpararametric estimation for incomplete observations. J. Am. Stat. Assoc. 53: 457 481, 1958.
 
11) Donovan K, Sanson Fisher RW, Redman S: Measuring the quality of life of cancer patients. J. Clin. Oncol. 7: 959, 1989.
PubMed
12) Bonomi AE, Cella DF, Hahn EA, et al: Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual. Life Res. 5: 309 320, 1996.
 
13) Aaronson NK, et al: Amodular approach to quality of life assessment in cancer clinical trials. Recent Results Cancer Res. 111: 231, 1988.
 
14) 江口研二, 栗原 稔, 下妻晃二郎・他: がん薬物療法におけるQOL調査票. 日癌治療会誌28 (8) : 1140-1144, 1993.
 
15) Alley MC, Scudiero DA, Monks Hursey ML, et al: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48: 589 601, 1988.
 
16) 抗悪性腫瘍薬の臨床評価ガイドライン作成に関する研究班: 抗悪性腫瘍の臨床評価方法に関するガイドライン.
 
17) Freireich EJ, Gehan EA, Rall DP, et al: Quantitative comparision of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Res. 50: 219 244, 1966.
 
18) Owens, AH Jr: Predicting anticancer drug effects in man from laboratory animal studies J. Chronic Dis. 15: 223 228, 1962.
 
19) Abeloff MD, Slavik M, Luk GD, et al: Phase I trial and pharmacokinetic studies of alpha difluoromethylornithine An inhibitor of polyamine biosynthesis. J. Clin. Oncol. 2: 124 130, 1984.
 
20) Collins JM, Zaharko DS, Dedrick RL, et al: Potential roles for pharmacology in phase I clinical trials. Cancer Treat. Rep. 70: 73 80, 1986.
 
21) EORTC Pharmacokinetics and Metabolism Group: Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur. J. Cancer Clin. Oncol. 23: 1083 1087, 1987.
 
22) Bisset D, Graham MA, Setanoians A, et al: Phase I and pharmacokinetic study of Rizoxin. Cancer Res. 52: 2894 2898, 1992.
 
23) Storer BE: Design and analysis of phase I clinical trials. Biometrics 45: 925 937, 1989.
 
24) O'Quigley J, Chevret S: Methods for dose finding studies in cancer clinical trials: areview and results of a Monte Carlo study. Stat. in Med. 10: 1647 1664, 1991.
 
25) O'Quigley J, Pepe M, Fisher L: Continual reassessment method: Apractical design for phase I clinical trials in cancer. Biometrics 46: 33 48, 1990.
 
26) Ohtsu T, Sasaki Y, Tamura T, et al: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A3 hour infusion versus a 24 hour infusion. Clin. Cancer Res. 1: 599 606, 1995.
 
27) Mick R, Ratain MJ: Model guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision. J. NatL Cancer Inst. 85: 217 223, 1993.
 
28) Rubin P, Keys H, Salazar O: New designs for radiation oncology research in clinical trials. Seminars inOncology 8 (4) : 453, 1981.
 
29) Estey E, Hoth D, Simon R, et al: Therapeutic response in Phase I trials of anti neoplastic agents. Cancer Treat. Rep. 70: 1105 1115.
 
30) Smith TL, Lee JJ, Kantarjian HM, et al: Design and results of phase I cancer clinical trials: Three Year Experience at M. D. Anderson Cancer Center. J. Clin. Oncol. 14: 287 295, 1996.
 
31) Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer；astudy of eastern cooperative oncologygroup. J. Clin. Oncol. 7: 1602 1613, 1989.
 
32) Ratain MJ, Mick R, Schilsky RL, et al: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J. Natl. Cancer Inst. 85: 1637 1643, 1993.
 
33) Daugherty C, Ratain MJ, Grochowski E, et al: Perceptions of Cancer Patients and TheirPhysicians lnvolved in Phase I Trials J. Clin. Oncol. 13 (5) : 1062 1072, 1995.
 
34) Chang AY, Kim K, Glick J, et al: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lungcancer: The eastern cooperative oncology group results. J. Natl. Cancer Inst. 85 (5) : 388 394, 1993.
 
35) Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natr. Cancer Inst. 85 (5) : 384 388, 1993.
 
36) Radice PA, Bunn PA Jr, Ihde DC: Therapeutic trials with VP 16 213 and VM 26: Active agents in small cell lung cancer, non Hodgkin 's lymphomas and other malignancies. Cancer Treat. Rep. 63: 1231 1239, 1979.
 
37) 下山正徳, 富永祐民, 西條長宏・他: 臨床試験計画 (プロトコール) の作成と実施, 並びに結果の統計解析とその評価について. 癌の臨床36: 2503-2525, 1990.
 
38) Moore TD, Korn EL : Phase II trial design consideration for small cell lung cancer. J. Natl. Cancer Inst. 84: 150 154, 1992.
 
39) Ettinger DS, Finkelstein DM, Abeloff MD, et al: Justification for evaluating new anticancer drugs in selected untreated patients with extensive stage small cell lung cancer；an eastern cooperative oncology group randomized study. J. Natl, Cancer Inst. 84: 1077 1084, 1992.
 
40) Ettinger DS, Finkelstein D, Ritch P, et al: Randomized trial of single agents VS combination chemotherapy in extensive stage small cell lung cancer. Proc. ASCO l1: 295, 1992.
 
41) Stephan KC: Clinical aspects in the design and conduct of phase II trials. Cancer Clinical Trials.: 224 238, 1988.
 
42) Grant SC, Gralla RJ, Kris MG, et al: Single agent chemotherapy trials in small cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J. Clin. Oncol. 10 (3) : 484 498, 1992.
 
43) Gehan EA, Schneiderman MA: Experimental design of clinical trials. In Cancer Medicine, edited by JF Holland, E, Frei III, 2nd ed. Lea and Febiger, Philadelphia, 1982, pp. 531 553.
 
44) Fleming TR: One sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143 151, 1982.
 
45) Simon R: Optimal two stage designs for phase II clinical trials. Controlled Clin. Trials 10: 1 10, 1989.
PubMed
46) Green SJ, Dahlberg S: Planned versus attained design in phase II clinical trials. Stat. in Med. 111853 862, 1992.
 
47) Moertel CG, Thynne GS: Large bowel. In Cancer Medicine, edited by JF Hollandd, E Frei III, 2nd ed. Lea andFebiger, Philadelphia, 1982, pp. 1830 1859.
 
48) Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treat. Rep. 69: 1375 1381, 1985.
 
49) Liu PY, Dahlberg S, Crowley J: Selection designs for pilot studies based on survival. Biometrics 49: 391 398, 1993.
 
50) Tannock I, Murphy L: Reflections on medical oncology: An appeal for better clinical trials and improved reporting of their results. J. Clin. Oncol. 1: 66 70, 1983.
 
51) Weiss GB, Bunce H, Hokanson JA: Comparing survival of responders and non responders after treatment: A potential source of confusion in interpreting cancer clinical trials. Controlled Clin. Trials 4: 43 52, 1983.
 
52) Aisner J. Alverto P, Bitran J, et al: Role of chemotherapy in small cell lung cancer: Aconsensus report of the Internaional Association for the study of Lung cancer Workshop. Cancer Treat. Rep. 67: 37 43, 1983.
 
53) Tannock I: Reading the literature with a clinical eye. ASCO Education Book, 1992. pp. 114 117.
 
54) Tannock I: New perspective in combined radio therapy and chemotherapy treatment. IInd IASLC Workshop Inagural Conference: 1 39, 1992.
 
55) Zelen M: Play the winner rule and the controlled clinical trial. JAMA 64: 131 146, 1969.
 
56) Efron B: Forcing a sequential experiment to be balanced. Biometrika 58: 403 417, 1971.
 
57) Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N. Engl. J. Med. 312: 1604 1608, 1985.
 
58) Easterbrook PJ, Berlin JA, Gopalan R, et al: Publication bias in clinical research. Lancet 337: 867 872, 1991.
 
59) Gehan EA, Freireich EJ: Non randomized controls in cancer clinical trials. N. Engl. J. Med. 290: 198 203, 1974.
 
60) Chalmers TC, Block JB, Lee S l Controlled studies in clinical cancer research. N. Engl. J. Med. 287: 75 78, 1972.
 
61) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321: 406 412, 1989.
 
62) Passamani E: Clinical trials are they ethical? N. Engl. J. Med. 324: 1589 1592, 1991.
 
63) Zelen M: The randomization and stratification of patients to clinical trial. J. Chronic. Dis. 27: 365 375, 1974.
 
64) Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31: 103 115, 1975.
 
65) 下山正徳, 田島絹子, 恒松隆一郎・他: 厚生省がん研究助成金指定研究「固形がんの集学的治療の研究」班における臨床試験計画 (プロトコール) の作成と実施, 並びに結果の統計解析とその評価に関するガイドライン (改訂第3版) 第I部: プロトコールの作成に関する医学的並びに科学的事項とその審査. 癌の臨床 42: 197-229, 1996.
 
66) Simon RM: Design and conduct of clinical trials. In Cancer: Principles and Practice of Oncology, edited by VT DeVita Jr, S Hellman, SA Rosenberg, 1st ed, Lippincott, Philadelphia, 1982, pp. 198 225.
 
67) George SL: The required size and length of a phase III clinical trial. In Cancer Clinical Trials: Methods and Practice, edited by ME Buyse, MJ Staquet, RJ Sylvester, Oxford University Press, Oxford, 1984, pp. 287 310.
 
68) Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors: amultiinstitutional study. J. Clin. Oncol. 11 (4) : 598 606, 1993.
 
69) Loehrer PJ Sr, Johnson D, Elson P, et al: Importance of bleomycin in favorable prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 13 (2) : 470 476, 1995.
 
70) The Continuous Infusion versus Double Bolus Administration of Alteplase (COBALT) Investigators: A comparison of contibuous infusion of anteplase with double bolus administration for acute myocardial infarction. N. Engl. J. Med. 337: 1124 1130, 1997.
 
71) Ware JH, Antman EM: Equivalence trials. N. Engl. J. Med. 337: 1159 1161, 1997.
 
72) Canner PL, for The Coronary Drug Project Research Group: Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N. Engl. J. Med. 303: 1038 1041, 1980.
 
73) Gehan E: Ageneralized Wilcoxon test for comparing arbitrarily singly censored samples. Biometrika 52: 203 224, 1965.
 
74) Peto R, Pike MC, Armitage P, et al: J: Design and analysis of randomized clinical trials requiring Prolonged observation of each patient II. Br. J. Cancer 35: 1 39, 1977.
 
75) Cox DR: Regression models and life tables. J. Royal Stat. Soc. Series B 34: 187 220, 1972.
 
76) Schein PS, for the Gastrointestinal Tumor Study Group: Acomparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 49: 1771 1777, 1982.
 
77) Ohta M, Tsuchiya R, Shimoyama M, et al: Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 106: 703 708, 1993.
 
78) Fleming TR, Green SJ, Harrington DP: Considerations of monitoring and evaluating treatment effects in clinical trials. Control. Clin. Trials 5: 55 66, 1984.
 
79) Pocock SJ: Group sequential methods in the context of a programme of a clinical reseach. Biometrika 64: 191 199, 1977.
 
80) O'Brien PC, Fleming TR: Amultiple testing procedure for clinical trials. Biometrics 351549 556, 1979.
 
81) Braitman LE: Confidence Intervals Assess Both Clinical Significance and Statistical Significance. Ann. Intern. Med. 114: 515 517, 1991.
 
82) Wittes RE, Goldin A: Unresolved issues in combination chemotherapy. Cancer Treat. Rep. 70: 105 125, 1986.
 
83) Leyland Jones B, O'Dwyer PJ: Biochemical modulation. Application of laboratory models to the clinic. Cancer Treat. Rep. 70: 219 230, 1986.
 
84) Martin DS, Stolfi RL, Sawyer RC, et al : Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat. Rep. 69: 421 423, 1985.
 
85) Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: aphase I and pharmacologic study. J. Clin. Oncol. 9 (9) : 1692 1703, 1991.
 
86) Schellens JH, Ma J, Bruno R, et al: Pharmacokinetics of cisplatin and Taxotere (docetaxel) and WBC DNA adduct formation of cisplatin in the sequence Taxotere/cisplatin and cisplatin/Taxotere in a Phase I/II study in solid tumor patients. Proc. ASCO 131323, 1994.
 
87) Goodman SN: Have you ever meta analysis you didn 't like? Ann. Intern. Med. 114: 244 246, 1991.
 
88) Glass G: Primary, secondary and meta analysis of research. Educ. Res. 5: 3 9, 1976.
 
89) Non small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small-cell lung cancer: ametaanalysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899 909, 1995.
 
90) Cappelleri JC, Ioannidis JpA, Schmid CH, et al: Large trials vs meta analysis of smaller trials: how do their results compare? JAMA 276: 1332 1338, 1996.
 
91) LeLorier J, Gregoire G, Benhaddad A, et al : Discrepancies between meta analyses and subsequent large randomized, controlled trials. N. Engl. J. Med. 337: 536 542, 1997.
 
92) Bailar JC III: The promise and problems of meta analysis. N. Engl. J. Med. 337: 559 561, 1997.
 
93) Simon R: Randomized clinical trials in oncology. Principles and obstacles. Cancer 74 (9 SuppL) : 2614 2619, 1994.
 
94) 佐久間昭: 医学統計 Q&A. 金原出版, 東京, 1987.
 
95) Pocock SJ: Clinical trials: a practical approach. John Wiley & Sons, Chichester, 1983.
 
96) 厚生省医薬安全局GCP研究会監修: 改訂GCPハンドブック. 薬業時報社, 東京, 1997.
 
97) Hennekens CH, Buring JE, Manson JE, et al: Lack of effect of long term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334: 1145 1149, 1996.
 
98) Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin a on lung cancer and cardiovascular disease. N. Engl. J. Med. 334: 1150 1155, 1996.
 
99) Barinaga M: From bench to bedside. Science 278: 1036 1039, 1997.
 
100) Fornasiero A, Daniele O, Ghiotto C, et al: Chemotherapy of invasive thymoma. J. Clin. Oncol. 8: 1419 1423, 1990.
 
101) Loehrer PJ, Kirn K M, Aisner SC, et al: Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. J. Clin. Oncol. 12: 1164 1168, 1994.
 
102) Makuch RW, Simon R: Sample size considerations for nonrandomzed c6mparative studies. J. Chronic Dis. 33: 171 175, 1980.
 
103) Laupacis A, Connolly SJ, Gent M, et al: How Should Results from Completed Studies Influence Ongoing Clinical Trials? Ann. Intern. Med. 115: 818 822, 1991.
 
104) Dillman RO, Seagren SL, Propert KJ, et al: ARandomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small-cell lung cancer. N. Engl. J Med. 323: 940 945, 1990.
 
105) Sause WT, Scott C, Taylor S: Radiation therapy oncology group (RTOG) 88 08 and eastern cooperative oncology group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J. Natl. Cancer Inst. 87: 198 205, 1995.
 
106) Parmar MKB, Ungerleider RS, Simon R: Assessing whether to perform a confirmatory randomized clinical trial. J. Natl. Cancer Inst. 88: 1645 1651, 1996.
 
P.738 掲載の参考文献
1) Beecher HK: Ethics and clinical research. N. Engl. J. Med. 274: 1354 1360, 1966.
 
2) Goldberg RJ: Disclosure of information to adult cancer patients: Issues and update. J. Clin. Oncol. 12: 948 955, 1984.
 
3) Appelbaum, PS, Lidz CW, Meisel A: インフォームド・コンセント (杉山弘行訳) . 文光堂, 東京, 1994.
 
4) Faden RR, Beauchamp TL: A history and theory of informed consent. Oxford University Press, NY, 1986. (酒井忠昭, 秦浄一訳: インフォームド・コンセント-患者の選択, みすず書房, 1994.)
 
5) Pocok SJ: クリニカルトライアル (コントローラー委員会監訳) . 篠原出版, 東京, 1989.
 
6) 砂原茂一: 臨床医学研究序説 方法論と倫理. 医学書院, 東京, 1988.
 
7) 田沢公樹, 中島宏昭, 石原潤一・他: わが国の肺癌化学療法におけるinformed consent全国アンケート調査. J. Jpn. Soc. Cancer Ther. 21: 2454-2459, 1986.
 
8) 篠田雅幸, 江口研二, 大田恵一朗・他: 癌臨床試験でのインフォームド・コンセントに対する医師の認識度のアンケート調査. 日癌会総会記 633, 1994.
 
9) 久保昭仁, 中川和彦, 宮本裕介・他: 肺癌患者におけるinformed consent: 大阪市立羽曳野病院第2内科における現状. J. Jpn. Soc. Cancer. Ther. 30: 664-679, 1995.
 
10) The Neuremberg Code, Ethics in Medicine: Historical perspectives and contemporary concerns. (Reiser SJ, Dyck AJ, Curren WJ. eds.) M. 1. T. Press, Cambridge, Mass., 1977, pp. 272 273.
 
11) Declaration of Helsinki: Recommendations guiding medical doctors in biochemical research involving human subjects. (光石忠敬訳: ヘルシンキ宣言: 世界医師会総会, ヘルシンキ1964, 東京1975, ベニス1983, ホンコン1989, 改訂版. 臨床評価 22: 289-291, 1994.)
 
12) The Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO) , International ethical guidelines for biomedical research involving human subjects, Geneva, 1993. (光石忠敬訳: 国際医科学評議会 (世界保健機関協力) , 被験者に対する生物医学研究についての国際的倫理指針 (1993年ジュネーブ) . 臨床評価 22: 261-288, 1994.)
 
13) The Council for International Organizations of Medical Sciences (CIOMS) , International guidelines for ethical review of epidemiological studies, Geneva, 1991. (光石忠敬訳: 国際医科学評議会, 疫学研究の倫理審査のための国際的指針 (1991年ジュネーブ) . 臨床評価20: 563-578, 1992.)
 
14) President 's Commission for the study of ethical problems in medicine at biochemical and behavioral research: Final report on studies of the ethical and legal problems in medicine and biomedical and behavioral research- summing up-, 1993. (医務局医事課監訳, 牛場大蔵・他訳: アメリカ大統領委員会, 生命倫理総括レポート. 篠原出版, 1984.)
 
15) 加藤尚武: 環境倫理学のすすめ (丸善ライブラリー032) . 丸善, 東京, 1991, pp. 1-226.
 
16) 日本医師会生命倫理懇談会報告: 説明と同意についての報告. 日本医事新報 3430: 109-112, 3431: 112-113, 3432: 118-119, 平成2年1月, 2月.
 
17) 星野一正: 医療の倫理 (岩波新書201) . 岩波書店, 東京, 1991.
 
18) 光石忠敬: 共同作業への参加の証としてのインフォームド・コンセント. 臨床評価 16: 569-580, 1988.
 
19) GCPハンドブック: 医薬品の臨床試験の実施に関する基準. 厚生省薬務局審査第一課監修, 薬業時報社, 東京, 平成2年.
 
20) International conference on harmonization of technical requirements for registration of pharmaceuticals for human use-Guideline for good clinical practice-ICH expert working group, ICH Steering Committee IFPMA, Geneva May, 1995. (医薬品の臨床試験の実施に関する基準 (GCP) のガイドライン (案) : 平成7年7月厚生省薬務 局審査課. 臨床評価 23: 369-484, 1995.)
 
21) 厚生省令第28号, 薬務局長通知430号, 審査課長通知445号, 安全課長通知68号: 新GCP関連資料集. 日本製薬工 業会医薬品評価委員会編 ミクス, 東京, 1997, pp. 89-342.
 
22) 厚生省令10号: 平成9年3月10日.
 
23) 下山正徳, 江口研二, 恒松隆一郎・他: 臨床試験の作成と実施, ならびに結果の統計解析とその評価に関するガイドライン (改訂第3版) . 癌の臨床・篠原出版, 東京, 42: pp. 339-352, 1996.
 
24) OPRR Protecting Human Research Subjects: Institutional Review Board Guidebook. US Department of Health and Hurnan Services, Pubic Health Service, National Institute of Health, 1993.
 
25) 下山正徳: 抗悪性腫瘍薬臨床評価方法に関するガイドライン解説. 新薬臨床評価ガイドライン1994. 日本公定書協会編, 薬業日報社, 東京, 1994, pp. 358-377.
 
26) 島田安博: 進行胃癌グループのプロトコール研究におけるICの実態. 薬物療法を主体とする固形癌の集学的治療の臨床試験研究 (垣添忠生, 下山正徳監修) . 協和企画通信, 東京, 1991.
 
27) 柳田邦男編: 元気の出るインフォームド・コンセント. 中央法規, 東京, 1995.
 
28) Girgis A, Sanson Fisher RW: Breaking Bad News: Consensus Guidelines for Medical Practitioners. J. Clin. Oncol. 13: 2449 2456, 1995.
 
29) Okamura H, Uchitomi Y, Sasako M. et al.: Guidelines for telling the truth to cancer patients. Jpn. J. Clin. Oncol. 28 (1) : 1 4, 1998.
 
30) 内藤周幸, 光石忠敬: 医学実験無作為化臨床試験の論理と倫理. 篠原出版, 東京, 1987.
 
31) Leventhal BG, Wittes RE: Research methods in clinical oncology. Raven Press, New York, 1988
 
32) The Physician and Unorthodox Cancer Therapies: ASCO special article JCO 15: 401 406, 1997.
 
33) 浜島信之: 無作為化割付臨床試験. 癌と化学療法社, 東京, 1993.
 
34) 小島大輔: 癌の告知について. 日医大誌 58: 39-49, 1991.
 
35) 佐藤郁世, 田沢公樹, 深浦麻人・他: 癌告知に関する意識調査-外来患者に対するアンケート調査-. J. Jpn. Soc. Cancer Ther. 29: 1677-1685, 1994.
 
36) 小林国彦, 川崎千佳, 矢島千歳・他: 肺癌患者における告知状況の解析. J. Jpn. Soc. Cancer Ther. 29: 1001-1009, 1994.
 
37) 日本消化器病学会倫理委員会: 医の倫理に関するアンケート調査結果の報告. 日消誌 90: 2775-2794, 1993.
 
38) 松栄達郎, 清水美登里, 吉田博子・他: がん死亡者の告知, 生活の質, 説明と同意. 厚生の指標 40: 19-27, 1993.
 
39) 毎日新聞世論調査部: 第10回『がん』に関する全国世論調査報告書. 1990年12月.
 
40) Lind SE, Good MJD, Seidel S, et al: Telling the diagnosis of cancer. J. Clin. Oncol. 7: 583 589, 1989.
 
41) Dunn SM, Patterson PU, Butow PN, et al : Cancer by another name: arandomized trial of the effects of euphemism and uncertainity in communicating with cancer patients. J. Clin. Oncol. 11: 989 996, 1993.
 
42) Thomson OO, Wulfe HR, Martin A, et al: What do gastroenterologists in Europe tell cancer patients? Lancet 341: 473 476, 1993.
 
43) Sardell AN, Trierweiler SJ: Disclosing the cancer diagnosis procedures that influence patient hopefulness. Cancer 72: 3355 3365, 1993.
 
44) Miyaji NT: The power of compassion: truth telling among American doctors in the care of dying patients. Soc. Sci. Med. 36: 249 264, 1993.
 
45) Kemp N, Skinner E, Toms J: Randomized clinical trials of cancer treatment a public opinion survey. Clin. Oncol. 10: 155 161, 1984.
 
46) Maslin A: Asurvey of the opinion on informed consent of women currently involved in clinical trials within a breast unit. Eur. J. Cancer Care 3: 153 162, 1994.
 
47) Mackillop WJ, Palmer MJ, O'Sullivan B, et al: Clinical trials in cancer: the role of surrogate patients in defining what constitutes an ethically acceptable clinical experiment. Br. J. Cancer 59: 388 395, 1989.
 
48) Penman DT, Holland JC, Bahna GF, et al: Informed consent for investigational chemotherapy: patients 'and physicians 'perceptions. J. Clin. Oncol. 2: 849 855, 1984.
 
49) 江口研二 兵頭一之介, 渡辺 亨・他: がん治療におけるインフォームドコンセントの在り方とそれに関連する諸問題の検討. 厚生省がん研究助成金による研究報告集平成5年度, 平成7年, pp. 456-460.
 
50) Turner SL, Maher EJ: Information and choice in decisions about cancer treatment. BMJ 309: 955, 1994.
PubMed
51) Zelen M: Anew design for randolnized clinical trials. N. Engl. J. Med. 300: 1242 1245, 1979.
 
52) Schafer A: The ethics of the randomized clinical trial. N. Engl. J. Med. 307: 719 724, 1982.
 
53) Ellemberg SS: Randomization designs in comparative clinical trials. N. Engl. J. Med. 310: 1404 1408, 1984.
 
54) Hellman S, Hellman DS: Of mice but not men；probelms of the randomized clinical trial. N. Engl. J. Med. 324: 1585 1589, 1991.
PubMed
55) Passamani E: Clinical trials are they ethical? N. Engl. J. Med. 324: 1589 1591, 1991.
 
56) 浜島信之: 癌患者を対象とした市販後薬剤の無作為化比較試験. J. Jpn. Soc. Cancer Ther. 27: 1701-1706, 1992.
 
57) Mackillop WJ, Ward GK, O'Sullivan B: The use of expert surrogates to evaluate clinical trials in non-small-cell lung cancer. Br. J. Cancer 54: 661 667, 1986.
 
58) Taylor KM, Feldstein ML, Skeel RT, et al: Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1737 Eastern Cooperative Oncology Group investigators. J. Clin. OncoL 12: 1796 1805, 1994.
 
59) Williams CJ, Zwitter M: Informed Consent in European Multicentre Randomized Clinical Trials Are Patients Really Informed? Eur. J. Cancer 30 A: 907 910, 1994.
 
60) Tobias JS, Houghton J: Is informed consent essential for all chemotherapy studies? Eur. J. Cacner 30 A: 897-899, 1994.
 
61) Tobias JS, Souhami RL: Fully informed consent can be needlessly cruel. BMJ 307: 1199 1201, 1993.
 
62) Rodenhuis S, van den Heuvel WJ, Annyas AA, et al: Patient motivation and informed consent in a phase I study of an anticancer agent. Eur. J Cancer Clin. Oncol. 20: 457 462, 1984.
 
63) Dobbs NA, Twelves CJ, Ramirez AJ, et al: Patient acceptability and practical implications of pharmacokinetic studies in patients with advanced cancer. Eur. J. Cancer 29 A: 1707 1711, 1993.
 
64) Kodish E, Stocking C, Ratain MJ, et al: Ethical issues in phase I oncology research: acomparison of investigators and institutional review board chairpersons. J. Clin. Oncol. 10: 1810 1816, 1992.
 
65) Itoh K, Sasaki Y, Miyata Y, et al: Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cacner Chemother. Pharmacol. 34: 451 454, 1994.
 
66) Ratain MJ, Mick R, Schilsky RL, et al: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J. Natl. Cancer Inst. 85: 1637 1643, 1993.
 
67) Itoh K, Sasaki Y, Fujii H, et al: Patients in phase I trials of anti cancer agents in Japan: motivation, comprehension and expectations. Br. J. Cancer 76: 107 113, 1997.
 
68) Dougherty C, Ratain MJ, Grochowski E, et al: Perceptions of cancer patients and their physicians involved in phase I trials. J CIin. Oncol. 13: 1062 1072, 1995.
 
69) Tomamichel M, Sessa C, Herzig S, et al: Informed consent for phase I studies: evaluation of quantity and quality of information provied to patients. Ann. Oncol. 6: 363 369, 1995.
 
70) Taylor KM, Kelner M: Informed consent: the physicians 'perspective. Soc. Sci. Med. 24: 135 143, 1987.
 
71) Simes RJ, Tattersall MHN, Coates AS, et al: Randomized comparison of procedures for obtaining informed consent in clinical trials of treatment of cancer. BMJ 293: 1065 1068, 1986.
 
72) Jensen AB, Madsen B, Andersen P, et al: Information for cancer patients entering a clinical trial an evaluation of an information strategy. Eur. J. Cancer 29 A: 2235 2238, 1993.
 
73) Cassileth BR, Zupkis RV, Sutton Smith K, et al: Informed consent Why are its goals imperfectly realized? N. Engl. J. Med. 302: 896-900, 1980.
PubMed
74) Grossman SA, Piantadosi S. Covahey C.: Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families? J. Clin. Oncol. 12: 2211-2215, 1994.
PubMed
75) Olver IN, Turrell SJ, Olszewski NA, et al: The impact of a full disclosure information and consent form on patients receiving standard cytotoxic chemothrapy. Proc. ASCO 13: 14-71, 1994.
 
76) Reynolds PM, Snson fisher RW, Poole AD, et al: Cancer and communication: information giving in an oncology clinic. BMJ 282: 1449-1451, 1981.
 
77) Tattersall MHN, Butow PN, Griffin AM, et al: The take home message: patients prefer consultation audiotapes to summary letters. J. Clin. Oncol. 12: 1305-1311, 1994.
 
78) Aaronson NK, Vissor Pol E, Leenhouts G, et al: Telephone based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials. J. Clin. Oncol. 14: 984-996, 1996.
 
79) 芳賀敏彦: がんの治療と研究. メヂカルヒューマニティ 3: 15-21, 1988.
 
80) 上田慶二: 治験におけるGCPの現状と問題点. GCPはどう変わるのか厚生省GCP説明会. ミクス, 東京, 1996, pp. 60-78.
 
P.766 掲載の参考文献
1) 久繁哲徳: 臨床経済的評価の枠組み, その2. 保険診療 50 (10) : 21-28, 1995.
 
2) 厚生省大臣官房統計情報部: 平成8年度国民医療費. 厚生省統計協会, 東京, 1996.
 
3) Brown ML: The national economic burden of cancer: an update. J. Natl. Cancer Inst. 82: 1811-1814, 1990.
PubMed
4) Bailar III JC, Gornik HL: Cancer undefeated. N. Engl. J. Med. 336: 1569-1574, 1997.
 
5) Sporn MB: The war on cancer. Lancet 347: 1377-1381, 1996.
PubMed
6) 久繁哲徳: 医療システムの転換と経済的評価. 保険診療 50 (2) : 21-26, 1995.
 
7) Evans RG: Strained mercy. Butterworth, 1984.
 
8) 久繁哲徳: 医療のテクノロジー・アセスメント. 病院 52: 10-13, 1993.
 
9) 久繁哲徳: ベッドサイドの医療評価学, 1: せめて害以上の良い医療を. Cardiologist 1: 47-52, 1996.
 
10) Drummond MF: Economics in cancer care. Eur. J. Cancer 31 A: 1387, 1995.
 
11) Kesteloot K: The economics of reimbursement and technological change in cancer care. Eur. J. Cancer 31 A: 1406-1409, 1995.
 
12) Williams C, Coyle D, Hutton GJ, et al: European school of oncology advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme", Cost effectiveness in cancer care. Eur. J. Cancer 31 A: 1410-1424, 1995.
 
13) 久繁哲徳: 臨床経済学のスタンス. 保険診療 50 (3) : 19-23, 1995.
 
14) Detsky AS: The economic foundation of national health policy. Ballinger Pub, Cambridge, 1978.
 
15) ドラモンドら (編著) : 久繁哲徳, 西村周三 (監訳) , 臨床経済学, 篠原出版, 東京, 1990.
 
16) 久繁哲徳: 臨床経済的評価の枠組み, その1. 保険診療 50 (9) : 21-26, 1995.
 
17) Gold MR, Siegel JE, Russell LB: Cost effectiveness in health and medicine. Oxford Univ Press, NY, 1996.
 
18) Goddard M, Drummond M: The economic evaluation of cancer treatments and programms. Eur. J. Cancer 27: 1191-1196, 1991.
 
19) 久繁哲徳: 医薬品の経済的評価. 月刊薬事 38: 2921-2929, 1996.
 
20) 久繁哲徳: 経済的効率のリーグ表. 保険診療 51 (5) : 57-61, 1996
 
21) Laupacis A, Feeney D, Detsky AS, et al: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. CMAJ 146: 473-481, 1992.
 
22) 久繁哲徳: 薬剤の経済的評価, 効果と効率から見た社会的利益. 医薬品研究 27: 215-234, 1996.
 
23) Scientific American: What you need to know about cancer. WH Freeman and Co, NY, 1996.
 
24) 久繁哲徳: 疾病予防対策の評価と実行に向けての合意形成, 成人病の二次予防と一次予防の効果をめぐって. 日本医事新報 3516: 48-52, 1991.
 
25) 久繁哲徳: 効果的・効率的医療の検討 (上・下) . 社会保険旬報 1751: 10-13, 1752: 16-21, 1992.
 
26) US Preventive Services Task Force: Guide to Clinical Preventive Services. William & Wilkins, 2 nd ed, New York, 1996.
 
27) Kerlikowske K, Grady D, Rubin SM, et al: Efficacy of screening mammography, a meta analysis. JAMA 273: 149-154, 1995.
PubMed
28) Brown ML, Fintor L: Cost effectiveness of breast cancer screening, preliminary results of a systematic review of the literature. Br. Cancer Res. Treat. 25: 113-118, 1993.
 
29) Byers T, Gorsky R: Estimates of costs and effects of screening for colorectal cancer in the United States. Cancer 70 (5 Supp1.) : 1288-1295, 1992.
 
30) Eddy DM: Screening for colorectal cancer. Ann. Intern. Med. 113: 373 384, 1990.
 
31) Wagner JL, Herdman RC, Wadhwa S: Cost effectiveness of colorectal cancer screening in the elderly. Ann. Intern. Med. 115: 807-817, 1991.
PubMed
32) Austoker J: Cancer prevention in primary care. BMJ pub, London, 1995.
 
33) The Smoking Cessation Clinical Practice Guideline Panel and Staff: The Agency for Health Care Policy and Research smoking cessation clinical practice guideline. JAMA 275: 1270-1280, 1996.
PubMed
34) Silagy C, Mant D, Fowler G, et al: Meta analysis on efficacy of nicotine replacement therapies in somoking cessation. Lancet 343: 139-142, 1994.
PubMed
35) Warner KE: Cost effectiveness of smoking cessation therapies. Pharmacoeconomics 11: 538-549, 1997
PubMed
36) Casicato DA, Lowitz BB (eds) : Manual of clinical oncology, 3rd ed, Lippincott Raven, Philadelphia, 1995.
 
37) Berger DH, Feig BW, Fuhrman GM: The M. D. Anderson surgical oncology handbook, Little Brown, NY, 1995.
 
38) Smith TJ, Hillner BE, Desh CE: Efficacy and cost effectiveness of cancer treatment. Rational allocation of resources based on decision analysis. J. Natl. Caner Inst. 85: 1460-1474, 1993.
 
39) Coates A, Abraham S, Kay S, et al: On the receiving end patient perception of the side effects of cancer chemotherapy. Eur. J. Cancer Oncol. 19: 203 208, 1983.
 
40) 久繁哲徳, 片山貴文, 小池道子・他: 生活の質に基づく乳癌治療法選択の判断分析. 乳癌の臨床 12: 3-12, 1997.
Medical*Online
41) 久繁哲徳: 早期乳癌治療のテクノロジー・アセスメント, わが国における医療テクノロジー・アセスメントの適用に関する研究. 平成8年度厚生科学研究報告書, 1997.
 
42) Verhoef LCG, Stalpers LJA, Verbeek ALM, et al: Breast conserving treatment or mastectomy in early breastcancer. Eur. J. Cancer 9: 1132-1137, 1991.
 
43) Bryson HM, Plosker GL: Tamoxifen. Pharmacoeconomics 4: 40-66, 1993.
PubMed
44) Missori A, Becagli P, Trippoli S, et al: Cost effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate-fluorouracil in patients with node positive breast cancer. Eur. J. Clin. Pharmacol. 51: 111-116, 1996.
 
45) Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node negative breast cancer. N. Engl. J. Med. 324: 160-168, 1991.
PubMed
46) Dillman RO, Seagan SL, Herndon J, et al: Randomized trial of induction chemotherapy plus radiation therapyvs RT alone in stage III non-small-cell lung cancer. Proc. ASCO 12: 329, 1993.
 
47) Souquet PJ, Chauvin F, Boissel Jp, et al: Meta analysis of randomized trials of systematic chemotherapy versussupportive treatment in non-small-cell lung cancer. Lung Cancer 12 (Suppl. 1) : s147-s157, 1995.
 
48) Jaakkimainen L, Goodwin PJ, Pater J, et al: Counting the costs of chemotherapy in a National Cancer lnstituteof Canada randomized controlled trial in nonsmall cell lung cancer. J. Clin. Oncol. 8: 1301-1309, 1990.
 
49) Smith TJ, Hillner BE, Neighbors DM, et al: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J. Clin. Oncol. 13: 2166-2173, 1995.
PubMed
50) 大野竜三: 白血病の診断, 治療. 第2版, 中外医学社, 東京, 1994.
 
51) Burt RK, Deeg HJ, Lothian ST, et al: On call in, bone marrow transplantation. Chapman Hill, NY, 1996.
 
52) 長尾 大: わが国における造血幹細胞移植の全国集計 (1993) . 今日の移植 7: 93-101, 1994.
 
53) United States General Accounting Office: Bone marrow transplantation, International comparisons of availability and appropriateness of use, 1994.
 
54) Welch HG, Larson EB: Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N. Engl. J. Med. 321: 807-812, 1989.
PubMed
55) 久繁哲徳: 急性白血病に対する骨髄移植の経済的評価. 平成7年度厚生科学研究, 臓器技術臨床研究開発事業研究報告書, 1995.
 
56) Plosker GL, Milne RJ: Ondansetron, a pharmacoeconomic and quality of life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Pharmacoeconomics 2: 285-304, 1992.
PubMed
57) Cox F, Hirsh J: Ondansetron: Acost effective advance in anti emetic therapy. Oncology 50: 186-190, 1993.
 
58) 久繁哲徳, 片山貴文, 三笠洋明: 抗悪性腫瘍剤に起因する嘔吐のTropisetron (5-HT3受容体拮抗剤) による予防に関する経済的評価. 薬理と治療 25: 2203-2212, 1997.
Medical*Online
P.773 掲載の参考文献
1) Kiuchi T, Ohashi Y, Konishi M, et al: AWorld Wide Web based user interface for use in multi institutional clinical trials development and experimental operation of an automated patient registration and random allocation system. Control. Clin. Trials 17: 476 493, 1996.
 
2) 開原成允: 総括班報告書. 遠隔医療に関する研究. 平成8年度厚生省情報技術開発研究事業研究成果報告書. 1996, pp. 1-23.
 
3) 山口直人: 診療支援システム. 遠隔医療に関する研究. 平成8年度厚生省情報技術開発研究事業研究成果報告書. 1996, pp. 85-162.
 
4) Tanaka H, Hiyama T, Hanai A, et al: Interhospital differences in cancer survival: magnitude and trend in 1975, 1987 in Osaka, Japan. Jpn. J. Cancer Res. 85: 680-685, 1994.
PubMed
P.788 掲載の参考文献
1) 光石忠敬訳: 「被験者に対する生物医学研究についての国際的倫理指針」. 臨床評価 22: 261-297, 1994.
 
2) 臨床試験とバイオエシックス (津谷喜一郎司会による坂上正道, 長澤俊彦, 光石忠敬の座談会) . からだの科学196号, 1997 年9 月.
 
3) Approval of New Drugs in the United States-Comparison Wite the United Kingdom, Germany, and Japan. JAMA, december 11, 1996-Vol. 276. No. 22 (田中正彦訳, 津谷喜一郎解説, JAMA日本語版 1997年8 月号) .
 
4) 光石忠敬: 「臨床試験」に対する法と倫理. 「臨床試験-医薬品の適正評価と適正使用のために-」 (内藤周幸編) , 薬事日報社, 1996年9月.
 
5) 光石忠敬: 臨床研究におけるインフォームド・コンセントの基本問題. 呼吸と循環 45 (11) : 1997.
 
6) P. Lurie ＆ S. M. Wolfe: Unethical Trials of Intervention to reduce Perinatal Transmission of the HIV in Developing Countries. N. Engl. J. Med. 337 (12) : 853-855, 1997.
 
P.808 掲載の参考文献
1) ICH E 9 Step 2 guideline: Statistical principles for clinical tricals. 1997. (日本語訳, 原文: 薬理と治療 25 (supple. 4) : S 879-916 (訳) , S 917-962 (原文) , 1997.
 
2) Senn S: Statistical issues in drug development, Willey, 1997.
 
3) Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic research-principle and quantitative methods. Van Norstrand Reinhold Company, NY, 1982.
 
4) Celsus AG, De Medicina (Spencer WG, 1935-1938 (translator) , W. Heineman, London and Havard University Press, Cambridge.)
 
5) Bernard C: Introduction a letude de la medicine experimentale. Paris, 1865. (日本語訳: 実験医学序説. クロード・ベルナール (三浦岱栄訳) , 東京創元社, 1961.)
 
6) Cushing H: The life of Sir William Osler, Vols 1 and 2, 0xford University Press, London, 1940.
 
7) ニュールンベルグ綱領, 1947. (原典: United States v. Karl Brandt, Trials of war criminals befor the Nuremberg military tribunals under council law No. 10 vols 1 and 2, "The Medical Case" (Medical Tribunal 1, 1947: Washington, D. C., U. S. government printing office, 1948-49) : Katz J, Experimentation with human being, 292- 306, New York, Russell Sage Foundation, 1972. および Alexander L, Medical science under dictatorship, N. Engl. J. Med. 241: 39-47, 1949. を参照)
 
8) Faden RR, Beauchamp TL: A history and theory of informed consent. Oxford University Press, NY, 1986. (日本語訳: 酒井忠昭, 秦浄一訳: インフォームド・コンセント 患者の選択. みすず書房, 1994.)
 
9) The world medical association, INC.: Declaration of Helsinki: Recommendations guiding physisans in biomedical research involving human subjects (Helsinki 1964, Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West 1996) . (原文, 日本語訳: 日本製薬工業協会医薬品評価委員会 (編集) : 新GCP関連資料集. (株) ミクス, 1997, pp. 491-501.)
 
10) 下山正徳: インフォームド・コンセント-歴史的展開と最近の動向. 臨床科学 33: 389-397, 1997.
 
11) 厚生省薬務局長通知: 医薬品の臨床試験の実施に関する基準 (GCP) について. 厚生省薬発第874号, 平成元年10月2日. (GCPとそのマニュアルおよびGCP関係通知, 関連事項などについては「GCPハンドブック: 医薬品の臨床試 験の実施に関する基準, 厚生省薬務局審査第一課監修, 産業時報社, 1990」, および「GCPの理解のために-厚生省説明会講演内容を中心として-. (株) ミクス, 1990. 」 などに一括されているほか, 臨床評価 17: 323-332, 1989; 同 18: 159-168, 1990; 同 18: 169-194, 1990. にも掲載されている.
 
12) Shimoyama M, Fukuda K, Saijo N, et al: Japan Clinical Oncology Group (JCOG) . Jpn. J. Clin. Oncol. 28 (3) : 158-162, 1998.
 
13) 下山正徳, 江口研二 , 恒松隆一郎・他: 厚生省がん研究助成金指定研究「固形がんの集学的治療の研究」班における臨床試験計画 (プロトコール) の作成と実施, 並びに結果の統計解析と評価について (改訂第3版) . 第II部がん臨床試験のインフォームド・コンセントの指針. 癌の臨床 42: 441-454, 1996.
 
14) 厚生省健康政策局総務課監修: 元気の出るインフォームド・コンセント (柳田邦男編集) , 中央法規, 東京, 1996. (柳田邦男 (座長) ほかによる厚生省「インフォームド・コンセントの在り方に関する検討会」: インフォームド・コンセントの在り方に関する報告書. 厚生福祉(第4375号) : 10-15, 1995.)
 
15) ICH E 6: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline. GUIDELINE FOR GOOD CLINICAL PRACTICE. Recommended for Adoption at Step 4 of the ICH Process on 1 May 1996 by the ICH Steering Committee, 1996.
 
16) 下山正徳, 大橋靖雄, 西條長宏・他, 厚生省厚生科学研究費による「抗悪性腫瘍薬の第I相試験に関するガイドライン適正化研究」班: 抗悪性腫瘍薬の第I相試験のガイドライン. 薬理と治療 26 (4) : 441-454, 1998.
Medical*Online
17) 江口研二編: がん治療・臨床試験のインフォームド・コンセント. 南江堂, 東京, 1997.
 
18) Federal Register, part 56. Institutional Review Boards, Vol 46, No. 17, January 27, 1981, pp. 8975-8980.
 
19) Human subjects research: A handbook for institutional review boards (ed by Greenwald RA, Ryam MK, Celvihill JE) , Plenum Press, NY, 1982. (日本語訳: 阿岸鉄三, 今里嘉夫, 土肥修司 (訳) : 被験者保護ハンドブック-アメリカIRB の活動-. 地人書館, 東京, 1987.
 
20) ICH E 2 a: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline. CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING. Recommended for Adoption at Step 4 of the ICH Process on 27 October 1994 by the ICH Steering Committee, 1994.
 
21) 下山正徳, 田島絹子, 大橋靖雄: がん臨床試験の統計センターシステムの開発研究 I. 統計センターシステムの開発. 癌の臨床 43: 87-116, 1997.
 
22) South West Oncology Group (SWOG) , Statistical center, Fred Hutchinson Cancer Research Center, Washington, March 1997.
 
23) 日本製薬工業協会医薬品評価委員会 (西岡正基・他) : 米国における治験実施の実状と今後の日本への提言-モニタリングおよびデータマネジメント米国調査団における調査結果を踏まえて-. 臨床医薬 13: 3337-3357, 1997.
Medical*Online
24) Gabor A: The man who discovered quality. How W. E. Deming brought the quality revolution to America-The stories of Ford, Xerox, and GM. Random House Inc, New York, 1990. (日本語訳: 鈴木主税訳: デミングで甦ったアメリカ企業. 草思社, 東京, 1994.)
 
25) 広井良典: 医療保険改革の構想, 日本経済新聞社, 東京, 1997.
 
15a) 日本版新 GCP: 医薬品の臨床試験の実施に関する基準に関する省令 (厚生省令第28号) , 官報 (号外第58号) pp. 6-12 (平成9年3月27日) . (この取扱いは平成9年3月27日薬発第 430 号薬務局長通知「医薬品の臨床試験の実施 の基準に関する省令の施行について」に示されている. また平成9年3月13日付で「医薬品の臨床試験の実施の基準 (GCP) の内容」として, 中央薬事審議会答申 (中薬審第40号) がまとめられている. さらに, 平成9年5月29日薬 審第445号薬務局審査課長通知/薬安第68号薬務局安全課長通知として「医薬品の臨床試験の実施の基準の運用について」が出されている. これには省令の条文ごとに薬務局長通知や答申の内容が整理されている.)
 
20a) 日本公定書協会編: 治験中に得られる安全性情報の取扱いについて. (厚生省薬務局審査課長通知, 薬審第227号, 平成7年3月20日. 原文をもとに意訳してあるが, 削除されている部分がある) . 新薬臨床評価ガイドライン, 薬事 日報社, 東京, 1995, pp. 439-451.
 
20b) 島田安博, 下山正徳, 田村友秀・他, 厚生省がん研究助成金指定研究「固形がんの集学的治療の研究」班 (8S-1) の効果・安全性評価委員会: Japan Clinical Oncology Group (JCOG) の臨床安全性情報取扱いガイドライン. 薬理 と治療 26: 263-274, 1998.
 
P.825 掲載の参考文献
1) Urtasun RC: Does improved depth dose characteristics and treatment plannning correlate with a gain in therapeutic results. Int. J. Radiat. Oncol. Biol Phys. 22: 235-239, 1991.
 
2) Suit HD, Westgate SJ: Impact of improved local control on survival. Int. J. Radiat. Oncol. Biol. Phys. 12: 453-458, 1986.
PubMed
3) Leibel SA, Ling CC, Kutcher GJ, et al: The biological basis for conformal three dimentional radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 21: 805-811, 1991.
 
4) Conquest of Cancer, Report of the National Panel of Consultants of the Committee on Labor and Public Welfare United States Senate, November 1970, p. 51.
 
5) 辻井博彦: 線量集中照射法の可能性について. 癌の臨床 43: 215-220, 1997.
Medical*Online
6) Larsson B: The new radiations in cancer therapy. Hadrontherapy in Oncology (Eds. by Amaldi U and Larsson B) . Elsevier Science B. V., Amsterdam, 1994, pp. 33-44.
 
7) Amaldi U: The Italian Hadrontherapy Project (Eds. by Amaldi U and Larsson B) . Elsevier Science B. V., Amsterdam, 1994, pp. 45-58.
 
8) Chen GTY, Castro JR, Quivey JM: Heavy charged particle radiotherapy. Ann. Rev. Biophys. Bioeng. 10: 499-529, 1981.
 
9) Castro JR, Chen GTY, Blakely EA: Current consideration in charged-particle radiotherapy. Rad. Rev. 104: S263-S271, 1985.
 
10) Withers HR, Taylor JM, Maciejewski B: Treatment volume and tissue tolerance. Int. J. Radiat. Oncol. Biol. Phys. 14: 751-759, 1988.
PubMed
11) Leith JT: Heavy-ion radiobiology: Normal tissue studies. Adv. Radiol. Biol. 10: 191-236, 1983.
 
12) Petti PL, Lennox AJ: Hadronic radiotherapy. Ann. Rev. Nucl. Part, Sci. 44: 155-197, 1994.
 
13) Raju MR: Heavy Particle Radiotherapy. Academic Press, New York, 1980.
 
14) Hall E: New radiation modalities. Radiobiology for the Radiologist (Ed. Hall EJ) . 4th ed. J. B. Lippincott Co., Philadelphia, 1994, pp. 231-244.
 
15) Suit HD, Goitein, M: Rationale for use of carged-particle and fast neutron beams in radiation therapy. Radiation Biology in Cancer Res (ed. by Meyn RE) . Raven Press, New York, 1980, pp. 547-565.
 
16) Chapman JD, Blakely EA, Smith KC, et al: Radiobiological characterization of the inactivating events produced in mammalian cells by helium and heavy ions. Int. J. Radiat. Oncol. Biol. Phys. 3: 97-102, 1977.
PubMed
17) Field SB, Hornsey S, Kutsutani Y: Effects of fractionated irradiation on mouse lung and a phenomenon of slow repair. Br. J. Rad. 49: 700-707, 1976.
 
18) Wambersie A: Is there any future for high-LET radiation? Strahlenther. Onkol. 165: 348-356, 1989.
PubMed
19) Griffin TW: Fast neutron radiation therapy. Critical Reviews in Oncology/Hematology. 13: 17-31, 1992.
PubMed
20) Castro JR: Future research strategy for heavy ion radiotherapy. Progress in Radio-Oncology (ed. by Kogelnik HD) , Monduzzi Editore, Italy, 1995, pp. 643-648.
 
21) Linstadt DE, Castro JR, Philips TL, et al: Neon ion radiotherapy: results of the phase I/II clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 20: 761-769, 1991.
 
22) Tobias JS: Clinical practice of radiotherapy. Lancet 339: 159-163, 1992.
PubMed
23) Alamdi U, Arduini G, Cambria R, et al: A hospital-based hadrontherapy facility in Italy. Hadrontherapy in Oncology (eds. by Amaldi U, Larsson B) , Elsevier Sciences B. V., Netherlands, 1994, pp. 329-339.
 
24) Bryant Ph, Kogelnik HD, Pavlovic M, et al: Ion cancer therapy research as part of the AUSTRON project. Hadrontherapy in Oncology (eds. by Amaldi U, Larsson B) , Elsevier Sciences B. V., Netherlands, 1994, pp. 390-399.
 
25) Slater JM, Miller DW, Archanbeau JO, et al: Development of a hospital-based proton beam treatment center. Int. J. Radiat. Oncol. Biol. Phys. 14: 761-775, 1988.
 
26) Goitein M: Application of computed tomography in radiotherapy treatment planning. Progress in Medical Radiation Physics (ed. by Orton CG) , Plenum Pub. Co., New Yark 1982, pp. 195-293.
 
27) Endo M, Koyama-Ito H, Minohara S, et al: HIPLAN-A heavy ion treatment planning system at HIMAC. J. Jpn. Soc. Ther. Radiol. Oncol. 8: 231-238, 1996.
 
28) Boone ML, Lawrence JH, Connor WG, et al: Introduction to the use of protons and heavy ions in radiation therapy: Historical Perspective. Int. J. Radiat. Oncol. Biol. Phys. 3: 65-69, 1977.
 
29) Osaka Y, Kamada T, Matsuoka Y, et al: Clinical experience of heavy ion irradiation synchronous with respiration. Proc. of XII ICCR. 176-177, 1997.
 
30) Wilson RR: Radiological use of fast protons. Radiology 47: 487-491, 1946.
PubMed
31) Suit HD, Urie M: Proton beams in radiation therapy. JNCI 84: 155-159, 1992.
 
32) Peters LJ, Fischer JJ, Fuks Z, et al: Proton beam therapy: rationale, current status, future prospects and economic implications. A report of the NCAB by a select panel appointed by the Board of Scientific Counsellors, Division of Cancer Treatment, 1992.
 
33) Linstadt D, Castro JR, Char D, et al: Long-term results of helium ion irradiation of uveal melanoma. Int. J. Radiat. Oncol. Biol. Phys. 19: 613-618, 1990.
 
34) Tsujii H, Tsuji H, Inada T, et al: Clinical results of fractionated proton therapy at Tsukuba. Int. J. Radiat. Oncol. Biol. Phys. 25: 49-60, 1993.
PubMed
35) Tsujii H, Morita S, Miyamoto T, et al: The current status and perspective of heavy-ion therapy. International Meetiong on Progress in Radio-Oncology VI. Ed. Kogelnik HD, and Sedlmayer F, Monduzzi Editore, Milano, pp. 709-721, 1998.
 
36) Tsujii H, Morita S, Miyamoto T, et al: Preliminary results of Phase I/II carbon-ion therapy. J. Brachytherapy Int. 13: 1-8, 1997.
 
37) Lillis-Hearne PK, Castro JR: Indications for heavy-ions-Lesson from Berkeley. Ion Beams in Tumor Therapy (ed. Linz U) , Chapman ＆ Hall, London, 1995, pp. 133-141.
 
P.830 掲載の参考文献
1) Bachor R, Reich E, Ruck A, et al: Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells. Urol. Res. 24: 285-289, 1996.
PubMed
2) Chang SC, MacRobert AJ, Bown SG: Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: light diffusion and histological changes. J. Urol. 155: 1749-1753, 1996.
PubMed
3) Kriegmair M, Baurngartner R, Lumper W, et al: Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br. J. Urol. 77: 667-671, 1996.
 
4) Barr H, Shepherd NA, Dix A, et al: Eradication of high-grade dysplasia in columner-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348: 584-585, 1996.
 
5) Ruck A, Beck G, Bachor R, et al: Dynamic fluorescence changes during photodynamic therapy in vivo and in vitro of hydrophilic A1 (III) phthalocyanine tetrasulphonate and lipophilic Zn (II) phthalocyanine administered in liposomes. J. Photochem. Photobiol. B 36: 127-133, 1996.
PubMed
6) Iliaki OE, Naoumidi II, Tsilimbaris MK, et al: Photothorombosis of retinal and choroidal vessels in rabbit eyes using chloroaluminum sulfonated phthalocyanine and a diode laser. Lasers Surg. Med. 19: 311-323, 1996.
 
7) Katsumi T, Aizawa K, Kuroiwa Y, et al: Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspertyl chlorin e 6. Photochem. Photobiol. 64: 671-675, 1996.
 
8) Schmidt-Erfurth U, Flotte TJ, Gragoudas ES, et al: Benzoporphyrin-lipoprotein-mediated photodestruction of intraocular tumors. Exp. Eye Res. 62: 1-10, 1996.
PubMed
9) Husain D, Miller JW, Michaud N, et al: Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch. Ophthalmol. 114: 978-985, 1996.
PubMed
10) Steiner RA, Tadir Y, Tromberg B, et al: Benzoporphyrin derivative mono acid for photodynamic therapy of the endometrium. Geburtshilfe Frauenheilkd. 56: 1-7, 1996.
PubMed
11) Wierrani F, Fiedler D, Schnitzhofer G, et al: A new approach to cancer therapy due to appropriate uptake and retention kinetics of meta-tetrahydroxy-phenylchlorin in a human fibroblast cell line. Cancer Biochem. Biophys. 15: 171-176, 1996.
 
12) Chang SC, Buonaccorci G, MacRobert A, et al: Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Int. J. Cancer 67: 555-562, 1996.
 
13) Pandy RK, Sumlin AB, Constantine S, et al: Alkyl ether analogs of chlorophyll-a derivatives: Part 1. Synthesis, photophysical properties and photodynamic efficacy. Photochem. Photobiol. 64: 194-204, 1996.
 
14) Payne JT, McCaw DL, Casteel SW, et al: Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog. Lasers Surg. Med. 18: 406-409, 1996.
PubMed
15) Estey EP, Brown K, Diwu Z, et al: Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study. Cancer Chemother. Pharmacol. 37: 343-350, 1996.
PubMed
16) Divu ZJ, Haugland RP, Liu J, et al: Photosensitization by anticancer agents 21: new perylene-and aminona-phthoquinones. Free Radic. Biol. Med. 20: 589-593, 1996.
 
17) Koren H, Schenk GM, Jindra RH, et al: Hypericin in phototherapy. J. Photochem. Photobiol. B 36: 113-119, 1996.
PubMed
18) Vandenbogaerde AL, Geboes KR, Cuveele JF, et al: Antitumor activity of photosensitized hypericin on A 431 cell xenografts. Anticancer Res. 16: 1619-1625, 1996.
 
19) Finger VH, Siegel KA, Wieman TJ, et al: The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy. Photochem. Photobiol. 58: 393-399, 1993.
 
20) Webber J, Luo Y, Crilly R, et al: An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo. J. Photochem. Photobiol. B 35: 209-211, 1996.
PubMed
21) Agarwal R, Korman NJ, Mohan RR, et al: Apoptosis is an early event during phthalocyanine photodynamic therapy-induced ablation of chemically induced squamous papillomas in mouse skin. Photochem. Photobiol. 63: 547-552, 1996.
PubMed
22) Luo Y, Chang CK, Kessel D: Rapid initiation of apoptosis by photodynamic therapy. Photochem. Photobiol. 63: 528-534, 1996.
PubMed
23) Zhou C, Shunji C, Jinsheng D, et al: Apoptosis of mouse MS-2 fibrosarcoma cells induced by photodynamic therapy with Zn (II) -phthalocyanine. J. Photochem. Photobiol. B 33: 219-223, 1996.
PubMed
24) Kessel D: Porphyrin-lipoprotein association as a factor on porphyrin localization. Cancer Lett. 33: 183-188, 1986.
PubMed
25) 中島進, 坂田功, 竹村健: ポルフィリン誘導体の腫瘍組織集積性のメカニズムとがん診断, 治療への応用. ポルフィリン・ヘムの生命科学, 東京化学同人, 東京, 1994, pp. 209-216.
 
26) Irie K, Nakamura Y, Ohigashi H, et al: Photocytotoxicity of water-soluble fullerene derivatives. Biosci. Biotechnol. Biochem. 60: 1359-1361, 1996.
PubMed
27) Orenstein A, Kostenich G, Roitman L, et al: A comparative study of tissue distribution and photodynamic therapy selectivity of chlorine 6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Br. J. Cancer 73: 937-944, 1996.
 
28) Ma LW, Berg K, Danielson HE, et al: Enhanced antitumor effect of photodynamic therapy by microtubule. Cancer Lett. 109: 129-139, 1996.
 
29) Gantchev TG, Brasseur N, van Lier JE: Combination toxicity of etoposide (VP-16) and photosensitisation with a water-soluble aluminum phthalocyanine in K 562 human leukaemic cells. Br. J. Cancer 74: 1570-1577, 1996.
 
30) Peterson CM, Lu JM, Sun Y, et al: Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56: 3980-3985, 1996.
 
31) 熊坂英雄, Ilyar X, 荒明美奈子・ほか: アドリアマイシン耐性株に対し, ME 2906を用いたPDT効果. 第7回国際光化学治療学会日本支部例会, 1997.
 
32) Baas P, van Geel IP, Oppelaar H, et al: Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Br. J. Cancer 73: 945-951, 1996.
PubMed
33) Krosl G, Korbelik M, Krosl J, et al: Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res. 56: 3281-3286, 1996.
PubMed
34) 金子貞男, 松本亮二, 小濱好彦: 悪性腫瘍患者に対する光線力学療法の治療成績. 第15回日本レーザー医学会大会, 45-48, 1994.
 
35) Konaka C, Okunaka T, Kato H: Combined use of photodynamic therapy and surgery. Ann. Thora. Cardiovasc. Surg. 1 (1) : 55-59, 1995.
 
36) Gomer CJ, Ryter SW, Ferrario A, et al: Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res. 56: 2355-2360, 1996.
PubMed
37) Kick G, Messer G, Plewig G, et al: Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. Br. J. Cancer 74: 30-36, 1996.
 
38) Tao J, Sangehera JS, Pelech SL, et al: Stimulation of stress-activated protein kinase and p 38 H G 1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative. J. Biol. Chem. 271: 27107-27115, 1996.
 
39) Chan WS, Brasseur N, La Madeleine C, et al: Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated alminum phthalocyanine or photofrin: tumor cell survival and blood flow. Anticancer Res. 16: 1887-1892, 1996.
PubMed
40) Korbelik M, Krosl G, Krosl J, et al: The role of host lymphoid populations in the response of mouse EMT 6 tumor to photodynamic therapy. Cancer Res. 56: 5647-5652, 1996.
 
41) Konaka C, Okunaka T, Furukawa K, et al: Photodynamic therapy for maltiple primary lung cancer. Jpn. J. Cancer Chem. 23: 31-35, 1996.
 
42) Shimao H, Hiki Y: Photodynamic therapy for esophageal cancer. Jpn. J. Cancer Chem. 23: 36-40, 1996.
 
43) Mimura S, Ito Y, Nagayo T, et al: Cooperative clinical trial of photodynamic therapy with Photofrin II and excimer dye laser for early gastric cancer. Lasers Surg. Med. 19: 168-172, 1996.
 
44) Muroya T, Suehiro Y, Umayahara K, et al: Photodynamic therapy (PDT) for early cervical cancer. Jpn. J. Cancer Chem. 23: 47-56, 1996.
 
45) Molpus KL, Kato D, Hamblin MR, et al: Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res. 56: 1075-1082, 1996.
 
46) Kessel D, Jeffers R, Fowlkes JB, et al: Effects of sonodynamic and photodynamic treatment on cellular thiol levels. J. Photochem. Photobiol. B 32: 103-106, 1996.
 
47) Ward T, Rollan A, Flynn G, et al: The effects of electric fields on photosensitized erythrocytes: possible enhancement of photodynamic activation. Cancer Lett. 106: 69-74, 1996.
PubMed
P.836 掲載の参考文献
56) Sindelar WF, Tepper JE, Kinsella TJ, et al: Late effects of intraoperative radiation therapy on retroperitoneal tissues, intestine, and bile duct in a large animal model. Int. J. Radiat. Oncol. Biol. Phys. 29: 781-788, 1994.
 
P.838 掲載の参考文献
1) Beck C: On external roentgen treatment of internal structures (eventration treatment) . NY Med. J. 89: 621-622, 1990.
 
2) Abe M, Takahashi M: Intraoperative radiotherapy: The Japanese experience. Int. J. Radiat. Oncol. Biol. Phys. 7: 863-868, 1981.
PubMed
3) 高橋正治, 芝本雄太, 阿部光幸: 術中照射. がん放射線治療マニュアル (柄川順編) . 中外医学社, 東京, 1989, pp. 386- 399.
 
4) 坂本澄彦: 術中照射の放射線生物学的考察. 最新醫學 41: 1468-1472, 1986.
Medical*Online
5) Abe M, Takahashi M, Yabumoto E, et al: Clinical experiences with intraoperative radiotherapy of locally advanced cancers. Cancer 45: 40-48, 1980.
PubMed
6) Shipley WU, Kaufman SD, Prout GR: Intraoperative radiation therapy in patients with bladder cancer. A review of techniques allowing improved tumor doses and providing high cure rates without loss of bladder function. Cancer 60: 1485-1488, 1987.
PubMed
7) Abe M, Takahashi M, Yabumoto E, et al: Techniques, indications and results of intraoperative radiotherapy of advanced cancers. Radiology 116: 693-702, 1975.
PubMed
8) 秦 一雄, 三好真琴, 上原 智・他: 従来の放射線機器を用いた新しい放射線療法: 術中照射. 癌と化学療法 14: 1564-1569, 1987.
 
9) 尾崎秀雄, 木下 平, 小菅智男・他: 切除可能膵癌における集学的治療の成績. 代謝 27: 339-344, 1990.
 
10) Hiraoka T, Uchino R, Kanemitsu K, et al: Combination of intraoperative radiation with resection of cancer of the pancreas. Int. J. Pancreatol 7: 201-207, 1990.
PubMed
11) Sindelar WF: Intraoperative radiotherapy in carcinoma of the stomach and pancreas. Recent Results Cancer Res. 110: 226-243, 1988.
PubMed
12) 田中良明, 松田忠義, 竹下祥敬・他: 膵癌の術中照射治療成績-術後原体照射を組み合わせた治療法の検討-. J. Jpn. Soc. Cancer Ther. 22: 573-581, 1987.
 
13) 若杉英之, 瀬尾洋介, 秦 一雄・他: 切除不能膵癌の放射線療法. 胆と膵 11: 933-939, 1990.
 
14) 秦 一雄, 和田 進, 宮崎麻知子・他: 膵癌-非切除進行癌に対する治療: 術中照射. 肝胆膵 25: 795-799, 1992.
 
15) Kawamura M, Kataoka M, Fujii T, et al: Electron beam intraoperative radiation therapy (EBIORT) for localized pancreatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 23: 751-757, 1992.
PubMed
16) Roldan GE, Gunderson LL, Nagorney DM, et al: External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61: 1110-1116, 1988.
PubMed
17) Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil) , and high dose radiation+5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 48: 1705-1710, 1981.
 
18) Whittington R, Neuberg D, Tester WJ, et al: Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 13: 227-232, 1995.
 
19) Luderhoff EC, Gonzalez GD, Bakker P: Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil. Radiother. Oncol. 40: 241-243, 1996.
 
20) Ishii H, Okada S, Tokuuye K, et al: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79: 1516-1520, 1997.
PubMed
21) Mohiuddin M, Regine WF, Stevens J, et al: Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J. Clin. Oncol. 13: 2764-2768, 1995.
PubMed
22) 河村 正, 片岡正明, 高嶋成光・他: 膵がんにおける術中照射の検討. 日医放会誌 51: 1442-1453, 1991.
 
23) 竜 崇正, 小西 大, 古瀬純司・他: 膵胆道がんに対する集学的治療. 臨床医 21: 64-68, 1995.
 
24) Shipley WU, Wood WC, Tepper JE, et al: Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann. Surg. 200: 289-296, 1984.
PubMed
25) Buskirk SJ, Gunderson LL, Adson MA, et al: Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 10: 2013-2023, 1984.
PubMed
26) Molt P, Hopfan S, Watson RC, et al: Intraluminal radiatin therapy in the management of malignant biliary obstruction. Cancer 57: 536-544, 1986.
 
27) 竜 崇正, 佐藤滋宏, 渡辺一男・他: 進行胆道癌に対するremote after loading system (RALS) を用いた胆管腔内照射法の検討. 胆道 2: 127-137, 1988.
Medical*Online
28) Houry S, Schlienger M, Huguier M, et al: Gallbladder carcinoma: role of radiation therapy. Br. J. Surg. 76: 448-450, 1989.
PubMed
29) Flicknger JC, Epstein AH, Iwatsuki S, et al: Radiation Therapy for primary carcinoma of the extrahepatic biliary system. An Analysis of 63 Cases. Cancer 68: 289-294, 1991.
 
30) Iwasaki Y, Todoroki T, Fukao K, et al: The role of intraoperative radiation therapy in the treatment of bile duct cancer. World J. Surg. 12: 91-98, 1988.
PubMed
31) Todoroki T, Iwasaki Y, Orii K, et al: Resection combined with intraoperative radiation therapy (IORT) for stage IV (TNM) gallbladder carcinoma. World J. Surg. 15: 357-366, 1991.
PubMed
32) 轟 健, 川本 徹, 小池直人: 胆道癌-切除例に対する治療: 放射線療法. 術中照射. 肝胆膵 25: 763-773, 1992.
 
33) Busse PM, Stone MD, Sheldon TA, et al: Intraoperative radiation therapy for biliary tract carcinoma: results of a 5-year experience. Surgery 105: 724-733, 1989.
PubMed
34) Busse PM, Cady B, Bothe A Jr, et al: Intraoperative radiation therapy for carcinoma of the gallbladder. World J. Surg. 15: 352-356, 1991.
PubMed
35) Abe M, Takahashi M, Ono K, et al: Japan gastric trials in intraoperative radiation therapy. Int. J. Radiat. Oncol Biol. Phys. 15: 1431-1433, 1988.
PubMed
36) Sindelar WF, Kinsella TJ, Tepper JE, et al: Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am. J. Surg. 165: 178-186, 1993.
PubMed
37) Avizonis VN, Buzydlowski J, Lanciano R, et al: Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: a phase II study from Radiation Therapy Oncology Group 85-04. Ann. Surg. Oncol. 2: 295-302, 1995.
PubMed
38) Suzuki K, Gunderson LL, Devine RM, et al: Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer 75: 939-952, 1995.
PubMed
39) Matsutani M, Nakamura O: Intraoperative radiation therapy (IORT) for cerevral glioblastoma. Neuro-Oncology (eds. by Paoletti P, Takakura K, Walker MD, Butti G and Pezzotta S) , Kluwer Academic Publishers, Netherlands 1991, pp. 181-183, Dev. Oncol. 66: 181-183, 1991.
 
40) Shibamoto Y, Yamashita J, Takahashi M, et al: Intraoperative radiation therapy for brain tumors with emphasis on retreatment for recurrence following full-dose external beam irradiation. Am. J. Clin. Oncol. 17: 396-399, 1994.
PubMed
41) Matsumoto K, Kakizoe T, Mikuriya S, et al: Clinical evaluation of intraoperative radiotherapy for carcinoma of the urinary bladder. Cancer 47: 509-513, 1981.
PubMed
42) Takahashi M, Okada K, Shibamoto Y, et al: Intraoperative radiotherapy in the definitive treatment of localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 11: 147-151, 1985.
PubMed
43) 児島真一, 佐竹一郎, 辻井俊彦・他: 前立腺癌に対する術中照射術. 泌尿器科紀要 34: 1397-1402, 1988.
 
44) Kotoura Y, Yamamura T, Kasahara K, et al: Intraoperative radiation therapy for osteosarcoma (meeting abstract) . International Congress of Radiation Oncology 1993. June 21-25, 1993, Kyoto, Japan, p. 359.
 
45) Calvo FA, Ortiz de Urbina D, Sierrasesumaga L, et al: Intraoperative radiotherapy in the multidisciplinary treatment of bone sarcomas in children and adolescents. Med. Pediatr. Oncol. 19: 478-485, 1991.
 
46) Gunderson LL, Nagorney DM, Mcilrath DC, et al: External beam and intraoperative electron irradiation for locally advanced soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 25: 647-656, 1993.
PubMed
47) Willett CG, Suit HD, Tepper JE, et al: Intraoperative electron radiation therapy for retroperitoneal soft tissue sarcoma. Cancer 68: 278-283, 1991.
PubMed
48) Dubois JB, Debrigode C, Hay M, et al: Intraoperative radiotherapy in soft tissue sarcomas. Radiother. Oncol. 34: 160-163, 1995.
PubMed
49) Hoekstra HJ, Sindelar WF, Szabo BG, et al: Hemipelvectomy and intraoperative radiotherapy for bone and soft tissue sarcomas of the pelvic girdle. Radiother. Oncol. 37: 160-163, 1995.
PubMed
50) Sindelar WF, Tepper JE, Travis EL, et al: Tolerance of retroperitoneal structures to intraoperative radiation. Ann. Surg. 196: 601-608, 1982.
 
51) Ahmadu-Suka F, Gillette EL, Withrow SJ, et al: Pathologic response of the pancreas and duodenum to experimental intraoperative irradiation. Int. J. Radiat. Oncol. Biol. Phys. 14: 1197-1204, 1988.
PubMed
52) Gillette EL, Powers BE, McChesney SL, et al: Aortic wall injury following intraoperative irradiation. Int. J. Radiat. Oncol. Biol Phys. 15: 1401-1406, 1988.
PubMed
53) Powers BE, Gillette EL, McChesney SL, et al: Bone necrosis and tumor induction following experimental intraoperative irradiation. Int. J. Radiat. Oncol. Biol. Phys. 17: 559-567, 1989.
PubMed
54) LeCouteur RA, Gillette EL, Powers BE, et al: Peripheral neuropathies following experimental intraoperative radiation therapy (IORT) . Int. J. Radiat. Oncol. Biol. Phys. 17: 583-590, 1988.
 
55) 柄川 順, 築山 巌, 秋根康之・他: 術中照射における後障害に関する考察. 癌の臨床 36: 815-820, 1990.
Medical*Online
P.853 掲載の参考文献
1) Marcel T, Grausz D: The TMC worldwide gene therapy enrollment report, end 1996. Hum. Gene Ther. 8: 775-800, 1997.
 
2) Coffin JM: Retroviridare and their replication. Virology (eds by Field BN, Knipe DM, Chanock RM, et al) , 2nd Eds, Raven Press, New York, 1990, pp. 1437-1500.
 
3) von Kalle C, Kiem HP, Goehle S, et al: Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood 84: 2890-2897, 1994.
PubMed
4) Ory DS, Neugeboren BA, Mulligan RC, et al: A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93: 11400-11406, 1996.
PubMed
5) Mammano F, Salvatori F, Indraccolo S, et al: Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD 4+cells. J. Virol. 71: 3341-3345, 1997.
 
6) Akkiba RK, Walton RM, Chen ML, et al: High-efficiency gene transfer into CD 34+cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol 70: 2581-2585, 1996.
 
7) Lindemann D, Bock M, Schweizer M, et al: Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J. Virol. 71: 4815-4820, 1997.
PubMed
8) Ginsberg HS: The Adenoviruses. Plenum, New York, 1984.
 
9) Mendelson E, Grossman Z, Mileguir F, et al: Replication of adeno-associated virus type 2 in human lymphocytic cells and interaction with HIV-1. Virology 187: 453-463, 1992.
PubMed
10) Neda H, Takahashi M, Itoh Y, et al: Successful transfection of biotinylated B-galactosidase gene conjugated with transferrin into leukemia cells and interleukin-2-stimulated lymphocytes via transferrin receptor. Ann. NY Acad. Sci. 716: 336-337, 1994.
 
11) Chen J, Gamou S, Takayanagi A, et al: A novel gene delivery system using EGF receptor-mediated endocytosis. FEDS Lett. 338: 167-169, 1994.
 
12) Felgner PL, GAdek TR, Holm M, et al: Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84: 7413-7417, 1987.
PubMed
13) Kato K, Kaneda Y, Sakurai M, et al: Direct injection of hepatitis B virus DNA into liver induced hepatitis in adult rats. J. Biol. Chem. 266: 22071-22074, 1991.
PubMed
14) Isner JM, Pieczek A, Schainfeld R, et al: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF 165 in patient with ischaemic limb. Lancet 348: 370-374, 1996.
 
15) Rakhmilevich AL, Janssen K, Turner J, et al: Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum. Gene Ther. 8: 1303-1311, 1997.
PubMed
16) Huber BE, Richards CA, Krentisky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88: 8039-8043, 1991.
 
17) Osaki T, Tanio Y, Tachibana I, et al: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54: 5258-5261, 1994.
PubMed
18) Parr MJ, Manome Y, Tanaka T, et al: Tumor-selective transgene expression in vivo mediated by an E 2 Fresponsive adenoviral vector. Nat. Med. 3: 1145-1149, 1997.
 
19) Huang Y, Snyder R, Kligshteyn M, et al: Prevention of tumor formation in a mouse model of Burkitt’s lymphoma by 6 weeks of treatment with antic-myc DNA phosphorothioate. Mol. Med. 1: 647-658, 1995.
 
20) de Fabritiis P, Skorski T, De Propris MS, et al: Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells. Leukemia 11: 811-819, 1997.
PubMed
21) Ratajczak MZ, Kant JA, Luger SM, et al: In vivo treatment of human leukemia in a scid mouse model with cmyb antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 89: 11823-11827, 1992.
 
22) Bayever E, Iversen P, Smith L, et al: Guest editorial: Systemic human antisense therapy begins. Antisense Res. Dev. 2: 109-110, 1992.
 
23) Inouye M: Antisense RNA: Its function and applications in gene regulation. Gene 72: 25-34, 1988.
 
24) Sklar MD, Thompson E, Welsh MJ, et al: Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3 T 3 cells. Mol. Cell Biol. 11: 3699-3710, 1991.
 
25) Mukhopadhyay T, Tainsky M, Cavender AC, et al: Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 51: 1744-1748, 1991.
PubMed
26) Georges RN, Mukhopadhyay T, Zhang Y, et al: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 53: 1743-1746, 1993.
PubMed
27) Ledwith BJ, Manam S, Kraynak AR, et al: Antisense-fos RNA causes partial reversion of the transformation phenotypes induced by the c-H-ras oncogene. Mol. Cell Biol. 10: 1545-1555, 1990.
 
28) von Ahsen U, Schroeder R: RNA as a catalyst: Natural and designed ribozymes. BioEssays 15: 299-307, 1993.
PubMed
29) Kashani-Sabet M, Funato T, Florenes VA, et al: Suppression of the neoplastic phenotype in vivo by an antiras ribozyme. Cancer Res. 54: 900-902, 1994.
PubMed
30) Koizumi M, Kamiya H, Ohtsuka E: Ribozyme designed to inhibit transformation of NIH 3 T 3 cells by the activated c-H-ras gene. Gene 117: 179-184, 1992.
 
31) Cheng J, Yee JK, Yeargin J, et al: Suppression of acute lymphoblastic leukemia by the human wild-type p 53 gene. Cancer Res. 52: 222-226, 1992.
 
32) Roth JA, Nguyen D, Lawrence DD, et al: Retrovirus-mediated wild-type p 53 gene transfer to tumors of patients with lung cancerure Nat. Med. 2: 985-991, 1996.
 
33) Heise C, Sampson-Johannes A, Williams A, et al: Onyx-015, an E 1 B gene-attenuated adenovirus, causes tumorspecific cytolysis and antitumoral efficacy that can be augmented by standard, chemotherapeutic agents. Nat. Med. 3: 639-645, 1997.
 
34) Moolten FL, Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82: 297-300, 1990.
PubMed
35) Roth JA, Cristiano RJ: Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89: 21-39, 1996.
 
36) Culver KW, Ram Z, Wallbridge S, et al: Vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
PubMed
37) Bi WL, Parysek LM, Warnick R, et al: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum. Gene Ther. 4: 725-731, 1993.
PubMed
38) Rosenberg SA: Gene therapy for cancer. JAMA 268: 2416-2419, 1992.
PubMed
39) Gansbacher B, Zier K, Cronin K, et al: Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood 80: 2817-2825, 1992.
 
40) Golumbek PT, Lazenby AJ, Levitsky HI, et al: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716, 1991.
PubMed
41) McBride WH, Thacker JD, Comora S, et al: Genetic modification of a murine fibrosarcoma to produce interleukin-7 stimulates host cell infiltration and tumor immunity. Cancer Res. 52: 3931-3937, 1992.
PubMed
42) Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543, 1993.
PubMed
43) Townsebd S, Allison J: Tumor rejection after direct co-stimulation of CD 8+ T cells by B 7-tranfected melanoma cells. Science 259: 368-370, 1993.
 
44) Tahara H, Zeh III HJ, Storkus WJ, et al: Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182-189, 1994.
 
45) Van der Bruggen P, Traversari C, Chomez P, et al: Agene encoding an antigen recognized by cytotoxic T lymphocytes on human melanoma. Science 254: 1643-1647, 1991.
 
46) Kawakami Y, Eliyahu S, Delgado CH, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91: 3515-3519, 1994.
PubMed
47) Hsu FJ, Benike C, Levy R, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52-58, 1996.
PubMed
48) Putzer BM, Hitt M, Muller WJ, et al: Interleukin 12 and B 7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA 94: 10889-10894, 1997.
 
49) Chen CJ, Chin JE, Ueda K, et al: Internal duplication and homology with bacterial transport protein in the MDR 1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389, 1986.
 
50) Sakamaki S, Kuga T, Niitu Y, et al: In preparation.
 
51) Rosenberg SA, Aebersold P, Cornetta K, et al: Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323: 570-578, 1990.
PubMed
P.865 掲載の参考文献
1) 多田正弘, 村田 誠, 村上不二夫・他: Strip-off biopsy の開発, Gastroenterol. Endosc. 26: 833-839, 1984.
 
2) 常岡健二 , 内田隆也: われわれの考案した内視鏡下の胃ポリープ切断採取法-ポリープ切断器および採取器について. Gastroenterol. Endosc. 11: 174-183, 1969.
 
3) 丹羽寛文: 生検用ファイバースコープの改良並びにカラーテレビジョンおよび高周波電流の内視鏡への応用. Gas- troenterol. Endosc. 10: 315, 1968.
 
4) Dehyle P, Largiader F, Jenny S, et al: A method for endoscopic electroresection of sessile colonic polyps. Endoscopy 5: 38-40, 1973.
 
5) 小黒八七郎, 福富久之, 崎田隆夫・他: 隆起型早期癌に対するポリペクトミーの経験. 消化器内視鏡の進歩 5: 77-80, 1974.
 
6) 竹腰隆男, 田尻久男, 大橋計彦・他: 胃生検とPolypectomy標本診断の対比検討-Endoscopic double snare polypectomy の有用性について. 日癌治会誌 16: 395, 1980.
 
7) 平尾雅紀, 小林多加志, 長谷良志男・他: 胃の腫瘍性病変に対する内視鏡的切除法. Gastroenterol. Endosc. 25: 194- 195, 1983.
 
8) 多田正弘, 村田 誠, 村上不二夫・他: Strip-off biopsy の開発. Gastroenterol. Endosc. 26: 833-839, 1984.
 
9) 渡辺 豊, 神山正之, 長尾房大: 胃癌の内視鏡的治療-外科の立場からの適応と問題点. 胃と腸 19: 873-833, 1984.
 
10) 田尻久雄, 向井俊一, 吉田茂昭・他: 消化器癌に対する内視鏡治療の適応と問題点. 癌と化学療法 15: 1429-1434, 1988.
 
11) 梨本 篤, 田中甲介, 宮下 薫・他: 早期胃癌の臨床理学的検討-早期胃癌に対する内視鏡治療の適応と限界を知るために. 日外会誌 89: 1780-1788, 1988.
 
12) 多田正弘, 苅田幹雄, 柳井秀雄・他: Strip biopsy による早期胃癌の内視鏡治療. 癌と化学療法 15: 1460-1465, 1988.
 
13) 井上晴洋, 遠藤光夫, 竹下公矢・他: 透明プラスチックキャップを用いた内視鏡的食道粘膜切除術 (EMRC) . Gas- trointerol. Endosc. 34: 2387-2390, 1992.
 
14) 増田勝紀, 篠崎順子, 鈴木博昭・他: Ligating device を利用した内視鏡的粘膜 (EMRL) . 消化器内視鏡 5: 1215- 1219, 1993.
 
15) 赤坂祐三, 奥田順一, 井上和徳: 食道ルゴール法の基礎と臨床的応用について. Gastroenterol. Endosc. 18: 84-91, 1976.
 
16) 神津照雄, 山田英夫, 小野田昌一・他: 表在食道癌におけるルゴール染色の診断的価値. 胃と腸 22: 1395-1401, 1987.
 
17) 幕内博康: 食道粘膜癌に対する内視鏡の治療の適応と限界. 日消外会誌 24: 2599-2603, 1991.
 
18) 有馬美和子, 神津照雄: 食道の内視鏡的粘膜切除術の適応, 食道, 胃の内視鏡的粘膜切除術. (幕内博康編集) 日本メディカルセンター, 東京, 1997, p. 23.
 
19) 森川丘道, 神津照雄, 有馬美和子・他: 高周波数細経超音波プローブによる食道内ラジアル走査-表在食道癌深達度診断の検討, 腹部画像診断 14: 604-614, 1994.
 
20) 有馬美和子, 神津照雄, 森川丘道・他: 食道癌の深達度, リンパ節転移診断, 消化器内視鏡 8: 100-106, 1996.
 
22) 門馬久美子, 吉田 操, 山田義也・他: 早期食道癌に対する内視鏡的粘膜切除術の実際. 胃と腸 28: 141-151, 1993.
 
23) 幕内博康: 食道癌の診断と治療の進歩. 最新醫學 52: 175-186, 1997.
 
24) Everett SM, Axon AT: Review； Early gastric cancer in Europe. Gut 41: 142-150, 1997.
PubMed
25) 中野和夫, 柳澤昭夫, 宇都出公也・他: 未分化型胃癌に対する内視鏡的粘膜切除 (EMR) の適応限界. 胃と腸 30: 1289-1294, 1995.
 
26) Noda M, Kodama T, Atsumi M, et al: Possibilities and a limitations of endoscopic resection of early gastric cancer. Endoscopy 29: 361-365, 1997.
 
27) 細川浩一, 白尾国昭, 小黒八七郎・他: 早期胃癌における内視鏡的粘膜切除術-適応の再検討. 消化器内視鏡の進歩 42: 11-15, 1993.
 
28) 竹腰隆男: 内視鏡による早期胃癌治療の適応と限界. 日本医事新報 3720: 3-16, 1995.
 
29) 蜂巣 忠: 改良型クリップ装置 (XL-3L) による経内視鏡的止血. 消化器内視鏡 1: 325-332, 1989.
 
30) 原 宏介: 高齢者部検例における腸管隆起性病変. 日外会誌 74: 18-32, 1973.
 
31) 多田正大, 藤田直子: 微小病変, 小病変はどこまで治療すべきか. 大腸ポリペクトミーはどこまで必要か. (中村孝司 監修) , 日本メディカルセンター, 東京, 1997, p. 25.
 
32) 岡本春彦, 畠山勝義: 微小病変, 小病変はどの程度発見されるか. (3) 大学病院の場合. 大腸ポリペクトミーはどこまで必要か. 日本メディカルセンター, 東京, 1997, p. 35.
 
33) 小平 進, 八尾恒良, 中村恭一・他: sm癌細分類からみた転移陽性大腸sm癌の実態, アンケート調査集計報告. 胃と腸 29: 1137-1142, 1994.
 
34) 河野弘志, 鶴田 修: 現時点における内視鏡治療の実態. (中村孝司監修) , 日本メディカルセンター, 東京, 1997, p. 17.
 
35) 片倉重弘: クリップ付加法. 消化器内視鏡の基本手技, 金原出版, 東京, 1996, p. 243.
 
36) Hachisu T: A new detachable snare for hemostasis in the removal of large polyps or other elevated lesions. Surg. Endosc.: 570-574, 1991.
 
37) 工藤進英: 早期大腸癌. 平坦陥凹型のアプローチ. (長廻紘編) , 医学書院, 東京, 1993, p. 78.
 
38) Hachisu T: A new detachable snare for hemostasis in the removal of large polyps or other elevated lesions. Surg. Endosc.: 570-574, 1991.
 
39) 工藤進英: 早期大腸癌. 平坦・陥凹型へのアプローチ. 医学書院, 東京, 1993, p. 58.
 
40) 工藤進英, 中島孝司: 粘膜切除, 大腸. 消化器内視鏡の基本手技. (藤田力也編) , 金原出版, 東京, 1996, p. 101.
 
41) 渡邊昌彦, 大上正裕, 寺本龍王・他: 早期大腸癌に対する腹腔鏡下大腸切除. 手術 47: 651-658, 1993.
 
42) 林 賢, 宗像康博: 結脹切除術-主としてどんな疾患に-. カレントテラピー 12: 76-82, 1994.
 
43) 北條慶一・他: 日本大腸肛門会誌 50: 1128-1131, 1997.
 
44) Jacobs M. Verdeja JC, Plasencia G: Laparscopic surgery. In: Surgical Laparoscopy Update (ed by Zucker KA) , Quality Medical, St. Loui, 1993, pp. 327-354.
 
45) 宗像康博, 林 賢: 大腸癌に対する腹腔鏡下リンパ節郭清術. 手術 48: 861-867, 1994.
 
46) 大橋秀一: 腹腔鏡下胃内手術. 手術 48: 333-337, 1994.
 
47) 大上正祐, 若林 剛, 才川義明・他: 早期胃癌に対する腹腔鏡下手術-腹腔鏡下胃局所切除術及び腹腔鏡併用胃内粘膜切除術. 手術 48: 817-827, 1994.
 
48) Cuschievi JR, Shimi S, Banting S: Endoscopic esophagotomy through a right thoracoscopic approach. J. R. Coll. Surg. Edind. 37: 7-11. 1992.
 
49) 若林 剛, 北島政樹: 腹腔鏡下肝切除術. 内視鏡下外科手術の現況. 消化器病セミナー 65: 121-130, 1996.
 
50) 二ツ木浩一, 井田和徳, 小黒八七郎: 進行性消化管癌のレーザー治療の現状-レーザー内視鏡委員会による第7回集計報告-. Gastroenterol. Endosc. 35: 128-134, 1993.
 
51) Kawai K, Akasaka T, Hashimoto Y, et al: Preliminary report on endoscopic papillotomy. J. Kyoto Pref. Unv. Med. 82: 353-355, 1973.
 
52) Classen M, Demling L: Endoskopische sphincterotomie des papilla vateri und steinextraktion aus dem ductus choledochus. Dtsch. Med. Wochenschur. 99: 496-497, 1974.
 
53) 相馬 智, 立川 勲, 岡本安弘・他: 内視鏡的乳頭切開術および遺残結石摘出の試み (第一報) . Gastroenterol. Endosc. 16: 446-452, 1974.
 
54) Nagai N: Continuous endoscopic pancreatocholedochal catheterization. Gastrointest. Endosc. 23: 78-81, 1976.
PubMed
55) Soehendra N, Reynders-Frederix V, et al: Palliaative Gallengangsdrainage； Eine neue Methode zur endoskopichen Einfuhrung eines inneren Drains. Dtsch. Med. Wochenschr. 104: 206-207, 1979.
 
56) 小川 薫, 長田太郎, 松山秀二郎・他: 悪性胆道狭窄に対する self-expandable metalic stent (金属ステント) による胆道内瘻術の治療成績. 消化器科 24: 82-85, 1997.
 
57) 宇野耕治, 中島正継, 安田健二郎・他: 内視鏡下 stenting における各種ステントの評価. 胆と膵 18: 549-554, 1997.
 
P.880 掲載の参考文献
1) Sanderson DR, Neel HB, Fontana RS: Bronchoscopic cryotherapy. Ann. Otol. Laryllgol. 90: 354-358, 1981.
PubMed
2) Maiwand MO: Cryotherapy advanced carcinoma of the trachea and bronchi. BMJ 293: 181-182, 1986.
PubMed
3) Maiwand MO, Homasson JPL: Cryotherapy for tracheobronchial disorders. In: Clinics in chest medicine. Interventional pulmonology eds by Muthur PN, Beamis JN, Sanders, Tokyo, 1995, p. 436.
 
4) Vergnon JM, Brail A, Court Fortune I, et al: Initial combined cryotherapy and irrigation for unresectable non-small-cell lung cancer. Chest 102: 1436-1440, 1992.
 
5) Mathur PN, Wolf KM, Busk MF, et al: Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction. Chest 110: 718-723, 1996.
PubMed
6) Hommason JP, Peckinng A, Roden S, et al: Tumor fixation of bleomycin labeled with 57 cobalt before and after cryotherapy of bronchial carcinoma. Cryobiology 29: 543-548, 1992.
 
7) Vergnon JM, Schmitt T, Alamartine E, et al: Initial combined cryotherapy and irradiation for unresectable nonsmall cell lung cancer. Preliminary results. Chest 102: 1436-1440.
PubMed
8) Weyer U, Petersen I, Ehrke C, et al: Immunorriodulation by cryosurgery in malignant melanoma. Onkologie 12: 291-296, 1989.
PubMed
9) Strong Sm, Jako Gj, Polanyi T, et al: Laser surgery in the aerodigestive tract. Am. J. Surg. 1206: 529-533, 1973.
 
10) LaForet EG, Berger RL, Vaughan CW: Treatment by laser resection. N. Engl. J. Med. 294: 941, 1976.
PubMed
11) Personne C, Colchen A, Leroy M, et al: Indications and technique for endoscopic laser resections in bronchology. J. Thorac. Cardiovasc. Surg. 91: 710-715, 1986.
PubMed
12) Cavaliere S, Foccoli PO, Toninelli C, et al: Nd: YAG laser in lung cancer: A 11 year experience with 2253 applications in 1585 patients. J. Broncol. 1: 105-111, 1994.
 
13) Dedhia RA, Lapp NL, Jain PR, et al: Endoscopic laser therapy for respiratory disorders due to obstructive airway tumors. Crit. Care Med. 13: 464-467, 1985.
 
14) Unger M: Neodymium: YAG laser therapy for malignant and benign endobronchial obstruction. Clin. Chest Med. 6: 277-290, 1985.
PubMed
15) Brutinel WM, Cortese DA, McDougall JC, et al: A two year experience with the neodymium-YAG laser inendobronchial obstruction. Chest 91: 159-165, 1987.
PubMed
16) Dumon JF, Shapshay SM, Boucereau J, et al: Principle for safety in application of neodymium YAG laser inbronchology. Chest 86: 163-168, 1984.
 
17) Vandershueren RCJRA, Westermann CJJ: Complications of endobronchial Neodymium-YAG (Nd: YAG) laser applications. Lung 168 (suppL) : 1089-1094, 1990.
 
18) Casey KR, Fairfax WR, Smith SJ, et al: Inter-tracheal fire ignited by the Nd； YAG laser treatment of tracheal stenosis. Chest 84: 295-296, 1983.
 
19) Denton RA, Dedhia HV, Abrons HL, et al: Long term survival after endobronchial fire during treatment ofsevere malignant air way obstruction with the Nd: YAG laser. Chest 94: 1086-1088, 1988.
 
20) Beamis JF, Vergos K, Rebeiz EE, et al: Endoscopic laser therapy for obstructing tracheobronchial lesions. Ann. Otol. Rhinol. Laryngol. 100: 413-419, 1991.
PubMed
21) Ross DJ, Mohsenifor Z, Po Hun RT, et al: Pathogenesis of cerebral air embolism during neodymium-YAG laser photoresection. Chest 94: 660-662, 1988.
 
22) Bell AG: The use of radium. Am. J. Med. 6: 261, 1903.
 
23) Ono R, Hirano H, Egawa S, et al: Bronchoscopic Ultrasonography and Brachytherapy in Roentgenologically occult bronchogenic carcinoma. J. Bronchology 1: 281-287, 1994.
 
24) Gustafson G, Vicini F, Freedmann L, et al: High dose rate endobronchial brachytherapy in the management of primary and recurrent bronchogenic malignancies. Cancer 75: 2345-2350, 1995.
 
25) Yankauer S: Lung tumor treated bronchoscopically. NY Med. J. 115: 741-742, 1922.
 
26) Saito M, Yokoyama A, Kurita, et al: Treatment of roentgenographycally occult endobronchial carcinoma with external beam radiotherapy and intraluminal low dose rate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 34: 1029-1035, 1996.
PubMed
27) Fuwa N: The clinical utility of 192 iridium endobronchial irradiation for chest X-P negative lung cancer. JJSB 16: 723-729, 1994.
 
28) Speiser B, et al: High dose rate remote afterloading endobronchial carcinoma. In: Brachytherapy HDR and LDR (eds by Martinez AA, Orton CG, Mould RF) , Nucletron, Columbia, 1989, pp. 10-26.
 
29) Lo TCM, Girsshovich L, Healey GA, et al: Low dose rate versus high dose rate intraliminal brachytherapy for malignant endobronchial tumor. Radiother. Oncol. 35: 193-197, 1995.
 
30) Speiser BL, Sprarling L: Remote after loading brachytherapy for the local control of endobronchial carcinorna. Int J. Radiat. Oncol. Biol. Phys. 25: 579-587, 1993.
 
31) Metha MP, Petereit D, Chosy L, et al: Sequential comparison of low dose rate and hyperfractionated high doserate endobronchial radiation for malignant airway occlusion. Int. J. Radiat. Oncol. Biol. Phys. 23: 133-139, 1992.
 
32) Tredaniel J, Hennequin C, Zalcman G, et al: Prolonged survival after high-dose rate endobrochial radiation for malignant airway obstruction. Chest 105: 767-772, 1994.
 
33) Nori D, Allison R, Kaplan B, et al: High dose rate intralurninal irradiation in bronchogenic carcinoma. Chest 1O4: 1006-1011, 1993.
 
34) Brut PA, O’Driscoll R, Notely HM, et al: Intraluminal irradiation for the palliation of lung cancer with the high dose rate micro-Selectron. Thorax 45: 765-768, 1990.
 
35) Bedwinek J, Petty A, Bruton C, et al: The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 22: 23-30, 1992.
PubMed
36) Zajac AJ, Kohn ML, Heiser D, et al: Hig-dose-rate intraluminal brachytherapy in the treatment of endobronchial malignancy. Radiology 187: 571-575, 1993.
 
37) Gollins SW, Burt PA, Barber PV, et al: High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother. Oncol. 33: 31-40, 1994.
PubMed
38) Chang LFL, Horvath J, Peyton W, et al: High dose rate afterloading intraluminal brachytherapy in malignantair way obstruction of lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 28: 589-596, 1994.
 
39) Maria RM, Fischer R, Hautmann H, et al: Palliative endobronchial brachytherapy for central lung tumor. A prospective, randomized comparison of two fractionation schedules. Chest 107: 463-470, 1995.
 
40) Hernandez P, Gursahaney A, Roman T, et al: High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation. Thorax 51: 354-358.
PubMed
41) Sutedja G, Kralingen K, Schramel FMNH, et al: Fiberoptic bronchoscopic electrosurgery under local anaesthesia for rapid palliation in patients with central air way malignancies: a preliminary report. Thorax 49: 1243-1246, 1994.
 
42) 水渡哲史, 谷 源一, 関 隆郎・他: 気道閉塞に対する気管支鏡的マイクロ波凝固の使用経験. 気管支学 11: 88-92, 1989.
 
43) 瀬戸貴司, 千葉 浩, 深井祐治・他: マイクロウェーブによる気道内腫瘍凝固術の有効性. 気管支学 18: 430-436, 1996.
 
44) Petrou M, Kaplan D, Goldstraw P: Bronchoscopic diathermy resection and stent insertion: a cost effective treatment for teracheobronchial obstruction. Thorax 48: 1156-1159, 1993.
PubMed
45) Petrou M, Kaplan D, Goldstraw P: Bronchoscopic diathermy resection and stent insertion: a cost effective treatment for tracheobronchial obstruction. Thorax 48: 1156-1159, 1993.
PubMed
46) Dumon JF: A dedicated tracheobronchial stent. Chest 97: 328-332, 1990.
PubMed
47) Freitag L, Eicher R, Linz B, et al: Theoretical and experimental basis for the development of a dynamic air stent. Eur. Respr. J. 7: 2038-2045, 1994.
 
48) Wallace MJ, Charnsangavej C, Ogawa K, et al: Tracheobronchial tree: Expandable metallic stents used in experimental and clinical applications. Radiology 158: 309-312, 1986.
PubMed
49) Maeda M, Uchida H, Otsuji H, et al: Spiral zigzag stents for tracheobronchial stenosis. Radiology 185 (P) (suppl.) : 357, 1992. 78th Scientific Assembly and Annual Meeting.
 
50) Tsang V, Goldstraw P: Self-expanding metal stent for tracheobronchial strictures. Eur. J. Cardiothorac. Surg. 6: 555-560, 1992.
PubMed
51) Becker HD: Stenting of the central airways. J. Bronchol. 2: 98-106, 1995.
 
52) Montogomery WW: T-tube tracheal stent. Arch. Otolaryngol. 82: 47-53, 1965.
 
53) Harkins WB: An endotracheal metallic prosthesis in the treatment of stenosis the upper trachea. Ann. Otol. Rhinol. Laryngol. 61: 663-675, 1952.
PubMed
54) Bucher RM, Burnett WE, Rosemond GP: Experimental reconstruction of tracheal and bronchial defects with stainless steel wire mesh. J. Thorac. Surg. 21: 572-583, 1951.
 
55) Sawada A, Tanigawa N, Kobayashi M, et al: Malignant tracheobronchial obstructive lesions: Treatment with Gianturco expandable metallic stents. Radiology 188: 205-208, 199.
 
56) Pagliero KM, Shephered MP: Use of stainless steel wire coil in treatment of anastomotic dehiscence after cervical tracheal resection. J. Thorac. Cardiovasc. Surg. 67: 932-935, 1974.
 
57) Simmonds AK, Irving JD, Clarke SW, et al: Use of expandable metal stents in the treatment of bronchial obstruction. Thorax 44: 680-681, 1989.
 
58) 飯岡壮吾, 東条 尚, 尾辻秀明・他: 癌性気道閉塞に対する内視鏡的治療-金属ステントとcontact YAG-laserを用いて-. 気管支学 13: 154-158, 1991.
 
59) Rauber K, Weimar B, Hofmann M, et al: Klinische Erfarungen mit Gianturco-Z-Stents bei endotrachealen undbronchialen Stenosen. Fortschr. Rontogenstr. 156: 41-46, 1992.
 
60) Palmaz JC, Sibbitt RR, Reuter SR, et al: Expandable intraluminal graft: a preliminary study. Radiology 156: 73-77, 1985.
 
61) Breyer G, Haussinger K: Tracheobronchiale Stents-Indikationen und Moglichkeiten. Pneumologie 45: 997-1003, 1991.
PubMed
62) 飯岡壮吾, 東条 尚, 北村惣一郎・他: 癌性気管支狭窄に対する金属ステント拡張術. 気管支学 13: 500-505, 1991.
 
63) Bolliger CT, Heitz M, Hanser R, et al: An airway wallstent for the treatment of tracheobronchial malignancies. Thorax 51: 1127-1129, 1996.
 
64) George PJM, Irving JD, Mantell BS, et al: Covered expandable metal stent for recurrent tracheal obstruction. Lancet 335: 582-584, 1990.
 
65) Monnier P, Mudry A, Stanzel F, et al: Use of the covered wallstent for the palliative treatment of in operable tracheobronchial cancers. A prospective multicentric study. Chest 110: 1161-1168, 1996.
PubMed
66) 岸 和史, 小林 尚, 駿田直俊・他: 癌性気管支狭窄に対するDacron mesh 張り金属stent による治療. 気管支学 14: 443-448, 1992.
 
67) Schafers HJ, Hamm M, Wagner TOF: Gianturco self-expanding metallic stents. (Letter to the editor) . Eur. J. Cardiothorac. Surg. 6: 278, 1992.
 
68) Maeda M, Timmermans HA, Uchida BT, et al: In vitro comparison of the spiral Z stent and the Gianturco Z stent. J. Vasc. Intervent. Radiol. 3: 565-569, 1992.
 
69) Maeda M, Uchida H, Otsuji H, et al: Spiral zigzag stents for tracheobronchial stenosis. Radiology 185 (P) (suppl.) : 357, 1992. 78 th Scientific Assembly and Annual Meeting.
 
70) Tsang V, Williams AM, Goldstraw P: Sequential silastic and expandable metal stenting for tracheobronchial strictures. Ann. Thorac. Surg. 53: 856-860, 1992.
PubMed
71) Bohndorf K, Gunther RW, Hurter T, et al: Implantation selbstexpandierender Metallprothesen (Stent) im Bronchialsystem bei zentralen Neoplasien. Fortscher. Rontgenstr. 155: 223-227, 1991.
 
72) Hurter Th, Bohndorf K, Kropff M, et al: Bronchiale Endoprosthesen (Stents) beim inoperablen Bronchialkarzinom. Pneumologie 45: 19-22, 1991.
 
73) Martini N, Melamed MR: Occult carcinoma of the lung. Ann. Thorac. Surg. 30: 215-221, 1980.
PubMed
74) Mason MK, Jordan JW: Outcome of carcinomas in situ and early invasive carcinoma of the bronchus. Thorax 37: 453-456, 1982.
PubMed
75) Cortese DA, Parirolero PC, Gergstrail EJ, et al: Roentgenographically occult lung cancer. J. Thorac. Cardiovasc. Surg. 86: 373-380, 1980.
 
76) Saito Y, Sato M, Sagawa M, et al: Multicentricity in resected occult bronchogenic squamous cell carcinoma. Ann. Thorac. Surg. 57: 1200-1205, 1994.
PubMed
77) Woolner LB, Fontana RS, Cortese DA, et al: Roentogenographically occult lung cancer: Pathologic findings and frequency of multicentricity during a ten-year period. Mayo Clin. Proc. 59: 453-466, 1984.
 
78) Furuse K, Fukuoka M, Kati II, et al: A prospective phase II study of photodynamic therapy with Photofrin II for centrally located early-stage lung cancer. J. Clin. Oncol. 11: 1852-1857, 1993.
 
79) 塚越 茂: ポルフィマーナトリウム (Photofrin II) について. 癌と化学療法 22: 1271-1278, 1995.
Medical*Online
80) 小中千守, 奥中哲也, 古川欣也・他: 原発性多発肺癌の光線力学的治療. 癌と化学療法 23: 31-35, 1996.
 
81) Sutedja T, Baas P, Stewart F, et al: A pilot study of photodynamic therapy in patients with inoperable nonsmall cell lung cancer. Eur. J. Cancer 28: 1370-1373, 1992.
 
82) Cortese DA, Kinsey JH: Endoscopic management of lung cancer with hematoporphyrin derivative phototherapy. Mayo Clin. Proc. 57: 543-547, 1982.
PubMed
83) LoCicero J, Metzdorff M, Almgren C: Photodynamic therapy in the palliation of late stage obstructing nonsmall cell lung cancer. Chest 98: 97-100, 1990.
PubMed
84) Hayata Y, Kato H, Konaka C, et al: Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer. Chest 81: 269-276, 1982.
PubMed
85) Kato H, Konaka C, Ono J, et al: Preoperative laser photodynamic therapy in combination with operation in lung cancer. J. Thorac. Cardiovasc. Surg. 90: 420-429, 1985.
PubMed
86) 加藤治文, 奥中哲弥, 小中千守: 肺癌に対する光線力学的治療. 日外会誌 98: 36-40, 1997.
 
87) Edell ES, Cortese DA: Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection. Chest 102: 1319-1322, 1992.
PubMed
88) Imamura S, Kusunoki Y, Takifuji N, et al: Photodynamic therapy and/or external beam radiation therapy for roentgenologically occult lung cancer. Cancer 73: 1608-1614, 1994.
PubMed
89) Lam S: Photodynamic therapy of lung cancer. Semin. Oncol. 21 (suppl. 15) : 15-19, 1994.
 
90) Pass HI: Photodynamic therapy for lung cancer. Chest Surg. Clin. North Am. 1: 135-151, 1991.
 
91) Sutejia T, Baris G, Zoetmulder F, et al: High dose rate brachytherapy improves resectability in squamous cell lung cancer. Chest 102: 308-309, 1992.
 
92) Sutedja G, Baris G, Zandwijk N, et al: High-dose rate brachytherapy has a curative potential in patients with intraluminal squamous cell lung cancer. Respiration 61: 167-168, 1993.
 
93) Macha HN, Wahlers B: Endobronchiale Brachytherapie: Die endoluminale Kleinraum-bestrahlung von Bronchialtumoren mit dem Afterloading HDR-Verfahren. Pneumonologie 45: 95-99, 1991.
 
94) Perl M, Pommier P, Montbarbon X, et al: Curative irradiation of limited endobronchial carcinomas with highdose rate brachytherapy. Results of a pilot study. Chest 111: 1417-1423, 1997.
 
95) 植島久雄, 飯岡壮吾, 多田弘人・他: 肺門部早期肺癌に対するBrachytherapyの問題点. 肺癌 37: 622, 1997. 第38 回日本肺癌学会総会号抄録.
 
P.907 掲載の参考文献
1) 佐藤武男: 現状の概観と問題点, 図説臨床[癌]シリーズ. 頭頸部癌 No. 11 (末舛恵一, 佐藤武男編) , メジカルビュー社, 東京, 1987, pp. 6-13.
 
2) Schottenfeld D: Epidemiology, etiology, and pathogenesis of head and neck cancer. In: Head and Neck Cancer vol 1 (ed by Chretien PB, Johns ME, et al) , B. C. Decker, Philadelphia, 1985, pp. 6-18.
 
3) 日本頭頸部腫瘍学会編: V. 病理組織分類, 臨床・病理頭頸部癌取扱い規約. 金原出版, 東京, 1991, pp. 15-18.
 
4) 古川政樹, 古川まどか, 松田秀樹・他: (特集) 外来診療と検査, 超音波検査法-外来診療を中心に. JOHNS 10: 1419- 1426, 1994.
 
5) 小山和行: (特集) これからの画像診断X線CT画像の基礎と撮影法. JOHNS 12: 1227-1236, 1996.
 
6) 小山和行: (特集) これからの画像診断 頭頸部MR診断に必要な基礎知識. JOHNS 12: 1275-1286, 1996.
 
7) 戸辺公子, 多湖正夫, 吉川宏起: (特集) これからの画像診断三次元CT. JOHNS 12: 1253-1262, 1996.
 
8) 宇野公一, 内田佳孝, 今関恵子・他: (特集) これからの画像診断 PETによる腫瘍診断. JOHNS 12: 1363-1370, 1996.
 
9) 木田亮紀, 横出 裕: (特集) 頭頸部癌診療 腫瘍マーカー. JOHNS 7: 575-578, 1991.
 
10) 横浜優樹, 滝沢昌彦, 犬山征夫・他: 頭頸部扁平上皮癌における新しい腫瘍マーカーサイトケラチン19 (CYFRA21-1) の臨床的有用性の検討. 頭頸部腫瘍21: 370, 1995.
 
11) 行木英生: (特集) Quality of Life と再建外科, QOLを考慮した頭蓋底の再建外科. JOHNS 10: 87-93, 1994.
 
12) 犬山征夫: (特集) 頭頸部の早期癌, 放射線治療・化学療法併用の適応となる頭頸部早期癌. JOHNS 13: 567-573, 1997.
 
13) UICC: TNM Classification of Malignant Tumours. fifth revised edition, Springer-Verlag, Berlin, New York, Tokyo, 1997.
 
14) Easson EC, Palmer MK: Prognostic factors in oral cancer. Clin. Oncol. 2: 191-202, 1976.
PubMed
15) Amsterdam JT, Strawitz JG: Squamous cell carcinoma of the oral cavity in young adults. J. Surg. Oncol. 19: 65-68, 1982
 
16) Byers RM: Squamous cell carcinoma of the oral tongue in patients less than thirty years of age. Am. J. Surg. 130: 475-478, 1975.
PubMed
17) Usenius T, Karaja J, Collan Y: Squamous cell carcinoma of the tongue in children. Cancer 60: 236-239, 1987.
 
18) Langdon JD: Epidemiology and aetiology. In: Malignant Tumours of the Oral Cavity (ed by Henken JM, Langdon JD) , Edward Arnold Publications, London, 1985, pp. 1-5.
 
19) Lederman M: Cancer of the larynx. Natural history in relation to treatment. Br. J. RadioL 44: 569-578, 1971.
PubMed
20) Rudert H, Neumann FW, Gremmel H: Results of the treatment of 197 squamous cell carcinomas of the oropharynx (1964-1982 treatment period) . HNO 34: 357-364, 1986.
PubMed
21) Katz AE: Immunologic staging of patients with carcinoma of the head and neck. Laryngoscope 93: 445-463, 1983.
PubMed
22) Wolf GT: Tumor immunology, immune surveillance and immunotherapy of head and neck cancer in Wolf GT. Head and Neck Oncology, Martinus Nijhoff Publishing, Boston, 1984, pp. 375-410.
 
23) Lundy J, Raaf JH, Deakins S, et al: The acute and chronic effects of alcohol on the human immune system. Surg. Gynecol. Obstet. 141: 212-218, 1975.
PubMed
24) Brookers GB, Clifford P: Nutritional status and general immune competence in patients with head and neck cancer. J. R. Soc. Med. 74: 132-137, 1981.
 
25) Douglas A, Fein W, Robert L, et al: Pretreatment hemoglobin level influences local control and survival of T1-T 2 squamous cell carcinomas of the glottic larynx. J. Clin. Oncol. 13: 2077-2083, 1995.
 
26) Hibbert J, Marks NJ, Winter PJ, et al: Prognostic factors in oral squamous carcinoma and their relation to clinical staging. Clin. Otolaryngol. 8: 197-203, 1983.
PubMed
27) Martin SA, Marks JE, Lee JY, et al: Carcinoma of the pyriform sinus: Predictions of TNM relapse and survival. Cancer 46: 1974-1981, 1980.
 
28) Bennett SH, Futrell IW, Roth JA, et al: Prognostic significance of histologic host response in cancer of the larynx or hypopharynx. Cancer 28: 1255-1265, 1871.
 
29) Cachin Y, Sancho-Garnier H, Micheau C, et al: Nodal metastasis from carcinomas of the oropharynx. Otolaryngol. Clin. North Am. 12: 145-154, 1979.
PubMed
30) Snow GB, Balm AJM, Arendse JW, et al: Prognostic factors in neck node metastasis. In: Cancer in the Neck: Evaluation and Treatment (eds by Larson DL, Ballantyne AJ, Guillamondegui OM) , McMillan, New York, 1977, pp. 53-63.
 
31) Kalnins IK, Leonard AG, Sako K, et al: Correlation between prognosis and degree of lymph node involvementin carcinomas of the oral cavity. Am. J. Surg. 134: 450-454, 1977.
 
32) Spiro RH, Alfonso AE, Farr HW, et al: Cervical node metastasis from epidermoid carcinoma of the oral cavity and oropharynx； A critical assessment of current staging. Am. J. Surg. 128: 562-567, 1974.
PubMed
33) Snow GB, Annyas AA, van Slooten EA, et al: Prognostic factors of neck node metastasis. Clin. Otolaryngol. 7: 185-192, 1982.
PubMed
34) Johnson JT, Barnes EL, Myers EN, et al: The extracapsular spread of tumors in cervical node metastasis. Arch. Otolaryngol. 107: 725-729, 1981.
PubMed
35) Grandi C, Alloisio M, Mogila D, et al: Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutic implications. Head Neck Surg. 8: 67-73, 1985.
 
36) Noone RB, Bonner H, Raymond S, et al: Lymph node metastasis in oral carcinoma. A correlation of histopathology with survival. Plast. Reconstr. Surg. 53: 158-166, 1974.
PubMed
37) Sessions DG: Surgical pathology of cancer of the larynx and hypopharynx. Laryngoscope 86: 814-839, 1976.
PubMed
38) Shah JP, Cendon RA, Farr HW, et al: Carcinoma of the oral cavity. Factors affecting treatment failure at the primary site and neck. Am. J. Surg. 132: 504-507, 1976.
PubMed
39) Zoller M, Goodman ML, Cummings CW: Guidelines for prognosis in head and neck cancer with nodal metastasis. Laryngoscope 88: 135-140, 1978.
PubMed
40) Vikram B, Strong EW, Shah JP, et al: Failure at distant sites following multimodality treatment for advanced head and neck cancer. Head Neck Surg. 6: 730-733, 1984.
PubMed
41) Kokal WA, Gardive RL, Sheibani Z, et al: Tumor DNA content as a prognostic indication in squamous cell carcinoma of the head and neck region. Am. J. Surg. 156: 276-280, 1988.
 
42) Bradford CR, Zhu S, Poore J, et al: p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Head Neck Surg. 123: 605-609, 1997.
PubMed
43) Brennan JA, Mao L, Sidransky D, et al: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332: 429-435, 1995.
PubMed
44) Sidransky D: Molecular markers in head and neck cancer. Proc of 4th International Conference on Head and Neck Cancer, SHNS and ASHNS, Pittsburgh, 1996, pp. 509-515.
 
45) Raybaud-Diogene H, Fortin A, Morency R, et al: Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic immunohistochemical study. J. Clin. Oncol. 15: 1030-1038, 1997.
PubMed
46) Sato Y, Morita M, Takahashi H, et al: Combined surgery, radiotherapy, and regional chemotherapy in carcinoma of the paranasal sinuses. Cancer 25: 79-84, 1970.
 
47) 犬山征夫編著: 頭頸部癌治療における化学療法の役割. 東京医学社, 東京, 1997, pp. 168-184.
 
48) Fujino T, Inuyama Y, Inoue T, et al: Reconstruction of the cheek defect by free myocutaneous flap. Auris Nasus Larynx 12 (Suppl II) : S156-S 160, 1985.
 
49) 犬山征夫監修: 頭頸部がんの境界領域における治療法の最新の進歩. 協和企画通信, 東京, 1995, pp. 124-131.
 
50) Shah JP: Head and Neck Surgery. 2nd ed, Mosby-Wolfe, New York, 1996, pp. 85-141.
 
51) Cantu G, Solero CL, Salvatori P, et al: Anterior craniofacial resection for ethmoidal malignant tumors. A series of 91 patients. Proc 4 th International Conference on Head and Neck Cancer, 1996, p. 69.
 
52) Robbins KT: Targetted supradose cisplatin and concomitant radiotherapy for advanced upper aerodigestive tract carcinoma. Scientific Program and Abstracts of International Meeting on Intra-arterial Chemotherapy in Head and Neck Cancer, 1997, p. 17.
 
53) 犬山征夫, 福田 諭, 八木克憲・他: (特集) 口腔癌治療方針とその選択-化学療法の立場から-. JOHNS 6: 199- 205, 1990.
 
54) 堀内淳一: II. 頭頸部腫瘍放射線治療の実際, 2. 口腔, 頭頸部腫瘍の放射線治療-よりよいQOLと集学的治療- (堀内淳一, 大川智彦編) , 金原出版, 東京, 1993, pp. 156-170.
 
55) Wolf GT, Lippman SM, Hong WK, et al: Head and neck cancer. In: Cancer Medicine vol 1 (eds by Holland JF, Frei III E, et al) , 3rd ed, Lea ＆ Febiger, Philadelphia, 1993, pp. 1228-1230.
 
56) Dimery IW, Legha SS, Peters LJ, et al: Adjuvant chemotherapy for advanced nasopharyngeal carcinoma. Cancer 60: 943-949, 1987.
PubMed
57) Bachouchi M, Cvitkovic E, Armand JP, et al: High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin and cisplatin before radiotherapy. J. Natl. Cancer Inst, 82: 616-620, 1990.
 
58) Al-Sarraf M, LeBlanc M, Giri PGS, et al: Superiority of chemoradiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer. Preliminary results of Intergroup (0099) randomized study. Proc. ASCO15: 313, 1996.
 
59) Wei IW, Lam LK, Yuen PW, et al: Surgical resection for recurrent nasopharngeal carcinoma-the pathologicbasis. Proc of 4 th International Conference on Head and Neck Cancer, SHNS and ASHNS, 1996, pp. 611-616.
 
60) 鎌田信悦: 頭蓋底外科-[附]頭蓋底手術におけるMRI診断のキー・ポイント. 耳喉頭頸 67: 618-635, 1995.
 
61) 犬山征夫編著: 頭頸部癌治療における化学療法の役割. 東京医学社, 東京, 1997, pp. 235-263.
 
62) 藤田昌宏, 真崎規江, 村山重行・他: 頭頸部腫瘍に対する少量 Cisplatin の連日投与併用放射線治療. 日放腫会誌 2: 255-262, 1990.
 
63) Pfister DG, Harrison LB, Strong EW, et al: Organ-function preservation in advanced oropharynx cancer: Results with induction chemotherapy and radiation. J. Clin. Oncol. 13: 671-680, 1995.
PubMed
64) Fletcher GH: Squamous cell carcinomas of the oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 5: 2075-2090, 1979.
PubMed
65) Mendenhall WM, Parsons JT, Stringer SP, et al: Radiotherapy in the treatment of squamous cell carcinoma of the hypopharynx and cervical esophagus. Proc of 4 th International Conference on Head and Neck Cancer, SHNS and ASHNS, 1996, pp. 175-180.
 
66) 中塚貴志: (特集) Quality of Lifeと再建外科 遊離空腸. JOHNS 10: 55-58, 1994.
 
67) 中塚貴志: 遊離結腸移植を用いた下咽頭癌切除後の再建. 頭頸部腫瘍 20: 214, 1994.
 
68) 奥芝俊一, 加藤紘之, 犬山征夫・他: 頭頸部領域癌に対する食道切除・再建症例の検討. 日臨外医会誌 54: 861-864, 1993.
 
69) Lefbbvre J-L: Cancer of the hypopharynx: Strategies for larynx preservation. Proc of 4 th International Conference on Head and Neck Cancer, SHNS and ASHNS, 1996, pp. 170-174.
 
70) Bryce PP: The management of laryngeal cancer. J Otolaryngol. 8: 105-126, 1979.
 
71) Coates HL, DeSanto LW, Devine KD, et al: Carcinoma of the supraglottic larynx. A review of 221 cases. Arch. Otolaryngol, 102: 686-689, 1976.
PubMed
72) Kirchner JA, Som ML: Clinical and histologic observation on supraglottic cancer. Ann. Otol. Rhinol. Laryngol. 80: 638-645, 1971.
PubMed
73) DeSanto LW: Early supraglottic cancer. Ann. Otol. Rhinol. Laryngol. 99: 593-597, 1990.
PubMed
74) Levendag P, Sessions R, Vikram B, et al: The problem of neck relapse in early stage supraglottic larynx. Cancer 63: 345-348, 1989.
PubMed
75) Snow JB, Gelber RD, Kramer S, et al: Comparison of preoperative and postoperative radiation therapy forpatients with carcinoma of the head and neck. Interim report. Acta Otolaryngol. 91: 611-626, 1981.
 
76) Marks JE, Freeman RB, Lee F, et al: Carcinoma of the supraglottic larynx. AJR 132: 255-260, 1979.
PubMed
77) Spaulding CA, Krocha RJ, Hahn SS, et al: Radiotherapeutic management of cancer of the supraglottis. Cancer 57: 1292-1298, 1986.
 
78) Harwood AR, Hawkins NV, Rider WD, et al: Radiation therapy of early glottic cancer. Int. J. Radiat. Oncol. Biol. Phys. 5: 473-476, 1979.
PubMed
79) Karim AB, Snow GB, Hasman A, et al: Dose res radiotherapy for glottic carcinoma. Cancer 41: 1728-1735, 1978.
 
80) Goepfert H, Jesse RH, Fletcher GH, et al: Optimal treatment for technically resectable squamous cell carcinoma of the supraglottic larynx. Laryngoscope 85: 14-32, 1975.
PubMed
81) DeSanto LW: T3 glottic cancer: options and consequences of the options. Laryngoscope 94: 1311-1315, 1984.
PubMed
82) Kaplan MJ, Johns ME, Clark DA, et al: Glottic carcinoma: The role of surgery and irradiation. Cancer 53: 2641-2648, 1984.
 
83) Leroux-Robert J: A statistical study of 620 laryngeal carcinoma of the glottic region personally operated upon more than 5 years ago. Laryngoscope 85: 1440-1452, 1985.
 
84) Yuen A, Medina JE, Goepfert H, et al: Management of stage T 3 and T 4 glottic carcinoma. Am. J. Surg. 148: 467-472, 1984.
 
85) Croll GA, Gerritsen GJ, Tiwari RM, et al: Primary radiotherapy with surgery in reserve for advanced laryngealcarcinoma: Results and complications. Eur. J. Surg. Oncol. 15: 350-356, 1989.
 
86) Mittal B, Marks JE, Ogura JH: Transglottic carcinoma. Cancer 53: 151-161, 1984.
PubMed
87) Harwood AR, Bryce DP, Rider WD: Management of T 3 glottic cancer. Arch. Otolaryngol. 106: 697-699, 1980.
 
88) Shaha AR, Shah Jp: Carcinoma of the subglottic larynx. Am. J. Surg. 144: 456-472, 1982.
PubMed
89) Vermund H: Role of radiotherapy in cancer of the larynx as related to the TNM system of staging. Cancer 25: 485-504, 1970.
 
90) Keim WF, Shapiro MJ, Rosin HD: Study of post laryngectomy stomal recurrence. Arch. Otolaryngol. 81: 183-186, 1965.
 
91) The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy and radiation for laryngeal cancer. N. Engl. J. Med. 324: 1685-1690, 1991.
 
92) Hong WK, Lippman SM, Wolf GT: Recent advances in head and neck cancer-Larynx preservation and cancer chemoprevention. Cancer Res. 53: 5113-5120, 1993,
PubMed
93) Wolf GT, Hong WK, Fisher S, et al: Larynx preservation with induction chemotherapy and radiation inadvanced laryngeal cancer: Final results of the VA Laryngeal Cancer Study Group Cooperative Trial. Proc. ASCO 12: 277, 1993.
 
94) Spaulding MB, Fisher SG, Wolf GT, et al: Tumor response, toxicity and survival after neo-adjuvant organ preserving chemotherapy for advanced laryngeal carcinoma. J. Clin. Oncol. 12: 1592-1599, 1994.
 
95) Tapley N: Irradiation treatment of malignant tumors of the salivary glands. Ear Nose Throat. J. 56: 110-114, 1977.
PubMed
96) Fitzpatrick PJ, Therialut C: Malignant salivary gland tumors. Int. J. Radiat. Oncol. Biol. Phys. 12: 1743-1747, 1986.
 
97) Griffin TW, Pajak TF, Laramore GE, et al: Neutron vs photon irradiation of inoperable salivary gland tumors: Results of an RTOG-MRC Cooperative Randomized Study. Int. J. Radiat. Oncol. Biol. Phys. 15: 1085-1090, 1988.
PubMed
98) Laramore GE, Krall JM, Griffin TW, et al: Neutron versus photon irradiation for unresectable salivary gland tumors l final report of an RTOG-MRC randomized clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 27: 235-240, 1993.
 
99) Johns ME, Kaplan MJ: Malignant neoplasms. In: Otolaryngology Head and Neck Surgery vol 2 (eds by Cummings CW, Fredreickson JM, et al) , Mosby, St Louis, 1986, pp. 1043-1078.
 
100) Vermeer RJ, Pinedo HM: Partial remission of advanced adenoid cystic carcinoma obtained with adriamycin: Acase report with a review of the literature. Cancer 43: 1604-1606, 1979.
 
101) Dimery IW, Legha SS, Shirinian H, et al: Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J. Clin. Oncol. 8: 1056-1062, 1990.
PubMed
102) Robbins KT: Neck dissection: classification and incisions. In: The Neck, diagnosis and surgery (eds byShockery WW, Pillsbury III HC) , Mosby, St Louis, 1994, pp. 381-391.
 
P.931 掲載の参考文献
1) 厚生省老人保健福祉部老人保健課: 老人保健法による肺がん検診マニュアル. 日本醫事新報社, 東京, 1992, pp. 6.
 
2) Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer 75: 191-202, 1995.
PubMed
3) Ihde DC, Pass HI, Glatstein E: Small cell lung cancer. In: Cancer: Principles ＆ Practice of Oncology. 5th Edition (eds. by DeVita VT Jr, Hellman S, Rosenberg SA) , Lippincott-Raven, Philadelphia, 1997, pp. 911-949.
 
4) 岡村明治, 坂井田紀子: I. 診断と病態 5. 病理-組織分類と腺癌の発生母地. 日内会誌 86: 27-32, 1997.
 
5) 北川正信, 浅川三男, 井内康輝・他: 6. 組織分類, 臨床・病理. 肺癌取り扱い規約 (日本肺癌学会編) , 金原出版, 東京, 1995, pp. 89-121.
 
6) Hirsch FR, Matthews MJ, Aisner S, et al: Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 62: 973-977, 1988.
PubMed
7) Minna JD, Sekido Y, Fong K, et al: Molecular biology of lung cancer. In: Cancer: Principles ＆ Practice of Oncology. 5th Edition (eds. by DeVita VT Jr, Hellman S, Rosenberg SA) , Lippincott-Raven, Philadelphia, 1997, pp. 849-857.
 
8) Johnson BE: The role of MYC, JUN, and FOS oncogenes in human lung cancer. In: Lung cancer: Principles and Practice (eds. by Pass HI, Mitchell JB, Johnson DH, et al) . Lippincott-Raven, Philadelphia, 1996, pp. 83-98.
 
9) Johnson BE, Russell E, Simmons AM, et al: MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem. (Suppl.) 24: 210-217, 1996.
PubMed
10) Jiang SX, Kameya T, Sato Y, et al: Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am. J. Pathol. 148: 837-846, 1996.
PubMed
11) Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
PubMed
12) Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
PubMed
13) 秋田弘俊, 川上義和: 小細胞肺がんにおける遺伝子異常. 最新醫學 52: 2661-2666, 1997.
 
14) Whang-Peng J, Kao-Shan CS, Lee EC, et al: Specific chromosome defect associated with human small-cell lung cancer； deletion 3 p (14-23) . Science 215: 181-182, 1982.
 
15) 桑原正喜, 柴田典子, 有吉 寛: 腫瘍マーカーの進歩. 日内会誌 86: 20-26, 1997.
 
16) Stahel RA, Aisner J, Ginsberg R, et al: Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5: 119-126, 1989.
 
17) Albain KS, Crowley JJ, LeBlanc M, et al: Determination of improved outcome in small cell lung cancer. An analysis of the 2, 580-patients Southwest Oncology Group data base. J. Clin. Oncol. 8: 1563-1574, 1990.
 
18) Dearing MP, Steinberg SM, Phelps R, et al: Outcome of patients with small cell lung cancer: Effects of changes in staging procedures and imaging technology on prognostic factors over 14 years. J. Clin. Oncol. 8: 1042-1049, 1990.
PubMed
19) Rawson NS, Peto J: An overview of prognostic factors in small cell lung cancer: A report from the Subcommittee for the management of lung cancer of the United Kingdom Coodinating Committee on Cancer Research. Br. J. Cancer 61: 597-604, 1990.
PubMed
20) Sagman U, Maki E, Evans WK, et al: Small-cell carcinoma of the lung: Derivation of a prognostic staging system. J. Clin. Oncol. 9: 1639-1649, 1991.
PubMed
21) Spiegelman D, Maurer LH, Ware JH, et al: Prognostic factors in small cell carcinoma of the lung: A analysis of 1, 521 patients. J. Clin. Oncol. 7: 344-354, 1989.
PubMed
22) DeWys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. 69: 491-497, 1980.
PubMed
23) Poplin E, Thompson B, Whitacre M, et al: Small cell carcinoma of the lung: Influence of age on treatment outcome. Cancer Treat. Rep. 71: 291-296, 1987.
PubMed
24) Zelen M: Keynote adress on biostatistics and data retrieval Cancer Chemother. Rep. 4: 31-42, 1973.
 
25) Fox W, Scadding JG: Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 2: 63-65, 1973.
PubMed
26) Seydel HG, Creech R, Pagano M, et al: Combined modality treatment of reginal small cell undifferentiated carcinoma of the lung: A cooperative study of the RTOG and ECOG. Int. J. Radiat. Oncol. Biol. Phys. 9: 1135-1141, 1983.
 
27) Petrovich Z, Ohanian M, Cox J: Clinical research on the treatment of locally advanced lung cancer: Final report of VALG Protocol 13 limited. Cancer 42: 1129-1134, 1978.
PubMed
28) Carr DT, Childs DS Jr, Lee RE: Radiotherapy plus 5-FU compared to radiotherapy alone for inoperable and unresectable bronchogenic carcinoma. Cancer 29: 375-380, 1972.
PubMed
29) Choi CH and Carey RW: Small cell anaplastic carcinoma of lung. Reappraisal of current management. Cancer 37: 2651-2657, 1976.
PubMed
30) Green RA, Humphrey E, Close H, et al: Alkylating agents in bronchogenic carcinoma. Am. J. Med. 46: 516-525, 1969.
PubMed
31) Aisner J, Alberto P, Bitran J, et al: Role of chemotherapy in small cell lung cancer: A consensus report of the international association for the study of lung cancer workshop. Cancer Treat. Rep. 67: 37-43, 1983.
 
32) 根来俊一, 福岡正博, 仁井谷久暢・他: カンプトテシン誘導体CPT-11の原発性肺癌に対する後期第II相臨床試験. 癌と化学療法 18: 1013-1019, 1991.
Medical*Online
33) Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC) . Proc, Am. Soc. Clin. Oncol. 101241, 1991 (abstr.) .
 
34) Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10: 1225-1229, 1992.
PubMed
35) Le Chevalier T, Ibrahim N, Chomy P, et al: A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT) . Proc. Am. Soc. Clin. Oncol. 16: 450a, 1997 (abstr.) .
 
36) Schiller JH, Kim KM, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. 14: 2345-2352, 1996.
 
37) Perez-Soler R, Glisson BS, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the to poisomerase I poison topotecan. J. Clin. Oncol. 14: 2785-2790, 1996.
PubMed
38) Eckardt J, Depierre A, Ardizzoni A, et al: Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. 16: 452 a, 1997 (abstr.) .
 
39) Ettinger DS, Finkelsteine DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-diseasesmall-cell lung cancer: An Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 13: 1430-1435, 1995.
 
40) Kirschling RJ, Jung SH, Jett JR: A phase II Study of taxol and GCSF in previously unterated patients with extensive stage small cell lung cancer (SCC) . Proc. Am. Soc. Clin. Oncol. 13: 326, 1994 (abstr.) .
 
41) Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. Eur. J. Cancer 30A: 1058-1060, 1994.
PubMed
42) 横山 晶, 栗田雄三, 渡辺古志郎・他: 原発性肺癌に対するRP 56976 (docetaxel) の前期第II相臨床試験. 癌と化学療法 21: 2609-2616, 1994.
Medical*Online
43) Latreille J, Cormier Y, Martins H, et al: Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. Invest. New Drugs 13: 343-345, 1996.
PubMed
44) Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC) . Ann. Oncol. 51283-285, 1994.
 
45) Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe Ch, et al: Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur. J. Cancer 29A: 1720-1722, 1993.
PubMed
46) Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 53: 169-172, 1996.
PubMed
47) Lake D, Johnson E, Herndon J, et al: Phase II trial of Navelbine (NVB) in relapsed small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. 16: 473 a, 1997 (abstr.) .
 
48) 根来俊一, 梁 尚志, 横田総一郎・他: SM-5887 (amrubicin) の進展型小細胞肺癌に対する第II相臨床試験. 日癌治療会誌 32: 508, 1997 (抄録) .
 
49) 福岡正博: 肺癌, 呼吸器腫瘍, 小細胞癌. 最新内科学大系63, (井村裕夫, 尾形悦郎, 高久文麿, 他編) , 中山書店, 東京, 1994, pp. 163-181.
 
50) Einhorn LH, Greco A, Wampler G, et al: Cytoxan, adriamycin, etoposide versus cytoxan, adriamycin, vincristine in the treatment of small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 6: 168, 1987 (abstr.) .
 
51) Jett JR, Everson L, Therneau TM, et al: Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: A randomized study of the North Central Cancer Treatment Group. J. Clin. Oncol. 8: 33-38, 1990.
PubMed
52) Jackson DV Jr, Case LD, Zekan PJ, et al: Improvement of long-term survival in extensive small cell lung cancer. J. Clin. Oncol. 6: 1161-1169, 1988.
PubMed
53) Messeih AA, Schweitzer JM, Lipton A, et al: Addition of etoposide to cyclophosphamide, doxorubicine, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat. Rep. 71: 61-66, 1987.
PubMed
54) Lowenbraun S, Birch R, Buchanan R, et al: Combination chemotherapy in small cell lung carcinoma: A randomized study of two intensive regimens. Cancer 54: 2344-2350, 1984.
PubMed
55) Schabel FM, Trader MW, Laster WK, et al: Cisdichlorodiammineplatinum (II) : Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat. Rep. 63: 1459-1473, 1979.
 
56) Evans WK, Osoba D, Feld R, et al: Etoposide (VP-16) and cisplatin: An effective treatment for relapse of small-cell lung cancer. J. Clin. Oncol. 3: 65-71, 1985.
PubMed
57) Porter LL 3 rd, Johnson DH, Hainsworth JD, et al: Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat. Rep. 69: 479-481, 1985.
 
58) Einhorn LH, Crawford J, Birch R, et al: Cisplatin plus etoposide consolidation in following cyclophosphamide, doxorubicin, and vincristine in limited small cell lung cancer. J. Clin. Oncol. 6: 451-456, 1988.
PubMed
59) Evans WK, Shepherd FA, Feld R, et al: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J. Clin. Oncol. 3: 1471-1477, 1985.
PubMed
60) Sierocki JS, Hilaris BS, Hopfan S, et al: Cisdichlorodiammineplatinum (II) and VP-16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat. Rep. 63: 1593-1597, 1978.
 
61) Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J. Natl. Cancer Inst. 83: 855-861, 1991.
PubMed
62) Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the southeastern cancer study group. J. Clin. Oncol. 10: 282-291, 1992.
 
63) Smith IE, Evans BD, Gore ME, et al: Carboplatin (Paraplatin；JM 8) and etoposide (VP-16) as first-line combination therapy for small cell lung cancer. J. Clin. Oncol. 5: 185-189, 1987.
PubMed
64) BishoP JF, Raghavan D, Stuart-Harris R, et al: Carboplatin (CBDCA, JM 8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J. Clin. Oncol. 5: 1574-1578, 1987.
PubMed
65) Evans WK, Eisenhauer E, Hughes P, et al: VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Br. J. Cancer 58: 464-468, 1988.
 
66) Thatcher N, Cerny T, Stout R, et al: Ifosfamide, etoposide and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer 60: 2382-2387, 1987.
PubMed
67) Wolf M, Havemann K, Holle R, et al: Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J. Clin. Oncol. 5: 1880-1889, 1987.
 
68) Thatcher N, Lind M, Stout R, et al: Carboplatin, ifosfamide, and etoposide with mid-course vincristine and thoracic radiotherapy for limited stage small cell lung carcinoma of the bronchus. Br. J. Cancer 60: 98-101, 1989.
PubMed
69) Smith IE, Perren TJ, Ashley SA, et al: Carboplatin, etoposide and ifosfamide as intensive chemotherapy for small-cell lung cancer. J. Clin. Oncol. 8: 899-905, 1990.
PubMed
70) Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat. Rep. 66: 439-449, 1982.
PubMed
71) Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized trial by the National Cancer Institute of Canada. Ann. Intern. Med. 107: 451-458, 1987.
PubMed
72) Feld R, Evans WK, Coy P, et al: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small cell carcinoma of the lung. J. Clin. Oncol. 5: 1401-1409, 1987.
PubMed
73) Bunn PA, Curren M, Fukuoka M, et al: Chemotherapy in small cell lung cancer: aconsensus report. Lung Cancer 5: 127-134, 1989.
 
74) Coldman AJ, Goldie JH: Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin. Oncol. 14 (Suppl. 4) : 29-33, 1987.
 
75) Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 2: 1281-1288, 1984.
PubMed
76) Sculier Jp, Klastersky J, Finet C, et al: Intensive multiple drug induction chemotherapy for small cell lungcancer: apilot study. Drug Invest. 2 (2) : 99-104, 1990.
 
77) Taylor CW, Crowley J, Williamson SK, et al: Treatment of small cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. J. Clin. Oncol. 8: 1811-1817, 1990.
 
78) Miles DW, Earl HM, Souhami RL, et al: Intensive weekly chemotherapy for good-rognosis patients with small cell lung cancer. J. Clin. Oncol. 9: 280-285, 1991.
 
79) Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J. Clin. Oncol. 9: 1632-1638, 1991.
PubMed
80) Fukuoka M, Masuda N, Negoro S, et al: CODE chemotherapy with and without granulocyte colony-stimulating factor in smal1-cell lung cancer. Br. J. Cancer 75: 306-309, 1997.
PubMed
81) Furuse K, Fukuoka M, Nishiwaki Y, et al: Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small cell lung cancer. J. Clin. Oncol. 16: 2126-2132, 1998.
PubMed
82) Murray N, Livingston R, Shepherd F, et al: A randomized study of CODE plus thoracic irradiating versus alternating CAV/EP for extensive stage small cell lung cancer (ESCLC) . Proc. Am. Soc. Clin. Oncol. 16: 456a, 1997 (abstr.) .
 
83) Miles DW, Souhami RL, Spiro SG, et al: A randomized trial comparing standard 3 weekly with weekly chemotherapy in patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 11: 289, 1992 (abstr.) .
 
84) Figueredo AT, Hryniuk WM, Strautmanis I, et al: Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J. Clin. Oncol. 3: 54-63, 1985.
PubMed
85) Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 5: 1731-1738, 1987.
 
86) Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-doseetoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 12: 2022-2034, 1994.
PubMed
87) Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. J. Med. 329: 1848-1852, 1993.
PubMed
88) Ihde DC, Deisseroth AB, Lichter AS, et al: Late intensive combined modality therapy followed by autologousbone marrow infusion in extensive-stage small-cell lung cancer. J. Clin. Oncol. 4: 1443-1454, 1986.
 
89) Harper PG, Souhami RL: Intensive chemotherapy with autologous bone marrow transplantation in small cell lung carcinoma of the lung. Recent Results Cancer Res. 97: 146-156, 1985.
PubMed
90) Elias AD, Ayash L, Frei E 3 rd, et al: Intensive combined modality therapy for limited-stage small-cell lung cancer. J. Natl. Cancer Inst. 85: 559-566, 1993.
 
91) Kudoh S, Fujiwara Y, Takada Y, et al: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J. Clin. Oncol. 16: 1068-1074, 1998.
PubMed
92) Hainsworth JD, Stroup SL, Greco FA: Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma. Cancer 77: 2458-2463, 1996.
PubMed
93) Hainsworth JD, Gray JR, Hopkins LG, et al: Paclitaxel (1-hour infusion) , carboplatin, and extended schedule etoposide in small cell lung cancer (SCLC) : areport on 117 patients (pts) treated by the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin, Oncol. 16: 451 a, 1997 (abstr.)
 
94) Gatzemeier U, Jagos U, Kaukel E, et al: Phase II study of paclitaxel, carboplatin and etoposide in patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 16: 468 a, 1997 (abstr.) .
 
95) Nair S, Marschke R, Grill J, et al: Aphase II study of paclitaxel (Taxol) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC) . Proc. Am. Soc. Clin. Oncol. 16: 454 a, 1997 (abstr.) .
 
96) Glisson BS, Kurie JM, Fox NJ, et al: Phase I-II study of cisplatin, etoposide, and paclitaxel (PET) in patients with extensive small cell lung cancer (ESCLC) . Proc. Am. Soc. Clin. Oncol. 16: 455 a, 1997 (abstr.) .
 
97) Higgins GA, Shields TW, Keehn RJ: The solitary pulmonary nodule. Ten-year follow-up of Veterans Administration-Armed Forces Cooperative Study. Arch. Surg. 110: 570-575, 1975.
PubMed
98) Davis S, Wright PW, Schulman SF, et al: Long-term survival in small cell carcinoma of the lung: a population experience. J. Clin. Oncol. 3: 80-91, 1985.
PubMed
99) Ginsberg RJ: Surgery and small cell lung cancer-an overview. Lung Cancer 5: 232-236, 1989.
 
100) Ohta M, Hara N, Ichinose Y, et al: The role of surgical resection in the management of small cell carcinoma of the lung. Jpn. J. Clin. Oncol. 16: 289-296, 1986.
PubMed
101) Shepherd FA, Ginsberg RJ, Patterson GA, et al: A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. J. Thorac. Cardiovasc. Surg. 97: 177-186, 1989.
PubMed
102) Holoye PY, McMurtrey MJ, Mountain CF, et al: The role of adjuvant surgery in the combined modality therapy of small cell bronchogenic carcinoma after a chemotherapy induced partial remission. J. Clin. Oncol. 8: 416-422, 1990.
PubMed
103) Williams CJ, McMillan I, Lea R, et al: Surgery after initial chemotherapy for localized small cell carcinoma of the lung. J. Clin. Oncol. 5: 1579-1588, 1987.
PubMed
104) Johnson DH, Einhorn LH, Mandelbaum I, et al: Postchemotherapy resection of residual tumor in limited stage small cell lung cancer. Chest 92: 241-246, 1987.
PubMed
105) Lad T, Thomas P, Piantadosi S, et al: Surgical resection of small cell lung cancer-a prospective randomized evaluation. Proc. Am. Soc. Clin. Oncol. 10: 244, 1991 (abstr.) .
 
106) Pignon JP, Arriagada R, Ihde DC, et al: Ameta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327: 1618-1624, 1992.
 
107) Tada T, Minakuchi K, Akae M, et al: Local failure in patients treated with chemo-radiotherapy for limited disease small cell lung cancer. Proc. RSNA Radiology l997 (abstr.) .
 
108) Perez CA, Stanley K, Grundy G, et al: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-small cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer 50: 1091-1099, 1982.
PubMed
109) Healey EA, Abner A: Thoracic and cranial radiotherapy for limited-stage small cell lung cancer. Chest 107 (6 Suppl.) : 249 S-254 S, 1995.
 
110) Mornex F, Trillet V, Chauvin F, et al: Hyperfractionated radiotherapy alternating with multidrug chemotherapy in the treatment of limited small cell lung cancer (SCLC) . Groupe Lyonnais d’Oncologie Thoracique. Int. J. Radiat. Oncol. Biol. Phys. 19: 23-30, 1990.
 
111) Tada T, Minakuchi K, Fujioka T, et al: Pilot study of intermittent irradiation synchronized with respiratory motion with use of original system in lung cancer. Proc. RSNA Radiology 1997 (abstr.) .
 
112) Withers HR: Response of tissue to multiple small dose fractions. Radiat. Res. 71: 24-33, 1977.
PubMed
113) Begg AC, Hofland I, Van Glabekke, et al: Predictive value of potential doubling time for radio therapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin. Radiat. Oncol. 2: 22-25, 1992.
 
114) Saunders MI and Dische S: Continuous hyperfractionated accelerated radiotherapy. Semin. Radiat. Oncol. 2: 41-44, 1992.
 
115) Johnson DH, Turrisi AT, Chang AY, et al: Alternating chemotherapy and twice-daily thoracic radiotherapy inlimited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 11 (5) : 879-884, 1993.
 
116) Johnson DH, Bass D, Einhorn LH, et al: Combination chemotherapy with or without thoracic radiotherapy inlimited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 11 (7) : 1223-1229, 1993.
PubMed
117) Johnson DH, Kim K, Sause W, et al: Cisplatin (P) ＆ etoposide (E) + thoracic radiotherapy (TRT) administeredonce or twice daily (BID) in limited stage (LS) small cell lung cancer (SCLC) : Final report of Intergroup Trial OO96. Proc. Am. Soc. Clin. Oncol. 15: 374, 1996 (abstr.) .
 
118) Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N. Engl. J. Med. 316: 912-918, 1987.
 
119) Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J. Clin. Oncol. 11: 336-344, 1993.
PubMed
120) Murray N, Payne DG, Coldman AJ: Multimodality therapy for limited small cell lung cancer: Combining chemotherapy and thoracic irradiation. In: Lung cancer: principles and practice (eds. by Pass HI, Mitchell JB, Johnson DH, et al) , Lippincott-Raven, Philadelphia, 1996, pp. 875-898.
 
121) Fox RM, Woods RL, Brodie GN, et al: A randomized study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 6: 1083-1085, 1980.
PubMed
122) Souhami RL, Geddes DM, Spiro SG, et al: Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br. Med. J. 288: 1643-1646, 1984.
 
123) Kies MS, Mira JG, Crowley JJ, et al: Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders；and with wide-field versus reduced-field radiation in partial responders: A Southwest Oncology Group study. J. Clin. Oncol. 5: 592-600, 1987.
PubMed
124) Nou, Brodin O, Bergh J: A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens. Cancer 62: 1079-1090, 1988.
 
125) Perez CA, Einhorn L, Oldham RK, et al: Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: A preliminary report. J. Clin. Oncol. 2: 1200-1208, 1984.
 
126) Gregor A, Drings P, Burghouts J, et al: Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: A European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group study. J. Clin. Oncol. 15: 2840-2849, 1997.
 
127) Lebeau B, Chastang CI, Urban T, et al: Arandomized clinical trial comparing concurrent and alternated thoracic irradiation in limited small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. 15: 383, 1996 (abstr.) .
 
128) McCracken JD, Janaki LM, Crowley JJ, et al: Concurrent chemotherapy/radiotherapy for limited small cell lung carcinoma: a Southwest Oncology Group study. J. Clin. Oncol. 8: 892-898, 1990.
 
129) Kwiatkowski DJ, Propert KJ, Carey RW, et al: A phase II trial of cyclophosphamide, etoposide, and cisplatin with combined chest and brain radiotherapy in limited small cell lung cancer: a Cancer and Leukemia Group B study. J. Clin. Oncol. 5: 1874-1879, 1987.
 
130) Turrisi AT, Glover DJ, Mason BA: A preliminary report: Concurrent twice-daily radiotherapy plus platinumetoposide chemotherapy for limited small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 15: 183-187, 1988.
PubMed
131) Turrisi AT, Wagner D, Glover B, et al: Limited small cell lung cancer: concurrent BID thoracic radiotherapy with platinum-etoposide: an ECOG study. Proc. Am. Soc. Clin. Oncol. 9: 230, 1990 (abstr.) .
 
132) Johnson BE, Bridges JD, Sobczeck M, et al: Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J. Clin. Oncol. 14: 806-813, 1996.
PubMed
133) Takada M, Fukuoka M, Furuse K, et al: Phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (C) and etoposide (E) for limited-stage (LS) small cell lung cancer (SCLC) : Preliminary results of the Japan Clinical Oncology Group (JCOG) . Proc. Am. Soc. Clin. Oncol. 15: 372, 1996 (abstr.) .
 
134) Roach M, Gandara DR, Yuo HS, et al: Radiation pneumonitis following combined modality therapy for lungcancer: analysis of prognostic factors. J. Clin. Oncol. 13 (10) : 2606-2612, 1995.
 
135) 新部英男, 長谷川正俊: 放射線治療に伴う副作用 急性障害とその対策. 癌・放射線療法 ' 95 (大川智彦編) , 篠原出版, 東京, 1995, pp. 395-406.
 
136) 酒井邦夫, 末山博男: 放射線治療の晩期障害とその対策. 癌・放射線療法'95 (大川智彦編) , 篠原出版, 東京, 1995, pp. 407-418.
 
137) Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Engl. J. Med. 325: 164-170, 1991.
PubMed
138) Trillet-Lenoir N, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer 29 A: 319-324, 1993.
 
139) Spiro SG, Souhami RL, Geddes DM, et al: Duration of chemotherapy in small cell lung cancer: A Cancer Research Campaign trial. Br. J. Cancer 59: 578-583, 1989.
PubMed
140) Bleehan NM, Fayers PM, Girling DJ, et al: Controlled trial of twelve versus six courses of chemotherapy in thetreatment of small cell lung cancer: Report to the Medical Research Council by its Lung Cancer Working Party. Br. J. Cancer 59: 584-590, 1989.
 
141) Giaccone G, Dalesio O, McVie GJ, et al: Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial. J. Clin. Oncol. 11: 1230-1240, 1993.
 
142) Jackson DV, Richards F 2 d, Cooper MR, et al: Prophylactic cranial irradiation in small cell carcinoma of the lung. JAMA 237: 2730-2733, 1977.
 
143) Cox JD, Petrovich Z, Paig C, et al: Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. Cancer 42: 1135-1140, 1978.
PubMed
144) Beiler DD, Kane RC, Bernath AM, et al: Low dose elective brain irradiation in small cell carcinoma of the lung. Int. J. Radiat. Oncol. Biol. Phys. 5: 941-945, 1979.
PubMed
145) Maurer LH, Tulloh M, Weiss RB, et al: A randomized combined modality trial in small cell carcinoma of the lung: Comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy: Effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 45: 30-39, 1980.
PubMed
146) Hansen HH, Dombernowsky P, Hirsch FR, et al: Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma: A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy. Cancer 46: 279-284, 1980.
PubMed
147) Eagan RT, Frytak S, Lee RE, et al: Acase for preplanned thoracic and prophylactic whole brain radiation therapy in limited small cell lung cancer. Cancer Clin. Trials 4: 261-266, 1981.
 
148) Katsenia AT, Karpasitis N, Giannakakis D, et al: Elective brain irradiation in patients with small-cell carcinoma of the lung: Preliminary report. Lung Cancer International Congress Series 558, Excepta Medica, Amsterdam, 1982, pp, 277-284.
 
149) Seydel HG, Creech R, Pagano M, et al: Prophylactic versus no brain irradiation in regional small cell carcinoma of the lung. Am. J. Clin. Oncol. 8: 218-223, 1985.
PubMed
150) Aroney RS, Aisner J, Wesley MN, et al: Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat. Rep. 67: 675-682, 1983.
PubMed
151) Niiranen A, Holsti P, Salmo M: Treatment of small cell lung cancer. Two-drug versus four-drug chemotherapy and loco-regional irradiation with or without prophylactic cranial irradiation. Acta Oncol. 28: 501-505, 1989.
PubMed
152) Arriagada R, Le Chevalier T, Borie F, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. Natl. Cancer. Inst. 87: 183-190, 1995.
PubMed
153) Kristjansen PEG: Prophylactic cranial irradiation. In: Lung cancer (eds. by Johnson BE, Johnson DH) , Wiley-Liss, New York, 1995, pp. 303-318.
 
154) Shaw EG, Su JQ, Eagan RT, et al: Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J. Clin. Oncol. 12 (11) : 2327-2332, 1994.
 
155) Cull A, Gregor A, Hopwood P, et al: Neurological and cognitive impairment in long-term survivors of small cell lung cancer. Eur. J. Cancer 30 (8) : 1067-1074, 1994.
 
156) 上岡 博, 大熨泰亮, 沼田健之・他: 肺小細胞癌における再発様式の検討とその対策. 日胸疾会誌 28: 1581-1587, 1990.
 
157) Work E, Bentzen SM, Nielsen OS, et al: Prophylactic cranial irradiation in limited stage small cell lung cancer: survival benefit in patients with favourable characteristics. Eur. J. Cancer 32 A (5) : 772-778, 1966.
 
158) 多田卓仁, 水口和夫, 甲田真由子・他: 限局型小細胞肺癌完全寛解症例に対する Prophylactic Cranial Irradiation. 肺癌37: 849-854, 1997.
 
159) Healey EA, Abner A: Thoracic and cranial radiotherapy for limited-stage small cell lung cancer. Chest 107 (6 SuppL) : 249 S-254 S, 1995.
 
160) Gregor A, Cull A, Stephens RJ, et al: Effects of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC) ；Results of UKCCCR/EORTC randomized trial. Proc. Am. Soc. Clin. Oncol. 15: 381, 1996 (abstr.) .
 
161) Nussbaum ES, Djalilian HR, Cho KH, et al: Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78 (8) : 1781-1788, 1996.
PubMed
162) Bach F, Sorensen JB, Adrian L, et al: Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiation. Lung Cancer 15 (2) : 171-181, 1996.
PubMed
163) Kurtz JM, Gelber R, Brady LW, et al: The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 7: 891-895, 1981.
 
164) Bogelt B, Gelber R, Larsen M, et al: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final result of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 7: 1633-1638, 1981.
 
165) 池田裕子, 田中正博, 小田淳郎・他: 転移性脳腫瘍に対する定位手術的照射と全脳照射. 日放腫会誌 10: 61-68, 1988.
 
166) Smith IE, Sappino AP, Bondy PK, et al: Long-term survival five years or more after combination chemotherapy and radiotherapy for small cell lung carcinoma. Eur. J. Cancer Clin. Oncol. 17: 1249-1253, 1981.
PubMed
167) Livingston RB, Stephens RL, Bonnet JD, et al: Long-term survival and toxicity in small cell lung cancer. Am. J. Med. 77: 415-417, 1984.
PubMed
168) Vogelsang GB, Abeloff MD, Ettinger DS, et al: Long-term survivors of small cell carcinoma of the lung. Am. J. Med. 79: 49-56, 1985.
PubMed
169) Johnson BE, Grayson J, Makuch RW, et al: Ten-year survival of patients with small cell lung cancer treated with combination chemotherapy with or without irradiation. J. Clin. Oncol. 8: 396-401, 1990.
PubMed
170) Jacobs RH, Greenburg A, Bitran JD, et al: Aten-year experience with combined modality therapy for stage III small cell lung carcinoma. Cancer 58: 2177-2184, 1986.
 
171) Osterlind K, Hansen HH, Hansen M, et al: Long-term disease-free survival in small-cell lung carcinoma of the lung: Astudy of clinical determinants. J. Clin. Oncol. 4: 1307-1313, 1986.
 
172) Fukuoka M, Masuda N, Matsui K, et al: Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of 5-year follow-up. Cancer 65: 1678-1684, 1990.
 
173) Johnson BE, Ihde DC, Matthews MJ, et al: Non-small cell lung cancer: Major cause of latemortality in small cell lung cancer patients. Am. J, Med. 80: 1103-1110, 1986.
 
174) DeVore RF, Blanke CD, Denham CA, et al: Phase II study of irinoteca (CPT-11) in patients with previous lytreated small-cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. 17: 451 a, 1998 (abstr.) .
 
175) Burris HA, Crowley JJ, Williamson DR, et al: Docetaxel (Taxotere) in extensive stage small cell lung cancer (SCLC) : Aphase II trial of the Southwest Oncology Group (SWOG) . Proc. Am. Soc. Clin. Oncol. 17: 451 a, 1998 (abstr.) .
 
176) Masuda N, Matsui K, Negoro S, et al: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 16: 3329-3334, 1998.
 
177) Geoffroy FJ, Perez EA, Durazo-Arvizu R, et al: Phase II study of oral etoposide and intravenous (IV) paclitaxelin extensive small cell lung cancer (SCLC) : A North Central Cancer Treatment Group. Proc. Am. Soc. Clin. Oncol. 17: 474 a, 1998 (abstr.) .
 
178) Smit EF, Fokkema E, Biesma B, et al: Aphase II study of paclitaxel (P) and carboplatin (C) in patients (PTS) with early relapse small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. 17: 474 a, 1998 (abstr.) .
 
179) Sonpavde G, Ansari R and Einhorn LH: Aphase II trial of bolus doxorubicin and 3-hour paclitaxel as second line chemotherapy of small-cell lung cancer: AHoosier Oncology Group (HOG) Trial. Proc. Am. Soc. Clin. Oncol. 17: 475 a, 1998 (abstr.) .
 
180) Crossen JR, Garwood D, Glatstein E, et al: Neurobehavioral sequelae of cranial irradiation in adults: A revie wof radiation-induced encephalopathy. J. Clin. Oncol. 12: 627-642, 1994.
 
181) 野本靖史, 宮本忠昭, 安川朋久・他: 肺小細胞癌脳転移に対する放射線療法-適正制御線量の検討-. 日医放会誌 58: 226-234, 998.
 
182) Turrisi AT: Personal communication. May 1998.
 
117 ') Turrisi A, Kim K, Sause W, et al: Observations after Syear follow-up of Intergroup Trial OO96: 4 cycles of cisplatin (P) Etoposide (E) and concurrent 45 Gy thoracic radio therapy (TRT) given in daily (QD) or twice daily fractions followed by 25 Gy PCI. Survival differences and patterns of failure. Proc. Am. Soc. Clin. Oncol. 17: 457a, 1998 (abstr.) .
 
118 ') Perry Me, Herndon III JE, Eaton WL, et al: Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of Cancer and Leukemia Group B Study 8083. J. Clin. Oncol. 16: 2466-2467, 1998.
 
P.960 掲載の参考文献
1) Pisani P, Parkin DM, Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer 55: 891-903, 1993.
PubMed
2) 国民衛生の動向. 厚生の指標 (臨時増刊) 44巻9号, 厚生統計協会, 1997.
 
3) Bellin NI, Buncher CR, Fontana RS, et al: National Cancer Institute Cooperative lung Cancer Detection Program: Results of initial screen (prevalence) early lung cancer detection-Introduction. Am. Rev. Resp. Dis. 130: 545-549, 1984.
 
4) Bellin NI, Buncher CR, Fontana RS, et al: Early lung cancer detection: Summary and conclusions. Am. Rev. Resp. Dis. 130: 565-570, 1984.
 
5) Sobue T, Suzuki T, Naruke T: A case-control study for evaluating lung-cancer screening in Japan. Int. J. Cancer 50: 230-237, 1992.
PubMed
6) Kreyberg L, for The World Health Organization: The World Health Organization histological typing of lung tumors. Am. J. Clin. Pathol. 77: 123-136, 1982.
 
7) 日本肺癌学会組織分類委員会: 組織分類. 臨床・病理肺癌取扱い規約 (日本肺癌学会編) , 改訂第4版, 金原出版, 東京, 1995, pp. 90-121,
 
8) Vansteenkiste JF, Stroobants SG, De Leynet PR, et al: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J. Clin. Oncol. 16: 2142-2149, 1998.
 
9) Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
PubMed
10) Ginsberg R, Rubinstein L, and the Lung Cancer Study Group: Randomized trial of lobectomy versus limited resection for T 1 N 0 non-small cell lung cancer. Ann. Thorac. Surg. 60: 615-622, 1995.
 
11) Paone JF, Spees EK, Newton CG, et al: An appraisal of en bloc resection of peripheral bronchogenic carcinoma involving the thoracic wall. Chest 81: 203-207, 1982.
PubMed
12) Patterson GA, Ilves R, Ginsberg RJ, et al: The value of adjuvant radiotherapy in pulmonary and chest wall resection for bronchogenic carcinoma. Ann. Thorac. Surg. 34: 692-697, 1982.
PubMed
13) Piehler JM, Pairolero PC, Weiland LH, et al: Bronchogenic carcinoma with chest wall invasion: Factors affecting survival following en bloc resection. Ann. Thorac. Surg. 34: 684-692, 1982.
PubMed
14) McCaughan BC, Martini N, Bains MS, et al: Chest wall invasion in carcinoma of the lung: Therapeutic and prognostic implications. J. Thorac. Cardiovasc. Surg. 89: 836-841, 1985.
PubMed
15) Allen MS, Mathisen DJ, Grillo HC, et al: Bronchogenic carcinoma with chest wall invasion. Ann. Thorac. Surg. 51: 948-951, 1991.
PubMed
16) Rice TW, Pringle JF, Sinclair JE, et al: Superior sulcus tumors: results of treatment. Lung Cancer 2: 156, 1986 (Abstr.) .
 
17) Anderson TM, Moy PM, Homes EC: Factors affecting survival in superior sulcus tumors. J. Clin. Oncol. 4: 1598-1603, 1986.
 
18) Dartevelle P, Marzelle J, Chapelier A, et al: Extended operations for T 3-T 4 primary lung cancers: Indications and results. Chest 96 (suppl.) : 51-53, 1989.
 
19) Komaki R, Mountain CF, Holbert JM, et al: Superior sulcus tumors: Treatment selection and results for 85 patients without metastasis (M 0) at presentation. Int. J. Radiat. Oncol. Biol. Phys. 19: 31-36, 1990.
 
20) Ginsberg RJ, Martini N, Zaman M, et al: Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann. Thorac. Surg. 57: 1440-1445, 1994.
PubMed
21) Naruke T, Goya T, Tsuchiya R, et al: The importance of surgery to non-small cell carcinoma of the lung with mediastinal lymph node metastasis. Ann. Thorac. Surg. 46: 603-610, 1988.
PubMed
22) Goldstraw P, Mannam GC, Kaplan DK, Michail P: Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N 2 disease) . J Thorac. Cardiovasc. Surg. 107: 19-27, 1994.
 
23) Kirsch MM, Sloan M: Mediastinal metastasis in bronchogenic carcinoma: Influence of postoperative irradiation, cell type and location. Ann. Thorac. Surg. 33: 459-463, 1982.
 
24) Martini N, Flehinger BJ: The role of surgery in N 2 lung cancer. Surg. Clin. North Am. 67: 1037-1049, 1987.
 
25) Mountain CF: The biological operability of stage III non-small cell lung cancer. Ann. Thorac. Surg. 40: 60-64, 1985.
PubMed
26) Pearson FG, Delarue NC, Ilves R, et al: Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J. Thorac. Cardiovasc. Surg. 83: 1-11, 1982.
PubMed
27) Coughlin M, Deslauriers J, Beaulieu M, et al: Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann. Thorac. Surg. 40: 556-560, 1985.
PubMed
28) Naruke T, Goya T, Tsuchiya R, et al: Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiovasc. Surg. 96: 440-447, 1988.
PubMed
29) Deslauriers J: Survival in patients undergoing tracheal sleeve pneumonectomy for bronchogenic carcinoma. J. Thorac. Cardiovasc. Surg. 84: 489-496, 1982.
 
30) Dartevelle PG, Khalife J, Chapelier A, et al: Tracheal sleeve pneumonectomy for bronchogenic carcinoma: Report of 55 cases. Ann. Thorac. Surg. 46: 68-72, 1988.
PubMed
31) Mastrorilli M, Bragaglia RB, Cippola D, et al: The tracheo-bronchioplastic procedure for lung cancer. Lung Cancer 4: 87, 1988 (Abstr.) .
 
32) Salerno TA, Little JR, Munro DD: Bronchogenic carcinoma with a brain metastasis: A continuing challenge. Ann. Thorac. Surg. 27: 235-237, 1979.
PubMed
33) Mussi A, Janni A, Pistolesi M, et al: Surgical treatment of primary lung cancer and solitary brain metastasis. Thorax 40: 191-193, 1985.
PubMed
34) Maglligan DJ, Duvernoy C, Malik G, et al: Surgical approach to lung cancer with solitary cerebral metastasis: Twenty-five year 's experience. Ann. Thorac. Surg. 42: 360-364, 1986.
 
35) Read RC, Boop WC, Yoder G, et al: Management of non-small-cell lung carcinoma with solitary brain metastasis. J. Thorac. Cardiovasc. Surg. 98: 884-891, 1989.
 
36) Van Houtte P, Rocmans P, Smets P, et al: Postoperative radiation therapy in lung cancer: A controlled trial after resection of curative design. Int. J. Radiat. Oncol. Biol. Phys. 6: 983-986, 1980.
PubMed
37) Weisenburger TH (for the Lung Cancer Study Group) : Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid carcinoma of the lung. N. Engl. J. Med. 315: 1377-1381, 1986.
 
38) Slack NH: Bronchogenic carcinoma: Nitrogen mustard as a surgical adjuvant and factors influencing survival. University surgical adjuvant lung Project. Cancer 25: 987-1002, 1970.
PubMed
39) Shields TW, Higgins Jr GA, Humphrey EW, et al: Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer 50: 1713-1721, 1982.
 
40) Brunner KW, Marthaler T, Muller W: Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-2627. 2) for radically resected bronchogenic carcinoma. Cancer Chemother. Rep. 4: 125-132, 1973.
 
41) Holmes EC, Gail M, for the Lung Cancer Study Group: Surgical adjuvant therapy for stage II and III adenocarcinoma and large-cell undifferentiated carcinoma. J. Clin. Oncol. 4: 710-715, 1986.
 
42) Lad T, Rubinstein L, Sadeghi A: The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer. J. Clin. Oncol. 6: 9-17, 1988.
 
43) Feld R, Rubenstein L, Thomas P, et al: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. J. Natl. Cancer Inst. 85: 299-306, 1993.
 
44) Figlin RA, Piantadosi S: A phase III randomized trial of immediated combination chemotherapy versus delayed combination chemotherapy in patients with stage II and III non-small cell carcinoma of the lung. Chest 106: 310S-312S, 1994.
 
45) Niiranen A, Niitamo-Korhonen S, Kouri M, et al: Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: a randomized study. J. Clin. Oncol. 10: 1927-1932, 1992.
PubMed
46) Ohta M, Tsuchiya R, Shimoyama M, et al: Adjuvant chemotherapy for completely resected stage III non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 106: 703-708, 1993.
PubMed
47) Wada H, Hitomi S, Teramatsu T: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J. Clin. Oncol. 14: 1048-1054, 1996.
 
48) Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
 
49) Ginsberg RJ: Neoadjuvant (induction) treatment for non-small cell lung cancer. Lung Cancer 12 (Suppl. 2) : S33-S40, 1995.
 
50) Martini N, Kris MG, Flehinger BJ, et al: Preoperative chemotherapy for III a (N 2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg. 55: 1365-1373, 1993.
 
51) Burkes RL, Ginsberg RJ, Shepherd FA, et al: Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J. Clin. Oncol. 10: 580-586, 1992.
PubMed
52) Takifuji N, Fukuoka M, Yasumitsu T, et al: Neoadjuvant chemotherapy in stage IIIA N 2 non-small cell lung cancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. 11: 309, 1992 (Abstr.) .
 
53) Rusch VW, Albain KS, Crowley JJ, et al: Surgical resection of stage IIIA and stage IIIB non-small cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J. Thorac. Cardiovasc. Surg. 105: 97-104, 1993.
 
54) Rusch VW, Albain KS, Crowley JJ, et al: Neoadjuvant therapy: anovel and effective treatment for stage IIIB non-small cell lung cancer. Southwest Oncology Group. Ann. Thorac. Surg. 58: 290-294, 1994.
 
55) Skarin A, Jochelson M, Sheldon T, et al: Neoadjuvant chemotherapy in marginally resectable stage III M O non-small cell lung cancer: Long-term follow-up in 41 patients. J. Surg. Oncol. 40: 266-274, 1989.
 
56) Eagan RT, Ruud C, Lee RE, et al: Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M O non-small cell lung cancer. Cancer Treat. Rep. 71: 895-900, 1987.
 
57) Taylor SG, Trybula M, Bonomi PD, et al: Simultaneous cisplatin, fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III non-small cell lung cancer. Ann. Thorac. Surg. 43: 87-91, 1987.
PubMed
58) Weiden Pl, Piantadosi S: Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer: a phase II study of the Lung Cancer Study Group. J. Natl. Cancer Inst. 83: 266-273, 1991.
 
59) Strauss GM, Herndon JE, Sherman DD, et al: Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage III A non-small cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study. J Clin. Oncol. 10: 1237-1244, 1992.
 
60) Kirn DH, Lynch TJ, Mentzer SJ, et al: Multimodality therapy of patients with stage IIIA, N 2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging. J. Thorac. Cardiovasc. Surg. 106: 696-702, 1993.
PubMed
61) Pass HI, Pogrebniak HW, Steinberg SM, et al: Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann. Thorac. Surg. 53: 992-998, 1992.
PubMed
62) Rosell R, Codina JG, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 330: 153-158, 1994.
 
63) Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 86: 673-680, 1994.
PubMed
64) Hong XZ, Wei BY, Li JZ, et al: Curative radiotherapy of early operable non-small cell lung cancer. Radiother. Oncol. 14: 89-94, 1989.
 
65) Hafty BG, Goldberg NB, Gerstley J, et al: Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 15: 69-73, 1988.
 
66) Noordijk EM, Poest CE, Hermans J, et al: Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother. Oncol. 13: 83-89, 1988.
 
67) Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 38: 521-525, 1997,
 
68) Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60. 0 Gy to 79. 2 Gy: possible survival benefit with greater than or equal to 69. 6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J. Clin. Oncol. 8: 1543-1555, 1990.
PubMed
69) Sause W, Scott C, Taylor S, et al: RTOG 88-08 and ECOG 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J. Natl. Cancer Inst. 87: 198-205, 1995.
 
70) Saunders M, Dische S: Continuous hyperfractionated accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int. J. Radiat. Oncol. Biol. Phys. 19: 1211-1215, 1990.
 
71) Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet 350: 161-165, 1997.
PubMed
72) Johnson DH, Einhorn LH, Bartolucci A, et al: Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann. Intern. Med. 113: 33-38, 1990.
PubMed
73) Kubota K, Furuse K, Kawahara M, et al: Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J. Clin. Oncol. 12: 1547-1552, 1994.
PubMed
74) Mattson K, Holsti L, Holsti P, et al: Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur. J. Cancer 24: 477-482, 1988.
PubMed
75) Trovo M, Minatel E, Veronesi A, et al: Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma: a randomized study. Cancer 65: 400-404, 1990.
PubMed
76) Morton RF, Jett JR, McGinnis WL, et al: Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer: a randomized, phase III trial. Ann. Intern. Med. 115: 681-686, 1991.
PubMed
77) Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N. Engl. J. Med. 323: 940-945, 1990.
PubMed
78) Dillman RO, Seagren SL, Herndon J, et al: Randomized trial of induction chemotherapy plus radiation therapy vs. RT alone in stage III non-small cell lung cancer: five year follow-up of CALGB 84-33. Proc. Am. Soc. Clin. Oncol. 12: 329, 1993 (Abstr.) .
 
79) Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. 83: 417-423, 1991.
PubMed
80) Le Chevalier T, Arriagada R, Tarayre M, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma [letter]. J. Natl. Cancer Inst. 84: 58, 1992.
PubMed
81) Friess GG, Baikadi M, Harvey WH: Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer. Cancer Treat. Rep. 71: 681-684, 1987.
PubMed
82) Breneman JC, Mitchell SE, Hawley DK, et al: Concurrent radiotherapy and chemotherapy for locally advanced non-small-cell cancer of the lung. Report of a clinical trial and review of the literature. Am. J. Clin. Oncol. 14: 9-15, 1991.
PubMed
83) Shaw EG, McGinns WL, Jett JR, et al: Pilot study of accelerated hyperfractionated thoracic radiotherapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell car-cinoma of the lung. J. Natl. Cancer Inst. 85: 321-323, 1993.
 
84) Bonner JA, McGinnis WL, Stella PJ, et al: The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer 82: 1037-1048, 1998.
PubMed
85) Furuse K, Kubota K, Kawahara M, et al: Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small cell lung cancer. J. Clin. Oncol. 13: 869-875, 1995.
PubMed
86) Furuse K, Fukuoka M, Takada Y, et al: A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M) , vindesine (V) , and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC) : preliminary analysis. Proc. Am. Soc. Clin. Oncol. 16: 459a, 1996 (Abstr.) .
 
87) Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 326: 524-530, 1992.
PubMed
88) Hazuka MB, Crowley JJ, Bunn PA, et al: Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. J. Clin. Oncol. 12: 1814-1820, 1994.
 
89) Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J. Clin. Oncol. 14: 1065-1070, 1996.
 
90) Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. a meta-analysis. Ann. Intern. Med. 125: 723-729, 1996.
PubMed
91) Kudoh S, Kurihara N, Okishio K, et al: A phase I-II study of weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. 15: 372, 1996 (Abstr.) .
 
92) Yokoyama A, Kurita Y, Saijo N, et al: Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br. J. Cancer 78 (2) : 257-262, 1998.
PubMed
93) Graham MV, Jahanzeb M, Dresler CM, et al: Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 36: 1215-1220, 1996.
PubMed
94) Herscher LL, Hahn SM, Kroog G, et al: Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J. Clin. Oncol. 16: 635-641, 1998.
PubMed
95) Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J. Clin. Oncol. 12: 2681-2686, 1994.
 
96) Frasci G, Comella P, Scoppa G, et al: Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study. J. Clin. Oncol. 15: 1409-1417, 1997.
PubMed
97) reco FA, Stroup SL, Gray JR, et al: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 14: 1642-1648, 1996.
 
98) Mauer AM, Masters GA, Haraf DJ, et al: Phase I study of docetaxel with concomitant thoracic radiation therapy. J. Clin. Oncol. 16: 159-164, 1998.
PubMed
99) Masters GA, Haraf DJ, Hoffman PC: Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J. Clin. Oncol. 16: 2157-2163, 1998.
PubMed
100) Laffaioli RV, Caponigro F, Tortoriello A, et al: Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer. Eur. J. Cancer 32 A (11) : 1901-1904, 1996.
 
101) Bakowski MT, Crouch JC: Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat. Rev. 10: 159-172, 1983.
 
102) Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: astudy of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 7: 1602-1613, 1989.
 
103) Klastersky J, Sculier Jp, Lacroix H, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol O7861. J. Clin. Oncol. 8: 1556-1562, 1990.
PubMed
104) Gralla RJ, Casper ES, Kelsen DP, et al: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann. Intern. Med. 95: 414-420, 1981.
 
105) Kris M, Gralla R, Kalman L, et al: Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patient with non-small cell lung cancer with an analysis of methods of response assessment. Cancer Treat. Rep. 69: 387-395, 1985.
PubMed
106) Longeval E, Klastersky J: Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium) . Cancer 50: 2751-2756, 1982.
PubMed
107) Klastersky J, Sculier Jp, Ravez P, et al: A randomized study comparing a high and a standard dose cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J. Clin. Oncol. 4: 1780-1786, 1986.
 
108) Klastersky J, Sculier Jp, Bureau G, et al: Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J. Clin. Oncol. 7: 1087-1092, 1989.
PubMed
109) Rosso R, Salvati F, Ardizzoni A, et al: ETP versus etoposide plus high dose cisplatin in the management of advanced non-small cell lung cancer: results of a prospective randomized FONICAP trial. Cancer 66: 130-134, 1990.
 
110) Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al: A randomized trial of the four most active regimens for non-small-cell lung cancer. J. Clin. Oncol. 4: 14-22, 1986.
PubMed
111) Dhingra H, Valdivieso M, Carr D, et al: Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small cell lung cancer. J. Clin. Oncol. 8: 176-184, 1985.
PubMed
112) Elliott JA, Ahmedzai S, Hole D, et al: Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur. J. Cancer Clin. Oncol. 20: 1025-1032, 1984.
PubMed
113) Einhorn LH, Loehrer PJ, Williams SD, et al: Random prospective study of vindesine versus vindesine plus highdose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small cell lung cancer. J. Clin. Oncol. 4: 1037-1043, 1986.
PubMed
114) Kawahara M, Furuse K, Kodama N, et al: A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell carcinoma. Cancer 68: 714-719, 1991.
PubMed
115) Crino L, Tonato M, Darwish S, et al: A randomized trial of 3 cisplatin-containing regimens in advanced nonsmall cell lung cancer (NSCLC) . a study of the Umbrian Lung Cancer Group. Cancer Chemother. Pharmacol. 26: 52-56, 1990.
 
116) Gandara DR, Crowley J, Livingston RB, et al: Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J. Clin. Oncol. 11: 873-878, 1993.
 
117) Kris M, Gralla R, Wertheim M: Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat. Rep. 70: 1091-1096, 1985.
 
118) Joss R, Burki K, Dalquen P, et al: Combination chemotherapy with mitomycin, vindesine, and cisplatin for nonsmall cell lung cancer. Cancer 65: 2426-2434, 1990.
PubMed
119) Fukuoka M, Negoro S, Masuda N, et al: Mitomycin, vindesine and cisplatin in advanced non-small cell lung cancer: A phase II study. Am. J. Clin. Oncol. 15: 18-22, 1992.
PubMed
120) Folman RS, Rosman M: The role of chemotherapy in non-small cell lung cancer: the community perspective. Semin. Oncol. 15 (suppl. 4) : 16-21, 1988.
 
121) Weick J, Crowley J, Natale R, et al: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer. J. Clin. Oncol. 9: 1157-1162, 1991.
 
122) Klastersky J, Sculier Jp, Nicaise C, et al: Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party. Cancer Treat. Rep. 67: 727-730, 1983.
PubMed
123) Hainsworth JD, Porter LL, Johnson DH, et al: Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the Southeastern Cancer Study Group. Cancer Treat. Rep. 70: 339-341, 1986.
 
124) Giron C, Ordonez A, Jalon I, et al: Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non-small cell lung cancer. Cancer Treat. Rep. 71: 851-853, 1987.
 
125) Cullen M, Joshi R, Chetiyawardana A, et al: Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br. J. Cancer 58: 359-361, 1988.
PubMed
126) Paccagnella A, Favaretto A, Brandes A, et al: Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma: A phase II randomized study with cisplatin and etoposide as the control arm. Cancer 65: 2631-2634, 1990.
PubMed
127) Honda R, Fujita A, Inoue Y, et al: Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: acombination phase II study. Cancer Chemother. Pharmacol. 26: 373-376, 1990.
 
128) 西脇 裕, 児玉哲郎, 林辺 晃 他: 進行非小細胞肺癌に対するCDDP+VDSとCDDP+MMC+VDSの比較試験: 肺癌 28: 581, 1988 (Abstr.) .
 
129) Shinkai T, Eguchi K, Sasaki Y, et al: A randomized clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur. J. Cancer 27: 571-575, 1991.
 
130) Fukuoka M, Masuda N, Furuse K, et al: A randomized trial in inoperable non-small cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J. Clin. Oncol. 9: 606-613, 1991.
PubMed
131) Klastersky J, Sculier Jp, Ries F, et al: A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party. Ann. Oncol. 5: 641-643, 1994.
PubMed
132) Gandara DR, Wold H, Perez EA, et al: Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J. Natl. Cancer Inst. 81: 790-794, 1989.
 
133) Rapp PA, Pater JL, Willian A, et al: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer-Report of a Canadian multicentre randomized trial. J. Clin. Oncol. 6: 633-641, 1988.
 
134) Ganz PA, Figlin RA, Haskell CM, et al: Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer: does chemotherapy make a difference? Cancer 63: 1271-1278, 1989.
PubMed
135) Woods RL, Williams CJ, Levi J, et al: A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br. J. Cancer 61: 608-611, 1990.
 
136) Cellerino R, Tummarello D, Guidi F, et al: A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer, J Clin. Oncol. 9: 1453-1461, 1991.
PubMed
137) Quoix E, Dietemann A, Charbonneau J, et al: Is cisplatin-based chemotherapy useful in disseminated non-small cell lung cancer? Report of a French multicenter randomized trial. Cancer Bull. 78: 341-346, 1991.
 
138) Kassa S, Lund E, Thorud E, et al: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 67: 2443-2447, 1991.
 
139) Leung WT, Shiu WC, Pang JC, et al: Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer. Oncology 49: 321-326, 1992.
PubMed
140) Cartei G, Cartei F, Cantone A, et al: Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J. Natl. Cancer Inst. 85: 794-800, 1993.
PubMed
141) Souquet PJ, Chauvin F, Boissel Jp, et al: Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet 342: 19-21, 1993.
 
142) Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J. Clin. Oncol. 11: 1866-1872, 1993.
PubMed
143) Marino P, Pampallona S, Preatoni A, et al: Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Chest 106: 861-865, 1994.
PubMed
144) Bunn PA Jr, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future. Clin. Cancer Res. 4: 1087-1100, 1998.
PubMed
145) Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecine, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10: 16-20, 1992.
 
146) Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J. Clin. Oncol. 10: 1775-1780, 1992.
PubMed
147) Masuda N, Fukuoka M, Fujita A, et al: A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer 78: 251-256, 1998.
PubMed
148) Mori K, Hirose T, Machida S, et al: A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur. J. Cancer 33: 503-505, 1997.
PubMed
149) Kobayashi K, Shinbara A, Kamimura M, et al: Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. Cancer Chemother. Pharmacol. 42: 53-58, 1998.
PubMed
150) Oshita F, Noda K, Nishiwaki Y, et al: Phase II study of irinotecan and etoposide in patients with metastatic non small-cell lung cancer. J. Clin. Oncol. 15: 304-309, 1997.
PubMed
151) Lynch TJ, Kalish L, Strauss G, et al: Phase II study of topotecan in metastatic non-small cell lung cancer. J. Clin. Oncol. 12: 347-352, 1994.
PubMed
152) Perez-Soler R, Fossella FV, Glisson BS, et al: Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol. 14: 503-513, 1996.
PubMed
153) Murphy WK, Fassella FV, Winn RJ, et al: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 85: 384-386, 1993.
 
154) Chang AY, Kim K, Glick J, et al: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-smallcell lung cancer: the Eastern Cooperative Oncology Group results. J. Natl. Cancer Inst. 85: 388-394, 1993.
 
155) Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12: 2654-2666, 1994.
PubMed
156) Sekine I, Nishiwaki Y, Watanabe K, et al: Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin. Caner Res. 2: 941-945, 1996.
 
157) Furuse K, Naka N, Takada M, et al: Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. Oncology 54: 298-303, 1997.
PubMed
158) Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin. A phase I and pharmacologic study. J. Clin. Oncol. 9: 1692-1703, 1991.
PubMed
159) Belli L, Le Chevalier T, Gottfried M, et al: Phase I-II trial of paclitaxel (taxol(R)) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. 14: 350, 1995 (Abstr.) .
 
160) von Pawel J, Wagner H, Niederle N, et al: Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol. 23 (6 Suppl. 16) : 47-50, 1996.
 
161) Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide (E) -cisplatin (C) versus Taxol (T) with cisplatin-G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperable, Oncology Group (ECOG) trial. Proc. Am. Soc. Clin. Oncol. 15: 382, 1996 (Abstr.) .
 
162) Giaccone G, Splinter TA, Debruyne C, et al: Randomized study of paclitaxel-cisplatin versus cisplatinteniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer. Lung Cancer Cooperative Group. J. Clin. Oncol. 16: 2133-2141, 1998.
 
163) Gatzemeier U, von Pawel J, Gottfried M, et al: Phase III study of high-dose cisplatin (HD-cis) versus a combination of paclitaxel (TAX) and cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. 17: 454 a, 1998 (Abstr.) .
 
164) Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J. Clin. Oncol. 13: 1860-1870, 1995.
PubMed
165) Belani CP, Aisner J, Hiponia D, et al: Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin. Oncol. 22 (Suppl. 9) : 7-12, 1995.
 
166) Muggia FM, Vatai D, Natale R, et al: Paclitaxel 3-hour infusion given alone and combination with carboplatin: preliminary results of dose-escalation trials. Semin. Oncol. 22 (Suppl. 9) : 63-66, 1995.
 
167) Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of Vanderbilt University phase II trial-LUN-46. Semin. Oncol. 22 (Suppl. 9) 130-33, 1995.
 
168) Huizing MT, Giaccone G, van Warmerdam LJ, et al: Pharmacokinetics of paclitaxel and carboplatin in a doseescalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J. Clin. Oncol. 15: 317-329, 1997.
 
169) Rowinsky EK, Flood WA, Sartorius SE, et al: Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Invest. New Drugs 15: 129-138, 1997.
PubMed
170) Paccagnella A, Favaretto A, Oniga F, et al: Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer. Semin. Oncol. 23 (6 Suppl. 16) 176-79, 1996.
 
171) Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7: 1748-1756, 1989.
PubMed
172) Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/ paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. 17: 455a, 1998 (Abstr.) .
 
173) Burris H, Eckardt N, Fields S, et al: Phase II trial of taxotere in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12: 335, 1993 (Abstr.) .
 
174) Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trial Group (ECTG) . Br. J. Cancer 70: 384-387, 1994.
PubMed
175) Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-smallcell lung cancer. J. Clin. Oncol. 12: 1232-1237, 1994.
 
176) Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cencer. J. Clin. Oncol. 12: 1238-1244, 1994.
PubMed
177) Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinumrefractory non-small cell lung cencer. J. Clin. Oncol. 13: 645-651, 1995.
 
178) 工藤翔二, 日野光紀, 藤田昭久・他: 非小細胞肺癌に対するRP 56976 (Docetaxel) の後期第II相臨床試験. 癌と化学療法 21: 2617-2623, 1994.
Medical*Online
179) Kunitoh H, Watanabe K, Onoshi T, et al: Phase II trial of docetaxel in previously untreated advanced non- small-cell lung cancer: aJapanese cooperative study. J Clin. Oncol. 14: 1649-1655, 1996.
 
180) Georgoulias V, Androulakis N, dimopoulos AM, et al: First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: amulticenter phase II study. Ann. Oncol. 9: 331-334, 1998.
 
181) Millward MJ, Zalcberg J, BishoP JF, et al: Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 15: 750-758, 1997.
PubMed
182) Le Chevalier T, Belli L, Monnier A, et al: Phase II study of docetaxel (taxotere(R)) and cisplatin in advanced non-small-cell lung cancer (NSCLC) : an interim analysis. Proc. Am. Soc. Clin. Oncol. 14: 350, 1995 (Abstr.) .
 
183) Cole JT, Gralla RJ, Marques CB, et al: Phase I-II study of cisplatin+docetaxel (taxotere) in non-small cell lung cancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. 14: 357, 1995 (Abstr.) .
 
184) Zalcberg J, Millward M, BishoP J, et al: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 16: 1948-1953, 1998.
PubMed
185) Depierre A, Lemarie E, Dabouis G, et al: A phase II study of Naverbine (Vinorelbine) in the treatment of nonsmall cell lung cancer. Am. J. Clin. Oncol. 14: 115-119, 1991.
PubMed
186) Furuse K, Kubota K, Kawahara M, et al: A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 11: 385-391, 1994.
PubMed
187) Furuse K, Fukuoka M, Kuba M, et al: Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage III B or IV non-small-cell lung cancer (NSCLC) . The Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann. Oncol. 7: 815-820, 1996.
 
188) Le Chevalier T, Brisgard D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a european multicenter trial including 612 patients. J. Clin. Oncol. 12: 360-367, 1994.
 
189) Dipierre A, Chastang C, Quoix E, et al: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann. Oncol. 5: 37-42, 1994.
PubMed
190) Perol M, Guerin JC, Thomas P, et al: Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. Lung Cancer 14: 119-134, 1996.
PubMed
191) Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: aSouthwest Oncology Group study. J. Clin. Oncol. 16: 2459-2465, 1998.
 
192) Le Chevalier T, Gottfried M, Gatzemeier U, et al: Confirmatory activity of gemicytabine in non-small cell lung cancer. Eur. J. Cancer 29 a: 160, 1993 (Abstr.) .
 
193) Abratt R, Bezwoda W, Falkson G, et al: Efficacy and safety of gemicytabine in non-small cell lung cancer: a phase II study results. J. Clin. Oncol. 12: 1535-1540, 1994.
PubMed
194) Anderson H, Lund B, Bach F, et al: Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J. Clin. Oncol. 12: 1821-1826, 1994.
PubMed
195) Takada M, Negoro S, Kudo S, et al: Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study. Cancer Chemother. Pharmacol. 41: 217-222, 1998.
 
196) Yokoyama A, Nakai Y, Yoneda S, et al: Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: amulticenter phase II study. Anticancer Drugs 8: 574-581, 1997.
 
197) Fossella FV, Lippman SM, Shin DM, et al: Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dosecscalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 15: 310-316, 1997.
PubMed
198) Sandler AB, Ansari R, McClean J, et al: Gemcitabine plus cisplatin in non-small cell lung cancer. A phase II study. Eur. J. Cancer 131 A: S225, 1995 (Abstr.) .
 
199) Crino L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 15: 297-303, 1997.
PubMed
200) Steward WP, Dunlop DJ, Dabouis G, et al: Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. Semin. Oncol. 23 (5 Suppl. 10) : 43-47, 1996.
 
201) Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J. Clin. Oncol. 15: 744-749, 1997.
PubMed
202) Shepherd FA, Cormier Y, Burkes R, et al: Phase II trial of gemcitabine and weekly cisplatin for advanced nonsmall cell lung cancer. Semin. Oncol. 24 (3 Suppl. 8) : S 8-27-S 8-30, 1997.
 
203) Shephard FA, Anglin G, Abratt R, et al: Influence of gemcitabine (GEM) and cisplatin (CP) schedule on response and survival in advanced non-small cel川ung cancer. Proc. Am. Soc. Clin. Oncol. 17: 472 a, 1998 (Abstr.) .
 
204) Perng RP, Chen YM, Ming-Liu J, et al: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell Lung cancer in a phase II randomized study. J. Clin. Oncol. 15: 2097- 2102, 1997.
 
205) Manegold C, Bergman B, Chemaissani A, et al: Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann. Oncol. 8: 525-529, 1997.
PubMed
206) Cardenal F, Rosell R, Anton A, et al: Gemcitabine+cisplatin versus etoposide+cisplatin in advanced non-small cell lung cancer patients: preliminary randomized phase III results. Proc. Am. Soc. Clin. Oncol. 16: 458 a, 1997 (Abstr.) .
 
207) Crino L, Conte P, De Marinis F, et al: A randomized trial of gemcitabine and cisplatin (GP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC) . Amulticenter phase III study. Proc. Am. Soc. Clin. Oncol. 17: 455 a, 1998 (Abstr.) .
 
208) Sandler A, Nemunaitis J, Dehnam Y, et al: Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. 17: 454 a, 1998 (Abstr.) .
 
209) Furuse K, Fukuoka M, Ohshima S, et al: Phase II clinical study of (glycolato-0, O') diammine platinum (II) (254-S) , anew platinum complex, for primary lung cancer. Proc. Am. Soc. Clin. Oncol. 8: 238, 1989 (Abstr.) .
 
210) Takifuji N, Negoro S, Ariyoshi Y, et al: Phase II study of amurubicin (SM-5887) , anovel 9-amino-anthracycline in advanced non-small cell lung cancer (NSCLC) : the studies of West Japan Lung Cancer Group. Proc. Am. Soc. Clin. Oncol. 16: 485 a, 1997 (Abstr.) .
 
211) Hayata Y, Kato H, Konaka C, et al: Photoradiation therapy with hematoporhyrin derivertive in early and stage 1 lung cancer. Chest 86: 169-177, 1984.
 
212) Furuse K, Fukuoka M, Kato H, et al: Aprospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage Lung cancer. J. Clin. Oncol. 11: 1852-1857, 1993.
 
213) Ostrowski MJ, Priestman TJ, Houston RF, et al: A randomized trial of intracavitary bleomycin and corynebacterium in the control of malignant pleural effusions. Radiother. Oncol. 14: 19-26, 1989.
 
214) Ruckdeschel JC, Moores D, Jeannette YL, et al: Intrapleural therapy for malignant pleural effusions. Chest 100: 1528-1535, 1991.
 
215) Rush VW, Figlin R, Godwin D, et al: Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: ALung Cancer Study Group Trial. J. Clin. Oncol. 9: 313-319, 1991.
 
216) Aitini E, Cavazzini G, Pasquini E, et al: Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. Acta Oncol. 33: 191-194, 1994.
PubMed
217) Yana T, Fukuoka M, Kurihara N, et al: Intrapleural (IP) cisplatin (P) and etoposide (E) in the management of non-small-cell lung cancer (NSCLC) with malignant pleural effusions (MPE) . Proc. Am. Soc. Clin. Oncol. 14: 361, 1995 (Abstr.) .
 
218) Feld R, Arriagada R, Ball DL, et al: Prognostic factors in non-small cell lung cancer: aconsensus report. Lung Cancer 7: 3-5, 1991.
 
219) Feld R, Borges M, Giner V, et al: Prognostic factors in non-small cell lung cancer. Lung Cancer 11 (Suppl. 3) : S19-S23, 1994.
 
220) Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J. Natl. Cancer Inst. 65: 25-32, 1980.
PubMed
221) Finkelstein DM, Ettinger DS, Ruckdeschel JC, et al: Long-term survivors in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group. J. Clin. Oncol. 4: 702-709, 1986.
 
222) O'Connell Jp, Kris MG, Gralla RJ, et al: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced norsmall cell lung cancer treated with combination chemotherapy. J. Clin. Oncol. 4: 1604-1614, 1986.
PubMed
223) Sorensen JB, Badsberg JH, Olsen J: Prognostic factors in inoperable adenocarcinoma of the lung: Amultivariate regression analysis of 259 patients. Cancer Res. 49: 5748-5754, 1989.
 
224) Shinkai T, Eguchi K, Sasaki Y, et al: Aprognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother. Pharmacol. 30: 1-6, 1992.
 
225) Slebos RJ, Kibbelaar RE, Dalesio O: K-ras oncogene activation as a prognostic marker in adenocarcinoma ofthe lung. N. Engl. J. Med. 323: 561-565, 1990.
 
226) Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p 53 protein correlates with a poor prognosisin human lung cancer. Cancer Res. 52: 4828-4831, 1992.
 
227) McLaren R, Kuzu I, Dunnill M, et al: The relationship of p 53 immunostaining to survival in carcinoma of thelung. Br. J. Cancer 66: 735-738, 1992.
 
228) Mitsudomi T, Oyama T, Kusano T, et al: Mutations of the p 53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 85: 2018-2023, 1993.
 
229) Zimmerman PV, Hawson GA, Bint MH, et al: Ploidy as a prognostic determinant in surgically treated lung Lancet: 530-533, 1987.
PubMed
230) Volm M, Hahn EW, Mattern J, et al: Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res. 48: 2923-2928, 1988.
PubMed
P.982 掲載の参考文献
1) Leyvraz S, Henle W, Chahinian AP, et al: Association of Epstein-Barr virus with thymic carcinoma. N. Engl. J. Med, 312: 1296-1299, 1985.
PubMed
2) Shimosato Y, Mukai K: Tumors of the mediastinum. AFIP, Bethesda, 1997, pp. 120-158.
 
3) Mario M, Muller-Hermelink HK: Thymoma and thymic carcinoma epithelial cells to the cortical and medullary differentiation of thymus. Virchow Arch. 407: 119-149, 1985.
 
4)) Quintanilla-Martinez L, Wilkins EW, Choi N, et al: Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 74: 606-617, 1994.
PubMed
5) Kirchner T, Schalke B, Buchwald J, et al: Well-differentiated thymic carcinoma: An organotypical low-grade carcinoma with relationship to cortical thymoma. Am. J Surg. Pathol. 16: 1153-1169, 1992.
PubMed
6) Masaoka A, Monden Y, Nakahara K, et al: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-2492, 1981.
PubMed
7) Maggi G, Casadio C, Cavallo A, et al: Thymoma: Results of 2410perated cases. Ann. Thorac. Surg. 51: 152- 156, 1991.
 
8) Pescarmona E, Rendina EA, Venuta F, et al: Analysis of prognostic factors and clinicopathological staging of thymoma. Ann. Thorac. Surg. 50: 534-538, 1990.
PubMed
9) Koga K, Matsuno Y, Noguchi M, et al: Areview of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma Pathol. Int. 44: 359-367, 1994.
 
10) Curran JW, Kornstein M, Brooks JJ, et al: Invasive thymoma: The role of mediastinal irradiation following complete or incomplete surgical resection. J Clin. Oncol. 6: 1722-1727, 1988.
PubMed
11) Pollack A: Thymoma: treatment and prognosis. Int. J. Radiat. Biol. Phys. 2311037-1043, 1992.
 
12) Blumberg D: Thymoma: amultivariate analysis of factors predicting survival. Ann. Thorac. Surg. 54: 311-315, 1992.
 
13) Fornasiero A: Chemotherapy of invasive thymoma. J. Clin. Oncol. 8: 1419-1423, 1990.
PubMed
14) Loehrer PJ, Kim K, Aisner SC, et al: Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of a intergroup trial. J. Clin. Oncol. 12: 1164-1168, 1994.
PubMed
15) Oshita F: Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphimide etoposide and colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results. Jpn. J. Clin. Oncol. 25: 208-212, 1995.
PubMed
16) 浅村尚生, 森永正二郎, 下里幸雄・他: 縦隔原発びまん性硬化性大細胞型悪性リンパ腫の3例. 病理と臨床 6: 81-87, 1988.
 
17) Perrone T, Frizzera G, Rosai J: Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am. J. Surg. Pathol. 10: 176-191, 1986.
PubMed
18) Isaacson PG, Chan JKC, Tang C, et al: Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the thymus. A thymic lymphoma mimicking myoepithelial sialadenitis. Am. J. Surg. Pathol. 14: 342- 351, 1990.
 
19) Bajorin D, Katz A, Chan E, et al: Comparison of criteria for assigning germ cell tumor patients to "good risk and "poor risk" studies. J. Clin. Oncol. 6: 786-792, 1988.
PubMed
20) Ozols RF: A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J. Clin. Oncol. 6: 1031-40, 1988.
 
21) Wright CD, Kesler KA, Nichols CR, et al: Primary mediastinal nonseminomatous germ cell tumors. Results of amultimodality approach. J. Thorac. Cardiovasc. Surg. 99: 210-217, 1990.
PubMed
22) Saxman S, Nichols CR, Williams SD, et al: Mediastinal yolk sac tumor. J. Thorac. Cardiovasc. Surg. 102: 913- 916, 1991.
 
23) Bush SE, Martinez A, Bagshaw MA: Primary mediastinal seminoma. Cancer 48: 1877-1882, 1981.
PubMed
24) Hurt RD, Bruckman JE, Farrow GM: Primary anterior mediastinal seminoma. Cancer 49: 1658-1663, 1982.
PubMed
25) Hainsworth JD, Greco FA: Mediastinal germ cell neoplasms. In: Thoracic Oncology (eds. by Roth JA, Ruckdeschel JC, Weisenburger TH) . W. B. Saunders, Philaderlphia, 1989, pp. 478-489.
 
26) Shimosato Y, Mukai K: Tumors of the mediastinum. AFIP, Bethesda, 1997, pp. 263-267.
 
27) Katlic MR, Chiu-an Wang, Grillo HC: Substernal goiter. Ann. Thorac. Surg. 39: 391-399, 1985.
 
P.997 掲載の参考文献
1) Parkin M, Muir C, Whelan S, et al: Cancer incidence in five continents, vol 6. International Agency for Research on Cancer. Lyon, France, 1992.
 
2) Yang CS: Research on esophageal cancer in China: a review. J. Thorac. Cardiovasc. Surg. 40: 2633, 1980.
 
3) Zeng W, Jin F, Devesa SS, et al: Declining incidence is greater for esophageal than gastric cancer in Shanghai, People 's Republic of China. Br. J. Cancer 68: 978-982, 1993.
 
4) Day NE, Varghese C: Oesophageal cancer. Cancer Surv. 19/20: 43-54, 1994.
 
5) Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289, 1991.
PubMed
6) Blot WJ: Cancer of the esophagus: its causes and changing patterns of occurrence. Proc. Am. Soc. Clin. Oncol. 16: 159-163, 1997.
 
7) がんの統計編集委員会編: がんの統計 1997.
 
8) Blot WJ: Esophageal cancer trends and risk factors. Semin. Oncol. 21: 403-410, 1994.
PubMed
9) Munoz N, Day NE: Esophageal cancer. In: Cancer epidemiology and prevention (eds. by Schottenfeld D, Fraumeni J Jr) (ed 2) . University Press, New York, NY Oxford, 1996, pp. 681-706.
 
10) Blot WJ: Alcohol and cancer. Cancer Res. 52: 2119 s-2123 s, 1992.
 
11) Yokoyama A, Muramatsu T, Ohmori T, et al: Multiple primary esophageal and concurrent upper aerodigestive tract cancer and the aldehyde dehydrogenase-2 genotype of Japanese alcoholics, Cancer 77: 1986-1990, 1996.
PubMed
12) Spechler SJ: Barrett 's esophagus. Semin. Oncol. 21: 435-437, 1994.
 
13) Brown LM, Silverman DS, Pottern LM, et al: Adenocarcinoma of the esophagus and esophaogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control. 5: 333-341, 1994.
 
14) Brown LM, Swanson CA, Gridely G, et al: Adenocarcinoma of the esophagus: role of obesity and diet. J. Natl. Cancer Inst. 87: 104-109, 1995.
 
15) Gammon MD, Schoenberg JB, Ahsan H, et al: Tobacco, alcohol, and socioeconomic status and adenocarcinoma of the esophagus. J. Natl. Cancer Inst. 89: 1277-1284, 1997.
PubMed
16) Shu YJ: Cytopathology of the esophagus: an overview of esophageal cytopathology in China. Acta Cytol. 27: 7-16, 1983.
PubMed
17) Froelicher G, Miller G: The European experience with esophageal cancer limited to the mucosa and submucosa. Gastrointest. Endosc. 32: 88-90, 1986.
 
18) Yokoyama A, Ohmori T, Makuuchi H, et al: Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosal iodine staining. Cancer 76: 928-934, 1995.
PubMed
19) Meyer V, Burtin P, Bour B, et al: Endoscopic detection of early cancer in a high-risk population: does Lugol staining improve videoendoscopy? Gastrointest. Endosc. 45: 480-484, 1997.
 
20) Shiozaki H, Tahara H, Kobayashi K, et al: Endoscopic screening of early esophageal cancer with the lugol dye method in patients with head and neck cancers. Cancer 66: 2068-2071, 1990.
PubMed
21) 食道疾患研究会 (編) : 臨床・病理食道癌取扱い規約. 第8版, 金原出版, 東京, 1992.
 
22) Watanabe H, Jass JR, Sobin LH: Histological typing of oesophageal and gastric tumours. WHO 's international histological classification of tumours, Springer-Verlag, Berlin, 1990.
 
23) Takubo K, Sasajima K, Yamashita K, et al: Morphological heterogeneity of esophageal carcinoma. Acta Pathol. Jpn. 39: 180-189, 1989.
PubMed
24) Epstein JI, Sears DL, Tucker RS: Carcinoma of the esophagus with adenoid cystic differentiation. Cancer 53: 1131-1134, 1984.
PubMed
25) Suzuki H, Nagayo T: Primary tumors of the esophagus other than squamous cell carcinoma. Histologic classification and statistics in the surgical and autopsied materials in Japan. Int. Adv. Surg. Oncol. 3: 73-109, 1980.
PubMed
26) 真船健一, 田久保海誉, 田中洋一: 食道原発腺様嚢胞癌の1例. 癌の臨床 32: 513-519, 1986.
 
27) Bedi DG, Shaw MT: Oat cell carcinoma of the esophagus: unusual radiologic appearance. Eur. J. Radiol. 6: 233-237, 1986.
PubMed
28) 食道疾患研究会, 国立がんセンター: 全国食道がん登録調査報告. 第12号 (昭和59年症例) : 69, 1992.
 
29) Kelsen DP, Weston E, Kurtz R: Small cell carcinoma of the esophagus: treatment by chemotherapy alone. Cancer 45: 1558-1561, 1980.
PubMed
30) Rosenthal SN, Lemkin JA: Multiple small cell carcinoma of the esophagus. Cancer 51: 1944-1946, 1983.
PubMed
31) Iyomasa S, Kato H, Tachimori Y, et al: Carcinosarcoma of the esophagus: a twenty-case study. Jpn. J. Clin. Oncol. 20: 99-106, 1990.
PubMed
32) Matsusaka T, Watanabe H, Enjoji M, et al: Pseudosarcoma and carcinosarcoma of the esophagus. Cancer 31: 1546-1555, 1976.
 
33) Osamura RY, Shimamura K, Hata J: Polypoid carcinoma of the esophagus. A unifying term for "carcinosarcoma" and "pseudosarcoma". Am. J. Surg. Pathol. 2: 201-208, 1978.
PubMed
34) 小玉正智: 食道表在癌の全国集計報告. 第49回食道疾患研究会アンケート調査, 1995.
 
35) Sugimachi K, Ohno S, Matsuda H, et al: Lugol-combined endoscopic detection of minute malignant lesions of the thoracic esophagus. Ann. Surg. 208: 179-183, 1988.
PubMed
36) Bogomoletz WV, Molas G, Gayet B, et al: Superficial squamous cell carcinoma of the esophagus. A report of 76cases and review of the literature. Am. J. Surg. Pathol. 13: 535-546, 1989.
PubMed
37) 井出博子, 野上 厚, 葉梨智子 他: 食道sm癌の臨床診断と予後. 胃と腸 25: 1067-1074, 1990.
 
38) 吉田 操, 室井正彦, 門馬久美子 他: 食道m・sm癌の質的診断ならびに鑑別診断. 胃と腸 25: 1059-1066, 1990.
 
39) Steinbach G, Hong WK: Early detection of esophageal cancer by chromoendoscopy. Cancer 76: 919-921, 1995.
PubMed
40) Mandard AM, Tourneux J, Gignoux M, et al: In sitza carcinoma of the esophagus. Endoscopy 12: 51-57, 1980.
PubMed
41) 幕内博康, 町村貴郎, 水谷郷一・他: 内視鏡による食道表在癌-癌の深達度診断の精度-. 胃と腸 27: 175-184, 1992.
 
42) Murata Y, Hayashi K, Kobayashi A, et al: Preoperative staging of esophageal carcinoma by ultrasound. Asian J. Surg. 17: 200-207, 1994.
 
43) Sugimachi K, Ohno S, Fujishima H, et al: Endoscopic ultrasonographic detection of carcinomatous invasion and lymph nodes in the thoracic esophagus. Surgery 107: 366-371, 1990.
PubMed
44) Makuuchi H, Shimada H, Mizutani K, et al: Endoscopic criteria for invasive depth of superficial esophageal cancer. Dig. Endosc. 9: 110-115, 1995.
 
45) 井出博子: 食道がん治療における最近の動向. 臨床腫瘍学 (日本臨床腫瘍研究会編) . 癌と化学療法社, 東京, 1994, pp. 570-594.
 
46) 岩崎善毅, 小池盛雄, 滝沢登一郎・他: 食道表在癌の病理. 病理と臨床 12: 536-541, 1994.
 
47) 鶴丸昌彦, 宇田川晴司, 梶山美明・他: 手術成績からみた食道癌に対する術式選択 1) 胸部食道扁平上皮癌に対する拡大郭清の適応と限界. 外科診療 57: 1032-1046, 1995.
 
48) 中村正徳, 永井 鑑, 河野辰幸・他: 食道癌治療上の問題点: 診断はどこまで可能か, 深達度 (内視鏡, EUS) -表在癌の細分類診断を中心に-. 外科診療 37: 649-657, 1995.
 
49) 中村 努, 井手博子, 江口礼紀・他: 食道癌の病理・2) 早期癌, 表在癌. 外科 57: 1020-1022, 1995.
 
50) 幕内博康, 町村貴郎, 水谷郷・他: 早期食道癌に対する内視鏡的粘膜切除術-EEMR-tube法の実際-. 胃と腸 28: 153-159, 1993.
 
51) 幕内博康, 町村貴郎, 島田英雄・他: 早期食道癌に対する内視鏡的粘膜切除術-内視鏡的粘膜切除術-. 外科 57: 1027-1031, 1995.
 
52) Makuuchi H: Endoscopic mucosal resection for early esophageal cancer-indications and techniques-. Dig. Endosc. 8: 175-179, 1996.
 
53) Lambert R: Endoscopic treatment of esophagogastric tumors. Endoscopy 28: 27-37, 1996.
 
54) Dawsey SM, Yu Y, taylor PR, et al: Esophageal cytology and subsequent risk of esophageal cancer: a prospective follow-up study from Linxian, China. Acta Cytol. 38: 183-192, 1994.
PubMed
55) 門馬久美子, 吉田 操, 山田義也・他: 早期食道癌に対する内視鏡的粘膜切除の実際-2チャンネル法-胃と腸 28: 141-151, 1993.
 
56) 井上晴洋, 竹下公矢, 長浜雄志・他: 早期食道癌に対する内視鏡的粘膜切除の実際-EMRTとEMRC-. 胃と腸 28: 161-169, 1993.
 
57) 小山恒男, 宮田佳典, 岡庭信司・他: 内視鏡的食道粘膜切除後の局所再発. 胃と腸 31: 1217-1233, 1996.
 
58) 門馬久美子, 吉田 操, 加藤久人・他: 内視鏡的食道粘膜切除後にm3・sm1と判明した癌への対応. 胃と腸 28: 1207-1215, 1996.
 
59) Newaishy GA, Read GA, Duncan W, et al: Results of radical radiotherapy of squamous cell carcinoma of the esophagus. Clin. Radiol. 33: 347-352, 1989.
 
60) Okawa T, Kita M, Tanaka M, et al: Results of radiotherapy for inoperable locally advanced esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 17: 49-54, 1989.
PubMed
61) De-Ren S: Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int. J. Radiat. Oncol. Biol. Phys. 16: 329-334, 1989.
 
62) Slevin NJ, Stout R: Carcinoma of the esophagus: a review of 108 cases treated by radical radiotherapy. Clin. Radiol. 40: 200-203, 1989.
PubMed
63) Harrison L, Fogel T, Picone J, et al: Radiation therapy for squamous cell carcinoma of the esophagus. J. Surg. Oncol. 37: 40-43, 1988.
PubMed
64) Roth JA, Putnam JB, Rich TA, et al: Cancer of the esophagus. Cancer;principles and practice of oncology. 5 th edition (ed. by Devita VT, et al) , Lippincott-Raven, Philadelphia, 1997, pp. 980-1021.
 
65) Herskovic A, Martz K, Sarraf MA, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326: 1593-1598, 1992.
 
66) Nishimura Y, Ono K, Tsutsui K, et al: Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int. J. Radiat. Oncol. Biol. Phys. 30: 1099-1105, 1994.
PubMed
67) Jager JJ, Pannebakker M, Rijken J, et al: Palliation in esophageal cancer with a single session of intraluminal irradiation. Radiother. Oncol. 25: 134-136, 1992.
PubMed
68) Hareyama M, Nishio M, Kagami Y, et al: Intracavitary brachytherapy combined with external-beam irradiation for squamous cell carcinoma of the thoracic esophagus. Int. J. Radiat. Oncol. Biol. Phys. 24: 235-240, 1992.
PubMed
69) Sander R, Hagenmueler F, Sander C, et al: Laser versus laser plus afterloading with iridium-192 in the palliative treatment of malignant stenosis of the esophagus: aprospective, randomized, and control study. Gastrointest. Endosc. 37: 433, 1991.
 
70) Marks RD, Scruggs HJ, Wallace KM: Preoperative radiation therapy for carcinoma of the esophagus. Cancer 38: 84-89, 1976.
PubMed
71) Coia L, Engstrom P, Paul A, et al: Long-term results of infusional 5-FU, mitomycin-C, and radiation as primary management of esophageal carcinoma. Int. J Radiat. Oncol. Biol. Phys. 20: 29-36, 1991.
PubMed
72) Welvaart K, Caspers RJL, Verkses RJ, et al: The choice between surgical resection and radiation therapy for patients with cancer of the esophagus and cardia: a retrospective comparison between two treatments. J. Surg. Oncol. 47: 225-229, 1991.
 
73) Caspers R, Welvaart K, Verks R, et al: The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer. J. Rad. Ther. Oncol. 12: 15-19, 1988.
 
74) Rosen N: The molecular basis for cellular transformation: implication for esophageal carcinogenesis (Review) . Semin. Oncol. 21: 416-424, 1994.
PubMed
75) Sauter ER, Coia LR, Eisenberg BL, et al: Transforming growth factor alpha expression as a potential survival prognosticator in patients with esophageal adenocarcinoma receiving high-dose radiation and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 31: 567-569, 1995.
PubMed
76) Seitz JF, Monges G, Perrier H, et al: Abscence of surexpression of protein p 53 is a powerful and independent predictor of response to treatment of squamous cell esophageal cancer by concurrent radiochemotherapy: Proc. Am. Soc. Clin. Oncol. 13: 193, 1994.
 
77) Muro K, Ohtsu A, Boku N, et al: Association of p 53 protein expression with response and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. JPn. J. Clin. Oncol. 26: 65-69, 1996.
 
78) Ajani JA: Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin. Oncol. 21: 474-482, 1994.
PubMed
79) Leichman L, Berry BT: Experience with cisplatin in treatment regimens for esophageal cancer. Semin. Oncol. 18: 64-71, 1991.
PubMed
80) Scanlon KJ, Newman YL, Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA 83: 8923-8925, 1986.
 
81) Byfield JE: Combined modality infusional chemotherapy with radiation. In: Cancer chemotherapy by infusion (ed. by Lokich JJ) , 2nd ed, Percepta Press, Chicago, 1990, pp. 521-551.
 
82) Douple EB, Richmond RC: Areview of interactions between platinum coordination complexes and ionizing radiation: implication for cancer therapy. In cisplatin;current status and new developments (eds. by Prestayko AW, Crooke ST, Karter SK) , FL Academic, Orland, 1980, pp. 125-147.
 
83) Edzinli EZ, Gelber R, Desai DV, et al: Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46: 2149-2153, 1980.
 
84) Lokich JJ, Shea M, Chaffey J: Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 60: 275-279, 1987.
PubMed
85) Engstrom PF, Lavin PT, Klassen DJ: Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. 67: 713-715, 1983.
 
86) Whittington R, Close H: Clinical experience with mitomycin-C. Cancer Chemother. Rep. 54: 195-198, 1970.
PubMed
87) Wittes RE, Adrianza ME, Parsons R, et al: Compilation of phase II results with single antineoplastic agents. Cancer Treatment Symposia 4: 91-130, 1985.
 
88) Murthy SK, Prabhakaran PS, Chandashekar M, et al: Neoadjuvant cis-DDP in esophageal cancers: An experience at a regional center, India. J. Surg. Oncol. 45: 173-176, 1990.
 
89) Bleiberg H, Jacob J, Bedenne L, et al: Randomized phase II trial of 5-fluorouracil and cisplatin versus cisplatin alone in advanced esophageal cancer. Proc. Am. Soc. Clin. Oncol. 10 (abstr.) : 145, 1991.
 
90) Bonadonna G, de Lena M, Monfardini S, et al: Clinical trial with bleomycin in lymphomas and in solid tumors. Eur. J. Cancer 8: 205-215, 1972.
 
91) Ravry M, Moertel CG, Schutt AJ, et al: Treatment of advanced squamous cell carcinoma of the gastrointestinal tract with bleomycin (NSC 125066) . Cancer Chemother. Rep. 57: 493-495, 1973.
PubMed
92) Yagoda A, Mukherji B, Young C, et al: Bleomycin, an antitumor antibiotic: clinical experience in 274 patients. Ann. Intern. Med. 77: 861-870, 1972.
PubMed
93) Kelsen DP, Bains M, Cvitkovic E, et al: Vindesine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat. Rep. 63: 2019-2021, 1979.
PubMed
94) Bedikian AY, Valdivieso M, Bodey GP, et al: Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. Cancer Chemother. Pharmacol. 2: 263-266, 1979.
PubMed
95) Bezwoda WR, Derman DP, Weaving A, et al: Treatment of esophageal cancer with vindesine: an open trial. Cancer Treat. Rep. 68: 783-785, 1984.
PubMed
96) Kolaric K, Maricic Z, Roth A, et al: Adriamycin alone and in combination with radiotherapy in the treatment of inoperable esophageal cancer. Tumori 63: 485-491, 1977.
PubMed
97) Sternberg C, Kelsen D, Dukemen M, et al: Carboplatin: anew platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer Treat. Rep. 69: 1305-1307, 1985.
 
98) Coonley CJ, Bains M, Heelan R, et al: Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat. Rep. 67: 397-398, 1983.
PubMed
99) Aj ani JA, Ilson DH, Daughetry K, et al: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl. Cancer Inst. 86: 1086-1091, 1994.
 
100) Conroy T, Etienne PL, Adenis A, et al: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J. Clin. Oncol 14: 164-170, 1996.
PubMed
101) 田口鐵男, 涌井 昭, 鍋谷欣市・他: 254-S (Cis-diammine glycolate platinum) の消化器癌に対する第II相臨床試験. 癌と化学療法 19: 483-488, 1992.
 
102) Kelsen D, Hilaris B, Coonley C, et al: Cisplatin, vindesine, and bleomycin chemtherapy of local-regional and advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Am. J. Med. 75: 645-652, 1983.
 
103) Dinwoodie WR, Bartolucci AA, Lyman GH, et al: Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: A Southeastern Cancer Study Group trial. Cancer Treat. Rep. 70: 267-270, 1986.
 
104) Hilgenberg AD, Carey RW, Wilkins EW, et al: Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann. Thorac. Surg. 45: 357-363, 1988.
PubMed
105) Ajani JA, Ryan B, Rich TA, et al: Prolonged chemotherapy for localized squamous cell carcinoma of the esophagus. Eur. J. Cancer 28 A: 880-884, 1992.
PubMed
106) Mercke C, Albertsson M, Hambraeus G, et al: Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of the esophagus. Acta Oncol. 30: 617-622, 1991.
PubMed
107) Feliu J, Baron G, Giron G, et al: Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. Am. J. Clin. Oncol. 19: 577-580, 1996.
 
108) Wadler S, Haynes H, Beitler JJ, et al: Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2 a, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 78: 30-34, 1996.
 
109) Temeck BK, Liebman JE, Theodossiou C, et al: Phase II trial of 5-fluorouracil, Leucovorin, Interferon-α-2 a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma. Cancer 77: 2432-2439, 1996.
 
110) Leichman L, Steiger Z, Seidel HG, et al: Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: apotentially curative approach. J. Clin. Oncol. 2: 75-79, 1984.
 
111) Leichman L, Herskovic A, Leichman CG, et al: Nonoperative therapy for squmous cell cancer of the esophagus. J. Clin. Oncol. 51365-370, 1987.
 
112) Coia LR, Engstrom PS, Paul A: Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. J. Clin. Oncol. 5: 1783-1790, 1987.
 
113) John MJ, Flam MS, Mowry PA, et al: Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer 63: 2397-2403, 1989.
PubMed
114) Forastier AA, Orringer MB, Perez-Tamayo C, et al: Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J. Clin. Oncol. 11: 1118-1123, 1993.
 
115) Seitz JF, Giovannini M, Padaut-Cesana J, et al: Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer 66: 214-219, 1990.
PubMed
116) Ohtsu A, Yoshida S, Boku N, et al: Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn. J. Clin. Oncol. 25: 261-266, 1995.
PubMed
117) Coia LR, Engstrom PS, Paul A, et al: Long-term results of infusional 5-FU, and mitomycin-C and radiation as primary management of esophageal carcinoma. Int. J. Radiat. Oncol, Biol. Phys. 20: 29-36, 1991.
 
118) Roussel A, Bleiberg H, Dalesio O, et al: Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 16: 67-72, 1989.
PubMed
119) Araujo CMM, Souhami L, Gil RA, et al: A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 67: 2258-2261, 1991.
 
120) Sischy B, Ryan L, Haller D, et al: Interim report of EST 1282 phase III protocol for the evaluation of combined modalities in the treatment of patients with carcinoma of the esophagus. Proc. Am. Soc. Clin. Oncol. 9 (abstr.) : 105, 1990.
 
121) Al Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J. Clin. Oncol. 15: 277-284, 1997.
PubMed
122) Minsky BD: Nonsurgical treatment approaches for esophageal cancer. Proc. Am. Soc. Clin. Oncol. (Educational Book) : 164-174, 1997.
 
123) Nygaard K Hagen S, Hansen HS, et al: Preoperative radiotherapy prolongs survival in operable esophageaI carcinoma: a randomized multicenter study of preoperative radiotherapy and chemotherapy. World J. Surg. 16: 1104-1109, 1992.
PubMed
124) Le Prise E, Etienne P, Meunier B, et al: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73: 1779-1784, 1994.
PubMed
125) Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335: 462-467, 1996.
PubMed
126) Wilke H, Fink U: Multimodal therapy for adenocarcinoma of the esophagus and esophagogastric junction. N. Engl. J. Med. 335: 509-510, 1996.
PubMed
127) Urba S, Orringer M, Turrisi R, et al: A randomized trial comparing surgery to preoperative concomitant chemoradiation plus surgery in patients with resectable esophageal cancer. Proc. Am. Soc. Clin. Oncol. 16: 277, 1997.
 
128) Bosset JF, Gignoux M, Triboulet Jp, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N. Engl. J. Med. 337: 161-167, 1997.
PubMed
129) Poplin EA, Khanuja PS, Kraut MJ, et al: Chemoradiotherapy of esophageal carcinoma. Cancer 74: 1217-1224, 1994.
PubMed
130) Poplin EA, Jacobson J, Herskovic A, et al: Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Cancer 78: 1851-1856, 1996.
 
131) Ganem G, Dubray B, Raoul Y, et al: Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. J. Clin. Oncol. 15: 701-711, 1997.
PubMed
132) Javed T, Reed C, Walle T, et al: Aregimen of paclitaxel (P) , cisplatin (CP) and 5-fluorouracil followed by G-CSF is highly active against epidermoid and adenocarcinoma of the esophagus. Proc. Am. Soc. Clin. Oncol. 14: 456, 1995.
 
133) Ajani JA, Ilson D, Bhala K, et al: Taxol, cisplatin and 5 FU: A multi-institutional phase II study in patients with carcinoma of the esophagus. Proc. Am. Soc. Clin. Oncol. 14: 489, 1995.
 
134) Ilson D, Arquette M, Costa F, et al: Preoperative paclitaxel/cisplatin in esophageal carcinoma: a phase II multicenter trial. Proc. Am. Soc. Clin. Oncol. 16: 926, 1997.
 
135) Meluch AA, Hainsworth JD, Thomas M, et al: Preoperative therapy with paclitaxe1, carboplatin, 5-FU, and radiation yields 69％pathologic complete response (CR) rate in the treatment of local esophageal carcinoma. Proc. Am. Soc. Clin. Oncol. 16: 927, 1997.
 
136) Ando N, Iizuka T, Kakegawa T, et al: A randomized trial of surgery with and without chemotherapy for localized squamous cell carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study. J. Thorac. Cardiovasc. Surg. 114: 205-209, 1997.
 
137) Isaac JR, Sim EK, Ngoi SS, et al: Safe and rapid palliation of dysphagia for carcinoma of the esophagus. Am. Surg. 57: 245, 1991.
PubMed
138) Siegel HI, Laskin KJ, Dabezies MA, et al: The effect of endoscopic laser therapy on survival in patients with squamous-cell carcinoma of the esophagus: further experience. J. Clin. Gastroenterol. 13: 142, 1991.
PubMed
139) Alderson D, Wright PD: Laser recanalization versus endoscopic intubation in the palliation of malignant dysphagia. Br. J. Surg. 77: 1151, 1990.
PubMed
140) Barr H, Krasner N, Raouf A, et al: Prospective randomized trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia. Gut 31: 252, 1990.
PubMed
141) Domschke W, Foerster EC, Matek W, et al: Self-expanding mesh stent for esophageal cancer stenosis. Endoscopy 22: 134-136, 1990.
PubMed
142) Knylrim K, Wagner HJ, Bethge N, et al: Acontrolled trial of an expansive metal stent for palliation of esophageal obstruction due to inoperable cancer. N. Engl. J. Med. 329: 1302-1307, 1993.
 
143) Vakil N, Bethge N: Metal stent for malignant esophageal obstruction. Am. J. Gastroenterol. 91: 2471-2476, 1996.
PubMed
144) Spivak H, Katariya K, Lo AY, et al: Malignant tracheo-esophageal fistula: use of esophageal prosthesis. J. Surg. Oncol. 63: 65-70, 1996.
PubMed
145) Yamada S, Takai Y, Ogawa Y, et al: Radiotherapy for malignant fistula to other tract. Cancer 64: 1026-1028, 1989.
PubMed
146) Malik SM, Krasnow SH, Wadeigh RG, et al: Closure of tracheoesophageal fistulas with primary chemotherapy in patients with esophageal cancer. Cancer 73: 1321-1323, 1994.
 
147) Muro K, Ohtsu A, Boku N, et al: Treatment for locally advanced esophageal carcinoma complicated by fistulas: case report. Int. J. Clin. Oncol. 1: 176-181, 1996.
 
148) Dorta G, Binek J, Blum L, et al: Comparison between esophageal Wallstent and Ultraflex stents in the treatment of malignant stenoses of the esophagus and cardia. Endoscopy 29: 149-154, 1997.
 
P.1014 掲載の参考文献
1) Orringer M: Technical aids in performing transhiatal esophagectomy without thoracotomy. Ann. Thorac. Surg. 38: 128-132, 1984.
PubMed
2) 甲 利幸, 古河 洋, 今岡真義・他: 手術単独治療例の再発形式からみた胸部食道癌治療の問題点-とくに上縦隔郭清の必要性について. 日外会誌 89: 1458-1460, 1989.
 
3) 松原敏樹, 土屋繁祐, 木下 巌・他: 再発形式からみた胸部食道癌外科療法の問題点. 日外会誌 89: 1461-1464, 1989.
 
4) Akiyama H: Squamous cell carcinoma of the thoracic esophagus. Surgery for cancer of the esophagus. Williams &Wilkins, Baltimore, 1990, pp. 28-41.
 
5) 食道疾患研究会: 食道癌取扱い規約. 第8版, 金原出版, 東京, 1992.
 
6) 安藤暢敏, 小澤壮治, 辻塚一幸・他: 胸部食道癌に対する3領域郭清の功罪. 日消外会誌 28: 937-941, 1995.
 
7) 鶴丸昌彦: 胸部食道癌に対するリンパ節郭清. 日消外会誌 31: 128-132, 1998.
 
8) Nishihira T, Sayama J, Ueda H, et al: Lymph flow and lymph node metastasis in esophageal cancer. Surg. Today 25: 307-317, 1995.
PubMed
9) Isono K, Sato H, Nakayama K: Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 48: 411-420, 1991.
 
10) 掛川暉夫: 食道リンパ流の特性に基づいた胸部食道癌の合理的手術方法の研究. 厚生省癌研究助成金による研究報告集(平成2年度) . 国立がんセンター, 東京, 1991, pp. 285-288.
 
11) 森 昌造: 食道癌の外科的治療-成績向上の道程-. 日外会誌 98: 700-705, 1997.
 
12) Kato H, Watanabe H, Tachimori Y, et al: Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann. Thorac. Surg. 51: 931-935, 1991.
PubMed
13) Akiyama H, Tsurumaru M, Udagawa H, et al: Radical lymph node dissection for cancer of the thoracic esophagus. Ann. Surg. 220: 364-373, 1994.
PubMed
14) Roder JD, Bush R, Stein HJ, et al: Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the esophagus. Br. J. Surg. 81: 410-413, 1994.
 
15) Baba M, Aikoh T, Yoshinaka H, et al: Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann. Surg. 219: 310-316, 1994.
 
16) 室井正彦: 胸部食道癌に対するリンパ節拡大郭清法の意義に関する臨床病理学的研究. 日胸外会誌 43: 287-299, 1995.
 
17) Matsubara T, Ueda M, Yanagida O, et al: How extensive should lymph node dissection befor cancer of the thoracic esophagus? J. Thorac. Cardiovasc. Surg. 107: 1073-1078, 1994.
 
18) Nishimaki T, Tanaka O, Suzuki T, et al: Clinical implication of cervical lymph node metastasis patterns in thoracic esophageal cancer. Ann. Surg. 220: 775-781, 1994.
PubMed
19) Altorki NK, Skinner DB: Occult cervical nodal metastasis in esophageal cancer: preliminary results of threefield lymphadenectomy. J. Thorac. Cardiovasc. Surg. 113: 540-544, 1997.
PubMed
20) Orringer MB: Editorial on "Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy". J. Thorac. Cardiovasc. Surg. 113: 538-539, 1997.
PubMed
21) Orringer MB, Marshall B, Stirling MC: Transhiatal esophagectomy for benign and malignant disease. J. Thorac. Cardiovasc. Surg. 105: 265-277, 1993.
 
22) Goldminc M, Maddern G, Le Pricse E, et al: Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br. J. Surg. 80: 367-370, 1993.
PubMed
23) Tilanus HW, Hop WC, Langenhorst BL, et al: Esophagectomy with or without thoracotomy. Is there any difference ? J. Thorac. Cardiovasc. Surg. 105: 898-903, 1993.
 
24) Pac M, Basoglu A, Kocak H, et al: Transhiatal versus transthoracic esophagectomy for esophageal cancer. J. Thorac, Cardiovasc. Surg. 106: 205-209, 1993.
PubMed
25) Bolton JS, Ochsner JL, Abdoh AA: Surgical management of esophageal cancer. A decade of change. Ann. Surg. 219: 475-480, 1994.
PubMed
26) Bolton JS, Ochsner JL, Abdoh AA: Surgical management of esophageal cancer. A decade of change. Ann. Surg. 219: 475-480, 1994.
PubMed
27) Chu KM, Law SY, Fok M, et al: Aprospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am. J. Surg. 174: 320-324, 1997
 
28) Peracchia A, Bardini R: Total esophagectomy without thoracotomy: Results of a European Questionnaire (GEEMO) . Int. Surg. 71: 171-175, 1986.
PubMed
29) 神津照雄, 磯野可一: 胸部食道全摘後の胃管による食道再建. 手術 46: 691-698, 1992.
 
30) Ando N, Shinozawa Y, Ikehata Y, et al: Postoperative nutritional status in patients with esophageal carcinoma. Diseases of the Esophagus. (ed. by Mark K. Ferguson, Alex G. Little and David B. Skinner) , Futra Publishing, New York, 1990, pp. 261-269.
 
31) 安藤暢敏, 小澤壮治, 北島政樹: 結腸を用いた食道再建. 外科 58: 1532-1536, 1996.
 
32) Inokuchi K: Milestones along the road to improvement of results in the treatment of squamous cell carcinoma of the esophagus. Color atlas of surgica anatomy for esophageal cancer. Springer-Verlag, Tokyo, 1992, pp. 1-8.
 
33) 馬場政道, 愛甲 孝, 浅谷倫代・他: 胸部食道癌再建術後の問題点と対策-後縦隔経路と胸骨後経路の優劣-. 日消外会誌 28: 2047-2051, 1995.
 
34) 丸山圭一, 加藤抱一, 北島政樹: 消化管吻合法のコツGambee1層吻合の利点とその手技. 外科治療 40: 705-713, 1979.
 
35) 安藤暢敏, 小澤壮治, 三木浩栄 他: 頸部における食道・胃管/結腸器械吻合術. 臨床外科 49: 1233-1240, 1994.
 
36) Law S, Fok M, Chu KM, et al: Comparison of hand-sawn and stapled esophagogastric anastomosis after esophageal resection for cancer;aprospective randomized controlled trial. Ann. Surg. 226: 169-173, 1997.
 
37) Takiyama W, Moriwaki S, Mandai K, et al: Relationship of esophageal dysplasia to associated head and neck cancer in patients with esophageal carcinoma. JPn. J Clin. Oncol. 26: 12-17, 1996.
PubMed
38) 青山法夫, 小泉博義: 切除不能食道癌に対するバイパス手術, ステント挿入. 消化器病セミナー 69: 169-181, 1997.
 
39) Ellul Jp, Watkinson A, Khan RJ, et al: Self-expanding metalic stents for the palliation of dysphagia due to inoperable esophageal carcinoma. Br. J. Surg. 82: 1678-1681, 1995.
PubMed
40) Saxon RR, Barton RE, Katon RM, et al: Treatment of malignant esophageal obstructions with covered metalic Zstents: long term results in 52 patients. J. Vasc. Interv. Radiol. 6: 747-754, 1995.
 
41) Iizuka T, Ide H, Kakegawa T, et al: Preoperative radioactive therapy for esophageal carcinoma. Randomized evaluation trial in eight institutions. Chest 93: 1054-1058, 1988.
PubMed
42) Japanese Esophageal Oncology Group: A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Chest 104: 203-207, 1993.
 
43) Ando N, Iizuka T, Kakegawa T, et al: A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study. J. Thorac. Cardiovasc. Surg. 114: 205-209, 1997.
 
44) Iizuka T, Kakegawa T, Ide H, et al: Phase II evaluation of cisplatin and vindesine in advanced squamous cell carcinoma of the esophagus: Japanese Esophageal Oncology Group Trial. JPn. J. Clin. Oncol. 21: 176-179, 1991.
 
45) Iizuka T, Kakegawa T, Ide H, et al: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japanese Esophageal Oncology Group Trial. JPn. J. Clin. Oncol. 22: 172-176, 1992.
PubMed
46) Pouliquen X, Levard H, Hay JM, et al: 5-fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann. Surg. 223: 127-133, 1996.
PubMed
47) Reed CE: Neoadjuvant therapy of esophageal carcinoma. Chest Surg. Clin. N. Am. 4: 299-314, 1994.
PubMed
48) 安藤暢敏, 小澤壮治, 三木浩榮・他: 食道癌に対する術前化学療法と化学放射線療法. 癌と化学療法 22: 1878-1885, 1995.
 
49) Okuma T, Yoshioka M, Iseki S, et al: Preoperative chemotherapy for esophageal cancer based on chemosensitivity testing. J. Thorac. Cardiovasc. Surg. 108: 823-829, 1994.
 
50) 南出純二, 小泉博義, 青山法夫・他: 食道癌集学的治療における術前Cisplatin, 5-Fluorouracil併用化学療法の安全性と直接効果に関する検討. 日消外会誌 27: 2384-2390, 1994.
 
51) 吉田一成, 井手博子, 林 和彦・他: 食道癌に対するCisplatin, 5-FU, Leucovorin 3剤併用による術前化学療法の臨床・病理学的研究. 日胸外会誌 43: 159-167, 1995.
 
52) Roth JA, Pass HI, Flanagan MM, et al: Randomized clinical trial of pre operative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J. Thorac. Cardiovasc. Surg. 96: 242-248, 1988.
 
53) Schlag P: Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. Arch. Surg. 127: 1446-1450, 1992.
PubMed
54) Kelsen DP, Minsky B, Smith M, et al: Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. J. Clin. Oncol. 8: 1352-1361, 1990.
PubMed
55) Law S, Fok M, Chow S, et al: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective randomized trial. J. Thorac. Cardiovasc. Surg. 114: 210-217, 1997.
 
56) Kelsen DP, Ginsberg R, Qian C, et al From RTOG, CALGB, SWOG and ECOG: Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: apreliminary report of intergroup study 13 (RTOG 89-11) . Proc. Am. Soc. Clin. Oncol. 16: 276 a, 1997.
 
57) Kok TC, Lanschot JV, Siersema PD, et al: Rotterdam Esophageal Tumor Study Group: Neoadjuvant chemo- therapy in operable esophageal squamous cell cancer: final report of a phase III multicenter randomized controlled trial. Proc. Am. Soc. Clin. Oncol. 16: 277 a, 1997.
 
58) Herskovic A, Martz K, al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiother- apy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326: 1593-1598, 1992.
 
59) al-Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer. J. Clin. Oncol. 15: 277-284, 1997.
PubMed
60) Franklin L, Steiger Z, Vaishampayan G, et al: Combined modality therapy for esophageal squamous cell carcinoma. Cancer 51: 1062-1071, 1983.
 
61) Leichman L, Steiger Z, Seydel HG, et al: Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: Apotentially curative approach. J. Clin. Oncol. 2: 75-79, 1984.
 
62) Poplin E, Fleming T, Leichman L, et al: Combined therapies for squamous cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-SO37) . J. Clin. Oncol. 5: 622-628, 1987.
 
63) Seydel HG, Leichman L, Byhardt R, et al: Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: ARTOG study. Int. J. Radiat. Oncol. Biol. Phys. 14: 33-35, 1988.
 
64) Forastiere AA, Orringer MB, Perez-Tamayo C, et al: Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report. J. Clin. Oncol. 11: 1118-1123, 1993.
PubMed
65) Wolf WG, Vaughn AL, Seigler HF, et al: Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J. Thorac. Cardiovasc. Surg. 105: 749-756, 1993.
 
66) Hoff SJ, Stewart JR, Sawyers JL, et al: Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. Ann. Thorac. Surg. 56: 282-287, 1993.
PubMed
67) Laterza E, Griso C, Urso US, et al: Induction therapy for squamous carcinoma of the thoracic esophagus. Ann. Thorac. Surg. 57: 1126-1132, 1994.
PubMed
68) Bates BA, Detterbeck FC, Bernard SA, et al: Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin. Oncol. 14: 156-163, 1996.
PubMed
69) Stahl M, Wilke H, Fink U, et al: Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J. Clin. Oncol. 14: 829-837, 1996.
PubMed
70) Prise EL, Etienne PL, Meunier B, et al: A randomized study of chemotherapy, radiation therapy and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73: 1779-1784, 1994.
 
71) Apinop C, Puttisak P, Preecha N: Aprospective study of combined therapy in esophageal cancer. Hepatogastroenterology 41: 391-393, 1994.
 
72) Urba S, Orringer M, Turrisi A, et al: A randomized trial comparing surgery to preoperative concomitant chemoradiation plus surgery in patients with resectable esophageal cancer: update analysis. Proc. Am. Soc. Clin. Oncol. 16: 277 a, 1997.
 
73) Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335: 462-467, 1996.
PubMed
74) Ishida K, Iizuka T, Ando N, et al: Phase II study of chemotherapy for advanced squamous cell carcinoma of the thoracic esophagus: Nine Japanese Institutions Trial. Jpn. J. Clin. Oncol. 26: 310-315, 1996.
PubMed
75) 安藤暢敏, 小澤壮治, 北川雄光・他: T4食道癌に対する化学放射線併用療法後の根治手術. 日外会誌 98: 767-772, 1997.
 
P.1046 掲載の参考文献
1) Halsted W: The results of operations for cure of cancer of the breast performed at Johns Hopkins Hospital. Johns Hopkins Bull. 4: 497, 1894.
 
2) Fisher B: The evolution of paradigms for the management of breast cancer: apersonal perspective[Prior annotation incorrect] [published erratum appears in Cancer Res 1992 Jun 15;52 (12) : 3512]. Cancer Res. 52: 2371-2383, 1992.
 
3) 垣添忠生: 癌の統計. 癌研究振興財団, 1997.
 
4) Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. Cancer J. Clinicians 47: 5-27, 1997.
 
5) Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. Ca: a Cancer J. Clinicians 48: 6-29, 1998.
 
6) Harris JR, Lippman ME, Veronesi U, et al: Breast cancer (1-3) . N. Engl. J. Med. 327: 319-328;390-398;473- 480, 1992.
 
7) Chu KC, Tarone RE, Kessler LG, et al: Recent trends in US. breast cancer incidence, survival, and mortality rates. J. Natl. Cancer Inst. 88: 1571-1579, 1996.
PubMed
8) Chamberlain J: Epidemiology of breast cancer. In: Breast Cancer. UICC current treatment of cancer (eds. by Hoogstraten B, Burn I, Bloom HJG) . Springer-Verlag, Berlin, 1988.
 
9) Wakai K, Suzuki S, Ohno Y, et al: Epidemiology of breast cancer in Japan. Int. J. Epidemiol. 24: 285-291, 1995.
PubMed
10) Ziegler RG, Hoover RN, Pike MC, et al: Migration patterns and breast cancer risk in Asian-American women. J. Natl. Cancer Inst. 85: 1819-1827, 1993.
PubMed
11) Levi F, La Vecchia C, Lucchini F, et al: Cancer mortality in Europe, 1990-92. Eur. J. Cancer Prev. 4: 389-417, 1995.
PubMed
12) Tominaga S: Breast cancer risk. Nyugan no Rinsho 3: 251-271, 1988.
 
13) Bain C, Speizer FE, Rosner B, et al: Family history of breast cancer as a risk indicator for the disease. Am. J. Epidemiol. 111: 301-308, 1980.
PubMed
14) Ottman R, Pike MC, King MC, et al: Practical guide for estimating risk for familial breast cancer. Lancet 2: 556-558, 1983.
PubMed
15) Hall JM, Lee MK, Newman B, et al: Linkage of early-onset familial breast cancer to chromosome 17 q 21. Science 250: 1684-1689, 1990.
 
16) Miki Y, Swensen J, Shattuck-Eidens D, et al: Astrong candidate for the breast and ovarian cancer susceptibility gene BR (]Al. Science 266: 66-71, 1994.
 
17) Inoue R, Fukutomi T, Ushijima T, et al: Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res. 55: 3521-3524, 1995.
PubMed
18) Wooster R, Neuhausen SL, Mangion J, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13 q 12-13. Science 265: 2088-2090, 1994.
 
19) Inoue R, Ushijima T, Fukutomi T, et al: BRCA2 germline mutations in Japanese breast cancer families. Int. J. Cancer 74: 199-204, 1997.
PubMed
20) Wynder EL, Rose DP, Cohen LA: Diet and breast cancer in causation and therapy. Cancer 58: 1804-1813, 1986.
PubMed
21) Howe GR, Hirohata T, Hislop TG, et al: Analysis of dietary fat, calories, body weight, and the development of mammary tumors in rats and mice: a review. Cancer Res. 50: 5710-5719, 1990.
 
22) Hunter DJ, Spiegelman D, Adami HO, et al: Cohort studies of fat intake and the risk of breast cancer-a pooled analysis[see comments]. N. Engl. J. Med. 334: 356-361, 1996.
 
23) Smith-Warner SA, Spiegelman D, Yaun SS, et al: Alcohol and breast cancer in women: apooled analysis of cohort studies. JAMA 279: 535-540, 1998.
PubMed
24) Dodd GD: American Cancer Society guidelines on screening for breast cancer. Cancer 69: 1885-1887, 1992.
PubMed
25) NSABP P 1 trial: Breast cancer prevention trial shows major benefit, some risk. http: //rex. nci. nih. gov/ massmedia/pressreleases/prevtrial. htm., 1998.
 
26) Fisher B, Costantion JP, Wickerham DL, et al: Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl. Cancer Inst. 90 (18) : 1371-1388, 1998.
 
27) PDQ of NCI: Screening for breast cancer. http://cancernet. nci. nih. gov/clinpdq/screening/Screening_for_breast_cancer_Physician. html., 1998.
 
28) Fletcher SW, Black W, Harris R, et al: Report of the international workshop on screening for breast cancer. J. Natl. Cancer Inst. 85: 1644-1656, 1993.
PubMed
29) National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: Breast Cancer Screening for Women Ages 40-49, January 21-23, 1997. J. Natl. Cancer Inst. 89: 1015-1026, 1997.
PubMed
30) 福田 譲: 乳癌集団検診の現状と問題点. 乳癌の臨床 5: 374, 1990.
 
31) 渡辺 弘, 福田 譲: 乳癌と集団検診. 外科 54: 495-497, 1992.
 
32) Ota J: Mass screening for breast cancer. Comparison of the clinical stages and prognosis of breast cancer detected by mass screening and in out-patients clinic. JPn. J. Cancer Res. 80: 1028, 1989.
PubMed
33) Ohuchi N, Yoshida K, Kimura M, et al: Improved detection rate of early breast cancer in mass screening combined with mammography. JPn. J. Cancer Res. 84: 807-812, 1993.
PubMed
34) Ohuchi N, Yoshida K, Kimura M, et al: Comparison of false negative rates among breast cancer screening modalities with or without mammography: Miyagi trial. Jpn. J. Cancer Res. 86: 501-506, 1995.
PubMed
35) International Union Against Cancer: TNM classification of malignant tumours. (eds. by Sobin L, Wittekind C) (ed 5 th) . Wiley-Liss, Inc., New York, 1997.
 
36) National Institutes of Health Consensus Development Panel: Consensus Treatment: treatment of early-stage breast cancer. Monogr. Natl. Cancer Inst. 11: 1-5, 1992.
PubMed
37) Kajiwara T (Japanese Breast Cancer Society) : Results of questionnaires concerning breast cancer surgery in Japan. Breast Cancer 2: 77, 1995.
 
38) 日本乳癌学会編: 臨床・病理乳癌取扱い規約. 第12版, 金原出版, 東京, 1996.
 
39) Nixon AJ, Troyan SL, Harris JR.: Options in the local management of invasive breast cancer. Semin. Oncol. 23: 453-463, 1996.
PubMed
40) Kurtz JM, Jacquemier J, Amalric R, et al: Breast-conserving therapy for macroscopically multiple cancers. Ann. Surg. 212: 38-44, 1990.
PubMed
41) Farrow DC, Hunt WC, Samet JM: Geographic variation in the treatment of localized breast cancer. N. Engl. J. Med. 326: 1097-1101, 1992.
PubMed
42) 池田 正, 富永 健, 山口 晋・他: 乳房温存療法に関するアンケート調査-54施設の集計から-. 乳癌の臨床 10: 526-532, 1995.
 
43) Fisher B, Bauer M, Margolese R, et al: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med. 320: 822-828, 1989.
PubMed
44) Veronesi U, Volterrani F, Luini A, et al: Quadrantectomy versus lumpectomy for small size breast cancer. Eur. J. Cancer 26: 671-673, 1990.
PubMed
45) Veronesi U, Salvadori B, Luini A, et al: Conservative treatment of early breast cancer. Ann. Surg. 211: 250- 259, 1990.
 
46) Haffty BG, Fischer D, Rose M, et al: Prognostic factors for local recurrence in the conservatively treated breast cancer patient: Acautious interpretation of the data. J. Clin. Oncol. 9: 997-1003, 1991.
 
47) Neff PT, Bear HD, Pierce CV, et al: Long-term results of breast conservation therapy for breast cancer. Ann. Surg. 223: 709-717, 1996.
PubMed
48) Leborgne F, Leborgne JH, Ortega B, et al: Breast conservation treatment of early stage breast cancer. Patterns of failure. Int. J Radiat. Oncol. Biol. Phys. 31: 765-775, 1995.
PubMed
49) Abner AL, Recht A, Eberlein T, et al: Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J. Clin. Oncol. 11: 44-48, 1993.
PubMed
50) Forrest AP, Stewart HJ, Everington D, et al: Randomized control trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet 348: 708-713, 1996.
 
51) Veronesi U, Salvadori B, Luini A, et al: Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N. Engl. J. Med. 328: 1587-1591, 1993.
 
52) Ballard-Barbash R, Potosky AL, Harlan LC, et al: Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J. Natl. Cancer Inst. 88: 716-726, 1996.
PubMed
53) Recht A, Come SE, Henderson IC, et al: The sequencing of chemotherapy and radiation therapy after conservative surgery of early-stage breast cancer. N. Engl. J. Med. 334: 1356-1361, 1996.
PubMed
54) Schnitt SJ, Connolly JL, Khettry U, et al: Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy. Cancer 59: 675-681, 1987.
PubMed
55) Anscher MS, Jones P, Roseman J, et al: Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann. Surg. 218: 22-28, 1993.
 
56) Zafrani B, Vielh P, Mosseri V, et al: Conservative treatment of early breast cancer: prognostic value of ductal carcinoma in situ component and other pathological variables on local control and survival. Eur. J. Cancer Clin. Oncol. 25: 1645-1650, 1989.
PubMed
57) Holland R, Connoly J, Harris JR, et al: The presence of an intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J. Clin. Oncol. 8: 113-118, 1990.
 
58) Kurtz JM, Jacquemier J, Amalric R, et al: Why are local recurrences after breast-conserving therapy more frequent in younger patients? J. Clin. Oncol. 8: 591-598, 1990.
PubMed
59) Fisher B, Constantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment\ of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N. Engl. J. Med. 320: 479-484, 1989.
 
60) McCready DR, Hanna W, Kahn H, et al: Factors associated with local breast cancer recurrence after lumpectomy alone. Ann. Surg. Oncol. 3: 358-366, 1996.
PubMed
61) Barger J, Kemperman H, Hart A, et al: Risk factors in breast-conservation therapy. J. Clin. Oncol. 12: 653-660, 1994.
 
62) Bornstein BA, Recht A, Harris JR, et al: Results of treating ductal carcinoma in situ of the breast with conservative surgery and radiotherapy. Cancer 67: 7-13, 1991.
PubMed
63) Silverstein MJ, Waisman JR, Gierson ED, et al: Radiation therapy for intraductal carcinoma. Arch. Surg. 126: 424-428, 1991
PubMed
64) Gallagher WJ, Koerner FC, Wood WC, et al: Treatment of intraductal carcinoma with limited surgery. J. Clin. Oncol. 7: 376-380, 1989.
PubMed
65) Solin LJ, Kurtz J, Fourquet A, et al: Fifteen-year results of breast conserving surgery and difinitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J. Clin. Oncol. 14: 754-763, 1996.
 
66) Hilner BE, Desch CE, Carlson RW, et al: Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma in sitor of the breast. J. Clin. Oncol. 14: 70-77, 1996.
 
67) Stotter A, Atkinson EN, Balch CM, et al: Survival following locoregional recurrence after breast conserving therapy for cancer. Ann. Surg. 212: 166-172, 1990.
 
68) Silverstein MJ, Gierson ED, Colburn WJ, et al: Can intraductal breast carcinoma be excised completely by local excision? Cancer 73: 2985-2989, 1994.
PubMed
69) Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl. Cancer Inst. 82: 1539-1545, 1990.
PubMed
70) Schwartz GF, Birchansky CA, Komarnicky LT, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73: 362-369, 1994.
PubMed
71) Haffty BG, Ward B, Pathare P, et al: Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J. Clin. Oncol. 15: 691-700, 1997.,
PubMed
72) Guiliano AE, Dale PS, Turner RR, et al: Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann. Surg. 222: 394-401, 1995.
 
73) Crowe Jp Jr, Gordon NH, Antunez AR, et al: Local-regional breast cancer recurrence following mastectomy. Arch. Surg. 126: 429-432, 1991.
PubMed
74) Stefanik D, Goldberg R, Byrne P, et al: Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 3: 660-665, 1985.
PubMed
75) Griem KL, Henderson IC, Gelman R, et al: The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J. Clin. Oncol. 5: 1546-1555, 1987.
PubMed
76) Fowble B, Gray R, Gilchrist K, et al: Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J. Clin. Oncol. 6: 1107-1117, 1988.
PubMed
77) Early Breast Cancer Trialists 'Collaborative Group: Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials[see comments]. [published erratum appears in N. Engl. J. Med. 1996 Apr 11;334 (15) : 1003]. N. Engl. J. Med. 333: 1444-1455, 1995.
 
78) Arriagada R, Mouriesse H, Sarrazin D, et al: Radiotherapy alone in breast cancer. 1. Analysis of tumor parameters, tumor dose and local control: the experience of the Gustave-Roussy Institute and the Princess Margaret Hospital. Int. J. Radiat. Oncol. Biol. Phys. 11: 1751-1757, 1985.
 
79) Spanos WJ Jr, Montague ED, Fletcher GH: Late complications of radiation only for advanced breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 6: 1473-1476, 1980.
PubMed
80) Bedwinek J, Rao DV, Perez C, et al: Stage III and localized stage IV breast cancer: irradiation alone vs irradiation plus surgery. Int. J. Radiat. Oncol. Biol. Phys. 8: 31-36, 1982.
PubMed
81) Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer[see comments]. N. Engl. J. Med. 337: 956-962, 1997.
 
82) Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82 b Trial [see comments]. N. Engl. J. Med. 337: 949-955, 1997.
 
83) Hellman S: Stopping metastases at their source[editorial;comment]. N. Engl. J. Med. 337: 996-997, 1997.
PubMed
84) Fisher B, Ravdin RG, Ausman RK, et al: Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann. Surg. 168: 337-356, 1968.
PubMed
85) Dhingra K, Hortobagyi GN: Critical evaluation of prognostic factors. Semin. Oncol. 23: 436-445, 1996.
PubMed
86) Kaufmann M: Review of known prognostic variables. Recent Results Cancer Res. 140: 77-87, 1996.
PubMed
87) Rutgers EJ, Peterse HL: Future prospects for the staging of breast cancer. Semin. Surg. Oncol. 12: 3-11, 1996.
PubMed
88) International Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 335: 1565-1568, 1990.
 
89) Veronesi U, Paganelli G, Galimberti V, et al: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349: 1864-1867, 1997.
PubMed
90) Giuliano AE, Jones RC, Brennan M, et al: Sentinel lymphadenectomy in breast cancer. J. Clin. Oncol. 15: 2345- 2350, 1997.
 
91) Adair F, Berg J, Joubert L, et al: Long-term follow up of breast cancer patients: the 30-year report. Cancer33: 1145-1150, 1974.
 
92) Bradley SJ, Weaver DW, Bouwman DL: Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am. Surg. 56: 428-432, 1990.
PubMed
93) Schnitt SJ, Silen W, Sadowsky NL, et al: Ductal carcinoma in sitzt (intraductal carcinoma) of the breast. N. Engl. J. Med. 318: 898-903, 1988.
 
94) Rosen PP, Groshen S, Kinne DW, et al: Factors influencing prognosis in node-negative breast carcinoma: \ analysis of 767 TINOMO/T2NOMO patients with long-term follow-up. J. Clin. Oncol. 11: 2090-2100, 1993.
 
95) Bloom HJ, Richardson WW: Histological grading and prognostis in breast cancer. Br. J. Cancer 11: 359-377, 1957.
 
96) Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 65: 1794-1800, 1990.
PubMed
97) Yoshimoto M, Sakamoto G, Ohashi Y: Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 72: 2993-3001, 1993.
PubMed
98) Henson DE: The histological grading of neoplasms. Arch. Pathol. Lab. Med. 112: 1091-1096, 1988.
PubMed
99) NIH Consensus Development Conference: Steroid receptors in breast cancer. Cancer 46: 2759-2963, 1980.
PubMed
100) Elledge RM, Osborne CK: Oestrogen receptors and breast cancer[editorial]. Br. Med. J. 31411843-1844, 1997.
 
101) Berger U, Wilson P, Thethi S, et al: Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors. Cancer Res. 49: 5176-5179, 1989.
PubMed
102) Molino A, Micciolo R, Turazza M, et al: Estrogen receptors in 699 primary breast cancers: acomparison of immunohistochemical and biochemical methods. Breast Cancer Res. Treat. 34: 221-228, 1995.
 
103) Nichols GE, Frierson HF Jr, Boyd JC, et al: Automated immunohistochemical assay for estrogen receptor status in breast cancer using monoclonal antibody CC 4-50n the Ventana ES. Am. J. Clin. Pathol. 106: 332-338, 1996.
 
104) Knight WA, Livingston RB, Gregory EJ, et al: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37: 4669-4671, 1977.
PubMed
105) Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin. Oncol. 15: 20-25, 1988.
PubMed
106) Foekens JA, Portengen H, van Putten WL, et al: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 49: 5823-5828, 1989.
PubMed
107) Lupu R, Lippman ME: William L. McGuire Memorial Symposium. The role of erbB 2 signal transduction pathways in human breast cancer. Breast Cancer Res. Treat. 27: 83-93, 1993,
 
108) Andrulis IL, Bull SB, Blackstein ME, et al: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J. Clin. Oncol. 16: 1340-1349, 1998.
PubMed
109) Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group[see comments]. J. Clin. Oncol. 10: 1049-1056, 1992.
 
110) Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in sitza carcinoma. J. Clin. Oncol. 10: 599-605, 1992.
PubMed
111) Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer[see comments][published erratum appears in N. Engl. J. Med. 1994 Jul 21; 331 (3) : 211]. N. Engl. J. Med. 330: 1260-1266, 1994,
 
112) Yamauchi H, O'Neill A, Gelman R, et al: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol. 15: 2518-2525, 1997.
 
113) Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum ccrbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 13: 1129-1135, 1995.
 
114) Clark GM: Prognostic and predictive factors for breast cancer. Breast Cancer 2: 79-89, 1995.
 
115) McGuire WL: Breast cancer prognostic factors: evaluation guidelines[editorial;comment]. J. Nat. Cancer Inst. 83: 154-155, 1991.
PubMed
116) Fisher B, Carbone P, Economou SG, et al: 1-Phenylalanine mustard (LPAM) in the management of primary breast cancer. A report of early findings. N. Engl. J. Med. 292: 117-122, 1975.
PubMed
117) Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up[see comments]. N. Engl. J. Med. 332: 901- 906, 1995.
 
118) Goldhirsch A, Glick JH, Gelber RD, et al: Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J. Natl. Cancer Inst. 90 (21) : 1601-1608, 1998.
PubMed
119) Anonymous: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. International Breast Cancer Study Group. J. Clin. Oncol. 14: 1885-1894, 1996.
 
120) Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J. Clin. Oncol. 1: 2-10, 1983.
PubMed
121) Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol. 8: 1483-1496, 1990.
 
122) Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med. 330: 1253-1259, 1994.
PubMed
123) Goldhirsch A, Coates A, Colleoni M, et al: Adjuvant chemotherapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J. Clin. Oncol. 16: 1358-1362, 1998.
PubMed
124) Watanabe T: Phase III Randomized Comparison of Postoperative Adjuvant Chemotherapy with 2-year oral UFT (uracil/tegafur) versus 6-cycle CMF (cyclophosphamide/methotrexate/5-fluorouracil) in High-risk Node Negative Breast Cancer Patients. JPn. J. Clin. Oncol. 28: 77-80, 1998.
 
125) American Society of Clinical Oncology: Recommended breast cancer surveillance guidelines. J. Clin. Oncol. 15: 2149-2156, 1997.
 
126) Hortobagyi GN, Singletary SE, McNees MD: Treatment of locally advanced and inflammatory breast cancer. In: Disease of the breast (eds. by Harris JR, Lippman ME, Morrow M, et al) (ed 1st) . Lippincott-Raven Publishers, Philadelphia, 1996.
 
127) Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 16: 93-100, 1998.
PubMed
128) Buzdar AU, Hortobagyi GN, Asmar L, et al: Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/ doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Sem. Oncol. 24: S17-31-S17-34, 1997.
 
129) Brain E, Garrino C, Misset JL, et al: Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br. J. Cancer 75: 1360-1367, 1997.
PubMed
130) Fisher B, Mamounas EP: Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer [editorial]. J. Clin. Oncol. 13: 537-540, 1995.
 
131) Akashi-Tanaka S, Tsuda H, Fukuda H, et al: Prognostic value of histopathological therapeutic effects and mitotic index in locally advanced breast cancer treated with neoadjuvant chemotherapy. JPn. J. Clin. Oncol.: 1996.
PubMed
132) Ellis P, Smith I, Ashley S, et al: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. 16: 107-114, 1998.
PubMed
133) Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B- 18[see comments]. J. Clin. Oncol. 15: 2483-2493, 1997.
 
134) Haagensen CD, Stout AP: Carcinoma of the breast, criteria of operability. Ann. Surg. 118: 859-870;1032-IO51, 1943.
 
135) Fernando IN, Powles TJ, Dowsett M, et al: Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry. Virchows Archiv. 426: 155-161, 1995.
PubMed
136) Minkowitz S, Moskowitz R, Khafif RA, et al: TRU-CUT needle biopsy of the breast. An analysis of its specificity and sensitivity. Cancer 57: 320-323, 1986.
PubMed
137) O'Neil S, Castelli M, Gattuso P, et al: Fine-needle aspiration of 697 palpable breast lesions with histopathologic correlation. Surgery 122: 824-828, 1997.
PubMed
138) Abeloff MD, Lichter AS, Niederhuber JE, et al: Breast. In: Clinical Oncology (eds. by Abeloff MD, Armitage JO, Lichter AS, et al) . Churchill Livingstone, New York, 1995, pp. 1617-1714.
 
139) Gradishar WJ: Inflammatory breast cancer: the evolution of multimodality treatment strategies. Semin. Surg. Oncol. 12: 352-363, 1996.
PubMed
140) Vahdat L, Antman K: High-dose chemotherapy with autologous stem cell support for breast cancer. Curr. Opin. Hematol. 4: 381-389, 1997.
PubMed
141) Anonymous: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology[see comments]. J. Clin. Oncol. 14: 2843-2877,
 
142) Humphrey LJ, Moore DL, Lytle GH: Postmastectomy locally recurrent breast cancer. J. Surg. Oncol. 43: 88- 91, 1990.
 
143) Toi M, Tanaka S, Bando M, et al: Outcome of surgical resection for chest wall recurrence in breast cancer patients. J. Surg. Oncol. 64: 23-26, 1997.
PubMed
144) Scatarige JC, Fishman EK, Zinreich ES, et al: Internal mammary lymphadenopathy in breast carcinoma: CT appraisal of anatomic distribution. Radiology 167: 89-91, 1988.
PubMed
145) Aberizk WJ, Silver B, Henderson IC, et al: The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 58: 1214-1218, 1986.
PubMed
146) Yamamoto N, Katsumata N, Watanabe T, et al: Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. JPn. J. Clin. Oncol. 28: 1998.
PubMed
147) Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14: 2197-2205, 1996.
PubMed
148) Venturini M, Bruzzi P, DelMastro L, et al: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J. Clin. Oncol. 14: 764-773, 1996.
PubMed
149) Blanco G, Holli K, Heikkinen M, et al: Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br. J. Cancer 62: 142-146, 1990.
PubMed
150) DiStefano A, Yong Yap Y, Hortobagyi GN, et al: The natural history of breast cancer patients with brain metastases. Cancer 44: 1913-1918, 1979.
PubMed
151) Fey MF, Brunner KW, Sonntag RW: Prognostic factors in metastatic breast cancer. Cancer Clin. Trials 4: 237-247, 1981.
PubMed
152) Hortobagyi GN, Smith TL, Legha SS, et al: Multivariate analysis of prognostic factors in metastatic breast cancer. J. Clin. Oncol. 1: 776-786, 1983.
PubMed
153) Clark GM, Sledge GW Jr, Osborne CK, et al: Survival from first recurrence: relative importance of prognostic factors in 1, 015 breast cancer patients. J. Clin. Oncol. 5: 55-61, 1987.
PubMed
154) Zinser JW, Hortobagyi GN, Buzdar AU, et al: Clinical course of breast cancer patients with liver metastases. J. Clin. Oncol. 5: 773-782, 1987.
PubMed
155) Carr B: Disorders of the ovary and female reproductive tract. In: Textbook of Endocrinology (eds. by Wilson J, Foster D) (ed 8 th) . W. B. Saunders Company, Philadelphia, 1992, pp. 733-798.
 
156) Honig S: Treatment of metastatic disease. In: Disease of the breast (eds. by Harris JR, Lippman ME, Morrow M, et al) (ed 1st) . Lippincott-Raven Publishers, Philadelphia, 1996, pp. 669-768.
 
157) Taylor C, Green S, Dalton W, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J. Clin. Oncol. 16: 994-999, 1998.
PubMed
158) Klijn J, Seynaeve C, Beex L, et al: Combined treatment with buserelin (LH-RH-A) and tamoxifen vs single treatment with each drug alone in premenopausal metastatic breast cancer;preliminary results of EORTC study 10881. Proc. Am. Soc. Clin. Oncol. 15: 117, 1996.
 
159) Falkson Cl, Falkson HC: Arandomised study of CGS 16949 A (fadrozole) versus tamoxifen in previously untreated postmenopausal patierlts with metastatic breast cancer[see comments]. Ann. Oncol. 7: 465-469, 1996.
 
160) Thurlimann B, Beretta K, Bacchi M, et al: First-line fadrozole HCl (CGS 16949 A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88[see comments]. Ann. Oncol. 71471-479, 1996.
 
161) Buzdar AU, Smith R, Vogel C, et al: Fadrozole HCL (CGS-16949 A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer 77: 2503-2513, 1996.
 
162) Taylor SG, Gelber RD: Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patierlts with previously untreated breast cancer[letter]. Cancer Treat. Rep. 66: 1594-1595, 1982.
PubMed
163) Jones SE, Durie BGM, Salmon SE: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36: 90-97, 1975.
 
164) Bull JM, Tormey DC, Li SH, et al: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649-1657, 1978.
PubMed
165) Tranum B, Hoogstraten B, Kennedy A, et al: Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study. Cancer 41: 2078-2083, 1978.
 
166) Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each+/-MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J. Clin. Oncol. 5: 1523-1533, 1987.
 
167) A 'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br. J. Cancer 67: 801-805, 1993.
PubMed
168) Tranum BL, McDonald B, Thigpen T, et al: Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study. Cancer 49: 835-839, 1982.
 
169) Nemoto TJH, Simon R, et al: Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin. Cancer 49: 1988-1993, 1982.
 
170) French Epirubicin Study Group: Aprospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J. Clin. Oncol. 6: 679-688, 1988.
 
171) Lopez M, Contegiacomo A, Vici P, et al: Aprospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 64: 2431-2436, 1989.
 
172) Leonard RC, Cornbleet MA, Kaye SB, et al: Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J. Clin. Oncol. 5: 1056-1063, 1987.
PubMed
173) Bennett JM, Muss HB, Doroshow JH, et al: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J. Clin. Oncol. 6: 1611-1620, 1988.
PubMed
174) Henderson IC, Allegra JC, Woodcock T, et al: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7: 560-571, 1989.
PubMed
175) Robertson JF, Willsher PC, Cheung KL, et al: The clinical relevance of static disease (no change) category for 6months on endocrine therapy in patients with breast cancer. Eur. J. Cancer 33: 1774-1779, 1997.
 
176) Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat. Rep. 66: 439-449, 1982.
PubMed
177) Falkson G, Gelman RS, Dreicer R, et al: Myelodysplastic syndrome and acute nonlymphocytic leukemiasecondary to mitolactol treatment in patients with breast cancer[see comments]. J. Clin. Oncol. 7: 1252-1259, 1989.
 
178) Smalley RV, Murphy S, Hunguley CM, et al: Combination versus sequential five-drug chemotherapy on metastatic carcinoma of the breast. Cancer Res.: 3911-3916, 1976.
 
179) Muss HB, Case LD, Richards FD, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association[see comments]. N. Engl. J. Med. 325: 1342-1348, 1991.
 
180) Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 317: 1490-1495, 1987.
PubMed
181) Harris AL, Cantwell BM, Carmichael J, et al: Comparison of short-term and continuous chemotherapy (mitoxantrone) for advanced breast cancer[see comments]. Lancet 335: 186-190, 1990.
 
182) Glaholm J, Mort C, Ashley S, et al: Duration of chemotherapy in advanced breast carcinoma[letter;comment]. Lancet 335: 1033, 1990.
PubMed
183) Henderson IC, Harris JR: Principles in the management of metastatic disease. In: Breast Disease (eds. by Henderson IC, Harris JR) (ed 2 nd) . Lippincot, New York, 1990, pp. 547-677.
 
184) Adachi I, Watanabe T, Takashima S, et al: Alate phase II study of RP 56976 (docetaxe1) in patients with advanced or recurrent breast cancer. Br. J. Cancer 73: 210-216, 1996.
PubMed
185) Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 13: 314-322, 1995.
 
186) Hudis CA, Seidman AD, Crown JP, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14: 58-65, 1996.
PubMed
187) Ravdin PM, Burris HAr, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer[see comments]. J. Clin. Oncol. 13: 2879-2885, 1995.
 
188) Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: anew, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer[see comments]. J. Clin. Oncol. 13: 2886-2894, 1995.
 
189) Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol. 16: 187-196, 1998.
 
190) Ravdin P, Valeno V, Nabholtz J-M, et al: Efficacy of a five-day corticosteroid premedication in ameliorating taxotere-induced fluid retention. Proc. Am. Soc. Clin. Oncol. (Abstr. #124) . 15: 115, 1996.
 
191) Ando M, Watanabe T, Sasaki Y, et al: A phase I trial of docetaxel and 5-day continuous infusion of 5- fluorouracil in patients with advanced or recurrent breast cancer. Br. J. Cancer: 1998. (in press)
 
192) Cooper RG: Combination chemotherapy in hormone resistant breast cancer. Proc. Am. Assoc. Cancer Res. 10: 15, 1969.
 
193) Muss HB, White DR, Cooper MR, et al: Combination chemotherapy in advanced breast cancer: a randomized trial comparing a three-vs a five-drug program. Arch. Intern. Med. 137: 1711-1714, 1977.
 
194) Segaloff A, Hankey BF, Carter AC, et al: An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer. Breast Cancer Res. Treat. 5: 311-319, 1985.
PubMed
195) Tormey DC, Gelman R, Band PR, et al: Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer 50: 1235-1244, 1982.
PubMed
196) Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol. 6: 1377-1387, 1988.
PubMed
197) The Australian and new Zealand Breast Cancer Trials Group: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J. Clin. Oncol. 4: 186-193, 1986.
 
198) Falkson G, Gelman RS, Tormey DC, et al: Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 5: 881-889, 1987.
 
199) Taylor ST, Gelman RS, Falkson G, et al: Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann. Intern. Med. 104: 455-461, 1986.
 
200) Perry MC, Kardinal C, Korzun AH, et al: Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081. J. Clin. Oncol. 5: 1534-1545, 1987.
 
201) Watanabe T: Improving the quality of life of patients with metastatic breast cacner., 1994.
 
202) Peters WP: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cacner: yes, In: Important advance in oncology 1995 (eds. by DeVita VTJ, Hellman S, Rosenberg SA) . J. B. Lippincott Company, Philadelphia, 1995.
 
203) Rahman ZU, Frye DK, Buzdar AU, et al: Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer[see comments]. J. Clin. Oncol. 15: 3171-3177, 1997.
 
204) Garcia-Carbonero R, Hidalgo M, Paz-Ares L, et al: Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer[see comments]. J. Clin. Oncol. 15: 3178-3184, 1997.
 
205) Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial[see comments]. J. Clin. Oncol. 13: 2483-2489, 1995.
 
206) Smith GA, Henderson IC: High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. In: Important advance in oncology 1995 (eds. by DeVita VTJ, Hellman S, Rosenberg SA) . J. B. Lippincott Company, Philadelphia, 1995.
 
207) Yamamoto N, Watanabe T, Katsumata N, et al: Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J. Clin. Oncol. (in press)
 
P.1072 掲載の参考文献
1) 津熊秀明, 北川貴子, 田中明夫・他: 1975-89年の全国罹患率に基づく将来推計. 地域がん登録の精度向上と活用に関する研究 平成6年度研究班報告書 (花井 彩編) , pp. 72-83, 1994.
 
2) がん研究振興財団: がんの統計 ' 93. 1993.
 
3) Murakami R, Tsukuma H, Ubukata T, et al: Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 65: 1255-1260, 1990.
PubMed
4) Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289, 1991.
PubMed
5) Meyers WC, Damiano RJ, Postlethwailt RW, et al: Adenocarcinoma of the stomach. Ann. Surg. 205: 1-8, 1987.
 
6) Salvon-Harman JC, Nikulasson S, Khettry U, et al: Shifting proportions of gastric adenocarcinomas. Arch. Surg. 129: 381-388, 1994.
PubMed
7) Powell J, McConkey CC: Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br. J. Cancer 62: 440-443, 1990.
PubMed
8) Hotz J, Goebell H, et al: Epidemiology and pathogenesis of gastric carcinoma. In: Gastric carcinoma (eds by Meyer HJ, Schmoll H-J, Hotz J) , Springer-Verlag, New York, 1989, p. 3.
 
9) Correa P, Cuello C, Duque E, et al: Carcinoma and intestinal metaplasia in the stomach in Columbian migrants. J. Natl. Cancer Inst. 44: 297-306, 1970.
 
10) Imai T, Kubo T, Watanabe H: Chronic gastritis in Japanese with reference to high incidence of gastric carcinoma. J. Natl. Cancer Inst. 179-195, 1971.
PubMed
11) Staszewski J: Migrants studies in alimentary tract cancer. RRCR 39: 85, 1972.
 
12) Haenszel W, Kurihara M, Segi M, et al: Lee RKC. Stomach cancer among Japanese in Hawaii. J. Natl. Cancer Inst. 49: 969-988, 1972.
 
13) Correa P: Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin. Oncol. 12: 2-10, 1985.
PubMed
14) Boeing H: Epidemiological research in stomach cancer: progress over the last ten years. J. Cancer Res. Clin. Oncol. 117: 133-143, 1991.
PubMed
15) Chyou P-H, Nomura AMYH, Hankin JH, et al: Acase-cohort study of diet and stomach cancer. Cancer Res. 50: 7501-7504, 1990.
 
16) Nomura A, Grove JS, Stemmermann GN, et al: A prospective study of stomach cancer and its relation to diet., cigarettes, and alcohol consumption. Cancer Res. 50: 627-631, 1990.
PubMed
17) Balfour DC: Factors influencing the life expectancy of patients operated on for gastric surgery. Ann. Surg. 76: 405, 1992.
 
18) Lygidakis NJ: Gastric stump carcinoma after surgery for gastroduodenal ulcer. Ann. R. Coll. Surg. Engl. 63: 203, 1981.
PubMed
19) Giarelli L, Melato M, Stanta G, et al: Gastric resection: acause of high frequency of gastric carcinoma. Cancer 52: 1113-1116, 1983.
 
20) Stalnikowicz R, Benbassat J: Risk of gastric cancer after surgery for benign disorders. Arch. Intern. Med. 150: 2022-2026, 1990.
PubMed
21) Tersmette AC, Offerhaus GJA, Tersmette KWF, et al: Meta-analysis of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer Res. 50: 6486-6489, 1990.
 
22) Maehara Y, Watanabe A, Kakeji Y, et al: Prognosis for surgically treated gastric cancer patients is poorer for women than men in all patients under age 50. Br. J. Cancer 65: 417-420, 1992.
PubMed
23) La Vecchia C, Negri E, D 'Avanzo B, et al: Histamine-2-receptor antagonists and gastric cancer risk. Lancet 336: 355-357, 1990.
PubMed
24) Schumacher MC, Jick SS, Jick H, et al: Cimetidine use and gastric cancer. Epidemiology 1: 251-254, 1990.
PubMed
25) Burstein M, Monge E, Leon-Barua R, et al: Low peptic ulcer and high gastric prevalence in a developing country with a high prevalence of infection by Helicobacter pylori. J. Gastroenterol. 13: 54-156, 1991.
 
26) Dooley CP, Cohen H, Fitzgibbons PL, et al: Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N. Engl. J. Med. 321: 1562-1566, 1989.
 
27) Parsonnet J, Vandersteen J, Goates J, et al: Helicobacter pylori infection in intestinal-and diffuse-type gastric adenocarcinomas. J. Natl. Cancer Inst. 83: 640-643. 1991.
 
28) Parsonnet J, Friedman GD, Vandersteen DP, et al: Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325: 1127-1131, 1991.
PubMed
29) Nomura A, Stemmermann GN, Chyou P-H, et al: Helicobacter pylori infection and gastric carcinoma among Japanese American in Hawaii. N. Engl. J Med. 325: 1132-1136, 1991.
PubMed
30) Lin J-T, Lee W-C, Wu M-S, et al: Diagnosis of gastric adenocarcinoma using a scoring system: combined assay of serological markers of Helicobacter Pylori infection, pepsinogen I and gastrin. J. Gastroenterol. 30: 156- 161, 1995.
 
31) Hanson L-E, Engstrand L, Noreen O, et al: Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology 105: 1098-1103, 1993.
 
32) Endo S, Ohkusa T, Saito Y, et al: Detection of Helicobacter py lo ri infection in early stage gastric cancer. Cancer 75: 2203-2208, 1995.
 
33) Burke AP, Yen TSB, Shekitka KM, et al: Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod. Pathol. 3: 377-380, 1990.
 
34) Shibata D, Tokunaga M, Uemura Y, et al: Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Am. J. Pathol. 139: 469-474, 1991.
PubMed
35) Tokunaga M, Uemura Y, Tokudome T, et al: Epstein-Barr virus related gastric cancer in Japan: Amolecular patho-epidemiological study. Acta Pathol. Jpn. 43: 574-581, 1993.
 
36) 胃癌研究会編: 胃癌取扱い規約 (改訂第12版) , 金原出版, 東京, 1993.
 
37) Lauren P: The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma. Acta Pathol. 64: 31, 1965.
PubMed
38) Zinninger M: Extension of gastric cancer in the intramural lymphatics and its relation to gastrectomy. Am. Surg. 20: 920, 1954.
PubMed
39) Meijer S, De Bakker OJGB, Hoitsma HFW: Palliative resection in gastric cancer. J. Surg. Oncol. 23: 77-80, 1983.
 
40) Kaneko E, Nakamura T, Umeda N, et al: Outcome of gastric carcinoma detected by gastric mass survey in Japan. Gut 18: 626-630, 1977.
PubMed
41) Noguchi Y, Imada T, Matsumoto A, et al: Radical surgery for gastric cancer: review of the Japanese experience. Cancer 64: 2053-2062, 1989.
PubMed
42) Maruyama K, Okabayashi K, Kinoshita T: Progress in gastric cancer surgery in Japan and its limits of radicality. World J. Surg. 11: 418-425, 1987.
PubMed
43) Boku T, Nakane Y, Minoura T, et al: Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br. J. Surg. 77: 436-439, 1990.
PubMed
44) Baba H, Korenaga D, Okamura T, et al: Prognostic factors in gastric cancer with serosal invasion. Arch. Surg. 124: 1061-1064, 1989.
PubMed
45) Hermanek P: Prognostic factors in stomach cancer surgery. Eur. J. Surg. Oncol. 12: 241-246, 1986.
PubMed
46) Shiu MH, Perrotti M, Brennan MF: Adenocarcinoma of the stomach: amultivariate analysis of clinical, pathologic and treatment factors. Hepatogastroenterology 36: 7-12, 1989.
 
47) Okusa T, Nakane Y, Boku T, et al: Quantitative analysis of nodal involvement with respect to survival rate after curative gastrectomy for carcinoma. Surg. Gynecol. Obstet. 170: 488-494, 1990.
PubMed
48) Adachi Y, Kamakura T, Mori M, et al: Prognostic significance of the number of positive lymph nodes in gastric carcinoma. Br. J. Surg. 81: 414-416, 1994.
PubMed
49) Bonenkamp JJ, Songun I, Hermans J, et al: Randomised comparison of morbidity after D 1 and D 2 dissection for gastric cancer in 996 Dutch patients. Lancet 345: 745-748, 1995.
 
50) Yonemura Y, Tsugawa K, Fonseca L, et al: Lymph node metastasis and surgical management of gastric cancer invading the esophagus. Hepatogastroenterology 42: 37-42, 1995.
PubMed
51) Bozzetti F, Bonafanti G, Morabito A, et al: A multifactorial approach for the prognosis of patients with carcinoma of the stomach after curative resection. Surg. Gynecol. Obstet. 162: 229-234, 1986.
 
52) Maehara Y, Moriguchi S, Sugimachi K, et al: Prognostic factors in adenocarcinoma in the upper one-third of the stomach. Surg. Gynecol. Obstet. 173: 223-226, 1991.
PubMed
53) Hesketh P, Clapp R, Doos W, et al: The increasing frequency of adenocarcinoma of the esophagus. Cancer 64: 526-535, 1989.
PubMed
54) Ohno S, Tomisaki S, Sugimachi K, et al: Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J. Am. Coll. Surg. 180: 577-582, 1995.
PubMed
55) 多田正弘, 村上敦司, 苅田幹夫・他: strip biopsyによる早期胃癌の内視鏡治療における長期観察成績. 消化器内視鏡 8: 1515, 1990.
 
56) 多田正弘, 村田 誠・他: Strip off biopsyの開発. Gastroenterol. Endosc. 26: 833-839, 1984.
 
57) 平尾雅紀, 高桑良平・他: 早期胃癌に対するHSE局注を併用した内視鏡的粘膜切除法. 胃と腸 23: 399-409. 1988.
 
58) 竹腰隆雄, 藤井 彰・他: endoscopic double snare polypectomy (EDSP) の方法と評価. 胃と腸 23: 387-398. 1988.
 
59) 田尻久雄: 早期胃癌に対するレーザー内視鏡治療-接触照射法と非接触照射法の特徴-. 日本レーザー医学会誌 11: 41-44, 1990.
Medical*Online
60) 二ツ木浩一, 山本邦男・他: 進行胃癌の癌性狭窄に対するレーザー治療の限界. 臨床消化器内科 8: 681-688, 1993.
 
61) Tajiri H, Oguro Y: Laser endoscopic treatment for upper gastrointestinal cancers. J. Laparoendoscop. Surg. 1: 71-78, 1991. .
 
62) 谷村 弘, 永井祐吾: 内視鏡的マイクロ波凝固法. 綜合臨床 41: 3240-3247, 1992.
 
63) 浅木 茂, 佐藤 彰, 斉藤行世: 内視鏡的治療-適応・方法・成績. 局注療法, 胃癌診断と治療 (丹羽寛文編) . 日本メディカルセンター, 東京, 1995, pp. 402-409.
 
64) 嶋尾 仁, 比企能樹: 狭窄拡張術. 臨床消化器内科 2: 743-751, 1987.
 
65) Hachisu T: Evaluation of endoscopic hemostasis using an improved clipping apparatus. Surg. Endosc. 2: 13-17, 1988.
PubMed
66) Yamao T, Shirao K, Ono H, et al: Risk factors for lymph node metastasis from intramucosal gastric carcinoma. Cancer 77: 603-606, 1996.
 
67) 細川浩一, 白尾国昭・他: 早期胃癌における内視鏡的粘膜切除術-適応の再検討-. 消化器内視鏡の進歩 42: 11-15, 1993.
 
68) 芳野純治: 早期胃癌の内視鏡的粘膜切除-適応拡大をめぐる問題点-. 胃と腸 31: 1065-1066, 1996.
 
69) 梶山美明, 鶴丸昌彦, 宇田川清司・他: 胃Sm癌の細分類からみた縮小手術の可能性 多変量解析を用いたリンパ節転移の予測と腹腔鏡下切除の可能性. 胃と腸 32: 63-69, 1997.
 
70) 掛地吉弘, 杉町圭蔵: 胃Sm癌の浸潤・転移・再発と生物学的特徴. 胃と腸 32: 57-62, 1997.
 
71) 表 和彦, 磨伊正義, 溝口雅之・他: 胃Sm癌の細分類とリンパ節転移に関する検討根治的内視鏡的切除術の適応拡大の可能性. 胃と腸 32: 49-55, 1997.
 
72) 辻 直子, 石黒信吾, 春日井務・他: 胃Sm癌の病理組織学的検討リンパ節転移を指標として. 胃と腸 32: 41-47, 1997.
 
73) 柳澤昭夫, 宇都出公也, 加藤 洋: 胃癌Sm浸潤の判定と深達度Sm1の考え方. 胃と腸 32: 15-19, 1997.
 
74) 猪狩 亨, 中村二郎, 滝澤登一郎・他: 胃Sm癌の病理 内視鏡的治療の可能性および根治性の検討. 胃と腸 32: 21- 29, 1997.
 
75) 大谷吉秀, 大上正裕, 久保田哲朗・他: 早期癌に対する腹腔鏡外科の立場からみた内視鏡的粘膜切除への提言. 胃と腸 31: 1121-1128, 1996.
 
76) 藤崎順子, 池上雅博, 新井弥生・他: 早期胃癌粘膜切除の適応拡大の限界病理立場から. 胃と腸 31: 1091-1100, 1996.
 
77) 長南明道, 望月福治, 結城豊彦・他: 早期胃癌の内視鏡的粘膜切除の適応拡大をめぐる現状の問題点遺残再発病変の特徴およびその取り扱い. 胃と腸 31: 1083-1090, 1996.
 
78) Furue H, Hara Y, Imai Y, et al: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy Japan society for cancer therapy. J. JPn. Soc. Cancer Ther. 28: 101-130, 1993.
 
79) Comis S: Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat. Rep. 1: 221-238, 1974.
 
80) Cocconi G, DeLisi V, DiBlasio B: Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat. Rep. 66: 1263-1266, 1982.
PubMed
81) Grohn P, Heinonen E, Kumpulainen E, et al: Oral carmofur in advanced gastrointestinal cancer. Am. J. Clin. Oncol. 13: 477-479, 1990.
PubMed
82) Bjerkeset T, Fjosne H: Comparison of oral futraful and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. Oncology 43: 212-215, 1986.
PubMed
83) Kimura K, Suga S, Shimaji T, et al: Clinical basis of chemotherapy for gastric cancer with uracil and 1- (2 '- tetrahydrofuryl) -5-fluorouracil. GastroenteroL Japonica 15: 324-3299, 1980.
 
84) 仁井谷久暢・他: 5 '-deoxy-5-fluorouridine (5'-DFUR) の各種悪性腫瘍に対する第2相多施設共同研究. 癌と化学療法 12: 2044-2051, 1985.
Medical*Online
85) Gastrointestinal Tumor Study Group: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat. Rep. 63: 1871-1883, 1979.
 
86) Moertel CG, Lavin PT: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat. Rep. 63: 1863-1869, 1979.
PubMed
87) Preusser P, Achterrath W, Wilke H, et al: Chemotherapy of gastric cancer. Cancer Treat. Rev. 15: 257-277, 1988.
PubMed
88) Levi J, Fox R, Tattersall M, et al: Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNYU in advanced gastric cancer: implications for future studies. J. Clin. Oncol. 4: 1348-1355, 1986.
PubMed
89) Cazup E, Estevez R, Bruno M, et al: Phase II trial of 4 '-epi-doxorubicin in locally advanced or metastatic gastric cancer. Cancer Treat. Rev. 741313, 1988.
 
90) Lacave AJ, Izarzugaza I, Aparicio IMAG, et al: Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am. J. Clin. Oncol. 6: 35-38, 1983.
 
91) Aabo K, Pedersen H, Rorth M: Cisplatin in the treatment of advanced gastric carcinoma: a phase II study. Cancer Treat. Rep. 69: 449-450, 1985.
PubMed
92) Lacave, AJ, Wils J, Diaz-Rubio E, et al: Cisplatinum as second-line chemotherapy in advanced gastric adenocarcinoma: a phase II study of the EORTC gastrointestinal tract cancer cooperative group. Eur. J. Cancer Oncol. 21: 1321-1324, 1985.
 
93) Perry MC, Green MR, Mick R, et al: Cisplatin in patients with gastric cancer: a cancer and leukemia group B phase II study. Cancer Treat. Rep. 70: 415-416, 1986.
 
94) Miyamoto K, Yoshida S, Saito D, et al: Pilot phase II study of cis-diaminedichloroplatinum (II) against metastatic gastric cancers. Jpn. J. Clin. Oncol. 20: 169-176, 1990.
PubMed
95) Yamao T, Shimada Y, Ohtsu A, et al: An early Phase II study of Etoposide (VP-16) in Advanced Gastric Cancer. Jpn. J. Clin. Oncol. 26: 36-41, 1996.
PubMed
96) Kelsen DP, Magill R, Cheng E, et al: Phase II trial of etoposide (VP-16) in the treatment of upper gastrointestinal tract malignancies. Cancer Treat. Rep. 67: 509-510, 1983.
 
97) Futatsuki K, Wakui A, Nakao I, et al: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. JPn. J. Cancer Chemother. 21: 1033-1038, 1994.
 
98) Shirao K, Shimada Y, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J. Clin. Oncol. 15: 921-927, 1997.
PubMed
99) Einzig AI, Lipsitz S, Wiernik PH, et al: Phase II trial of taxotere in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy;the Eastern Cooperative Oncology Group (ECOG) results. Proc. Am. Soc. Clin. Oncol. 14: 191 (441) , 1995.
 
100) Ohtsu A, Sakata Y, Horikoshi N, et al: A phase II study of S-1 in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 17: 262, 1998.
 
101) Kurihara M, Koizumi W, Hasegawa K, et al: Late phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 17: 262, 1998.
 
102) 日本医薬品情報センター編: 医療薬, 日本医薬品集. 薬業時報社, 東京, 1977.
 
103) 村上 稔・他: 多施設共同研究によるメソトレキセート・5-FU交代療法の進行胃癌および結腸・大腸癌に対するPhase II study. 癌と化学療法 14: 2482-2490, 1987.
 
104) Sato H, Sugiyama K, Hoshi M, et al: Angiotensin II (A II) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging. World J. Surg. 19: 836-842, 1995.
 
105) MacDonald JS, Schein PS, Woolley PV, et al: 5-Fluorouracil, mitomycin-C, and adriamycin (FAM) : anew combination chemotherapy program for advanced gastric carcinoma. Ann. Intern. Med. 93: 533-536, 1980.
 
106) Ogawa M: Arecent overview of chemotherapy for advanced stomach cancer in Japan. Appl. Cancer Chemother. 24: 149, 1978.
 
107) Gastrointestinal Tumor Study Group: Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. J. Natl. Cancer Inst. 80: 1011-1015, 1988.
 
108) Epelbaum R, Haim N, Stein M, et al: Treatment of advanced gastric cancer with DDP (cisplatin) , Adriamycin, and 5-fluorouracil (DAF) . Oncology 44: 201-206, 1987.
PubMed
109) Cunningham D, Cahn A, Menzies-Gow N: Cisplatin, epirubicin and 5-fluorouracil (CEF) has significant activity in advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 9: 123, 1990.
 
110) Caccia G, Alasino C, Fein L: 5-Fluorouracil+epirubicin+cisplatin in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 9: 123, 1990.
 
111) DiLauro L, Capomolla E, Vici P, et al: Cisplatin, epirubicin and fluorouracil (PEF) for advanced measurable gastric carcinoma. Proc. Am. Soc. Clin. Oncol. 14: 206 (503) , 1995.
 
112) Ohtsu A, Shimada Y, Yoshida S, et al: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG) . Eur. J. Cancer 30 A: 2091-2093, 1994.
 
113) Lacave AJ, Baron FJ, Anton LM, et al: Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer. Ann. Oncol. 2: 751-754, 1991.
PubMed
114) Kondo K, Murase M, Kodera Y, et al: Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 53: 64-67, 1996.
PubMed
115) Chung YS, Yamashita Y, Inoue T, et al: Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 80: 1-7, 1997.
PubMed
116) Mabel JA, Little AD: Therapeutic synergism in murine tumors for combinations of cisdichlorodiammine platinum with VP-16-2130r BCNU. Proc. Am. Assoc. Cancer Res. Am. Soc. Oncol. 20: 230, 1979.
 
117) Seeber S, Osieka R, Schmidt CG, et al: , In vivo resistance towards anthracyclines, etoposide, and cisdiamminedichloroplatinum ( II) . Cancer Res. 67: 4719-4725, 1982.
 
118) Kelsen DP, Buckner J, Einzig A, et al: Phase II trial of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract. Cancer Treat. Rep. 71: 329-330, 1987.
PubMed
119) Elliot T, Moertel C, Wieand H, et al: A phase II study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer. Cancer 65: 1491-1494, 1990.
 
120) Preusser P, Wilke H, Achtermath W, et al: Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J. Clin. Oncol. 7: 1310-1317, 1989.
 
121) Wilke H, Preusser P, Fink U, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin and cisplatin. J. Clin. Oncol. 7: 1318-1326, 1989.
PubMed
122) Katz A, Gansl R, Simon S, et al: Phase II trial of VP-16, adriamycin, and cisplatinum in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 8: 98, 1989.
 
123) Taguchi T: Combination chemotherapy with etoposide, adriamycin and cisplatin (EAP) for advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 8: 108, 1989.
 
124) Lerner A, Steele GD, Mayer RJ, : Etoposide, doxorubicin, cisplatin for advanced gastric adenocarcinoma: Results of a phase II trial. Proc. Am. Soc. Clin. Oncol. 9: 103, 1990.
 
125) Wilke H, Preusser P, Fink U, et al: New developments in the treatment of gastric carcinoma. Semin. Oncol. 17: 61-70, 1990.
PubMed
126) 赤沢修吾, 太田和雄, 栗原 稔・他: 多施設共同研究による l-Leucovorin・5-FU併用療法の進行胃癌に対する後期第 II相試験. J. Jpn. Soc. Cancer Ther. 30: 569-583, 1995.
 
127) 竹田彬一, 田口鐵男, 太田 潤・他: 多施設共同研究による l-Leucovorin・5-FU併用療法の進行胃癌に対する後期第 II相試験. 癌と化学療法 22: 903-910, 1995.
Medical*Online
128) Klein HO: Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer. Cancer Res. 9: 1025, 1989.
PubMed
129) Blijham G, Bleiberg H, Duez N, et al: An EORTC phase II study of sequential methotrexate-fluorouracil in locally advanced or metastatic gastric cancer. Eur. J. Cancer 26: 63-65, 1990.
PubMed
130) Kurihara M, Izumi T, Yoshida S, et al: Acooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. JPn. J. Cancer Res. 82: 613-620, 1991.
 
131) Koizumi W, Kurihara M, Sasai T, et al: A phase II study of combination therapy with 5 '-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 72: 658-662, 1993.
PubMed
132) Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol. 12: 2296-2300, 1994.
PubMed
133) Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061-2067, 1985.
PubMed
134) Kim NK, Park YS, Heo DS, et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5- fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993.
PubMed
135) Cocconi G, Bella M, Zironi S, et al: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: aprospective randomized trial of the Italian oncology group for clinical research. J. Clin. Oncol. 12: 2687-2693, 1994.
 
136) Kelsen D, Atiq O, Saltz L, et al: FAMTX (fluorouracil, methotrexate, adriamycin) is as effective and less toxic than EAP (etoposide, adriamycin, cisplatin) : arandom assignment trial in gastric cancer, Proc. Am. Soc. Clin. Oncol. 10: 137, 1991.
 
137) 佐々木常雄・他: 胃癌に対するメソトレキセート・5-FU交代療法と5-FU単独療法の比較試験-メソトレキセート・ 5-FU交代療法共同Phase III study-. 癌と化学療法 16: 2545-2555, 1989.
Medical*Online
138) Wils JA, Klein HO, Wagener DJT, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 9: 827-831, 1991.
 
139) Wilke H, Wils J, Rougier P, et al: Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer: atrial of the EORTC gastrointestinal tract cancer cooperative group and the AIO. Proc. Am. Soc. Clin. Oncol. 14: 206 (500) , 1995.
 
140) Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrex ate. In advanced gastric cancer. Cancer 72: 37-41, 1993.
 
141) Glimelius B, Hotfmann K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann. Oncol. 5: 189-190, 1994.
PubMed
142) Pyrhonen S, Kuitunen T, Nyandoto P, et al: Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 71: 587-591, 1995.
PubMed
143) Scheithauer W, Kornck G, Zeh B, et al: Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: randomized trial. (Abstract) Second International Conference on Biology;Prevention and Treatment of GI Malignancy, Koln, Germany, 1995, p. 68.
 
144) Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49: 1116-1122, 1982.
 
145) Engstrom P, Labin P, Douglas H, et al: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cancer 55: 1868-1873, 1985.
 
146) Higgins G, Amadeo J, Smith D, et al: Efficacy of prolonged intermittent therapy with combined 5-FU and\ methyl CCNU following resection for gastric carcinoma. Cancer 52: 1105-1112, 1983.
PubMed
147) Estrada E, Lacave L, Valle M, et al: Methyl-CCNU, 5-fluorouracil, and adriamycin (MeFA) as adjuvant chemotherapy in gastric cancer. Proc. Soc. Clin. Oncol. 7: 94, 1988.
 
148) Alcobendas F, Milla A, Estape J, et al: Mitomycin C as an adjuvant treatment to resected gastric cancer. Ann. Surg. 198: 13-17, 1983.
PubMed
149) Grau JJ, Estape J, Alcobendas F, et al: Positive results of adjuvant mitomycin-C in resected gastric cancer. Eur. J. Cancer 29: 340-342, 1993.
 
150) Carrato A, Diaz-Rubio E, Medrano J, et al: Phase III trial of surgery versus adjuvant chemotherapy with mitomycin C and tegafur plus uracil, starting within the first week after surgery, for gastric adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 14: 198, 1995.
 
151) Allum W, Hallissey N, Kelly K: Adjuvant chemotherapy in operable gastric cancer: 5-year follow-up of first British stomach cancer group trial. Lancet 1: 571-580, 1989.
 
152) Nakajima T, Fukami A, Takagi K, et al: Adjuvant chemotherapy with mitomycin C, and with a multi-drug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn. J. Clin. Oncol. 10: 187-194, 1980.
 
153) 今永 一, 中里博昭: 3つのprospective controlled study-その1-. 臨床外科 36: 175-183. 1981.
 
154) Hattori T, et al: Five-year survival rate of gastric cancer patients treated by gastrectomy, large dose of mitomycin-C, and/or allogeneic bone marrow transplantation. GANN 63: 517-522, 1972.
 
155) 中島聰線, 梶谷 銀, 深見敦夫・他: 胃ガン治癒手術症例に対するMMC大量短期投与法の遠隔成績. 癌の臨床 22: 21-27, 1976.
 
156) Nakajima T, Takahashi T, Yakagi K, et al: Comparison of 5-fluorouracil with futraful in adjuvant chemotherapy with combined inductive and maintenance therapies for gastric cancer. J. Clin. Oncol. 2: 1366-1371, 1984.
 
157) 山村義孝, 西村美知子, 坂本純一・他: Mitomycin-C, 5-Fluorouracil, OK-432併用による胃癌の補助免疫化学療法. 癌と化学療法 13: 2134-2140, 1986.
Medical*Online
158) 藤井雅志, 坂部 孝, 若林和彦・他: 胃癌術後補助化学療法における経口フッ化ピリミジン類の至適投与期間の検討-5-FU錠を用いた手術単独群との比較によるPilot Study-. 癌と化学療法 21: 1199-1208, 1994.
Medical*Online
159) Coombes R, Schein P, Chilvers C, et al: A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J. Clin. Oncol. 8: 1362-1369, 1990.
PubMed
160) Gagliano R, McCracken J, Chen T: Adjuvant chemotherapy with FAM in gastric cancer: aSWOG study. Proc. Am. Soc. Clin. Oncol. 2: 114, 1983.
 
161) Krook J, O'Connell M, Wieand H, et al: Aprospective randomized, evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 67: 2454-2458, 1991.
 
162) Fisher V, Gunduz N, Saffer E: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis. Cancer Res. 43: 1488-1492, 1983.
 
163) Schabel FM Jr.: Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40: 558-568, 1977.
PubMed
164) Skipper HE: Experimental adjuvant chemotherapy: An overview. Recent Results Cancer Res. 103: 6-29, 1986.
PubMed
165) Markman M: Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract. Surg. Gynecol. Obstet. 164: 89-93, 1987.
PubMed
166) Sugarbaker PH, Cunliffe WJ, Belliveau J, et al: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin. Oncol. 16: 83-97, 1989.
PubMed
167) Hagiwara A, Takahashi T, Kojima O, et al: Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339: 629-631, 1992.
PubMed
168) Schiessel R, Funovics J, Schick B, et al: Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomized trial. Acta Med. Austriaca 16: 68-69, 1989.
PubMed
169) Sautner T, Hofbauer F, Depisch D, et al: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J. Clin. Oncol. 12: 970-974, 1994.
 
170) Alexander HR, Buell JF, Fraker DL: Rationale and clinical status of continuous hyperthermic peritoneal perfusion for the treatment of peritoneal carcinomatosis. In: Principles and practice of oncology: PPO updates (eds by DeVita VT, Jr, Hellman S, Rosenberg SA) , JB Lippincott, Philadelphia, 1995, p. 1.
 
171) Dedrick RL: Theoretical and experimental bases of intraperitoneal chemotherapy. Semin. Oncol. X 11: 1-6, 1985.
 
172) Kitamura K, Kuwano H, Matsuda H, et al: Synergistic effects of intratumor administration of cis-diamminedichloroplatinum ( II) combined with local hyperthermia in melanoma bearing mice. J. Surg. Oncol. 51: 188-194, 1992.
PubMed
173) Los G, Smals OAG, van Vugt MJH, et al: A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 52: 1252-1258, 1992.
 
174) Fujimoto S, Shrestha RD, Kokubun M, et al: Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer 64: 154-160, 1989.
PubMed
175) Fujimoto S, Shgrestha RD, Kokubun M, et al: Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann. Surg. 208136-41, 1988.
 
176) Fujimura T, Yonemura Y, Fushida S, et al: Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65: 65-71, 1990.
PubMed
177) Fujimoto S, Shrestha RD, Kokuban K, et al: Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann. Surg. 212: 592-596, 1990.
 
178) Hamazoe R, Maeta M, Kaibara N: Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer 73: 2048-2052, 1994.
PubMed
179) Koga S, Hamazoe R, Maeta M, et al: Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion mitomycin C. Cancer 61: 232-237, 1988.
PubMed
180) Fujimoto S, Shrestha RD, Kokubun M, et al: Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer. Reg. Cancer Treat. 2: 198, 1989.
 
181) Gilly FN, Sayag AC, Carry PY, et al: Intraperitoneal chemo-hyperthermic (CHIP) : anew therapy in the treatment of the peritoneal seedings. Int. Surg. 76: 164-167, 1991.
 
182) Nakazato H, Koike A, Saji S, et al: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122-1126, 1994.
PubMed
183) Ochiai T, Sato H, et al: Arandomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res. 43: 3001-3007, 1983.
 
184) Kim Jp, Kwon OJ, Oh ST, et al: Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann. Surg. 216: 269-278, 1992.
PubMed
185) Harrison JD, Morris DL, Ellis IO, et al: The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma. Cancer 64: 1007-1010, 1989.
PubMed
186) Suga S, Iwase H, Shimada M, et al: Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Intern. Med. 35: 930-936, 1996,
PubMed
187) Konishi T, Hirata T, Miyama T, et al: Mechanism of synergism and clinical results of sequential methotrexate and 5-fluorouracil in the treatment of gastric cancer. 癌と化学療法 19: 946-953, 1992.
 
188) Ajani JA, Mayer RJ, Ota DM, et al: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J. Natl. Cancer Inst. 85: 1839-1844, 1993.
PubMed
189) Ajani JA, Ota DM, Jessup JM, et al: Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer 68: 1501-1506, 1991.
PubMed
190) Melcher AA, Mort D, Maughan TS, et al: Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br. J. Cancer 74: 1651-1654, 1996.
PubMed
191) Kondo K, Murase M, Yokoyama Y, et al: Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin. 癌と化学療法 23: 1299-1303, 1996.
 
192) Kelsen D, Karpeh M, Schwartz G, et al: Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J. Clin. Oncol. 14: 1818-1828, 1996.
PubMed
193) Kitamura M, Arai K, Iwasaki Y, et al: Leucovorin+5-FU therapy for advanced gastric cancer as a neoadjuvant chemotherapy. 癌と化学療法 22: 2115-2117, 1995.
 
194) Leichman L, Silberman H, Leichman CG, et al: Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: aUniversity of Southern California pilot program. J. Clin. Oncol. 10: 1933-1942, 1992.
 
195) Crookes P, Leichman CG, Leichman L, et al: Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal. therapy: afinal report. Cancer 79: 1767-1775, 1997.
 
196) Alexander HR, Grem JL, Hamilton JM, et al: Thymidylate synthase protein expression association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Cancer J. Sci. Am. 1: 49, 1995.
PubMed
197) Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy curative resection for gastric cancer: Metaanalysis of randomized trials. J. Clin. Oncol 11: 1441-1447, 1993.
PubMed
198) Hermans J, Bonenkamp JJ: Meta-analysis of adjuvant chemotherapy in gastric cancer-In reply. J. Clin. Oncol. 12: 879-880, 1994.
 
199) Childs D, Moertel C, Holbrook M, et al: Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-Fluorouracil and radiation. Am. J. Roentgenol. Radium Ther. Nucl. Med. 102: 541, 1968.
PubMed
200) Hallissey MT, Dunn JA, Ward LC, et al: The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five year follow-up. Lancet 343: 1309-1312, 1994.
PubMed
201) Moertel C, Childs D, O'Fallon J, et al: Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poQr prognosis gastric carcinoma. J. Clin. Oncol. 2: 1249-1254, 1984.
 
202) Gunderson L, Sosin H: Combined modality treatment of gastric cancer. Int. J. Radiat. Oncol. Biol. Phys. 9: 965- 975, 1983.
 
203) Caudry M, Escarmant P, Maire J, et al: Radiotherapy of gastric cancer with a three field combination: feasibility, tolerance, and survival. Int. J. Radiat. Oncol. Biol. Phys. 13: 1821-1827, 1987.
PubMed
204) Abe M, Nishimura Y, Shibamoto Y: Intraoperative radiation therapy for gastric cancer. World J. Surg. 19: 544- 547, 1995.
 
205) Gunderson LL, Burch PA, Donohue JH: The role of irradiation as a component of combined modality treatment for gastric cancer. J. Infusional Chemother. 5: 117-124, 1995.
 
206) Coquard R, Azyac L, Gilly FN, et al: Intraoperative radiation therapy combined with limited lymph node resection in gastric cancer: an alternative to extended dissection ? Int. J. Radiat. Oncol. Biol. Phys. 39: 1093- 1098, 1997.
 
207) Abe M, Takahashi M: Intraoperative radiotherapy: the Japanese experience. Int. J. Radiat. Oncol. Biol. Phys. 7: 863-868, 1981.
PubMed
208) Sindelar WF, Kinsella TJ, Tepper JE, et al: Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am. J. Surg. 165: 178-186, 1993.
PubMed
209) Avizonis VN, Buzydlowski J, Lanciano R, et al: Treatment of adenocarcinoma of the stomach with resection intraoperative radiotherapy, and adjuvant external beam radiation: a phase II study from radiation therapy oncology group 85-04. Ann. Surg. Oncol. 2: 295-302, 1995.
PubMed
210) Ogata T, et al: A10-year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients. Int. J. Radiat. Oncol. Biol. Phys. 32: 341-347, 1995.
 
211) Calvo FA, Aristu JJ, Azinovic I, et al: Intraoperative and external radiotherapy in resected gastric cancer: updated report of a phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 24: 729-736, 1992.
PubMed
212) Willett C, Tepper J, Orlow E, et al: Renal complications secondary to radiation treatment of upper abdominal malignancies. Int. J. Radiat. Oncol. Biol. Phys. 12: 1601, 1986.
PubMed
213) Alexander HR, Kelsen DP, Tepper JE: Cancer of the stomach. "Cancer, principles&practice of oncology". 5th ed., J B. Lippincott, Philadelphia, 1997, pp. 1021-1054.
 
214) Micbel C: Gastric cancer: Radiotherapy and approaches to locally unresectable or recurrent disease. "Gastrointestinal oncology". (Ahlgren ed) , J. B. Lippincott, Philadelphia, 1997, pp. 181-187.
 
215) Kosaka T, Sejima T, Sugaya J, et al: Radiation therapy for advanced gastric cancer. 癌と化学療法 24: 1701- 1711, 1997.
 
216) minsky BD: The role of radiation therapy in gastric cancer. Semin. Oncol. 23: 390-396, 1996.
PubMed
217) Kelsen D, Atiq O: Therapy of upper gastrointestinal tract cancers. In: Current problems in cancer (ed by Hakell CM) , vol15, St Louis: Mosby-Year Book, 1991, p. 235.
 
P.1090 掲載の参考文献
1) 胃癌研究会編: 胃癌取扱い規約改訂第12版. 金原出版, 東京, 1993.
 
2) UICC International Union Against Cancer: TNM CIassification of Malignant Tumours. Fifth Edition (ed. by Sobin LH, Wittekind C) , Wiley-Liss, New York, 1997.
 
3) Japanese Research Society for Gastric Cancer: The general rules for the gastric cancer study in surgery and pathology. JPn. J. Surg. 11: 127-145, 1981.
 
4) Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma. First English Edition. Kanehara Co., Tokyo, 1995.
 
5) Roder JD, Bottcher K, Busch R, et al: Classification of regional lymph node metastasis from gastric carcinoma. Cancer 82: 621-631, 1998.
PubMed
6) Ichikura T, Tomimatsu S, Okusa Y, et al: Comparison of the prognostic significance between the number of metastatic lymph nodes and nodal stage based on their location in patients with gastric cancer. J. Clin. Oncol. 11: 1894-1900, 1993.
PubMed
7) 高木國夫, 岩切啓二, 武長誠三・他: 早期胃癌に対する内視鏡的切除を応用した胃局所切除. 消化器外科 15: 1429-1439, 1992.
 
8) Burke EC, Karpeh MS, Conlon KC, et al: Laparoscopy in the management of gastric adenocarcinoma. Ann. Surg. 225: 262-267, 1997.
PubMed
9) van Dijkum EJ, de Wit LT, van Delden OM, et al: The efficacy of laparoscopic staging in patients with upper gastrointestinal tumors. Cancer 79: 1315-1319, 1997.
 
10) Wu CC, Chen JT, Chang MC, et al: Optimal surgical strategy for potentially curable serosa-involved gastric carcinoma with intraperitoneal free cancer cells. J. Am. Coll. Surg. 184: 611-617, 1997.
PubMed
11) Sasako M, McCulloch P, Kinoshita T, et al: New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br. J. Surg. 82: 346-351, 1995.
PubMed
12) 佐野 武, 片井 均, 笹子三津留・他: 早期胃癌の転移: 胃癌研究会から. 胃と腸 32: 809-813, 1997.
 
13) Maruyama K, Sasako M, Kinoshita T, et al: Pancreas-preserving total gastrectomy for proximal gastric cancer. World J. Surg. 19: 532-536, 1995.
 
14) Cuschieri A, Fayers P, Fielding J, et al: Postoperative morbidity and mortality after D 1 and D 2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 347: 995-999, 1996.
 
15) Griffith Jp, Sue-Ling HM, Martin I, et al: Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut 36: 684-690, 1995.
PubMed
16) Furukawa H, Hiratsuka M, Iwanaga T, et al: Extended surgery-left upper abdominal exenteration plus Appleby 's method-for type 4 gastric carcinoma. Ann. Surg. Oncol. 4: 209-214, 1997.
 
17) Neugut AI, Hayek M, Howe G: Epidemiology of gastric cancer. Semin. Oncol. 23: 281-291, 1996.
PubMed
18) 荒井邦佳, 北村正次, 岩崎善毅: 術後のquality of lifeおよび予後からみた切除不能胃癌に対する空置的胃空腸吻合術の有用性. 日消外会誌 28: 645-649, 1995.
 
19) Sano T, Sasako M, Kinoshita T, et al: Recurrence of early gastric cancer: follow-up of 1475 patients and review of the Japanese literature. Cancer 72: 3174-3178, 1993.
PubMed
P.1119 掲載の参考文献
1) 大腸癌研究会編: 大腸癌取扱い規約. 改訂第5版. 金原出版, 東京, 1994.
 
2) TNM classification of malignant tumors: (ed. by Sobin LH, Wittekind Ch) , Fifth Ed,. Wiley-Liss, New York, 1997.
 
3) Morikawa E, Yasutomi M, Shindou K, et al: Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis. Colon Rectum 37: 219-223, 1994.
PubMed
4) 泉本源太郎, 八田昌樹, 西山真一・他: クリアリング法による結腸癌リンパ節転移に関する研究. 日本大腸肛門病会誌 36: 523-531, 1983.
 
5) Kinzler KW, Nilbert MC, Su LK, et al: Identification of FAP locus genes from chromosome 5q21. Science 253: 661-665, 1991.
PubMed
6) Joslyn G, Carlson M, Thliveris A, et al: Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 66: 601-603, 1991.
PubMed
7) Groden J, Thliveris A, Samowitz W, et al: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 586-600, 1991.
 
8) Bussey HJR: Gastrointestinal Pylyposis. Gut 11: 970-978, 1970.
 
9) Erbe RW: Inherited gastrointestinal polyposis syndrome. N. Engl. J. Med. 294: 1101-1104, 1975.
 
10) DeCosse JJ, Adaurs MB, Condon RF: Familial polyposis. Cancer 39: 267-273, 1997.
 
11) McKusick VA: Genetics and large-bowel cancer. Am. Dig. Dis. 19: 954-957, 1974.
 
12) Gardner EJ: Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. Am. J. Hum. Genet. 14: 376-390, 1962.
PubMed
13) Arvanitis ML, Jagelman DG, Fazio VW, et al: Mortality in patients with familial adenomatous polyposis. Dis. Colon Rectum 33: 639-642, 1990.
PubMed
14) Turcot J, Despres Jp, St. Pierre F: Malignant tumor of the central nervous system associated with familial polyposis of the colon: Report of two cases. Dis. Colon Rectum 2: 465-468, 1959.
PubMed
15) Reid JD: Intestinal carcinoma in the Peutz-Jeghers syndrome. JAMA 229: 833-834, 1974.
PubMed
16) Kussin SZ, Lipkin M, Winawer SJ: lnherited colon cancer；Clinical implications. Am. J. Gastroenterol 72: 443- 457, 1979.
 
17) Lynch HT, albano WA, Lynch JF, et al: Recognition of the cancer family syndrome. Gastroenterology 84: 672-673, 1983.
PubMed
18) Law JP, Herberman RB, Oldham RL: Familial occurrence of colon, uterine and Iymphoproliferative malig. . nancies；Clinical description. Cancer 39: 1224-1228, 1977.
 
19) Lynch HT, Richardson JD, Amin M, et al: Variable gastrointestinal and urologic cancers in a Lynch syndromeII kindred. Dis. Colon Rectum 34: 891-895, 1991.
 
20) Itoh H, Houlston RS, Harocopos C, et al: Risk of cancer death in first-degree relatives of patients with hereditary non-polyposis cancer syndrome (Lynch type II) : Astudy of 130 kinders in the United Kingdom. Br. J. Surg. 77: 1367-1371, 1990.
 
21) Edwards FC, Truelove SC: The courese and prognosis of ulcerative colitis. Gut 5: 1-22, 1964.
 
22) Morson BC: Cancer and ulcerative colitis. Gut 7: 425-426, 1996.
 
23) Ekbon A, Helmick C, Zack M, et al: Ulcerative colitis and colorectal cancer；Aprospective study. N. Eng. J Med. 323: 1228-1233, 1990.
 
24) Ohman U: Colorectal carcinoma in patients with ulcerative colitis. Am. J. Surg. 144: 344-349, 1982.
PubMed
25) Katzka I, Brody RS, Morris E, et al: Assessment of colorectal cancer risk in patients with ulcerative colitis；Experience from a private practice. Gastoenterology 85: 22-29, 1983.
 
26) Hamilton RS: Colorectal carcinoma in patients with Crohn 's disease. Gastroenterology 89: 398-407, 1989.
 
27) Morson BC: Genetics of colorectal cancer. Clin. Gastroenterol. 5: 505-525, 1976.
 
28) Heald RJ, Bussey HJR: Clinical experience at St. Mark’s Hospital with multiple synchronous cancers of the colon and rectum. Dis. Colon Rectum 18: 6, 1975.
 
29) MacMahon CE, Rowe JW: Rectal reaction following radiation therapy of cervical carcinoma；Particular reference to subsequent occurrence of rectal carcinoma. Ann. Surg. 173: 264-269, 1971.
PubMed
30) Gastro EB, Rosen PP, Quan SH: Carcinama of large intestine in patients irradiated for carcinoma of cervix and uterus. Cancer 31: 45-52, 1973.
 
31) McMichael AJ, Potter JD: Host factors in carcinogenesis；certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J. Natl. Cancer. Inst. 75: 185-191, 1985.
PubMed
32) Lowenfels AB, Domellof L, Lindstrom CG, et al: Cholelithiasis, cholecystectomy, and cancer；Acase controlled study in Sweden. Gastroenterology 83: 672-676, 1982.
 
33) Bristol JB, Wiliamson RCN: Ureterosigmoidostomy and colon carcinogenesis. Science 214: 351, 1981.
 
34) ApPel MF, Psjur HJ, Estroda RG: The significance of villous componentin colonic polyps. Am. J. Surg. 134: 770-771, 1977.
 
35) Morson BC: Evolution of cancer of the colon and rectum. Cancer 34: 845-849, 1974.
 
36) Muto T, Bussey HJR, Morson BC: The evaluation of cancer of the colon and rectum. Cancer 36: 2251-2270, 1975.
 
37) MacDermott FT, Hughes ESR, Pihl E, et al: Prognosis in relation to symptom duration in colon cancer. Br. J. Surg. 13: 846-849, 1981.
 
38) Songster CL, Barrows GH, Jarrer DD: Immunochemical detection of fecal blood；the fecal smear pinch disctest；Anew non-invasive screening test for colorectal cancer. Cancer 45: 1099-1102, 1980.
 
39) Saito H, Tsuchida S, Nakaji S, et al: An immunological test for fecal occult blood by counter immunoelectrophoresis. Cancer 56: 1549-1552, 1985.
PubMed
40) Winawer SJ, Fleisher M: Sensitivity and specificity of the fecal occult blood test for colorectal neoplasia. Gastroenterology 82: 986-991, 1982.
PubMed
41) Griffith CDM, Turner DJ, Saunders JH: False-negative results of hemoccult test in colorectal cancer. BJM 283: 472, 1981.
 
42) Batson OV: The function of the vertebral veins and their role in the spread of metastases. Ann. Surg. 112: 138-149, 1940.
PubMed
43) 加藤知行, 小島 宏, 平井 孝・他: 直腸癌治癒切除後の骨盤腔内局所再発に対する術中の対策. 外科 51: 1328- 1331, 1989.
 
44) Umpleby HC, Williamson RCN: Anastomotic recurrence in large bowel cancer. Br. J. Surg. 74: 873-878, 1987.
 
45) 加藤知行, 近藤三隆, 安井健三・他: 大腸癌患者における術中腹腔細胞診の検討. 日消外会誌 17: 1865-1869, 1984.
 
46) Moore GE, Sako K, Kondo T, et al: Assessment of the exfoliation of tumor cells into the body cavities. Surg. Gynecol. Obstet. 112: 469-474, 1961.
PubMed
47) Dukes CE: The classification of cancer of the rectum. J. Pathol. 35: 323-332, 1932.
 
48) Dukes CE: The surgical pathology of rectal cancer. J. Clin. Pathol. 2: 95-99, 1949.
PubMed
49) Turnbull RB Jr, Kyle K, Watson FR, et al: Cancer of the colon；The influence of the no-touch isolation technique on survival rates. Ann. Surg. 166: 420-427, 1967.
 
50) Astler VB, Coller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann. Surg. 139: 846-851, 1954.
PubMed
51) Wolmark N, Fisher B, Wieand HS: The prognostic value of the modifications of the Dukes’Cclass of colorectal cancer. Ann. Surg. 203: 115-122, 1986.
 
52) Phillips RKS, Hittinger R, Blesovsky L, et al: Large bowel cancer；Surgical pathology and its relationship to surviva1. Br. J. Surg. 71: 604-610, 1984.
 
53) Chapuiss PH, Dent OF, Newland RC, et al: An evaluation of the American Joint Committee (pTNM) staging method for cancer of the colon and rectum. Dis. Colon Rectum 29: 6-10, 1986.
 
54) Hermanek P: Problem of pTNM classification of carcinoma of the stomach, colorectum and anal margin. Pathol. Res. Pract. 181: 296-300, 1986.
PubMed
55) Chapuis PH, Dent OF, Fisher R, et al: Amultivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br. J Surg. 72: 698-702, 1985.
 
56) Dukes CE, Bussey HJR: The spread of rectal cancer and its effect on prognosis. Br. J. Cancer 12: 309-320, 1958.
 
57) Coffey RJ, Cardenas F: Cancer of the bowel in the young adult. Dis. Colon Rectum 7: 491-492, 1964.
 
58) Van Langenberg AV, Ong GB: Carcinoma of large bowel in the young. BMJ 3: 374-376, 1972.
 
59) Odone V, Chang L, Caces J, et al: The natural history of colorectal carcinoma in adolescents. Cancer 49: 1716-1720, 1982.
PubMed
60) Umpleby HC, Williamson RCN: Carcinoma of the large bowel in the first decades. Br. J. Surg. 71: 272-277, 1984.
 
61) 加藤知行, 森本剛史, 渡辺晃祥・他: 若年者の直腸癌. 外科 40: 802-807, 1978.
 
62) Beahrs OH, Sanfelippo PM: Factors in the prognosis of colon and rectal cancer. Cancer 28: 213-217, 1971.
PubMed
63) Pescatori M, Maria G, Beltrani B, et al: Site, emergency, and duration of symptoms in the prognosis of colorectal cancer. Dis. Colon Rectum 25: 33-40, 1982.
PubMed
64) Willet C, TepPer JE, Cohen A, et al: Obstructive and perforative colonic carcinoma；Patterns of failure. J. Clin. Oncol. 3: 379-384, 1985.
 
65) Steinberg SM, Barkin JS, Kaplan RS, et al.: Prognostic indicators of colon tumors；The Gastrointestinal Tumor Study Group experience. Cancer 57: 1866-1870, 1986.
 
66) Wolmark N, Wieand HS, Rockette HE, et al: The prognostic significance of tumor and location and bowel obstruction in Dukes B and C colorectal cancer；Findings from the NSABP clinical trials. Ann. Surg. 198: 743-752, 1983.
 
67) Foster RS Jr, Costanza MC, Foster JC: Adverse relationship between blood transfusions and survival after colectomy for colon cancer. Cancer 55: 1195-1201, 1985.
PubMed
68) Marsh J, Donnan PT, Hamer-Hodges DW: Association between transfusion with plasma and the recurrence of colorectal carcinoma. Br. J. Surg. 77: 623-626, 1990.
PubMed
69) Dwight RW, Higgins GA, Keehan RJ: Factors influencing survival after resection in cancer of the colon and rectum. Am. J. Surg. 117: 512-522, 1969.
 
70) Freedman LS, Macaskill P, Smith AN: Multivariate analysis of prognostic factors for operable rectal cancer. Lancet 2: 733-736, 1984.
PubMed
71) 北條慶一: 一次予防と二次予防;大腸癌. がんの一次予防と二次予防 (市川平三郎, 久道茂編集) , 篠原出版, 東京, 1987, pp. 178-192.
 
72) Cohen AM, Wood WC, Gunderson LL, et al: Pathological studies in rectal cancer. Cancer 45: 2965-2968, 1980.
PubMed
73) Wolmark N, Fisher ER, Wieand HS, et al: The relationship of deapth of penetration and tumor size to the number of positive nodes in Dukes C colorectal cancer. Cancer 53: 2707-2712, 1984.
 
74) Stahle E, Glimerius B, Bergstrom R, et al: Preoperative prediction of outcome in patients with rectal and rectosigmoid cancer. Cancer 63: 1831-1837, 1989.
 
75) Burrows L, Tartter P: Effect of blood transfusion on colonic malignancy recurrence rate. Lancet 2: 662, 1982.
PubMed
76) Tartter PI: Perioperative blood transfusion and colorectal cancer recurrence；Areview. J. Surg. Oncol. 39: 197-200, 1988.
 
77) Bokey EL, Chapuis DS, Dent OF, et al: Factors affecting survival after excision of the rectum for cancer. Dis. Colon Rectum 40: 3-10, 1997.
 
78) Simons AJ, Ker R, Groshen S, et al: Variations in treatment of rectal cancer. Dis. Colon Rectum 40: 641-646, 1997.
PubMed
79) Minsky BD, Mies C, Recht A, et al: Resectable adenocarcinoma of the rectosigmoid and rectum；1. Patterns of failure and survival. Cancer 61: 1408-1416, 1988.
 
80) Minsky BD, Mies C, Recht A, et al: Potentially curative surgery of the colon cancer；1. Patterns of failure and survival. J. Clin. Oncol. 6: 106-118, 1988.
PubMed
81) Spratt JS Jr, Spjut HJ: Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer 20: 1976-1985, 1967.
PubMed
82) 長谷和生, 望月英隆, 吉村一克・他: 直腸癌先進部組織型の臨床的意義に関する検討. 日本大腸肛門病会誌 50: 71- 79, 1997.
 
83) 滝沢 建: 直腸癌の予後因子に関する病理組織学的研究; 組織型と細胞性間質反応を中心に. 日本大腸肛門病会誌 42: 190-201, 1989.
 
84) Symonds DA, Vickery al Jr: Mucinous carcinoma of the colon and rectum. Cancer 37: 1891-1900, 1976.
 
85) Umpleby HC, Ranson DL, Williamson HC: Peculiarities of mucinous colorectal carcinoma. Br. J. Surg. 72: 715- 718, 1985.
 
86) Minsky BD, Mies C, Rich TA, et al: Colloid carcinoma of the colon and rectum. Cancer 60: 3103-3112, 1987.
PubMed
87) Brown CE, Warren S: Viscera1 metastases from rectal carcinoma. Surg. Gynecol. Obstet. 66: 611-621, 1938.
 
88) Minsky BD, Mies C, Rich TA, et al: Potentially curative surgery of colon cancer；The influence of blood vessel invasion. J. Clin. Oncol. 6: 119-127, 1988.
PubMed
89) Minsky BD, Mies C, Recht A, et al: Resectable adenocarcinoma of the rectosigmoid and rectum. 2) the influence of blood vessel invasion. Cancer 61: 1417-1424, 1988.
 
90) Dukes CE, Bussey HJR: Venous spread in rectal cancer. Proc. R. Soc. Med. 34: 571-581, 1941.
 
91) Khankhanian N, Maulight GM, Russel WO, et al: Prognostic significance of vascular invasion in colorectal cancer of Dukes’Bclass. Cancer 39: 1195-1200, 1977.
 
92) Horn A, Dah10, Morild I: Venous and neural invasion as predictors of recurrence in rectal adenocarcinoma. Dis. Colon Rectum 34: 798-804, 1991.
PubMed
93) Minsky BD, Mies C, Rich TA, et al: Lymphatic vesseI invasion is an independent prognostic factor for survival in colorectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 17: 311-318, 1989.
 
94) Michelassi F, Vannucci L, Ayala JJ, et al: Local recurrence after curative resection of colorectal adenocarcinoma. Surgery 108: 787-793, 1990.
PubMed
95) Seefeld P, Bargen JA: The spread of carcinoma of the rectum；Invasion of lymphatics, veins and nerves. Ann. Surg. 118: 76-90, 1943.
PubMed
96) Krasna MJ, Flancbaum L, Cody RP, et al: Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 61: 1018-1023, 1988.
PubMed
97) 加藤知行, 森本剛史, 渡辺晃祥・他: 下部直腸癌の局所再発; 特に癌先進部から外科的剥離断端までの距離 (ew) につ いて. 日外会誌 80: 642-650, 1979.
 
98) Quirke P, Durdey P, Dixon MF, et al: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection；Histopathological study of lateral tumor spread and surgical excision. Lancet 1: 996-999, 1986.
 
99) 長谷和生, 望月英隆, 宇都宮勝之・他: 大腸癌の浸潤増殖様式 (INF) の予後規定因子としての意義に関する検討. 日本大腸肛門病会誌 49: 463-469, 1996.
 
100) 諸冨雅之: 進行直腸癌における臨床病理学的研究;術前生検材料からみたリンパ節転移程度の予測. 日外会誌 89: 352-364, 1988.
 
101) 長谷和生, 望月英隆, 小池聖彦・他: 直腸癌における腫瘍籏出の予後規定因子としての意義に関する検討. 日消外会誌 25: 2765-2772, 1992.
 
102) Jass JR, Love SB, Northover JM: Anew prognostic classification of rectal cancer. Lancet 1: 1303-1306, 1987.
 
103) Murray D, Hreno A, Dutton J, et al: Prognosis in colon cancer；Apathologic reassessment. Arch. Surg. 110: 908-913, 1975.
PubMed
104) Jass JR, Atkin WS, Cuzick I, et al: The grading of rectal cancer；Histological perspectives and a multivariate analysis of 447 cases. Histopathology 10: 437-459, 1986.
 
105) Carlon CA, Fabris G, Arslan-Pagnini, et al: Prognostic correlations of operable carcinoma of the rectum. Dis. Colon Recturn 28: 47-50, 1985.
PubMed
106) Sevennevig JL, Lunde OC, Holter J, et al: Lymphoid infiltration and prognosis in colorectal carcinoma. Br. J. Cancer 49: 375-377, 1984.
 
107) Patt DJ, Brynes RK, Vardiman JW, et al: Mesocolic lymph node histology is an important prognostic indicator for patients with carcinoma of the sigmold colon；An immuno-morphologic study. Cancer 35: 1388-1397, 1975.
 
108) Tsakraklides V, Wanebo HJ, Sternberg SS, et al: Prognostic evaluation of regional lymph node morphology in colorectal cancer. Am. J. Surg. 129: 174-180, 1975.
PubMed
109) Pihl E, Malahy MA, Khankhanian N, et al: Immunomorphological features of prognostic significance in Dukes’class B colorectal carcinoma. Cancer Res. 37: 4145-4149, 1977.
 
110) Wanebo JH, Rao B, Pinsky CM, et al: Pre-operative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N. Engl. J. Med. 299: 448-451, 1978.
 
111) Evans JT, Mittelman A, Chu M, et al: Pre-and Post-operative uses of CEA. Cancer 42: 1419-1421, 1978.
 
112) Staab HJ, Anderer FA, Brummendorf T, et al: Prognostic value of pre-operative serum CEA level compared to clinical staging: Icolorectal carcinoma. Br. J. Cancer 44: 652-662, 1981.
 
113) Szymendera J, Nowacki MP, Szalowski AW, et al: Predictive value of plasma CEA levels；Preoperative prognosis and postoperative monitoring of patients with colorectal carcinoma. Dis. Colon Rectum 25: 46-52, 1982.
 
114) Blake KE, Dalbow MH, Concannon JP, et al: Clinical significance of preoperative plasma carcinoembryonic antigen (CEA) level in patients with carcinoma of the large bowel. Dis. Colon Rectum 25: 24-32, 1982.
PubMed
115) Lewi H, Blumgart LH, Carter DC, et al: Pre-operative carcinoembryonic antigen and survival in patients with colorectal cancer. Br. J. Surg. 71: 206-208, 1984.
PubMed
116) Steele G Jr, Ellenberg S, Ramming K, et al: CEA monitoring among Patients in multiinstitutional adjuvant G. 1. therapy protocols. Ann. Surg. 196: 162-169, 1982.
 
117) Offerhaus GJ, Giardiello FM, Bruijn JA, et al: The value of immunochemistry for collagen IV expression in colorectal carcinoma. Cancer 67: 99-105, 1991.
PubMed
118) Wobbes T, Hendriks T, DE Bower HHM: Collagen in colorectal cancer in relation to clinicopathologic stage and histologic grade. Dis. Colon Rectum 31: 778-780, 1988.
 
119) Kokal WA, Gardine RL, Shelbani K, et al: Tumor DNA content in resectable, primary colorectal carcinoma. Ann. . Surg. 209: 188-193, 1989.
 
120) Armitage NC, Ballantyne KC, Evans DF, et al: The influence of tumor cell DNA content of survival in colorectal carcinoma. Br. J. Cancer 62: 852-856, 1990.
PubMed
121) Jass JR, Mukawa K, Goh HS, et al: Clinical importance of DNA content in rectal cancer measured by flow cytometry. J. Clin. Pathol. 42: 254-259, 1989.
PubMed
122) Rognum TO, Thorud E, Lund E: Survival of large bowel carcinoma patients with different DNA ploidy. Br. J. Cancer 56: 633-636, 1987.
PubMed
123) Wiggers T, Arends JW, Schuttle B, et al: A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 61: 386-395, 1988.
 
124) Melamed MR, Enker WE, Banner P, , et al: Flow cytometry of colorectal carcinoma with three-year follow-up. Dis. Colon Rectum 29: 184-186, 1986.
PubMed
125) Witzig TE, Loprinzi CL, Gonchoroff NJ, et al: DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stage B 2 colorectal adenocarcinoma. Cancer 68: 879-888, 1991.
 
126) 加藤知行, 小島 宏, 平井 孝・他: 大腸癌における術前生検と切除標本の病理組織診断の比較. 癌の臨床 35: 1119- 1122, 1989.
 
127) 武藤徹一郎, 上谷潤二郎, 沢田俊夫・他: 大腸診断学の歩みと外科. 胃と腸 20: 273-281, 1985.
 
128) 長谷川かをり, 谷口友章, 野口友義・他: 大腸癌の生検診断における問題点 (第1報) . Gastroenterol. Endosc. 22: 56-60, 1980.
 
129) 安富正幸: 大腸癌手術における諸問題. 外科治療 47: 199-206, 1982.
 
130) 武藤徹一郎, 西澤 護, 小平 進・他: 大腸sm癌アンケート集計報告; sm癌の転移リスクファクターを求めて. 胃と腸 26: 911-918, 1991.
 
131) 加藤知行, 平井 孝: 治療成績からみた大腸早期癌の治療方針; とくにsm癌の治療方針について. 手術 46: 461- 467, 1992.
 
132) 工藤進英, 曽我 淳, 下田 聡・他: 大腸sm癌のsm浸潤の分析と治療方針. 胃と腸 19: 1349-1356, 1984.
 
133) Cranley JP, Petras RE, Carey WD, et al: When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma?Gastroenterology 91: 419-427, 1987.
 
134) Wilcox JM, Anderson PB, Colacchio TA: Early invasive carcinoma in colonic polyps；Areview of the literature with emphasis on the assessment of the risk of metstasis. Cancer 57: 160-171, 1986.
 
135) 加藤知行, 平井 孝: 結腸癌;進行癌の手術と補助療法. 癌の臨床 40: 1416-1424, 1994.
 
136) Morikawa E, Yasutomi M, Shindou K, et al: Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis. Colon Rectum 37: 219-223, 1994.
PubMed
137) 泉本源太郎, 八田昌樹, 西山真一・他: クリアリング法による結腸癌リンパ節転移に関する研究. 日本大腸肛門病会誌 36: 523-531, 1983.
 
138) Eisenberg B, DeCosse JJ, Harford F, et al: Carcinoma of the colon and rectum；The natural history reviewed in 1704 patients. Cancer 49: 1131-1134, 1982.
PubMed
139) Panettiere FJ, Chen TT: The SWOG large bowel study benefits from therapy. Proc. ASCO 4: 76, 1985.
 
140) Laurie J, Moertel C, Flemming, et al: Surgical adjuvant therapy of poor prognosis colorectal cancer with levamisole alone or combined levamisole and 5-fluorouracil. Proc. ASCO 5: 81, 1986.
 
141) Newland RC, Chapuis PH, Smyth EJ: The prognostic value of substaging colorectal carcinoma；Aprospective study of 1117 cases with standardized pathology. Cancer 60: 852-857, 1987.
 
142) Cohen AM, Tremittera S, Candela F, et al: Prognosis of node-positive colon cancer. Cancer 67: 1859-1861, 1991.
 
143) Japanese Research Society for Cancer of the Colon and Rectum: Multi-lnstitutional registry of large bowe: cancer in Japan vol 9；cases treated in 1985, 1994.
 
144) 森谷宜皓: 大腸癌の治療成績は向上したか. CRC 2: 301-310, 1993.
 
145) Enker WE, Laffer UT, Block GE: Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. Ann. Surg. 190: 350-360, 1979.
PubMed
146) 加藤知行, 平井 孝: 腫瘍の局在と進行度からみた手術術式の選択. 消化器外科 13: 289-297, 1990.
 
147) 高橋 孝, 梶谷 鐶: 直腸癌における側方向リンパ流への転移とその郭清の意義について. 日本大腸肛門病会誌 31: 207-219, 1978.
 
148) 加藤岳人, 高橋 孝, 太田博俊・他: 直腸癌側方リンパ節転移の検討. 日消外会誌 19: 963-968, 1989.
 
149) 大見良裕, 大木繁男, 江口英雄・他: 直腸癌のリンパ節転移の特徴;拡大郭清による摘出リンパ節の検討. 日外会誌 81: 676-687, 1980.
 
150) 白井芳則, 斉藤典男, 布村正夫・他: 直腸癌側方リンパ節転移の態様と治療成績. 日本大腸肛門病会誌 44: 1061- 1066, 1991.
 
151) 須田武保, 畠山勝義, 岡本春彦・他: 直腸癌における壁内進展. 日本大腸肛門病会誌 45: 421-426, 1992.
 
152) 小林宣昭: 直腸癌の病理組織学的研究 (第2報) ;特に壁内進展について. 日本大腸肛門病会誌 30: 426-436, 1977.
 
153) Hughes TG, Jenevein EP, Poulos E: Intrarnural spread of colon carcinoma. Am. J. Surg. 146: 697-699, 1983.
PubMed
154) Lazorthes F, Voigt JJ, Roques J, et al: Distal intramural spread of carcinoma of the rectum correlated with lymph nodal involvement. Surg. Gynecol. Obstet. 170: 45-48, 1990.
PubMed
155) Andreola S, Leo E, Beli F, et al: Distal spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. Dis. Colon Rectum 40: 25-29, 1997.
 
156) Williams NS, Dixon MF, Johnston D: Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum；Astudy of distal intramural spread and of patient’s survival. Br. J. Surg. 70: 150-154, 1983.
 
157) 今 充, 森田隆幸, 山中祐治・他: 術後排便機能からみた手術術式の選択. 消化器外科 17: 307-314, 1990.
 
158) 畠山勝義, 島村公年, 須田武保・他: 下部直腸癌に対するJ型結腸嚢肛門吻合術. 消化器外科 17: 301-306, 1994.
 
159) Hallbook O, Nystrom P, Sjodahl R: Physiologic characteristics of straight and colonic J-pouch anastomoses after rectal excision for cancer. Dis. Colon Rectum 40: 332-338, 1997.
PubMed
160) Ortiz H, De Miguel M, Armendariz P, et al: Coloanal anastomosis: Are functional results better with a pouch? Dis. Colon Rectum 38: 375-377, 1995.
PubMed
161) Ramirez JM, Mortensen NJM, Takeuchi N, et al: Colonic J-pouch rectal reconstruction；Is it really a neorectum? Dis. Colon Rectum 39: 1286-1288, 1996.
 
162) Hida J, Yasutomi M, Fujimoto K, et al: Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Dis. Colon Rectum 39: 986-991, 1996.
PubMed
163) Pezim ME, Nicholls RJ: Survival after high or low ligation of the inferior messenteric artery during curative surgery for rectal cancer. Ann. Surg. 200: 729-733, 1984.
PubMed
164) Grinnell RS: Results of ligation of inferior messenteric artery at the aorta in resections of carcinoma of the descending and sigmoid colon and rectum. Surg. Gynecol. Obstet. 120: 1031-1036, 1965.
 
165) Hojo K, Koyama Y, Moriya Y: Lymphatic spread and its prognostic value in patients with rectal cancer. Am. J. Surg. 144: 350-354, 1982.
PubMed
166) Sterns MW, Deddish MR: Five year results of abdominopelvic lymphnode dissection for carcinoma of the rectum. Dis. Colon Rectum 2: 169-172, 1977.
 
167) Glass RE, Ritchie JK, Thompson HR, et al: The results of surgical treatment of cancer of the rectum by radical resection and extended abdomino-iliac lymphadenectomy. Br. J. Surg. 72: 599-601, 1985.
PubMed
168) Deddish MR: Surgical procedures for carcinoma of the left colon and rectum with five year end results following abdominopelvic dissection of lymph nodes. Am. J. Surg. 99: 188-191, 1960.
PubMed
169) Sauer I, Bacon HE: Influence of lateral spread of the rectum on radicability of operation and prognosis. Am. J. Surg. 81: 111-120, 1951.
PubMed
170) 小山靖夫: 直腸癌における拡大根治手術. 外科治療 36: 41-45, 1977.
 
171) 加藤知行, 平井 孝: 下部直腸癌における側方リンパ節郭清の意義と問題点;側方リンパ節群の範囲の同定を中心に. 消化器癌 3: 65-71, 1993.
 
172) 小林宣昭: 下部進行直腸癌に対する側方郭清の意義と問題点. 消化器癌 3: 357-363, 1993.
 
173) Enker WE, Heilweil ML, Hertz REL, et al: En bloc pelvic lymphadenectomy and sphincter preservation in the surgical management of rectal cancer. Ann. Surg. 203: 426-433, 1986.
 
174) 加藤知行, 平井 孝, 小寺泰弘・他: 下部直腸癌における拡大リンパ節郭清の功罪. 日消外会誌 28: 903-907, 1995.
 
175) 加藤知行, 小平 進: 直腸癌・長期予後とQOLからみた神経温存手術の適応. 日臨外医会誌 56: 1079-1087, 1995.
 
176) Brunschwig A: Complete excision of pelvis viscera for advanced carcihoma: a one-stage abdominoperineal operation with colostomy and bilateral ureteral implantation into colon above the colostomy. Cancer 1: 177-183, 1948.
PubMed
177) Lopez MJ, Standiford SB, Skibba JL: Total pelvic exenteration: A50-year experience at the Ellis Fischel Cancer Center. Arch. Surg. 129: 390-396, 1994.
 
178) Hafner GH, Herrera L, Petrelli NJ: Patterns of recurrence after pelvic exenteration for colorectal adenocarcinoma. Arch. Surg. 126: 1510-1513, 1991.
PubMed
179) Hafner GH, Herrera L, Petrelli NJ: Morbidity and mortality after pelvic exenteration for colorectal adenocarcinoma. Ann. Surg. 215: 63-67, 1992.
PubMed
180) 加藤知行, 平井 孝: 局所進行直腸癌に対する骨盤内臓器全摘術. 医学のあゆみ 172: 693-696, 1995.
 
181) Lopez MJ, Monafo WW: Role of extended resection in the initial treatment of locally advanced colorectal carcinoma. Surgery 113: 365-372, 1993.
PubMed
182) Brophy PF, Hoffman JP, Eisenberg BL: The role of palliative pelvic exenteration. Am. J. Surg. 167: 386-390, 1994.
PubMed
183) Williams LF, Huddleston CB, Sawyers JL, et al: Is total pelvic exenteration reasonable primary treatment for rectal carcinoma?Ann. Surg. 207: 670-678, 1988.
PubMed
184) Wanebo HJ, Koness RJ, Vezeridis MP, et al: Pelvic resection of recurrent rectal cancer. Ann. Surg. 220: 586-597, 1994.
PubMed
185) Wilson SM, Beahrs OH: A curative treatment of carcinoma of the sigmoid, rectosigmoid and rectum. Ann. Surg. 183: 556-565, 1976.
PubMed
186) McDermott FT, Hughes ESR, Pihl E, et al: Prognosis in relation to symptom duraion in colon cancer. Br. J. Surg. 13: 846-849, 1981.
 
187) Larach SW, Patankar SK, Ferrara A, et al: Complications of laparoscopic colorectal surgery. Dis. Colon Rectum 40: 592-596, 1997.
PubMed
188) Goh YC, Eu KW, Seow-Choen F: Early postoperative results of a prospective series of laparoscopic vs. open anterior resections for rectosigmoid cancers. Dis. Colon Rectum 40: 776-780, 1997.
PubMed
189) Wexner SD, Cohen SM, Ulruch A, et al: Laparoscopic colorectal surgery；Are we being honest with our patients?Dis. Colon Rectum 38: 723-727, 1995.
 
190) The American Society of Colon and Rectal Surgeons: Approved statement on laparoscopic colectomy. Dis. Colon Rectum 37: 1994.
 
191) 加藤清司: 腹腔鏡手術における麻酔管理上の問題点. 日外科系連会誌 20: 377-380, 1995.
 
192) Ortega AE, Beart RW Jr, Steele GD Jr, et al: Laparoscopic bowel surgery registry；Preliminary results. Dis. Colon Rectum 38: 681-686, 1995.
PubMed
193) Lord SA, Larach SW, Ferrera A, et al: Laparoscopic resections for colorectal carcinoma；A three-year experience. Dis. Colon Rectum 39: 148-154, 1996.
 
194) Falk PM, Beart RW Jr, Wexner SD, et al: Laparoscopic colectomy；Acritical apPrisal. Dis. Colon Rectum 36: 28-34, 1993.
 
195) Simons AJ, Anthone GJ, Ortega AE, et al: Laparoscopic-assisted colectomy learning curve. Dis. Colon Rectum 38: 600-603, 1995.
PubMed
196) Ota DM: Laparoscopic resection for colon cancer；Afavorable view. Important Adv Oncol. Lippincott-Raven, Philadelphia, 1996, pp. 227-229.
 
197) Jacquet P, Averbach AM, Stephens BS, et al: Cancer recurrence following laparoscopic colectomy. Dis. Colon Rectum 38: 1110-1114, 1995.
 
198) Reilly WT, Nelson H, Schroeder G, et al: Wound recurrence following conventional treatment of colorectal cancer. Dis. Colon Rectum 39: 200-207, 1996.
PubMed
199) Cirocco WC, Schwartzman A, Golub RW: Abdominal wall recurrence after laparoscopic colectomy for colon cancer. Surgery 116: 842-846, 1994.
PubMed
200) Jacquet P, Averbach AM, Jacquet N: Abdominal wall metastasis and peritoneal carcinomatosis after laparos-copic-assisted colectomy for colon cancer. Eur. J. Surg. OncoL 21: 568-570, 1995.
 
201) Jones DB, Guo L, Reinhard MK, et al: Impact of pneumoperitoneum on trocar site implantation of colon cancer in hamster model. Dis. Colon Rectum 38: 1182-1188, 1995.
PubMed
202) Higgins GA, Amadeo JH, McElminney J, et al: Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and Me-CCNU following resection for carcinoma of colon cancer；Results of a prospectively randornized trial. Cancer 53: 1-8, 1984.
 
203) Gastrointestinal Tumor Study Group: Adjuvant therapy of colon cancer；Results of a prospectively randomized trial. N. Engl. J. Med. 310: 737-743, 1984.
 
204) Wolmark N, Fisher B, Rockette H, et al: Postoperative adjuvant chemotherapy or BCG for colon cancer. Results from NSABP protocol C-01. J. Nat. Cancer Inst. 80: 30-36, 1988.
 
205) Panetierre FJ, Goodman PJ, Costanyi JJ, et al: Adjuvant therapy in large bowel adenocarcinoma；Long-term results of a Southwest Oncology Group study. J. Clin. OncoL 6: 947-954, 1988.
 
206) Abdi E, Harbora D, Hanson J, et al: Adjuvant chemoimmuno-and immuno-therapy in stage B 2 and C colorectal cancer. Proc. Am, Soc. Clin. Oncol. 6: 93, 1987.
 
207) Sertori MR, Guarneri D, Rubagotti A, et al: Adjuvant chemotherapy and immunochemotherapy in colorectal cancer Dukes’C. Oncology 44: 78-81, 1987.
 
208) Windle R, Bell PRF, Shaw D.: Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 74: 569-572, 1987.
 
209) Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large bowel carcinoma. An evaluaton of levamisole and the combination of levamisole and fluorouracil. J. Clin. Onco1. 7: 1447-1456, 1989.
 
210) Moertel CG, Fleming TR, MacDonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann. Intern. Med. 122: 321-326, 1995.
PubMed
211) NIH consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1264: 1444-1450, 1990.
 
212) 安富正幸, 北條慶一, 土屋周二: KW-2299の結腸癌治癒切除例に対する臨床試験. 日癌治療会誌 31: 819, 1996.
 
213) Wolmark N., Bryant J., Hyams DM, et al: The relative efficacy of 5-FU+leucovorin (FU-LV) and 5-FULV+interferon alfa-2 a (IFN) in patients with Dukes 'B and C carcinoma of the colon；First report of NSABP C-05. Proc. Am. Soc. Clin. Oncol. 17: 255 a, 1998.
 
214) Haller DG., Catalano PJ., Macdonald JS.: Fluorouracil (FU) , leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer；five-year final report of INT-0089. Proc. Am. Soc. Clin. Oncol. 17: 256 a, 1998.
 
215) Kato T, Nakazato H: Surgical adjuvant chemotherapy for colorectal cancer. Cancer chemotherapy；Challenges for the future. Excerpta Medica, Amsterdum, 1986, pp. 250-259.
 
216) 北條慶一, 梶谷環: 大腸癌の補助化学療法 (梶谷班一次方式) の成績. 癌と化学療法 13: 3063-3073, 1986.
 
217) 松田泰次, 安富正幸, 菊池金男・他: 共同研究による大腸癌手術のINTENSIVE ADJUVANT CHEMOTHERAPY の検討 (第3報) ; 術後5年成績について. 癌と化学療法 18: 461-469, 1991.
 
218) The Colorectal Cancer Chemotherapy Study Group of Japan: Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. JPn. J. Clin. Oncol. 25: 91-103, 1995.
 
219) 西田修, 内野純一, 菊池金男・他: 共同研究による大腸癌の術後補助化学療法の検討; 第2次研究 (第3報) 治癒切除例の術後5年成績について. 癌と化学療法 20: 101-108, 1993.
 
220) がん集学的治療研究財団: 特定研究7; 大腸癌術後補助化学療法としてのフッ化ピリミジン系抗癌剤の有用性に関する臨床比較試験・研究報告書. 1996.
 
221) Nakazato H., Koike A., Sail L., et al: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer；aprospective randomized clinical trial. Proc. Am. Soc. Clin. Oncol. 16: 279 a, 1997.
 
222) Espinosa E., Gonzalez Baron M., Feliu J., et al: UFT-leucovorin as adjuvant treatment for Dukes’B 2-C colon cancer. Proc. Am. Soc. Clin. Oncol. 17: 275 a, 1998.
 
223) Taylor I, Rowling JT, West C.: Adjuvant cytotoxic liver perfusion for colorectal cancer. Br. J. Surg. 66: 833-837, 1979.
 
224) Taylor I, Machin D, Mulee M, et al: A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br. J. Surg. 72: 359-363, 1985.
 
225) Wereldsma JCJ, Bruggink EDM, Meijer WS, et al: Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus control；Results of a prospective randomized clinical trial. Cancer 65: 425-432, 1990.
 
226) Metzger U, Laffer U, Castiglione M, et al: Adjuvant intraportal chemotherapy for colorectal cancer；4year results of the randomized Swiss study. Proc. Am. Soc. Clin. Oncol. 8: 105, 1989.
 
227) Beart RW, Moertel CG, Wieand HS, et al: Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. Arch. Surg. 125: 897-901, 1990.
PubMed
228) Wolmark N, Rockette H, Wiokerham D, et al: Adjuvant therapy of Dukes’A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepain infusion. Preliminary results of national surgical adjuvant breast and bowel project protocol C-02. J. Clin. Oncol. 8: 1466-1475, 1990.
 
229) Laffer U., Maibach R., Metzger U., et al: Randomized trail of adjuvant perioperative chemotherapy in radically resected colorectal cancer (SAKK 40/87) . Proc. Am. Soc. Clin. Oncol. 17: 256 a, 1998.
 
230) Piedbois P, Buyse M, Gray R, et al: Vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc. Am. Soc. Clin. Oncol. 14: 192, 1995.
 
231) Leaming RH, Sterns MW, Deddish MR, et al: Preoperative irradiation in rectal cancer. Radiology 77: 257-263, 1961.
 
232) Stevens KS, allen CV, Flecher WS.: preoperative radiotherapy for adenocarcinoma of the rectosigmoid. Cancer 37: 2866-2874, 1976.
 
233) Stearns MW, Deddish MR, Quan SH: Preoperative roentgen therapy for cancer of the rectum. Surg. Gynecol. Obstet. 109: 225-229, 1959.
PubMed
234) Stearns MW, Deddish MR, Quan SH: Preoperative roentgen therapy for cancer of the rectum and rectosigmoid. Surg. Gynecol. Obstet. 138: 584-589, 1974.
PubMed
235) Higgins GA, Conn JH, Jordan PH Jr, et al: Preoperaive radiotherapy for colorectal cancer. Ann. Surg. 181: 624-631, 1975.
 
236) Klingerman MM: Radiotherapy and rectal cancer. Cancer 39: 896-900, 1977.
 
237) Higgins GA, Humphrey EW, Dwight RW, et al: Preoperaive radiation and surgery for cancer of the rectum. Veterans Administration Surgical Oncology Group Trial II. Cancer 58: 352-359, 1986.
 
238) Rider WD, Palmer JA, Mahoney LJ, et al: Preoperative irradiation in operable cancer of the rectum；Report of the Tront trial. Can. J. Surg. 20: 335-338, 1977.
 
239) Boulis-Wassif S, Gerard A, Loygue J, et al: Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil followed by radical surgery. Cancer 53: 1811-1818, 1984.
PubMed
240) Second report of an MRC working party. The evaluation of low dose preoperative X-ray therapy in the management of operable rectal cancer；Results of a randomely controlled trial. Br. J. Surg. 71: 21-25, 1984.
 
241) Gerard A, Buyse M, Nordlinger B, et al: Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the Europian Organization for Reaearch and Treatment of Cancer. Ann. Surg. 208: 606-614, 1988.
 
242) 木村幸三郎, 山本啓一郎, 花輪聡・他: 進行直腸癌に対する放射線療法. 消外 6: 695-699, 1983.
 
243) 木村幸三郎, 中島厚, 勝又健次・他: 局所再発予防のための補助療法; 放射線療法を中心として. 消外 13: 343-351, 1990.
 
244) Ahmad N R, Anne PR, Nagle DA, et al: Preoperative chemoradiation therapy appears superior to preoperative radiation alone in the management of clinical T 3/T 4 rectal cancer, Proc. Am. Soc. Clin. Oncol. 16: 256 a, 1997.
 
245) Maghfoor I, Wilkes J, Kuvshinoff B, et al: Neoadjuvant chemoradiotherapy with sphincter-sparing surgery for low lying rectal cancer. Proc. Am. Soc. Clin. Oncol. 16: 274 a, 1997.
 
246) Janjan NA, Khoo VS, Rich TA, et al: Magnitude of responce to preoperative chemoradiation；prognostic implication in patients with locally advanced rectal cancer. Proc. Am. Soc. Clin. Oncol. 16: 273 a, 1997.
 
247) Papillon J: Endocavitary irradiation in the curative treatment of early recatl cancers. Dis. Colon Rectum 17: 172-180, 1974.
PubMed
248) Jelden G, Dhaliwal R, Rodriguez-Antunez A, et al: Definitive treatment of carcinoma of the rectum by intracavitary radiation therapy. Am. J. Roentgenol. 126: 877-879, 1976.
 
249) Jackson BR: Iridium implants in treatment of anorecatal carcinoma. Dis. Colon Rectum 23: 145-150, 1980.
 
250) Gunderson LL, Cohen AM, Dosoretz DE, et al: Residual, unresectable, or recurrent colorecatl cancer；External beam irradiation and intraoperative electron beam boost±resection. Int. J. Radiat. Oncol. Biol. Phys. 9: 1597- 1609, 1983.
 
251) Tepper JE: Radiation therapy of colorectal cancer. Cancer 51: 2528-2534, 1983.
PubMed
252) Mohiuddin M, Derdel J, Marks G, et al: Results of adjuvant radiation therapy in cancer of the rectum；Thomas Jefferson University Hospital experience. Cancer 55: 350-353, 1985.
 
253) Mendiondo OA, Wang CC, Welch Jp, et al: Postoperative radiotherapy in carcinoma of the rectum and distal sigmoid colon. Radiology 119: 673-676, 1976.
PubMed
254) Turner SS, Vieira EF, Ager DJ, et al: Elective postoperative radiotherapy for locally advanced colorectal cancer. Cancer 40: 105-108, 1977.
 
255) Hoskins RB, Gunderson LL, Dosoretz DE, et a1: Adjuvant postoperative radiotherapy in carcinoma of the rectum and rectosigmoid. Cancer 55: 61-71, 1985.
 
256) Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N. Engl. J. Med. 312: 1465-1472, 1985.
 
257) Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324: 709-715, 1991.
PubMed
258) Fisher B, Wolmark N, Rockette H, et al: Postoperative adjuvant chemotherapy or radiation therapy for recatl cancer；Results from NSABP protocol R O1. J. Nat. Cancer Inst. 80: 21-29, 1988.
 
259) Weaver D, Lindblad AS: Radiation therapy and 5-fluorouracil (5-FU) with or without MeCCNU for the treatment of patients with surgically adjuvant adenocarcinoma of the rectum. Proc. Am. Soc. Clin. Oncol. 9: 106, 1990.
 
260) 0’connel M, Wieand H, Krook J, et al: Lack of value for methyl-CCNU (MeCCNU) as a component of effective rectal cancer surgical adjuvant therapy；Interimanalysis of intergroup protocol 86-47-51. Proc. Am. Soc. Clin. Oncol. 10: 134, 1991.
 
261) Gunderson LL, Dosoretz DZ, Hedberg SE, et al: Low dose preoperative radiation surgery and elective postoperative radiation therapy for resectable rectum and rectosigmoid carcinoma. Cancer 52: 446-451, 1983.
 
262) Douglas HO Jr, Moertel CG, Mayer RJ, et a1: Survival after postoperative combination treatment of rectal cancer. N, Engl. J. Med. 315: 1294-1295, 1986.
 
263) Roswit B, Higgins GA, Humphrey EW, et al: Preoperative irradiation of operable adenocarcinoma of the rectum and rectosigmoid colon. Radiology 108: 389-395, 1973.
PubMed
264) Gerard A, Berrod JL, Pene F, et al: Interim analysis of a phase III study on preoperative radiation therapy in resectable rectal carcinoma. Cancer 55: 2373-2379, 1985.
PubMed
265) Stevens KR, Fletche WS, allen CV.: Anterior resection and primary anastomosis following high-dose preoperative irradiation for adenocarcinoma of the rectosigmoid. Cancer 41: 2065-2071, 1978.
 
266) Temple WJ, Ketcham AS: Sacral resection for control of pelvic tumors. Am. J. Surg. 163: 370-374, 1992.
PubMed
267) Stipa S, Nicolanti V, Botti C, et al: Local recurrence after curative resection for colorectal cancer: Frequency, risk factors and treatment. J. Surg. Oncol. 2 (suppl.) : 155-160, 1991.
 
268) 加藤知行, 坂本純一, 安井健三・他: 直腸癌手術後の局所再発の診断と治療. 日消外会誌 20: 2584-2592, 1987.
 
269) Moossa AR, Ree PC, Marks JE, et al: Factors influencing local recurrence after abdominoperineal resection for cancer of the rectum and rectosigmoid. Br. J. Surg. 62: 727-730, 1975.
PubMed
270) Wanebo HJ, Marcove RC: Abdominal sacral resection of locally recurrent rectal cancer. Ann. Surg. 194: 458-471, 1981.
PubMed
271) 加藤知行, 平井 孝, 荒井保明: 直腸癌局所再発の治療. 消化器外科 17: 317-324, 1994.
 
272) Cohen AM, Minsky BD: Aggressive surgical management of locally advanced primary and recurrent rectal cancer. Dis. Colon Rectum 33: 432-438, 1990.
PubMed
273) Wanebo HJ, Koness RJ, Vezeridis MP, et al: Pelvic resection of recurrent rectal cancer. Ann. Surg. 220: 586-597, 1994.
PubMed
274) Hafner GH, Herrera L, Petrelli N: Morbidity and mortality after pelvic exenteration for colorectal adenocarcinoma. Ann. Surg. 215: 63-67, 1992.
PubMed
275) Polk HC Jr, Spratt JS Jr: The results of treatment of perineal recurrence of cancer of the rectum. Cancer 43: 952-955, 1979.
PubMed
276) Welch JP, Donaldson GA: The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann. Surg. 189: 496-502, 1979.
PubMed
277) Schiessel R, Wunderlich M, Herbst F: Local recurrence of colorectal cancer: effect of early detection and aggressive surgery. Br. J. Surg. 73: 342-344, 1986.
PubMed
278) Pearlman NW, Donojue RE, Stiegmann GV, et al: Pelvic and sacropelvic exenteration for locally advanced or recurrent anorectal cancer. Arch. Surg. 122: 537-541, 1987.
PubMed
279) 森 武生: 骨盤内臓器全摘術の改良と成績. 手術 43: 1735-1744, 1989.
 
280) Hafner GH, Herrera L, Petrelli NJ: Patterns of recurrence after pelvic exenteration for colorectal adenocarcinoma. Arch. Surg. 126: 1510-1513, 1991.
PubMed
281) Maetani S, Nishikawa T, Iijima Y, et al: Extensive en bloc resection of regionally recurrent carcinoma of the rectum. Cancer 69: 2876-2883, 1992.
PubMed
282) 小林宣昭, 杉原健一, 赤須孝之・他: 骨盤内臓全摘術; 適応と手技の要点. 消化器外科 17: 307-314, 1994.
 
283) Suzuki K, Dozois RR, Devine RM, et al: Curative reoperations for locally recurrent rectal cancer. Dis. Colon Rectum 39: 730-736, 1996.
PubMed
284) Wiggers T, de Vries MR, Veeze-Kuypers B: Surgery for local recurrence of rectal carcinoma. Dis. Colon Rectum 39: 323-328, 1996.
PubMed
285) Wanebo HJ, Gaker DL, Whitehill R, et al: Pelvic recurrence of rectal cancer: Options for curative resection. Ann. Surg. 205: 482-495, 1987.
PubMed
286) Jaffe BM, Donegman WL, Watson F, et al: Factors influencing survival in patients with untreated hepatic metastases. Surg. Gynecol. Obstet. 127: 1-11, 1968.
 
287) Petrelli NJ, Nambisan RN, Herrera K: Hepatic resection for isolated metastasis from colorectal carcinoma. Am. J. Surg. 149: 205-209, 1985.
 
288) 太田博俊, 西 満正, 堀 雅晴・他: 大腸癌肝転移に対する治療とその成績. 消化器外科 16: 1641-1651, 1993.
 
289) Wood CB, Gillis CR, Blumgart LH: Aretrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin. Oncol. 2: 285-288, 1976.
 
290) 山崎 晋, 長谷川博, 幕内雅敏: 転移性肝腫瘍に対する肝切除の意義と限界. 外科治療 52: 241-247, 1985.
 
291) 安井健三, 加藤知行: 大腸癌肝転移に対する肝切除の適応と系統的肝切除術. 消化器外科 16: 1693-1699, 1993.
 
292) Fortner JG, Silva JS, Golbey RB, et al: Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. Ann. Surg. 199: 306-316, 1984.
PubMed
293) Scheele J, Stangle R, altendorf-Hofmann A, et al: Indications of prognosis after hepatic resection for colorectal secondaries. Surgery 110: 13-29, 1991.
 
294) 杉原健一, 北條慶一, 小林宣昭・他: 大腸癌肝転移の外科治療. 日消外会誌 24: 1147-1151, 1991.
 
295) Attiyeh FF, Wanebo HJ, Sterns MW: Hepatic resection for metastasis from colorectal cancer. Dis. Colon Rectum 21: 160-162, 1978.
 
296) Heidelberger CG, Chandhari NK, Dannenberg P, et al: Fluorinated pyrimidines: anew class of tumor inhibitory compounds. Nature 179: 663-666, 1957.
 
297) Moertel CG: Clinical management of advanced gastrointestinal cancer. Cancer 36: 675-682, 1975.
PubMed
298) Lokich JJ, Ahlgren JD, Gullo JJ, et al: Aprospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: Amid-Atlantic Oncology Program study. J. Clin Oncol. 7: 425-432, 1989.
 
299) Weinerman B, Shah A, Fields A, et al: Arandomized trial of continuous systemic infusion versus bolus therapy 5-fluorouracil in metastatic measurable colorectal cancer. Proc. Am. Soc. Clin. Oncol. 10: 143, 1990.
 
300) Leichman CG, Muggia EM: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: aSouthwest Oncology Group study. J. Clin. OncoL 13: 1303-1311, 1995.
 
301) Harris BE, Song R, Soong S, et al: Relationship between dihydrophyrimidine dehydrogrnase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patiens receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50: 197-201, 1990.
 
302) Levi F, Zidani R, Misset J-L, et al: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350: 681-686, 1997.
PubMed
303) Hohn DC, Stagg RJ, Friedman MA, et al: Arandomized trial of continuous intravenous versus hepatic intraaterial floxuridine in patinets with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J. Clin. OncoL 7: 1646-1654, 1989.
 
304) Rougier PL, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J. Clin. Oncol. 10: 1112-1118, 1992.
 
305) Kemeny N, Conti JA, Cohen AM, et al: Phase II study of hepatic arterial floxuridine, leucovorin and dexamethasone for unresectable liver metastases from colorectal carcinoma. J. Clin. Oncol. 12: 2288-2295, 1994.
 
306) Meta-analysis group in cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J. Nat1. Cancer Inst. 88: 252-258, 1996.
 
307) Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989.
PubMed
308) Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 11: 909-913, 1993.
PubMed
309) Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res, 54: 3723-3725, 1994.
PubMed
310) Rothenberg ML, Eckardt JA, Kuhn JG, et al: Phase II study of irinotecan in patients with progressive or rapidly reccurrent colorectal cancer. J. Clin. Oncol. 14: 1128-1135, 1996.
 
311) Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Onco1. 14: 709-715, 1996.
 
312) Pitot HC, Wender DB, 0’Connell MJ, et al: A phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J. Clin. Oncol. 15: 2910-2919, 1997.
 
313) Abigerges D, Chabot GG, Armand J-P, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 13: 210-221, 1995.
PubMed
314) Saltz LB, Kanowitz J, Kemeny NE, et al: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J. Clin. Oncol. 14: 2959-2967, 1996.
PubMed
315) Zalcberg JR, Cunningham D, Van Cutsem E, et al: ZD1694: Anovel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J. Clin. Oncol. 14: 716-721, 1996.
 
316) Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 14: 2950-2958, 1996.
PubMed
317) Leichman CG, Lenz HJ, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15: 3223-3229, 1997.
PubMed
318) Bertino JR, Sawicki WL, Lindquist CA, et al: Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res. 37: 327-328, 1977.
PubMed
319) Houghton JA, Maroda SJ Jr. Phillips JO, et al: Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res. 41: 144-149, 1981.
PubMed
320) Valone FH, Friedman MA, Wittlinger PS, et al: Tretment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin: arandomized trial of the Northern California oncology group. J. Clin. Oncol. 7: 1427-1436, 1989.
 
321) Petrelli N, Herrea L, Rustum Y, et al: Aprospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J. Clin. Oncol. 5: 1559-1565, 1987.
 
322) Marsh JC, Bertino JR, Katz KH, et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J. Clin. Oncol. 9: 371-380, 1991.
PubMed
323) Advanced Colorectal Cancer Meta-Analysus Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic coloreatl cancer. J. Clin. Oncol. 12: 960-969, 1994.
 
324) Blijham G, Wagener T, Wils J, et al: Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: Final results of a randomized Europian Organization for Research and Treatment of Cancer study. J. Clin. Oncol. 14: 2266-2273, 1996.
 
325) Erlichman C, Fine S, Wong A, et al: Arandomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J. Clin Oncol. 6: 469-475, 1988.
 
326) Poon MA, 0’Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: evidence significant improvement of survival and quality of life in patients with advanced colorectal carcinora. J. Clin. Oncol. 7: 1407-1418, 1989.
 
327) Petrelli N, Douglass HO Jr, Herrea L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: Aprospective randomized phase III trials. J. Clin. Oncol. 7: 1419-1426, 1989.
 
328) Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate, fluorouraciI and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J. Clin. Oncol. 7: 1437-1446, 1989.
 
329) Doroshaw JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high dose continous infusion leucovorin calcium for the treatment of advanced measurable clorectal cancer iIl patients previously unexposed to chemotharapy. J. Clin. Oncol. 8: 491-501, 1990.
 
330) Di Costanzo FB, Bartolucci R, Calabresi F, et al: FluorouraciFalone versus high-dose folonic acid and fluorouracil in advanced colorectal cancer: arandomized trials of the Italian Oncology Group for Clinical Trials. Ann. Oncol. 3: 371-376, 1992.
 
331) Poon MA, 0’Connell MJ, Wieand HS, et al: Biochemical moduration of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. 9: 1967-1972, 1991.
 
332) Jager E, Heike M, Bernhard H, et al: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J. Clin. Oncol. 14: 2274-2279, 1996.
 
333) Wadler S, Schwartz EL, Goldman M, et al: Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorecatal carcinoma. J. Clin. Oncol. 7: 1769-1775, 1989.
 
P.1144 掲載の参考文献
1) 日本肝癌研究会: 原発性肝癌に関する追跡調査-第11報-. 肝臓 36: 208-218, 1995.
 
2) 日本肝癌研究会編: 原発性肝癌取扱い規約. (第3版) , 金原出版, 東京, 1992.
 
3) 山崎 晉, 長谷川博, 幕内雅敏: 最小肝癌の臨床病理学的分析と, それに基づく新しい概念の切除法-27切除例の検討肝臓 22: 1714-1724, 1981.
 
4) Okazaki N, Yoshida T, Yoshino M, et al: Screening of patients with chronic liver disease for hepatocellular carcinoma by ultrasonography. Clin. Oncol. 10: 241-246, 1984.
PubMed
5) Arakawa M, Kage M, Sugihara S, et al: Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver-observation in five cases. Gastroenterology 91: 198-208, 1986.
 
6) Wada K, Kondo F, Kondo Y, et al: Large regenerative nodules and dysplastic nodules in cirrhotic livers: a histopathologic study. Hepatology 8: 1684-1688, 1988.
 
7) Furuya K, Nakamura M, Yamamoto Y, et al: Macrogenerative nodule of the liver-a clinicopathological study of 345 autopsy cases of chronic liver disease. Cancer 61: 99-105, 1988.
PubMed
8) Takayama T, Makuuchi M, Hirohashi S, et al: Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 36: 1150-1153, 1990.
 
9) Kanai T, Hirohashi S, Upton MP, et al: Pathology of small hepatocellular carcinoma-a proposal for a new gross classification. Cancer 60: 810-819, 1987.
PubMed
10) Sakamoto M, Hirohashi S, Shimosato Y, et al: Early stages of multistep hepatocarcinogenesis-adenomatous hyperplasia and early hepatocellular carcinoma. Hum. Pathol. 22: 172-178, 1991.
PubMed
11) Aihara T, Noguchi S, Sasaki Y, et al: Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology 107: 1805-1811, 1994.
PubMed
12) International Working Party: Terminology of nodular hepatocellular lesions. Hepatology 22: 983-993, 1995.
PubMed
13) Takayasu K, Moriyama N, Muramatsu Y, et al: The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. Am. J Roentgenol. 155: 49-54, 1990.
 
14) Matsui O, Kadoya M, Kameyama T, et al: Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178: 493-497, 1991.
PubMed
15) Muramatsu Y, Nawano S, Takayasu K, et al: Early hepatocellular carcinoma: MR imaging. Radiology 181: 209-213, 1991.
PubMed
16) Itai Y, Araki T, Furui S, et al: Differential diagnosis of hepatic masses on computed tomography, with particular reference to hepatocellular carcinoma. J. Comput. Assisst. Tomogr. 5: 834-842, 1981.
 
17) Ros PR, Murphy BJ, Buck JL, et al: Encapsulated hepatocellular carcinoma: radiologic findings and pathologic correlation. Gastrointest. RadioL 15: 233-237, 1990.
PubMed
18) Sato M, Watanabe Y, Lee T, et al: Well-differentiated hepatocellular carcinoma: clinicopathological features and results of hepatic resection. Am. J. Gastroenterol. 90: 112-116, 1995.
PubMed
19) Takayasu K, Furukawa H, Wakao F, et al: CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. Am. J. Roentgenol. 164: 885-890, 1995.
 
20) Aihara T, Noguchi S, Sasaki Y, et al: Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 111: 455-461, 1966.
 
21) 原発性肝がんの病態に応じた治療方針の選択に関する研究, 厚生省平成3年度対がん10ヵ年総合戦略プロジェクト研究報告書. 1992, pp. 151-155.
 
22) 原発性肝がんの病態に応じた治療方針の選択に関する研究, 厚生省平成5年度対がん10ヵ年総合戦略プロジェクト研究報告書. 1996, pp. 176-181.
 
23) Gozzetti G, Mazziotti A, Cavallari A, et al: Clinical experience with hepatic resections for hepatocellular carcinoma in patients with cirrhosis. Surg. Gynecol. Obstet. 166: 503-510, 1988.
PubMed
24) Nagasue N, Kohno H, Chang YC, et al: Liver resection for hepatocellular carcinoma. Ann. Surg. 217: 375-384, 1993.
PubMed
25) Iwatsuki S, Startzl TE: Personal experience with 411 hepatic resections. Ann. Surg. 208: 421-434, 1988.
 
26) Tsuzuki T, Sugioka A, Ueda M, et al: Hepatic resection for hepatocellular carcinoma. Surgery 107: 511-520, 1990.
PubMed
27) Sasaki Y, Imaoka S, Masutani S, et al: Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma. Surgery 112: 515-521, 1992.
PubMed
28) Chen PJ, Chen DS, Lai MY, et al: Clonal origin of recurrent hepatocellular carcinoma. Gastroenterology 87: 1514-1519, 1990.
 
29) Hsu HC, Chion TJ, Chen JY, et al: Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology 13: 923-928, 1991.
 
30) Eguchi A, Nakashima O, Okudaira S, et al: Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma. Hepatology 151843-848, 1992.
 
31) Oda T, Tsuda H, Sakamoto M, et al: Mutation pattern of the p 53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res. 52: 3674-3678, 1992.
 
32) Tsuda H, Oda T, Sakamoto M, et al: Different pattern of chromosomal alle loss in multiple hepatocellular carcinoma as evidence of their multifocal origin. Cancer Res. 52: 1504-1509, 1992.
 
33) Esumi M, Aritaka T: Clonal origin of human hepatoma determined by integration of hepatitis virus DNA. Cancer Res. 46: 5767-5771, 1986.
PubMed
34) Sakamoto M, Hirohashi S, Tsuda H, et al: Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am. J. Surg. Pathol. 13: 1064-1068, 1989.
PubMed
35) Aihara T, Noguchi S, Sasaki Y, et al: Differentiation of multifocal and multicentric hepatocellular carcinomas by DNA finger print analysis: case report. Surgery 121: 711-714, 1997.
 
36) 池田健次: 肝癌の外科切除と再発. 肝細胞癌の予知, 診断, 治療. 第1版, メジカルビュー社, 大阪, 1995, pp. 48- 66.
 
37) Sasaki Y, Imaoka S, Ishiguro S, et al: Clinical features of small hepatocellular carcinomas as assessed by histologic grades. Surgery 119: 252-260, 1996.
PubMed
38) Wu CC, Ho WL, Yeh DC, et al: Hepatic resection of hepatocellular carcinoma in cirrhotic patients: Is it unjustified in impaired liver function?Surgery 120: 34-39, 1996.
PubMed
39) 岩本伸一, 佐々木洋, 今岡真義・他: Stage IV肝細胞癌に対する肝切除の意義. 日消外会誌 25: 2118-2122, 1992.
 
40) 佐々木洋, 今岡真義, 岩本伸一・他: Stage IV肝細胞癌に対する肝切除の意義とその適応-TAE治療との比較検討-. 日外会誌 93: 1107-1110, 1992.
 
41) Shimada M, Takenaka K, Kawahara N, et al: Surgical treatment strategy for patients with stage IV hepatocellular carcinoma. Surgery 119: 517-522, 1996.
PubMed
42) Sasaki Y, Imaoka S, Shibata T, et al: Decollateralization with silicone rubber sheeting for advanced hepatoce1-lular carcinoma: apreliminary report. Surgery 108: 840-846, 1990.
 
43) Ng I, Ng M, Lai E, et al: Better survival in female patients with hepatocellular carcinoma. Cancer 75118-22, 1995.
 
44) Okada S, Ishii H, Nose H, et al: Effect of heavy alcohol intake on long-term results after curative resection of hepatitis C virus-related hepatocellular carcinoma. JPn. J. Cancer Res. 87: 867-873, 1996.
PubMed
45) Nagao T, Inoue S, Yoshimi F, et al: Postoperative recurrence of hepatocellular carcinoma. Ann. Surg. 211: 28-33, 1990.
PubMed
46) 泉 良平, 小林弘信, 谷屋隆雄・他: 肝細胞癌の再発例の検討. 日消外会誌 21: 831-835, 1988.
 
47) Vauthey JN, Klimstra D, Franceschi D, et al: Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am. J. Surg. 169: 28-35, 1995.
PubMed
48) Yamanaka N, Okamoto E, Toyosaka A, et al: Prognostic factors after hepatectomy for hepatocellular carcinoma. A univariate and multivariate analysis. Cancer 65: 1104-1110, 1990.
PubMed
49) Shirabe K, Kanematsu T, Matsumata T, et al: Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy. Univariate and multivariate analysis. Hepatology 14: 802-805, 1991.
PubMed
50) Nonami T, Isshiki K, Katoh H, et al: The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas. Ann. Surg. 213: 222-226, 1991.
PubMed
51) Arii S, Tanaka J, Yamazoe Y, et al: Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 69: 913-919, 1992.
PubMed
52) Ikeda K, Saitoh S, Tsubota A, et al : Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 71: 19-25, 1993.
 
53) Lai ECS, Ng IOL, Ng MMT, et al: Long-term results of resection for large hepatocellular carcinoma. A multivariate analysis of clinicopathological factors. Hepatology 11: 815-818, 1990.
 
54) Ishizu H, Uchino Y, Une Y, et al: Ploidy pattern of nuclear DNA of hepatocellular carcinoma and its biologic characteristics. Acta Hepatol. Jpn. 29: 1078-1086, 1988.
 
55) Haratake J, Takeda S, Kasai T, et al: Predictive factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer 72: 1178-1183, 1993.
PubMed
56) 渡辺 心: モノクロナール抗体Ki-67を用いたフローサイトメトリーによる原発性肝細胞癌増殖活性の検討. 日外会誌 96: 439-447, 1995.
 
57) Kitamoto M, Nakanishi T, Kita S, et al: The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 72: 1859-1865, 1993.
 
58) 岩本伸一, 石黒信吾, 佐々木洋・他: 肝細胞癌の病理学的悪性度とcadherin. 病理と臨床 12: 1859-1865, 1993.
 
59) Hsu HC, Tseng HJ, Lai PL, et al: Expression of p 53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res. 53: 4691-4694, 1993.
PubMed
60) Masutani S, Sasaki Y, Imaoka S, et al: The prognostic significance of survival in liver resection of patients with hepatocellular carcinoma. Arch. Surg. 129: 1025-1030, 1994.
PubMed
61) Ozawa K, Takayasu T, Kumada K, et al: Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period. Am. J. Surg. 161: 677-682, 1991.
 
62) Nagasue N, Yukawa H, Chang YU, et al: Assessment of pattern and treatment of intrahepatic recurrence after resection of hepatocellular carcinoma. Surg. Gynecol. Obstet. 171: 217-222, 1990.
 
63) Balsells R, Chaco R, Lazaro L, et al: Resection of hepatocellular carcinoma in patients with cirrhosis. Br. J. Surg. 83: 758-761, 1996.
 
64) Sasaki Y, Imaoka S, Fujita M, et al: Regional therapy in the management of intrahepatic recurrence after surgery for hepatoma. Ann. Surg. 206: 40-47, 1987.
PubMed
65) Shimada M, Kakenaka K, Gion T, et al: Prognosis of recurrent hepatocellular carcinoma: a10-year surgical experience in Japan. Gastroenterology 111 : 720-726, 1996.
 
66) 佐々木洋, 今岡真義, 中野博史・他: 肝細胞癌の残肝再発と遠隔転移に対する外科的治療. 消化器病・UP TO DATE (consensus & controversies, 1996) (小林絢三編) , 永井書店, 大阪, 1997, pp. 58-63.
 
67) Shimada M, Matsumata, Taketomi A, et al: Repeated hepatectomy for recurrent hepatocellular carcinoma. Surgery 115: 703-706, 1994.
 
68) Suenaga M, Sugiura H, Kokubo Y, et al: Repeated hepatic resection for recurrent hepatocellular carcinoma in eighteen cases. Surgery 115: 452-457, 1994.
 
69) Kakazu T, Makuuchi M, Kawasaki S, et al: Repeat hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology 40: 337-341, 1993.
PubMed
70) Matsuda Y, Ito T, Oguchi Y, et al: Rationale of surgical management for recurrent hepatocellular carcinoma. Ann. Surg. 217: 28-34, 1993.
PubMed
71) Ohto M, Ebara M, Watanabe Y, et al: Percutaneous ethanol injection therapy (PEI) for small hepatocellular carcinoma. Evaluation of its utility on the basis of tumor-image and survival after therapy. JPn. J. Med. Imaging 7: 25-33, 1988.
 
72) Ebara M, Ohto M, Sugihara N, et al: Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 cases. J Gastroenterol. Hepato1. 5: 616-626, 1990.
 
73) Ishii H, Okada S, Nose H, et al: Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 77: 1792-1796, 1996.
PubMed
74) 北 和彦, 江原正明, 杉浦信之・他: 小肝細胞癌に対する経皮的エタノール注入療法 (PEI) -長期観察に基づく抗腫瘍効果と予後の検討-. 日消病誌 91: 1949-1955, 1994.
 
75) Tanikawa K, Majima Y: Percutaneous ethanol injection therapy for recurrent hepatocellular carcinoma. Hepatogastroenterology 40: 324-327, 1993.
PubMed
76) 池田健次: 肝細胞癌に対するエタノール局注療法. 肝細胞癌の予知, 診断, 治療. 第1版, メジカルビュー社, 大阪, 1995, pp. 67-83.
 
77) Livraghi T, Giorgio A, Marin G, et al: Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 197: 101-108, 1995.
PubMed
78) Lencioni R, Bartolozzi C, Caramella D, et al: Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Cancer 76: 1737-1746, 1995.
PubMed
79) Breedis C, Yong G: The blood supply of neoplasms in the liver. Am. J. Pathol. 30: 969-985, 1954.
 
80) Wheeler PG, Melia W, Dubbins P, et al: Non-operative arterial embolization in primary liver tumors. Br. Med. J. 2: 242-244, 1979.
PubMed
81) Chuang VP, Wallace S: Current status of transcatheter management of neoplasms. Cardiovasc. Intervent. Radiol. 3: 256-267, 1980.
PubMed
82) Yamada R, Sato M, Kawabata M, et al: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology l48: 397-401, 1983.
 
83) Hirai K, Kawazoe Y, Yamashita K, et al: Arterial chemotherapy and transcatheter arterial embolization therapy for non-resectable hepatocellular carcinoma. Cancer Chemother. Pharmacol. 23 (Suppl.) : s37-s 41, 1989.
 
84) Venook AP, Stagg RJ, Lewis BJ, et al: Chemoembolization for hepatocellular carcinoma. J. Clin. Oncol. 8: 1108-1114, 1990.
PubMed
85) 打田日出夫, 大石 元: Interventional angiography: embolizationの基本事項. 治療 68: 699-702, 1986.
 
86) Sasaki Y, Imaoka S, Kasugai H, et al: Anew approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60: 1194-1203, 1987.
 
87) Nakamura H, Hashimoto T, Oi H, et al: Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170: 783-786, 1989.
PubMed
88) Uchida H, Ohishi H, Matsuo N, et al: Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 13: 140-145, 1990.
PubMed
89) Matsui O, Kadota M, Yoshikawa J, et al: Subsegmental transcatheter arterial embolization for small hepatocellular carcinoma: local therapeutic effect and 5-year survival rate. Cancer Chemother. Pharmacol. 33 (Suppl) : s84-s 88, 1994.
 
90) Groupe D’Etude et de traitement du carcinome hepatocellulaire: Acomparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N. Engl. J. Med. 332: 1256-1261, 1995.
 
91) Imaoka S, Sasaki Y, Shibata T, et al: Apre-operative chemoembolization therapy using lipiodol, cisplatin, and gewlatin sponge for hepatocellular carcinoma. Cancer Chemother. Pharmaco1. 23 (Suppl.) : s126-s 128, 1989.
 
92) 柴田 高, 佐々木洋, 今岡真義・他: 肝細胞癌に対するリピオドール, シスプラチンサンドイッチ療法の抗腫瘍効果と遠隔成績. 日外会誌 91: 859-863, 1989.
 
93) Ikeda K, Kumada H, Saitoh S, et al: Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by Cox proportional hazard model. Cancer 68: 2150-2154, 1991.
PubMed
94) 池田健次, 村島直哉, 竹内和男・他: 肝癌に対する動脈塞栓術後の肝動脈主幹部閉塞と肝動脈spasmとの関連について. 肝臓 25: 1153-1159, 1984.
 
95) Tabuse K, Katsumi M, Kobayashi Y, et al: Microwave surgery；hepatectomy using a microwave tissue coagulator. World J. Surg. 9: 136-143, 1985.
PubMed
96) Saitsu H, Maeda Y, Tanikawa S, et al: Investigation of microwave coagulo-necrotic therapy for 21 patients with small hepatocellular carcinoma less than 5 cm in diameter. J. Jpn. Surg. Soc. 94: 359-365, 1993.
 
97) Sato M, Watanabe Y, Ueda S, et al: Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology 110: 1507-1514, 1996.
PubMed
98) 佐々木洋, 今岡真義, 中野博史・他: 寄生栄養動脈の発達によるTAE無効再発肝細胞癌に対する開胸下マイクロ波凝固療法. 癌と化学療法 24: 1647-1650, 1997.
Medical*Online
99) Seki T, Wakabayashi M, Nakagawa T, et al: Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74: 817-825, 1994.
PubMed
100) 才津秀樹, 吉田 正, 大堂雅晴・他: 5cm以下の肝細胞癌に対するマイクロ波凝固壊死療法 (MCN) について. 臨床外科 49: 309-315, 1994.
 
101) Ohnishi K, Yoshioka H, Fujiwara K, et al: Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 27: 67-72, 1998.
PubMed
102) Muto Y, Moriwaki H, Ninomiya M, et al: Prevention of second primary tumors by an acycric retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N. Engl. J, Med. 334: 1561-1567, 1996.
PubMed
103) Oka H, Yamamoto S, Kuroki T, et al: Prospective study of chemoembolization of hepatocellular carcinoma with Sho-saiko-to (TJ-9) . Cancer 76: 743-749, 1995.
 
104) Okuda K, Kubo Y, Okazaki N, et al: Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma. A study of 57 autopsy-proven cases. Cancer 39: 232-246, 1977.
PubMed
105) 山崎 晉, 山本順司: 肝内胆管癌: 新しい肉眼分類. 肝胆膵 30: 480-484, 1995.
 
106) 杉浦信之, 甲島洋平, 真田昌彦・他: 肝内胆管癌: 画像診断. 肝胆膵 30: 459-468, 1995.
 
107) Takayasu K, Ikeda S, Mukai K, et al: CT of hilar cholangiocarcinoma: Late contrast enhancement in six patients. Am. J. Roentgenol. 1524: 1203-1206, 1990.
 
108) 篠原靖志, 竜 崇正, 渋谷幸喜・他: 胆管造影CT三次元イメージングによる肝内胆管枝の描出. 日本臨牀 49: 1893- 1897, 1991.
 
109) Dooms GC, Kerlan KR, Hricak H, et al: Cholangiocarcinoma: Imaging by MR. Radiology 159: 89-94, 1986.
 
110) 北野 悟, 広橋伸治, 打田日出夫・他: 胆管細胞癌のMRI, 特に造影MRIの有用性. 日磁医誌 12: 237-244, 1992.
 
111) Chen MF, Jan YY, Wang CS, et al: Clinical experience in 20 hepatic resections for peripheral cholangiocarcinoma. Cancer 64: 2226-2232, 1989.
PubMed
112) Kawarada Y, Mizumoto R: Diagnosis and treatment of cholangiocellular carcinoma of the liver. Hepatogastroenterology 37: 176-181, 1990.
PubMed
P.1158 掲載の参考文献
1) Williamson RCN: Pancreatic cancer: the greatest oncological challenge. Br. Med. J. 296: 445-446, 1988.
 
2) Gordis L, Gold EB: Epidemiology of pancreatic cancer. World J. Surg. 8: 808-821, 1984.
PubMed
3) 厚生省大臣官房統計情報部: 平成6年人口動態統計, 東京, 1996, pp. 274-277.
 
4) Japanese Cancer Association: Cancer mortality and morbidity statistics. Japan and the world-1994. Japan Scientific Societies Press, Tokyo, 1994, pp. 186-187.
 
5) Silverman DT, Dunn JA, Hoover RN, et al: Cigarette smoking and pancreas cancer: acase-control study based on direct interviews. J. Natl. Cancer Inst. 86: 1510-1516, 1994.
 
6) Boyle P, Maisonneuve P, Mesquita BB, et al: Cigarette smoking and pancreas cancer: acase-control study of the search programme of the IARC. Int. J. Cancer 67: 163-167, 1996.
 
7) Fuchs CS, Colditz GA, Stampfer MJ, et al: Aprospective study of cigarette smoking and the risk of pancreatic cancer. Arch. Intern. Med. 156: 2255-2260, 1996.
 
8) Vecchia CL, Negri E, Franceschi S, et al: Acase-control study of diabetes mellitus and cancer risk. Br. J. Cancer 70: 950-953, 1994.
 
9) Chow WH, Gridley G, Nyren O, et al: Risk of pancreatic cancer following diabetes mellitus: anationwide cohort study in Sweden. J. Natl. Cancer Inst. 87: 930-931, 1995.
 
10) Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. JAMA 273: 1605-1609, 1995.
PubMed
11) Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. N. Engl. J. Med. 328: 433-437, 1993.
 
12) Bansal P, Sonnenberg A: Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 109: 247-251, 1995.
PubMed
13) Silverman DT, Brown LM, Hoover RN, et al: alcohol and pancreatic cancer in blacks and whites in the United States. Cancer Res. 55: 4899-4905, 1995.
PubMed
14) Ji BT, Chow WH, Hsing AW, et al: Green tea consumption and the risk of pancreatic and colorectal cancers. Int. J. Cancer 70: 255-258, 1997.
PubMed
15) 斉藤洋一: 膵癌全国登録調査報告. 膵臓 11: 479-506, 1996.
 
16) 日本膵臓学会編: 膵癌取扱い規約. 第4版, 金原出版, 東京, 1993.
 
17) Reinhold C, Bret PM: MR cholangiopancreatography. Abdom. Imaging 21: 105-116, 1996.
PubMed
18) Soto JA, Barish MA, Yucel EK, et al: Magnetic resonance cholangiography: Comparison with endoscopic retrograde cholangiopancreatography. Gastroenterology 110: 589-597, 1996.
PubMed
19) Furukawa H, Okada S, Saisho H, et al: Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 78: 986-990, 1996.
PubMed
20) Tada M, Omata M, Ohto M: Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 100: 233-238, 1991.
PubMed
21) Tada M, Omata M, Kawai S, et al: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 53: 2472-2474, 1993.
PubMed
22) Watanabe H, Sawabu N, Ohta H, et al: Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. JPn. J. Cancer Res. 84: 961-965, 1993.
PubMed
23) Kondo H, Sugano K, Fukayama N, et al: Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 73: 1589-1594, 1994.
 
24) Suzuki H, Yoshida S, Ichikawa Y, et al: Ki-ras mutations in pancreatic secretions and aspirates from two patients without pancreatic cancer. J. Natl. Cancer Inst. 86: 1547-1548, 1994.
PubMed
25) Iguchi H, Sugano K, Fukayama N, et al: Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology 110: 221-226, 1996.
PubMed
26) Tada M, Ohashi M, Shiratori Y, et al: Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110: 227-231, 1996.
PubMed
27) Todorov P, Cariuk P, McDevitt T, et al: Characterization of a cancer cachectic factor. Nature 379: 739-742, 1996.
PubMed
28) Hiyama E, Kodama T, Shinbara K, et al: Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res. 57: 1326-1333, 1997.
PubMed
29) Okada S, Yoshimori M, Kakizoe T: Pancreatic cancer: Medical aspects. Pancreas 13: 1998. (in press)
 
30) 日本癌治療学会固形がん化学療法効果判定基準. 日癌治療会誌 21: 929-942, 1986.
 
31) 膵癌の治療効果判定基準 (案) . 膵臓 7: 107-121, 1992.
 
32) Aoki K, Okada S, Moriyama N, et al: Accuracy of computed tomography in determining pancreatic cancer tumor size. Jpn. J. Clin. Oncol. 24: 85-87, 1994.
PubMed
33) Ishii H, Okada S, Okusaka T, et al: CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 44: 279-283, 1997.
 
34) Okusaka T, Okada S, Ishii H, et al: Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jpn. J. Clin. OncoL 26: 215-220, 1996.
PubMed
35) Shibamoto Y, Manabe T, Ohshio G, et al: High-dose intraoperative radiotherapy for unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 34: 57-63, 1996.
PubMed
36) Roldan GE, Gunderson LL, Nagorney DM, et al: External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61: 1110-1116, 1988.
PubMed
37) TepPer JE, Noyes D, Krall JM, et al: Intraoperative radiation therapy of pancreatic carcinoma: Areport of RTOG-8505. Int. J. Radiat. Oncol. Biol. Phys. 21: 1145-1149, 1991.
 
38) Dobelbower RR, Konski AA, Merrick HW, et al: Intraoperative electron beam radiation therapy (10EBRT) for carcinoma of the exocrine pancreas. Int. J. Radiat. Oncol. Biol. Phys. 20: 113-119, 1991.
PubMed
39) Seydel HG, Stablein DM, Leichman LP, et al: Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group Experience. Cancer 65: 1478-1482, 1990.
 
40) Gastrointestinal Tumor Study Group: Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of Iocally unresectable pancreatic carcinoma. Cancer 56: 2563-2568, 1985.
 
41) Earle JD, Foley JF, Wieand HS, et al: Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 28: 207-211, 1994.
PubMed
42) Moertel CG, Gunderson LL, Mailliard JA, et al: Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. J. Clin. Oncol. 12: 21-27, 1994.
PubMed
43) Moertel CG, Childs DS, Reitemeier RJ, et al: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2: 865-867, 1969.
PubMed
44) Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma. A randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads+5-fluorouracil) , and high dose radiation+5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 48: 1705-1710, 1981.
 
45) Klaassen DJ, Maclntyre JM, Catton GE, et al: Treatment of locally unresectable cancer of the stomach and pancreas: Arandomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 3: 373-378, 1985.
 
46) Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J. Natl. Cancer Inst. 80: 751-755, 1988.
 
47) Whittington R, Neuberg D, Tester WJ, et al: Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: Aphase I Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 13: 227-232, 1995.
 
48) Ishii H, Okada S, Tokuuye K, et al: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79: 1516-1520, 1997.
PubMed
49) Wagener DJTh, Hoogenraad WJ, Rougier Ph et al: Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study. Eur. J. Cancer 32 A: 1310-1313, 1996.
 
50) Safran H, King TP, Choy H, et al: Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: aphase I study. J. Clin. Oncol. 15: 901-907, 1997.
 
51) Ishikawa O, Ohigashi H, Sasaki Y, et al: Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am. J. (Surg. 168: 361-364, 1994.
PubMed
52) Louvet C, Beerblock K, Gramont A, et al: High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: apilot study. Eur. J. Cancer 29 A: 1217, 1993.
 
53) Weinerman BH, MacCormick RE: Aphase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. (Am. J. Clin. Oncol. 17: 467-469, 1994.
 
54) Pazdur R, Ajani JA, Abbruzzese JL, et al: Phase II evaluation of fluorouracil and recombinanta-2 a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70: 2073-2076, 1992.
 
55) Bernhard H, Jager-Arand E, Bernhard G, et al: Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2 A: results of a phase II trial Br. J. Cancer 71: 102-105, 1995.
PubMed
56) Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2, 2 '-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drug 12: 29-34, 1994.
PubMed
57) Rothenberg ML, Moore MJ, CripPs MC, et al: Aphase II trial of gemcitabine in patients with 5-FU-refactory pancreas cancer. Ann. Oncol. 7: 347-353, 1996.
 
58) Moore M, Andersen J, Burris H, et al: Arandomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer. Proc. ASCO 14: 199, 1995.
 
59) Wils JA, Kok T, Wagener DJTh, et al: Phase II trial with ifosfamide in pancreatic cancer. Eur. J. Cancer 29A: 290, 1993.
 
60) Aoki K, Shimada Y, Okazaki N, et al: Aphase II study of epirubicin in patients with advanced adenocarcinoma of the pancreas. Eur. J. Cancer 28: 1590, 1992.
 
61) Wils JA, Kok T, Wagener DJTh, et al: Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J. Cancer 29A: 203-204, 1993.
 
62) Hubbard KP, Pazdur R, Ajani JA, et al: Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am. J. Clin. Oncol. 15: 524-527, 1992.
PubMed
63) Gebbia N, Gebbia V: Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. Eur. J. Cancer 32 A: 1822-1823, 1996.
PubMed
64) Rougier P l Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Anticancer Drugs 6 (Suppl. 4) : 25-29, 1995.
 
65) CPT-11 Study Group on Gastrointestinal Cancer: alate phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. Jpn. J. Cancer Chemother. 21: 1039-1046, 1994.
 
66) 0’Reilly S, Dollehower RC, Rowinsky EK, et al: Aphase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs 7: 410-414, 1996.
 
67) Scher RM, Kosierowski R, Lusch C, et al: Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest. New Drugs 13: 347-354, 1996.
PubMed
68) Oster MW, Gray R, Panasci L, et al: Chemotherapy for advanced pancreatic cancer. A comparison of 5- fluorouracil, adriamycin, and mitomycin C (FAM) with 5-fluorouracil, streptozotocin, and mitomycin C (FSM) . (Cancer 57: 29-33, 1986.
PubMed
69) The Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin Cplus fluorouracil. J. Clin. Oncol. 4: 1794-1798, 1986.
 
70) Kelsen D, Hudis C, Niedzwiecki D, et al : A phase III comparison trial of streptozotocin, mitomycin C, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68: 965-969, 1991.
PubMed
71) Moertel CG, Rubin J, 0’Connell MJ, et al: Aphase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J. Clin. Oncol. 4: 1053-1057, 1986.
 
72) Cullinan S, Moertel CG, Wieand HS, et al: Aphase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65: 2207-2212, 1990.
 
73) Topham C, Glees J, Rawson NSB, et al: Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br. J. Cancer 64: 179-181, 1991.
 
74) Bartolomeo MD, Zampino MG, Leo AD, et al: Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma. Eur. J. Cancer 29 A: 1215-1216, 1993.
 
75) Bukowski RM, Fleming TR, Macdonald JS, et al: Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group Study. Cancer 71: 322-325, 1993.
 
76) Rothman H, Cantrell JE, Lokich J, et al: Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. Cancer 68: 264-268, 1991.
PubMed
77) Rougier P, Zarba JJ, Ducreux M, et al: Phase II study of cisplatin and 120-hour continuous infusion of 5- fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann. Oncol. 4: 333-336, 1993.
PubMed
78) Andre T, Lotz Jp, Bouleuc C, et al: Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann. Oncol. 7: 73-78, 1996.
 
79) Evans TRJ, Lofts FJ, Mansi JL, et al: Aphase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br. J. Cancer 73: 1260-1264, 1996.
 
80) Costanzo FD, Tagliaventi M, Carlini P, et al: High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G O. I. R. C.) . Am. J. Clin. Oncol. 19: 307-310, 1996.
 
81) Ishii H, Okada S, Nose H, et al: Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 12: 267-271, 1996.
PubMed
82) Wong A, Chan A: Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 71: 2200-2203, 1993.
PubMed
83) Taylor OM, Benson EA, McMahon MJ, et al: Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br. J. Surg. 80: 384-386, 1993.
PubMed
84) Friess H, Buchler M, Beglinger C, et al: Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 8: 540-545, 1993.
 
85) Philip PA, Carmichael J, Tonkin K, et al: Hormonal treatment of pancreatic carcinoma: aphase II study of LHRH agonist goserelin plus hydrocortisone. Br. J. Cancer 67: 379-382, 1993.
 
86) Sumi S, Beauchamp RO, Townsend CM, et al: Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103: 982-989, 1992.
 
87) Ura H, Obata T, Nishino N, et al: Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn. J. Cancer Res. 85: 633-638, 1994.
 
88) Nagasu T, Yoshimatsu K, Rowell C, et al: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B 956. Cancer Res. 55: 5310-5314, 1995.
PubMed
89) Aoki K, Yoshida T, Sugimura T, et al: Liposome-mediated in vivo gene transfer of antisense K-ras contruct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. 55: 3810-3816, 1995.
 
P.1168 掲載の参考文献
1) Whipple AO, Parsons WB, Mullins CR: Treatment of carcinoma of the ampulla of Vater. Ann. Surg. 102: 763- 779, 1935.
 
2) Traverso WL, Longmire WP Jr: Preservation of the pylorus in pancreaticoduodenectomy. Surg. Gynecol. Obstet. 146: 959-962, 1978.
 
3) Ozaki H, Kinoshita T, Kosuge T, et al: an aggressive therapeutic approach to carcinoma of the body and tail of the pancreas. Cancer 77: 2240-2245, 1996.
PubMed
4) Appleby LH: The coeliac axis in the expansion of the operation for gastric carcinoma. Cancer 6: 704-707, 1953.
PubMed
5) Mayumi T, Nimura Y, Kamiya J, et al: Distal pancreatectomy with en bloc resection of the celiac artery for carcinoma of the body and tail of the pancreas. Int. J. Pancreatol. 22: 15-21, 1997.
PubMed
6) 日本膵臓学会編: 膵癌取扱い規約. 第4版, 金原出版, 東京, 1993.
 
7) Sobin LH, Wittekind Ch (eds) . UICC: TNM classification of malignant tumours. 5th ed, Wiley-Liss, New York, 1997.
 
8) Fortner JG: Regional resection of cancer of the pancreas: anew surgical approach. Surgery 73: 307-320, 1973.
 
9) Sindelar WF: Clinical experience with regional pancreatectomy of adenocarcinoma of the pancreas. Arch. Surg. 124: 127-132, 1989.
PubMed
10) Gudjonsson B: Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J. Am. Coll. Surg. 181: 483-503, 1995.
PubMed
11) 斎藤洋一: 膵癌全国登録調査報告. 膵臓 11: 479-506, 1996.
 
12) Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120: 899-903, 1985.
PubMed
13) Bakkevold KE, Arnesjo B, Dah10, et al: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-Results of a controlled, prospective, randomised multicentre study. Eur. J. Cancer 29 A: 698-703, 1993.
 
14) Lygidakis NJ, Stringaris K: Adjuvant therapy following pancreatic resection for pancreatic duct carcinoma: aprospective randomized study. Hepatogastroenterology 43: 671-680, 1996.
 
15) Yeung RS, Weese JL, Hoffman Jp, et al: Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. (APhase lI Study. Cancer 72: 2124-2133, 1993.
 
P.1184 掲載の参考文献
1) 厚生省大臣官房統計情報部: 昭和25年-平成7年人口動態統計. 厚生統計協会, 1995.
 
2) 富永佑民, 青木國雄, 花井 彩・他 (編) : 癌統計白書, 篠原出版, 東京, 1993.
 
3) 日本胆道外科研究会, 胆道癌登録事務局 (編) : 全国胆道癌登録調査報告, 1996年度症例, 1997.
 
4) 日本胆道外科研究会 (編) : 胆道癌取扱い規約, 第4版, 金原出版, 東京, 1997.
 
5) 二村雄次, 早川直和, 豊田澄夫・他: 経皮経肝胆道内視鏡. 胃と腸 16: 681-689, 1981.
 
6) 二村雄次, 神谷順一, 早川直和・他: PTCSによる表層拡大型胆管癌の診断. 腹部画像診断 6: 333-345, 1986.
 
7) Nimura Y, Shionoya S, Hayakawa N, et al: Value of percutaneous transhepatic cholangioscopy (PTCS) . Surg. Endosc. 2: 213-219, 1988.
PubMed
8) Nimura Y, Kamiya J: Cholangioscopy. Endoscopy 28: 138-146, 1996.
 
9) 乾 和郎, 中沢三郎, 芳野純治・他: 胆管内超音波検査による胆管癌の深達度診断. 胆と膵 15: 1037-1041, 1994.
 
10) Tamada K, Ido K, Ueno N, et al: Preoperative staging of extrahepatic bile duct cancer with intraductal ultrasonography. Am. J. Gastroenterol. 90: 239-246, 1995.
PubMed
11) Kanai M, Nimura Y, Kamiya J, et al: Preoperative intrahepatic segmental cholangitis in patients with advanced carcinoma involving the hepatic hilus. Surgery 119: 498-504, 1996.
PubMed
12) 坂本英至, 二村雄次, 神谷順一・他: 肝門部胆管癌に対する胆管上流側切除範囲-PTBD造影およびPTCSによる進展範囲診断-. 日消外会誌 30: 2069-2073, 1997.
 
13) Sugiyama M, Hagi H, Atomi Y, et al: Diagnosis of portal venous invasion by pancreatobiliary carcinoma: value of endoscopic ultrasonography. Abdom. Imaging 22: 434-438, 1997.
PubMed
14) 權 雅憲: ヘリカル (スパイラル) CTによる胆道癌の診断の動向-血管, 膵浸潤について-. 胆と膵 18: 729-738, 1997.
 
15) Nimura Y, Hayakawa N, Kamiya J, et al: Hilar cholangioma-Surgical anatomy and curative resection. J. Hep. Bil. Pancr. Surg. 2: 239-248, 1995.
 
16) 崔 仁煥, 有山 襄, 須山正文・他: 胆道癌の早期診断におけるMRCPの有用性. 胆と膵 18: 721-727, 1997.
 
17) Nagino M, Nimura Y, Hayakawa N, et al: Percutaneous transhepatic portal embolization using newly devised catheters: Preliminary report. World J. Surg. 17: 520-524, 1993.
PubMed
18) Nagino M, Nimura Y, Kamiya J, et al: Selective percutaneous transhepatic portal vein embolization in preparation for extensive liver resection: the ipsilateral approach. Radiology 200: 559-563, 1996.
PubMed
19) Bhuiya MMR, Nimura Y, Kamiya J, et al: Clinicopathological studies on perineural invasion of bile duct carcinoma. Ann. Surg. 215: 344-349, 1992.
 
20) Nimura Y, Hayakawa N, Kamiya J, et al: Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J. Surg. 14: 535-544, 1990.
PubMed
21) 上坂克彦, 二村雄次, 早川直和・他: 下部胆管癌に対する幽門輪温存膵頭十二指腸切除術の適応-臨床病理学的検討-. 日消外会誌 26: 1233-1238, 1993.
 
22) 山田康夫, 山内英生, 柿崎健二: 中下部胆管癌の予後因子の検討-特に核DNA量, MIB-1 score, p 53蛋白発現について-. 日消外会誌 30: 2265-2273, 1997.
 
23) Hadjis NS, Blenkharn JI, alexander N, et al: Outcome of radical surgery in hilar cholangiocarcinoma. Surgery 1O7: 597-604, 1990.
 
24) Miyagawa S, Makuuchi M, Kawasaki S: Outcome of extended right hepatectomy after biliary drainage in hilar bile duct cancer. Arch. Surg. 130: 759-763, 1995.
PubMed
25) Klempnauer J, Ridder GJ, Werner M, et al: What constitutes long-term survival after surgery for hilar cholangiocarcinoma?Cancer 79: 26-34, 1997.
PubMed
26) Pichlmayr R, Weimann A, Klempnauer J, et al: Surgical treatment in proximal bile duct cancer. A single-center experience. Ann. Surg. 224: 628-638, 1996.
PubMed
27) Nimura Y, Hayakawa N, Kamiya J, et al: Combined portal vein and liver resection for carcinoma of the biliary tract. Br. J. Surg. 78: 727-731, 1991.
PubMed
28) 梛野正人, 二村雄次, 神谷順一・他: 膵・胆道癌に対する門脈合併切除. 静脈学 4: 63-69, 1993.
 
29) Tashiro S, Uchino R, Hiraoka T, et al: Surgical indication and significance of portal vein resection in biliary and pancreatic cancer. Surgery 109: 481-487, 1991.
PubMed
30) Nimura Y, Hayakawa N, Kamiya J, et al: Hepatopancreatoduodenectomy for advanced carcinoma of the biliary tract. Hepatogastroenterology 38: 170-175, 1991.
PubMed
31) Nimura Y: Hepatopancreatoduodenectomy for biliary cancer. In: Pancreatoduodenectomy (ed by Hanyu F, Takasaki K) , Springer-Verlag, Tokyo, 1997, pp. 177-184.
 
32) Miyagawa S, Makuuchi M, Kawasaki S, et al: Outcome of major hepatectomy with pancreatoduodenectomy for advanced biliary malignancies. World J. Surg. 20: 77-80, 1996.
PubMed
33) Fong Y, Blumgart LH, Lin E, et al: Outcome of treatment for distal bile duct cancer. Br. J. Surg. 83: 1712-1715, 1996.
PubMed
34) Wade TP, Prasad CN, Virgo KS, et al: Experience with distal bile duct cancers in U. S. Veterans Affairs hospitals: 1987-1991. J. Surg. Oncol. 64: 242-245, 1997.
PubMed
35) Nagorney DM, Donohue JH, Farnell MB, et al: Outcomes after curative resections of cholangiocarcinoma. Arch. Surg. 128: 871-879, 1993.
PubMed
36) Pitt HA, Nakeeb A, Abrams RA, et al: Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann. Surg. 22: 788-798, 1995.
 
37) Lee BH, Choe DH, Lee JH, et al: Metalic stents in malignant biliary obstruction. Prospective long-term clinical results. AJR 168: 741-745, 1997.
PubMed
38) Bowling TE, Galbraith SM, Hatfield AR, et al: Aretrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 39: 852-855, 1996.
 
39) 神谷順一, 二村雄次, 早川直和・他: 経皮経肝胆道鏡 (PTCS) によるT-tubeを用いた胆汁内瘻術. 胆道 3: 106-111, 1989.
 
40) 広岡芳樹, 後藤秀実, 伊藤彰浩・他: カラードプラ断層法による胆嚢疾患の診断. 胆と膵 18: 739-745, 1997.
 
41) Ogura Y, Mizumoto R, Isaji S, et al: Radical operations for carcinoma of the gallbladder: present status in Japan. World J. Surg. 15: 337-343, 1991.
PubMed
42) Fujita N, Noda Y, Kobayashi G, et al: Analysis of the layer structure of the gallbladder wall delineated by endoscopic ultrasonography. Dig. Endosc. 7: 353-356, 1995.
 
43) Yamaguchi K, Chijiiwa K, Sakai S, et al: Retrospective analysis of 70 operations for gallbladder carcinoma. Br. J. Surg. 84: 200-204, 1997.
 
44) 浅田康行, 三浦将司, 三井 毅・他: 胆嚢癌の病理学的予後規定因子. とくにss胆嚢癌についての検討. 日臨外医会誌 57: 2390-2396, 1996.
 
45) Lee CS: Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67antigen immunoreactivity in in sitza and invasive carcinomas of the extrahepatic biliary tract. Cancer 78: 1881-1887, 1996.
 
46) 二村雄次, 早川直和, 神谷順一・他: Stage IV胆嚢癌に対する拡大手術の意義. 日外会誌 88: 1343-1346, 1987.
 
47) 吉川達也: 高度進行癌の外科治療. 日消外会誌 30: 1895-1899, 1997.
 
48) Tsukada K, Hatakeyama K, Kurosaki I, et al: Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage. Surgery 120: 816-821, 1996.
 
49) 須山政文, 有山 襄, 佐藤一弘・他: 経皮経肝胆管内瘻術 (PTBE) による悪性胆管狭窄の治療. 胆と膵 18: 515-519, 1997,
 
50) 福田秀一, 奥田康司, 木下壽文・他: 胆道癌に対する5-FU, CDDP少量持続肝動注療法の有用性. 胆道 10: 333-340, 1996.
Medical*Online
51) Tio TL, Sie LH, Kallimanis G, et al: Staging of ampullary and pancreatic carcinoma: comparison between endosonography and surgery. Gastrointest. Endosc. 44: 706-713, 1996.
PubMed
52) Itoh A, Goto H, Naitoh Y, et al: Intraductal ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest. Endosc. 45: 251-260, 1997.
PubMed
53) 安田健治朗, 中島正継, 趙 栄済・他: 十二指腸乳頭部癌の診断, EUSの立場から. 胃と腸 32: 151-156, 1997.
 
54) 宮崎 亮, 池田靖洋, 岩永真一・他: 十二指腸乳頭部癌の外科治療, 幽門輪温存膵頭十二指腸切除術を中心に. 胃と腸 32: 173-179, 1997.
 
55) Talamini MA, Moesinger RC, Pitt HA, et al: Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann. Surg. 225: 590-600, 1997.
PubMed
56) Bottger TC, Boddin J, Heintz A, et al: Clinicopathologic study for the assessment of resection for ampullary carcinoma. World J. Surg. 21: 379-383, 1997.
PubMed
57) Kayahara M, Nagakawa T, Ohta T, et al: Surgical strategy for carcinoma of the papilla of Vater on the basis of lymphatic spread and mode of recurrence. Surgery 121: 611-617, 1997.
PubMed
58) Shirai Y, Ohtani T, Tsukada K, et al: Patterns of lymphatic spread of carcinoma of the ampulla of Vater. Br. J. Surg. 84: 1012-1016, 1997.
PubMed
59) Branum GD, Pappas TN, Meyers WC: The management of tumors of the ampulla of Vater by local resection. Ann. Surg. 224: 621-627, 1996.
PubMed
60) Cahen DL, Fockens P, de Wit LT, et al: Local resection or pancreaticoduodenectomy for villous adenoma of the ampulla of Vater diagnosed before operation. Br. J. Surg. 84: 948-951, 1997.
PubMed
61) 古川 剛, 大橋計彦, 栗本組子・他: 内視鏡的に切除しえた径35mmの十二指腸乳頭部腺腫の1例. Gastroenterol. Endosc. 38: 2201-2206, 1996.
 
62) 真口宏介, 柳川伸幸, 須賀俊博・他: 十二指腸乳頭部の内視鏡的治療の現状, 内視鏡的乳頭部腫瘍切除術を施行した1例. 胃と腸 32: 182-185, 1997.
 
P.1199 掲載の参考文献
1) Linehan WM, Shipley WU, Parkinson DR: Cancer of the kidney and ureter. In DeVita VT, Hellman S, Rosenberg SA (eds) : Cancer-Principles and practice of oncology (4th edition) . Philadelphia, JB Lippincott, 1993, pp. 1023-1051.
 
2) Aso Y, Homma Y: Asurvey on irlcidental renal cell carcinoma in Japan. J. Urol. 147: 340-343, 1992.
 
3) Thompson IM, Peek M: Improvement in survival of patients with renal cell carcinoma-The role of the sedendipitously detected tumor. J. Urol. 140: 487-490, 1988.
PubMed
4) 厚生統計協会: 国民衛生の動向 厚生の指標. 42 (臨時増刊) : 429-430, 1996.
 
5) 富永裕民, 青木国雄, 花井 彩・他: がん統計白書-罹患/死亡/予後-1993. 篠原出版, 東京, 1993.
 
6) McLaughlin JK, Mandel JS, Blot WJ, et al: Apopulation-based case-control study of renal cell carcinoma. JNCI 72: 275-284, 1984.
 
7) Yu MC, Mack TM, Hanish R, et al: Cigarette, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. JNCI 77: 351-356, 1986.
 
8) McLaufhlin JK, Lindblad P, Mellemgaad A: International renalcell carcinoma cancer study. 1. Tabacco use. Int. J. Cancer 60: 194-198, 1995.
 
9) McLaufhlin JK, Chow WH, Mandel JK, et al: International renal-cell carcinoma cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int. J. Cancer 63: 216-221, 1995.
 
10) Lindblad P, Mellengaard A, Schlehofer B, et al: International renal-cel1 carcinoma cancer study. V. Reproductive factors, gynecologic operations and exgenous hormones. Int. J. Cancer 61: 192-198, 1995.
 
11) Mellengaard A, Lindbald P, Schlehofer B, et al: International renal-cell carcinoma cancer study. III. Role of weight, height, physical activity, and use of amphetamines. Int. J. Cancer 60: 350-354, 1995.
 
12) Wolk A, Gridley G, Niwa S, et al: International renal-cell carcinoma cancer study. VII. Role of diet. Int. J. Cancer 65: 67-73, 1996.
PubMed
13) Mandel JS, McLaughlin JK, Schlehofer B, et al: International renal-cell carcinoma cancer study. IV. Occupation. Int. J. Cancer 61: 601-605, 1995.
PubMed
14) Washecka R, Hanna M: Malignant renal tumors in tuberous sclerosis. Urology 37: 340-343, 1991.
PubMed
15) Ichikawa I: Uremic acquired renal cyst disease: natural history and complications. Nephron 58: 257-267, 1991.
 
16) Yao M, Shuin T: Familial renal cell carcinoma: review of recent molecular genetics. Int. J. Urol. 2: 61-70, 1995.
PubMed
17) 八尾正裕, 執印太郎: 家族性腎癌. 癌の臨床 42: 1215-1223, 1996.
 
18) Glenn GM, Choyke PL, Zbar B, et al: von Hippel-Lindau disease: clinical review and molecular genetics. Probl. Urol. 4: 312-330, 1990.
 
19) Maher EM, Yates JRW, Harriews R, et al: Clinical features and natural history of von Hippel-Lindau disease. Q. J. Med. 77: 1151-1163, 1990.
 
20) Yao M, Latif F, Orcutt ML, et al: von Hippel-Lindau disease: Identification of deletion mutation by pulsedfield gel electrophoresis. Hum. Genet. 92: 605-614, 1993.
PubMed
21) Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320, 1993.
PubMed
22) Shuin T, Kondo K, Torigoe S, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau disease tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54: 2852-2855, 1994.
 
23) Teh BT, Giraud S, Sari NF, et al: Familial non-VHL non-papillary clear cell renal cancer. Lancet 349: 848-849, 1997.
PubMed
24) Lipponen P, Eskelinen M, Syrjanen K: Expression of tumour-suppressor gene RB, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br. J. Cancer 71: 863-867, 1995.
 
25) Nanus DM, Mentle IR, Motzer RJ, et al: Infrequent ras oncogene point mutations in renal cell carcinoma. J. Urol. 143: 175-178, 1990.
PubMed
26) Brooks JD, Bova S, Mershall FF, et al: Tumor supPressor gene allelic loss in human renal cancers. J. Urol. 150: 1278-1283, 1993.
 
27) Uchida T, Wada C, Shitara T, et al: Infrequent involvement of p 53 mutations and loss of heterozygosity of 17 pin the tumorigenesis of renal cell cancer. J. Urol. 150: 1298-1301, 1993.
 
28) Uhlman DL, Nguyen PL, Manivel C, et al: Association of immunohistochemical staining for p 53 with metastatic progression and poor survival in patient with renal cell carcinoma. JNCI 86: 1470-1475, 1994.
 
29) Oda H, Nakatsuru Y, Ishikawa T: Mutation of the p 53 gene and p 53 protein overexpression are associated with sarcomatoid transformation in renal cell cancer. Cancer Res. 55: 658-662, 1995.
 
30) Sporn MB, Todaro GJ: Autosecretion and malignant transformation of cell. N. Engl. J. Med. 303: 878-885, 1980.
 
31) Atlas I, Mendelsohn J, Baselga J, et al: Growth regulation of human renal carcinoma cells: role of transforming growth factora. Cancer Res. 52: 3335-3339, 1992.
 
32) Miki S, Iwano M, Miki Y, et al: Interleukin 6 (IL-6) functions as an in vitro autcrine growth factor in renal cell carcinomas. FEBS Lett. 250: 607-610, 1988.
 
33) Blay JY, Negrier S, Combaret V, et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52: 3317-3322, 1992.
PubMed
34) Stadler WM, Richard JM, Vogelzang NJ, et al: Serum interleukin-61evels in metastatic renal cancer: Correlation with survival but not an independent prognostic indicator. JNCI 84: 1835-1836, 1992.
 
35) Dosquet C, Schaetz A, Fraucher C, et al: Tumour necrosis factor-a, interleukin-1 and interleukin-6 in patients with renal cell carcinoma. Eur. J. Cancer 30 A: 162-167, 1994.
 
36) Fujimoto K, Ichimori Y, Kakizoe T, et al: Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem. Biophys. Res. Commun. 180: 386-392, 1991.
PubMed
37) Takahashi A, Sasaki H, Kim SJ, et al: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 54: 4223-4237, 1994.
 
38) Iliopoulos O, Levy AP, Jiang C, et al: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93: 10595-10599, 1996.
 
39) Gnarra JR, Zhou S, Merrill MJ, et al: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA 93: 10589-10594, 1996.
PubMed
40) 日本泌尿器科学会他編: 腎癌取扱い規約 (第2版) , 金原出版, 東京, 1992.
 
41) Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N. Engl. J. Med. 335: 865-875, 1996.
PubMed
42) Thoenes W, Storkel St, Rumpelt HJ: Histopathology and classification of renal cell tumours (Adenomas, Oncocytomas and Carcinomas) . Pathol. Res. Pract. 181: 125-143, 1986.
 
43) Thoenes W, Storkel St, Rumpelt HJ, et al: Cytomorphological typing of renal cell carcinoma-A new apProach. Eur. (UroL 18 (suppl. 2) : 6-9, 1990.
 
44) Boxer RJ, Waismann J, Lieber MM, et al: Non-metastatic hepatic dysfunction associated with renal carcinoma. J. Urol. 119: 468-471, 1978.
 
45) 三原修一: 超音波検診における腎細胞癌の早期発見. 日本内科超音波学会誌 20: 24-32, 1993.
 
46) Kallman DA, King BF, Hattery RR, et al : Renal vein and inferior vena cava tumor thrombus in renal celI carcinoma: CT, US, MRI and venacavography. J. Comput. Assist. Tomogr. 16: 240-247, 1992.
 
47) Studer UE, Scherz S, Scheidegger J, et al: Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J. Urol. 144: 243-245, 1990.
 
48) Sekido N, Kawai K, Satoh M, et al: Acase of angiomyolipoma diagnosed by thin-slice non-enhanced CT and needle biopsy. Int. J. Urol. 3: 77-79, 1996.
 
49) Bosniak MA: The current radiological approach to renal cysts. Radiology 158: 1-10, 1986.
PubMed
50) Lieber MM: Renal oncocytoma: prognosis and treatment. Eur. Urol. 18 (suppl. 2) : 7-21, 1990.
 
51) 伊野宮秀志, 井坂茂夫, 岡野達弥・他: 転移のない腎細胞癌の予後因子解析. 日泌尿会誌 87: 1099-1104, 1996.
 
52) Targonski PV, Frank W, Stuhldreher D, et al: Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases stage 1 and stage 2 patients. J. Urol. 152: 1389-1392, 1994.
PubMed
53) 里見佳昭: 腎癌の予後に関する臨床的研究-特に生体側の因子を中心に-. 日泌尿会誌 64: 195-216, 1973.
 
54) 里見佳昭: 腎癌の治療の現況と今後の課題. 日泌尿会誌 81: 1-13, 1990.
 
55) 大西哲朗, 大石幸彦, 増田富士男・他: 腎摘施行Stage4 B腎細胞癌の予後を左右する因子. 日泌尿会誌 85: 1664- 1672, 1994.
 
56) Maldazys JD, DeKernion JB: Prognostic factors in metastatic renal carcinoma. J. Uro1. 136: 376-379, 1986.
 
57) 塚本泰司: 腎細胞癌の浸潤転移と血管新生. 日泌尿会誌 87: 1-12, 1996.
 
58) Saitoh H: Distant metastasis of renal adenocarcinoma. Cancer 48: 1487-1491, 1981.
PubMed
59) Saitoh H, Nakayama M, Nakamura K, et al: Distant metastasis of renal adenocarcinoma in nephrectomized cases. J. Urol. 127: 1092-1095, 1982.
 
60) Johnsen JA, Hellsten S: Lymphatogenous spread of renal cell carcinoma: An autopsy study. J. Urol. 157: 450-453, 1997.
PubMed
61) Shimazui T, Oosterwijk E, Debruyne MJ, et al: Molecular prognostic factor in renal cell carcinoma. Semin. Urol. (Oncol. 14: 250-255, 1996.
 
62) Shimazui T, Tomobe M, Hattori K, et al: A prognostic significance of nucleolar organizer region (AgNOR) in renal cell carcinoma. J. Urol. 154: 1522-1526, 1995.
PubMed
63) Herrlinger A, Schrott KM, Schott G, et al: What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma?J. Urol. 146: 1224-1227, 1991.
PubMed
64) Shalev M, Cipolla B, Guille F, et al: Is ipsilateral adrenalectomy a necessary component of radical nephrectomy ? J. Urol. 153: 1415-1417, 1995.
PubMed
65) Licht MR, Novick AC: Nephron sparing surgery for renal cell carcinoma. J. Urol. 149: 1-7, 1993.
PubMed
66) Poston CD, Jaffe GS, Lubensky IA, et al: Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J. Urol. 153: 22-26, 1995.
PubMed
67) Novick AC, Streem S, Montie JE, et al: Conservative surgery for renal cell carcinoma: asingle-center experience with 100 patients. J. Urol. 141: 835-839, 1989.
 
68) Morgan WR, Zincke H: Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J. Urol. 144: 852-858, 1990.
PubMed
69) Steinbach F, Stockle M, Muller SC, et al: Conservative surgery of renal cell tumors in 140 patients: 21 years of experience. J. Urol. 148: 24-30, 1992.
PubMed
70) Moll V, Becht E, Ziegler M: Kidney preserving surgery in renal cell tumors: indications, techniques and results in 152 patients. J. Urol. 150: 319-323, 1993.
PubMed
71) Nissenkorn I, Bernheim J: Multicentricity in renal cell carcinoma. J. Urol. 153: 620-622, 1995.
PubMed
72) Oya M, Nakamura K, Baba S, et al: Intrarenal satellites of renal cell carcinoma: histopathologic manifestation and clinical implication. Urology 46: 161-164, 1995.
PubMed
73) Whang M, 0’toole K, Bixon R, et al: The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J. Urol. 154: 968-971, 1995.
 
74) Campbell SC, Novick AC, Streem SB, et al: Complication of nephron sparing surgery for ranal tumor. J. Urol. 151: 1177-1180, 1994.
 
75) Skinner DG, Pritchett TR, Lieskovsky G, et al: Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann. Surg. 210: 387-394, 1989.
PubMed
76) Libertino JA, Zinman L, Watkins E Jr: Long-term results of resection of renal cell cancer with extension into inferior vena cava. J. Urol. 137: 21-24, 1987.
PubMed
77) Hatcher PA, Anderson EE, Paulson DF, et al: Surgical management and prognosis of renal cell carcinoma invading the vena cava. J. Urol. 145: 20-24, 1991.
PubMed
78) Glazer AA, Novick AC: Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J. Urol. 155: 448-450, 1996.
PubMed
79) Gohji K, Yamashita C, Ueno K, et al: Preoperative computerized tomography detection of extensive invation of the inferior vena cava by renal cell carcinoma: possible indication for resection with partial cardiopulmonary bypass and patch grafting. J. Urol. 152: 1993-1997, 1994.
 
80) 大園誠一郎, 岡島英五郎, 平尾佳彦: 進行癌に対する拡大手術. 癌の臨床 42: 1241-1263, 1996.
 
81) Bennett RT, Lerner SE, Taub HC, et al: Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol. 154: 32-34, 1995.
PubMed
82) Pogrebniak HW, Haas G, Linehan WM, et al: Renal cell carcinoma: resection of solitary and multiple metastases. Ann. Thorac. Surg. 54: 33-38, 1992.
PubMed
83) Kim B, Louie A: Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch. Surg. 127: 1343-1349, 1992.
PubMed
84) Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for renal-cell carcinoma: 1983-1993. Semin. Oncol. 22: 42-60, 1995.
PubMed
85) Stahl M, Wilke HJ, Seeber S, et al: Cytokines and cytotoxic agents in renal cell carcinoma: Areview. Semin. Oncol. 19 (Suppl. 4) : 70-79, 1992.
 
86) 里美佳昭, 福田百邦: 腎癌治療の最前線-免疫療法. 癌の臨床 42: 1251-1264, 1996.
 
87) Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. North Am. 20: 283-295, 1993.
PubMed
88) 丸茂 健, 早川正道, 村井 勝: 進行腎細胞癌に対するヒト型インターフェロンの抗腫瘍効果とその免疫学的検討. 日泌尿会誌 76: 965-973, 1985.
 
89) 大西哲朗, 大石幸彦, 飯塚典男: 進行性腎細胞癌の生存率に関するインターフェロン療法の効果に関する検討. 日泌尿会誌 88: 463-472, 1997.
 
90) Gutterman JU: Cytokine therapeutics: Lessons from interferon-a. Proc. Natl. Acad. Sci. USA 491: 1198-1205, 1994.
 
91) Nicolson NL, Talpaz M, Nicolson GL: Interferon-adirectly inhibits DNA polymerase activity in isolated chromatin nucleoprotein complexes: Correlation with IFN-atreatment outcome in patients with chronic myelogenous leukemia. Gene 159: 105-111, 1995.
 
92) Fyfe G, Fischer RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13: 688-696, 1995.
 
93) Stadler WM, Vogelzang NJ: Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin. Oncol. 22: 67-73, 1995.
PubMed
94) Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancy: areview. Cancer Res. 50: 3473-3486, 1990.
 
95) Rosenberg SA, Lotze MT, Muul Lm, et al: Aprogress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-20r high-dose interleukin-2 alone. N Engl. J. Med. 316: 889-897, 1987.
 
96) Pierce WC, Belldegrun A, Figlin RA: Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin. Oncol. 22: 74-80, 1995.
PubMed
97) Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. JNCI 85: 622-632, 1993.
PubMed
98) Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57: 1537-1546, 1997.
PubMed
99) Gaugler B, Brouwenstijn N, Vantomme V, et al: Anew gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 44: 323-330, 1996.
 
100) Liu SQ, Shiraiwa H, Kawai K, et al: Tumor-specific autologous cytotoxic T lymphocytes from tissue section. Nat. Med. 2: 1283, 1996.
PubMed
101) 沖 明典, 大野忠夫: 癌治療における細胞療法の現状と今後の展望: 養子免疫療法を中心として. バイオサイエンスとインダストリー 55: 16-20, 1997.
 
102) Motzer RJ, Schwartz L, Law TM, et al: Interferon alfa-2 a and 13Cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J. Clin. Oncol. 13: 1950-1957, 1995.
 
103) Motzer RJ, Lyn P, Fischer P, et al: Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J. Clin. Oncol. 13: 1958-1965, 1995.
PubMed
104) Takahashi Y: Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. JNCI 87: 1262, 1995.
PubMed
P.1220 掲載の参考文献
1) 垣添忠生: がんの統計. 財団法人がん研究振興財団, 東京, 1997.
 
2) Wynder EC, Fujita Y, Harris RE, et al: Comparative epidermiology of cancer between the United States and Japan. Cancer 67: 746-763, 1991.
 
3) Berenblum I: The cocarcinogenic action of craton resin. Cancer Res. 1: 44-48, 1941.
 
4) Cohen SM, Arai M, Jacobs JB, et al: Promoting effect of saccharin and DL-triptophan in urinary bladder carcinogenesis. Cancer Res. 39: 1207-1217, 1979.
 
5) Tsuji I: Environmental and industrial cancer of the bladder in Japan. Acta Un Int Cancer. 18: 662-666, 1962.
 
6) 松島正浩, 村上憲彦, 深沢 潔・他: 職業性膀胱癌-スクリーニング開始後15年間における臨床成績とその意義-. 日泌尿会誌 74: 81-99, 1983.
 
7) Doll R: Strategy for detection of cancer hazards to man. Nature 265: 589-596, 1977.
 
8) 日本泌尿器科学会, 日本病理学会(編) : 膀胱癌取扱い規約. 金原出版, 東京, 1993.
 
9) UICC: TNM classification of malignant tumours. 4th Ed, 2nd revision (eds. by Hermanek P and Sobin LH) , Springer, Berlin, Heidelberg, New York, 1992.
 
10) Kim B, Semelka RC, Ascher SM, et al: Bladder tumor staging: Comparison of contrast-enhanced CT, T 1- and T2-weighted MR Imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology l93: 239-245, 1994.
 
11) UICC: TNM classification of malignant tumours. (eds. by Sobin LH and Wittekind Ch, Wiley-Liss) , 5th Ed, New York, Chichester, Weiheim, Brisbane, Singapore, Toronto, 1997.
 
12) Koss LG, Tiamson EM, Robbins MA: Mapping cancerous and precancerous bladder changes. JAMA 227: 281-286, 1974.
PubMed
13) Farrow GM, Barlebo H, Enjoji M: Transitional cell carcinoma in situ. Progree in clinical and biological research. In: Developments in Bladder Cancer (eds. by Louis D, Niijima T, Prout G) , Alan R. Liss, New York, 1986, pp. 85-96.
 
14) Sarosdy MF, de Vere White RW, Soloway MS, et al: Results of a multicenter trial using the BTA test to monitor for and diagnose reccurent bladder cancer. J. Urol. 154: 379-384, 1995.
 
15) Kinoshita H, Ogawa O, Kakehi Y, et al: Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J. Natl. Cancer Inst. 89: 724-730, 1997.
PubMed
16) Miyanaga N, Akaza H, Ishikawa S, et al: Clinical evaluation of Nuclear Matrix Protein 22 (NMP 22) in urine as a novel marker for urothelial cancer. Eur. Urol. 31: 163-168, 1997.
 
17) Miyanaga N, Akaza H, Kameyama S, et al: Significance of the BTA test in bladder cancer: Amulticenter trial. Int. J. Urol. (in press)
 
18) 島居 徹, 笠谷俊也, 今田世紀: 人間ドックの経腹的超音波検査で発見された膀胱腫瘍. 日泌尿会誌 83: 1847-1851, 1992.
 
19) Nakamura S, Niijima T: Staging of bladder cancer by ultrasonography: A new technique by transurethral intravesical scanning. J. Urol. 124: 341-344, 1980.
PubMed
20) 服部一紀, 樋之津史郎, 島居 徹・他: 内視鏡用細径プローブを用いた膀胱腫瘍の経尿道的超音波診断. 超音波医学 20: 543-547, 1993.
Medical*Online
21) Hoshi S: Evaluation of neoadjuvant therapy in locally invasive bladder cancer: Core biopsy of bladder tumors and aspiration biopsy of regional nodes. In: Evaluation of chemotherapy in bladder cancer (eds. by Villavicencio H, Fair WR) , Churchill Livingstone, Edinburgh, 1992, p. 61.
 
22) Narumi Y, Kadota T, Inoue E, et al: Bladder tumors: staging with gadolinium-enhaced oblique MR imaging. Radiology l87: 145-150, 1993.
 
23) Hopman AH, Moesker O, Smeets AW, et al: Numerical chromosome 1, 7, 9 and 11 aberrations in bladder cancer detected by in situ hybridizarion. Cancer Res. 51: 644-651, 1991.
PubMed
24) Sidransky D, von Eschenbach A, Tasi YC, et al: Identification of p 53 gene mutations in bladder cancers and urine samples. Science 252: 706-709, 1991.
 
25) Cairns P, Shaw ME, Knowles MA: Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome. Oncogene 8: 1083-1085, 1993.
PubMed
26) Spruck CH III, Ohneseit PF, Conzalez-Zuluetta M, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54: 784-788, 1994.
 
27) Uchida T, Wada C, Ishida H, et al: p53 mutations and prognosis in bladder tumor. J. Urol. 153: 1097-1194, 1995.
PubMed
28) Bringuier PP, Umbas R, Schaafama HE, et al: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 53: 3241-3245, 1993.
 
29) Shimazui T, Schalken JA, Giroldi LA, et al: Prognostic value of cadherin-associated molecules (α-, β-, andγ-catenins and p 120 cas) in bladder tumors. Cancer Res. 56: 4154-4158, 1996.
 
30) Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67, 1990.
 
31) Liotta LA: Tumor invasion and metastasis-Role of the extracellular matrix: Rhoads memorial award lecture. Cancer Res. 46: 1-7, 1986.
 
32) Vet JAM, Witjes JA, Salvatore AE, et al: Predictive value of p 53 mutations analyzed in bladder washings for progression of high risk superficial bladder cancer. Clin. Cancer Res. (in press)
 
33) 香川 征: 泌尿器科腫瘍学における分子生物学. 日泌尿会誌 86: 963-978, 1995.
 
34) 赤座英之: 膀胱腫瘍. 日医誌 111: 365-367, 1994.
 
35) Akaza H, Koiso K, Kotake T, et al: Long-term results of intravesical chemotherapylaxis of superficial bladder cancer: experience of the Japanease Urological Cancer Research Group for Adriamycin. Cancer Chemother. Pharmacol. 30 (Suppl.) : S15-S 20, 1992.
 
36) Maffezzini M, Aimonato A, Zanon M, et al: Up-front intravesical chemotherapy for low stage, low grade reccurent bladder cancer. J. Urol. 155: 91-93, 1996.
 
37) Bono Av, Hall Pr, Denis L, et al: Chemoresection in Ta-T 1 bladder cancer. Eur. Urol. 29: 385-390, 1996.
 
38) Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J, Urol. 116: 180-183, 1976.
PubMed
39) Akaza H, Hinotsu S, Aso Y, et al: Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 75: 552-559, 1995.
PubMed
40) Lamm DL, Blumenstein BA, Crawford ED, et al: A randomized trial of intravesical doxorubicin and immuno therapy with bacille Calmette-Guerin for transitional cell carcinoma of the bladder. N. Engl. J. Med. 325: 1205-1209, 1991.
 
41) Lamm DL, Van der Meijden APM, Moreles A, et al: Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol. 147: 596-600, 1992.
 
42) Birch BRP, Hartland SJ: Review, The pT 1, G 3 bladder tumour. Br. J. Urol. 64: 109, 1989.
 
43) Martinez-Pineiro JA, Martinez-Pineiro L: BCG update: Intravesical therapy. Eur. Urol. 31: 31-41, 1997.
PubMed
44) Gruenwald IE, Stein A, TRashcovitsky R, et al: A 12 versus 6-week course of bacillus calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer. J. Urol. 157: 487-491, 1997.
 
45) Tobisu K, Tanaka Y, Mizutani T, et al: Transitional cell carcinoma of the urethral in men following custectomy for bladder cancer: Multivariate analysis for risk factors. J. Urol. 146: 1551-1554, 1991.
PubMed
46) Skinner DG: Management of invasive bladder cancer: Ameticulous pelvic lymph node dissection can make a difference. J. Urol. 128: 34-36, 1982.
PubMed
47) Kock NG, Nilson AE, Nilson LO, et al: Urinary diversion via a continent ileal reservoir: Clinical results in 12 patients. J. Urol. 128: 469-475, 1982.
 
48) Rowland RG, Mitchell ME, Bihrle R: The cecoileal continent urinary reservoir. World J. Urol. 3: 185-190, 1985.
 
49) Thuroff JW, Alken P, Riedmiller H, et al: The Mainz pouch(mixed augmentation ileum and cecum) for bladder augmentation and continent diversion. J. Urol. 136: 17-26, 1986.
PubMed
50) 鳶巣賢一: 自然排尿型尿路変向術. アトラス尿路変向術(垣添忠生, 岡田裕作編) , 南江堂, 東京, 1993, p. 109.
 
51) Studer U, Ackermann D, Casanova GA, et al: Anewer form of bladder substitute based on historical perspectives. Semin. Urol. 6: 57-65, 1988.
PubMed
52) Hautmann RE, Egghart G, Frohneberg D, et al: The ideal neobladder. J. Urol. 139: 39-42, 1988.
 
53) Thrasler JB, Crawford ED: Current management of invasive and metastatic transitional cell carcinoma of the bladder. J. Urol. 149: 957-972, 1993.
 
54) Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC(methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium, J. Urol. 1331403-407, 1985.
 
55) Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of responce and relapse. Cancer 64: 2448-2458, 1989.
 
56) Logothetis CJ, Dexeus FH, Chong C, et al: Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the MD. Anderson esxperience. J Urol. 141: 33-37, 1989.
 
57) Logothetis CJ, Dexeus FM, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastasic urothelial tumors. J. Clin. Oncol. 8: 1050, 1990.
 
58) Kuroda M, Meguro N, Maeda O, et al: Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer. Cancer Chemother. Pharmacol. 35(suppl.) : s9-13, 1994.
 
59) Miyanaga N, Akaza H, Shimazui T, et al: The effect of dose intensity on M-VAC therapy for advanced urothelial cancer. Cancer Chemother. Pharmacol. 35(suppl.) : s5-8, 1994.
 
60) Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on netropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N. Engl. J. Med. 318: 1414-1422, 1988.
 
61) Sternberg CN, Raghaven D, Ochi Y, et al: Neoadjuvant and adjuvant chemotherapy in advanced disease-what are the effects on survival and prognosis？Int. J. Urol. 2(suppl. 2) : 76-88, 1995.
 
62) Scher HI, Yagoda A, Herr HW, et al: Neoadjuvant M-VAC(methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J. Urol. 139: 470-474, 1988.
PubMed
63) Logothetis CJ, Johnson DE, Chong C, et al: Adjuvant chemotherapy of bladder cancer: A preliminary report. J. Urol. 134: 1207-1211, 1988.
 
64) Stockel M, Meyenburg W, Wellek S, et al: Advanced bladder cancer(stage pT 3 b, pT 4 a, pN, and pN 2) : Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 148: 302-307, 1992.
 
65) Smith Jr JA, Crawford EP, Paradelo JC: Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: Aphase III intergroup study. J. Urol. 157: 805-808, 1997
 
66) Shipley WU, Prout GR Jr, Einstein AB, et al: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931-935, 1987.
PubMed
67) Kaufman DS, Shipley WU, Griffin PP, et al: Selective bladder preservation by combination treatment of invasive bladder cancer. N. Engl. J. Med. 329: 1377-1382, 1993.
PubMed
68) 宮永直人, 大谷幹伸, 赤座英之・他: 浸潤性膀胱癌に対する下腎動注と放射線照射の併用. 日泌尿会誌 82: 1583- 1587, 1991.
 
69) 宮永直人, 赤座英之: 局所浸潤癌における膀胱温存をめざした集学的治療. 癌の臨床 42: 1309-1314, 1996.
Medical*Online
70) Pocock RJ, Ponder BAJ, 0’Sullivan Jp, et al: Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. Br. J. Urol. 54: 711-715, 1982.
 
71) Holmang S, Hedelin H, Anderstrom C, et al: The importance of depth of invasion in stage T 1 bladder carcinoma: a prospective cohort study. J. Urol. 157: 800-804, 1997.
 
72) Williams CB, Mitchell JP: Carcinoma of the uretera review of 54 cases-. Br. J. Urol. 45: 377-387, 1973.
PubMed
73) Steffens J, Nagel R: Tumours of the renal pelvis and ureter: Observation in 170 patients. Br. J. Urol. 61: 277-283, 1989.
 
74) 日本泌尿器科学会, 日本病理学会(編) : 腎孟・尿管癌取扱い規約. 金原出版, 東京, 1990.
 
75) Bagley, DH: Endoureteral diagnosis and treatment. Jpn. J. Endourol. ESWL 9: 20-25, 1996.
 
76) Weeks SM, Brown ED, Brown JJ, et al: Transitional cell carcinoma of the upPer urinary tract: staging by MRI. Abdom. Imaging 20: 365-567, 1995.
PubMed
77) Harada M: Ureteroscopic treatment of transitional cell carcinoma and fibroepithelial polyp of the upper urinary tract. JPn. J. Endourol. ESWL 9: 43-46, 1996.
 
78) Schmeller, NT, Hofstetter AG: Laser treatment of ureteral tumors. J. Urol. 141: 840-843, 1989.
PubMed
79) Plancke HRF, Strijbos WEM, Delaere KPJ: Percutaneous endoscopic treatment of urothelial tumours of the renal pelvis. Br. J. Urol. 75: 736-739, 1995.
 
80) Akaza H, Koiso K, Niijima T: Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on anew classificaiton system. Cancer 59: 1369-1375, 1987.
 
81) Ray B, Grabstald H: Experience with primary carcinoma of the male urethra. J. Urol 117: 591-594, 1977.
 
82) Zeidman EJ, Desmond P, Thompson I: Surgical treatment of carcinoma of the male urethra. Urol. Clin. North Am. 19: 359-372, 1992.
 
83) Narayan P, Konety B: Surgical treatment of female urethral carcinoma. Urol. Clin. North Am. 19: 373-382, 1992.
 
84) Grigsby PW, Corn BW: Localized urethral tumors in women: Indications for conservative versus exenterative therapoes. J. Urol. 147: 1516-1520, 1992.
PubMed
P.1244 掲載の参考文献
1) 厚生省大臣官房統計情報部編: 表5. 24悪性新生物の主要部位別にみた性・年次別死亡数及び率(pp. 276-277) , 第1表-1死亡数, 性・年齢(5歳階級) ・死因(三桁基本分類) 別(p. 100) . 平成6年人口動態統計上巻, (財) 厚生統計協会, 1996.
 
2) 日本病理学会編: 日本病理剖検輯報. 19-34輯, 日本病理剖検輯報刊行会, 1976-1992.
 
3) 富永祐民, 青木國雄, 花井 彩・他: がん・統計白書-罹患/死亡/予後-1993. 篠原出版, 東京, 1993.
 
4) Shiraishi T, Watanabe M, Matsuura H, et al: The Frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo 8: 445-447, 1994.
PubMed
5) Anderson GA, Lawson RK, Gottlieb MS: Quantitation on potentially undiagnosed incidental carcinoma of the prostate in patients treated non-surgically for benign prostatic hyperplasia. Br. J. Urol. 72: 465-469, 1993.
PubMed
6) 藤田知洋, 蟹本雄右, 秋野裕信・他: 前立腺偶発癌に関する研究. 泌尿器科紀要 37: 695-703, 1991.
 
7) Van Andel G, Vleeming R, Kurth K, et al: Incidental carcinoma of the prostate. Semin. Surg. Oncol. 11: 36-45, 1995.
PubMed
8) Kabalin JN, McNeal JE, Price HM, et al: Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J. Urol. 141: 1091- 1094, 1989.
 
9) Breslow N, Chan CW, Dhom G, et al: Latent carcinoma of prostate at autopsy in seven areas. lnt. J. Cancer 20: 680-688, 1977.
 
10) Yatani R, Chigusa I, Akazaki K, et al: Geographic pathology of latent prostatic carcinoma. Int. J. Cancer 29: 611-616, 1982.
PubMed
11) 原田昌興, 根本良介, 内田克紀・他: 日米前立腺癌の病理組織学的比較. 日泌尿会誌 84: 1110-1118, 1993.
 
12) Parkin DM, Muir CS, Whelan SL, et al: Cancer Incidence in Five Countries, Vol. VI, No. 120, IARC Scientific Publications, Lyon, 1992.
 
13) Shimizu H, Ross RK, Bernstein L, et al: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 63: 963-966, 1991.
PubMed
14) Pour PM, Groot K, Kazakoff K, et al: Effects of high-fat diet on the patterns of prostatic cancer induced in rats by N-nitrosobis(2-oxopropyl) amine and testosterone. Cancer Res. 51: 4757-4761, 1991.
 
15) Wang Y, Corr JG, Thaler HT, et al: Decreased growth of established human prostate LNCaP tumors in nude mice fed a low fat diet. J. Natl. Cancer Inst. 87: 1456-1462, 1995.
PubMed
16) Andersson SO, Baron J, Wolk A, et al: Early life risk factors for prostate cancer: apopulation-based case control study in Sweden. Cancer Epidemiol. Biomarkers Prev. 4: 187-192, 1995.
 
17) Whittemore AS, Kolonel LN, Wu AH, et al: Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J. Natl. Cancer Inst. 87: 652-661, 1995.
 
18) Pollard M, Luckert PH: Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats. Prostate 6: 1-5, 1985.
PubMed
19) 吉田 修, 大石賢二, 岡田謙一郎・他: 日本人: 前立腺癌の疫学的研究. 前立腺癌の基礎と臨床(前立腺研究財団編) . 金原出版, 東京, 1988, pp. 61-77.
 
20) Waalkes MP, Rehm S: Cadmium and prostate cancer. J. Toxicol. Environ. Health 43: 251-269, 1994.
PubMed
21) Gronberg H, Damber L, Damber JE: Studies of genetic factors in prostate cancer in a twin population. J Urol. 152: 1484-1489, 1994.
 
22) Ghadirian P, Cadotte M, Lacroix A, et al: Family aggregation of cancer of the prostate in Quebec: the tip of the iceberg. Prostate 19: 43-52, 1991.
 
23) Spitz MR, Currier RD, Fueger JJ, et al: Familial patterns of prostate cancer: acase-control analysis. J. Urol. 146: 1305-1307, 1991.
 
24) Meikle AW, Smith JA, West DW: Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate 6: 121-128, 1985.
PubMed
25) Yatani R, Shiraishi T, Nakakuki K, et al: Trends in frequency of latent prostate carcinoma in Japan from 1965 1979to 1982-1986. J. Natl Cancer Inst. 80: 683-687, 1988.
 
26) Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993.
PubMed
27) Potosky AL, Miller BA, Ablertsen PC, et al: The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552, 1995.
PubMed
28) 日本泌尿器科学会・日本病理学会編: 前立腺癌取扱い規約(第2版) . 金原出版, 東京, 1992.
 
29) Gleason DF, VACURG: Histologic grading and clinical staging of prostatic carcinoma. In Urologic Pathology: The prostate(ed by Tannenbaum M) , Lea and Febiger, Philadelphia, 1977, pp. 171-198.
 
30) Gleason DF: Histologic granding of prostate cancer: a perspective. Hum. Pathol. 23: 273-297, 1992.
 
31) McNeal JE, Bostwick DG: Intraductal dysplasia: a premalignant lesion of the prostate. Hum. Pathol. 17: 64-71, 1986.
PubMed
32) Brawer MK: Prostatic intraepithelial neoplasia: a premalignant lesion. Hum. Pathol. 23: 242-248, 1992.
PubMed
33) Keetch DW, Humphrey P, Stahl D, et al: Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J. Urol. 154: 347-351, 1995.
 
34) Davidson D, Bostwick DG, Qian J, et al: Prostatic Intraepithelial Neoplasma: Predictive accuracy in needle biopsy. J. Urol. 154: 1295-1299, 1995.
 
35) Bostwick DG, Qian J: Atypical adenomatous hyperplasia of the prostate. Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am. J. Surg. Pathol. 19: 506-518, 1995.
 
36) di Sant’Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer (supPl.) 70: 254-268, 1992.
 
37) Gkonos PJ, Krongrad A, Roos BA: Neuroendocrine peptides in the prostate. Urol. Res. 23: 81-87, 1995.
PubMed
38) TNM Classification of Malignant Tumours. 5th. ed, edited by Sobin LH and Wittekind Ch, 1997.
 
39) Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable(stage Tlc) prostate cancer. JAMA 271: 368-374, 1994.
 
40) Brendler CB: Characteristics of prostate cancer found with early detection regimens. Urology 46(Suppl. A) : 71-76, 1995.
 
41) Ohori M, Wheeler TM, Dunn JK, et al: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol. 152: 1714-1720, 1994.
PubMed
42) Cooper EH: Tumour markers in prostatic cancer. Scand. J. Clin. Lab. Invest. 206(suppl) : 42-51, 1991.
 
43) Bogdanowicz JF, Bentvelsen FM, Oosterom R, et al: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. Scand. J. Urol Nephrol. 138 (Suppl.) : 97-103, 1991.
 
44) Wirth MP, FrohmUIIer HG: Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases. Eur. Urol. 22: 27-32, 1992.
 
45) Lowe FC, Trauzzi SJ: Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol. Clin. North Am. 20: 46) 589-595, 1993.
 
46) Lee F, Gray JM, McLeary RD, et al: Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. Prostate 7: 117-129, 1985.
PubMed
47) Hodge KK, McNeal JE, Terris MK, et al: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol. 142: 71-74, 1989.
PubMed
48) Coplen DE, Andriole GL, Yuan JJ, et al: The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia. J. Urol. 146: 75-77, 1991.
PubMed
49) Armbruster DA: Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin. Chem. 39: 181-195, 1993.
PubMed
50) Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest. Urol. 17: 159-163, 1979.
PubMed
51) Hara M, Inoue T, Koyanagi Y, et al: Immunoelectrophoretic studies of the protein component in human seminal plasma(especially its specific component) . (Forensic immunological study of body fluid and secretions. VI) Jpn. J Legal Med. 23: 117-122, 1969.
 
52) Stenman UH, Leinonen J, Zhang WH: Standardization of PSA determinations. Scand. J. Clin. Lab. Invest. 221(Suppl.) : 45-51, 1995.
 
53) Kuriyama M, Akimoto S, Akaza H, et al: Comparison of various assay systems for prostate-specific antigen. Jpn. J. Clin. Oncol. 22: 393-399, 1992.
PubMed
54) Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate specific antigen. J. Urol. 147: 841-845, 1992.
PubMed
55) Small EJ: Prostate cancer: who to screen, and what the results mean. Geriatrics 48: 28-30, 35-38, 1993.
 
56) Hammerer P, Huland H: Systematic sextant biopsies in 651 patients referred for prostate evaluation. J. Urol. 151: 99-102, 1994.
PubMed
57) Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J. Urol. 152: 2037-2042, 1994.
PubMed
58) Kirby RS, Kirby MG, Feneley MR, et al: Screening for carcinoma of the prostate: a GP based study. Br. J. Urol. 74: 64-71, 1994.
PubMed
59) Tibblin G, Welin L, Vergstrom R, et al: The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913. J. Urol. 154: 1386-1389, 1995.
 
60) Yamamoto M, Hibi H, Miyake K: Prostate-specific antigen levels in acute and chronic bacterial prostatitis. Acta. Urol. Jpn. (泌尿器科紀要) 39: 445-449, 1993.
 
61) Nadler RB, Humphrey PA, Smith DS, et al: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J. Urol. 154: 407-413, 1995.
 
62) Breul J, Binder K, Block T, et al: Effect of digital rectal examination on serum concentration of prostatespecific antigen. Eur. Urol. 21: 195-199, 1992.
PubMed
63) Chyvowski FM, Bergstralh EJ, Osterling JE: The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J. Urol. 148: 83-86, 1992.
 
64) Crawford ED, Schutz MJ, Clejan S, et al: The effect of digital rectal examination on prostate-specific antigen levels. JAMA 267: 2227-2228, 1992.
PubMed
65) Thomson RD, Clejan S: Digital rectal examination-associated alterations in serum prostate-specific antigen. Am. J. Clin. Pathol. 97: 528-534, 1992.
PubMed
66) Littrup PJ, Williams CR, Egglin TK, et al: Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques. Radiology 179: 49-53, 1991.
PubMed
67) Benson MC, Whang IS, Pantuck A, et al: Prostate specific antigen density: ameans of distinguishing benign prostate hypertrophy and prostate cancer. J. Urol. 147: 815-816, 1992.
 
68) Aziz DC, Barathur RB: Prostate-specific antigen and prostate volume: ameta-analysis of prostate cancer screening criteria. J. Clin. Lab. Anal. 7: 283-292, 1993.
 
69) Wolff JM, Scholz A, Boeckmann W, et al: Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density. Eur. Urol. 25: 295-298, 1994.
PubMed
70) Ramon J, Boccon-Gibod L, Billebaud T, et al: Prostate-specific antigen density: ameans to enhance detection of prostate cancer. Eur. Urol. 25: 288-294, 1994.
 
71) Bretton PR, Evans WP, Borden JD, et al: The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. Cancer 74: 2991-2995, 1994.
PubMed
72) Shinohara K, Wolf JS Jr, Narayan P, et al: Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications. J. Uro1. 152: 120-123, 1994.
 
73) Benson MC, Olsson CA: Prostate specific antigen and prostate specific antigen dentisy. Roles in patient evaluation and management. Cancer 74: 1667-1673, 1994.
 
74) Van Iersel MP, Witjes WP, de la Rosette JJ, et al: Prostate-specific antigen density: correlation with his- tological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis. Br. J. Urol. 76: 47-53, 1995.
 
75) Bare R, Hart L, McCullough DL: Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy. Urology 43: 191-196, 1994.
PubMed
76) Smith DS, Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J. Urol. 152: 1163-1167, 1994.
PubMed
77) Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
 
78) el-Galley RE, Petros JA, Sanders WH, et al: Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 46: 200-204, 1995.
PubMed
79) Zhou AM, Tewari PC, Bluestein BI, et al: Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin. Chem. 39: 2483-2491, 1993.
PubMed
80) Lilja H, Christensson A, Dahlen U, et al: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37: 1618-1625, 1991.
PubMed
81) Wu JT, Wilson L, Zhang P, et al: Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J. Clin. Lab. Anal. 9: 15-24, 1995.
PubMed
82) Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol. 154: 1090-1095, 1995.
PubMed
83) Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
PubMed
84) Paul R, Breul J, Hartung R: Prostate-specific antigen density and age-specific prostate-specific antigen values: the solution of prostate cancer screening？. Eur. Urol. 27: 286-291, 1995.
PubMed
85) Meshref AW, Bazinet M, Trudel C, et al: Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges. Urology 45: 972-979, 1995.
PubMed
86) Sutton MA, Gibbons RP, Correa RJ Jr: Is deleting the digital rectal examination a good idea？. West. J. Med. 155: 43-46, 1991.
PubMed
87) Palken M, Cobb OE, Simons CE, et al: Prostate cancer: comparison of digital rectal examination and tran- srectal ultrasound for screening. J. Urol. 145: 86-92, 1991.
 
88) Akdas A, Tarcan T, TUrkeri L, et al: The diagnostic accuracy of digital rectal examination, transrectal ultrasonography, prostate-specific antigen(PSA) and PSA density in prostate carcinoma. Br. J. Urol. 76: 54- 56, 1995.
PubMed
89) Smith DS, Catalona WJ: Interexaminer variability of digital rectal examination in detecting Prostate cancer. Urology 45: 70-74, 1995.
PubMed
90) Gerber GS, Thompson IM, Thisted R, et al: Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 269: 61-64, 1993.
PubMed
91) 今井強一, 山中英寿: Screening examination for prostate cancer. Early detection and mass screening. 日泌尿会誌 84(7) : 1175-1187, 1993.
 
92) Flanigan RC, Catalona WJ, Richie Jp, et al: Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J. Urol. 152: 1506-1509, 1994.
PubMed
93) Matthews GJ, Fracchia JA: PSA-detected prostate cancer: contrasts with palpable disease. J. Surg. Oncol. 59: 28-30, 1995.
 
94) Ohori M, Wheeler TM, Greene DR, et al: Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation. Prostate 23: 271-281, 1993.
PubMed
95) Perrin P, Maquet JH, Bringeon G, et al: Screening for prostate cancer. Comparison of transrectal ultrasound, prostate specific antigen and rectal examination. Br. J. Urol. 68: 263-265, 1991.
PubMed
96) Gustafsson O, Norming U, Almgard LE, et al: Diagnostic methods in the detection of prostate cancer: astudy of a randomly selected population of 2, 400 men. J. Urol. 148: 1827-1831, 1992.
 
97) 渡辺 泱: 経直腸的超音波断層法の開発と応用. 日泌尿会誌 65: 613-632, 1974.
 
98) Shinohara K, Wheeler TM, Scardino PT: The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J. Urol 142: 76-82, 1989.
PubMed
99) Villers A, Terris MK, McNeal JE, et al: Ultrasound anatomy of the prostate: the normal gland and anatomical variations. J. Urol. 143: 732-738, 1990.
PubMed
100) Ferguson JK, Bostwick DG, Suman V, et al : Prostate-specific antigen detected prostate cancer: pathological characteristics of ultrasound visible versus ultrasound invisible tumors. Eur. Urol. 27: 8-12, 1995.
PubMed
101) Andriole GL, Coplen DE, Mikkelsen DJ, et al: Sonographic and pathological staging of patients with clinically localized prostate cancer. J. Urol. 142: 1259-1261, 1989.
PubMed
102) Carter HB, Brem RF, Tempany CM, et al: Nonpalpable prostate cancer: detection with MR imaging. Radiology 178: 523-525, 1991.
PubMed
103) Engeler CE, Wasserman NF, Zhang G: Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology 40: 346-350, 1992.
PubMed
104) Schnall MD, Lenkinski RE, Pollack HM, et al: Prostate: MR imaging with an endorectal surface coil. Radiology 172: 570-574, 1989.
PubMed
105) Saitoh H, Hida M, Shimbo T, et al: Metastatic patterns of prostatic cancer. Correlation between sites and numer of organs involved. Cancer 54: 3078-3084, 1984.
 
106) Narayan P, Fournier G, Gajendran V, et al: Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 44: 519-524, 1994.
PubMed
107) Levran Z, Gonzalez JA, Diokno AC, et al: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer？. Br. J. Urol. 75: 778-781, 1995.
PubMed
108) Vijayakumar V, Vijayakumar S, Quadri SF, et al: Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer ？. Am. J CIin. Oncol. 17: 432-436, 1994.
 
109) Grossman IC, Carpiniello V, Greenberg SH, et al: Staging pelvic lymphadenectomy for adenocarcinoma of the prostate review of 91 cases. J. Urol. 124: 632-634, 1980.
 
110) Smith JA Jr, Seaman Jp, Gleidman JB, et al: Pelvic lymph node metastasis from prostatic cancer: influence of tumor grade and stage in 452 consecutive patients. J. Urol. 130: 290-292, 1983.
PubMed
111) Petros JA, Catalona WJ: Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J. Urol. 147: 1574-1575, 1992.
PubMed
112) 冨田京一, 鳶巣賢一, 庭川 要・他: 前立腺癌根治症例におけるリンパ節転移と予後. 日泌尿会誌 86(8) : 1322- 1327, 1995.
 
113) Rosen MA, Goldstone L, Lapin S, et al: Frequency and location of extracapsular extention and positive surgical margins in radical prostatectomy specimens. J. Urol. 148: 331-337, 1992.
 
114) Irwin MB, Trapasso JG: Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 44: 862-867, 1994.
PubMed
115) Dietrick DD, McNeal JE, Stamey TA: Core cancer length in ultrasound-guided systematic sextant biopsies: apreoperative evaluation of prostate cancer volume. Urology 45: 987-992, 1995.
 
116) Cupp MR, Bostwick DG, Myers RP, et al: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J. Urol. 153: 1543-1548, 1995.
 
117) Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993.
PubMed
118) Smith DS, Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol. 152: 1732-1736, 1994.
PubMed
119) Huggins C, Hodges CV: Studies on Prostate Cancer. 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1: 293-297, 1941.
 
120) Murphy GP: Hormonal therapies in prostatic cancer. Urol. Int. 43(Suppl. 1) : 2428, 1988.
 
121) Van de Voorde WM, Elgamal AA, Van Poppel HP, et al: Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 74: 3164-3175, 1994.
PubMed
122) Cox LR, Crawford DE: Estrogens in the treatment of prostate cancer. J. Urol. 154: 1991-1998, 1995.
 
123) Kadohama M, Kirdani RY, Madajewicz S, et al: Estramustine. Metabolic pattern and possible mechanisms for its action in prostate cancer. N. Y. State J. Med. 79: 1005-1009, 1979.
 
124) McLeod DG: Antiandrogenic drugs. Cancer 71(3 Suppl) : 1046-1049, 1993.
 
125) Sartor O, Cooper M, Weinberger M, et al: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of"hormone-refractory"prostate cancer. J. Natl. Cancer Inst. 86: 222-227, 1994.
PubMed
126) Nieh PT: Withdrawal phenomenon with the antiandrogen casodex. J. Urol. 153: 1070-1072, 1995.
PubMed
127) Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 11: 1566-1572, 1993.
PubMed
128) Kelly WK, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol. 149: 607-609, 1993.
PubMed
129) Huben RP: Hormone therapy of prostatic bone metastases. Adv. Exp. Med. Biol. 324: 305-316, 1992.
PubMed
130) Guess HA, Gormley GJ, Stoner E, et al: The. effect of finasteride on prostate specific antigen: review of available data. J. Urol. 155: 3-9, 1996.
 
131) Crawford ED, Eisenberger MA, Mcleod DG, et al: Acontrolled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321: 419-424, 1989.
 
132) McLeod DG, Crawford ED, Blumenstein BA, et al: Controversies in the treatment of metastatic prostate cancer. Cancer 70(1 Suppl.) : 324-328, 1992.
 
133) Debruyne FM, Witjes WP: Overview of current status of total androgen deprivation in metastasized prostate cancer. Eur. Urol. 24(Suppl. 2) : 67-71, 1993.
 
134) Dijkman GA, Fernandez del Moral P, Debruyne FM, et al: Improved subjective responses to orchiectomy plus nilutamide(anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group. Eur. Urol. 27: 196-201, 1995.
 
135) 斉藤 泰: 2. 内分泌療法 b) 去勢術・エストロゲン剤・アンチアンドロゲン剤療法(内分泌療法の効果と限界) . 前立腺癌診療マニュアル(前立腺研究財団編) , 金原出版, 東京, 1995, pp. 334-349.
 
136) Walsh PC: Radical retropubic prostatectomy. In: Campbell’s Urology 6 th ed. (ed by Walsh PC, et al) , Saunders, Philadelphia, pp. 2865-2886.
 
137) Paulson DF: Perineal prostatectomy. In: Campbell 's Urology 6 th ed. (ed by Walsh PC. et al) , Saunders, Philadelphi. a, 1992, pp. 2887-2899.
 
138) Carlin BI, Resnick MI: Anatomic approach to radical perineal prostatectomy. Urol. Clin. North Am. 22: 461-473, 1995.
PubMed
139) Frazier HA, Robertson JE, Paulson DF: Radical prostatectomy: the pros and cons of the perineal versus retropubic approach. J. Urol. 147: 888-890, 1992.
PubMed
140) Haab F, Boccon-Gibod L, Delmas V, et al: Perineal versus retropubic radical prostatectomy for T 1, T 2prostate cancer. Br. J. Urol. 74: 626-629, 1994.
 
141) Teichman JM, Reddy PK, Hulbert JC: Laparoscopic pelvic lymph node dissection, laparoscopically assisted seminal vesicle mobilization, and total perineal prostatectomy versus radical retropubic prostatectomy for prostate cancer. Urology 45: 823-830, 1995.
PubMed
142) Zincke H, Osterling JE, Blute ML, et al: Long-term(15 years) results after radical prostatectomy for clinically localized(stage T 2 c or lower) prostate cancer. J. Urol. 152: 1850-1857, 1994.
PubMed
143) Cisek LJ, Walsh PC: Thromboembolic complications following radical retropubic prostatectomy. Influence of external sequential pneumatic compression devices. Urology 42: 406-408, 1993.
PubMed
144) Steiner MS, Morton RA, Walsh PC: Impact of anatomical radical prostatectomy on urinary continence. J. Urol. 145: 512-515, 1991.
PubMed
145) Geary ES, Dendinger TE, Freiha FS, et al: Nerve sparing radical prostatectomy: adifferent view. J. Urol. 154: 145-149, 1995.
 
146) Catalona WJ, Dresner SM: Nerve-sparing radical prostatectomy: extraprostatic tumor extention and preservation of erectile function. J. Urol. 134: 1149-1151, 1985.
 
147) Stamey TA, Villers AA, McNeal JE, et al: Positive surgical margins at radical prostatectomy: importance of the apical dissection. J. Urol. 143: 1166-1173, 1990.
PubMed
148) Bigg SW, Kavoussi LR, Catalona WJ: Role of nerve-sparing radical prostatectomy for clinical stage B 2prostate cancer. J. Urol. 144: 1420-1424, 1990.
 
149) Ohori M, Wheeler TM, Kattan MW, et al: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol. 154: 1818-1824, 1995.
PubMed
150) Zincke H, Bergstralh EJ, Blute ML, et al: Radical prostatectomy for clinically localized prostate cancer: long-term results of 1, 143 patients from a single institution. J. Clin. Oncol. 12: 2254-2263, 1994.
PubMed
151) Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol. 152: 1831-1836, 1994.
PubMed
152) Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol. 152: 1837-1842, 1994.
PubMed
153) Paulson DF, Moul JW, Robertson JE, et al: Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J. Urol. 143: 1178-1182, 1990.
PubMed
154) Beyer A, Leitenberger A, Altwein JE: Adjuvant hormonal therapy following radical prostatectomy. Eur. Urol. 24(Suppl. 2) : 51-56, 1993.
 
155) Morgan WR, Bergstralh EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C(T 3) prostate cancer. Urology 41: 113-120, 1993.
 
156) Yamada AH, Lieskovsky G, Petrovich Z, et al: Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stageTC, prostate cancer. Am. J. Clin. Onco1. 17: 277-285, 1994.
 
157) Freeman JA, Lieskovsky G, Grossfeld G, et al: Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D 1 adenocarcinoma of the prostate. Urology 44: 719-725, 1994.
 
158) Lerner SE, Blute ML, Zincke H: Extended experience with radical prostatectomy for clinical stage T 3 prostate cancer: outcome and contemporary morbidity. J. Urol. 154: 1447-1452, 1995.
 
159) Soloway MS, Sharifi R, Wajsman Z, et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B 2(T 2 bNxM O) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol 154: 424-428, 1995.
 
160) Isaka S, Shimazaki J, Akimoto S, et al: A prospective randomized trial for treating stages B 2 and C prostate cancer: radical surgery or irradiation with neoadjuvant endocrine therapy. Jpn. J. Clin. Oncol. 24: 218-223, 1994.
PubMed
161) Maeda O, Meguro N, Saiki S, et al: Preoperative endocrine therapy in patients with locally advanced prostate cancer. Jpn. J. Clin. Oncol. 25: 135-139, 1995.
PubMed
162) Soloway MS, Hachiya T, Ruiz HE, et al: Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen. World J. Urol. 11: 221-226, 1993.
PubMed
163) Soloway MS, Hachiya T, Civantos F, et al: Androgen deprivation prior to radical prostatectomy for T 2 b and T3prostate cancer. Urology 43(2 Suppl.) : 52-56, 1994.
 
164) Van Poppel H, De Ridder D, Elgamal AA, et al: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T 2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J. Urol. 154: 429-434, 1995.
 
165) Witjes WP, Horenblas S, Oosterhof GO, et al: Neoadjuvant therapy in prostate cancer-is it of any use？. Eur. Urol. 24: 433-437, 1993.
PubMed
166) Aprikian AG, Fair WR, Reuter VE, et al: Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br. J. Urol. 74: 630-636, 1994.
PubMed
167) Oesterling JE, Andrews PE, Suman VJ, et al: Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J. Urol. 149: 779-782, 1993.
PubMed
168) Cher ML, Shinohara K, Breslin S, et al: High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br. J. Urol. 75: 771-777, 1995.
 
169) Bastacky SI, Walsh PC, Estein JI: Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am. J. Surg. Pathol. 17: 336-341, 1993.
 
170) Catalona WJ, Basler JW: Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J. Urol. 150: 905-907, 1993.
PubMed
171) Quinlan DM, Epstein JI, Carter BS, et al: Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J. Urol. 145: 998-1002, 1991.
PubMed
172) Bundrick WS, Culkin DJ, Mata JA, et al: Evaluation of the current incidence of nodal metastasis from prostate cancer. J. Surg. Oncol. 52: 269-271, 1993.
PubMed
173) Golimbu M, Provet J, AI-Askari S, et al: Radical prostatectomy for stage D 1 prostatecancer. Prognostic variables and results of treatment. Urology 30: 427-435, 1987.
 
174) Frazier HA 2 nd, Robertson JE, Paulson DF: Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival？World J. Urol. 12: 308-312, 1994.
 
175) Fournier GR Jr, Narayan P: Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer. Br. J. Urol. 72: 484-488, 1993.
PubMed
176) Ackerman DA, Barry JM, Wicklund RA, et al: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol. 150: 1845-1850, 1993.
 
177) Bluestein DL, Bostwick DG, Bergstralh EJ: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J. Urol 151: 1315-1320, 1994.
PubMed
178) Sullivan LD, Rabbani F: Should we reconsider the indications for ileo-obturator node dissection with localized prostate cancer？Br. J. Urol. 75: 33-37, 1995.
PubMed
179) Bishoff JT, Reyes A, Thompson IM, et al: Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology 45: 270-274, 1995.
PubMed
180) M. claughlin AP, Saltzstein SL, Mccullough DL, et al: Prostatic carcinoma: Incidence and location of unsuspected lymphatic metastasis. J. Urol. 115: 89-94, 1976.
 
181) Schoborg TW: Laparoscopic staging of prostatic carcinoma. Semin. Surg. Oncol. 10: 422-430, 1994.
PubMed
182) Kerbl K, Clayman RV, Petros JA, et al: Staging Pelvic lymphadenectomy for prostate cancer: acomparison of laparoscopic and open techniques. J. Urol. 150: 396-399, 1993.
 
183) Parra RO, Boullier JA, Rauscher JA, et al: The value of laparoscopic lymphadenectomy in conjunction with radical perineal or retropubic prostatectomy. J. Urol. 151: 1599-1602, 1994.
PubMed
184) Campbell SC, Klein EA, Levin HS, et al: Open pelvic lymph node dissection for prostate cancer: areassessment. Urology 46: 352-355, 1995.
 
185) Steiner MS, Marshall FF: Mini-laparotomy staging pelvic lymphadenectomy(minilap) . Alternative to standard and laparoscopic pelvic lymphadenectomy. Urology 41: 201-206, 1993.
PubMed
186) Greskovich FJ, Zagars GK, Sherman NE, et al: Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J. Urol. 146: 798-802, 1991.
PubMed
187) Jonler M, Ritter MA, Brinkmann R, et al: Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. Urology 44: 876-882, 1994.
 
188) Helgason AR, Fredrikson M, Adolfsson J, et al: Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life. Int. J. Radiat. Oncol. Biol. Phys. 32: 33-39, 1995.
PubMed
189) Cho KH, Lee CK, Levitt SH: Proctitis after conventional external radiation therapy for prostate cancer: importance of minimizing posterior rectal dose. Radiology 195: 699-703, 1995.
PubMed
190) Hanks GE, Hanlon A, Owen JB, et al: Patterns of radiation treatment of elderly patients with prostate cancer. Cancer 74(7 Suppl.) : 2174-2177, 1994.
 
191) Geist RW: Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. Urology 45: 1016-1021, 1995.
PubMed
192) Kavadi VS, Zagars GK, Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int. J. Radiat. Oncol. Biol. Phys. 30: 279-287, 1994.
PubMed
193) Zelefsky MJ, Leibel SA, Wallner KE, et al: Significance of normal serum prostate-specific antigen in the follow-up Period after definitive radiation therapy for prostatic cancer. J. Clin. Oncol. 13: 459-463, 1995.
PubMed
194) Hanks GE, Perez CA, Kozar M, et al: PSA confirmation of cure at 10 years of T l B, T 2. N O, M O prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int. J. Radiat. Oncol. Biol. Phys. 30: 289-292, 1994.
 
195) Bagshaw MA, Cox RS, Hancock SL: Control of prostate cancer with radiotherapy: long-term results. J. Urol. 152: 1781-1785, 1994.
PubMed
196) Hanks GE, Hanlon A, Schultheiss T, et al: Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. J. Urol. 152: 1775-1780, 1994.
PubMed
197) Zietman AL, Coen JJ, Shipley WU, et al: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J. Urol. 151: 640-645, 1994.
PubMed
198) Rosenzweig KE, Morgan WR, Lytton B, et al: Prostate specific antigen following radiotherapy for local prostate cancer. J. Urol. 153: 1561-1564, 1995.
PubMed
199) Akakura K, Akimoto S, Ohki T, et al: Radiation therapy for prostate cancer confined to pelvis. Int. J. Urol. 1: 268-272, 1994.
PubMed
200) Zietman AL, Coen JJ, Dallow KC, et al: The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int. J. Radiat. Oncol. Biol. Phys. 32: 287-292, 1995.
PubMed
201) Zagars GK, Ayala AG, von Eschenbach AC, et al: The prognostic importance of Gleason grade in prostatic adenocarcinoma: along-term follow-up study of 648 patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 31: 237-245, 1995.
 
202) Centeno BA, Zietman AL, Shipley WU, et al: Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. Int, J. Radiat. Oncol. Biol. Phys. 30: 309-315, 1994.
 
203) Zagars GK, Pollack A, Kavadi VS, et al: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol Phys. 32: 293-306, 1995.
PubMed
204) Crook JM, Perry GA, Robertson S, et al: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45: 624-631, 1995.
PubMed
205) Freiha FS, Bagshaw MA: Carcinoma of the prostate: results of post-irradiation biopsy. Prostate 5: 19-25, 1984.
 
206) Kabalin JN, Hodge KK, McNeal JE, et al: Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J. Urol. 142: 326-331, 1989.
PubMed
207) Zagars GK, Pollack A, von Eschenbach AC: Prostate cancer and radiation therapy-the message conveyed by serum prostate-specific antigen. Int. J. Radiat. Oncol. Biol. Phys. 33: 23-35, 1995.
PubMed
208) Gottesman JE, Tesh DG, Weissman WD: Failure of open radioactive 125 iodine implantation to control localized prostate cancer: a study of 41 patients. J. Urol. 146: 1317-1320, 1991.
 
209) Khan K, Thompson W, Bush S, et al: Transperineal percutaneous iridium-192 interstitial template implant of the prostate: results and complications in 321 patients. Int. J. Radiat, Oncol. Biol. Phys. 22: 935-939, 1992.
PubMed
210) Bagshaw MA, Kaplan ID, Cox RC: Prostate cancer. Radiation therapy for localized disease. Cancer 71 (3Suppl.) : 939-952, 1993.
 
211) Lannon SG, eLAraby AA, Joseph PK, et al: Long-term results of combined interstitial gold seed implantation plus external beam irradiation in localized carcinoma of the prostate. Br. J. Urol. 72: 782-791, 1993.
PubMed
212) Russell KJ, Caplan RJ, Laramore GE, et al: Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial. Int. J. Radiat. Oncol. Biol. Phys. 28: 47-54, 1994.
PubMed
213) Stromberg J, Martinez A, Benson R, et al: Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low does rate iridium-192 prostate implantation and external beam irradiation. Int. J. Radiat. Oncol. Biol. Phys. 28: 67-75, 1994.
PubMed
214) Hochstetler JA, Kreder KJ, Brown CK, et al: Survival of patients with localized prostate cancer treated with percutaneous transperineal placement of radioactive gold seeds: stageA 2, B, and C. Prostate 26: 316-324, 1995.
 
215) Stromberg J, Martinez A, Gonzalez J, et al: Ultrasound-guided high does rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I. /II clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 33: 161-171, 1995.
 
216) Haraf DJ, Rubin SJ, Sweeney P, et al: Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 33: 3-14, 1995.
PubMed
217) Woznialk AJ, Blumenstein BA, Crawford ED, et al: Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer 71: 3975-3978, 1993.
 
218) Mahjoubi M, Azab M, Ghosn M, et al: Phase II trial of ifosfamide in the treatment of metastatic hormonerefractory patients with prostatic cancer. Cancer Invest. 8: 477-481, 1990.
PubMed
219) Straus MJ, Fleit Jp, Engelking C: Treatment of advanced prostate cancer with cyclophosphamide, doxorubicin, and methotrexate. Cancer Treat. Rep. 66: 1797-1802, 1982.
PubMed
220) Canobbio L, Guarneri D, Miglietta L, et al: Carboplatin in advanced hormone refractory prostatic cancer patients. Eur. J. Cancer 29A: 2094-2096, 1993.
PubMed
221) Hussain MH, Pienta KJ, Redman BG, et al: Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 74: 100-103, 1994.
PubMed
222) Roth BJ, Yeap BY, Wilding G, et al: Taxol in advanced, hormone-refractory carcinoma of the prostate. A Phase II trial of the Eastern Cooperative Oncology Group. Cancer 72: 2457-2460, 1993.
PubMed
223) Jodrell DI, Reyno LM, Sridhara R, et al: Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J. Clin. Oncol. 12: 166-175, 1994.
PubMed
224) Eisenberger MA, Sinibaldi VJ, Reyno LM, et al: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J. Clin. Oncol. 13: 2174-2186, 1995.
PubMed
225) Reyno LM, Egorin MJ, Eisenberger MA, et al: Developrnent and validation of a pharmacokinetically based fixed dosing scheme for suramin. J. Clin. Onco1. 13: 2187-2195, 1995.
 
226) Kobayashi K, Vokes EE, Vogelzang NJ, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J. Clin, Oncol. 13: 2196-2207, 1995.
 
227) Kubota Y, Nakada T, Imai K, et al: Chemo-endocrine therapy in patients with stage D 2 prostate cancer. Prostate 26: 50-54, 1995.
 
228) Servadio C, Mukamel E, Nussbaum B: Fifteen years’experience of combined hormone/chemotherapy in metastatic prostate cancer Urology 39: 274-276, 1992.
 
229) Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol. 12: 2005-2012, 1994.
PubMed
230) Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28: 36-40, 1986.
PubMed
231) Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J. Clin. Oncol. 8: 1675-1682, 1990.
 
232) Austenfeld MS: Treatment of stage A l prostate cancer: the case for observation. Semin. Urol. 11: 58-63, 1993.
 
233) Rossignol G, Leandri P, Ramon J, et al: Radical prostatectomy in the management of stage A carcinoma of the prostate. Eur. Urol. 21: 269-273, 1992.
 
234) Matzkin H, Patel Jp, Altwein JE, et al: Stage T l A carcinoma of prostate. Urology 43: 11-21, 1994.
 
235) Epstein JI, Walsh PC, Brendler CB: Radical prostatectomy for impalapable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection(stage T l A and T l B) and on needle biopsy(stage T l C) . J. Urol. 152: 1721-1729, 1994.
 
236) Stormont TJ, Farrow GM, Myers RP, et al: Clinical Stage B O or T l c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigeIl concentration. Urology 41: 3-8, 1993.
 
237) Jones GW: Prospective, conservative management of localized prostate cancer. Cancer 70(1 Suppl.) : 307-310, 1992.
 
238) Fleming C, Wasson JH, Albertsen PC, et al: Adecision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Reserch Team. JAMA 269: 2650-2658, 1993.
 
239) Johansson JE: Expectant management of early stage prostatic cancer: Swedish experience. J. Urol. 152: 1753-1756, 1994.
PubMed
240) Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 330: 242-248, 1994.
PubMed
241) Johansson JE, Adami HO, Andersson SO, et al: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267: 2191-2196, 1992.
PubMed
242) Johansson JE: Result of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 330: 242-248, 1994.
PubMed
243) Beck JR, Kattan MW, Miles BJ: A critique of the decision analysis for clinically localized prostate cancer. J. Urol. 152: 1894-1899, 1994.
PubMed
244) Chodak GW: The role of watchful waiting in the management of localized prostate cancer. J. Urol. 152: 1766-1768, 1994.
PubMed
245) Middleton RG, Thompson IM, Austenfeld MS, et al: Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J. Urol. 154: 2144-2148, 1995.
PubMed
246) Fleming C, Wasson JH, Albertsen PC, et al: Adecision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcome Reserch Team. JAMA 269: 2650-2658, 1993.
 
247) Wilt TJ, Brawer MK: The Prostate Cancer lntervention Versus Observation Trial: arandomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J. Urol. 152: 1910-1914, 1994.
 
248) Lerner SP, Seale-Hawkins C, Carlton CE Jr, et al: The risk of dying of prostate cancer in patients with clinically localized disease. J. Urol. 146: 1040-1045, 1991.
 
249) Studer UE: Radical prostatectomy or deferred treatment？. Semin. Surg. Oncol. 11: 46-49, 1995.
 
250) Pilepich MV, Bagshaw MA, Asbell SO, et al: Definitive radiotherapy in resectable(stage A 2 and B) carcinoma of the prostate-results of a nationwide overview. Int. J. Radiat. Oncol. Biol Phys. 13: 659-663, 1987.
 
251) Jones GW: Prospective, conservative management of localized prostate cancer. Cancer 70(1 Suppl.) : 307-310, 1992.
 
252) Coleman CN, Beard CJ, Kantoff PW, et al: Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports. Int. J. Radiat. Oncol. Biol. Phys. 28: 303-313, 1994.
PubMed
253) Adolfsson J: Radical prostatectomy, radiotherapy or deferred treatment for localized prostate cancer？. Cancer Surv. 23: 141-148, 1995.
 
254) Fowler JE Jr, Braswell NT, Pandey P, et al: Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center. J. Urol. 153: 1026-1031, 1995.
 
255) Lim AJ, Brandon AH, Fiedler J, et al: Quality of life: Radical prostatectomy versus radiation therapy for prostate cancer. J. Urol. 154: 1420-1425.
PubMed
256) Byer DP: The Veterans Administration Cooperative Urological Reserch Group’s study of Cancer of the prostate. Cancer 32: 1126-1130, 1973.
 
257) Paulson DF, Cline WA Jr, Koefoot RB Jr, et al: Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma. J. Urol. 127: 935-937, 1982.
PubMed
258) Davidson PJT, Hop W, Kurth KH, et al: European Organization for Research and Treatment of Cancer Genitourinary Group: Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stageTOto4, Nlto3, MO, D1) . J. Urol 154: 2118-2122, 1995.
 
259) Bagshaw MA: Radiotherapeutic treatment of prostatic carcinoma with pelvic node involvement, Urol. Clin. North Am. 11: 297-304, 1984.
PubMed
260) Smith JA Jr, Haynes TH, Middleton RG: Impact of external irradiation on local symptoms and survival free of disease in patients with pelvic lymph node metastasis from adenocarcinoma of the prostate. J. Urol. 131: 705-707, 1984.
PubMed
261) Zagars GK, Sands ME, Pollack A, et al: Early androgen ablation for stage D 1(N1 to N3, M0) prostatecancer: prognostic variables and outcome. J. Urol. 151: 1330-1333, 1994.
 
262) Cheng CW, Bergstralh EJ, Zincke H: Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer 71(3 Suppl) : 996-1004, 1993.
 
263) Golimbu M, Provet J, Al-Askari S, et al: Radical prostatectomy for stage D 1 prostate cancer. Prognostic variables and results of treatment. Urology 30: 427-435, 1987.
 
264) Sgrignoli AR, Walsh PC, Steinberg GD, et al: Prognostic factors in men with stage D 1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J. Urol. 152: 1077-1081, 1994.
 
265) Steinberg GD, Estein JI, Piantadosi S, et al: Management of stage D 1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J. Urol. 144: 1425-1432, 1990.
 
266) Whittington R, Malkowicz B, Barnes MM, et al: Combined hormonal and radiation therapy for lymph nodepositive prostate cancer. Urology 46: 213-219, 1995.
PubMed
267) Frohmuller HG, Theiss M, Manseck A, et al: Survival and quality of life of patients with stage D 1(T1-3pN1-2MO) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur. Urol. 27: 202-206, 1995.
 
268) Zincke H, Utz DC: Observation on surgical management of carcinoma of prostate with limited nodal metastases. Urology 24: 137-145, 1984.
PubMed
269) deKernion JB, Neuwirth H, Stein A, et al: Prognosis of patients with stage D 1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J. Urol. 144: 700-703, 1990.
 
270) Myers RP, Larson Keller JJ, Bergstralh EJ, et al: Hormonal treatment at time of radical retropubic prostatectomy for stage D 1 prostate cancer: results of long-term followup. J. Urol. 147: 910-915, 1992.
 
271) Soloway MS, Hardeman SW, Hickey D, et al: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988.
PubMed
272) Herr HW, Kornblith AB, Ofman U: A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71(3 Suppl.) : 1143-1150, 1993.
PubMed
273) Labrie F, Dupont A, Cusan L, et al: Major advantages of"early"administration of endocrine combination therapy in advanced prostate cancer. Clin. Invest. Med. 16: 493-498, 1993.
PubMed
274) da Silva FC: Quality of life in prostatic cancer patients. Cancer 72(12 Suppl.) : 3803-3806, 1993.
 
275) Cassileth BR, Solowy MS, Vogelzang NJ, et al: Patients’choice of treatment in stage D prostate cancer. Urology 33(5 Suppl) : 57-62, 1989.
 
276) Droz Jp, Kattan J, Bonnay M, et al: High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer. Cancer 71(3 Suppl.) : 1123-1130, 1993.
 
277) Droz Jp, De Smedt E, Kattan J, et al: Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate. Prostate 24: 62-66, 1994.
PubMed
278) Bissada NK, Kaczmarek AT: Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestro1. J. Urol. 153: 1944-1945, 1995,
PubMed
279) Villavicencio H: Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur. Urol. 24 (Suppl. 2) : 118-121, 1993.
 
280) World Health Organization: Cancer pain relief and palliative care. Technical Report Series No. 804, WHO, Geneva, 1990.
 
281) Crawford ED, Kozlowski JM, Debruyne FM, et al: The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology 44: 481-485, 1994.
PubMed
P.1264 掲載の参考文献
1) Forman D, Moller H: Testicular cancer. Cancer Surv. 19: 323-341, 1994.
 
2) Hawkins C, Miaskowski C: Testicular cancer: a review. Oncol. Nurs. Forum 23(8) : 1203-1211, 1996.
PubMed
3) Bosl GJ, Dmitrovsky E, Reuter VE, et al: Isochromosome of chromosome 12: clinically useful marker for mal germ cell tumors. J. Natl. Cancer Inst. 81: 1874-1878, 1989.
 
4) Oliver RT: Testicular cancer. Curr. Opin. Oncol. 8: 252-258, 1996.
PubMed
5) 日本泌尿器科学会・病理学会編: 精巣腫瘍取扱い規約. 第2版, 金原出版, 東京, 1997, pp. 65-75.
 
6) Richie JP: Advances in the diagnosis and treatment of testicular cancer. Cancer Invest. 11: 670-675, 1993.
PubMed
7) Bartlett NL, Freiha FS, Torti FM: Serum markers in germ cell neoplasms. Hematol. Oncol. Clin. North Am. 5: 1245-1260, 1991.
PubMed
8) Richie JP: Testicular cancer: What staging investigations are indicated？Semin. Urol. Oncol. 14: 13-16, 1996.
PubMed
9) Bokemeyer C, Kuczyk MA, Serth J, et al: Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J. Cancer Res. Clin. Oncol 122: 575-584, 1996.
 
10) Rajpert DME, Kvist M, Skakkebaek NE: Heterogeneity of expression of immunohistochemical tumour markers in testicular carcinoma in situ: pathogenetic relevance. Virchows Arch. 428: 133-139, 1996.
 
11) Chresta CM, Masters JR, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p 53 and a high Bax: Bcl-2 ratio. Cancer Res. 56: 1834-1841, 1996.
 
12) Sobin LH, Wittekind CH: TNM classification of malignant tumors. 5th ed, Wiley-Liss, New York, 1977, pp. 174- 177.
 
13) Moul JW, Heidenreich A: Prognostic factors in low-stage nonseminomatous testicular cancer. Oncology 10: 1359-1374, 1996.
PubMed
14) Javadpour N, Young JD: Prognostic factors in nonseminomatous testicular cancer. J. Urol. 135: 497-499, 1986.
PubMed
15) Klepp O, Olsson AM, Henrikson H, et al: Prognostic factors in clinical stage in nonseminomatous germ cell tumors of the testis: Multivariate analysis of a prospective multicenter study. J. Clin. Oncol. 8: 509-518, 1990.
PubMed
16) Bosl GJ, Geller NL, Cirrincione C, et al: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 43: 3403-3407, 1983.
PubMed
17) Bosl GJ, Geller NL, Bajorin D: Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. Cancer 67: 1299-1304, 1991.
PubMed
18) Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J. Clin. Oncol. 4: 400-407, 1986.
PubMed
19) Ozols RF, Diesseroth AB, Javadpour N, et al: Treatment of poor prognosis nonseminomatous testicular cancer with a"high-dose"platinum combination chemotherapy regimen. Cancer 51: 1803-1807, 1983.
 
20) Stoter G, Denis L: The chemotherapy of disseminated testicular non-seminomatous germ cell tumors and the clinical research of the EORTC genitourinary group. Acta Uro1. Belg. 53: 428-435, 1985.
 
21) Bajorin D, Katz A, Chan E, et al: Comparison of criteria for assigning germ cell tumor patients to"good risk" and "poor risk"studies. J. Clin. Oncol. 6: 786-792, 1988.
PubMed
22) Priest ER, Vogelzang NJ: Optimal drug therapy in the treatment of testicular cancer. Drugs 42: 52-64, 1991.
PubMed
23) Einhorn LH: Treatment of testicular cancer: anew and improved model. J. Clin. Oncol. 8: 1777-1781, 1990.
 
24) Loehrer PJ: Salvage therapy in recurrent germ cell cancer. Hematol. Oncol. Clin. North Am. 5: 1211-1221, 1991.
PubMed
25) Richie JP: Surgical aspects in the treatment of patients with testicular cancer. Hematol. Oncol. Clin. North Am. 5: 1127-1142, 1991.
PubMed
26) Donohue Jp, Zachary JM, Maynard BR: Distribution of nodal metastases in nonseminomatous testis cancer. J. Urol. 128: 315-320, 1982.
PubMed
27) Wood DP, Herr HW, Heller G, et al: Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J. Urol. 148: 1812-1816, 1992.
PubMed
28) Colleselli K, Poisel S, Schachtner W, et al: Nervepreserving bilateral retroperitoneal lymphadenectomy: anatomical study and operative approach. J. Urol. 144: 293-298, 1990.
PubMed
29) Qvist H, Fossa SD, Ous S, et al: Retroperitoneal surgery in patients with nonseminomatous testicular cancer and minimal residual tumor. J. Surg. Oncol. 50: 220-223, 1992.
PubMed
30) Fox EP, Loehrer PJ: Chemotherapy for advanced testicular cancer. Hematol. Oncol. Clin. North Am. 5: 1173-1187, 1991.
PubMed
31) Einhorn LH: Salvage therapy for germ cell tumors. Semin. Oncol. 21(suppl. 7) : 47-51, 1994.
 
32) Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N. Engl. J. Med. 316: 1435-1440, 1987.
 
33) Nichols C, Williams S, Loehrer P, et al: Randomized study of cisplatin dose intensity in advanced germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol. 9: 1163-1172, 1991.
 
34) Loehrer PJ, Lauer P, Roth BJ, et al: Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann. Intern. Med. 7: 540-546, 1988.
PubMed
35) Einhorn LH: VP l6 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer. Cancer Chemother. Pharmacol. 18(suppl. 2) : s45-s 50, 1986.
 
36) Broun ER, Nichols CR, Kneebone P, et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. Intern. Med. 117: 124-128, 1992.
PubMed
37) Motzer RJ, Bosl GJ: High dose chemotherapy for resistant germ cell tumors: recent advances and future directions J. Natl. Cancer Inst. 84: 1703-1709. 1992.
PubMed
38) Dosoretz DE, Shipley WU, Blitzer PH, et al: Megavoltage irradiation for pure testicular seminoma: results and patterns of failure. Cancer 48: 2184-2190, 1981.
PubMed
39) Sturgeon JF, et al: Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J. Clin. Oncol. 10: 564-568, 1992.
 
40) Weissbach L: Organ-preserving surgery of malignant germ-cell tumors J. Urol. 153: 90-93, 1995.
PubMed
41) Friedman EL, Garnick MB, Stomper PC, et al: Therapeutic guidelines and results in advanced seminoma. J. Clin. Oncol. 3: 1325-1332, 1985.
PubMed
42) Loehrer PJ, Birch R, Williams SD, et al: Chemotherapy of metastatic seminoma: The Southeastern Cancer Study Group experience J. Clin. Onco1. 5: 1212-1220, 1987.
 
43) McLeod DG, et al: Staging relationships and outcome in early stage testicular cancer: areport from the Testicular Cancer Intergroup Study. J. Urol. 145: 1178-1183, 1991.
 
44) Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J. Clin. Oncol. 8: 1683-1694, 1990.
PubMed
45) Donohue Jp, Thornhill JA, Foster RS, et al: Stage I nonseminomatous germ cell testicular cancer: management options and risk-benefit considerations. World J. Urol. 12: 170-176, 1994.
 
46) Foster RS, et al: Stage II nonseminomatous germ-cell testicular tumors: the Indiana experience and riskbenefit analysis. World J. Urol. 12: 143-146, 1994.
PubMed
P.1278 掲載の参考文献
1) 厚生省大臣官房統計情報部編: 平成7年人口動態統計. (財) 厚生総計協会, 1997, p. 274.
 
2) 滝 一郎: 子宮癌登録委員会報告: 昭和56年度子宮頸癌患者年報. 日産婦誌 29: 1779-1791, 1977.
 
3) 工藤隆一: 婦人科腫瘍委員会報告: 1993年度子宮頸癌患者年報. 日産婦誌 49: 41-75, 1997.
 
4) Christopherson WM, Parker JE: Relation of cervical cancer to early marriage and child bearing. N. Engl. J. Med. 273: 235-239, 1965.
 
5) Rotkin ID: Adolescent coitus and cervical cancer associations of related events with incerased risk. Cancer Res. 27: 603-617, 1967.
 
6) Keighley E. Carcinoma of the cervix among prostitutes in a women’s prison. Bt. J. Verner. Dis. 44: 245-255, 1968.
 
7) Schiffman MH, Bauer HM, Hoover RN, et al: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 85: 958-964, 1993.
PubMed
8) Brisson J, Morin C, Fortier M, et al: Risk factors for cervical intra-epithelial neoplasia differences between low and high grade lesions. Am. J. Epidemiol. 140: 700-710, 1994.
 
9) Tabbara S, Saleh AM, Andersen WA, et al: The Bethesda classification for squamous intraepithelial lesions: histologic, cytologic and viral correlates. Obstet. Gynecol. 79: 338-346, 1992.
 
10) Cuzick J, Terry G, Ho L, et al: Human papillomavirus type 16 DNA in cervical smears as predictor of highgrade cervical cancer. Lancet 339: 959-960, 1992.
PubMed
11) Richart RM, Wright TC: Controversies in the management of low-grade cervical intraepithelial neoplasia. Cancer 71: 1413-1421, 1993.
PubMed
12) Koutsky LA, Holmes KK, Critchlow CW, et al: Acohort study of the risk of cervical intraepithelial neoplasia grade 20r 3 in relation to papilloma-virus infection. N. Engl. J. Med. 327: 1272-1278, 1992.
 
13) Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papilloma virus in cervical cancer: aworldwide perspective. J. Natl. Cancer Inst. 87: 796-802, 1995.
 
14) Barron BA, Richart RM: Statistical model of the natural history of cervical carcinoma. II. Estimates of the transition time from dysplasia to carcinoma in situ. J. Natl. Cancer Inst. 45: 1025-1030, 1970.
PubMed
15) Kashigarian M, Dunn JE: The duration of intraepithelial and preclinical squamous cell carcinoma of the uterine cervix. Am. J. Epidemiol. 921221-222, 1970.
 
16) Cramer DW, Cutler SJ: Incidence and histopathology of malignancies of the female genital organs in the United States. Am. J. Obstet. Gynecol. 1181443-460, 1974.
 
17) Koss LG, Stewart FW, Foote FW, et al: Some histological aspects of behavior of epidermoid carcinoma in situ and related lesions of the uterine cervix. Cancer 16: 1160-1211, 1963.
 
18) Clemmesen J, Poulsen H: Report of the Ministry of the Interior Document 3. Copenhagen, 1971.
 
19) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会編: 子宮頸癌取扱い規約. 金原出版, 東京, 1997.
 
20) Creasman WT(Editorial) : New gynecologic cancer staging. Gynecol. Oncol. 58: 157-158, 1995.
PubMed
21) Delgado G, Bundy B, Zaino R, et al: Prospective surgical pathological study of disease-free interval in patients with stage I B squamous cell carcinoma of the cervix: Gynecologic Oncology Group study. Gynecol. Oncol. 38: 352-357, 1990.
 
22) Zaino RJ, Ward S, Delgado G, et al: Histopathologic predictors of the behavior of surgically treated stage I B squamous cell carcinoma of the cervix. Cancer 69: 1750-1758, 1992.
 
23) Burghardt E, Baltzer J, Tulusan AH, et al: Results of surgical treatment of 1028 cervical cancers studied with volumetry. Cancer 70: 648-655, 1992.
PubMed
24) Stehman FB, Bundy BN, DiSaia PJ, et al: Carcinoma of the cervix treated with radiation therapy I: Amultivariate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 67: 2776-2785, 1991.
 
25) Fagundes H, Perez CA, Grigsby PW, et al: Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 24: 197-204, 1992.
PubMed
26) Eifel PJ, Morris M, Oswald MJ, et al: Adenocarcinoma of the uterine cervix: Prognosis and patterns of failure in 367 cases. Cancer 65: 2507-2514, 1990.
PubMed
27) Gallup DG, Harper RH, Stock RJ: Poor prognosis in patients with adenosquamous cell carcinoma of the cervix. Obstet. Gynecol. 65: 416-422, 1985.
PubMed
28) Yazigi R, Sandstad J, Munoz AK, et al: Adenosquamous carcinoma of the cervix: Prognosis in stage IB. Obstet. Gynecol. 75(6) : 1012-1015, 1990.
PubMed
29) Bethwaite P, Yeong ML, Holloway L, et al: The prognosis of adenosquamous carcinomas of the uterine cervix, Br. J Obstet. Gynecol. 99: 745-750, 1992.
 
30) Maiman M, Fruchter RG, Guy L, et al: Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 71: 402-406, 1993.
PubMed
31) Bourhis J, Le MG, Barrois M, et al: Prognostic value of c-myc protooncogene overexpression in early invasive carcinoma of the cervix. J. Clin. Oncol. 8: 1789-1796, 1990.
PubMed
32) Strang P, Eklund G, Stendahl B, et al: S-phase rate as a predictor of early recurrences in carcinoma of the uterine cervix. Anticancer Res. 7: 807-810, 1987.
 
33) Kolstad P, Klelm V: Long term follow up of 1121 cases of carcinoma-in situ. Obstet. Gynecol. 48: 125-129, 1976.
 
34) Creasman WT, Rutledge FN: Carcinoma in situ of the cervix. Obstet. Gynecol. 3: 373-380, 1972.
 
35) Grigsby PW, Perez CA: Radiotherapy alone for medically inoperable carcinoma of the cervix: Stage IA and carcinoma in sitza. Int. J. Radiat. Oncol. Biol. Phys. 21: 375-378, 1991.
PubMed
36) Van Nagell JR, Roddick JW, Lowin DM: The staging of cervical cancer: Inevitable discrepancies between clinical staging and pathological findings. Am. J. Obstet. Gynecol. 1101973-978, 1971.
 
37) Hasumi K, Sakamoto A, Sugano H: Microinvasive carcinoma of the uterine cervix. Cancer 29: 928-931, 1980.
PubMed
38) Kolstad P: Follow-up study of 232 patients with stage IA 1 and 411 stage IA 2 squamous cell carcinoma of the cervix(microinvasive carcinoma) . Gynecol. Oncol. 33: 265-272, 1989.
 
39) Burghardt E, Girardi F, Lahousen M, et al: Microinvasive carcinoma of the uterine cervix(lnternational Federation of Gynecology and Obstetrics stage IA) , Cancer 67: 1037-1045, 1991:
 
40) Greer BE, Figge DC, Tamimi HK, et al: Stage IA 2 squamous carcinoma of the cervix: Difficult diagnosis and therapeutic dilemma. Am. J. Obstet. Gynecol. 162: 1406-1411, 1990.
 
41) Perez CA: Carcinoma of the uterine cervix. In: Principles and Practice of Radiation Oncology(eds. by Perez CA, Brady LW) , 2nd Ed, JB Lippincott, Philadelphia, 1992, pp. 919-965.
 
42) Perez CA, Kurman RJ, Stehman FB, et al: Uterine Cervix. Ch 271n: Principles and Practice of Clinical Gynecologic Oncology(eds. by Hoskins WJ, Perez CA, Young RC) , 2nd Ed, JB Lippincott, Philadelphia, 1992, pp. 591-662.
 
43) Durrance FY, Fletcher GH, Rutledge FN: Analysis of central recurrent disease in stages I and II squamous cell carcinoma of the cervix on intact uterus. Am. J. Roentgenol. Radium. Ther. Nucl. Med. 106: 831-838, 1969.
PubMed
44) Homesley HD, Raben M, Blake DD, et al: Relationship of lesion size to survival in patients with stage IB squamous cell carcinoma of the cervix uteri treated by radiation therapy. Surg. Gynecol. Oncol. 150: 529-531, 1980.
 
45) Maruyama Y, van Nagel JR, Yoneda J, et al: Dose-response and failure pattern for bulky or barrel-shaped stage IB cervical cancer treated by combined photon irradiation and extrafascial hysterectomy. Cancer 63: 70-76, 1989.
PubMed
46) 0’Quinn AG, Flecher GH, Wharton JT: Guidelines for conservative hysterectomy after irradiation. Gynecol. Oncol. 9: 68-79, 1980.
 
47) Hopkins MP, Morley GW: Radical hysterectomy versus radiation therapy for stage IB squamous cell cancer of the cervix. Cancer 68: 272-277, 1991.
PubMed
48) Van Nagell JP, Rayburn W, Donaldson ES: Therapeutic implication of patterns of recurrence in cancer of the uterine cervix. Cancer 44: 2354-2361, 1979.
 
49) Piver MS, Chung WS: Prognostic significance of cervical lesion size and pelvic node metastasis in cervicalcarcinoma. Obstet. Gynecol. 46: 507-542, 1975.
 
50) Photopulos GL: Surgery or radiation for early cervical cancer. Clin. Obstet. Gynecol. 33: 872-882, 1990.
PubMed
51) Mendenhall WM, McCarty PJ, Morgan LS, et al: Stage IB or IIA-B carcinoma of the intact uterine cervix≧ 6cm in diameter: Is adjuvant extrafacial hysterectomy beneficial？ lnt. J. Radiat. Oncol. Biol. Phys. 21: 899-904, 1991.
 
52) Alberts DS, Garcia D, Mason-Liddil N: Cisplatin in advanced cancer of the cervix: An update. Semin. Oncol. 18: 11-24, 1991.
PubMed
53) Sutton GP, Blessing JA, Adock L, et al: Phase II study of ifosfamide and mesna in patients with previously treated carcinoma of the cervix. A Gynecology Group study. Invst. New Drugs 7: 341-343, 1989.
 
54) Wallace H, Hreshchshyn M, Wilbanks G, et al: Comparison of the therapeutic effect of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat. Rep. 62: 1435-1441, 1978.
 
55) ThigPen JT: Single agent chemotherapy in carcinoma of the cervix. In: Cervix Cancer(ed. by Surwit W, Alberts DS) , Martinus Nijhoff, Boston, 1987.
 
56) Krakoff IH, Cvitkovic E, Currie V, et al: Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer 40: 2027-2037, 1977.
PubMed
57) 竹内正七, 土橋一慶, 藤本征一郎・他: 子宮頚癌および卵巣癌に対するCPT-11の後期第2相試験. CPT-11研究会婦人科癌分科会. 癌と化学療法 18: 1681-1689, 1991.
 
58) Wasserman T, Carter S: The integration of chemotherapy into combined modality treatment of solid tumors: V田. Cervical cancer. Cancer Treat. Rev. 4: 25-46, 1977.
 
59) McGuire WP, Arseneau JC, Blessing JA, et al: A randomized comparative trial of carboplatin and iproPlatin in advanced squamous carcinoma of the uterine cervix: AGynecologic Oncology Group study. J. Clin. Oncol. 7: 1462-1468, 1989.
 
60) Panici PB, Scambia G, Baiocchi G et al: Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Cancer 67: 372-379, 1991.
PubMed
61) Fontanelli R, Spatti G, Raspagliesi F, et al : A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann. Oncol. 3: 117-121, 1992.
PubMed
62) Friedlander ML, Atkinson K, Coppleson JVM, et al: The integration of chemotherapy into the management of locally advanced cervical cancer: Apilot study. Gynecol Oncol. 19: 1-7, 1984.
 
63) Kirsten F, Atkinson KH, Coppleson JVM, et al: Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer. Br. J. Obstet. Gynecol. 941583-588, 1987.
 
64) Sardi JE, Guillermo R, Paola D, et al: A possible new trend in the management of the carcinoma of the cervix uteri. Gynecol. Oncol. 25: 139-149, 1986.
 
65) Kim DS, Moon Y, Kim KT, et al: Two-year survival: Preoperative adjuvant chemotherapy in the treatment of cervical cancer Stage I B and II with bulky tumor. Gynecol. Oncol. 33: 225-230, 1989.
 
66) Chang HC, Lai CH, Chou PC, et al: Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early stage bulky cervical carcinoma. Cancer Chemother. Pharmacol. 30: 281-285, 1992.
PubMed
67) Sardi J, Sananes C, Giaroli A, et al: Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uterus. Gyneco1. Oncol. 38: 486-493, 1990.
PubMed
68) Rabinovich MG, Focaccia G, Ferreyra R, et al: Neoadjuvant chemotherapy for cervical carcinoma. Obstet. Gynecol. 78: 685-688, 1991.
PubMed
69) Symonds RE, Burnett RA, Habeshaw T, et al: The prognostic value of a response to chemotherapy given before radiotherapy in a dvanced cancer of cervix. Br. J. Cancer 59: 473-475, 1989.
 
70) Weiner SA, Aristizabal S, Alberts DS, et al: A phase II trial of mitomycin, vincristine, bleomycin(MOBP) as neoadjuvant therapy in high-risk cervical carcinoma. Gynecol. Oncol. 30: 1-6, 1988.
PubMed
71) Lipsztein R, Kredentser D, Dottino P, et al: Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix. Am. J. Clin. Oncol. (CCT) 10: 527-530, 1987.
 
72) Dottino PR, Plaxe SC, Beddoe AM, et al: Induction chemotherapy followed by radical surgery in cervical cancer. Gynecol. Oncol. 40: 7-11, 1991.
PubMed
73) Souhami L, Gil RA, Allan SE, et al: Randomized trial chemotherapy followed by pelvic radiation therapy in Stage III B carcinoma of the cervix. J. Clin. Oncol. 9: 970-977, 1991.
PubMed
74) Patton T Jr, Kavanagh JJ, Delclos L, et al: Five-year survival in patients given intra-arterial chemotherapy prior to radiotherapy for advanced squamous carcinoma of the cervix and vagina. Gynecol. Oncol. 42: 54-59, 1991.
PubMed
75) Deppe G, Malviya VK, Han I, et al: A preliminary report of combination chemotherapy with cisplatin and mitomycin-C followed by radical hysterectomy or radiation therapy in patients with locally advanced cervical cancer. Gynecol. Oncol. 42: 178-181, 1991.
PubMed
76) Panici PB, Scambia G, Baiocchi G, et al: Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Cancer 67: 372-379, 1991.
PubMed
77) Goldhirsch A, Greeiner R, Bleher A, et al: Combination of chemotherapy with methotrexate, bleomycin, and cisplatin, and radiation therapy for locally advanced carcinoma of the cervix. Am. J. Clin. Oncol. 9: 12-14, 1986.
 
78) Lara PC, Garcia-Puche JL, Pedraze V: Cisplatin-ifosfamide as neoadjuvant chemotherapy in Stage III B cervical uterine squamous-cell carcinoma. Cancer Chemother. Pharmacol. 26: S36-S38, 1990.
 
79) Kuhnle H, Meerpohl HG, Eiermann W, et al: Phase II study of carboplatin／ifosfamide in untreated advanced cervical cancer. Cancer Chemother. Pharmacol 26: S33-S35, 1990.
PubMed
80) Tobias J, Buxton EJ, Blackledge G, et al: Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. Cancer Chemother. Pharmocol. 26: S59-S62, 1990.
 
81) 平林光司: 子宮頸癌neoadjuvant chemotherapy. "図説産婦人科VIEW腫瘍薬物療法"メジカルビュー社, 東京, 1994, p. 4209.
 
82) 工藤隆一: 婦人科腫瘍委員会第34回治療年報. 日産婦誌 49: 273-306, 1997.
 
P.1290 掲載の参考文献
1) Hacker NF, Fifel P, McGuire W, et al: Vulva. In: Principles and Practice of Gynecologic Oncology(eds by Hoskins WJ, Perez CA, Young RC) , JB Lippincott, Philadelphia, 1992, pp. 537-566.
 
2) 杉森 甫, 工藤隆一(婦人科腫瘍委員会) : 本邦における外陰癌の臨床統計調査報告. 日産婦会誌 47: 685-693, 1992.
 
3) Crum CP, Liskow A, Pertas P, et al: Vulvar intraepithelial neoplasia(severe atypia and carcinoma in situ) . Cancer 54: 1429-1434, 1984.
 
4) Kaufman RH, Friearich EG Jr, Gardner HL: Benigndiseases of the vulva and vagina. 3rd Ed, Year-Book Medical Publishers, Chicago, 1989.
 
5) Karram M, Tabor B, Smotkin D, et al: Detection of human papilloma virus deoxyribonucleic acid from vulvar dystrophies and vulvar intraepithelial neoplastic lesions. Am. J. Obstet. Gynecol. 159: 22, 1988.
 
6) Synopsis of Gynecologic Oncology(eds by Morrow Cp, Curtin JP, Townsend DE) , 4th Ed, Churchill Livingstone, New York, 1993.
 
7) Homesley HD, Bundy BN, Sedlis A, et al: Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma related to prognostic factors for survival. A Gynecologic Oncology Group study. Am. J. Obstet. Gynecol. 1641997-1004, 1991.
 
8) DiSaia PJ, Creasman WT: Clinical Gynecologic Oncology, 4th Ed, Mosby-Year Book, St Louis, 1993.
 
9) Sedlis A, Homesley H, Bundy BN, et al: Positive groin lymph nodes in superficial squamous cell vulvar cancer. Am. J. Obstet. Gynecol. 156: 1159-1164, 1987.
PubMed
10) Boyce J, Fruchter RG, Kasambilides E, et al: Prognostic factors in carcinoma of the vulva. Gynecol. Oncol. 20: 364-377, 1985.
PubMed
11) Plentl AA, Friedman EA: Clinical significance of vulvar lymphatics. In: Lymphatic System of the Female Genitalia, W. B. Saunders, Philadelphia, 1971, pp. 28-29.
 
12) Stehman FB, Burdy BN, Dvoretsky PM, et al: Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Obstet. Gynecol. 79: 490-497, 1992.
 
13) FIGO News, Modifications in the staging of Stage I vulvar and Stage I cervical cancer. Report of the FIGO Committee on Gynecologic Oncology. Int. J. Gynecol. Obstet. 50: 215-216, 1995.
 
14) Homesley HD, Bundy BN, Sedlis A, et al: Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet. Gynecol. 68: 733-740, 1986.
PubMed
15) Homesley HD, Bundy BN, Sedlis A, et al: Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva. Gynecol. Oncol. 49: 279-283, 1993.
PubMed
16) Figge DC, Tamimi HK, Greer BE: Lymphatic spread in carcinoma of the vulva. Am. J. Obstet. Gynecol. 1521 387-394, 1985.
 
17) Cavanagh D, Fiorica JV, Hoffman MS, et al: Invasive carcinoma of the vulva. Am. J Obstet. Gynecol. 163: 1007-1015, 1990.
PubMed
18) Rutledge FN, Mitchell MF, Munsell MF, et al: Prognostic indicators for invasive carcinoma of the vulva. Gynecol. Oncol. 42: 239-244, 1991.
PubMed
19) Baggish MS, Dorsey JH: CO21aser for the treatment of vulvar carcinoma in situ. Obstet. Gynecol. 57: 371-375, 1981.
PubMed
20) Ferenczy A, Wright TC, Richart RM Jr: Comparison of CO21aser surgery and loop electrosurgical excision fulguration procedure(LEEP) for the treatment of vulvar intraepithelial neoplasia(VIN) . Int. J. Gynecol. Cancer 4: 22-28, 1994.
 
21) Kaufman RH: Intraepithelial neoplasia of the valva. Gynecol. Oncol. 56: 8-21, 1995.
 
22) Hacker NF, Berek JS, Lagasse LD, et al: Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet. Gynecol. 63: 155-162, 1984.
 
23) Disaia PJ, Creasman WT, Rich WM: An alternate apProach to early cancer of the vulva. Am. J. Obstet. Gynecol. 133: 825-832, 1979.
PubMed
24) Burger MPM, Hollema H, Bouma J: The side of groin node metastases in unilateral vulvar carcinoma. Int. J. Gynecol. Cancer 6: 318-322, 1996.
 
25) Boronow RC: Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer. Cancer 49: 1085-1091, 1982.
PubMed
26) 須川 佶, 橋本正淑, 鈴木雅州・他: 本邦における外陰癌の発症ならびに治療の現況. 日産婦会誌 32: 177-186, 1980.
 
27) Trope C, Johnsson JE, Larsson G, et al: Bleomycin alone or combined with mitomycin C in treatment of advanced or recurrent squamous cell carcinoma of the vulva. Cancer Treat. Rep. 64: 639, 1980.
 
28) 清水敬生, 荷見勝彦, 八木裕昭・他: FIGO IV期の外陰癌に対するBOMP療法. 日産婦会誌 41: 609-612, 1989.
 
29) Deppe G, Bruckner H and Cohen C: Adriamycin treatment of advanced vulvar carcinoma. Obstet. Gynecol. 50: 138, 1977.
 
30) Thomas G, Dembo A, Depetrillo A, et al: Concurrent radiation and chemotherapy in vulvar carcinoma. Gynecol. Oncol. 34: 263-267, 1989.
PubMed
31) Levin W, Goldberg G, Altaras, et al: The use of concomitant chemotherapy and radiotherapy prior to surgery in advanced stage carcinoma of the vulva. Gynecol. Oncol. 25: 20-25, 1986.
PubMed
32) Berek JS, Heaps JM, Fu YS, et al: Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol. Oncol. 42: 197-201, 1991.
PubMed
33) Russell AH, Mesic JB, Scudder SA, et al: Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva. Gynecol. Oncol. 47: 14-20, 1992.
PubMed
34) Sebag-Montefiore DJ, McLean C, Arnott SJ, et al: Treatment of advanced carcinoma of the vulva with chemotherapy. -can exenterative be avoided？Int. J. Gynecol. Cancer 4: 150-155, 1994.
PubMed
P.1304 掲載の参考文献
1) Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15: 10-17, 1983.
PubMed
2) Deligdisch L, Cohen CJ: Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 56: 1452-1455, 1985.
PubMed
3) Koss LG, Schreiber K, Oberlander SG, et al: Detection of endometrial cancer and hyperplasia in a symptomatic women. Obstet. Gynecol. 64: 1-11, 1984.
 
4) Robboy SJ, Bradley R: Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet. Gynecol. 54: 269-277, 1979.
PubMed
5) Robboy SJ, Miller AW, Kurman RJ: The pathologic features and behavior of endometrial carcinoma associated with exogenous estrogen administration. Pathol. Res. Pract. 174: 237-256, 1982.
PubMed
6) Smith M, McCartney AJ: Occult, high-risk endometrial cancer. Gynecol. Oncol. 22: 154-161, 1985.
PubMed
7) Morrow CP, Curtin Jp, Townsend DE et al: Synopsis of Gynecologic Oncology(eds by Morrrow CP, Curtin Jp, Townsend DE) , 4th ED. Churchill Livingstone, New York, 1993.
 
8) Hartz A, Fisheer M, Cassell E, et al: Obesity and endometrial cancer. Intern. Med. 6: 61-65, 1985.
 
9) Sperofff L, Glass RH, Kase NG: Clinical gynecologic endocrinology and infertility, 4th Ed. Williams and Wilkins, Baltimore, 1989.
 
10) Brakat RR, Park RC, Grigsby PW, et al: Corpus: Epithelial Tumors. In: Principles and Practice of Gynecologic Oncology(eds by Hoskins WJ, Perez CA, Young RC) , JB Lippincott, Philadelphia, 1997, pp. 359-896.
 
11) Gambrell Jr RD: Role of hormones in the etiology and prevention of endometrial and breast cancer. Acta Obstet. Gynecol. Scand. 106: 37-46, 1982.
 
12) Gambrell RD, Bagnell CA, Greenblatt RB: Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review. Am. J. Obstet. Gynecol. 146: 696-707, 1983.
PubMed
13) MacMahon B: Risk factors for endometrial cancer. Gynecol. Oncol. 2: 122-129, 1974.
PubMed
14) Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel. Project(NSABP) B-14: J. Natl. Cancer Inst. 86: 527-537, 1994.
PubMed
15) Jordan JC, Assikis VJ: Endometrial carcinoma and Tamoxifen: Clearing up a controversy. Clin. Cancer Res. 1: 467-472, 1995.
 
16) Ovarian Malignancies, Diagnostic and Therapeutic Advances(ed by Piver MD) , Churchill Livingstone, New York, 1987.
 
17) Hacker NF: Uterine Cancer. In Practical Gynecologic Oncology. 1996, pp. 285-326.
 
18) 婦人科腫瘍委員会第32回治療年報. 日産婦会誌 46: 935-1001, 1994.
 
19) 婦人科腫瘍委員会第34回治療年報. 日産婦会誌 49: 273-306, 1997.
 
20) 婦人科腫瘍委員会報告. 日産婦会誌 47: 177-211, 1995.
 
21) 婦人科腫瘍委員会報告. 日産婦会誌 49: 41-75, 1997.
 
22) DuBeshter B, Angel C, Lin J, et al: Gynecologic Tumors. In: Clinical Oncology, A Multidiciplinary Approach for Physicians and Students(ed by Rub in P) , 7th Ed. WB Saunders, Philadelphia, 1994, Chapter 22.
 
23) Kurman RJ, Kaminski PF, Norris HJ : The behavior of endometrial hyperplasia. A long-term study of"untreated"hyperplasia in 170 patients. Cancer 56: 403-412, 1985.
PubMed
24) Gal D : Horomonal therapy for lesions of the endometrium. Semin. Oncol . 13: 33-36, 1986.
 
25) Ferenczy A, Gelfand M: The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am. J. Obstet. Gynecol. 160: 126-131, 1989.
PubMed
26) Hawwa ZM, Nahhas WA, Copenhauer EH: Postmenopausal bleeding. Lahey Clin. Foundation Bull. 19: 61, 1970.
 
27) Pacheco JC, Kempers RD: Etiology of postmenopausal bleeding. Obstet. Gynecol. 32: 40-46, 1968.
PubMed
28) Granberg S, Wikland M, Karlsson B, et al: Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am. J. Obstet. Gynecol. 164: 47-52, 1991.
PubMed
29) Chun M, Ball HG, Doherty F, et al: Uterine thickness determination using real-time ultrasonography: A guide for intracavitary brachytherapy in the treatment of endometrial carcinoma. Gynecol. Oncol. 36: 176-180, 1990.
PubMed
30) Fleischer AC, Kalemeris GC, Machin JE, et al: Sonographic depiction of normal and abnormal endometrium with histopathologic correlation. J. Ultrasound Med. 5: 445, 1986.
PubMed
31) Gordon AN, Fleischer AC, Dudley BS, et al: Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography(US) and magnetic resonance imaging(MRI) . Gynecol. Oncol. 34: 175-179, 1989.
PubMed
32) 松浦佑介, 柏村正道, 篠原道興・他: 子宮体癌筋層浸潤の評価におけるMRIの有用性について. 日産婦会誌 44: 787-792, 1992.
 
33) Chen SS, Rumancik WM, Spiegel G: Magnetic resonance imaging in stage I endometrial carcinoma. Obstet. Gyneco1. 75: 274-277, 1990.
 
34) Powell MC, Wowmack C, Buckley J, et al: Preoperative magnetic resonance imaging of stage I endometrial adenocarcinoma. Br. J. Obstet. Gynecol. 93: 353-360, 1986.
 
35) Yazigi R, Cohen J, Munoz AK, et al: Magnetic resonance imaging determination of myometrial invasion in endometrial carcinoma. Gynecol. Oncol. 34: 94-97, 1989.
PubMed
36) Joja I, Asakawa M, Asakawa T, et al: Endometrial carcinoma: dynamic MRI with turbo-FLASH technique. J. Comput. Tomogr. 20: 878-887, 1996.
 
37) Niloff JM, Klug TL, Schaetsl E, et al: Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am. J. Obstet. Gynecol. 148: 1057-1058, 1984.
 
38) Patsner B, Mann WJ, Cohen H, et al: Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am. J. Obstet. Gynecol. 158: 399-402, 1988.
PubMed
39) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会: 子宮体癌取扱い規約, 金原出版, 東京, 1987.
 
40) Boronow RC, Morrow CP, Creaseman WT, et al: Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. Obstet. Gynecol. 63: 825-832, 1984,
 
41) Creaseman WT, Morrow CP, Bundy BN, et al: Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 60: 2035-2041, 1987.
 
42) FIGO: Classification and staging of malignant tumors in the female pelvis. Int. J. Gynaecol. Obstet. 9: 172, 1971.
 
43) 西谷雅史, 櫻木範明, 田中俊誠・他: 子宮体癌のFIGO新進行期分類(1989) についての検討-旧進行期分類(1983) との比較ならびに予後因子の解析. 日産婦会誌 43: 451-457, 1991.
 
44) FIGO: Annual Report on the Results of Treatment in Gynecological Cancer. Vol 21. Int. J. Gynecol. Obstet. 36 (Suppl.) : 1, 1991.
 
45) Chambers SK, Kapp DS, Peschel RF, et al: Prognostic factors and sites of failure in FIGO stage I, grade 3 endometrial carcinoma. Gynecol. Oncol. 27: 180-188, 1987.
 
46) Wilson TO, Podratz KC, Gaffey TA, et al: Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am. J. Obstet. Gynecol. 162: 418-426, 1990.
PubMed
47) Sutton GP: The significance of positive peritoneal cytology in endometrial cancer. Oncology 4: 21, 1990.
PubMed
48) Wharton JT, Mikura JJ, Mettlin C, et al: Risk factors and current management in carcinoma of the endometrium. Surg. Gynecol. Obstet. 162: 515-520, 1986.
 
49) Bucy GS, Mendenhall WM, Morgan LS, et al: Clinical stage I and II endometrial carcinoma treated with surgery and／or radiation therapy: Analysis of prognostic and treatment-related factors. Gynecol. Oncol. 33: 290-295, 1989.
PubMed
50) 竹島信宏, 梅沢 聡, 山脇孝晴・他: 子宮体癌筋層浸潤欠如症例に対する研究. 日産婦会誌 46: 553-558, 1995.
 
51) Hanson MB, van Nagell JR Jr, Powell DE, et al: The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 55: 1753-1757, 1985.
 
52) Sivridis E, Buckley CH, Fox H: The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma. Br. J. Obstet. Gynecol. 94: 991-994, 1987.
 
53) 西谷雅史, 櫻木範明, 田中俊誠・他: 子宮体癌の組織学的予後判定因子についての検討. 日産婦会誌 44: 453-460, 1992.
 
54) McLellan R, Dillon MB, Currie JL, et al: Peritoneal cytology in endometrial cancer: A review. Obstet. Gynecol. Surv. 44: 711-719, 1989.
PubMed
55) Konski A, Poulter C, Keys H, et al: Absence of prognostic significance, peritoneal dissemination and treatment advantage in endometrial cancer patients with positive peritoneal cytology. Int. J. Radiat. Oncol. Biol. Phys. 14: 49-55, 1988.
PubMed
56) Lurain JR, Rumsey NK, Schink JC, et al: Prognostic significance of positive peritoneal cytology in clinical stage Iadenocarcinoma of the endometrium. Obstet. Gynecol. 74: 175-179, 1989.
 
57) Yazigi R, Piver MS, Blumenson L: Malignant peritoneal cytology as prognostic indicators in stage I endometrial cancer. Obstet. Gynecol. 62: 359-362, 1983.
 
58) Turner DA, Gershenson DM, Arkinson N, et al: The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet. Gynecol. 74: 775-780, 1989.
 
59) Chrisopherson WM, Connelly PJ, Alberhasky RC: Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer 51: 1705-1709, 1983.
 
60) Nielson AL, Thomsen HK, Nyholm HC: Evaluation of the reproducibility of the revised 19881nternational Federation of Gynecology and Obstetrics grading system of endometrial cancer with special emphasis on nuclear grading. Cancer 68: 2303-2309, 1991.
 
61) Ambros RA, Kurman RJ: Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol. Oncol. 45: 235-239, 1992.
 
62) Iversen OE: Flow cytometric deoxyribonucleic acid index: aprognostic factor in endometrial carcinoma. Am. J. Obstet. Gynecol. 155: 770-776, 1986.
 
63) Stendahl U, Wagenuiis G, Strang P, et al: Flow cytometry in invasive endometrial carcinoma. In Vivo 2: 123- 127, 1988.
 
64) 塚本直樹: 婦人科癌に対する腹部大動脈周囲リンパ節廓清の適応と手技. 研修コーナー. 日産婦会誌 46: N103- N106, 1995.
 
65) Jones DA, Stout R: Results of intracavitary radium treatment for adenocarcinoma of the body of the uterus. Clin. Radiol. 37: 169-171, 1986.
PubMed
66) Greven K, Olds W: Radiotherapy in the management of endometrial carcinoma with cervical involvement. Cancer 60: 1737-1740, 1987.
PubMed
67) Larsen DM, Copeland LJ, Gallager HS, et al: The significance of residual tumor after preoperative pelvic irradiation for stage II endometrial carcinoma. Obstet. Gynecol. 70: 916-919, 1987.
 
68) Viaria M, Rosenman J, Halle J, et al: Primary radiation therapy for medically inoperable patients with endometrial carcinoma, stage I-II. Int. J. Radiat. Oncol. Biol. Phys. 13: 11-15, 1987.
 
69) Sears JD, Greven KM, Kathryn M, et al: Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 74: 1303-1308, 1994.
 
70) Morgan JD III, Reddy S, Sarin P, et al: Isolated vaginal recurrences of endometrial carcinoma. Radiology 189: 609-613, 1993.
 
71) Kucera H, Vavra N, Weghoupt K: Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received post operative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol. Oncol. 38: 99-104, 1993.
 
72) Marchetti DL, Piver MS, Tsukada Y, et al: Prevention of vaginal recurrence of stage I endometrial adenocarcinoma with postoperative vaginal radiation. Obstet. Gynecol. 67: 399-402, 1986.
 
73) Morrow CP, Bundy BN, Kurman RJ, et al: Relationship between surgical-pathologic risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 40: 55-65, 1991.
 
74) Potish RA, Twiggs LB, Adcok LL, et al: Role of whole abdominal radiation therapy in management of endometrial cancer；prognostic importance of factors indicating peritoneal metastases. Gynecol. Oncol. 21: 80-86, 1985.
 
75) Kauppila A: Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations (Review) . Acta Obstet. Gynecol. Scand. 63: 441-450, 1984.
PubMed
76) Lewis GC, Slack NH, Mortel R, et al: Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol. Oncol. 2: 368-376, 1974.
PubMed
77) Ayoub J, Audet-Lapointe P, Maschio A, et al: Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol. Oncol. 31: 327-337, 1988.
 
78) Creasman WT, Soper JT, McCarty KS Jr, et al: Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am. J. Obstet. Gynecol. 151: 922-932, 1985.
PubMed
79) MacDonald RR, Thorogood J, Mason MK: Arandomized trial of progestogens in the primary treatment of endometrial carcinoma. Br. J Obstet Gynecol. 95: 166-174, 1988.
 
80) Vergote I, Kjorstad K, Abeler V, et al: A randomized trial of adjuvant progestogen in early endometrial cancer. Cancer 64: 1011-1016, 1989.
PubMed
81) Gallagher CJ, Oliver RT, Oram DH, et al: A new treatment for endometrial cancer with gonadotropin releasinghormone analogue. Br. J. Obstet. Gynecol. 98: 1037-1041, 1991.
 
82) Swenerton KD: Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat. Rep. 64: 805-811, 1981.
 
83) Moore TD, Phillips PH, Nerestone SR, et al: Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J. Clin. Oncol. 9: 1071-1088, 1991.
 
84) Ball H, Blessing JA, Lentz S, et al: A Phase II trial of Taxol in advanced and recurrent adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Proceedings of the Society of Gynecologic Oncologists Annual Meeting. (Abstr＃69) 1995, p. 102.
 
85) Trope C, Johnson JE, Simonsen E, et al: Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am. J. Obstet. Gynecol. 149: 379-381, 1984.
 
86) Turbow MM, Thobon J, Ballon S, et al: Chemotherapy of advanced carcinoma with platinum, adriamycin, and cyclophosphamide. Proc. Am. Assoc. Cancer Res. 1: 108-112, 1982.
 
87) Creasman WT, Henderson D, Hinshq W, et al: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet. Gynecol. 46: 326-330, 1986.
 
P.1339 掲載の参考文献
1) がん統計白書-罹患/死亡/予後-1993. 富永祐民, 青木国雄, 花井 彩, 栗原 登 (編) , 篠原出版, 東京, 1993.
 
2) Greene MH, Clark JW, Blaynney DW: The epidermiology of ovarian cancer. Semin. Oncol. 11(3) : 209-226, 1984.
 
3) Rossing MA, Daling JR, Weiss NS, et al: Ovarian tumors in a cohort of infertile women. N. Engl. J. Med. 331: 765-771, 1994.
 
4) Gross Jp, Schlesselman JJ: The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet. Gynecol. 83: 419-424, 1992.
 
5) Parazzini F, Francheschi S, La Vecchia C, et al: The epidemiology of ovarian cancer. Gynecol. Oncol. 43: 9-23, 1991.
 
6) Gross PJ, Schlessen JJ: The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet. Gynecol. 83: 419-424, 1994.
 
7) Yancik R, Ries LG, LYates JW: Ovarian cancer in the elderly: an analysis of surveillance. Am. J. Obstet. Gynecol. 154: 639-647, 1986.
 
8) Lynch HT, Fitzscommons ML, Conway TA, et al: Hereditary carcinoma of the ovary and associated cancers: a study of two families. Gynecol. Oncol. 36: 48-55, 1990.
PubMed
9) Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA 1-mutation carriers. Am. J. Hum. Genet. 56: 265-271, 1995.
 
10) Hankinson SE, Hunter DJ, Colditz GA, et al: Tubal ligation, hysterectomy, and risk of ovarian cancer, A prospective study. JAMA 270: 2813-2818, 1993.
PubMed
11) Tobacman JK, Tucker MA, Kase R, et al: Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prome families. Lancet 2: 795-797, 1982.
 
12) Lauchlan SC: Non-invasive ovarian carcinoma. Int. J. Gynecol. Pahtol. 9: 158-169, 1990.
 
13) Bell D, Flott T, Pastel-Levy C, et al: DNA ploidy of ovarian serous borderline tumors (SBT) and their extraovarian implants. [Abstr. ] Mod. Pathol. 2: 8a, 1989.
 
14) Farrow DC, Weiss NS, Lyon JL, et al: Association of obesity and ovarian cancer in a case control study. Am. J. Epidemiol. 129: 1300-1304, 1989.
 
15) Kramer BS, Gohagan J, Prorok PC, et al: A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71: 589-593, 1993.
PubMed
16) Heaps JM, Neiberg RK, Gerek JS: Malignant neoplasms arising in endometriosis. Obstet. Gynecol. 85: 1023-1028, 1990.
 
17) Sampson JA: Endometrial carcinoma of the ovary. Arch. Surg. 10: 1-8, 1925.
 
18) Kurman RJ, Craig JM: Endometrioid and clear cell carcinomas of the ovary. Cancer 29: 1653-1664, 1972.
PubMed
19) Eifel P, Hendrickson M, Ross J, et al: Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer 50: 163-170, 1982.
PubMed
20) Symonds DA, Johnson DP, Wheeless CR Jr: Feulgen cytometry in simultaneous endometrial and ovarian carcinoma. Cancer 61: 2511-2516, 1988.
PubMed
21) Robey SS, Silva EG, Gershenson DM, et al: Transitional cell carcinoma in high-grade stage ovarian carcinoma: an indicator of favorable response to chemotherapy. Cancer 63: 839-847, 1989.
PubMed
22) Silva EG, Robey-Cafferty SS, Smith TL, et al: Ovarian carcinomas with transitional cell carcinoma pattern. Am. J. Clin. Pathol. 93: 457-465, 1990.
PubMed
23) Burghardt E, Hellmuth P, Lahousen M, et al: Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am. J. Obstet. Gynecol. 155: 315-319, 1986.
 
24) Rose PG, Piver MS, Isukada Y, et al: Metastatic patterns in histologic variants of ovarian cancer. Cancer 64: 1508-1513, 1989.
 
25) Young RC, Decker DG, Wharton JT, et al: Staging laparotomy in early ovarian cancer. JAMA 250: 3072-3076, 1983.
PubMed
26) Kimball RE, Schaerth JB, Kute TE, et al: Flow cytometric analysis of lymphnode metastases in advanced ovarian cancer: Clinical and biologic significance. Am. J. Obstet. Gynecol. 176: 1319-1327, 1997.
 
27) Slamon DDJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
 
28) Leary JA, Edwards BG, Houghton CRS: Amplification of HER-2/neu oncogene in human ovarian cancer. Int. J. Gynaecol. Oncol. 2: 293-298, 1993.
 
29) Reed E, Ostchega Y, Steinberg SM, et al: Evaluation of platinum-DNA adduct levels relative to known prognostic vaiables in a cohort of ovarian cancer patients. Cancer Res. 50: 2256-2260, 1990.
 
30) Skipper HE: Thoughts on cancer chemotherapy and combination modality therapy. JAMA 230: 1033-4036, 1974.
PubMed
31) Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42: 101-104, 1975.
PubMed
32) Hacker NF, Berek JS, Lagasse LD, et al: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61: 413-420, 1983.
PubMed
33) Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170: 974-980, 1994.
PubMed
34) Hoskins W, Bundy BN, Thigpen T, et al: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 47: 159-166, 1992.
 
35) van der Burg MEL, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N. Engl. J. Med. 332: 6629-6634, 1995.
 
36) Luesley D, Finn C, Varma R: The role of surgery in epithelial ovarian cancer. In: Ovarian Cancer 2, Biology, diagnosis and management (eds by Sharp F, Mason WP, Creasman W) . Chapman ＆ Hall Medical, London, pp. 357-366.
 
37) Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 303: 884-893, 1991.,
PubMed
38) Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: Ameta-analysis. J. Clin. Oncol. 9: 1668-1674, 1991.
 
39) Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol. 5: 756-767, 1978.
 
40) McGuire WP, Hoskins WJ, Brady MF, et al: A phase III trial of dose intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc. ASCO 11: 226, 1992.
 
41) Kaye SB: High dose cisplatin (100 mg/sm) is more effective than low dose (50 mg/sm) in combination with cyclophosphamide (750 mg/sm) for the treatment of advanced ovarian cancer. Proc. Int. Gynecol. Cancer Soc. 3: 170, 1991.
 
42) Gruppo Interregionale Cooperativo Oncologico Ginecologia: Long-term results of a randomized trial comparing cisplatin with cisplatin, cyclophosphamide and adriamycin in advanced ovarian cancer. Gynecol. Oncol. 45: 115-117, 1992.
PubMed
43) Ozols RF, Rubin SC, Dembo AJ, et al: Epithelial Ovarian Cancer. In: Principles and Practice of Gynecologic Oncology. JB. Lippincott, Philadelphia, 1992, pp. 731-781.
 
44) Bertelsen K, Jakobsen A, Stroyer I, et al: Aprospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian study Group Trial (DAXOVA) . Gynecol. Oncol. 49: 30-36, 1993.
 
45) Hunter RW, Alexander NDE, DipMathStat, Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery and independent determinant of prognosis? Am. J. Obstet. Gynecol. 166: 504-511, 1992.
 
46) McGuire WP, Hoskons WJ, Brady MF, et al: Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Gynecologic Oncology Group. Proc. Am. Soc. Clin. Oncol. 14: 274 (771) , 1995.
 
47) Piccart MJ, Bertelsen K, Stuart G, et al: Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca) ? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. ASCO 1258, 1997.
 
48) JP Neijt, M Hanse, SW Hansen, et al: Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage II B, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel carboplatin. ASCO 1259, 1997.
 
49) McGuire WP: Ovarian Cancer. In: Paclitaxel in Cancer Treatment. Marcel Dekker, New York, 1995, pp. 201-221.
 
50) McGuire WP, Rowinsky EK, Rosensheim NB, et al: Taxol: Aunique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111: 273-279, 1989.
 
51) Raptis G, Tiersten A, Fennelly D, et al: The addition of paclitaxel to high dose cyclophosphamide+filgrastim (G-CSF) markedly enhances the mobilization of CD 34+ peripheral blood progenitor cell (PBPC) in patients with responding metastatic breast cancer undergoing high dose chemotherapy. Proc. Am. Soc. Clin. Oncol. 14: 313 (919) , 1995.
 
52) Omura GA, Brady MF, Delmore JE, et al: A randomized trial of paclitaxel at 2 dose levels and filgrastim (GCSF) at 2 doses in platinum pretreated epithelial ovarian cancer: A Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. Proc. Am. Soc. Clin. Oncol. 15: 280(755) , 1996.
 
53) Chou T-C, Motzer RJ, Tong Y, et al: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: arational approach to clinical protocol design. J. Natl. Cancer Inst. 86: 1517-1524, 1994.
 
54) Rubin SC, Hoskins WJ, Markman M, et al: Long-term access to the peritoneal cavity in ovarian cancer patitents. Gyneqol. Oncol. 33: 46-48, 1989.
 
55) Davidson SA, Rubin SC, Markamn M, et al: Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol. Oncol. 41: 101-106, 1991.
 
56) Piccart MJ, Speyer JL, Markman M, et al: Intraperitoneal chemotherapy: technical experience at five institutions. Semin. Oncol. 12(3) : 90-96, 1985.
PubMed
57) Tarraza HM, Boyce CR, Smith WG, et al: Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol. Oncol. 50: 287-290, 1993.
PubMed
58) Alberts DS, Liu PY, Hannigan EV, et al: Phase III study of intraperitoneal cisplatin/intravenous cyclophosphamide vs IV CDDP/IV CPA in patients with optimal disease stage III ovarian cancer. A SWOG-GOG-ECOG intergroup study (INT OO51) . Proc. Am. Soc. Clin. Oncol. 14: 272(760) , 1995.
 
59) Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335: 1950-1955, 1996.
PubMed
60) Markman M, Blessing JA, Major F, et al: Salvage intraperitoneal therapy of ovarian cancer emptying CDDP and etoposide: AGynecologic Oncology Group Study. Gynecol. Oncol. 50: 191-195, 1993.
 
61) Markman M: personal communication.
 
62) Muggia FM, Braly PS, Brady MF, et al: Phase III of cisplatin (P) or paclitaxel (T) , versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC) : Gynecological Oncology Group (GOG) Study＃132. Proc. Am. Soc. Clin. Oncol. 14: 272, 1997.
PubMed
63) Hatae M, Onishi Y, Maeda Y: Current status of treatment for ovarian carcinoma in Japan. Cancer Chemotherapy. Challenges for the Future 10: 215-225, 1995.
 
64) Vermorken JB, Kobierska A, Chevallier B, et al: Phase II study of high-dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin. Proc. Am. Soc. Clin. Oncol. 14: 274, 1995.
 
65) Kohn EC, Sarosy G, Bicher A, et al: Dose-intense taxol: high response rate in patients with platinum-resistant ovarian cancer. J. NatlCancer Inst. 86: 18-24, 1994.
PubMed
66) Piccart M J, Gore M, Huinink WTB, et al: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J. Natl. Cancer Inst. 87: 676-681, 1995.
 
67) Burris H, Fields S: Clinical update on the topoisomerase 1 inhibitor. 31 st Annual Meeting, Am. Soc. Clin. Oncol. Educational Book, 1995, pp. 104-111.
 
68) Kavanagh J, Tresukosol D, Edwards C, et al: Carboplatin reinduction after taxane in patients with platinumrefractory epithelial ovarian cancer. J. Clin. Oncol. 13: 1584-1588, 1995.
PubMed
69) 山本謙二 , 菊池義公, 平松久和. ・他: タキソール併用投与におけるシスプラチン耐性克服の可能性. 日産婦誌 94臨増号S300, 1997.
 
70) Shpall EJ, Cagnoni PJ, Purdy M, et al: High-dose chemotherapy with autologous hematopoietic cell support (AHCS) for the treatment of epithelial ovarian cancer. Am. Soc. Clin. Oncol. Educational Book, 1995, pp. 360-364
 
71) Peter WP: The value of high-dose therapy in breast cancer. 12 th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium “New therapeutic strategies for higher cure rates. High-dose therapy and new therapeutic modality. ” pp. 36-37 (Abstr.) .
 
72) Scully RE: Tumors of the Ovary and Maldeveloped Gonads. Fascicle 16. Whashington, DC ' Armed Forces Institute of Pathology, 1979.
 
73) Kurman RJ, Norris HJ: Germ cell tumors of the ovary. Hum. Pathol. 1: 291-325, 1981.
 
74) Thomas GM, Dembo AJ, Hacker NF, et al: Current therapy for dysgerminoma of the ovary. Obstet. Gynecol. 70: 268-275, 1087.
 
75) Gershenson DEM, Morris M, Cangir A, et al: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J. Clin. Oncol. 8: 715-720, 1990.
 
76) Newlands ES, Southall pJ, Paradinas FJ, et al: Management of ovarian germ cell tumours. In: Textbook of Uncommon Cancer. (eds by Williams CJ, Kaikorian JG, Green MR, Raghaaran D) John Wiley ＆ Sons, NewYork, 1988, pp. 37-53
 
77) Gershenson DM, Wharton JT, Kline RC, et al: Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma. Potential for cure and preservation of reproductive capacity. Cancer 58: 2594-2599, 1986.
PubMed
78) Berek JS, Hacker NF: Ovarian and fallopian tubes. In: Cancer Treatment, 4th ed (ed. by Haskell CM) , WB Saunders, Phidadelphia, 1995.
 
79) Cangir A, Smith J: Van Eys J: Improved prognosis in children with ovarian cancers following modified VAC (vincristine sulfate, dactinomycin, and cyclophosphamide) chemotherapy. Cancer 43: 1234-1238, 1978.
 
80) Slayton RE: Management of germ cell and stromal tumors of the ovary. Semin. Oncol. 11: 299-313, 1984.
PubMed
81) Serov SF, Scully RE, Robin IH: Histological typing of ovarian tumors. International Histological Classification of Tumors, No. 9. World Health Organization, Geneva, 1973.
 
82) Williams SD, Blessing JA, Moore DH, et al: Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann. Intern. Med. 111: 22-27, 1989.
PubMed
83) Williams SD, Blesing JA, Hatch K, et al: Chemotherapy of advanced ovarian dysgerminoma: trials of the Gynecologic Oncology Group. J. Clin. Oncol9: 1950-1955, 1991.
 
84) Williams SD: Germ cell tumors. In: Ovarian Cancer (ed by Ozols RF) , WB Saunders, Philadelphia, 1992, pp. 967-974.
 
85) Norris HJ, Zirken HJ, Benson WI: Immature (malignant) teratoma of the ovary: aclinical and pathologic study of 58 cases. Cancer 37: 2359-2372, 1976.
 
86) Creasman WJ, Soper JT: Assessment of the contemporary management of germ cell malignancies of the ovary. Am. J. Obstet. Gynecoll53: 828-834, 1985.
 
87) Curry SL, Smith Jp, Gallagher HS: Malignant teratoma of the ovary: prognostic factors and treatment. Am. J. Obstet. Gynecol. 131: 845-849, 1978.
PubMed
88) Taylor MH, DePetrillo AD, Turner AR: Vinblastine, bleomycin and cisplatin in malignant germ cell tumors of the ovary. Cancer 56: 1341-1349, 1985.
PubMed
89) Williams SD, Blessing JA, Liao SY, et al: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: an adjuvant trial of the Gynecologic Oncology Group. J. Clin. Oncol. 12: 701-706, 1994.
 
90) Williams SD: Germ cell tumors. In: Ovarian Cancer (ed by Ozols RF) , Philadelphia, WB Saunders, 1992, pp. 967-974.
 
91) Loehrer PJ, Elson P, Johnson DH, Williams SD, Trump DL, Einhorn LH. A randomized trial of cisplatin plus etoposide with or without bleomycin in favorable prognosis disseminated germ cell tumors: an ECOG study. Proc. Am. Soc, Clin. OncollO: 540, 1991.
 
92) Bajorin DF, Sarosdy MF, Pfister DG, et al: A randomized trial of etoposide plus carboplatin versus etoposide plus cisplatin in patients with metastatic germ cell tumors. J. Clin. Oncol. 11: 598-606, 1993.
 
93) Gusberg SB, Kardon P: Proliferative endometrial response to theca-granulosa-cell tumors. Am. J. Obstet. Gynecol. 111: 633-643, 1971.
PubMed
94) Nakashima N, Young RH, Scully RE: Androgenic granulosa-cell tumors of the ovary: a clinicopathologic analysis of 17 cases and review of the literature. Arch. Pathol. Lab. Med. 108: 786-791, 1984.
PubMed
95) Norris HJ, Taylor HR: Virlization associated with cystic granulosa tumors. Obstet. Gynecol. 34: 629-635, 1969.
 
96) Bjorkholm E, Silfversward C: Prognostic factors in granulosa-cell tumors. Gynecol. Oncol. 11: 261-274, 1981.
PubMed
97) Malmstrom II, IIIogberg T, Risberg B, et al: Granulosa-cell tumors of the ovary; prognostic factors and outcome. Gynecol. Oncol. 52: 50-55, 1994.
 
98) Piura B, Nemet D, Yanai-Inbur I, et al: Granulosa-cell tumor of the ovary; astudy of 18 cases. J. Surg. Oncol. 55: 71-77, 1994.
 
99) Evans AT 3 d, Gaffey TA, Malkasisn GD, et al: Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet. Gynecol. 55: 231-238, 1980.
 
100) Stenwig JT, Hazekamp JT, Beecam JB. Granulosa-cell tumors of the ovary. A clinicopathological study of cases with long-term follow-up. Gynecol. Oncol. 7: 136-152, 1979.
 
101) Sluijmer AV, Heineman MJ, Evers JLH, et al: Peripheral vein, ovarian vein and ovarian tissue levels of inhibin in a postmenopausal patient with a granulosa-cell tumour. Acta Endocrinol. 129: 311-314, 1993.
 
102) Young RH, Dickersin GR, Scully RE: Juvenile granulosa-cell tumor of the ovary: aclinicopathological analysis of 125 cases. Am. J. Surg. Pathol. 8: 575-596, 1984.
 
103) Plantaz D, Flamant F, Vassal G, et al: Tumeurs de la ganulosa de l'ovaire chez l'enfant et l'adolescente. Arch. Fr. Pediatr. 49: 793-798, 1992.
 
104) Vassal G, fllamant F, Cailaud JM, et al: Juvenile granulosa-cell tumor of the ovary in children: aclinical study of 15 cases. J. Clin. Oncol. 6: 990-995, 1988.
 
105) Zaloudck C, Norris HJ: Granulosa tumors of the ovary in children: a clinical and pathologic study of 32 cases. Am. J. Surg. Pathol. 6: 503-512, 1982.
 
106) Fishman A, Kudelka A, Edwards C, et al: GnRH agonist (Depot-Lupron) in the treatment of refractory of persistent ovarian granulosa-cell tumor (GCT) [Abstr. ]. Proc. ASCO 13: 236, 1994.
 
107) Jeffers MD, 0 'Dwyer P, Curran B, et al: Partial hydatidiform mole: acornmon but under diagnostic disease. Int. J. Gynecol. Pathol. 12: 315-323, 1993.
 
108) Parazzini F, La Vecchia C, Mangili G, et al: Dietary factors and risk of trophoblastic disease. Am. J. Obstet. Gynecol. 158: . 93-99, 1988.
PubMed
109) Berkowitz RS, Cramer DW, Bernstein MR, et al: Risk factors for complete molar pregnancy from a casecontrol study. Am. J. Obstet. Gynecol. 152: 1016-1020, 1985.
PubMed
110) Parazzini F, La Vecchia C, Pampallona S: Parental age and risk of complete and partial hydatidiform mole. Br. J. Obstet. Gynaecol. 93: 582-585, 1986.
PubMed
111) Kajii T, Ohama K: Androgenetic origin of hydatidiform mole. Nature 268: 633-634, 1977.
PubMed
112) Yamashita K, Wake N, Araki T, et al: Human lymphocyte antigen expression hydatidiform mole: Androgenesis following fertilization by a haploid sperm. Am. J. Obstet. Gynecol. 135: 597-600, 1979.
PubMed
113) Pattillo RA, Sasaki S, Katayama KP, et al: Genesis of 46XY hydatidiform mole. Am, J. Obstet. Gynecol141: 104-105, 1981.
 
114) Azuma C, Saji F, Tokugawa Y, et al: Application of gene amplification by polymerase chain reaction to genetic analysis of molar mitochondrial DNA: the detection of a nuclear empty ovum as the cause of complete mole. Gynecol. Oncol. 40: 29-33, 1991.
 
115) Szulman AE, Surti V: The syndrome of hydatidiform mole. I Cytogenetic and morphologic correlations. Am. J. Obstet. Gynecol. 131: 665-671, 1978.
 
116) Lawler SD, Fisher RA, Dent J: A prospective genetic study of complete and partial hydatiodiform moles. Am. J. Obstet. Gynecol. 164: 1270-1277, 1991.
 
117) Berkowitz RS, Goldstein DP: Pathogenesis of gestational trophoblastic neoplasmas. Pathobiology. Annual. 11: 391-411, 1981.
 
118) Tow WSH: The influence of the primary treatment of the hydatidiform mole on its subsequent course. J. Obstet. Gynaecol. Br. Common. 73: 545-552, 1966.
 
119) Tsukamoto N, Iwasaka T, Kashimura Y, et al: Gestational trophoblastic disease in women aged 500r more. Gynecol. Oncol. 20: 53-61, 1985.
 
120) Berkowitz RS, Goldstein DP, Bernstein MR: Advances in management of partial molar pregnancy. Contemp. Obset. Gynecol. 36: 33-44, 1991.
 
121) Rice LW, Gerkowitz RS, Lage JM, et al: Persistent gestational; trophoblastic tumor after partial hydatidiform mole. Gyncol. Oncol. 36: 358-362, 1990.
 
122) Fine C, Bundy AL, Berkowitz RS, et al: Sonographic diagnosis of partial hydatidiform mole. Obstet. Gynecol. 73: 414-418, 1989.
PubMed
123) Berkowitz RS, Goldstein DP, DuBeshter B, et al: Management of complete molar pregnancy. J. Reprod. Med. 32: 634-639, 1987.
PubMed
124) Kim DS, Moon H, Kim KT, et al: Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet. Gynecol. 67: 690-694, 1986.
 
125) Genest DR, LaBorde O, Berkowitz RS, et al: A clinicopathologic study of 153 cases of complete hydatidiform mole (1980-990) : histologic garde lacks prognostic significance. Obstet. Gynecol. 78: 402-409, 1991.
 
126) Berkowitz RS, Goldstein DP: The management of molar pregnancy and gestational trophoblastic tumors. In: Gynecologic Oncology, 2nd Ed (eds by Knapp RC, Berkowitz RS) , McGraw-Hill, New York, 1993, pp. 328-338.
 
127) Finkler NJ, Berkowitz RS, Driscoll SG, et al: Clinical experience with placental site trophoblastic tumors at the New England Trophoblastic Disease Center. Obstet. Gynecol. 71: 854-857, 1988.
PubMed
128) Bagshawe KD, Harland S: Immunodiagnosis and monitoring of gonadotropin-producing metastases in the cetral nervous system. Cancer 38: 112-118, 1976.
 
129) Bakri Y, Berkowitz RS, Goldstein DP, et al: Brain metastases of gestational trophoblastic tumor. J. Reprod. Med. 39: 179-184, 1994.
PubMed
130) Rustin GJ, Newlands ES, Begent RHJ, et al: Weekly alternating etoposide, methotrexate, actinomycin D vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J. Clin. Oncol. 7: 900-903, 1989.
 
131) Weed JC Jr, Hammond CB: Cerbral metastatic choriocarcinoma: intensive therapy and prognosis. Obstet. Gynecol. 55: 89-94, 1980.
 
132) Homesley HD: Development of single-agent chemotherapy regimens for gestational trophoblastic disease. J. Reprod. Med. 39: 185-192, 1994.
PubMed
133) Berkowitz RS, Goldstein DP, Bernstein MR: The years 'experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol. Oncol. 23: 111-118, 1986.
 
134) Curry SL, Blessing JA, DiSaia PJ, et al: A prospective randomized comparison of methotrexate, dactinomycin and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine in “poor prognosis”metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Obstet. Gynecol. 73: 357-362, 1989.
 
135) Gordon AN, Gershenson DM, Copeland LJ, et al: High-risk metastatic gestational trophoblastic disease: further stratification into clinical entities. Gynecol Oncol. 34: 54-56, 1989.
PubMed
136) BuBeshter B, Berkowitz RS, Goldstein DP, et al: Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965-1985. Obstet. Gynecol. 58: 14-17, 1986.
 
137) Bagshawe KD: Treatment of high-risk choriocarcinoma. J. Reprod. Med. 29: 813-820, 1984.
PubMed
138) 波多江正紀: 婦人科癌. 妊娠性絨毛疾患. 抗癌剤の選び方, 南江堂, 東京, 1996, pp. 105-109.
 
P.1368 掲載の参考文献
1) Silvermberg E, Lubera J: Cancer statistics 1987. CA. 37: 2, 1987.
 
2) Malawer MM, Link MP, Donaldson SS: Sarcomas of Bone. In: Cancer: Principles and Practice of Oncology (ed by De Vita VT Jr, Hellman S, Rosenberg SA) . 5th ed, JB Lippincott, Philadelphia, 1997, pp. 1789-1852.
 
3) 日本整形外科学会骨, 軟部腫瘍委員会編: 全国骨腫瘍患者登録一覧表(平成7年度) . 国立がんセンター, 東京, 1996, pp. 23-45.
 
4) Wingo PA, Tong T, Bolden S: Cancer statistics 1995. CA. 45: 12, 1995.
 
5) Brennan MF, Casper ES, Harrison: Soft tissue sarcoma. In: Cancer: Principles and Practice of Oncology (ed by De Vita VT Jr, Hellman S, Rosenberg SA) . 5th ed, JB Lippincott, Philadelphia, 1997, pp. 1738-1788.
 
6) Cordon-Cardo C: Chapter 38. Sarcoma of the soft tissues and bone. Molecular biology of sarcomas. In: Cancer: Principles and Practice of Oncology (ed by DeVita V, Hellman Sm, Rosenberg S) . 5th ed, Lippincott-Raven, Philadelphia, 1997, pp. 1731-1738.
 
7) 戸口田淳也: 遺伝子解析. 骨腫瘍の診断と治療(平澤泰介編) . OS Now 18, メジカルビュー社, 東京, 1995, pp. 114- 120.
 
8) Kawaguchi N: Surgical treatment combined preoperative chemotherapy for musculoskeletal sarcoma. In: Cancer chemotherapy challenges for the future (ed by Kimura K, Ota K, Yamada K, Saito H, Ogawa M) . 10, Excerpta Medica, Tokyo, 1995, pp. 248-256.
 
9) Enneking WF, Spanier SS, and Goodman MA, et al: A system for the surgical staging of musculoskeletal sarcorna. Clin. Orthop. 153: 106-120, 1980.
 
10) Enneking WF: Asystem for the functional evaluation of the surgical management of musculoskeletal tumors. In: Limb salvage in musculoskeletal oncology (ed by Ennekin WF) . 1987, pp. 5-16.
 
11) 柴田大法: 外科的治療. Surgical stagingと surgical margin. 骨腫瘍の診断と治療(平澤泰介編) . OS Now 18, メジカルビュー社, 東京, 1995, pp. 158-163.
 
12) Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221-1230, 1982.
PubMed
13) Rosen G, Marcove RC, Caparros B, et al: Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J. Cancer Res. Clin. Oncol. 106: 55-67, 1983.
PubMed
14) Winkler K, Beron G, Kotz R, et al: Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German Austrian study. J. Clin. Oncol. 2: 617-624, 1984.
PubMed
15) Winkler K, Beron G, Dellinger G, et al: Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J. Clin. Oncol. 6: 329-337, 1988.
 
16) Winkler K, Bielack S, Delling G, et al: Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86) . Cancer 66: 1703-1710, 1990.
PubMed
17) Huvos AG: Bone tumors: diagnosis, treatment and prognosis. 2nd ed, WB Saunders, Philadelphia, 1991, pp. 368-373.
 
18) Gehan EA, Nesbit ME, Burgert OE, et al: Prognostic factors in children with Ewing 's sarcoma. J. Natl. Cancer Inst. Monogr. 56: 273-278, 1981.
 
19) Pomeroy TC, Johnson RE: Prognostic factors for survival in Ewing 's sarcoma. Am. J. Roentgenol. Radium Ther. Nucl. Med. 123: 598-606, 1975.
PubMed
20) Glaubiger D, Makuch R, Wackenhut J, et al: Early results of current combined modality therapy trials in Ewing 's sarcoma at the NCI. In: Jones Samon SE, Adjuvant chemotherapy of Cancer II. Grune and Stratton, New York, 1979, pp. 409-412.
 
21) Wilkins R, Douglas MS, Pritchard J, et al: Ewing 's sarcoma of bone: Experience with 140 patients. Cancer 58: 2551-2555, 1986.
 
22) Mendenhall CM, Marcus RB, Enneking WF, et al: The prognostic significance of soft tissue extension in Ewing 's sarcoma. Cancer 51: 913-917, 1983.
PubMed
23) Jurgen H, Gobel V, Michaelis J, et al: Die cooperative Ewing-Sarkom Studie CESS 81 der GPO-Analyse nach 4Jaren. Klin. Padiatr. 197: 225-232, 1985.
 
24) Nascimento AG: Clinicopathologic study of 20 cases of large-cell (atypical) Ewing 's sarcoma of bone. Am. J. Surg. Pathol. 4: 29-36, 1980.
PubMed
25) Picci P, Rougraff BT, Bacci G, et al: Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing 'ssarcoma of the extremities. J. Clin. Oncol. 11: 1763-1769, 1993.
 
26) Broders A: The microscopic grading of cancer. In: Pack GT et al, Treatment of cancer and apllied diseases. Paul B, Hoeber, London, 1940, pp. 19-41.
 
27) Pisters PWT, Leung DHY, Woodruff J, et al: Analysis of prognostic factors in 1, 041 patients with localized soft tissue sarcomas of the extremities. J. Clin. Oncol. 14: 1679-1689, 1996.
 
28) Coindre JM, Terrieer P, Bui NB, et al: Prognostic factors in adult patients with locally controlled soft tissue sarcoma: Astudy of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J. Clin. Oncol. 14: 869-877, 1996.
 
29) Beahrs AC, Henson DE, Hutter RV, et al: Mannual for staging of cancer. American Joint Committee on cancer. 4th ed, JB Lippincott, Philadelphia, 1992, pp. 145-149.
 
30) 日本整形外科学会骨軟部腫瘍委員会編: 整形外科・病理悪性軟部腫瘍取扱い規約. 第2版. 金原出版, 東京, 1989, pp. 59-67.
 
31) 日本整形外科学会骨軟部腫瘍委員会編: 骨, 軟部肉腫切除縁評価法. 金原出版, 東京, 1989, pp. 31-36.
 
32) Kotz R, and Salzer M∴Rotation-plasty for childhood osteosarcoma of the distal part of the femur. J, Bone Joint Surg. 64-A: 959-969, 1982.
 
33) 井上 治. 外科治療. Rotation-plasty (患肢温存的回転形成術) の適応と方法. 骨腫瘍の診断と治療(平澤泰介編) . OS Now 18, メジカルビュー社, 東京, 1995, pp, 203-209.
 
34) 森 茂樹, 吉川秀樹, 内田淳也・他: 転移性骨盤腫瘍に対する外科的治療. 中部日整災外会誌 38: 199, 1995.
 
35) Brennan MF, Hikaris B, Shiu MH, et al: Local recurrence in adult soft-tissue sarcoma. A randomized trial of brachytherapy. Arch. Surg. 122: 1289-1293, 1987.
 
36) Pisters PWT, Harrison LB, Woodruff JM, et al: A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J. Clin. Oncol. 12: 1150-1155, 1994.
 
37) 富田勝郎, 砂山千明: 骨肉腫の患肢温存療法. 骨腫瘍の診断と治療(平澤泰介編) . OS Now 18, メジカルビュー社, 東京, 1995, pp. 36-41.
 
38) Enneking WF, Dunham W, Gebhardt M, et al: Asystem for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin. Orthop. 286: 241-246, 1993.
 
39) Cortes EP, Holland JF, Glidewell O: Amputation and adriamycin in primary osteosarcomas: A 5 year report. Cancer Treat. Rep. 62: 271-277, 1978.
PubMed
40) Cortes E, Necheles TF, Holland JF, et al: Adriamycin alone vs. adriamycin and high dose methotrexate citrovorum factor rescue as adjuvant to operable primary osteosarcoma: A randomized study by Cancer and Leukemia Group B. Proc. Am. Soc. Clin. Oncol. 20: 412, 1979.
 
41) Cortes EP, Holland JF, Glidewell O: Osteogenic sarcoma studied by the Cancer and Leukemia Group B. J. Natl. Cancer Inst. Monogr. 5: 207-209, 1981.
 
42) Jaffe N, Frei E, Link M, et al: Adjuvant chemotherapy of osteogenic sarcoma: 5-years experience. Cancer Treat. Rep. 62: 259-264, 1978.
 
43) Jaffe N, Robertson R, Ayala A, et al: Comparison of cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J. Clin. Oncol. 3: 1101-1104, 1985.
PubMed
44) Herson J, Sutow WW, Elder K, et al: Adjuvant chemotherapy in nonmetastatic osteosarcoma: A Southwest Oncology Group Study. Med. Pediatr. Oncol. 8: 343-352, 1980.
 
45) Sutow WW, Gehan EA, Dyment PG, et al: Multidrug adjuvant chemotherapy for osteosarcoma: Interm report of the Southwest Oncology Group Studies. Cancer Treat. Rep. 62: 265-269, 1978.
 
46) Rosenberg WF, Ivins JC, Dahlin DC, et al: Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat. Rep. 63: 739-751, 1979.
 
47) Goorin A, Delorey M, Gelber R, et al: The Dana-Farber Cancer Institute/The children hospital adjuvant chemotherapy trials for osteosarcomas: Three sequential studies. Cancer Treat. Symp. 3: 155-159, 1985.
 
48) Goorin AM, Perez-Atayde A, Gebhardt M, et al: Weekly high dose methotrexate and doxorubicin for osteosarcoma: The Dana-Farber Cancer Institute/The Children 's Hospital; Study III. J. Clin. Oncol. 5: 1178-1184, 1987.
 
49) Krailo M, Ertel J, Mackley J: A randomized study comparing high dose methotrexate with moderate dose methotrexate as components of adjuvant chemotherapy in childhood non-metastatic osteosarcoma: A report from the Children 's Cancer Study Group. Med. Pediatr. Oncol. 15: 69-77, 1987.
 
50) Furuse K, Maeyama I, Yamawaki S, et al: Adjuvant chemotherapy for osteosarcoma with adriamycin, alone versus adriamycin vincristine and high dose methotrexate with citrovorum factor rescue. In Methotrexate in cancer therapy (ed by Kimura K, Wang Y-M) . Raven Press, New York, 1986, pp. 249-255.
 
51) Edmonson JH, Green SJ, Ivins JC, et al: A controlled pilot study of high dose methotrexate as post-surgical adjuvant treatment for primary osteosarcoma. J. Clin. Oncol. 2: 152-156, 1984.
 
52) Rosen G, Tan C, Sanmanechal A, et al: The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 35: 936-945, 1975.
PubMed
53) Rosen G, Murphy ML, Huvos AG, et al: Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37: 1-11, 1976.
PubMed
54) EORTC osteosarcoma Working Group (presented by Jasmin C) . Randomized trial of adjuvant chemotherapy in osteogenic sarcoma: Comparison of altering sequential administrations of high dose adriamycin, methotrexate and cyclophosphamide with a 6-month administration high-dose adriamycin followed by a low-dose semicontinous chemohterapy. Recent Results Cancer Res. 68: 28-32, 1978.
 
55) Pratt CB, Rivera G, Shanks E, et al: Combination chemotherapy for osteosarcoma. Cancer Treat. Rep. 62: 251-257, 1978.
PubMed
56) Ettinger LJ, Douglass HO, Higby DS, et al: Adjuvant adriamycin and cis-diamminedichloroplatinum (cisplatin) in primary osteosarcoma. Cancer 47: 248-254, 1981.
 
57) Eilber Fp, Giuliano A, Eckardt K: Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J. Clin. Oncol. 5: 21-26, 1987.
 
58) Provisor A, Nachman J, Krailo M, et al: Treatment of non-metastatic osteogenic sarcoma (os) of the extremities with pre and post-operative chemotherapy. Proc. Am. Soc. Clin. Oncol. 6: 217, 1987.
 
59) Kalifa C, Dubousset J, Grandner H, et al: Osteosarcoma (OS) ; An attempt to reproduce T 10 in a single institution. Proc. Am. Soc. Clin. Oncol4: 236, 1985.
 
60) Bacci G, Gherlinzoni F, Picci P, et al: Adriamycin-methotrexate high dose verus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: arandomized study. Eur. J. Cancer Clin. Oncol. 22: 1337-1345, 1986.
 
61) Bacci G, Picci P, Ruggieri P, et al: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of extremities. Cancer 65: 2539-2553, 1990.
PubMed
62) Bacci G, Picci P, Ferrari S, et al: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer 72: 3227-3238, 1993.
PubMed
63) Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 314: 1600-1606, 1986.
PubMed
64) Bramwell VHC, Burgers M, Sneath R, et al: A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European osteosarcoma intergroup. J. Clin. Oncol. 10: 1579-1591, 1992.
 
65) Jaffe N, Robertson R, Ayala A, et al: Comparison of cis-diamminedichloroplatinum II with high-dose methe otrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J. Clin. Oncol. 3: 1101-1104, 1985.
 
66) Jaffe N, Raymond AK, Carrasco H, et al: Effect of escalating courses of intraarterial cis-diamminedichloroplatinum-II (CDDP) on the primary tumor in pediatric osteosarcoma (OS) . Proc. Am. Soc. Clin. Oncol. 6: 217, 1987.
 
67) Jaffe N, Smith D, Jaffe R, et al: Intraarterial cisplatin in the management of stageII B osteosarcoma in the pediatric and adolescent age group. Clin. Orthop. 270: 15-21, 1991.
 
68) Benjamin RS, Chawla SP, Carrasco Ch, et al: Primary chemotherapy of patients with osteosarcoma of an extremity. Proc. Am. Soc. Clin. Oncol. 5: 139, 1986.
 
69) Benjamin RS, Chawla SP, Carrasco C, et al: Arterial infusion in the treatment of osteosarcoma. In: Recent Concepts in Sarcoma Treatment (ed by Ryan JR, Baker LO) . Kluwer Academic Publishers, Dordrecht, 1988, pp. 269-274.
 
70) Saeter G, Alvegard TA, Eloma L, et al: Treatment of osteosarcoma of the extremities with the T 10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandinavian sarcoma group study. J. Clin. Oncol. 9: 1766-1775, 1991.
 
71) Weiner MA, Harris MB, Lewis M, et al: Neoadjuvant high-dose methotrexate, cisplatin and doxorubicin for the management of patients with nonmetastatic osteosarcoma. Cancer Treat. Rep. 70: 14.
 
72) Petrill AS, Gentil FC, Epelman S, et al: Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 681733-737, 1991.
 
73) Meyer WH, Prat BN, Rao X, et al: Curative therapy for 31-1432, 1986. osteosarcoma without cisplatin-preliminary results of SJCRH OS-91. Proc. Am. Soc. Clin. Oncol. 16: 1844, 1997.
 
74) Tuchiya H, Tomita K, et al: Intraarterial cisplatin and caffeine with or without doxorubicn for musculoskeletal high-grade spindle cell sarcoma. Oncol. Reports 1: 27-36, 1984.
 
75) Niederle N, Scheulen ME, Cremer M, et al: Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat. Rev. 10: 129-135, 1983.
PubMed
76) Marti CH, Kroner T, Remagen W, et al: High-dose ifosfamide in advanced osteosarcoma. Cancer Treat. Rep. 69: 115-117, 1985.
 
77) Bramwell VHC, Mouriden HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur. J. Cancer Clin. Oncol. 23: 311-321, 1987.
 
78) Link MP, Groorin AM, Horowitz M, et al: Adjuvant chemotherapy of high grade osteosarcoma of the extremity: Update results of the MultHnstitutional Osteosarcoma Study. Clin. Orthop. 270: 8-14, 1991.
 
79) Bacci G, Toni A, Avella M, et al: Long-term results in 14410calized Ewing 's sarcoma patients treated with combined therapy. Cancer 63: 1477-1486, 1989. '
PubMed
80) Nesbit M, Gehan EA, Burgert O, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing 's sarcoma of bone: Along follow-up of the first intergroup study. J. Clin. Oncol. 8: 1664-674, 1990.
 
81) Burgert EO, Nesbit ME, Gehan EA, et al: Multimodal therapy for the management of nonpelvic localized Ewing 's sarcoma of bone: intergroup study IESS-II: J. Clin. Oncol. 8: 1514-1524, 1990.
 
82) Evans R, Nesbit M, Askin F, et al: Local recurrence rate and sites of metastases, and to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing 's sarcoma of pelvic bones. Int. J. Radiat. Oncol, Biol. Phys. 11: 129-136, 1985.
PubMed
83) Evans R, Nesbit M, Gehan EA, et al: Multimodal therapy for the management of localized Ewing 's sarcoma of pelvic and sacral bones: A report from the second intergroup study. J. Clin. Oncol. 9: 1173-1180, 1991.
 
84) Kinsella T, Miser JS, Waller B, et al: Long-term follow-up of Ewing 's sarcoma of bone treated with combined modality therapy. Int. J. Radiat. Oncol. Biol. Phys. 20: 389-395, 1991.
PubMed
85) Oberlin O, Patte C, Demeocq F, et al: The response to initial chemotherapy as a prognostic factor in localizedEwing 's sarcoma. Eur. J. Cancer Clin. Oncol. 21: 463-467, 1985.
PubMed
86) Oberlin O, Habrand JL, Zucker M, et al: No benefit of ifosfamide in Ewing 's sarcoma: A randomized study of the French Society of pediatric oncology. J. Clin. Oncol. 10: 1407-1412, 1992.
 
87) Zucker JM, Henry-Amar M, Sarrazin D, et al: Intensive systemic chemotherapy in localized Ewing 's sarcoma in childhood. A historical trials. Cancer 52: 415-423, 1983.
PubMed
88) Rosen G, Caparros B, Nirenberg A, et al: Ewing 's sarcoma. Ten year experience with adjuvant chemotherapy. Cancer 47: 2204-2213, 1981.
PubMed
89) Bacci G, Toni A, Avella M, et al: Long-term results in 14410 calized Ewing 's sarcoma patients treated with combined therapy. Cancer 63: 1477-1486, 1989.
 
90) Jurgen H, Exner U, Grander H, et al: Multidisciplinary treatment of primary Ewing 's sarcoma of bone. Cancer 61: 23-32, 1988.
 
91) Dunst J, Sauer R, Burgers R, et al: Radiation therapy as local treatment in Ewing 's sarcoma: Results of the cooperative Ewing 's sarcoma studies CESS 81 and CESS 86. Cancer 67: 2818-2825, 1991.
 
92) Burdach H, Jurgen C, Peters C, et al: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing 's sarcoma. J. Clin. Oncol. 11: 1482-1488, 1993.
 
93) Kinsella TJ, Glaubiger D, Disseroth A, et al: Intensive combined modality therapy including low-dose TBI in high-risk Ewing 's sarcoma patients. Int. J. Radiat. OncolBiol. Phys. 9: 1955-1960, 1983.
 
94) Miser JS, Kinsella TJ, Triche TJ, et al: Treatment of peripheral neuroepithelioma in children and young adults. J. Clin. Oncol. 5: 1752-1758, 1987.
 
95) Miser JS, Kinsella TJ, Triche TJ, et al: Preliminary results of treatment of Ewing 's sarcoma of bone in children and young adults: Six months of intensive combined modality therapy without maintenance. J. Clin. Oncol. 6: 484-490, 1988.
 
96) Huvos AG: Bone tumors; Diagnosis, treatment and prognosis. 2nd ed, WB Saunders, Philadelphia, London, Toronto, 1991, pp. 514-517.
 
97) Shuman LS, Chuang VP, Wallance S, et al: Intra-arterial chemotherapy of malignant fibrous histiocytoma of the pelvis. Radiology 142: 343-346, 1982.
 
98) Urban Ch, Rosen G, Huvos AG, et al: Chemotherapy of malighant fibrous histiocytoma of bone. Cancer 51: 795-802, 1983.
 
99) Rosenberg SA: Adjuvant chemotherapy of adult patients with soft tissue sarcoma. In: Important Advances in Oncology (ed by DeVita V, Hellman S, Rosenberg S) . Lippincott, Philadelphia, PA, 1985, pp. 273-294.
 
100) Antman K, Ryan L, Borden E, et al: Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of literature. In Adjuvant Therapy of Cancer VI (ed by Salmon SE) . PA, WB Saunders, Philadelphia, 1990, pp. 529-543.
 
101) Alvegard TA, Sigurdsson H, Mouridsen H, et al: Adjuvant chemotherapy with doxorubicin in high grade soft tissue sarcoma: A randomized trial of the Scandinavian Sarcoma Group. J. Clin. Oncol. 7: 1504-1513, 1989.
 
102) Eilber FR, Guiliano AE, Huth JF, et al: A randomized prospective trial using post-chemothe 'rapy (Adriamycin) in high grade extremity soft-tissue sarcoma. Am. J. Clin. Oncol. 11: 39-45, 1988.
 
103) Gherlinzoni F, Bacci G, Picci P, et al: A randomized trial for the treatment of high grade soft tissue sarcomas of the extremities: Preliminary observations. J Clin. Oncol. 4: 552-558, 1986.
PubMed
104) Gherlizoni F, Pignatti G, Fontana M, et al: Soft tissue sarcomas: The experience at the Istituto Ortopedic Rizzoli. Chir. Organi. Mov. 75: 150-154, 1990.
 
105) Benjamin RS, Terjanian TO, Genoglio CJ, et al: The importance of combination chemotherapy for adjuvant treatment of high risk patients with soft tissue sarcomas of the extremities. In: Adjuvant Therapy of Cancer V (ed by Salmon SE) . Grune ＆ Stratton, New York, 1987, pp. 735-744.
 
106) Edmonson JH, Fleming TR, Ivans JC, et al: A randomized study of systemic chemotherapy following complete excision of nonosseous sarcoma. J. Clin. Oncol. 2: 1390-1396, 1984.
 
107) Baker AR, Chang AE, Glastein E, et al: National Cancer Institute experience in the management of high grade extremity soft tissue sarcoma. In: Recent concepts in Sarcoma Treatment (ed by Ryan JR, Baker LO) . Kluwer Academic, Dordecht, 1988, pp. 123-129.
 
108) Bui NB, Maree D, Coindre JM, et al: First results of a prospective randomized study of CYVADIC adjuvant chemotherapy in adults with operable high risk soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol. 8: 318, 1989.
 
109) Ravaud A, Buinb, Coindre JM, et al: Adjuvant chemotherapy with CYVADIC in high risk soft tissue sarcoma: A randomized prospe6tive trial. In l Adjuvant Therapy of Cancer VI (Salmon SE) . Grune ＆ Stratton, New York, 1990, pp. 556-566.
 
110) Bramwell BV, Rouesse J, Steward W, et al: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma- Reduced local recurrence but no improvement in survival; A study of the European Organization for Research and Treatment of cancer soft tissue and bone sarcoma group. J. Clin. Oncol. 12: 1137-1149, 1994.
 
111) Gottlieb JA, Baker LH, Quagliana JM, et al: Chemotherapy of sarcomas with a combination of Adriamycin and diethyl triazeno imidazole-carboxamine. Cancer 30: 1632-1638, 1972.
 
112) Borden EC, Amato D, Rosenbaum C, et al: Randomized comparison of three adriamycin regimens for treatment of metastatic soft tissue sarcomas. J. Clin. Oncol5: 840-850, 1987.
 
113) Omura GA, Major Fj, Blessing JA, et al: A randomized study of adriamycin with and without dimethyletriazo imidazole carboxamine in advanced uterine sarcomas. Cancer 52: 626-632, 1983.
 
114) Pinedo HM, Bramwell VH, Mouridsen HT, et al: Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules. Cancer 53: 1825-1832, 1984.
PubMed
115) Schoenfeld DA, Rosenbaum C, Horton J, et al: A comparison of adriamycin versus vincristine and adriamycin and cyclophosphamide versus vincristine, actinomycin-D and cyclophosphamide for advanced sarcoma. Cancer 50: 2757-2762, 1982.
 
116) Baker L, Frank J, Fine G, et al: Combination chemotherapy using adriamycin, DTIC, cyclophosphamide and actinomycin D for advanced soft tissue sarcomas: A randomized comparative trial. J. Clin. Oncol. 5: 851-857, 1987.
 
117) Bramwell V, Mouridsen HT, Santoro A, et al: Cyclophosphamide vs ifosfamide and mesna: Final report of a randomized phase II trial｛n adult soft tissue sarcoma. Eur. J Cancer. Clin. Oncol. 7: 126-131, 1989.
 
118) Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma. J. Clin. Oncol. 11: 1276-1285, 1993.
PubMed
119) Santoro J, Mouridsen HT, Steward W: A randomized EORTC study in advanced soft tissue sarcomas: ADM vs ADM+IFOS vs CYVADIC. Proc. Am. Soc. Clin. Oncol. 9: 309, 1990.
 
120) Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 111 1269-1275, 1993.
PubMed
121) Mantravadi RV, Trippon MJ, Patel MK, et al: Limb salvage in extremity soft-tissue sarcoma: combined modality therapy. Radiology 1521523-526, 1984.
 
122) Denton JW, Dunham WK, Salter M, et al: Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. Surg. Gynecol. Obstet. 158: 545-551, 1984.
PubMed
123) Goodnight JE, Bargar WL, Voegeli T, et al: Limb-sparing surgery for extremity sarcomas after radiation therapy. Am. J. Surg. 150: 109-113, 1985.
PubMed
124) Eileber FR, Mirra J, Eckart J, et al: Intraarterial adriamycin, radiation therapy, and surgical excision for extremity skeletal and soft tissue sarcomas. Dev. Oncol. 26: 141-152, 1984.
 
125) Hoekstra HJ, Koops SH, Molenaar WM, et al: A combination of intraarterial chemotherapy, preoperative and postoperative radiotherapy, and surgery as limb saving treatment of primarily unresectable high-grade soft tissue sarcomas of the extremities. Cancer 63: 59-62, 1989.
 
126) Karakousis CP, Emrich LJ, Rao U, et al: Feasibility of limb salvage and survival in soft tissue sarcomas. Cancer 57: 484-491, 1986.
PubMed
127) Abbatucci JS, Boulier N, DE Ranieri J, et al: Local control and survival in soft tissue sarcomas of the limbs, trunk walls and head and neck: astudy of 113 cases. Int. J. Radiat. Oncol. Biol. Phys. 12: 579-586, 1986.
 
128) Rosenberg SA, Tepper J, Glatstein E, et al: The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann. Surg. 196: 305-315, 1982.
PubMed
129) Pisters PWT, Harrison L, Leung D, et al : Long-term results of prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J. Clin. Oncol. 14: 859-868, 1996.
 
12a) Bieling P, Rehan N, Winkler P, et al: Tumor size and prognosis in aggressively treated osteosarcoma. J. Clin. Oncol. 14: 848-858, 1996.
 
P.1383 掲載の参考文献
1) Balch CM, Houghton AN, Milton GW, et al: Cutaneous Melanoma. 2nd ed. JB Lippincott, Philadelphia, 1992.
 
2) 斎田俊明: 皮膚悪性黒色腫の診断と治療. Skin Cancer 8 (Special Issue) : 13-37, 1993.
 
3) 石原和之: 悪性黒色腫, 全国アンケートの集計と説明. Skin Cancer 9 (Special Issue) : 52-68, 1994.
 
4) UICC (International Union Against Cancer) : TNM classification of malignant tumors. 5th Ed, Wiley-Liss, New York, 1997.
 
5) Freidman RJ, Rigel DS, Kopf AW: Early detection of melanoma: The role of physician examination and self-examination of the skin. CA Cancer J. Clin. 35: 131-151, 1985.
 
6) Urist MM: Surgical Inanagement of primary cutaneous melanoma. CA Cancer J. Clin. 46: 217-224, 1996.
PubMed
7) Corona R, Sci6 M, Mele A, et al: Survival and prognostic factors in patients with localized cutaneous malignant melanoma observed between 1980 and 1991 at the Istituto Dermopatico dell 'Immacolata in Rome, Italy. Eur. J. Cancer 30 A: 333-338, 1994.
 
8) 若松一雅: 悪性黒色腫の生物学的指標としてのメラニン関連代謝物の臨床的意義に関する研究. 藤田学園医会誌15(臨時増刊) : 99-139, 1996.
 
9) Wakamatsu K, Ito S, Horikoshi T: Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression. Melanoma Res. 1: 141-147, 1991.
PubMed
10) Horikoshi T, Ito S, Wakamatsu K, et al: Evaluation of melanin-related metabolites as markers of melanoma Progression. Cancer 73: 629-636, 1994.
PubMed
11) Yamazaki N, Ishihara K, Wakamatsu K, et al: Evaluation of serum 5-S-cysteinyldopa as a biochemical marker of malignant melanoma. Eur. J. Dermatol. 4: 329-332, 1994.
 
12) Ringborg U, Andersson R, Eldh J, et al: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of O. 8to 2. Omm, A randomized study by the Swedish Melanoma Study Group. Cancer 77: 1809-1814, 1996.
 
13) Balch CM, Urist MM, Karakousis CP, et al: Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1 to 4 mm) : Results of a multiinstitutional randomized surgical trial. Ann. Surg. 218: 262-269, 1993.
PubMed
14) 山崎直也: 進行期悪性黒色腫の治療. 日皮会誌 106: 1055-1063, 1996.
 
15) Balch CM, Soong SJ, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of l to 4 mm thick melanomas for patients 60 years of age and younger. Ann. Surg. 224: 255-266, 1996.
 
16) Lee JE: Melanoma. The M. D. Anderson Surgical Oncology Handbook (eds. by Berger DH, Feig BW, Fuhrman GM) . Little Brown, USA, 1995, pp. 38-60.
 
17) 斎田俊明, 山本明史: メラノーマ, 診断と治療の手引き. 第96回日本皮膚科学会総会. 学術大会編, 1997, pp. 1-12.
 
18) Morton DL, Wen D-R, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127: 392-399, 1992.
PubMed
19) Nathanson SD, Nelson L, Karveils KC: Rates of flow of technetium 99m-labeled human serum albumin from peripheral injection sites to sentinel lymph nodes. Arch. Surg. Oncol3: 329-335, 1996.
 
20) Bocca E, Pignataro O: Aconservation technique in radical neck resection. Ann. Otol. Rhinol. Laryngol76: 975-988, 1967.
 
21) 福富隆志: 非定型乳房切除術 (Patey法) . 癌の外科-手術手技シリーズ2乳癌(福富隆志編) , メジカルビュー社, 東京, 1992, pp. 32-45.
 
22) 七沢 武: 非定型乳房切除術 (両胸筋温存乳房切除術) . 癌の外科-手術手技シリーズ2乳癌(福富隆志編) , メジカルビュー社, 東京, 1992, pp. 46-57.
 
23) 浅村尚生: 皮膚腫瘍 (特に melanoma) , 頭頸部腫瘍の肺転移の病態と治療. 第33回日本癌治療学会JSCT EDUCA- TIONAL BOOK, 1995, pp. 497-502.
 
24) Thomford NR, Woolner LB, Clagett OT: The surgical treatment of metastatic tumors in the lung. J. Thorac. Cardiovasc. Surg. 49: 357-363, 1965.
 
25) Karakousis CP, Velez A, Driscoll DL, et al: Metastasectomy in malignant melanoma. Surgery 115: 295-302, 1994.
PubMed
26) Harpole Jr DH, Johnson CM, Wolfe WG, et al: Analysis of 945 pulmonary metastatic melanoma. J. Thorac. Cardiovasc. Surg. 103: 743-750, 1992.
 
27) Thayer Jr JO, Overholt RH: Metastatic melanoma to the lung: long-term results of surgical excision. Am. J. Surg. 149: 558-562, 1985.
 
28) Gorenstein LA, Putnam JB, Natarajan G, et al: Improved survival after resection of pulmonary metastases from malignant melanoma. Ann. Thorac. Surg. 52: 204-210, 1991.
PubMed
29) Brega K, Robinson WA, Winston K, et al: Surgical treatment of brain metastases in malignant melanoma. Cancer 66: 2105-2110, 1990.
PubMed
30) Mufioz JE, Vifiolas N, Castro J, et al: Metastasis cerebrales de melanoma: estudio de 48 pacientes. Med. Clin. (Barc) 101: 684-687, 1993.
 
31) Oredsson S, Ingvar C, Str6mblad LG, et al: Palliative surgery for brain metastases of malignant melanoma. Eur. J. Surg. Oncol. 161451-456, 1990.
 
32) Comis RL: DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat. Rep. 60: 165-176, 1976.
PubMed
33) DTIC研究グループ(世話人 池田重雄, 石原和之) : 悪性黒色腫に対するdacarbazine (DTIC) の臨床的研究. 臨床皮膚科 36: 183-188, 1982.
 
34) Garbe C: Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res. 3: 291-299, 1993.
PubMed
35) 石原和之, 池川修一: 悪性黒色腫の診断と治療. 癌と化学療法 12: 1727-1734, 1985.
Medical*Online
36) 山崎直也, 佐々木英也, 浅野一弘・他: 進行期悪性黒色腫に対するcisplatin-dacarbazine-vindesine併用化学療法 -21例の投与経験-. 日皮会誌 105: 1439-1444, 1995.
 
37) Del Prete SA, Maurer LH, 0 'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 68: 1403-1405, 1984.
 
38) McClay EF, Mastrangelo MJ, Bellet RE, et al: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat. Rep. 71: 465-469, 1987.
PubMed
39) Richards JM, Gilewski TA, Ramming K, et al: Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69: 427-429, 1992.
PubMed
40) 山崎直也: CDV療法とDAC-Tam療法. 日皮会誌 107: 1661-1663, 1997.
 
41) Lattanzi SC, Tosteson T, Chertoff J, et al: Dacarbazine, cisplatin and carmustine with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res. 5: 365-369, 1995.
PubMed
42) Saba HI, Cruse CW, Wells KE, et al: Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin and tamoxifen regimens: Am University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann. Plast. Surg. 28: 65-69, 1992.
 
43) Barth A, Morton DL: The role of adjuvant therapy in melanoma management. Cancer 75: 726-734, 1995.
PubMed
44) Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncdlogy Group Trial EST 1684. J. Clin. Oncol. 14: 7-17, 1996.
PubMed
45) Yamamoto A, Ishihara K: Clinical study of DAV+IFN-B therapy (combination adjuvant therapy with intravenous DTIC, ACNU and VCR, and local injection of IFN-B) for malignant melanoma. Int. J. Immunotherapy 12: 73-78, 1996.
 
46) 石原和之: Human fibroblast interferon (Hu IFN-β) による皮膚悪性腫瘍に対する臨床的研究. 日癌治療会誌 18: 41-53, 1983.
 
47) Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313: 1485-1492, 1985.
PubMed
48) Rosenberg SA, Packard BS, Aebersold P, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319: 1676-1480, 1988.
PubMed
49) Khayat D, Borel C, Tourani JM, et al: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J. Clin. Oncol. 11: 2173-2180, 1993.
PubMed
50) Legha SS, Ring S, Bedikian A, et al: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Ann. Oncol. 7: 827-835, 1996.
 
51) 影下登志郎: 遺伝子治療-悪性黒色腫に対する臨床応用-. Skin Cancer 10: 99-103, 1995.
 
52) Rosenberg SA: Gene therapy for cancer. JAMA 268: 2416-2419, 1992.
PubMed
53) Rosenberg SA, Anderson WF, Blaese M, et al: The development of gene therapy for the treatment of cancer. Ann. Surg. 218: 455-464, 1993.
PubMed
54) 梅林芳弘: 皮膚腫瘍の陽子線療法. 皮膚臨床 37: 1121-1126, 1995.
 
55) Somaza S, Kondziolka D, Lunsford LD, et al: Stereotactic radiosurgery for cerebral metastatic melanoma. J. Neurosurg. 79: 661-666, 1993.
PubMed
56) Engenhart R, Kimmig BN, Hover KH, et al: Long-term follow-up for brain metastases treated by percutaneous stereotactic single high-dose irradiation. Cancer 71: 1353-1361, 1993.
PubMed
P.1394 掲載の参考文献
1) 斎田俊明: メラノーマ・皮膚がん. 臨床腫瘍学(日本臨床腫瘍研究会編) , 癌と化学療法, 東京, 1996, pp. 926-946.
 
2) 市橋正光: 日光と皮膚癌. 臨床皮膚科 47: 73-79, 1993.
 
3) Boring CC, Squires TS, Tong T: Cancer statistics, 1991. CA Cancer J. Clin. 41: 19-36, 1991.
 
4) Heaton KM: Nonmelanoma skin cancer, The M. D. Anderson surgical oncology handbook. Little, Brown, Boston, 1994, pp. 61-69.
 
5) がんの統計編集委員会編: がんの統計'97. 財団法人がん研究振興財団, 東京, 1997.
 
6) 石原和之, 池田重雄, 森 俊二: 皮膚悪性腫瘍の診断と治療指針ならびに全国アンケートの集計. Skin Cancer 9: 7-12, 1994.
 
7) Preston DS, Stern RS: Nonmelanoma cancers of the skin. N. Engl. J. Med. 327: 1649-1662, 1992.
PubMed
8) 斎田俊明: 有棘細胞癌の診断と治療指針. Skin Cancer 9: 69-72, 1994.
 
9) Sobin LH, Wittekind Ch (ed) : TNM classification of malignant tumours (fifth edition) . Wiley-Liss, New York, 1997, pp. 115-117.
 
10) 石原和之: 全国アンケートの集計と説明. Skin Cancer 9: 72-77, 1994.
 
11) 池田重雄, 鈴木 正, 清原祥夫・他: 有棘細胞癌, 基底細胞癌. 癌と化学療法 20: 1293-1301, 1993.
Medical*Online
12) Guthrie TH, Porubsky ES, Luxenberg MN, et al: Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin results in 28 patients including 13 patients receiving multimodality therapy. J. Clin. Oncol. 8: 342-346, 1990.
PubMed
13) Sadek H, Azli N, Wendling JL, et al: Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66: 1692-1696, 1990.
PubMed
14) 池田重雄, 石原和之, 大浦武彦・他: 有棘細胞癌および悪性黒色腫に対する塩酸イリノテカン (CPT-11) の後期第II相臨床試験. Skin Cancer 8: 503-513, 1993.
 
15) 小野友道: 基底細胞癌の診断と治療指針. Skin Cancer 9: 78-80, 1994.
 
16) 森 俊二: Paget病の診断と治療指針. Skin Cancer 9: 32-37, 1994.
 
17) 大原国章, 大西泰彦, 川端康浩: 乳房外Paget病の診断と治療. Skin Cancer 8: 187-208, 1993.
 
18) 山崎直也: 皮膚付属器腺癌-特に汗腺癌, 乳房外Paget病-. 癌と化学療法 20: 1302-1307, 1993.
Medical*Online
19) 徳田安孝, 小口真司, 山崎百合子・他: 5-FUとCDDPの低濃度持続投与法(low dose FP療法) が奏効した進行期 乳房外Paget病の3例. 日皮会誌 107: 21-27, 1997.
 
P.1407 掲載の参考文献
1) 脳腫瘍全国統計委員会, 日本病理学会(編) : 脳腫瘍取扱い規約; 臨床と病理カラーアトラス. 金原出版, 東京, 1995, pp. 1-72.
 
2) 久保田紀彦: 新WHO脳腫瘍分類の改良点と問題点. 脳神経外科23(2) : 97-110, 1995.
 
3) Kondziolka D, Lunsford LD, Coffey RJ, et al: Stereotactic radiosurgery of meningiomas. J. Neurosurg. 74: 552-559, 1991.
PubMed
4) Adegbite AB, Khan MI, Paine KWE, et al: The recurrence of intracranial meningiomas after surgical treatment. J. Neurosurg. 58: 51-56, 1983.
 
5) Maxwell M, Galanopoulos T, Neville-Golden J, et al: Expression of androgen and progesterone receptors in primary human meningiomas. J. Neurosurg. 78: 456-462, 1993.
PubMed
6) 久保長生: 髄膜腫の臨床: 第13回日本脳腫瘍病理研究会教育セミナーテキスト. pp. 18-25, 1994.
 
7) Schrell UM, Rittig MG, Anders M, et al: Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg. 86: 840-844, 1997.
PubMed
8) 山下純宏, 山嶋哲盛: 髄膜腫. 脳神経外科 17: 703-711, 1989.
 
9) Saito K, Kuwayama A, Yamamoto N, et al: The transsphenoidal removal of nonfunctioning pituitary adenomas with suprasellar extensions: The open sella method and intentionally staged operation. Neurosurgery 36(4) : 668-676, 1995.
PubMed
10) Rahn T, Thoren M, Hall K, et al: Stereotactic radiosurgery in Cushing 's disease. Acute radiation effects. Surg. Neurol. 14: 85-90, 1980.
PubMed
11) Kuwayama A, Kabeyama N, Nakane T, et al: Anterior pituitary function after transsphenoidal selective adenomectomy in patients with Cushing 's disease. J. Clin. Endocrinol. Metab. 53: 165-173, 1981.
 
12) Kageyama N, Kuwayama A, Takahashi T, et al: Diagnosis, treatment and postoperative results of Cushing 's disease. Neurosurg. Rev. 8: 177-183, 1985.
PubMed
13) 小林達也: ガンマナイフによる間脳下垂体腫瘍の治療. Clin. Neurosci. 12: 627-630, 1994.
 
14) Menon AG, Gusella JF, Seizinger BR: Progress toward the isolation and characterization of the genes causing neurofibromatosis. Brain Pathol. 1: 33-40, 1990.
 
15) Ebersold MJ, Harner SG, Beatty CW, et al: Current results of the retrosigmoid approach to acoustic neurinoma. J. Neurosurg. 761901-909, 1992.
 
16) Yoshida J, Shitara N, Takakura K, et al: Astatistical study of central neurofibromatosis in Japan. Tuberous sclerosis and neurofibromatosis. In: Epidemiology, pathophysiology, biology and management. (eds. by Ishibashi Y, Mori Y) , Elservier Science Publishers, B. V., 1990, pp. 315-321.
 
17) Flickinger JC, Lunsford LD, Linskey ME, et al: Gamma knife radiosurgery for acoustic tumors: multivariate analysis of four year results. Radiother. Oncol. 27: 91-98, 1993.
PubMed
18) Lunsford LD: Stereotactic treatment of craniopharyngiomas. Intracavitary Irradiation and Radiosurgery 11: 1-15, 1989.
 
19) Kobayashi T, Kageyama N, Ohara K: Internal irradiation for cystic craniopharyngioma. J. Neurosurg. 55: 896-903, 1981.
PubMed
20) Kobayashi T: Recent progress in the treatment of craniopharyngioma. Neurosurgeons 3: 101-112, 1984.
 
21) Kobayashi T, Tanaka T, Kida Y: Stereotactic gamma radiosurgery of craniopharyngioma. Pediatr. Neurosurg. 21 (Suppl. 1) : 69-74, 1994.
 
22) Walker MD, Green SB, Byer DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery, N. Engl. J. Med. 303: 1323-1329, 1980.
 
23) Walker MD, Strike TA: An evaluation of methyl-CCNU, BCNU and radiotherapy in the treatment of malignant glioma. Proc. A. Assoc. Cancer Res. 17: 163-168, 1976.
 
24) Kornblith PL, Walker MD: Chemotherapy for malignant gliomas. J. Neurosurg. 68: H7, 1988.
 
25) Takakura K, Abe H, Tanaka R, et al: Effects of ACNU and radiotherapy on malignant gliomas. J. Neurosurg. 64: 53-57, 1986.
PubMed
26) 片倉隆一, 桜井芳明, 吉本高志: 悪性グリオーマにおける放射線. 化学療法を中心とした治療の現状. Jpn. J. Neuro- surg. (Tokyo) 1: 100-109, 1992.
 
27) Nagai M, Arai T: Clinical effect of interferon in malignant brain tumours. Neurosurg. Rev. 7: 55-64, 1984.
PubMed
28) Yamamoto SH, Tanaka T, Kanamori M, et al: in vitro studies on potentiation of cytotoxic effect on anticancer drugs by interferon on a human neoplastic cell. Cancer Lett. 20: 131-138, 1983.
 
29) 吉田 純, 若林俊彦, 加藤恭三・他: 悪性脳腫瘍に対するHulFN-β とACNU併用療法の有効性. 癌と化学療法 13 (3) Part-I: 520-524, 1986.
 
30) Yoshida J, Kajita T, Wakabayashi T, et al: Long-term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir. (Wien) 127: 55-59, 1994.
 
31) 若林俊彦, 吉田 純: 脳腫瘍の集学的治療. 癌の臨床 40(11) : 1089-1094, 1994.
Medical*Online
32) Wakabayashi T, Yoshida J, Mizuno M, et al: Effectiveness of interferon-B, ACNU, and radiation therapy in pediatric patients with brainstem glioma. Neurol. Med. Chir. (Tokyo) 32: 942-946, 1992.
 
33) 若林俊彦, 吉田 純: 悪性脳腫瘍の放射線治療に対するACNU, インターフェロン併用療法の有効性. Biotherapy 4: 1264-1269, 1990.
 
34) Packer RJ, Ater J, Allen J, et al: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J. Neurosurg. 86: 747-754, 1997.
PubMed
35) Ushio Y, Arita N, Hayakawa T, et al: Chemotherapy of brain metastases from lung carcinoma: A controlled randomized study. Neurosurgery 28: 201-205, 1991.
PubMed
36) 野村和弘: 転移性脳腫瘍. 脳神経外科 18(5) : 407-411, 1990.
 
37) Coffey RJ, Flickinger JC, Bissonette DJ, et al: Radiosurgery for solitary brain metastases using the cobalt-60 gamma unit: methods and results in 24 patients. Int. J. Radiat. Oncol. Biol. Phys. 20: 1287-1292, 1991.
PubMed
38) 木田義久, 小林達也, 田中孝幸・他: 転移性脳腫瘍のガンマナイフ治療. 脳神経外科 21(11) : 991-997, 1993.
 
39) 松谷雅生, 佐野圭司, 高倉公朋・他: 頭蓋内germ cell tumors. Neurosurgeons 3: 83-100, 1984.
 
40) Teilum G: Classification of endodermal sinus tumor (mesoblastoma vitellium) and so-called “embryonal carcinoma” of the ovary. Acta Pathol. Microbiol. Scand. 64: 407-429, 1965.
 
41) Yoshida J, Sugita K, Kobayashi T, et al: Prognosis of intracranial germ cell tumours: effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16) . Acta Neurochir. (Wien) 120: 111-117, 1993.
PubMed
42) Kobayashi T, Yoshida J, Ishiyama J, et al: Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumours. An experimental and clinical study. J. Neurosurg. 70: 676-681, 1989.
PubMed
43) Matsutani M, Sano K, Takakura K, et al: Primary intracranial germ cell tumors: aclinical analysis of 153 histologically verified cases. J. Neurosurg. 86: 446-455, 1997.
 
44) 全国脳腫瘍統計委員会: Brain Tumor Registry of Japan, vol 9, 1969-1990, 1996.
 
45) Hochberg FH, Miller DC: Primary central nervous system lymphoma. Review article. J. Neurosurg. 68: 835-853, 1988.
PubMed
46) Murray K, Kun L, Cox J: Primary malignant lymphoma of the central nervous system. results of treatment of II cases and review of the literature. J. Neurosurg. 65: 600-607, 1986.
 
47) Fisher RI, Gayor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin 's lymphoma. N. Engl. J. Med. 328(4) : 1002-1006, 1993.
 
48) 0 'Neill BP, Lyon MK, Marsh WR, et al: Primary central nervous system non-Hodgkin 's lymphoma: Survival advantaged with combined initial therapy? Int. J. Radiat. Oncol. Biol. Phys. 33: 663-673, 1995.
 
49) Brada M: Central nervous system lymphomas: Progress in chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 33: 769-771, 1995.
PubMed
50) 早川 徹・平賀章壽, 青笹克之, 他: 中枢神経系悪性リンパ腫(高倉公朋監修, 山浦 晶編) , 篠原出版, 東京, 1994.
 
51) Craft DC, Levin VA, Edwards MS, et al: Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. J. Neurosurg. 49: 589-592, 1978.
 
52) Evans AE, Jenkin RT, Sposto R, et al: The treatment of medulloblastoma. J. Neurosurg. 72: 572-582, 1990.
PubMed
53) Ater JL, Moore B, Eys JV, et al: Optimizing the treatment of medulloblastoma in very young children. Abstract of 4 th international symposium on pediatric neuro-oncology. Tokyo, 1991, Nov, p. 59.
 
54) Sure U, Berghorn WJ, Bertalanffy H, et al: Staging, scoring and grading of medulloblastoma; A postoperativeprognosis predicting system based on the cases of a single institute. Acta Neurichirur. (Wien) 132: 59-65, 1995.
PubMed
55) Rorke LB: The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J. Neuropathol. Exp. Neurol. 42: 1-15, 1983.
PubMed
56) 井上 達, 吉田 純, 景山直樹: Medulloblastomaの予後を左右する因子. 脳神経外科 13(12) : 1283-1289, 1985.
 
57) David KM, Casey ATH, Hayward RD, et al: Medulloblastoma: is the 5-year survival rate improving? A review of 80 cases from a single institution. J. Neurosurg. 86: 13-21, 1997.
 
58) Cottu PH, Giacchetti S, Mignot L, et al: High dose chemotherapy with stem-cell transplantation in a metastatic medulloblastoma in an adult: acase report and review of the literature. J. Neurooncol. 18: 19-23, 1994.
 
59) Harisiadis L, Chang CH: Medulloblastoma in children: acorrelation between staging and results of treatment. Int. J. Radiat. Oncol. Biol. Phys. 2: 833-841, 1977.
 
60) 金井秀樹, 永井 肇, 間部英雄・他: CisplatinとEtoposideの併用療法(PE療法) が奏効した髄芽腫の神経管外転移再発例. 癌と化学療法 19(4) : 545-547, 1992.
 
P.1422 掲載の参考文献
1) 藤本吉秀: 甲状腺結節性病変. 内分泌疾患概念から外科治療まで(藤本吉秀編) , 中外医学社, 東京, 1989, pp. 43-130.
 
2) 武部晃司, 伊達 学, 山本洋介・他: 甲状腺癌検診の実際とその問題点-甲状腺微小癌の問題を中心として. 外科 58 (6) 651-654, 1996.
 
3) 甲状腺外科検討会: 甲状腺癌取扱い規約. 第5版, 金原出版, 東京, 1996.
 
4) 小原孝男: MEN 2家系における甲状腺髄様癌の診断と治療. ホルモンと臨床 44(4) : 337-342, 1996.
 
5) Wells SA Jr, Chi DD, Toshima K, et al: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2 A. Ann. Surg. 220(3) : 237-247, 1994.
PubMed
6) Gottlieb JA, Hill CS Jr: Chemotherapy of thyroid cancer with adriamycin: Experience with 30 patients. N. Engl. J. Med. 290(4) : 193-197, 1974.
PubMed
7) Shimaoka K, Schoenfeld DA, DeWys WD, et al: Arandomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56(9) : 2155-2160, 1985.
 
8) Williams SD, Birch R, Einhorn LH: Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group Trial Cancer Treat. Rep. 70(3) : 405-407, 1986.
 
9) De Besi P, Busnardo B, Toso S, et al: Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J. Endocrinol. Invest. 14(6) : 475-480, 1991.
PubMed
10) 山下共行, 嶋岡勝太郎, 伊藤国彦・他: 甲状腺未分化癌に対する化学療法の意義とその成績. 内分泌外科 9(3) : 213-218, 1992.
 
11) 筒井一哉: 甲状腺未分化癌の化学療法. 内分泌外科 12(2) : 133-139, 1995.
 
12) Anscombe AM, Wright DH: Primary malignant lymphoma of the thyroid-a tumour of mucosa-associated lymphoid tissue: Review of seventy-six cases. Histopathology 9(1) : 81-97, 1985.
PubMed
13) Hyjek E, Isaacson PG: Primary B cell lymphoma of the thyroid and its relationship to Hashimoto 's thyroiditis. Hum. Pathol. 19(11) : 1315-1326, 1988.
 
14) Doria R, Jekel JF, Cooper DL: Thyroid lymphoma. The case for combined modality therapy. Cancer 73(1) : 200-206, 1994.
PubMed
15) Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen(SHP) with three intensive chemotherapy regimens for advanced nonHodgkin 's lymphoma. N. Engl. J. Med. 328(14) : 1002-1006, 1993.
 
16) Obara T, Okamoto T, Kanbe M, et al: Functioning parathyroid carcinoma: Clinicopathologic features and rational treatment. Semin. Surg. Oncol. 13(2) : 134-141, 1997.
PubMed
17) Schantz A, Castleman B: Parathyroid carcinoma. A study of 70 cases. Cancer 31(3) : 600-605, 1973.
PubMed
18) Cryns VL, Rubio MP, Thor AD, et al: Loss of the retinoblastoma suppressor gene in parathyroid carcinoma. N. Engl. J. Med. 330: 757-761, 1994.
 
19) Subramaniam P, Wilkinson S, Shepherd JJ: Inactivation of retinoblastoma gene in malignant parathyroid growths: A candidate genetic trigger? Aust. N. Z. J. Surg. 65(10) : 714-716, 1995.
PubMed
20) Obara T, Okamoto T, Ito Y, et al: Surgical and medical management of patients with pulmonary metastasis from parathyroid carcinoma. Surgery 114(6) : 1040-1049, 1993.
PubMed
21) Bukowski RM, Sheeler L, Cunningham J, et al: Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch. Intern. Med. ll4: 399-400, 1984.
 
22) Calandre DB, Chejfec G, Foy BK, et al: Parathyroid carcinoma: Biochemical and pathologic response to DTIC. Surgery 96 (6) : 1132-1137, 1984.
 
23) Tisell LE, Hedback G, Jansson S, et al: Management of hyperparathyroid patients with grave hypercalcemia. World J. Surg. 15(6) : 730-737, 1991.
PubMed
24) 島崎 淳, 市川智彦, 始関吉生・他: 日本統計集・副腎癌. 日本臨牀 51(suppl.) : 766-782, 1993.
 
25) Wooten MD, King DKL: Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72(11) : 3145-3155, 1993.
 
26) Weiss LM: Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol 8 (3) : 163-169, 1984.
PubMed
27) Lee JE, Berger DH, el-Naggar AK, et al : Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118(6) : 1090-1098, 1995.
PubMed
28) Cohn K, Gottesman L, Brennan M I Adrenocortical carcinoma. Surgery 100(6) : 1170-1177, 1986.
PubMed
29) Icard P, Chanpius Y, Andreassian B, et al: Adrenocortical carcinoma in surgically treated patients: A retrospective study on l56 cases by the French Association of Endocrine Surgery. Surgery 112(5) : 972-979, 1992.
 
30) Luton JP, Cerdas S, Billaud L, et al: Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N. Engl. J. Med. 322(17) : 1195-1201, 1990.
PubMed
31) Pommier RF, Brennan MF: An eleven-year experience with adrenocortical carcinoma. Surgery 112(6) : 963-971, 1992.
PubMed
32) Jensen JC, Pass HI, Sindelar WF, et al: Recurrent or metastatic disease in select patients with adrenocortical carcinoma: Aggressive resection vs chemotherapy. Arch. Surg. 126(4) : 457-461, 1991.
PubMed
33) Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al: Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71(10) : 3119-3123, 1993.
PubMed
34) Barry B, Novick AC, Pontes JE, et al: The Cleveland Clinic experience with adrenal cortical carcinoma. J. Urol. 141: 257-260, 1989.
 
35) Haak HR, Hermans J, van de Velde CJH, et al: Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br. J. Cancer 69 (5) : 947-951, 1994.
 
36) Kvols LK, Buck M: Chemotherapy of endocrine malignancies: A review. Semin. Oncol. 14(3) : 343-353, 1987.
PubMed
37) Bukowski RM, Wolfe M, Levine HS, et al: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: ASouthwest Oncology Group study. J. Clin. Oncol. 11(1) : 161-165, 1993.
 
38) Decker RA, Elson P, Hogan TF, et al: Eastern Cooperative Oncology Group study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6) : 1006-1013, 1991.
 
39) van Slooten H, van Oosterom AT: CAP (cyclophosphamide, doxorubicin and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat. Rep. 67: 377-379, 1983.
PubMed
40) Burgess MA, Legha SS, Sellin RV: Chemotherapy with cis-platinum and etop 'oside(VP 16) for patients with advanced adrenal cortical-carcinoma (ACC) . Proc. Am. Soc. Clin. Oncol. 12(3) : 188, 1993.
 
41) Burgess MA: Adrenal cortical carcinoma: The role of adjuvant postoperative chemotherapy. Minerva Endocrinol. 20 (1) : 101-104, 1995.
PubMed
42) Zidan J, Shpendler M, Robinson E: Treatment of metastatic adrenal cortical carcinoma with etoposide(VP-16) and cisplatin after failure with o, p 'DDD. Clinical case reports. Am. J. Clin. Oncol. 19(3) : 229-231, 1996.
 
43) Markoe AM, Serber W, Micaily B, et al: Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am. J. Clin. Oncol. 14(2) : 170-174, 1991.
PubMed
44) Gifford RW Jr, Manger WM, Bravo EL: Pheochromocytoma. Endocrinol. Metab. Clin. North Am. 23(2) : 387-404, 1994.
PubMed
45) Ito Y, Fujimoto Y, Obara T: The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J. Surg. 16(4) : 759-764, 1992.
PubMed
46) Ito Y, Obara T, Okamoto M, et al: Efficacy of single-voided urine metanephrine and normetanephrine assay for diagnosing pheochromocytoma. World J. Surg. 22(7) : 684-688, 1998.
 
47) Shapiro B, Copp JE, Sisson JC, et al: Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 cases. J. Nucl. Med. 26(6) : 576-585, 1985.
 
48) Hosaka Y, Rainwater LM, Grant CS, et al: Pheochromocytoma: Nuclear deoxyribonucleic acid patterns studied by flow cytometry. Surgery 100(6) : 1003-1008, 1986.
PubMed
49) Wu LT, Chahinian AP, Baylin SB, et al: Neoplasms of the neuroendocrine system. In: Cancer Medicine(eds. by Holland JF, Frei E, Bast RC, et al) , 4th ed., Williams ＆ Wilkins, Baltimore, 1997.
 
50) Obara T, Kanbe M, Okamoto T, et al: Surgical strategy for pheochromocytoma: Emphasis on the pledge of flank extraperitoneal approach in selected patients. Surgery 118 (6) : 1083-1089, 1995.
PubMed
51) Akiba M, Kodama T, Ito Y, et al: Hypoglycemia induced by excessive rebound sexretion of insulin after removal of pheochromocytoma. World J. Surg. 14(3) : 317-324, 1990.
PubMed
52) Shapiro B, Fig LM: Malignant pheochromocytoma. Endocrinol. Metab. Clin. North Am. 18(2) : 443-481, 1989.
PubMed
53) Averbuch SD, Steakley CS, Young RC, et al: Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann. Intern. Med. 109(4) : 267-273, 1988.
PubMed
54) 水野 治: Cyclophosphamide, vincristine, dacarbazineによる化学療法を行った悪性褐色細胞腫の一例と本邦報告 例の文献的考察. 日内分泌会誌 70(9) : 1039-1046, 1994.
Medical*Online
55) Patel SR, Einchester DJ, Benjamin RS: A15-year experience with chemotherapy of patients with paraganglioma. Cancer 76(8) : 1476-1480, 1995.
 
56) Shapiro B, Sisson JC, Wieland DM, et al: Radiopharmaceutical therapy of malignant pheochromocytoma with [1311]metaiodo-benzylguanidine: Results from ten years of experience. J. Nucl. Biol. Med. 35(4) : 269-276, 1991.
 
57) 日下部きよ子, 金谷和子, 金谷信一・他: 131I-MIBGによる悪性褐色細胞腫の治療効果-長期経過観察の結果. 核医学 31 (12) : 1495-1501, 1994.
Medical*Online
58) 今村正之: 膵内分泌腫瘍. 第23回日本膵切研究会アンケート集計報告, 1996.
 
59) Soga J, Yakuwa Y: Pancreatic endocrinomas: Astatistical analysis of 1, 857 cases. J. Hep. Bil. Pancr. Surg. 1 (1) : 522-529, 1994.
 
60) Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type. Science 276 (5311) : 404-407, 1997.
PubMed
61) Fajans SS, Floyd JC: Hypoglycemia: How to manage a complex disease. Mod. Med. 41: 24-31, 1973.
 
62) Thompson NW, Eckhauser FE: Malignant islet-cell tumors of the pancreas. World J. Surg. 8(6) : 940-951. 1984.
PubMed
63) van Eyck CHJ, Bruining HA, Reubi J-C, et al: Use of isotope-labeled somatostatin analogs for visualization of silet cell tumors. World J. Surg. 17(4) : 444-447, 1993.
 
64) Doppman JL, Miller DL, Chang R: Intraarterial calcium stimulation test of detection of insulinomas. World J. Surg. 17 (4) : 439-443, 1993.
PubMed
65) van Heerden JA, Grant CS, Czako PF, et al: Occult functioning insulinomas: Which localizing studies are indicated? Surgery 112 (6) 11010-1015, 1992.
 
66) Thompson NW, Czako PF, Fitts LL, et al: Role of endoscopic ultrasonography in localization of insulinomas and gastrinomas. Surgery 116(6) : 1131-1138, 1994.
 
67) 細谷 亮, 加藤雅之, 土井隆一郎. 他: ガストリノーマの診断と治療の進歩. ホルモンと臨床 44(4) : 369-376, 1996.
 
68) Norton JA, Doppman JL, Gardner JD, et al: Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann. Surg. 203(4) : 352-359, 1986.
PubMed
69) Moertel CG, Johnson CM, McKusick MA, et al: The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann. Intern. Med. 120(4) : 302-309, 1994.
PubMed
70) Eriksson B, Oberg K: An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol. 32 (2) : 203-208, 1993.
PubMed
71) Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 326(8) : 519-523, 1992.
PubMed
P.1431 掲載の参考文献
1) Joseph WL, Murray JF, Mulder DG: Mediastinal tumors-problems in diagnosis and treatment. Dis. Chest 50: 150-160, 1966.
PubMed
2) Cox JD: Primary malignant germinal tumors of the mediastinum; astudy of 24 cases. Cancer 36: 1162-1168, 1975.
 
3) Polansky SM, Barxick KW, Ravin CE: Primary mediastinal seminoma. Am. J. Roentgenology 132: 17-21, 1979.
 
4) Martini N, Golbey RB, Hajdu SI, et al: Primary mediastinal germ cell tumors. Cancer 33: 763-769, 1974.
PubMed
5) Knapp RH, Hurt RD, Payne WS, et al: Malignant germ cell tumors of the mediastinum. J. Thorac. Cardiovasc. Surg. 89: 82-89, 1985.
PubMed
6) Jain KK, Bosl GJ, Bains MS, et al: The treatment of extragonadal seminoma. J. Clin. Oncol. 2: 820-827, 1984.
PubMed
7) Nichols CR, Saxman S, Williams SD, et al: Primary mediastinal nonseminomatous germ cell tumors-a modern single institution experience. Cancer 65: 1641-1646, 1990.
PubMed
8) Nichols CR, Heerrma NA, Palmer C, et al: Kleinfelter 's syndrome associated with mediastinal germ cell neoplasms. J. Clin. Oncol. 5: 1290-1294, 1987.
 
9) Nichols CR, Hoffman R, Einhorn LH, et al: Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann. Intern. Med. 102: 603-609, 1985.
PubMed
10) Orazi A, Neiman RS, Urbright TM, et al: Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer 71: 3873-3881, 1993.
 
11) Bosl GJ, Ilson DH, Rodriguez E, et al: Clinical relevance of the i(12 p) marker chromosome in germ cell tumors. J. Natl. Cancer Inst. 86: 349-355, 1994.
PubMed
12) Garnick MB, Griffin JD: Idiopathic thrombocytopenia in association with extragonadal germ cell cancer. Ann. Intern. Med. 98: 926-927, 1983.
PubMed
13) Woolner LB, Jamplis RW, Kirklin JW: Seminoma (germinoma) apparently primary in anterior mediastinum. N. Engl. J. Med. 252: 653-658, 1955.
PubMed
14) Cox JD: Primary malignant germinal tumors of the mediastinum. Cancer 36: 1162, 1975.
PubMed
15) Dulmet EM, Macchiarini P, Suc B, et al: Germ cell tumors of the mediastinum: a30 year experience. Cancer 72: 1894, 1993.
 
16) El-Domeirri AA, Hutter RVP, Pool JL, et al: Primary seminoma of the anterior mediastinum. Ann. Thorac. Surg. 6: 513, 1986.
 
17) Hurt RD, Buckman JE, Farrow GM, et al: Primary anterior mediastinal seminoma. Cancer 49: 1658, 1982.
 
18) Jain KK, Bosl GJ, Bains MS, et al: The treatment of extragonadal seminoma. J. Clin. Oncol. 2: 820, 1984.
PubMed
19) Medini E, Levitt SHG, Jones TK, et al: The management of extratesticular seminoma without gonadal involvement. Cancer 44: 2032, 1979.
 
20) Raghavan D, Barret A: Mediastinal seminomas. Cancer 46: 1187, 1980.
 
21) Schantz A, Sewall W, Castleman B: Mediastinal germinoma. A study of 21 cases with an excellent prognosis. Cancer 30: 1189, 1972.
PubMed
22) Bush SE, Martinez A, Bagshaw MA: Primary mediastinal seminoma. Cancer 48: 1877-1882, 1981.
PubMed
23) Einhorn LH, Williams SD: Chemotherapy of disseminated seminoma. Cancer Clin. Trials 3: 307-313, 1980.
PubMed
24) Stanton GF, Bosl GJ, Whitmore WF Jr: VAB-6 as initial treatment of patients with advanced seminoma. J. Clin. Oncol. 3: 336, 1985.
PubMed
25) Schultz SM, Einhorn LH, Conces DJ, et al: Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin. Oncol. 7: 1497, 1989.
PubMed
26) Motzer R, Bosl G, Heclan R, et al: Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J. Clin. Oncol. 5: 1064, 1987.
 
27) Puc HS, Heelan R, Mazumdar M, et al: Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J. Clin. Oncol. 141454, 1996.
 
28) The International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 15: 594, 1997.
 
29) Einhorn LH: Testicular cancer as a model for a curable neoplasm. The Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res. 141: 3275, 1981.
 
30) Saxman SB, Nichols CR, Einhorn LH: Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J. Clin. Oncol. 12: 1390, 1994.
PubMed
31) Fox EP, Weathers TD, Williams SD, et al: Outcome analysis for patients with persistent nonteratomatous germ cell tumor in post-chemotherapy retroperitoneal lymph node dissections. J. Clin. Oncol. 11: 1294, 1993.
 
32) Motzer RJ, Gulati S, Crown Jp, et al: High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: early intervention is better tolerated. Cancer 69: 550, 1992.
PubMed
33) Siegert W, Beyer J, Strochsheer I, et al: High dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: aphase I/IIstudy. J. Clin. Oncol. 12: 1223, 1994.
 
34) Motzer RJ, et al: High-dose carboplatin, etoposide and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. 14: 1098, 1996.
PubMed
35) Izant RJ, Filson IIC: Sacrococcygeal teratomas: analysis of forty-three cases. Am. J. Surg. 130: 617, 1975.
 
36) Luna MA, Valenzuela-Tamariz J: Germ-cell tumors of the mediastinum, postmortem findings. Am. J. Clin. Pathol. 65: 450, 1976.
PubMed
37) Economou JS, Trump DL, Holmes EC, et al: Management of primary germ cell tumors of the mediastinum. J. Thorac. Cardiovasc. Surg. 83: 643, 1982.
PubMed
P.1451 掲載の参考文献
1) Farber S: Chemotherapy in the treatment of leukemia and Wilms ' tumor. JAMA 198: 826-836, 1966.
PubMed
2) Hammond GD: Keynote address: the cure of childhood cancers. Cancer 5 8(Suppl) : 407, 1986.
 
3) Rabbitts TH: Chromosomal translocations in human cancer. Nature 372: 143-149, 1994.
PubMed
4) Saito T and the committee for the studies of the treatments and the biological characteristics of childhood cancers: Trends in survival of childhood malignancy for the past three decades 1: leukemia, malignant lymphoma, neuroblastoma, retinoblastoma and neoplasms of the urinary and digestive organs. Acta Pediatr. Jpn. 37: 479-486, 1995.
 
5) Crist W, Kun LE: Common solid tumors of childhood. N. Engl. J. Med. 324: 461-471, 1991.
PubMed
6) Bleyer WA: What can be learned about childhood cancer from “Cancer Statistics Review 1973-1988”. Cancer (suppl.) 71 (10) : 3229-3236, 1993.
 
7) 熊谷昌明, 恒松由記子: 小児悪性腫瘍. 専門医のためのがん治療学レビュー '98(最新主要文献と解説) . 総合医学社, 東京, 1997, pp. 223-227.
 
8) Gurney JG, Severson RK, Davis S, et al: Incidence of cancer in children in the United States. Sex, race, and 1 year age specific rates by histologic type. Cancer 75(8) : 2186-2195, 1995.
PubMed
9) Birch JM, Marsden, H. B.: A classification scheme for childhood cancer. Int. J. Cancer 40: 620-624, 1987.
PubMed
10) Ajiki W, Hanai A, Tsukuma H, et al: Incidence of childhood cancer in Osaka, Japan, 1971-1988: Reclassification of registered cases by Birch 's scheme using information on clinical diagnosis, histology and primary site. Jpn. J. Cancer Res. 85: 139-146, 1994.
 
11) 味木和喜子, 花井 彩, 津熊秀明・他: 大阪府における小児がんの罹患の動向. 成人病Adult diseases 33: 107-126, 1993.
 
12) (財) がんの子どもを守る会, 小児がん全国登録委員会: 5年報1979-83.
 
13) Young JlJr, Ries LG, Silverberg E, et al: Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 58: 598-602, 1986.
 
14) Parkin DM, Stiller CA, Draper GJ, et al (eds.) : “International incidence of childhood cancer, ” IARC Scientific Publications No. 87, IARC, Lyon, 1988.
 
15) Knudson AG: Hereditary cancers disclose a class of cacncer genes. Cancer 63: 1888-1891, 1985.
 
16) Li FP: Cancer families: human models of susceptibility to neoplasis. Cancer Res. 48: 5381, 1988.
 
17) Miller RW, Fraumeni JF Jr, Manning MD: Association of Wilms 'tumor with aniridia, hemihypertrophy and other congenital malformations. N. Engl. J. Med. 270: 922-927, 1964.
PubMed
18) Knudson AG Jr: Hereditary cancer, oncogenes and antioncogenes. Cancer Res. 45: 1437-1443, 1985.
PubMed
19) 恒松由記子: 小児がん臨床遺伝学とがん家系症候群. 日小血会誌 9(6) : 395-403, 1995.
 
20) 恒松由記子: 家族性腫瘍におけるがん体質の発症前診断に伴う倫理的・法的・社会的諸問題. 癌と化学療法 24(8) : 945-950, 1997.
Medical*Online
21) 恒松由記子, 掛江直子: DNAソースとなる試料の採取と保存に関連した倫理的問題. 臨床検査 42(3) : 344-346, 1998.
 
22) Gale KB, Ford AM, Repp R, et al: Backtracking leukemia to birth: Identification of clonotyping gene fusion sequences in neonatal blood spots. Proc. Natl. Acad. Sci. USA 94: 13950-13954, 1997.
PubMed
23) Ford AM, Bennett CA, Price CM, et al: Fetal origins of the TEL-AMlfusion gene in identical twins with leukemia. Proc. Natl. Acad. Sci. USA 95: 4584-4588, 1998.
 
24) 恒松由記子: 子どものがん. 家庭の医学, 保健同人社, 東京, 1994, pp. 752-758.
 
25) Pinkerton CR, Cushing P, Sepion B: 3. Making a clinical and pathological diagnosis. Childhood Cancer Management. A Practical Handbook, 1984, pp. 13-27.
 
26) Steuber CP, Nesbit ME: Clinical assessment and differential diagnosis of the child with suspected cancer. In: Priciple and Practice of Pediatric Oncology (eds. by Pizzo, P. A., Poplack, D. G.) , third ed., Lippencott-Raven, Philadelphia, 1997, pp. 129-139.
 
27) Triche TJ: Pathology and molecular diagnosis of pediatric malignancies. i. b. i. d. pp. 141-185.
 
28) Parker BR: Imaging studies in the diagnosis of pediatric malignancies. i. b. i. d. pp. 153-178.
 
29) 金子安比古: 小児固形腫瘍における染色体異常, がん関連遺伝子. 小児内科 30: 185, 1998.
 
30) 中田 信, 大木 操: 癌と融合遺伝子. 蛋白質核酸 酵素 42: 1978-1989, 1997.
Medical*Online
31) Kenny LB, Reaman GH: Special considerations for the infant with cancer. In: Priciple and Practice of Pediatric Oncology (eds. by Pizzo PA, Poplack DG) , 3「d ed., Lippencott-Raven, Philadelphia, pp. 343-356, 1997.
 
32) 恒松由記子, 塙 嘉之, 藤本孟男・他: 各種抗悪性腫瘍剤投与による悪心・嘔吐に対するOndansetron注射液の制吐 効果と安全性の検討-小児領域での検討-. 小児科診療 57(10) : 1871-1887, 1994.
 
33) 恒松由記子, 掛江直子: がんの子どもへのインフォームドコンセントとオープンコミュニケーション. 小児科 38(7) : 891-900, 1997.
 
34) 東山由美: 白血病の診断・治療とケア: 病名説明後の本人変化. 小児科看護 20: 319-324, 1997.
 
35) Convention on the Rights of the Child., 1989.
 
36) Meadows AT, Black B, Nesbit ME, et al: Long-term survival. Clinical care, Research and Education. Cancer (suppl.) 71 (10) : 3213-3215, 1993.
 
37) Meister LA, Meadows AT: Late effects of childhood cancer therapy. Curr. Probl. Pediatr.: 102-131, 1993.
PubMed
38) 恒松由記子, 田口信行, 佐伯守洋・他: 横紋筋肉腫の晩期障害. 小児外科 26(1) : 99-103, 1994.
 
39) 恒松由記子: 悪性固形腫瘍患児の晩期障害. 小児期の悪性固形腫瘍-系統的治療を中心に (山本正生編) . 永井書店, 大阪, 1996, pp. 315-328.
 
40) 恒松由記子: 小児の治療関連2次性白血病. 小児内科 28 (増刊号) : 1192-1196, 1996.
 
41) 恒松由記子: 小児悪性腫瘍の晩期障害と二次発癌. 小児医学の進歩 '91B. 新小児医学体系. 中山書店, 東京, 1991, pp. 279-293.
 
42) Green DM: Effects of treatment for childhood cancer on vital organ systems. Cancer 71 (suppl.) : 3299-3305, 1993.
 
43) Neglia Jp, Nesbit ME Jr: Care and treatment of long-term survivors of childhood cancer. Cancer 71(suppl.) : 3386-3391, 1993.
 
44) Nicholson HS, Byrne J: Fertility and pregnancy after treatment for cancer during childhood or adolescence. Cancer 71 (suppl.) (10) : 3392-3399, 1993.
 
45) Strong LC: Genetic implications for long-term survivors of childhood cancer. Cancer 71 (suppl.) : 3435-3440, 1993.
 
46) Whittam EH: Terminal care of the dying child: psychosocial implications of care. Cancer (suppl.) 71: 3450-3462, 1993.
 
47) 小原美江, 斉藤千恵子, 山田ことみ・他: 小児がんにおける疼痛アセスメント. がん看護3(2) : 118-124, 1998.
 
48) 日本小児外科学会悪性腫瘍委員会: 小児の外科的悪性腫瘍の予後調査結果の報告. 日小外会誌 21: 1222-1251, 1985.
 
49) Bessho F, Hashizume K, Nakajo T, et al: Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J. Pediatr. 119: 237-241, 1991.
 
50) Brodeur GM, Azar C, Brother M, et al: Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer 70 (6 Suppl) : 1685-1694, 1992.
 
51) Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl. Cancer Inst. 73: 405-416, 1984.
 
52) Brodeur GM, Seeger RC, Brrett A, et al: International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J. Clin. Oncol. 6: 1874-1881, 1988.
PubMed
53) Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol. 11: 1466--1477, 1993.
 
54) Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J Med. 328: 847-854, 1993.
PubMed
55) Silber JH, Evans AE, Fridman M: Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res. 51: 1426-1433, 1991.
PubMed
56) Brodeur GM, Castleberry RP: Neuroblastoma. In: Principles and Practice of Pediatric Oncology (eds. by Pizzo PA, Poplack DG. Lippincott-Raven, Philadelphia, 1997, pp. 761-797.
 
57) Haase GM, 0 'Leary MC, Ramsay NK, et al: Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J. Pediatr. Surg. 26: 1119-1124, 1991.
 
58) Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over l year of age. J. Clin. Oncol. 12: 2607-2613, 1994.
 
59) Shafford EA, Rogers DW, Pritchard J: Advanced neuroblastoma: Improved response rate using a multiagent regimen (OPEC) including seuential cisplatin and VM-26. J. Clin. Oncol. 2: 742-747, 1984.
 
60) Sawaguchi S, Kaneko M, Uchino J, et al: Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy: Areport from the study group of Japan. Cancer 66: 1879-1887, 1990.
 
61) Pritchard J, McElwain TJ, Graham-Pole J: High dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br. J. Cancer 45: 86, 1982.
 
62) Dini G, Lanino E, Garaventa A, et al: Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J. Clin. Oncol. 9: 962-969, 1991.
 
63) Ohnuma N, Takahashi H, Kaneko M, et al: Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan. Med. Pediatr. Oncol. 24: 18H87, 1995.
 
64) Stram DO, Matthey KK, 0 'Leary M, et al: Consolidation chemotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children 's Cancer Group studies. J. Clin. Oncol. 14: 2417-2426, 1996.
 
65) Shuster JJ: The role of autologous bone marrow transplantation in advanced neuroblastoma. J. Clin. Oncol. 14: 2413-2414, 1996.
PubMed
66) Mugishima H, Iwata M, Okabe I, et al: Autologous bone marrow transplantation in children with advanced neuroblastoma. Cancer 74: 972-977, 1994.
PubMed
67) Villablanca JD, Khan AA, Avramis VI, et al.
 
68) Reynolds CP: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J. Clin. Oncol. 13: 894-901, 1995.
PubMed
69) Hoefnagel CA, De Kraker J, Valdes Olmos RA, et al: 1311-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl. Med. Commun. 15: 712-717, 1994.
 
70) 神経芽腫委員会: 神経芽腫マススクリーニングの全国集計結果. 小児がん 32: 103-110, 1995.
 
71) Murphy S, Corn SL, Craft AW, et al: Do children benefit from mass screening for neuroblastoma? Lancet 337: 344-345, 1991.
 
72) Huddart SN, Mann JR: Screening for neuroblastoma. Arch. Dis. Child. 66: 1272-1274, 1991.
PubMed
73) Lemieux B, et al: The Quebec neuroblastoma screening program: An update. Third International Symposium on Neuroblastoma Screening. Kyoto, September, 1993.
 
74) Hachitanda Y, Ishimoto K, Hata J, et al: One hundred neuroblastomas detected through a mass screening system in Japan. Cancer 74: 3223-3226, 1994.
PubMed
75) Woods WG, Tuchman M, Robison LL, et al: A population-based study of the usefulness of screening for neuroblastoma. Lancet 348: 1682-1687, 1996.
PubMed
76) 西平浩一・豊田恭徳・井口昌裕: 神経芽腫マススクリーニング陽性例を無治療で経過観察する基準の検討-prospec- tive に長期間無治療で観察した5症例の経験から-. 日小外会誌 31(3) : 424, 1995.
 
77) 金子道夫・内野純一・武田武夫: 進行神経芽腫の現状と問題点. 小児がん 32(1) : 7-11, 1995.
 
78) Sawada T, Hirayama M, Nakata T, et al: Mass screening for neuroblastoma in infants in Japan. Lancet 2(8397) : 271-273, 1984.
PubMed
79) 菊地正悟, 石本浩市, 福渡 靖・他: 神経芽腫マス・スクリーニングの死亡率減少効果測定方法の考按. 日小児会誌 99 (10) : 1855-1858, 1995.
 
80) Green DM, Breslow NE, Evans I, et al: Effect of dose intensity of chemotherapy on the hematological toxicity of the treatment of Wilms tumor. A report from the National Wilms Tumor Study. Am. J. Pediatr. Hematol. Oncol. 16: 207-212, 1994.
PubMed
81) Green DM, Breslow NE, Evans I, et al: The relationship between dose schedule and charges for treatment on National Wilms Tumor Study-4. A report from the National Wilms Tumor Study Group. J. Natl. Cancer. Inst.
 
82) Grundy PE, Telzerow PE, Breslow N, et al: Loss of heterozygosity for chromosomes 16 q and 1 p in Wilms tumors predicts an adverse outcome. Cancer Res. 54: 2331-2333, 1994.
 
83) Greenberg M, Burnweit C, Filler R, et al: Preoperative chemotherapy for children with Wilms 'tumor. J. Pediatr. Surg. 26(8) : 949-953, discussion 953-956, 1991.
 
84) Green DM, Breslow NE, Ii Y, et al: The role of surgical excision in the management of relapsed Wilms 'tumor patients with pulmonary metastases: A report from the National Wilms 'Tumor Study. J. Pediatr. Surg. 26(6) : 728-733, 1991.
PubMed
85) Green DM, Breslow NE, Beckwith JB, et al: Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms tumor: A report from the National Wilms Tumor Study. Med. Pediatr. Oncol. 21(3) : 188-192, 1993.
PubMed
86) 金子安比古: Wilms腫瘍遺伝子とがん. CRC 1: 82-89, 1992.
 
87) Reeve AE: Role of genomic imprinting in Wilms 'tumor and overgrowth disordears. Med. Pediatr. Oncol 27: 470-470, 1996.
PubMed
88) MoultonT, Chung W, Yuan L, et al: Genomic imprinting and Wilm 's tumor. Med. Pediatric. Oncol. 27: 476-483, 1996.
 
89) 岡 敏明, 金子安比古: Denys Drash症候群. Mol. Med. 33: 136-137, 1996.
 
90) Huff V: Genotype phenotype correlations in Wilms 's tumor. Med. Pediatr. Oncol, 27: 408-414, 1996.
 
91) Li FP, Breslow NE, Morgan JM, et al: Germline WT 1 mutations in Wilms tumor Patients: Preliminary results. Med. Pediatr. Oncol. 271404-407, 1996.
 
92) Pelletier J, Li FP, Harber DA, et al: WT 1 mutations contribute to abnormal genital development and hereditary Wilms tumor. Nature 353: 431, 1991.
 
93) Rodary C, Gehan EA, Flamant F, et al: Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: A report from the International Rhabdomyosarcoma Workshop. Med. Pediatr. Oncol. 19: 89-95, 1991.
 
94) Crist W, Gehan EA, Ragab AH, et al: The third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 13(3) : 610-630, 1995.
PubMed
95) 徳田桐子, 高山 順, 大平睦郎: 小児横紋筋肉腫と自家幹細胞移植. 特集 固形腫瘍治療における造血幹細胞移植の現況と問題点. 小児外科 27(10) : 58-63, 1995.
 
96) Donaldson SS, Asmar L, Breneman J, et al: Hyperfractionated radiation in children with rhabdomyosarcoma: results of an Intergroup Rhabdomyosarcoma Pilot Study. Int. J. Radiat. Oncol. Biol. Phys. 32: 903-911, 1995.
PubMed
97) Andrassy RJ, Corpron CA, Hays D, et al: Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III. J. Pediatr. Surg. 31: 191-196, 1996.
 
98) Newton WA, Gehan EA, Webber BL, et al: Classification of rhabdomyosarcomas and related sarcomas: pathologic aspects and proposal for a new classification-an Intergroup Rhabdomyosarcoma Study. Cancer 76: 1073-1085, 1995.
PubMed
99) Filler RM, Ehrlich PF, Greenberg ML, et al: Preoperative chemotherapy in hepatoblastoma. Surgery 110: 591-597, 1991.
PubMed
100) Ninane J, Perilongo G, Stalens JP, et al: Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: ASIOP pilot study. Med. Pediatr. Oncol. 19: 199-203, 1991.
 
101) Urban CE, Mche CJ, Schwinger W, et al: Undifferentiated (embryonal) sarcoma of the liver in childhood. Cancer 72: 2511-2516, 1993.
 
102) Kushner BH, Meyers PA, Gerald WL, et al: Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing 's sarcoma, in children and young adults. J. Clin. Oncol. 13: 2796-2804, 1995.
 
103) Ladenstein R, Lasset C, Pinkerton R, et al: Impact of megatherapy in children with high-risk Ewing 's tumours in complete remission: areport from the EBMT Solid Tumour Registry. Bone Marrow Transplant. 15: 697-705, 1995.
 
104) Ablin AR, Krailo MD, Ramsay NKC, et al: Results of treatment of malignant germ cell tumors in 93 children: A report from the Childrens Cancer Study Group. J. Clin. Oncol. 9: 1782-1792, 1991.
 
105) Ichikawa H, Shimizu K, Hayashi Y, et al: An RNA-bining protein gene, TLS/FUS, is fudes to ERG in human myeloid leukemia with i (16; 21) chromosomal translocaion. Cancer Res. 54: 2865-2868, 1994.
 
106) 熊谷昌明, 恒松由記子, 平林万紀子: 小児がんの生存率の改善と長期生存の今後の問題. 化学療法の領域 6: 756-760, 1990.
 
107) Bleyer WA: The impact of childhood cancer on the united States and the world. CA 40: 355-367, 1990.
PubMed
P.1470 掲載の参考文献
1) Ries LA G, Hankey BF, et al: Cancer statistics Review 1973-1988, Bethesda, Md.: National lnstitute of Health, NIH publication. 91: 2789, 1991.
 
2) Miller RW: Persons with exceptionally high risk of leukemia. Cancer Res. 27: 2420, 1967.
PubMed
3) 藤本孟男: 小児白血病の治療. 白血病・悪性リンパ腫(高久史麿編) 改訂第2版, 南江堂, 東京, 1993, pp. 123-138.
 
4) Hammond GD, et al: Stratification by prognostic factors in the design and analysis of clinical trials for acute lymphoblastic leukemia. Haematol. Blood Trans. 30: 161, 1987.
 
5) 藤本孟男: 小児白血病治療の進歩. 日本医事新報 3500: 13-25, 1991.
Medical*Online
6) Neglia Jp, et al: Second neoplasms after acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 325: 1330, 1991.
PubMed
7) Goldie JH, Coldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat. Rep. 67: 923-931, 1983.
PubMed
8) Lampkin BC, Mauer AM, et al: Manipulation of the mitotic cycle in the treatment of acute myelogenous leukemia. Br. J. Hematol. 32: 29-40, 1976.
 
9) Weinstein HJ, Mayer RJ, et al: Treatment of acute myelogenous leukemia in children and adults. N. Engl. J. Med. 303: 473-478, 1980.
PubMed
10) Creutzig U, Ritter J, et al: Improved treatment results in childhood acute myelogenous leukemia: a report of the Germen co-operative study AML-BFM-78. Blood 65: 298-304, 1985.
 
11) Preisler H, Davis RB, et al: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute non-lymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 69: 1441-1449, 1987.
 
12) Wells RJ, Wood WG, et al: Impact of high dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Children 's Cancer Group. J. Clin. Oncol. 11: 538-545, 1993.
 
13) Ritter J, Creutzig U, et al: Treatment results of three consecutive German Childhood AML trials: BFM-78, -83, and -87. Leukemia 6: 59-62, 1992.
PubMed
14) Clift RA, Thomas ED, et al: The treatment of acute non-lymphocytic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant. 2: 243-258, 1987.
PubMed
15) Feig SA, Lampkin B, et al: Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the children 's Cancer Group. Bone Marrow Transplant. 2: 127-135, 1993
 
16) Degos L: Is acute promyelocytic leukemia a curable disease? Treatment strategy for a long-term survival. Leukemia 8: 911-913, 1994.
PubMed
17) Santana VM, Mirro J Jr, et al: 2-chlorodeoxy-adenosine products a high rete of complete hematologic remission in relapsed acute myeloid leukemia. J. Clin. Oncol. 10: 364-370, 1992.
 
18) 佐々木邦明, 藤木孟男: 小児悪性リンパ腫568例の病態と予後. 日小児会誌 91: 690-700, 1987.
 
19) Donaldson S: Hodgkin 's disease in children. Semin. Oncol. 17: 736-748, 1990.
PubMed
20) Wollner N, Burchenal JH, et al: Non-Hodgkin 's lymphoma in children. Med. Pediatr. Oncol. 1: 235-263, 1975.
PubMed
21) Weinstein HJ, Cassady JR, et al: Long-term results of the APO protocol (vincristine, doxorubicin, and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J. Clin. Oncol. 1: 537-541, 1983.
PubMed
22) Sullivan MP, Ramirez I: Curability of Burkitt 's lymphoma with high-dose cyclophosphamide, high-dose methotrexate therapy and intrathecal chemophylaxis. J. Clin. Oncol. 3: 105-112, 1979.
 
23) 藤本孟男, 佐々木邦明: 超大量Methotrexateの血中および髄液動態. 癌と化学療法 6: 105-112, 1979.
 
24) Shimizu H, Fujimoto T, et al: Improved treatment results of non-Hodgkin 's lymphoma in children: a report from the Children 's Cancer and Leukemia Study Group of Japan. Int. J. Hematol. 61: 85-96, 1995.
 
25) Koizumi S, Fujimoto T: Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children 's Cancer and Leukemia Study Group. Jnt. J. Hematol. 59: 99-112, 1994.
 
26) Bleyer WA: Principles of cancer chemotherapy in children. Cancer Bull. 44: 46L469, 1992.
 
27) Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J. Clin. Oncol. 14: 8-24, 1996.
 
P.1491 掲載の参考文献
1) Harris NL, Jaffe ES, Stein H, et al: A rvised European-American classification of lymphoid neoplasms: A proposal from the international lyrnphoma study group. Blood 84: 1361-1392, 1994.
 
2) 朝長万左男, 栗山一孝, 市丸道人・他: 原爆被害者に発生した白血病の診断と病型分類の再検討. 広島医学 41: 498- 503, 1988.
 
3) 厚生省大臣官房統計情報部編: 人口動態統計平成7年. 厚生統計協会, 東京, 1996.
 
4) Bennett JM, Catovsky D, Daniel M-T, et al: Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. 103: 620-625, 1985.
PubMed
5) Bennett JM, Catovsky D, Daniel M-T, et al: Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO) . Br. J. Haematol. 78: 325-329, 1991.
 
6) Catovsky D, Matutes E, Buccheri V, et al: A classification of acute leukaemia for the 1990 s (Leading article) . Ann. Hematol. 62: 16-21, 1991.
 
7) Skipper HE: Thoughts on cancer chemotherapy and combination modality therapy. JAMA 230: 1033-1036, 1974.
PubMed
8) Simone JV: Childhood leukemia as a model for cancer research. Cancer Res. 39: 4301-4307, 1979.
 
9) Rivera GK, Raimondi SC, Hancock ML, et al: Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337: 61-66, 1991.
PubMed
10) 清水宏之, 藤本孟男: 小児急性白血病治療の現状. Annual Review血液1992, 中外医学社, 東京, 1992, pp. 130-141.
 
11) Yamada M, Wasserman R, Lange B, et al: Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistance of leukemic cells during the first 18 months of treatment. N. Engl. J. Med. 323: 448-455, 1990.
PubMed
12) Ohno R, Kobayashi T, Tanimoto M, et al: Randomized study of individualized induction therapy with or without VCR, and of maintenance/intensification therapy between 4 or 12 courses in adult acute myeloid leukemia; Japan Adult Leukemia Study Group AML-87 Study. Cancer 71: 3888-3895, 1993.
 
13) Miyamoto T, Nagafuji K, Akashi K, et al: Persistence of multipotent progenitors expressing AML 1/ETO transcripts in long-term remission patients with t(8; 21) acute myelogenous leukemia. Blood 87: 4789-4796, 1996.
 
14) 小川一誠, 太田和雄: 細胞回転. 急性白血病, 金原出版, 東京, 1978, p. 77.
 
15) Kobayashi T, Miyawaki S, Tanimoto M, et al: Randomized trial between behenoyl cytarabine (BHAC) or cytarabine in combination induction and consolidation chemotherapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J. Clin. Oncol. 14: 204-213, 1996.
 
16) Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331: 896-903, 1994.
PubMed
17) Berman E, Heller G, Santorsa J, et al: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77: 1666-1674, 1991.
PubMed
18) Pui C-H, Behm FG, Raimondi SC, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N. Engl. J. Med. 321: 136-142, 1989.
PubMed
19) Buchner TH, Urbanitz D, Hiddemann W, et al: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML) : two multicenter studies of the German AML Cooperative Group. J. Clin. Oncol 3: 1583-1589, 1985.
 
20) Preisler H, Davis RB, Kirshner J, et al: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 69: 1441-1449, 1987.
 
21) Toronto Leukemia Study Group: Survival in acute myeloblastic leukemia is not prolonged by remission maintenance or early reinduction chemotherapy. Leuk. Res. 12: 195-200, 1988.
PubMed
22) Buchner TH, Hiddemann W, Wormann B, et al: Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. Leukemia 6(Suppl) : 68-71, 1992.
 
23) Rees JK, Gray RG, Swirsky D, et al: Principal results of the Medical Research Council 's 8th acute myeloid leukaemia trial. Lancet 2: 1236-1241, 1986.
 
24) Zittoun R, Jehn U, Frere D, et al: Alternating repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML 6) of the EORTC leukemia cooperative group. Blood 73: 896-906, 1989.
 
25) Cassileth PA, McGlave P, Harrington DP: Comparison of post remission therapy in AML: maintenance versus intensive consolidation therapy versus allogeneic bone marrow transplantation. Proc. Am. Soc. Clin. Oncol. 18: 197, 1989.
 
26) Volger WR, Velez Garcia E, Weiner RS, et al: A phase III trial comparing idarubicin and daunorubicin in comparison with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. J. Clin. Onocol. 10: 1103-1111, 1992.
 
27) Wiernik PH, Banks PLC, Case Jr DC, et al: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid luekemia. Blood 79: 313-319, 1992.
 
28) 大野竜三: 成人急性リンパ性白血病の治療指針. Annual Review 血液, 中外医学社, 1995, pp. 145-156.
 
29) Maurer J, Janssen JWG, Thiel E, et al: Detection of chemeric BCR-ABL genes in acute lymphoblastic leukemia by the polymerase chain reaction. Lancet 337: 1055-1058, 1991.
 
30) Sanchez-Fayos J, Outeirino J, Villalobos E, et al: Acute lymphoblastic leukemia in adults: results of a 'totaltherapy ' programme in 47 patients over 15 years old. Br. J. Haematol. 59: 689-696, 1985.
PubMed
31) Stryckmans P, Debusscher L: Chemotherapy of adult acute lymphoblastic leukaemia. Baillieres Clin. Haematol. 4: 115-130, 1991.
PubMed
32) Gimema Cooperative Group: GIMEMA ALL 0183: a multicentric study on adult acute lymphoblastic leukaemia in Italy. Br. J. Haematol 71: 377-386, 1989.
 
33) Hoelzer D, Thiel E, Loffler H, et al: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71: 123-131, 1988.
 
34) Nagura E, Yamada K: A controlled randomized clinical trial of adult acute leukemia. Rinsho Ketsueki 26: 821-830, 1985. (in Japanese) .
 
35) Hussein KK, Dahlberg S, Head D, et al: Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 73: 57-63, 1989.
PubMed
36) 高橋 功, 稲垣登稔, 仲田浩之・他: 成人急性リンパ性白血病の治療成績. 臨床血液 30: 1167-1170, 1989.
 
37) Radford JE, Burns CP, Hones MP, et al: Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protoco1. J. Clin. Oncol. 17: 58-66, 1989.
 
38) Linker CA, Levitt LJ, O'Donnell M, et al: Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 78: 2814-2822, 1991.
PubMed
39) Clarkson B, Gaynor J, Little C, et al: Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphblastic leukemia. Haematol. Blood Transf. 33: 397-408, 1990.
 
40) Kantarjian HM, Walters RS, Keating MJ, et al: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard-and high-risk acute lymphocytic leukemia. J. Clin. Oncol. 8: 994-1004, 1990.
PubMed
41) Lluesma-Gonalons M, Pavlovsky S, Santarelli MT, et al: Improved results of an intensified therapy in adult acute lymphocytic leukemia. Ann. Oncol. 2: 33-39, 1991.
PubMed
42) Ellison RR, Mick R, Cuttner J, et al: The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J. Clin. Oncol. 9: 2002-2015, 1991.
 
43) Tanimoto M, Miyawaki S, Ino T, et al: Responseoriented individualized induction therapy followed by intensive consolidation and maintenance for adult paitients with acute lymphoblsastic leu kemia. Int. J. Hemotol.: 1998. (in press)
 
44) Cuttner J, Mick R, Budman DR, et al: Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia 5: 425-431, 1991.
PubMed
45) Hoelzer D, Thiel E, Ludwig WD, et al: The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. Leukemia 6(Suppl. 2) : 175-177, 1992.
 
46) Bassan R, Battista R, Rohatiner AZS, et al: Treatment of adults acute lymphoblastic leukaemia (ALL) over a 16 year period. Leukemia 6(Suppl. 2) : 186-190, 1992.
 
47) Ohno R: Current progress in the treatment of adult acute leukemia in Japan. Jpn. J. Clin. Oncol. 22: 85-97, 1993.
 
48) Oh H, Gale RP, Zhang M-J, et al: Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant. 22: 253-257, 1998.
PubMed
49) Horowitz MM, Messerer D, Hoelzer D, et al: Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann. Intern. Med. 115: 13-18, 1991.
PubMed
50) Sebban C, Lepage E, Vernant JP, et al: Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: A comparative study. J. Clin. Oncol. 12: 2580-2587, 1994.
PubMed
51) Huang M, Ye Y, Chen S, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
PubMed
52) Ohno R, Yoshida H, Fukutani H, et al: Multi-institutional study of all-trans retinoic acid as a differentiation therapy of acute promyelocytic leukemia. Leukemia 7: 1722-1727, 1993.
PubMed
53) Kanamaru A, Takemoto N, Tanimoto M, et al: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85: 1202-1206, 1995.
 
54) Degos L, Dombret H, Chomienne C, et al: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85: 2643-2653, 1995.
PubMed
55) Asou N, Adachi K, Tamura J, et al: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all- trans-retinoic acid. J. Clin. Oncol. 16: 78-95, 1998.
PubMed
56) Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337: 1021-1028, 1997.
PubMed
57) Takeshita A, Sakamaki H, Miyawaki S, et al: Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. Cancer 76: 602-608, 1995.
PubMed
58) Tobita T, Takeshita A, Kitamura K, et al: Treatment with a new synthetic retinoid, Am 80, 0f acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90: 967-973, 1997.
 
59) 長尾 大: 我が国における造血幹細胞移植例の全国集計(1993) . 今日の移植 7: 93-101, 1994.
 
60) Kolb H-J, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: 2041-2050, 1995.
PubMed
61) Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N. Engl. J. Med. 323: 871-877, 1990.
PubMed
62) Ohno R, Miyawaki S, Hatake K, et al: Human urinary macrophage conony stimulating factor (M-CSF) reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of consolidation therapy in acute myeloid leukemia: A double-blind controlled study. J. Clin. Oncol. 15: 254-265, 1997.
 
63) Ohno R: G-CSF in the treatment of acute myeloid leukemia. Is it safe? Leuk. Lymphoma 11 (Suppl. 2) : 15-19, 1994.
 
64) Hahlmann H and the German CML study Group: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 82: 398-407, 1993.
 
65) Suzuki H, Ota K, Ohno R, et al: Recent trends in the treatment and prognosis of adult leukemia with characteristics of patients in Japan: transition during the fifteen years from 1971 to 1985. JPn. J. Clin. Oncol. 19: 338-347, 1989.
 
66) Ohnishi K, Ohno R, Tomonaga M, et al: A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86: 906-916, 1995.
PubMed
67) Kantarijan HM, Smith TL, O'Brien S, et al: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann. Intern. Med. 122: 254-261, 1995.
 
68) The Italian Cooperative Group on Chronic Myeloid Leukemia: Interferon alpha-2a compared with conventional chemotherapy of the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330: 820-825, 1994.
 
69) Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51: 189-199, 1982.
PubMed
70) Yoshida Y, Stephenson J, Mufti GJ: Myelodysplastic syndromes from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int. J. Hematol. 57: 87-97, 1993.
PubMed
71) Yoshida Y, Hirashima K, Asano S, et al: A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br. J. Haematol. 78: 378-384, 1991.
PubMed
72) Valagussa P, Santoro A, Fossati-Bellani F, et al: Second acute leukemia and other malignancies following treatment for Hodgkin 's disease. J. Clin. Oncol. 4: 830-837, 1986.
PubMed
73) Blayney DW, Longo DL, Young RC, et al: Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin 's disease. N. Engl. J. Med. 316: 710-714, 1987.
PubMed
74) Kaldor JM, Day NE, Clarke EA, et al: Leukemia following Hodgkin 's disease. N. Engl. J. Med. 322: 7-13, 1990.
PubMed
75) Abrahamsen JF, Andersen A, Hannisdal E, et al: Second malignancies after treatment of Hodgkin 's disease: the influence of treatment, follow-up time, and age. J. Clin. Oncol. 11: 255-261, 1993.
 
76) Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin 's disease: A 20-year follow-up study. J. Clin. Oncol. 12: 312-325, 1994.
PubMed
77) van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkin 's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J. Clin. Oncol. 12: 1063-1073, 1994.
 
78) Kaldor JM, Day NE, Pettersson F, et al: Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med. 322: 1-6, 1990.
PubMed
79) 上田龍三: 成人の難治性白血病の分子生物学的機構の解明と薬物療法の確立に関する研究. 平成5年度厚生省がん研究助成金による研究報告集, 国立がんセンター, 東京, 1995, pp. 290-298.
 
P.1503 掲載の参考文献
1) 田島和夫, 広瀬加緒瑠, 黒石哲夫: 悪性リンパ腫-わが国の記述免疫学的特徴-. 医学のあゆみ 175: 863-868, 1995.
 
2) Lukes RJ, Craver LF, Hall TC, et al: Report of the Nomenclature Committee. Cancer Res. 26: 1311, 1966.
 
3) von Wasielewski R, Mengel M, Fischer R, et al: Classical Hodgkin 's disease: clinical impact of the immunophenotype. Am. J. Pathol. 15: 1123-1130, 1997.
 
4) Marafioti T, Hummel M, Anagnostopoulos I, et al: Origin of nodular lymphocyte-predominant Hodgkin 's disease from a clonal expansion of highly mutated germinal-center B cells. N. Engl. J. Med. 337: 453-458, 1997.
PubMed
5) Ohno T, Judith AS, Gang Wo, et al: Clonality in nodular lymphocyte-predominant Hodgkin 's disease. N. Engl. J. Med. 337: 459-465, 1997.
 
6) Braeuninger A, Kuppers R, Strickler JG, et al: Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc. Natl. Acad. Sci. USA 94: 9337-9342, 1997.
PubMed
7) Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee on Hodgkin 's disease staging classification. Cancer Res. 31: 1860-1861, 1971.
 
8) Lister TA, Crowther D, Sutclioffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin 's disease. Cotswolds meeting. J. Clin. Oncol. 7: 1630-1636, 1989.
 
9) Horning SJ: Early stage Hodgkin 's disease: can we have our cake and eat it, too? Ann. Oncol. 7: 115-117, 1996.
PubMed
10) Gospodarowicz MK, Sutcliffe SB, Bergsagel DE, et al: Radiation therapy in clinical stage I and II Hodgkin 's disease. Eur. J. Cancer 28 A: 1841-1846, 1992.
 
11) Abrahamsen AF, Hannisdal E, Nome O, et al: Clinical stage I and II Hodgkin 's disease: long-term results of therapy without laparotomy-experience at one institution. Ann. Oncol. 7: 145-150, 1996.
 
12) Longo DL, et al: Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin 's disease: seven-year results of a prospective randomized trial. J. Clin. Oncol. 9: 906, 1991.
 
13) Valagussa P, Santoro A, Fossati-Bellani F, et al: Second acute leukemia and other malignancies following treatment for Hodgkin 's disease. J. Clin. Oncol. 4: 830-837, 1986.
PubMed
14) Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin 's disease. N. Engl. J. Med. 318: 76-81, 1988.
PubMed
15) van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkin 's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J. Clin. Oncol. 12: 1063-1073, 1994.
PubMed
16) Cannellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin 's disease with MOPP, ABVD or MOPP alternating with ABVD. N. Engl. J. Med. 327: 1478-1484, 1992.
PubMed
17) Swerdlow AJ, Douglas AJ, Hudson GV, et al: Risk of second primary cancers after Hodgkin 's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma investigation. Br. Med. J. 304: 1137-1143, 1992.
 
18) Logo DL, Russo A, Duffey PL et al: Treatment of advanced-stage massive mediastinal Hodgkin 's disease: the case for combined modality treatment. J. Clin. Oncol. 9: 227-235, 1991.
 
19) Crnkovich MJ, Hoppe RT, Rosenberg SA, et al: Stage II B Hodgkin 's disease: the Stanford experience. J. Clin. Oncol. 4: 472-479, 1986.
 
20) Joseph MC, Paul K, Grenfell A, et al: Treatment of advanced Hodgkin 's disease with chemotherapy-Compari. son of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: areport from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 15: 1638-1645, 1997.
 
21) John HD, Mary LY, David H, et al: MOPP/ABV hybrid chemotherapy for advanced Hodgkin 's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J. Clin. Oncol. 16: 19-26, 1998.
 
22) Santoro A, Viviani C, Villarreal CJR, et al: Salvage chemotherapy in Hodgkin 's disease irradiation failures: superiority of doxorubicin-containing regimens over MOpp. Cancer Treat. Rep. 70: 343-348, 1986.
 
23) Bonfante V, Santoro A, Viviani S, et al: Outcome of patients with Hodgkin 's disease failing after primary MOPP-ABVD. J. Clin. Oncol. 15: 528-534, 1997.
PubMed
24) Pfreundschuh MG, Schoppe WD, Fuchs R, et al: Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin 's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine(ABVD) : a multicenter trial of the German Hodgkin Study Group. Cancer Treat. Rep. 71: 1203-1207, 1987.
 
25) Zinzani PL, Barbieri E, Bendandi M, et al: CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin 's disease. Tumori 80: 438-442, 1994.
PubMed
26) Ferme C, Bastion Y, Lepage E, et al: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin 's disease. Ann. Oncol. 6: 543-549, 1995.
PubMed
27) Endlad G, Hagberg H, Gustavsson A, et al: Methy1-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin 's disease: a prospective study. Eur. J. Haematol. 60: 166-171, 1998.
 
28) Sweetenham JW, Taghipour G, Milligan D, et al: High-dose therapy and autologous stem cell rescue for patients with Hodgkin 's disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant. 20: 745-752, 1997.
PubMed
29) Gribben JG, Linch DC, Singer CR, et al: Successful treatment of refractory Hodgkin 's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73: 340-344, 1989.
PubMed
30) Patti C, Majolino I, Scime R, et al: High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. Eur. J. Haematol. 51: 18-24, 1993.
PubMed
31) Aaron PR, Jacob MR, Peter AK, et al: One hundred autotransplants for relapsed or refractory Hodgkin 's disease and lymphoma: value of pretransplant disease status for predicting outcome. J. Clin. Oncol. 11: 2351-2361, 1993.
PubMed
32) Jost LM, Widmer L, Honegger HP, et al: Index of pretreatment intensity predicts outcome of high-dose chemotherapy and autologous progenitor cell transplantation in chemosensitive relapse of Hodgkin 's disease. Ann. Oncol. 8: 785-790, 1997.
PubMed
33) Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347: 353-357, 1996.
PubMed
34) Majolino I, Pearce R, Taghipour G, et al: Peripheral-blood stem-ell transplantation versus autologous bone marrow transplantation in Hodgkin 's and non-Hodgkin 's lymphomas: a new matched-pair analysis of the European group for blood and marrow transplantation registry data. J. Clin. Oncol. 151509-517, 1997.
 
P.1526 掲載の参考文献
1) Kadin ME, Berard CW, Nanba K, et al: Lymphoproliferative diseases in Japan and western countries. Hum. Pathol. 14: 745-772, 1983.
PubMed
2) Devesa SS, Fears T: Non-Hodgkin 's lymphoma time trends: United States and international data. Cancer Res. 52(Suppl.) : 5432-5440, 1992.
 
3) Weisenburger DD: Epidemiology of non-Hodgkin 's lymphoma: Recent findings regarding an emerging epidemic. Ann. Oncol. (Suppl. 1) 119-24, 1994.
 
4) Poiesz BJ, Ruscetti FW, Gazdar AF, et al: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77: 7415, 1980.
PubMed
5) Hinuma Y, Nagata K, Misaka M, et al: Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA 78: 6476, 1981.
 
6) Yoshida M, Seiki M, Yamaguchi K, et al: Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-ell leukemia provirus in the disease. Proc. Natl. Acad. Sci. USA 81: 2534, 1984.
 
7) T・Bリンパ系腫瘍研究グループ: 第5次成人T細胞白血病/リンパ腫(ATL) 全国実態調査の報告-第4次全国実態調査の評価-. 癌の臨床 38: 405-416, 1992.
 
8) Nagai H, Kinoshita T, Imamura J, et al: Genetic alteration of p 53 in some patients with adult T-cell leukernia. Jpn. J. Cancer Res. 82: 1421-1427, 1991.
 
9) Hangaishi A, Ogawa S, Imamura N, et al: Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS 1/p l61NK4A, MTS 2/p 15iNK4B, p 53, and Rb genes in primary lymphoid malignancies. Blood 87: 4949-4958, 1996.
 
10) Uchida T, Kinoshita T, Watanabe T, et al: The CDKN 2 gene alterations in various types of adult T-cell leukaemia. Br. J. Haematol. 94: 665-670, 1996.
 
11) Yamada Y, Hatta Y, Murata K, et al: Deletions of p 15 and/or p 16 genes as a poor-prognosis factor in adult T-cell leukemia. J. Clin. Oncol. 15: 1778-1785, 1997.
PubMed
12) Okamoto T, Ohno Y, Tsugane S, et al: Multi-step carcinogenesis model for adult T-cell leukemia. Jpn. J. Cancer Res. 80: 191-195, 1989.
PubMed
13) Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and S6zary syndrome. Blood 88: 2385-2409, 1996.
 
14) Lorincz al: Cutaneous T-cell lymphoma(mycosis fungoides) . Lancet 347: 871-876, 1996.
PubMed
15) Kikuchi A, Nishikawa T, Ikeda Y, et al: Absence of human T-lymphotropic virus type I in Japanese patients with cutaneous T-cell lymphoma. Blood 89: 1529-1532, 1997.
PubMed
16) Bazarbachi A, Soriano V, Pawson R, et al: Mycosis fungoides and Sezary syndrome are not associated with HTLV-Iinfection: An international study. Br. J. Haematol. 98: 927-933, 1997.
PubMed
17) Jaffe ES, Chan JKC, Su I-J, et al: Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: Definitions, differential diagnosis, and epidemiology. Am. J. Surg. Pathol. 20: 103-111, 1996.
 
18) Aozasa K, Yang W-1, Lee YB, et al: Lethal midline granuloma in Seoul, Korea and Shanghai, China. Int. J. Cancer 52: 673-674, 1992.
 
19) Liang R, Todd D, Chan TK, et al: Treatment outcome and prognostic factors for primary nasal lymphoma. J. Clin. Oncol. 13: 666-670, 1995.
PubMed
20) Nakamura S, Katoh E, Koshikawa T, et al: Clinicopathologic study of nasal T/NK-cell lymphoma among Japanese. Pathol. Intern. 47: 38-53, 1997.
 
21) Levine AM: AIDS-related malignancies: The emerging epidemic (Review) : J. Natl. Cancer Inst. 85: 1382, 1993.
PubMed
22) Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi 's sarcoma in patients with and those without HIV infection. N. Engl. J. Med. 332: 1181-1185, 1995.
PubMed
23) Cesarman E, Chang Y, Moore PS, et al: Kaposi 's sarcoma-associated herpesvirus-like DNA sequences in AIDSrelated body-cavity-based lymphomas. N. Engl. J. Med. 332: 1186-1191, 1995.
 
24) Cesarman E, Moore PS, Rao PH, et al: In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi 's sarcoma-associated herpesvirus-like (KHSV) DNA sequences. Blood 86: 2708-2714, 1995.
 
25) Iuchi K, Ichimiya A, Akashi A, et al: Non-Hodgkin 's lymphoma of the pleural cavity developing from longstanding Pyothorax. Cancer 60: 1771-1775, 1987.
 
26) Aozasa K, Ohsawa M, Iuchi K, et al: Artificial pneumothorax as a risk factor for development of pleural lymphoma. JPn. J. Cancer Res. 84: 55-57, 1993.
PubMed
27) Fukayama M, Ibuka T, Hayashi Y, et al: Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am. J. Pathol. 143: 1044-1049, 1993.
PubMed
28) Sasajima Y, Yamabe H, Kobashi Y, et al: High expression of the Epstein-Barr virus latent protein EB nuclear antigen-20n pyothorax-associated lymphomas. Am. J Pathol. 143: 1280-1285, 1993.
 
29) Amakawa R, Fukuhara S, Ohno H, et al: Involvement of bcl-2 gene in Japanese follicular lymphoma. Blood 73: 787-791, 1989.
PubMed
30) Katsumata N, Matsuno Y, Nakayama H, et al: Prognostic factors and a predictive model of follicular lymphoma: a25-year study at a single institution in Japan. JPn. J. Clin. Oncol. 26: 445-454, 1996.
 
31) Ohsawa M, Aozasa K, Tsujimura T, et al: Non-Hodgkin 's lymphomas of follicular center cell type in Osaka, Japan. Eur. J. Cancer Clin. Oncol. 25: 1875-1878, 1989.
 
32) Yanagihara ET, Blaisdell RK, Hayashi T, et al: Malignant lymphoma in Hawaii-Japanese: A etrospective morphologic study. Hematol. Oncol. 7: 219-232, 1989.
 
33) Dorfman RF: Classification of non-Hodgkin 's lymphomas. Lancet 1: 1295-1296, 1974.
 
34) Lukes RJ, Collins RD: Immunologic characterization of human malignant lymphomas. Cancer 34: 1488-1503, 1974.
 
35) Lennert K, Feller AC: Histopathology of the non-Hodgkin 's lymphomas. Springer-Verlag, Berlin, 1992.
 
36) Suchi T, Tajima K, Nanba K, et al: Some problems on the histopathological diagnosis of non-Hodgkin 's malignant lymphoma: A proposal of a new type. Acta Pathol. Jpn. 29: 755-776, 1979.
 
37) Non-Hodgkin 's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin 's lymphomas: Summary and descriptions of a Working Formulation for clinical usage. Cancer 49: 2112-2135, 1982.
 
38) 下山正徳向井 清, 菊池昌弘・他: 専門病理医による非ポジキンリンパ腫の病理診断とホルマリン固定標本による T・Bマーカー免疫診断の一致率: LCPP(Lymphoma Clinico-pathology Panel) による共同研究. 癌の臨床 39: 739-765, 1993.
 
39) Armitage JO: Treatment of non-Hodgkin 's lymphoma. N. Engl. J. Med. 328: 1023-1030, 1993.
PubMed
40) 下山正徳, 向井 清, 菊池昌弘・他: 専門病理医の中央診断をうけた非ポジキンリンパ腫447例の重要な予後因子と予後予測に有用な臨床病理予後分類(Lymphoma Clinico-pathological Prognostic Classification: LCP分類) とLCP スキーマ. 日本リンパ網内系学会誌 38: 41-55, 1998.
 
41) Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal form the International Lymphoma Study Group. Blood 84: 1361-1392, 1994.
 
42) Banks P, Chan J, Cleary M, et al: Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data. Am. J. Surg. Patho1. 16: 637, 1992.
 
43) Weisenburger DD, Armitage JO: Mantle cell lymphoma: An entity comes of age. Blood 87: 4483-4494, 1996.
PubMed
44) Shimoyama M, Minato K, Saito H, et al: Immunoblastic lymphadenopathy (IBL) -like T-cell lymphoma. Jpn. J. Clin. Oncol. 9 (SupPl. 1) : 347, 1979.
 
45) Tobinai K, Minato K, Ohtsu T, et al: Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. Blood 72: 1000-1006, 1988.
PubMed
46) Uchiyama T, Yodoi J, Sagawa K, et al: Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50: 481-492, 1977.
PubMed
47) Stein H, Mason D, Gerdes J, et al: The expression of the Hodgkin 's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66: 848, 1985.
PubMed
48) Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid Bcell subcategories) : A Southwest Oncology Group Study. Blood 85: 1075-1082, 1995.
 
49) Melnyk A, Rodriguez A, Pugh WC, et al: Evaluation of the Revised European-American Lymphoma Classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin 's lymphoma. Blood 89: 4514-4520, 1997.
PubMed
50) Pittaluga S, Bijnens L, Teodorovic I, et al: Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the revised European-American Classification of Lymphoid Neoplasms: AComparison with the Working Formulation. Blood 87: 4358-4367, 1996.
 
51) The Non-Hodgkin 's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin 's lymphoma. Blood 89: 3909-3918, 1997.
 
52) The International Non-Hodgkin 's Lymphoma Prognostic Factors Project: Apredictive model for aggressive non-Hodgkin 's lymphoma. N. Engl. J Med. 329: 987-994, 1993.
 
53) Hiddemann W, Longo DL, Coiffier B, et al: Lymphoma classification: The gap between biology and clinical management is closing. Blood 88: 4085-4089, 1996.
PubMed
54) Shipp MA, Mauchi PM, Harris NL: Non-Hodgkin 's lymphoma. In: Cancer. Principles and Practice of Oncology, 5th edition (DeVita VT Jr, et al, eds.) , Lippincott-Raven, Philadelphia, PA, 1997, pp. 2165-2220.
 
55) DeVita VT Jr, Jaffe ES, Mauchi PM, et al: Lymphocytic lymphomas. In: Cancer. Principles and Practice of Oncology, 3rd edition (DeVita VT Jr, et al, eds.) , Lippincott-Raven, Philadelphia, PA, 1989, pp. 1741-1798.
 
56) Tsujimoto Y, Finger LR, Yunis J, et al: Cloning of the chromosome breakpoint of neoplastic B cell with the t(14;18) chromosome translocation. Science 226: 1097, 1984.
 
57) Rosenberg C, Wong E, Petty E, et al: Overexpression of PRAD 1, a candidate BCL 1 breakpoint region oncogene, in centrocytic lymphomas. Proc. Natl. Acad. Sci. USA 88: 9638, 1991.
 
58) Ye BH, Lista F, Coco FL, et al: Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large cell lymphoma. Science 262: 747-750, 1993.
 
59) Offit K, Coco FL, Louie DC, et al: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large- cell lymphoma. N. Engl. J. Med. 331: 74-80, 1994.
 
60) Sander CA, Yano T, Clark HM, et al: p53 mutation is associated with progression in follicular lymphomas. Blood 82: 1994-2004, 1993.
PubMed
61) Coco FL, Gainado G, Louie DC, et al: p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82: 2289-2295, 1993.
 
62) Uchida T, Watanabe T, Kinoshita T, et al: Mutational analysis of the CDKN 2(MTS 1/p 16ink4A) gene in primary B-cell lymphomas. Blood 86: 2724-2731, 1995.
 
63) Ichikawa A, Kinoshita T, Watanabe T, et al: Mutations of the p 53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med. 337: 529-534, 1997.
 
64) Isaacson P, Wright DH: Malignant lymphoma of mucosa-associated lymphoid tissue, A distinctive type of B-cell lymphoma. Cancer 52: 1410-1416, 1983.
PubMed
65) Isaacson P, Wright DH: Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 53: 2515-2524, 1984.
PubMed
66) Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee on Hodgkin 's disease staging. Cancer Res. 31: 1860-1861, 1971.
 
67) Coltman CA, Luce JK, McKelvy EM, et al: Chemotherapy of non-Hodgkin 's lymphoma: 10 years experience in the Southwest Oncology Group. Cancer Treat. Rep. 61: 1067-1078, 1977.
 
68) Jones SE, Miller TP, Connors JM: Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large cell lymphoma treated with initial chemotherapy with or without adjuvant radio therapy. J. Clin. Oncol. 7: 1186-1191, 1989.
PubMed
69) Connors JM, Klimo P, Fairey RN, et al: Brief chemotherapy and involved field radiation therapy for limited-stage histologically aggressive lymphoma. Ann. Intern. Med. 107: 25-30, 1987.
PubMed
70) Glick JH, Kim K, Earle J, et al: An ECOG randomized phase III trial of CHOP versus CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin 's lymphoma. Proc. Am. Soc. Clin. Oncol. 14: 391, 1995 (Abstr.) .
 
71) Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radio therapy for localized intermediate-and high-grade non-Hodgkin 's lymphoma. N. Engl. J. Med. 339: 21-26, 1998.
 
72) Shimoyama M, Ota K, Kikuchi M, et al: Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin 's lymphoma treated with VEPA or VEPA-M. J. Clin. Oncol. 6: 128-141, 1988.
PubMed
73) Tobinai K, Shimoyama M, Minato K, et al: Japan Clinical Oncology Group (JCOG) phase II trial of second generation "LSG 4 Protocol" in aggressive T-and B-lymphoma: A new predictive model for T-and B-lymphoma. Proc. Am. Soc. Clin. Oncol. 13: 378, 1994 (Abstr.) .
 
74) Shipp MA, Harrington DP, Klatt MM, et al: Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann. Intern. Med. 104: 757-765, 1986.
PubMed
75) Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Intern. Med. 102: 596-602, 1985.
PubMed
76) Longo DL, DeVita Jr VT, Duffey PL, et al: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J. Clin. Oncol. 9: 25-38, 1991.
 
77) Gordon LI, Harrington D, Andersen J, et al: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin 's Iymphoma. N. Engl. J. Med. 327: 1342-1349, 1992.
 
78) Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin 's lymphoma. N. Engl. J. Med. 328: 1002-1006, 1993.
PubMed
79) Cooper IA, Wolf MM, Robertson TI, et al: Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin 's lymphoma. J. Clin. Oncol. 12: 769-778, 1994.
PubMed
80) Jerkeman M, Cavallin-Stahl E, Hagberg H, et al: CHOP versus MACOP-B in high grade malignant non-Hodgkin 's lymphoma: A prospective randomized study by the Nordic Lymphoma Study Group. Ann. Oncol. 7 (Suppl. 3) : 24, 1996.
 
81) Linch DC, Hudson BV, Hancock BW, et al: A randomized comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin 's lymphoma: A British National Lymphoma Investigation report. Br. J. Cancer 74: 318-322, 1996.
 
82) Armitage JO, Cheson BD: Interpretation of clinical trials in diffuse large-cell lymphoma. J. Clin. Oncol. 6: 1335-1347, 1988.
PubMed
83) Paryani SB, Hoppe RT, Cox RS, et al: Analysis of non-Hodgkin 's lymphomas with nodular and favorable histologies, stages I and II. Cancer 52: 2300-2307, 1983.
 
84) McLaughlin P, Fuller LM, Velasquez WS, et al: Stage I-II follicular lymphoma: Treatment results for 76 patients, Cancer 58: 1596-1602, 1986.
 
85) Rosenberg SA: The low-grade non-Hodgkin 's lymphomas: Challenges and opportunities. J. Clin. Oncol. 3: 299-310, 1985.
 
86) Horning S: Treatment approaches to the low-grade lymphomas. Blood 83: 881-884, 1994.
 
87) Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the international index for aggressive lymphoma to patients with low-grade lymphoma. J. Clin. Oncol. 12: 1343-1348, 1994.
PubMed
88) Smalley R, Anderson J, Hawkins M, et al: Interferon alpha combined with cytotoxic chemotherapy in patients with non-Hodgkin 's lymphoma. N. Engl. J. Med. 327: 1336-1341, 1992.
 
89) Solal-Celigny P, Lepage E, Brousse N, et al: Recombinant interferon alpha-2 b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N. Engl. J. Med. 329: 1608-1614, 1993.
 
90) Peterson BA, Petroni G, Oken MM, et al: Cyclophosphamide versus cyclophosphamide plus interferon alfa-2 b in follicular low grade lymphomas: A preliminary report of an intergroup trial (CALGB 8691 and EST 7486) . Proc. Am. Soc. Clin. Oncol. 12: 366, 1993 (Abstr. ＃1240) .
 
91) Dana BW, Unger J, Fisher RI, et al: A randomized study of alpha-interferon consolidation in patients with lowgrade lymphoma who have responded to ProMACE-MOPP (day 1-8) (SWOG 8809) . Proc. Am. Soc. Clin. Oncol. 17: 3a, 1998(Abstr. ＃10) .
 
92) Rohatiner AZS, Gregory W, Peterson B, et al: A meta-analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma. Proc. Am. Soc. Clin. Oncol. 17: 4a, 1998 (Abstr. #11) .
 
93) Redman JR, Cabanillas F, Velasquez WS, et al: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J. Clin. Oncol. 10: 790-794, 1992.
PubMed
94) Salal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: Amulticenter study by the Groupe d 'Etude des Lymphomes de PAdulte. J. Clin. Oncol. 14: 514-519, 1996.
 
95) Kay AC, Saven A, Carrera CJ, et al: 2-hlorodeoxyadenosine treatment in low-grade lymphomas. J. Clin. Oncol. 10: 371-377, 1992.
PubMed
96) Hoffman M, Tallman MS, Hakimian D, et al: 2-hlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin 's lymphoma. J. Clin. Oncol. 12: 788-792, 1994.
PubMed
97) Saven A, Emanuele S, Kosty M, et al: 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin 's lymphoma. Blood 8611710-1716, 1995.
PubMed
98) Tobinai K, Ogura M, Hotta T, et al: Phase I study of cladribine(2-chlorodeoxyadenosine) in lymphoid malignancies. Jpn. J. Clin. Oncol. 27: 146-153, 1997.
PubMed
99) Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD 20. Blood 83: 435-445, 1994.
 
100) Maloney DG, Lilies TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD 20 monoclonal antibody (IDEC-C 2 B 8) in patients with recurrent B-cell lymphoma. Blood 84: 2457-2466, 1994.
 
101) Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C 2 B 8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin 's lymphoma. J. Clin. Oncol. 15: 3266-3274, 1997.
 
102) Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C 2 B 8 (Rituximab) anti-CD 20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin 's lymphoma. Blood 90: 2188-2195, 1997.
 
103) Tobinai K, Kobayashi Y, Narabayashi M, et al: Feasibility and pharmacokinetic study of chimeric anti-CD 20 monoclonal antibody (IDEC-C 2 B 8, rituximab) in relapsed B-cell lymphoma. Ann. Oncol. 9: 527-534, 1998.
 
104) Demidem A, Lam T, Alas S, et al: Chimeric anti-CD 20 (IDEC-C 2 B 8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12: 177-186, 1997.
 
105) Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with [1311] anti-B1 (anti-CD 20) antibody. N. Engl. J. Med. 329: 459-465, 1993.
 
106) Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B 1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14: 1974-1981, 1996.
 
107) Wilder RB, DeNardo GL, DeNardo SJ: Radioimmunotherapy: Recent results and future directions. J. Clin. Oncol. 14: 1383-1400, 1996.
PubMed
108) Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329: 1219-1224, 1993.
PubMed
109) Press O, Eary J, Appelbaum FR, et al: Phase II trial of 1311-B 1(anti-CD 20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphoma. Lancet 346: 336-340, 1995.
 
110) Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-1abeled anti-CD 20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2: 457-470, 1996.
 
111) Slater DE, Mertelsmann R, Koznier B, et al: Lymphoblastic lymphoma in adults. J. Clin. Oncol. 4: 57-67, 1986.
 
112) Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia in adults: A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85: 664-574, 1995.
PubMed
113) Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J. Clin. Oncol. 14: 925-934, 1996.
PubMed
114) Shimoyama M and members of the Lymphoma Study Group: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. Br. J. Haematol. 79: 428-437, 1991,
 
115) Shimoyama M, Ota K, Kikuchi M, et al: Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J. Clin. Oncol. 6: 1088-1097, 1988.
PubMed
116) Shimoyama M: Chemotherapy of ATL In: Adult T-Cell Leukemia(ed. by ed Takatsuki K) : Oxford University Press, Oxford, 1994, pp. 221-237.
 
117) Tobinai K, Shimoyama M, Tajima K, et al: Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma. Proc. Am. Soc. Clin. Oncol. 14: 390, 1995(Abstr.) .
 
118) Ohno R, Masaoka T, Shirakawa S, et al: Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis (2, 6-dioxopiperazine) . Cancer 71: 2217-2221, 1993.
 
119) Tsuda H, Takatsuki K, Ohno R, et al: Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride. Br. J. Cancer 70: 771-774, 1994.
PubMed
120) Waldman TA, Goldman CK, Bongiovanni KF, et al: Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72: 1805-1816, 1988.
 
121) Waldmann TA, White JD, Carrasquillo JA, et al: Radioimmunotherapy of interleukin-2 Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86: 4063-4075, 1995.
 
122) Gill PS, Harrington W, Kaplan MH, et al: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 332: 1744-1748, 1995.
PubMed
123) Hermine O, Bouscary D, Gessain A, et al: Brief report: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 332: 1749-1751, 1995.
PubMed
124) Tobinai K, Kobayashi Y, Shimoyama M: Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma. N. Engl. J. Med. 333: 1285, 1995.
PubMed
125) Edelson R, Berger C, Gasparro F, et al: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N. Engl. J. Med. 316: 297-303, 1987.
PubMed
126) Hoppe RT, Abel EA, Deneau DG, et al: Mycosis fungoides: Management with tropical nitrogen mustard. J. Clin. Oncol. 5: 1796-1803, 1987.
 
127) Kuzel TM, Roenigk HH, Rosen ST: Mycosis fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis, and therapy. J. Clin. Oncol. 9: 1298-1313, 1991.
PubMed
128) Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethazone (DHAP) . Blood 71: 117-122, 1988.
 
129) Velasquez WS, McLaughlin P, Tucker S, et al: ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J. Clin. Oncol. 12: 1169-1176, 1994.
PubMed
130) Rodriguez MA, Cabanillas F, Velasquez W, et al: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J. Clin. Oncol. 13: 1734-1741, 1995.
PubMed
131) Chao NJ, Rosenberg S, Horning SJ: CEPP(B) : An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin 's lymphoma. Blood 76: 1293-1298, 1990.
PubMed
132) Wilson WH, Bryant G, Bates S, et al: EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin 's lymphoma. J. Clin. Oncol. 11: 1573-1582, 1993.
PubMed
133) Wilson WH, Jamis-Dow C, Bryant G, et al: Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J. Clin. Oncol. 13: 1985-1994, 1995.
PubMed
134) Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin 's lymphoma. N. Engl. J. Med. 316: 1493-1498, 1987.
PubMed
135) Armitage JO: Bone marrow transplantation in the treatmellt of patients with lymphoma. Blood 73: 1749-1758, 1989.
PubMed
136) Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blσod progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 3471353-357, 1996.
 
137) Vose JM, Anderson JR, Kessinger A, et al: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin 's lymphoma. J. Clin. Oncol. 11: 1846-1851, 1993.
PubMed
138) Majolino I, Pearce R, Taghipour G, et al: Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin 's and non-Hodgkin 's lymphomas: Anew matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. J. Clin. Oncol. 15: 509-517, 1997.
 
139) Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin 's lymphoma. N. Engl. J. Med. 333: 1540-1545, 1995.
PubMed
140) Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin 's disease: Results of a BNLI randomized trial. Lancet 341: 1051-1054, 1993.
PubMed
141) Haioun C, Lepage E, Gisselbrecht C, et al: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin 's lymphoma in first complete remission: A study of 464 patients. J. Clin. Oncol. 12: 2543-2551, 1994.
PubMed
142) Verdonck LF, van Putten WLJ, Hagenbeek A, et al: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin 's lymphoma. N. Engl. J. Med. 332: 1045-1051, 1995.
 
143) Haioun C, Lepage E, Gisselbrecht C, et al: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin 's lymphoma: Updated results of the prospective study LNH 87-2. J. Clin. Oncol. 15: 1131-1137, 1997.
 
144) Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N. Engl. J. Med. 336: 1290-1297, 1997.
PubMed
145) Gisselbrecht C, Lepage E, Mortel P, et al: Short and intensified treatment with autologous stem-cell transplantation versus ACVB regimen in poor prognosis aggressive lymphoma: Prognostic factors of induction failure. Ann. Oncol. 7(SuppL 3) : 18, 1996.
 
146) Tobinai K: Chemotherapy: the more, the better in malignant lymphoma?Cancer Chemother. Pharmacol. 40 (Suppl.) : S110-S 114, 1997.
 
147) Freedman AS, Takvorian T, Neuberg D, et al: Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin 's lymphoma in first remission: Apilot study. J. Clin. Oncol. 11: 931-936, 1993.
 
148) Nademanee A, Monila A, 0 'Donnell MR, et al: Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate-and high-grade lymphoma: International index high and high-intermediate risk group. Blood 90: 3844-3852, 1997.
 
149) Stoppa AM, Bouabdallah R, Chabannon C, et al: Intensive sequential chemotherapy with repeated blood stemcell support for untreated poor-prognosis non-Hodgkin 's lymphoma. J. Clin. Oncol. 15: 1722-1729, 1997.
 
P.1560 掲載の参考文献
1) Herrinton LJ, Weiss NS, Olshan AF: The epidemiology of myeloma. In: Myeloma. Biology and Management (eds. by Malpas JS, et al) , Oxford Univ. Press, Oxford, 1995, pp. 127-168.
 
2) 戸川 敦, 天野正道, 高久史麿: 我が国の多発性骨髄腫の最近の動向. 日本医事新報 3462: 31-34, 1990.
 
3) Riggs JE: Increasing multiple myeloma mortality rates in the elderly: demonstration of increasing dependency with increasing age upon age group population size. Mech. Ageing Dev. 81: 131-138, 1995.
PubMed
4) Kyle RA: Multiple myeloma and other plasma cell disorders. In: Hematology. Basic principles and practice (eds. by Hoffman R, et al) , 2nd Ed, Churchill Livingstone Inc, New York, 1995, pp. 1354-1374.
 
5) Meis JM, Butler JJ, Osborne BM, et al: Solitary plasmacytomas of bone and extramedullary plasmacytomas. Cancer 59: 1475-1485, 1987.
PubMed
6) Wiltshaw E: The natural history of extramedullary plasmqcytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine 55: 217-238, 1976.
PubMed
7) Holland J, Trenkner DA, Wasserman TH, et al: Plasmacytoma. Treatment results and conversion to myeloma. Cancer 69: 1513-1517, 1992.
PubMed
8) Kyle RA, Maldonado JE, Bayrd ED, et al: Plasma cell leukemia. Report on 17 cases. Arch. Int. Med. 133: 813-818, 1974.
 
9) Dimopoulos MA, Palumbo A, Delasalle KB, et al: Primary plasma cell leukemia. Br. J. Haematol. 88: 754-759, 1994.
PubMed
10) Kyle RA, Greipp PR: Smoldering multiple myeloma. N. Engl. J. Med. 302: 1347-1349, 1980.
PubMed
11) Alexanian R: Localized and indolent myeloma. Blood 56: 521-525, 1980.
PubMed
12) Malpas JS: Clinical presentation and diagnosis. In: Myeloma. Biology and Management(eds. by Malpas JS, et al, Oxford Univ. Press, Oxford, 1995, pp. 169-190.
 
13) Facon T, Lai JL, Nataf E, et al: Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: A report on 46 patients. Br. J. Haematol. 84: 743-745, 1993.
PubMed
14) Lai JL, Zandecki M, Mary JY, et al: Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85: 2400-2497, 1995.
 
15) Smadja NV, Louvet C, Isnard F, et al: Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. Br. J. Haematol. 90: 619-624, 1995.
PubMed
16) Tesch H, Diehl V, Kube D: Molecular biology of myeloma. In: Myeloma. Biology and Management (eds, by Malpas JS, et al) , Oxford Univ. Press, Oxford, 1995, pp. 50-62.
 
17) Gould J, Alexanian R, Goodacre A, et al: Plasma cell karyotype in multiple myeloma. Blood 71: 453-456, 1988.
PubMed
18) Fractif M, Zandecki M, Lai JL, et al: Interphase fluorescence in sitza hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Br. J. Haematol. 90: 693, 1995.
 
19) Drach J, Angerler J, Schuster J, et al: Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86: 3915-3921, 1995.
PubMed
20) Garcia-Sana R, Orfao A, Gonaalez M, et al: Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Br. J. Haematol. 90: 106-112, 1995.
 
21) Sawyer JR, Tricot G, Mattox S, et al: Jumping translocations of chromosome lq in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 91: 1732-1741, 1998.
 
22) Bergsagel PL, Chesi M, Nardini E, et al: Promiscuous translocation into immunoglobulin heavy chain switch region in multiple myeloma. Proc. Natl. Acad. Sci. USA 93: 13931-13936, 1996.
PubMed
23) Nishida K, Tamura A, Nakazawa N, et al: The immunoglobulin heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia detected by is situ hybridization. Blood 90: 526-534, 1997.
PubMed
24) Fiedler W, Weh HJ, Hossfeld DK: Comparison of chromosome analysis and CBL-1 rearrangement in a series of patient with multiple myeloma. Br. J. Haematol. 81: 58-61, 1992.
 
25) Tricot G, Barlogie B, Jagannath S, et al: Poor prognosis in multiple myeloma is associeated only with partial or complete deletion of chromosome 130r abnormalities involving llq and not with other karyotype abnormalities. Blood 86: 4250-4256, 1995.
 
26) Chesi M, Nardini E, Brents LA, et al: Frequent translocation t(4; 14) (p16. 3; q32. 3) in multiple myeloma: Association with increased expression and activating mutations of fibroblast growth factor 3. Nat. Genet. 16: 260-264, 1997.
 
27) Iida S, Rao PH, Butler M, et al: Dysregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat. Genet. 17: 226-230, 1997.
 
28) Nobuyoshi M, Kawano M, Tanaka H, et al: Increased expression of c-myc gene may be related to the aggressive transformation of human myeloma cells. Br. J. Haematol. 81: 58-61, 1991.
 
29) Ong F, NieuwkooP JA, De Groot-Swings GMJS, et al: Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 9: 1282-1284, 1995.
 
30) Tsuchiya H, Epstein J, Selvanayagam P, et al: Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma. Blood 72: 796-800, 1988.
PubMed
31) Neri A, Murphy JP, Cro L, et al: Ras oncogene mutation in multiple myeloma. J. Exp. Med. 170: 1715-1725, 1989.
PubMed
32) Teoh G, Urashima M, Ogata A, et al: MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 90: 1982-1992, 1997.
PubMed
33) Neri A, Baldini L, Trecca D, et al: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81: 128-135, 1993.
PubMed
34) Juge-Morineau N, Mellerin MP, Francois S, et al: High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br. J. Haematol. 91: 664-667, 1995.
PubMed
35) Ng MHL, Chung KW, Lo KW, et al: Frequent hypermutation of p16 and p15 genes in multiple myeloma. Blood 89: 2500-2506, 1997.
 
36) Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma: increasing evidence for a multistep transformation precess. Blood 91: 3-21, 1998.
 
37) Tanabe O, Kawano M, Tanaka H, et al: BSF-2/IL-6 does not augment lg secretion but, stimulates proliferation in myeloma cells. Am. J. Hematol. 31: 258-262, 1989.
 
38) Klein B, Zhang X-G, Lu Z-Y, et al: Interleukin-6 in human multiple myeloma. Blood 85: 863-872, 1995.
PubMed
39) Lichtenstein A, Tu Y, Fady C, et al: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol. 162: 248-255, 1995.
PubMed
40) Chauhan D, Kharbanda S, Ogata A, et al: Interleukin-6 inhibits Fas-induced apoptosis and SAP kinase activation in multiple myeloma cells. Blood 89: 227-234, 1997.
 
41) Kawano M, Hirano T, Matsuda T, et al: Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332: 83-85, 1988.
 
42) Klein B, Zhang X-G, Jourdan M, et al: Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 73: 517-526, 1989.
PubMed
43) Ogata A, Chauhan D, Urashima M, et al : Interleukin-6 triggers multiple myeloma cell growth via the Ras dependent mitogen activated kinase cascade. J. Immunol. 159: 2212-2221, 1997.
PubMed
44) Lu ZY, Zhang XG, Rodriguez C, et al: Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 85: 2521-2527, 1995.
 
45) Retting MB, Ma HJ, Vescio RA, et al: Kaposi 's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients, Science 276: 1851-1854, 1997.
 
46) Cathomas G, Stalder A, Kurrer MO, et al: Multiple myeloma and HHV-8 infection. Blood: 4391-4392, 1998.
PubMed
47) Nishimoto N, Ogata A, Shima Y, et al: Oncostatin M, Leukemia inhibitory factor and interleukin 6 induced the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J. Exp. Med. 179: 1343-1349, 1994.
PubMed
48) Paul SR, Barut BA, Bennett F, et al: Lack of a role of interleukin ll in the growth of multiple myeloma. Leukemia Res. 16: 247-252, 1992.
 
49) Juge-Morineau N, Francois S, Puthier D, et al: The gp130 family cytokines IL-6, LIF, OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells. Br. J. Haematol. 80: 707-710, 1995.
 
50) Lemoli RM, Fortuna A, Grande A, et al: Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. Br. J. Haematol. 88: 700-709, 1994.
 
51) Zhang XG, Bataille R, Jourdan M, et al: Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 76: 2599-2605, 1990.
PubMed
52) Klein B: Cytokines, cytokine receptors, transduction signals and oncogenes in multiple myeloma. Semin. Hematol. 32: 4-19, 1995.
PubMed
53) Anderson KC, Jones RM, Morimoto C, et al: . Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73: 1915-1924, 1989.
PubMed
54) Leo R, Boeker M, Peest D, et al: Multiparameter analysis of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann. Hematol. 64: 132-139, 1992.
PubMed
55) San Miguel JF, Gonzalez M, Gasc6n A, et al: Immunophenotypic heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Br. J. Haematol. 77: 185-190, 1991.
PubMed
56) Durie BGM, Grogan TM: CALLA-positive myeloma: An aggressive subtype with poor survival. Blood 66: 229-232, 1985.
 
57) Epstein J, Barlogie B, Katzmann J, et al: Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. Blood 71: 861-865, 1988.
PubMed
58) Grogan TM, Huang N, Harada H, et al: Myelomonocytic antigen positive multiple myeloma. Blood 73: 763-769, 1993.
 
59) Harada H, Kawano MM, Huang N, et al: Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 73: 2658-2663, 1993.
 
60) Uchiyama H, Barut BA, Chauhan D, et al: Characterization of adhesion molecules on human myeloma cell lines. Blood 80: 2306-2314, 1992.
PubMed
61) Shibayama H, Tagawa S, Hattori H, et al: Laminin and fibronectin promote the chemotaxis of human malignant plasma cell lines. Blood 86: 719-725, 1995.
PubMed
62) Shibayama H, Tagawa S, Hattori H, et al: Interleukin-6 inhibits the chemotaxis of human malignant plasma cell Iines Br. J. Haematol. 93: 534-541, 1996.
 
63) Kawano MM, Huang N, Harada H, et al: Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 82: 564-570, 1993.
PubMed
64) Uchiyama H, Barut BA, Mohrbacher AF, et al: Adhesion of human myeloma cell lines to bone marrow stroma cells stimulates interleukin-6 secretion. Blood 82: 3712-3720, 1993.
 
65) Hamiltcn MS, Ball J, Bromidge E, et al: Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br. J. Haematol. 78: 60-65, 1991.
 
66) Kawano MM, Huang N, Tanaka H, et al: Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules. Br. J. Haematol. 79: 583-588, 1991.
PubMed
67) Ahsmarm EJM, Lokhorst HM, Dekker AW, et al: Lymphocytic function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood 79: 2068-2075, 1992.
 
68) Ridley RC, Xiao H, Hata H, et al: Expression of syndecan regulates human myeloma plasma cell adhesion to typeIcollagen. Blood 81: 767-774, 1993.
 
69) Dhodapkar MV, Abe E, Theus A, et al: Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91: 2679-2688, 1998.
PubMed
70) Tong AW, Zhang B-q, Mues G, et al: Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood 84: 3026-3033; 1994.
 
71) Shima Y, Nishimoto N, Ogata A, et al: Myeloma cells express Fas antigen/APO-1(CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85: 757-764, 1995.
PubMed
72) Mathew P, Ahmann GJ, Witzig TE, et al: Clinicopathological correlates of CD56 expression in multiple myeloma: A unique entity? Br. J. Haematol. 90: 459-461, 1995.
PubMed
73) Kaiser U, Jaques G, Havemann K, et al: Serum NCAM: A potential new prognostic marker for multiple myeloma. Blood 83: 871-873, 1994.
PubMed
74) Kubagawa H, Vogler CB, Capra JD, et al: Studies of the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B cell differentiation. J. Exp. Med. 1501792-807, 1979.
 
75) Berenson J, Wong R, Kim K, et al: Evidence of peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 70: 1550-1553, 1987.
 
76) Bakkus MHC, Heirman C, Van Riet I, et al: Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80: 2326-2335, 1992.
 
77) Billadeau D, Ahmann G, Greipp P, et al: The bone marrow of multiple myeloma patients contains B cell population that is clonally related to the malignant plasrna cell. J. Exp. Med. 178: 1023-1031, 1993.
 
78) Corradini P, Boccadoro M, Voena C, et al: Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cμsequence in immunoglobulin (IgG) -and IgA-secreting multiple myelomas. J. Exp. Med. 178: 1091-1096, 1993.
 
79) Cremer FW, Kiel K, Sucker C, et al: A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fraction of leukapheresis products do not contain malignant cells. Leukemia 11(suppl. 5) : S41-46, 1997.
PubMed
80) Szczepek AJ, Bergsagel PL, Axelsson L, et al: CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 89: 1824-1833, 1997.
PubMed
81) Foerster J: Multiple myeloma. In: Wintrobe 's Clinical Hematology(eds. by Lee GR, et al) , 9th Ed. Lea & Febiger, Philadelphia, 1993, pp. 2219-2249.
 
82) Shulman LN: Plasma cell diseases and related disorders. In: Blood: Principles and Practice of Hematology (eds. by Hardin RI, et al) , Lippincott Company, Philadelphia, 1995, pp. 885-913.
 
83) Bataille R, Chappard D, Klein B: Mechanisms of bone lesions in multiple myeloma. Hematol. Oncol. Clin. North Am. 6: 285-295, 1992.
PubMed
84) Garrett R, Durie BGM, Nedwin GE, et al: Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med. 317: 526-532, 1987.
 
85) Kawano M, Yamamoto I, Iwato K, et al: Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multipe myeloma. Blood 73: 1646-1649, 1989.
 
86) Beguin Y, Yerna M, Loo M, et al: Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br. J. Haematol. 82: 648-653, 1992.
PubMed
87) Greaves MF, Habeshaw JA, Stansfeld AG: Lymphoproliferative disorders. In: Atlas of blood cells (eds. by Zucker-Franklin D, et al) , Edi. Ermes, Milano, 1981, pp. 409-524.
 
88) 三輪哲義: 多発性骨髄腫の細胞形態. 日本臨牀 53: 538-542, 1995.
Medical*Online
89) Greipp PR, Raymond NM, Kyle RA, et al: Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood 65: 305-310, 1985.
PubMed
90) Bartl R, Frisch B, Diem H, et al: Histologic, biochemical, and clinical parameters for monitoring multiple myeloma. Cancer 68: 2241-2250, 1991.
PubMed
91) Broder S, Humphrey R, Durm M, et al: Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. Role of suppressor cells. N. Engl. J. Med. 293: 887-892, 1975.
PubMed
92) 梅田正法, 津布久雅彦: 多発性骨髄腫 最近の画像診断. 日本臨牀 53: 636-641, 1995.
 
93) Avrahami E, Tadmor R, Kaplinsky N: The role of T 2-weighted gradient echo in MRI demonstration of spinal multiple myeloma. Spine 18: 1812-1815, 1993.
 
94) Kyle RA: Diagnosis and management of multiple myeloma and related disorders. Prog. Hematol. 14: 257-282, 1986.
PubMed
95) Greipp PR: Advances in the diagnosis and management of myeloma. Semin. Hematol. 29: 24-45, 1992.
PubMed
96) Durie BGM, Salmon SE: Multiple myeloma, macrogrobulinemia and monoclonal gammopaties. In: Recent advances in hematology (eds. by Hoffbrand AV, et al) , Churchill-Livingstone, Edinburgh, 1977, pp. 243-261.
 
97) Sukpanichnant S, Cousar JB, Leelasiri A, et al: Diagnostic criteria and histologic grading in multiple myeloma. Hum. Pathol. 25: 308-318, 1994.
PubMed
98) Durie BGM, Salmon SE: Aclinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842-854, 1975.
 
99) Hjorth M, Hellquist L, Holmberg E, et al: Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma. Eur. J. Haematol. 50: 95-102, 1993.
PubMed
100) Dimopoulos MA, Moulopoulos A, Smith T, et al: Risk of disease progression in asymptomatic multiple myeloma. Am. J. Med. 94: 57-61, 1993.
PubMed
101) Alexanian R, Bonnet J, Gehan E, et al: Combination chemotherapy for multiple myeloma. Cancer 30: 382-389, 1979.
 
102) Chronic Leukemia-Myeloma Task Force, National Cancer Institute: Proposed guidelines for protocol studies: II, Plasma cell myeloma. Cancer Chemother. Rep. 4(suppl.) : 145-158, 1973.
 
103) Gore ME, Selby PJ, Viner C, et al: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 2: 879-882, 1989.
PubMed
104) 今村幸雄: 骨髄腫. 癌の臨床 27: 1067-1074, 1981.
 
105) Palmer M, Belch A, Hanson J, et al: Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. Br. J. Cancer 591110-112, 1989.
 
106) Hardin J, MacLeod S, Grigorieva 1, et al: Interleukin-6 prevents dexamethasone-induced myeloma cell growth. Blood 84: 3063-3070, 1994.
 
107) Alexanian R, Haut A, Ialan AU, et al: Treatment for multiple myeloma.: Combination chemotherapy with different melphalan dose regimens. JAMA 208: 1680-1685, 1969.
 
108) Alexanian R, Dreicer R: Chemotherapy for multiple myeloma. Cancer 53: 583-588, 1984.
PubMed
109) Case DC, Lee BJ, Clarkscn BD: Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am. J. Med. 63: 897-903, 1977.
 
110) Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J. Clin. Oncol. 10: 334-342, 1992.
PubMed
111) Oken MM: Standard treatment of multiple myeloma. Mayo Clin. Proc. 69: 781-786, 1994.
PubMed
112) Durie BGM, Dixon OO, Carter S, et al: Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group study. J. Clin. Oncol. 4: 1227-1237, 1986.
 
113) Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med. 310: 1353-1356, 1984.
PubMed
114) Bell JBG, Millar BC, Maitland JA, et al: Increase in clonogenic tumor cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methylpredinisolone. Lancet 2: 931-933, 1988.
 
115) Samson D, Galninara E, Newland A, et al: Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2: 882-885, 1989.
 
116) Anderson H, Scarffe JH, Ranson M, et al: VAD therapy as remission induction for multiple myeloma. Br. J. Cancer 71: 326-330, 1995.
PubMed
117) Delain M, Linassier C, Petitdidier C, et al: VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. J. Clin. Oncol. 123: 2706-2713, 1994.
 
118) Cook G, Sharp RA, Tansey P, et al: Aphase I/II trial of Z-Dex (oral idarubicin and dexamethasone) , an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br. J. Haematol. 93: 931-934, 1996.
PubMed
119) Ballester OF, Moscinski LC, Fields KK, et al: Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE) : a novel, intensive induction chemotherapy, regimen or patients with high-risk multiple myeloma. Br. J. Haematol. 96: 746-748, 1997.
PubMed
120) MacLennan ICM, Chapman C, Dunn J, et al: Combined chemotherapy with ABCM versus melphalan fomelphalan for treatment of myelomatosis. Lancet 339: 200-205, 1992.
 
121) McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 2: 822-824, 1983.
 
122) Cunningham D, Paz-Ares L, Gore ME, et al: High-dose melphalan for multiple myeloma: Long-term followup data. J. Clin. Oncol. 12: 764-768, 1994.
 
123) Buzaid AC, Durie BGM: Management of refractory myeloma: A review. J. Clin. Oncol. 6: 889-905, 1988.
 
124) Finnish Leukemia Group: Combination chemotherapy MOCCA in resistant and relapsing myeloma. Eur. J. Haematol. 48: 37-40, 1992.
PubMed
125) Lokhorst HM, Meuwissen OJAT, Bast EJEG, et al: VAD chemothearpy for refractory multiple myeloma. Br. J. Haematol. 71: 25-30, 1989.
 
126) Adam Z, Elbl L, Vorliek J, et al: Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide. Acta Med. Austriaca 21: 111-115, 1994.
 
127) Gimsing P, Bjerrum OW, Brandt E, et al: Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen) : a phase II study. Br. J. Haematol. 77: 73-79, 1991.
PubMed
128) Keldsen N, Bjerrum OW, Dahl IMS, et al: Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Eur. J. Haematol. 51: 80-85, 1993.
 
129) Blade J, San Miguel J. Sanz-Sanz MA, et al: Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high dose dexamethasone (VBAD) . Eur. J. Cancer 29A: 57-60, 1993.
 
130) Peest D, Schmoll H-J, Schedel I, et al: VBAMDex chemotherapy in advanced multiple myeloma. Eur. J. Haematol. 40: 245-249, 1988.
 
131) Barlogie B, Velasques WS, Alexanian R, et al: Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethason-refractory myeloma. J. Clin. Oncol. 7: 1514-1517, 1989.
 
132) Ohrling M, Bjorkholm M, Osterberg, A, et al: Etoposide, doxorubicin cyclophosphamide, and high dose betamethasone (EACB) as outpatient salvage therapy for refractory myeloma. Eur. J. Haematol. 51: 45-49, 1993.
 
133) Lenhard RE, Oken MM, Barnes JM, et al: High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 53: 1456-1460, 1984.
 
134) Dimopoulos MA, Delasalle KB, Champlin R, et al: Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br. J. Haematol. 83: 240-244, 1993.
 
135) Cooper MR, Welander CE: Interfcrons in the treatment of multiple myeloma. Cancer 59: 594-600, 1987.
 
136) Avvisati G, Mandelli F: The role of interforon-α in the management of myelomatosis. Hematol. Oncol. Clin. North Am. 6: 395-405, 1992.
 
137) Montuoro A, Rosa L, Blasio A, et al: Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br. J. Haematol. 76: 365-368, 1990.
 
138) Osterborg A, Bjorkholm M, Bjoreman M, et al: Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stage III and III: A randomized study from the myeloma group of central Sweden. Blood 81: 1428-1434, 1993.
 
139) Corrado C, Flores A, Pavlovsky S, et al: Randomized trial of melphalan (L-PAM) -Prednisone (PRED) with or without recombinant alpha 2 interferon(rα21FN) in multiple myeloma. Proc. Am. Soc. Clin. Oncol. 10: 27 Meet, 304, 1991.
 
140) Cooper MR, Dear K, Mclntyre OR, et al: A randomized clinical trial comparing melphalan/prednisone with or without interforon alpha-2b in newly diagnosed patients with multiple myeloma: A cancer and leukemia group B study. J. Clin. Oncol 11: 155-160, 1993.
 
141) Aitchison R, Willians A, Schey S, et al: A randomized trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma. Leuk. Lymphoma 9: 243-246, 1993.
 
142) Salmon SE, Crowley JJ, Grogan TM, et al: Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study. J. Clin. Oncol. 12: 2405-2414, 1994.
 
143) Miguel JFS, Moro M, Blade J, et al: Combination of interferon and dexamethasone in refractory multiple myeloma. Haematol. Oncol. 8: 185-189, 1990.
 
144) Palumbo A, Boccadolo M, Garino LA, et al: Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor controls in relapsed myeloma. Acta Haematol. 90: 71-76, 1993.
 
145) Alexanian R, Barlogie B, Gutterman J: α-interferon combination therapy of resistant myeloma. Am. J. Clin. Oncol. 14: 188-192, 1991.
 
146) Ludwig H, Cohen AM, Huber H, et al: Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission mainteance in multiple myeloma: Interim results. Eur. J. Cancer 27(SuppL 4) : S40-S45, 1991.
 
147) Cohen AM, Meytes D, Many A, et al: Interferon alfa-2b with VMCP for induction in multiple myeloma: The Israel myeloma cooperative group experience. Isr. J. Med. Sci. 31: 604-610, 1995.
PubMed
148) Aviles A, Alatriste S, Talavera A, et al: Altemating combination chemotherapy and interferon improves survival in poor prognosis multiple myeloma. Clin. Oncol. 7: 97-101, 1995.
 
149) Joshua DE, Penny R, Matthews Jp, et al.: Australian Leukemia study myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon maintenance in patients with multiple myeloma. Br. J. Haematol. 97: 38-45, 1997.
PubMed
150) Oken MM, Kyle RA, Greipp PR, et al: Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN α 2b) in patients with multiple myeloma. Leuk. Lymphoma 20: 447-452, 1996.
 
151) 木谷照夫: 骨髄腫の基礎と臨床. IFNを含む新しい併用療法. 臨床血液 34: 455-459, 1993.
 
152) 木谷照夫: 造血器腫瘍-どのように診断し治療するか. 多発性骨髄腫. 臨床血液 36: 471-479, 1995.
 
153) Mandelli F, Awisati G, Amadori S, et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. 322: 1430-1434, 1990.
 
154) Westin J, Rodjer S, Turesson I, et al: Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study. Br. J. Haematol. 89: 561-568, 1995.
PubMed
155) Browman GP, Bergsagel D, Sicheri D, et al: Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 13: 2354-2360, 1995.
 
156) Peest D, Deicher H, Coldewey R, et al: Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Onkologie 13: 458-460, 1990.
PubMed
157) Barlolgie B, Jagannath S, Epstein J, et al: Biology and therapy of multiple myeloma in 1996. Semin. Hematol. 34 (Suppl. 1) : 67-72, 1997.
 
158) Gahrton G, Tura S, Ljungman P, et al: Prognostic factors in allogenic bone marrow transplantation for multiple myeloma. J. Clin. Oncol. 13: 1312-1322, 1995.
 
159) Tricot G, Vesole DH, Jagannath S, et al: Graft-versus-myeloma defect: proof of principle. Blood 87: 1196-1198, 1996.
 
160) Harousseau J-L, Attal M, Devine M, et al: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French registry on autologous transplantation in multiple myeloma. Blood 85: 3077-3085, 1995.
 
161) Ataal M, Harousseau J-L, Stoppa AM, et al: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 335: 91-97, 1996.
 
162) Attal M, Huguet F, Schlaifer D, et al: Intensive combined therapy for previously untreated aggressive myeloma. Blood 79: 1130, 1992.
PubMed
163) Bralogie B, Jagannath S, Vesole DH, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89: 789-793, 1997.
 
164) Anderson KC, Barut BA, Ritz J, et al: Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 77: 712, 1991.
PubMed
165) Schiller G, Vescio R, Freyies C, et al: Transplantation of CD34+peripheral blood progenitor cells after highdose chemotherapy for patients with advanced multiple myeloma. Blood 86: 390-397, 1995.
 
166) Bjorkstrand B, Dilber S, Smith E, et al: Retroviral-mediated gene transfer into human myeloma cells. Br. J. Haematol. 88: 325-331, 1994.
 
167) Sonneveld P, Lokhorst HM, Vosseveld P: Drug resistance in multiple myeloma. Semin. Hematol. 34: 34-39, 1997.
PubMed
168) Merlin J-L, Guerci A, Marchal S, et al: Comparative evaluation of S9788, verapamil, and cyclosporin A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84: 262-269, 1994.
 
169) Bellamy WT, Dalton WS, Gleason MC, et al: The role of glutathion and its associated enzymes in multidrug resistant human myeloma cells. Biochem. Pharmacol. 38: 787-793, 1989.
 
170) Rowell NP, Tobias JS: The role of radiotherapy in the management of multiple myeloma. Blood Rev. 5: 84-89, 1991.
PubMed
171) Palumbo A, Battaglio S, Napoli P, et al: Retinoic acid inhibits the growth of human myeloma cells in vitro. Br. J. Haematol. 89: 555-560, 1995.
PubMed
172) Attisano C, Bianchi A, Montacchini L, et al: Generation of anti-tumor activity by OXT 3-stimulation in multiple myeloma. Br. J. Haematol. 87: 494-502, 1994.
 
173) Peest D, Leo R, Bloche S, et al: Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Br. J. Haematol. 89: 328-337, 1995.
PubMed
174) Kwak LW, Taub DD, Duuffey PL, et al: Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345: 1016-1020, 1995.
 
175) Dilber MS, Abedi MR, Bjorkstrand B, et al: Suicide gene therapy for plasma cell tumors. Blood 88: 2192-2200, 1996.
PubMed
176) Ludwig H, Fritz E, Kotzmam H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 322: 1693-1699, 1990.
 
177) Lahtinen R, Laakso M, Palva I, et al: Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1049-1052, 1992.
PubMed
178) Brenson JR, Lichtenstein A, Porter L, et al: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 16: 593-602, 1998.
 
179) Shipman CM, Rogers MJ, Apperley JF, et al: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br. J. Haematol. 98: 665-672, 1997.
PubMed
180) Sanders PW: Pathogenesis and treatment of myeloma kidney. J. Lab. Clin. Med. 124: 484-488, 1994.
 
181) Joshua DE, Snowdon L, Gibson J, et al: Multiple myeloma: Plateau phase revisited. Hematol. Rev. 5: 59-66, 1991.
 
182) Joshua DE, Gibson J, Brown RD: Mechanisms of the escape phase of myeloma. Blood Rev. 8: 13-20, 1994.
PubMed
183) Kyle RA: Why better prognostic factors for multiple myeloma are needed. Blood 83: 1713-1716, 1994.
PubMed
184) Greipp PR, Lust JA, O'Fallon WM, et al: Plasma cell labeling index and β2-microglobulin predicts survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81: 3382-3387, 1993.
 
185) Bergsagel DE, Phil D, Bailey AJ, et al : The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N. Engl. J. Med. 301: 743-748, 1979.
 
186) Kyle RA: Monoclonal gammopathy of undetermined significance. Blood Rev. 8: 135-141, 1994.
PubMed
187) Bardwick PA, Zvaifler NJ, Gill GN, et al: Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: The POEMS syndrome. Medicine 59: 311-322, 1980.
PubMed
188) Gherardi RK, B61ec L, Fromont G, et al: Elevated levels of interleukin-1β (IL-1β) and IL6 in serum and increased production of IL-1β mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood 83: 2587-2593, 1994.
 
189) Franklin EC: Amyloidosis. In: Williams Hematology (eds. by Beutler E, et al) , 4th Ed. McGraw-Hill, Inc, New York, 1990, pp. 1112-1118.
 
190) Gianni L, Bellotti V, Gianni AM, et al: New drug therapy of amyloidosis: Resorption of AL-type deposits with 4 '-iodo-4 '-deoxydoxorubicin. Blood 86: 855-861, 1995.
PubMed
P.1581 掲載の参考文献
1) Greco FA, Hainsworth JD: Cancer of unknown primary site. In: Cancer: Principles & Practice of Oncology (eds. by Devita Jr VT, Hellman S, Rosenberg SA) , 4th Ed., J. B. Lippincott, Philadelphia, 1993, pp. 2072-2092.
 
2) Daugaard G: Unknown primary tumours. Cancer Treat. Rev. 20: 119-147, 1994.
PubMed
3) Muir C: Cancer of unknown primary site. Cancer 75: 353-356, 1995.
PubMed
4) 万代光一, 森脇昭介, 山上啓太郎・他: 剖検例を対象とした原発不明癌症例の検討. 臨床病理 42: 75-82, 1994.
Medical*Online
5) Altman E. Cadman E: An analysis of 1539 patients with cancer of unknown prilnary site. Cancer 57: 120-124, 1986.
 
6) Abbruzzese JL, Abbruzzese MC, Hess KR, et al: Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients. J. Clin. Oncol. 12: 1272-1280, 1994.
PubMed
7) Hamilton CS, Langlands AO: ACUPS (adenocarcinoma of unknown primary site) : A clinical and cost benefit analysis. Int. J. Radiat. Oncol. Biol. Phys. 13: 1497-1503, 1987.
 
8) Jordan III WE, Shildt RA: A denocarcinoma of unknown primary site. The Brooke Army Medical Center experience. Cancer 55: 857-860, 1985.
 
9) Le Chevalier T, Cvitkovic E, Caille P, et al: Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch. Intern. Med. 148: 2035-2039, 1988.
PubMed
10) Maiche AG: Cancer of unknown primary. A retrospective study based on 109 patients. Am. J Clin. Oncol. 16: 26-29, 1993.
PubMed
11) Gaber AO, Rice P, Eaton C, et al: Metastatic malignant disease of unknown origin. Am. J. Surg. 145: 493-497, 1983.
PubMed
12) Mackay B, Ordonez NG: Pathological evaluation of neoplasms with unknown primary tumor site. Semin. Oncol. 20: 206-228, 1993.
PubMed
13) Leonard RJ, Nystrom JS: Diagnostic evaluation of patients with carcinoma of unknown primary tumor site. Semin. Oncol. 20: 244-250, 1993.
PubMed
14) Sporn JR, Greenberg BR: Empiric chemotherapy in patients with carcinoma of unknown primary site. Am. J. Med. 88: 49-55, 1990.
PubMed
15) Abbruzzese JL, Abbruzzese MC, Lenzi R, et al: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J. Clin. Oncol. 13: 2094-2103, 1995.
PubMed
16) Nissenblatt MJ: The CUP syndrome (carcinoma unknown primary) . Cancer Treat. Rev. 8: 211-224, 1981.
PubMed
17) Ultmann JE: Cancer of unknown primary site. J. Cancer Res. Clin. Oncol. 117: 505-509, 1991.
PubMed
18) Lenzi R, Hess KR, Abbruzzese MC, et al: Pooly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma? J. Clin, Oncol. 15: 2056-2066, 1997.
 
19) Hainsworth JD, Wright EP, Johnson DH, et al: Poorly differentiated carcinoma of unknown primary site: Clinical usefulness of immunoperoxidase staining. J. Clin. Oncol. 9: 1931-1938, 1991.
PubMed
20) Horning SJ, Carrier EK, Rouse RV, et al: Lymphomas presenting as histologically unclassified neoplasms: Characteristics and response to treatment. J. Clin. Oncol. 17: 1281-1287, 1989.
 
21) Hainsworth JD, Greco FA: Treatment of patients with cancer of an unknown primary site. N. Engl. J. Med. 329: 257-263, 1993.
PubMed
22) Vege DS, Soman CS, Joshi UA, et al: Undifferentiated tumors: An immunohistochemical analysis on biopsies. J. Surg. Oncol. 57: 273-276, 1994.
PubMed
23) de Braud F, Al-Sarraf M: Diagnosis and management of squamous cell carcinoma of unknown primary tumor site of the neck. Semin. Oncol. 20: 273-278, 1993.
PubMed
24) Marcial-Vega VA, Cardenes H, Perez CA, et al: Cervical metastases from unkown primaries: Radiotherapeutic management and appearance of subsequent primaries. Int. J. Radiat. Oncol. Biol. Phys. 19: 919-928, 1990.
 
25) Jacobs C: The internist in the management of head and neck cancer. Ann. Intern. Med. 113: 771-778, 1990.
PubMed
26) Guarischi A, Keane TJ, Elhakim T: Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 59: 572-577, 1987.
PubMed
27) Nicholson CP, Donohue JH, Thompson GB, et al: A study of metastatic cancer found during inguinal hernia repair. Cancer. 69: 3008-3011, 1992.
PubMed
28) Sears D, Hajdu SI: The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol. 31: 85-97, 1987.
PubMed
29) DiBonito L, Falconieri G, Colautti I, et al: The positive peritoneal effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol. 37: 483-488, 1993.
PubMed
30) Strnad CM, Grosh WW, Baxter J, et al: Peritoneal Carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann. Intern. Med. 111: 213-217, 1989.
PubMed
31) Dalrymple JC, Bannatyne P, Russell P, et al: Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 64: 110-115, 1989.
PubMed
32) Ransom DT, Patel SR, Keeney GL, et al: Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 66: 1091-1094, 1990.
PubMed
33) Fromm G-L, Gershenson DM, Silva EG: Papillary serous carcinoma of the peritoneum. Obstet. Gynecol. 75: 89-95, 1990.
PubMed
34) Svastics E, R6nay P, Bod6 M: Occult breast cancer presenting with axillary metastasis. Eur. J. Surg. Oncol. 19(Suppl. 1) : 575-580, 1993.
 
35) Baron PL, Moore MP, Kinne DW, et al: Occult breast cancer presenting with axillary metastases. Updated management. Arch. Surg. 125: 210-214, 1990.
PubMed
36) Kemeny MM, Rivera DE, Terz JJ, et al: Occult primary adenocarcinoma with axillary metastases. Am. J. Surg. 152: 43-47, 1986.
PubMed
37) Patel J, Nemoto T, Rosner D, et al: Axillary lymph node metastasis from an occult breast cancer. Cancer 47: 2923-2927, 1981
PubMed
38) Bhatia SK, Saclarides TJ, Witt TR, et al: Hormone receptor studies in axillary metastases from occult breast cancers. Cancer 59: 1170-1172, 1987.
PubMed
39) Ruddon RW, Norton SE: Use of biological markers in the diagnosis of cancers of unknown primary tumor. Semin. Oncol. 20: 251-260, 1993.
 
40) Pavlidis N, Kalef-Ezra J, Briassoulis E, et al: Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med. Pediatr. Oncol. 22: 162-167, 1994.
PubMed
41) Gamble AR, Bell JA, Ronan JE, et al: Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. BMJ 306: 295-298, 1993.
PubMed
42) Panza N, Lombardi G, de Rosa M, et al: High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites. Cancer 60: 2233-2236, 1987.
PubMed
43) Nishiya M, Miller GJ, Lookner DH, et al: Prostate specific antigen dens ity in patients with histologically proven prostate carcinoma. Cancer 74: 3002-3009, 1994.
 
44) Ilson DH, Motzer RJ, Rodriguez E, et al: Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. Semin. Oncol. 20: 229-237, 1993.
 
45) Fletcher JA, Kozakewich HP, Hoffer FA, et al: Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N. Engl. J. Med. 324: 436-442, 1991.
PubMed
46) Delattre O, Zucman J, Melot T, et al: The Ewing family of tumors-A subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 331: 294-299, 1994.
PubMed
47) Bosl GJ, Ilson DH, Rodriguez E, et al: Clinical relevance of the i(12 p) marker chromosome in germ cell tumors. J. Natl. Cancer Inst. 86: 349-355, 1994.
PubMed
48) Feinmesser R, Miyazaki I, Cheung R, et al: Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. N. Engl. J. Med. 326: 17-21, 1992.
PubMed
49) Motzer RJ, Rodriguez E, Reuter VE, et al: Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J. Clin. Oncol. 13: 274-282, 1995.
 
50) Logothetis CJ, Samuels ML, Selig DE, et al: Chemotherapy of extragonadal germ cell tumors. J. Clin. Oncol. 3: 316-325, 1985.
PubMed
51) Anderson H, Thatcher N, Rankin E, et al: VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. Eur. J. Cancer Clin. Oncol. 19: 49-52, 1983.
 
52) Moertel CG, Kvols LK, O'Connell MJ, et al: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68: 227-232, 1991.
 
53) van der Gaast A, Verweij J, Planting AST, et al: Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J. Clin. Oncol. 13: 1720-1725, 1995.
 
54) Spiro RH, De Rose G, Strong EW: Cervical node metastasis of occult origin. Am. J. Surg. 146: 441-446, 1983.
 
55) Coster JR, Foote RL, Olsen KD, et al: Cervical nodal metastasis of squamous cell carcinoma of unknown origin: Indications for withholding radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 23: 743-749, 1992.
PubMed
56) Yang ZY, Hu YH, Yan JH, et al: Lymph node metastases in the neck from an unknown primary. Report on 113 patients. Acta Radiol. Oncol. 22: 17-22, 1983.
PubMed
57) McCunniff AJ, Raben M: Metastatic carcinoma of the neck from an unknown primary. Int. J. Radiat. Oncol. Biol. Phys. 12: 1849-1852, 1986.
PubMed
58) Carlson LS, Fletcher GH, Oswald MJ: Guidelines for radiotherapeutic techniques for cervical metastases from an unknown primary. Int. J. Radiat. Oncol. Biol, Phys. 12: 2101-2110, 1986.
PubMed
59) Lee DJ, Rostock RA, Harris A, et al: Clinical evaluation of patients with metastatic squamous carcinoma of the neck with occult primary tumor. South. Med. J. 79: 979-983, 1986.
PubMed
60) Harper CS, Mendenhall WM, Parsons JT, et al: Cancer in neck nodes with unknown primary site: Role of mucosal radiotherapy. Head Neck 12: 463-469, 1990.
PubMed
61) Mack Y, Parsons JT, Mendenhall WM, et al: Squamous cell carcinoma of the head and neck: Management after excisional biopsy of a solitary metastatic neck node. Int. J. Radiat. Oncol. Biol. Phys. 25: 619-622, 1993.
PubMed
62) de Braud F, Heilbrun LK, Ahmed K, et al: Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment. Cancer 64: 510-515, 1989.
 
63) Jeremic B, Zivic LJ, Jevremovic S: Radiotherapy and cisplatin in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J Chemother. 4: 399-402, 1992.
 
64) Jeremic B, Zivic DJ, Matovic M, et al: Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. J. Chemother. 5: 262-265, 1993.
 
65) Nguyen C, Shenouda G, Black MJ, et al: Metastatic squamous cell carcinoma to cervicall lymph nodes from unknown primary mucosal sites. Head Neck 16: 58-63, 1994.
 
66) Bataini Jp, Rodriguez J, Jaulerry C, et al: Treatment of metastatic neck nodes secondary to an occult epidermoid carcinoma of the head and neck. Laryngoscope 97: 1080-1084, 1987.
 
67) Silverman CL, Marks JE, Lee F, et al: Treatment of epidermoid and undifferentiated carcinomas from occult primaries presenting in cervical lymph nodes. Laryngoscope 93: 645-648, 1983.
PubMed
68) Wang RC, Goepfert H, Barber AE, et al: Unknown primary squamous cell carcinoma metastatic to the neck. Arch. Otolaryngol. Head Neck Surg. 116: 1388-1393, 1990.
 
69) Lefebvre J-L, Coche-Dequeant B, Van JT, et al: Cervical lymph nodes from an unknown primary tumor in 190 patients. Am. J. Surg. 160: 443-446, 1990.
PubMed
70) Mohit-Tabatabai MA, Dasmahapatra KS, Rush BF, et al: Management of squamous cell carcinoma of unknown origin in cervical lymph nodes. Am. Surg. 52: 152-154, 1986.
PubMed
71) Lee NK, Byers RM, Abbruzzese JL, et al: Metastatic adenocarcinoma to the neck from an unknown primary source. Am. J. Surg. 162: 306-309, 1991.
 
72) Ringenberg QS, Doll DC, Loy TS, et al: Malignant ascites of unknown origin. Cancer 64: 753-755, 1989.
PubMed
73) Muggia FM, Baranda J: Management of peritoneal carcinomatosis of unknown primary tumor site. Semin. Oncol. 20: 268-272, 1993.
PubMed
74) Young RC, Perez CA, Hoskins WJ: Cancer of the ovary. In: Cancer: Principles & Practice of Oncology(eds. by Devita VT, Hellman S, Rosenberg SA) , 4th Ed., JB. Lippincott, Philadelphia, 1993, pp. 1226-1263.
 
75) A 'Hern RP, Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J. Clin. Oncol. 13: 726-732, 1995.
 
76) McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334: 1-6, 1996.
PubMed
77) Ellerbroek N, Holmes F, Singletary E, et al: Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 66: 1461-1467, 1990.
PubMed
78) Vilcoq JR, Calle R, Ferme F, et al: Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch. Surg. 117: 1136-1138, 1982.
PubMed
79) Merson M, Andreola S, Galimberti V, et al: Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 70: 504-508, 1992.
PubMed
80) Rosen PP, Kimmel M: Occult breast carcinoma presenting with axillary lymph node metastases: A follow-up study of 48 patients. Hum. Pathol. 21: 518-523, 1990.
PubMed
81) Sporn JR, Greenberg BR: Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin. Oncol. 20: 261-267, 1993.
PubMed
82) Goldberg RM, Smith FP, Ueno W, et al: 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknowrl primary. J. Clin. Oncol. 4: 395-399, 1986.
PubMed
83) Walach N, Horn Y: Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin. Cancer Treat. Rep. 71: 605-607, 1987.
PubMed
84) van der Gaast A, Verweij J, Th Planting A, et al: 5-fluorouracil, doxorubicin and mitomycin C(FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. Eur. J. Cancer Clin. Oncol. 24: 765-768, 1988.
 
85) Ahlgren JD, Bern M, Booth B, et al: Protracted infusional 5-FU(PIF) : An active, well-tolerated regimen in metastatic adenocarcinoma of undetermined primary (AUP) . Amid-atlantic oncology program (MAOP) study. Proc. ASCO 12: 401, 1993.
 
86) Theo Wagener DJ, de Mulder PHM, Burghouts JT, et al: Phase II trial of cisplatin for adenocarcinoma of unknown primary site. Eur. J. Cancer 27: 755-757, 1991.
 
87) Woods RL, Fox RM, Tattersall MHN, et al: Metastatic adenocarcinomas of unknown primary site. A randomized study of two combination chemotherapy regimens. N. Engl. J. Med. 303: 87-89, 1980.
 
88) Milliken ST, Tattersall MHN, Woods RL, et al: Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur. J. Cancer Clin. Oncol. 23: 1645-1648, 1987.
 
89) Pasterz R, Savaraj N, Burgess M: Prognostic factors in metastatic carcinoma of unknown primary. J. Clin. Oncol. 4: 1652-1657, 1986.
PubMed
90) Kambhu SA, Kelsen DP, Fiore J, et al: Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. Am. J. Clin. Oncol. l3: 55-60, 1990.
 
91) Alberts AS, Falkson G, Falkson HC, et al: Treatment and prognosis of metastatic carcinoma of unknown primary: Analysis of 100 patients. Med. Pediatr. Oncol. 17: 188-192, 1989.
PubMed
92) Greco FA, Vaughn WK, Hainsworth JD: Advanced poorly differentiated carcinoma of unknown primary site: Recognition of a treatable syndrome. Ann. Intern. Med. 104: 547-553, 1986.
PubMed
93) Hainsworth JD, Wright EP, Gray GF, et al: Poorly differentiated carcinoma of unknown primary site: Correlation of light microscopic findings with response to cisplatin-based combination chemotherapy. J. Clin. Oncol. 5: 1275-1280, 1987.
PubMed
94) Hainsworth JD, Johnson DH, Greco FA: Poorly differentiated neuroendocrine carcinoma of unknown primary site. Ann. Intern. Med. 109: 364-371, 1988.
PubMed
95) van der Gaast A, Verweij J, Henzen-Logmans SC, et al: Carcinoma of unknown primary: Identification of a treatable subset? Ann. Oncol. 1: 119-122, 1990.
 
96) Hainsworth JD, Johnson DH, Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J. Clin. Oncol. 10: 912-922, 1992.
PubMed
97) DeSanto LW, Bryan Neel III H, : Squamous cell carcinoma. Metastasis to the neck from an unknown or undiscovered primary. Otolaryngol. Clin. North Am. 18: 505-513, 1985.
PubMed
98) Tytor M, O1ofsson J: Cervical lymph node metastases with occult primary. Clin. Otolaryngol. 11: 463-467, 1986.
 
99) Glynne-Jones RGT, Anand AK, Young TE, et al: Metastatic carcinoma in the cervical lymph nodes from an occult primary: A conservative approach to the role of radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 18: 289-294, 1990.
 
100) Jeremic B, Djuric LJ, Jevremovic S, et al: Metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. J. Chemother. 4: 41-45, 1992.
 
101) Wax MK, Briant TDR: Surgery and postoperative radiotherapy in the management of extensive cancer of the cervical lymph nodes from an unknown primary. J. Otolaryngol. 22: 34-38, 1993.
 
102) McKeen E, Smith F, Haidak D, et al: Fluorouracil(F) , adriamycin(A) and mitomycin-C(M) , FAM, for adenocarcinoma of unknown origin (AUO) . Proc. of AACR and ASCO 21: 358, 1980.
 
103) Fiore JJ, Kelsen DP, Gralla RJ, et al: Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin. Cancer Treat. Rep. 69: 591-594, 1985.
PubMed
104) Bruckner HW, Crown J, McKenna A, et al: Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. Cancer Res. 48: 5570-5572, 1988.
PubMed
105) Treat J, Falchuk SC, Tremblay C, et al: Phase II trial of methotrexate-FAM(m-FAM) in adenocarcinoma of unknown primary. Eur. J. Cancer Clin. Oncol. 25: 1053-1055, 1989.
 
106) Kelsen D, Coit D, Houston C, et al: Phase II trial of PALA, methotrexate (MTX) , fluorouraci1(FU) , and leucovorin(L) in adenocarcinoma of unknown primary site (ACUP) . Proc. of ASCO 8: 293, 1989.
 
107) de Campos ES, Menasce LP, Radford J, et al: Metastatic carcinoma of uncertain primary site: A retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide(VAC) or VAC alternating with cisplatin and etoposide (VAC/PE) . Cancer 73: 470-475, 1994.
PubMed
108) van der Gaast A, Henzen-Logmans SC, Planting AST, et al: Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site. Ann. Oncol. 4: 789-790, 1993.
 
109) Akerley W, Thomas A, Miller M, et al: Phase II trial of oral etoposide for carcinoma of unknown primary (CUP) . Proc. of ASCO 13: 406, 1994.
 
110) Jadeja J, Legha S, Burgess M, et al: Combination chemotherapy with 5-FU, adriamycin, cyclophosphamide and cis-platinum (FACP) in the treatment of adenocarcinoma of unknown primary (ACUP) and undifferentiated carcinomas (UCUP) . Proc. of ASCO 2: 237, 1983.
 
111) Becouarn Y, Brunet R, Barbe-Gaston C: Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. Eur. J. Cancer Clin. Oncol. 25: 861-865, 1989.
PubMed
112) Ruffie P, Izzo J, Cvitkovic E, et al: Treatment of unknown primary adenocarcinoma (UPA) with fluorouracil(F) , mitomycin(M) , epirubicin(E) , and platinum(P) . Proc. of ASCO 10: 301, 1991.
 
113) Raber MN, Faintuch J, Abbruzzese JL, et al: Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloro-platinum in patients with metastatic carcinoma of unknown primary origin. Ann. Oncol. 2: 519-520, 1991.
 
114) Gill I, Guaglianone P, Grunberg SM, et al: High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary. Anticancer Res. 11: 1231-1236, 1991.
PubMed
115) Pavlidis N, Kosmidis P, Skarlos D, et al: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. Ann. Oncol. 3: 631-634, 1992.
PubMed
116) Lenzi R, Raber MN, Frost P, et al: Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. Eur. J. Cancer 29 A: 1634, 1993.
 
117) Trudeau M, Thirlwell MP, Boos G, et al: Cancer of unknown primary syndrome(CUPS) : Predictive value of CA-125 in patients treated with 5-fluorouracil, doxorubicin and cisplatin(FAP) . Proc. of ASCO 12: 399, 1993.
 
118) Piga A, Cardarelli N, Catalano V, et al: Cancer of unknown primary site(UPT) : A collaborative study on diagnosis and treatment. Proc. of ASCO 13: 404, 1994.
 
119) Merrouche Y, Lasset C, Trillet-Lenoir V, et al: Phase II study of cis platinum(CDDP) and etoposide(E) in a subgroup of patients(PT) with carcinoma of unknown primary(CUP) . Proc. of ASCO 13: 401, 1994.
 
120) Hainthworth JD, Erland JB, Kalman LA, et al: Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J. Clin. Oncol. 15: 2385-2393, 1997.
 
121) Shildt RA, Kennedy PS, Chen TT, et al: Management of patients with metastatic adenocarcinoma of unknown origin: A Southwest Oncology Group Study. Cancer Treat. Rep. 67: 77-79, 1983.
 
122) Eagan RT, Therneau TM, Rubin J, et al: Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. Am. J. Clin. Oncol. 10: 82-85, 1987.
PubMed
P.1593 掲載の参考文献
1) Beral V, Peterman TA, Berkelman RL, et al: Kaposi 's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335: 123-128, 1990.
 
2) Schultz TF, Boshoff C, Weiss RA, et al: HIV infection and neoplasia. Lancet 348: 587-591, 1996.
 
3) Moses AV, Williams SE, Strussenberg JG, et al: HIV-1 induction of CD 400n endthelial cells promotes the outgrowth of AIDS associated B cell lymphomas. Nat. Med. 3: 1242-1249, 1997.
 
4) Cooley TP: Kaposi 's sarcoma. In: HIV infection (eds. by Libman H, Witzburg RA) , Little Brown Co., Boston, USA, 1996, pp. 431-448.
 
5) Beral V: Epidemiology of Kaposi 's sarcoma in cancer surveys. In: Cancer, HIV and AIDS (eds. by Beral V, Jaffe HW, Weis R) , Vol. 10, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1991, pp. 5-22.
 
6) Chang Y, Cesarman E, Pessin M, et al: Identification of herpesvirus-like DNA sequence in AIDS-associated Kaposi 's sarcoma. Science 266: 1865-1869, 1994.
 
7) Friedman-Kien A, Saltzman B, Cao Y, et al.: Kapos 's sarcoma in HIV-negative homosexual men. Lanceti: 168-169, 1990.
 
8) 小池盛雄, 倉田 毅, 森 茂郎: 剖検例からみた日本のエイズ(厚生省科学研究費エイズ対策推進事業, HIV感染者発症予防治療に関する研究班, 文部省エイズ制圧のための基礎研究班共同研究) . 1994, pp. 123-126.
 
9) 森山佐知子, 猪狩 豪, 比島恒和・他: AIDS剖検例におけるKaposi肉腫の検討. 厚生省平成8年度HIV感染者発症予防治療に関する研究班研究報告書. 1997, pp. 303-308.
 
10) Rutherford GW, Schwarz SK, Lemp GF, et al: The epidemiology of AIDS-related Kaposi 's sarcoma in San Francisco. J. Infect. Dis. 159: 569-572, 1989.
 
11) Northfelt, DW: Kaposi 's sarcoma: Epidemiology and clinical characteristics. In: The AIDS Knowledge Base, 2nd Edition (eds. by Cohen PT, Sande MA, Volberding PA) , Little Brown and Company, Boston/New York/Toronto/London, 1994, pp. 7. 1-1-7. 1-6.
 
12) Ambroziak J, Blackbourn D, Hendier B, et al: Herpesvirus-like sequence in HIV-infected and uninfected Kaposi 's sarcoma patients (technical comments) . Science 268: 582-583, 1995.
 
13) Moore P, Chang Y: Detection of herpesvirus-like DNA sequence in Kaposi 's sarcoma patients with and those without HIV infection. N. Engl. J. Med. 332: 1181-1185, 1995.
PubMed
14) Schalling M, Ekman M, Kaaya EE, et al: A role for a new herpesvirus (KSAV) in different forms of Kaposi 's sarcoma. Nat. Med. 1: 707-708, 1995,
 
15) Chuck S, Grant RM, Katongole-Mbiddee E, et al: Frequent presence of herpesvirus-like DNA sequence in lesions of HIV negative Kaposi 's sarcoma. J. Infect. Dis. 173: 248-251, 1996.
 
16) Huang Y-Q, Huang Y, Li JJ, et al: Human herpes virus-like DNA sequence in various forms of Kaposi 's sarcoma. Lancet 345: 759-761, 1995.
PubMed
17) Boshoff C, Whitby D, Hatziannou T, et al: Kaposi 's sarcome associated herpes virus in HIV negative Kaposi 's sarcoma. Lancet 345: 1043-1044, 1995.
 
18) Russo JJ, Bohenzky RA, Cien A, et al: Nucleotide sequence of the Kaposi sarcoma associated herpesvirus 8 (HHV 8) . Proc. Natl. Acad. Sci. USA 93: 14862-14867, 1996.
 
19) Gao SJ, Kingsley L, Li M, et al: KSHV antibodies among Americans Italians and Ugandans with and without Kaposi sarcoma. Nat. Med. 2: 925-928, 1996.
PubMed
20) Lennette E, Blackbourn DJ, Levy JA: Antibodies to human herpesvirus type 8 in the general population and in Kaposi 's sarcoma patients. Lancet 348: 858-861, 1996.
PubMed
21) Simpson GR, Sdultz TF, Whitby D, et al: Prevalence of Kaposi 's sarcoma associated herpes virus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 348: 1133-1138, 1996.
 
22) Kedes DH, Operskalski E, Busch M, et al: The seroepidemiology of human herpesvirus 8(Kaposi 's sarcoma associated herpesvirus) : Distribution of infection in KS risk groups and evidence for sexual transmission. Nat. Med. 2: 918-924, 1996.
PubMed
23) Rady PL, Yen A, Rollefson JL, et al: Herpes Virus-like DNA sequences in non Kaposis sarcoma. Lancet 345: 1339-1342, 1995.
PubMed
24) Foreman K, Bonish B, Nikoloff B, et al: Absence of human herpes virus 8 DNA sequences in patiellts with immunosuppression-associated dermatofibromas. Arch. Dermatol. 133: 108-109, 1997.
 
25) Kaplan LD, Northfelt DW: Malignancies associated with AIDS. In: The Management of AIDS (eds. by Sarde MA, Volberding PA) . WB Saunders Co., Philadelphia, USA, 1995, pp. 555-590.
 
26) Knowles DM, Inghirami G, Ubraaco A, et al: Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivative and the possible pathogenetic role of EBV. Blood 73: 792-799, 1989.
 
27) Walts AE, Shintalen PI, Said JW: Diagnosis of malignant lymphoma in effusions from patients with AIDS by gene rearrangement. Am. J. Pathol. 94: 170-175, 1990.
 
28) Cesarman E, Chang Y, Moor PS, et al: Kaposi 's sarcoma associated herpesvirus-like DNA sequence in AIDS related body-cavity-based lymphoma. N, Engl. J. Med. 332: 1186-1191, 1995.
 
29) Ansari MQ, Dawson DB, Nador R, et al: Primary body cavity-based AIDS related lymphomas. Am. J. Clin. Pathol. 105: 221-229, 1996.
PubMed
30) Green I, Espiritu E, Ladanyi M, et al: Primary lymphomatous effusion in AIDS: a morphological immunophenotypic, and molecular study. Mod. Pathol. 8: 39-45, 1995.
 
31) Pastore C, Gloghini A, Volpe G, et al: Distributions of Kaposi 's sarcoma herpesvirus sequences among lymphoid malignancy in Italy and Spain. Br. J. Haematol. 91: 918-920, 1995.
 
32) Carbone A, Tierell U, Gloghini A, et al: Herpesvirus-like DNA sequences selectively cluster with body-cavity based lymphoma throughout the spectrum of AIDS related lymphomatous effusions. Eur. J, Cancer 32 A: 555-556, 1996.
 
33) Harris NL, Jaffe ES, Stein H, et al: A revised European American classification of lymphoid neoplasmas: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994.
 
34) Castleman B, Iverson L, Menendez VP: Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9: 822-830, 1956.
PubMed
35) Gaidano G, Pastore C, Gloghini A, et al: Human herpesvirus type 8(HHV-8) in haematopoietic neoplasia. Leuk. Lymphoma 24: 257-266, 1997.
PubMed
36) Soulier J, Grollet L, Oksenhendler E, et al: Kaposi 's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman 's disease. Blood 86: 1276-1280, 1995.
 
37) Yoshizaki K, Matsuda T, Nishimoto N, et al: Pathogenetic significance of interleukin-6(IL 6/BSF-2) in Castleman 's disease. Blood 74: 1360-1367, 1989.
 
38) Ensoli B, Nakamura S, Salahuddin SZ, et al: AIDS-Kaposi 's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243: 223-226, 1989.
PubMed
39) Ng VL, Komanduri KV, Luce JA, et al: Clinical and laboratory features of HIV-associated body cavity based lymphomas. Blood 86(suppl. 1) : 379 a (abstract no. 1506) , 1995.
 
40) Volberding PA, Kusicke P, Feigal DW: Effect of chemotherapy for HIV associated Kaposi 's sarcoma on longterm survival. Proceeding of the American Society of Clinical Oncology, San Francisco, 1989, 11.
 
41) Kaplan LD, Kahn J: Therapy for HIV-associated Kaposi 's sarcoma. In: The AIDS Knowledge Base, 2nd Edition (eds. by Cohen PT, Sande MA, Volberding PA) . Little Brown and Company, Boston/New York/Toronto/London, 1994, pp. 7. 3-1-7. 3-11.
 
42) Schultz TF, Boshoff CH, Weiss RA: HIV infection and neoplasma. Lancet 348: 587-591, 1996.
 
43) Tappero JG, Berger TC, Kaplan LD, et al: Cryotherapy for cutaneous Kaposi 's sarcoma(KS) associated with acquired immune defic. syndrome(AIDS) : a phase II trial. J. Acquir. Immune. Defic. Syndrome 4: 839-846, 1991.
 
44) Newman SB: Treatment of epidemic Kaposi 's Sarcoma(KS) with intralegionl vinblastine infusion(IL-VLB) . Proceedings of the American Society of Clinical Oncology, New Orleans, 1988, 19.
 
45) Gill PS, Paride MU, Espina B, et al: Advanced acquired immune deficiency syndrome-related Kaposi 's sarcoma, results of pilot studies using combination chemotherapy. Cancer 65: 1074-1078, 1990.
 
46) Laubenstein KJ, Krigel RL, Odajnyk CM, et al: Treatment of epidemic Kaposi 's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J. Clin. Oncol. 2: 1115-1120, 1984.
PubMed
47) Krown SE, Gold JW, Niedzwiecki D, et al: Interferon-alpha with zidovudine: Safety tolerance, and clinical and virologic affects in patients with Kaposi 's sarcoma associated with the acquired immunodeficiency syndrome (AIDS) . Ann. Intern. Med. 112: 812-821, 1990.
 
48) Greiner TC, Medeiros LJ, Jaffe ES: Non-Hodgkin 's lymphoma. Cancer 75(supPl. 1) : 370-380, 1995.
 
49) MacMahon EM, Glass JD, Hayward SD, et al: Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338: 969-973, 1991.
PubMed
50) Fillet AM: Cobtrolled study of human herpesvirus 6 detection in acquired immunodeficiency syndrome-associated non-Hodgkin lymphoma: The French study group for HIV-associated tumors. J. Med. Virol. 45: 106-112, 1995.
 
51) Kaplan LD, Abrams DL, Feigal E, et al: AIDS associated non Hodgkin 's lymphoma in San Francisco. JAMA 261: 719-724, 1989.
 
52) Levine AM, Sullivan-Halley J, Pike MC, et al: Human immunodeficiency virus related lymphoma: prognostic factors predictive of survival. Cancer 68: 2466-2472, 1991.
PubMed
53) Knowles DM, Chamulak G, Subar M, et al: Clinicopathological, immunophenotypic, and molecular genetic analysis of AIDS-associated lymphoid neoplasia: clinical and biologic implications. Pathol. Annu. 23: 33-67, 1988.
 
54) Bermudez MA, Grant KM, Rodvien R, et al: Non-Hodgkin 's lymphoma in a population with or at risk for acquired immunodeficiency syndrome: indications for intensive chemotherapy. Am. J. Med. 86: 71-76, 1989.
PubMed
55) Ziegler JL, Beckstead JA, Volberding PA, et al: Non-Hodgkin 's lymphoma in 90 homosexual men: relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N. Engl. J. Med. 311: 565-570, 1985.
 
56) Kaplan LD: Lymphomas: Clinical characteristics and diagnosis. In: The AIDS Knowledge Base, 2nd Edition (eds. by Cohen PT, Sande MA, Volberding PA) , Little Brown and Company, Boston/New York/Toronto/London, 1994, pp. 7. 5-1-7. 5-5.
 
57) Baumgartner SE, Rachlin JR, Beckstead JH, et al: Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J. NeuroSurg. 73: 206-211, 1990.
 
58) Gisselbrecht C, Oksenhendler E, Tierelli U, et al: Human immunodeficiency virus related lymphoma treatment with intensive combination therapy. Am. J. Med. 951180-185, 1993.
PubMed
59) Levine AM, Wenz JC, Kaplan L, et al: Low dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma: a prospective multi-institutional trial. JAMA 266: 84-88, 1991.
 
60) Vermund SH, Kelley KF, Klein RS, et al: High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am. J. Obstet. Gynecol. 165: 392-400, 1991.
PubMed
61) Pfister H: Relationship of papilloma viruses to anogenital cancer. Obstet. Gynecol. Clin. North. Am. 14: 349-361, 1987.
 
62) Maggwa BN, Hunter DJ, Mbugns S, et al: The relationship between HIV infection and cervical intraepithelial neoplasia among women attending two family planning clinics in Nairobi, Kenya. AIDS 7: 733-738, 1993.
PubMed
63) Schrager LK, Friedland GH, Maude D, et al: Cervical and vaginal squamatous cell abnormalities in women infected with human immunodeficiency virus. J. Acquir. Immune. Defic. Syndr. 2: 570-575, 1989.
 
64) Sun X-W, Kuhn L, Ellerbrook TV, et al: Human papillomavirus infection in woman infected with the human immuno deficiency virus. N. Engl. J. Med. 337: 1343-1349, 1997.
 
65) Shafer A, Friedmann W, Mielke M: The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am. J. Obstet. Gynecol. 164: 593-599, 1991.
 
66) Maiman M, Tarricone N, Vieira J, et al: Colcoscopic evaluation of human immunodeficiency virus-seropositive women. Obstet. Gynecol. 78: 84-88, 1991.
 
67) Rabkin CS, Yellin F: Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type. J. Natl. Cancer Inst. 86: 1171-1176, 1994.
 
68) Palefsky JM, Gonzales J, Greenlatt RM, et al: Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease. JAMA 263: 2911-2916, 1990.
 
69) Breese PL, Judson FN, Prenley KA, et al: Anal human papillomavirus infection among homosexual and bisexual men: prevalence of type-specific infection and association with human immunodeficiency virus. Sex Transm. Dis. 22: 7-14, 1995.
 
70) Northfeld DN: Anal Neoplasia. In: The AIDS Knowledge Base, 2nd Edition(eds. by Cohen PT, Sande MA, Volberding PA) . Little Brown and Company, Boston/New York/Toronto/London, 1994, pp. 7. 8-1-7. 8-4.
 
71) Gal AA, Meyer PR, Talyor CR: Papillomavirus antigens in anorectal condyloma and carcinoma in homosexual men. JAMA 257: 337-340, 1987.
 
72) Gal AA, Saul SH, Stoler MH: In situ hybridization analysis of human papillomavirus in anal squamous cell carcinoma. Mod. Pathol. 2: 439-443, 1989.
PubMed
73) Caussy D, Goedert J, Palefsky J, et al: Interaction of hulnan immunodeficiency and papilloma virus: association with anal intraepithelial abnormality in homosexual men. Int. J. Cancer 46: 214-219, 1990.
 
74) Lorenz HP, Wilson W, Leigh B, et al: Squamous cell carcinoma of the anus and HIV infection. Dis. Colon Rectum 34: 336-338, 1991.
PubMed
75) Hesool NA, Katz MH, Liu JK, et al: Increased incidence of Hodgkin disease in homosexual men with HIV infection. Ann. Intern. Med. 117: 309-311, 1992.
 
P.1609 掲載の参考文献
1) Eckhardt SJ: Paraneoplastic syndromes. Cancer Surveys Palliative Medicine: Problem areas in pain and symptom management. 21: 197-209, 1994.
 
2) Agarwala SS: Paraneoplastic syndromes. Med Clin North Am. 80: 173-184, 1996.
PubMed
3) Graaf JH, Tamminga RYJ, Kamps WA: Paraneoplastic manifestations in children. Eur. J. Pediatr. 153: 784-791, 1994.
 
4) Darnel RB: Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. USA 93: 4529-4536, 1996.
 
5) Lang B, Vincent A: Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr. Opin. Immunol. 8: 865-871, 1996.
PubMed
6) Drlick M, Bianchi G, Boglium G, et al: Antibodies of the anti-Yo and anti-Ri type in the absence of "paraneoplastic" neurological syndromes: along-term survey of ovarian cancer patients. J. Neurol 244: 85-89, 1997.
 
7) Hinton RC: Paraneoplastic neurologic syndromes. Hematology/Oncology Clin. North Am. 10: 909-925, 1996.
 
8) Dropcho EJ: Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options. Ann. Neurol. 37(S 1) : SlO2-S 113, 1995.
 
9) Clouston PD, Saper CB, Arbiz T, et al: Paraneoplastic cerebellar degeneration. III. cerebellar degeneration, cancer and the Lambert-Eaton myasthenic syndrome. Neurology 42: 1944-1950, 1992.
 
10) Anderson NE, Rosenplum MK, Posner JB: Paraneoplastic degeneration: Clinical-immunological correlations. Ann. Neurol. 241559-567, 1988.
 
11) Hetzel DJ, Stanhope R, O'Neil BP, et al: Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. Mayo Clin. Proc. 65: 1558-1563, 1990.
 
12) Harrack JE, Kimmel DW, O'Neil BP, et al: Paraneoplastic cerebellar degeneration: A clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. Mayo Clin. Proc. 65: 1424-1431, 1990.
 
13) Peterson K, Rosenblum MK, Kotanides H, et al: Paraneoplastic cerebellar degeneration. 1. A clinical analysis of 55 anti-Yo antibody positive patients. Neurology 42: 1931-1937, 1992.
 
14) Marchioli CC, Graziano SL: Paraneoplastic syndromes associated with small cell lung cancer. Chest Surgery Clin North Am. 7: 65-80, 1997.
 
15) Jaeckle KA, Graus F, Houghton A, et al: Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann. Neurol. 18: 592-600, 1985.
PubMed
16) Telander RL, Smithson WA, Groover V: Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J. Pediatr. Surg. 24: 11-14, 1989.
 
17) Anderson NE, Budde-Steffen C, Rosenblum MK, et al: Opsoclonus, myoclonus, ataxia and encephalopathy in adults with cancer: A distinct paraneoplastic syndrome. Medicine 67: 100-109, 1986.
 
18) Digre KB: Opsoclonus in adults. Arch. Neurol. 43: 1165-1175, 1986.
PubMed
19) Altman AJ, Baehner RL: Favorable prognosis for survival in children with coincident opso-myoclinus and neuroblastoma. Cancer 37: 846-852, 1976.
PubMed
20) Luque A, Furneaux HM, Ferziger R, et al: Anti Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer. Ann. Neurol. 29: 241-251, 1991.
 
21) Hersh B, Dalmau J, Dangold F, et al: Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology 44: 1754-1755, 1994.
 
22) Dalmau J, Graus F, Rosenblum MK, et al: Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuropathy. Medicine 71: 59-72, 1992.
PubMed
23) Graus F, Elkon KB, Cordon-Cardo C, et al: Sensory neuropathy and small cell lung cancer: antineuronal antibody that also reacts with the tumor. Am. J. Med. 80: 45-52, 1986.
 
24) Graus F, Cordon-Cardo C, Posner JB, et al: Neuronal antinuclear antibody in sensory neuropathy from lung cancer. Neurology 35: 538-543, 1985.
 
25) Anderson NE, Rosenplum MK, Graus F, et al: Autoantibodies in paraneoplastic syndromes associated with small cell lung cancer. Neurology 38: 1391-1398, 1988.
 
26) Jean WC, Dalmau J, Ho A, et al: Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-H and the paraneoplastic neurologic disorders: At the intersection of cancer immunity, and the brain. Proc. Natl. Acad. Sci. USA 93: 529-4536, 1996.
 
27) 広瀬源二郎: 辺縁系脳炎. 臨床神経化学 15: 912-913, 1997.
 
28) Dropcho EG: Antiamphiphysin antibodies with small cell lung carcinoma and "paraneoplastic" encephalomyelitis. Ann. Neurol. 39: 659-667, 1996.
 
29) Posner JB: Paraneoplastic syndrome. Neurol. Clin. 9: 919-937, 1991.
PubMed
30) Jacobson DM, Thirkill CE, Tipping SJ: A clinical triad to diagnose paraneoplastic retinopathy. Ann. Neurol. 28: 162-167, 1990.
PubMed
31) Grunwald GB, Klein R, Simmonds MA, et al: Autoimmune basis for visual paraneoplastic syndrome in patients with small-cell lung carcinoma. Lancet 1: 658-661, 1985.
 
32) Polans AS, Witkowska D, Haley TL et al: Recoverin, a photoreceptor-specific calcium-binding protein, expressed by the tumour of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA 92: 9176-9180, 1995.
PubMed
33) Folli F, Solimena M, Cofiel R, et al: Autoantibodies to a 128 kd synaptic protein in three women with the stffman syndrome and breast cancer. N. Engl. J. Med. 328: 546-551, 1993.
 
34) Croft PB, Urich H, Wilkinson M: Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain 90: 31-66, 1967.
PubMed
35) Lisak RP, Mitchel M, Zweiman B, et al: Guillain-Barre syndrome and Hodgkin 's disease: Three cases with immunological studies. Ann. Neurol. 1: 72-78, 1977.
 
36) Younger DS, Rowland LP, Latov N, et al: Lymphoma, motor neuron diseases and amyotrophic lateral sclerosis. Ann. Nerol. 29: 78-86, 1991.
 
37) O'neil JH, Murray NMF, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome. Brain 111: 577-596, 1988.
 
38) Fukunaga H, Engel AG, Lang B, et al: Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc. Natl. Acad. Sci. USA 80: 7636-7640, 1983.
 
39) Kim YI, Neher E: IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels. Science 239: 405-408, 1988.
PubMed
40) Lennon VA, Kryzer TJ, Griesmann GE, et al: Calcium channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N. Engl. J. Med. 332: 1467-1474, 1995.
PubMed
41) Takamori M, Takahashi M, Yasukawa Y, et al: Antibodies to recombinant synaptotagmin and calcium channel subtyper in Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 133: 95-101, 1995.
 
42) Targoff IN: Humoral immuiity in polymyositis/dermatomyositis. J. Invest. Dermatol. 100: 1165-1235, 1993.
 
43) 井村 裕夫, 清野 裕: 内分泌・代謝学第4版, 医学書院, 東京, 1997, pp. 397-407.
 
44) Howlett TA, Drury PL, Perry L, et al: Diagnosis and management of ACTH-dependent Cushing 's syndrome: Comparison of the features in ectopic and pituitary ACTH production. Clin. Endocrinol. 24: 699-713, 1986.
 
45) Imura H, Matsukura S, Yamamoto H, et al: Studies on ectopic ACTH-producing tumors. II Clinical and biochemical features of 30 cases. Cancer 35: 1430-1437, 1975.
PubMed
46) Lokich JJ: The frequency and clinical biology of the ectopic hormone syndromes of small cell carcinoma. Cancer 50: 2111-2114, 1982.
PubMed
47) Oldfield EH, Doppman JL, Nieman LK et al: Petrosal sinus sampling with and without corticotropin-releasing hormone for the differntial diagnosis of cushing 's syndrome. N. Engl. J. Med. 325: 897-905, 1991.
 
48) Mundy GR: Mechanism of bone metastasis. Skeletal complications of malignancy. Cancer(Suppl.) 80: 1546-1556, 1997.
 
49) Rankin WR, Grill V, Martin TJ: Parathyroid hormone-related protein and hypercalcemia. Skeletal complications of malignancy Camcer(Suppl.) 80: 1564-1571, 1997.
 
50) Guise TA: Parathyroid hormone-related protein and bone metastases. Skeletal complications of malignancy. Camcer(Suppl.) 80: 1572-1581, 1997.
 
51) Strewler GJ, Stern PH, Jacobs JW et al: Parathyroid hormonelike protein from human renal carcinoma cells: Structual and functional homology with parathyroid hormone. J. Clin. Invest. 80: 1803-1807, 1987.
 
52) Suva LJ, Winslow GA, Wettenhall REH, et al: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237: 893-896, 1987.
 
53) Guise TA, Yin JJ, Taylor SD, et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98: 1544-1549, 1996.
PubMed
54) Bringhurst FR, Bierer BE, Godeau F, et al: Humoral hypercalcemia of malignancy: Release of a prostaglandinstimulating bone-resorbing factor in vltro by human transitional-cell carcinoma cells. J. Clin. Invest. 77: 456-464, 1986.
 
55) Tashjian AH Jr, Voelkel EF, Lloyd W, et al: Actions of growth factors on plasma calcium: epidermal growth factor and human transforming growth factor-alpha cause elevation of plasma calcium in mice. J. Clin. Invest. 78: 1405-1409, 1986.
PubMed
56) Sato K, Fujii Y, Kasono K, et al: Production of interleukin-1 and a parathyroid hormone-like factor by a squamous cell carcinoma of the esophagus (EC-G 1) derived from a patient with hypercalcemia. J Clin. Endocrinol. Metab. 67: 592-601, 1988.
 
57) Roodman GD: Mechanism of bone lesions in multiple myeloma and lymphoma. Skeletal complications of malignancy. Cancer(Suppl.) 80: 1557-1563, 1997.
 
58) Sato K, Fujii Y, Kakiuchi T, et al: Paraneoplastic syndrome of hypercalcemia and hormone related protein, interleukin 1α, and granulocyto colony stimulating factor. Cancer Res. 49: 4740-4746, 1989.
 
59) Kristensen B, Ejlesten B, Hormegaard NS, et al: Predonisolone in the treatment of severe malignant hypercalcemia in metastatic breast cancer: a randomized study. J. Intern. Med. 232: 237-245, 1992.
 
60) Kimura S, Sato Y, Matsubara H, et al: Aretrospective evaluation of the medical treatment of malignancyassociated hypercalcemia. JPn. J. Cancer Res. 77: 85-91, 1986.
 
61) Thiebaud D, Jacquet F, Bruckhardt P: Fast and effective treatment of malignant hypercalcemia-combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Arch. Intern. Med. 150: 2125-2128, 1990.
 
62) Schwartz WB, Bennet W, Curelop S, et al: A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am. J. Med. 23: 529-542, 1957.
 
63) Amatruda HJ, Mulrow PJ, Gallagher JC, et al: Carcinoma of the lung with inapPropriate antidiuretics: Demonstration of antidiuretic hormone-like activity in tumor extract. N. Engl. J. Med. 269: 544-549, 1963.
 
64) Kondo Y, Mizumoto Y, Katayama S, et al: Inappropriate secretion of antidiuretic hormone in nude mice bearing a human bronchogenic oat cell carcinoma. Cancer Res. 41: 1545-1548, 1981.
PubMed
65) Hainsworth JD, Workman R, Greco RA: Management of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. Cancer 51: 161-165, 1983.
 
66) DeTroyer A: Demeclocycline treatment for syndrome of inappropriate antidiuretic hormone secretion. JAMA 237: 2723-2726, 1977.
 
67) Bliss DP, Battey JF, Linnoila, RI, et al: Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J. Natl. Cancer Inst. 82: 305-310, 1990.
PubMed
68) Kangawa K, Matsuo H: Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide. Biochem. Biophys. Res. Commun. 118: 131-139, 1984.
PubMed
69) Oikawa S, Imai M, Ueno A, et al: Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature 309: 724-726, 1984.
PubMed
70) Campling BG, Sarda IR, Baer KA, et al: Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer 75: 2442-2451, 1995.
PubMed
71) Gross AJ, Steinberg SM, Reilly JG, et al: A trial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res. 53: 67-74, 1993.
 
72) Blackman MR, Weintraub BD, Rosen SW, et al: Human placental and pituitary glycoprotein hormones and their subunits as tumor markers: aquantative assessment. J. Natl. Cancer Inst. 65: 81-93, 1980.
PubMed
73) Yoneda T, Nishimura R, Kato I, et al: Frequency of the hypercalcemia-leukocytosis syndrome in oral malignancies. Cancer 68: 617-622, 1991.
PubMed
74) Slungaard A, Ascensao J, Zanjani E, et al: Pulmonary carcinoma with eosinophilia: Demonstration of a tumordrived eosinophiliopoietic factor. N. Engl. J. Med. 309: 778-781, 1983.
PubMed
75) McArthy JH, Kahn CR, Roth J, et al: Two cases of carcinoma of the lung characterized by a bone marrow agar culture pattern resembling acute myeloid leukemia. Blood 54: 530-533, 1979.
 
76) Kim HD, Boggs DR: A syndrome resembling idiopathic thrombocytopenic npurpura in 10 patients with diverse form of cancer. Am. J. Med. 67: 371-377, 1979.
 
77) Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 322: 1689-1692, 1990.
PubMed
78) Tracy KJ, Wei H, Manogue KR: Cachectic/tumour necrosis factor induces cachexia, anemia and inflammation. J. Exp. Med. 167: 1211-1227, 1988.
 
79) Johnson RA, Roodman GD: Hematologic manifestations of malignancy. Dis. Mon. 35: 726-759, 1989.
 
80) Hammond D, Winnick S: Paraneoplastic erythrocytosis and ectopic erythropoietins. Ann. Intern. Med. 69: 587-606, 1974.
 
81) Sytokowski AJ, Richie Jp, Bicknell KA: New human renal carcinoma cell line established from a patient with erythrocytosis. Cancer Res. 43: 1414-1419, 1983.
 
82) Ricckles FR, Edwards RL: Activation of blood coagulation in cancer. Trousseau 's syndrome revised. Blood 62: 14-31, 1983.
 
83) Silverberg JM, Gordon S, Zucker S: Identification of tissue factor in two pancreatic cell lines. Cancer Res. 49: 5443-5447, 1989.
 
84) Lindahl AK, Odegaard OS, Sandset PM, et al: Coagulation inhibition in pasncreatic cancer. Cancer 70: 2067-2072, 1992.
 
85) Kruzrock R, Cohen PR: Cutaneous paraneoplastic syndromes in solid tumors. Am. J. Med. 99: 662-671, 1995.
 
86) Kruzrock R, Cohen PR: Mucocutaneous paraneoplastic manifestations of hematologic malignancies. Am. J. Med. 99: 207-216, 1995.
 
87) Dickinson CJ: The aetiology of clubbing and hypertrophic osteoarthropathy. Eur. J. Clin. Invest. 23: 330-338, 1993.
PubMed
88) Schneerson JM: Digital clubbing and hypertrophic osteoarthropathy: The underlying mechanisms. Br. J. Dis. Chest 75: 113-131, 1981.
 
89) Segal AM, Mackenzie AH: Hypertrophic osteoarthropathy: a l0-year retrospective analysis. Semin. Arthritis Rheum. 12: 220-232, 1982.
 
90) Holt PJA, Davies MG: Erythema gyratus repens-An immunologically mediated dermatosis?Br. J. Dermtol. 96: 343-347, 1977.
 
91) Cohen PR: Paraneoplastic dermatopathology: Cutaneous paraneoplastic syndromes. Adv. Dermatol. 11: 215-252, 1996.
PubMed
92) Anhalt GJ, Kim SC, Stanley JR, et al: Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N. Engl. J Med. 323: 1729-1735, 1990.
PubMed
P.1618 掲載の参考文献
1) Negrini D, Pistolesi M, Miniati M, et al: Regional protein absorption rates from the pleural cavity in dogs. J. Appl. Physiol. 58: 20622067, 1985.
 
2) Negrini D, Ballard ST, Benoit JN: Contribution of lymphatic myogenic activity and of respiratory movements to pleural lymph flow. J. Appl. Physiol. 76: 2267-2274, 1994.
 
3) Hausheer FH, Yarbro JW: Diagnosis and treatment of malignant pleural effusion. Semin. Oncol. 12: 54-75, 1985.
PubMed
4) 二宮和子, 松原義人, 青木 稔・他: 胸膜炎238例の臨床的検討. 日胸 43: 39-45, 1984.
 
5) 水島 豊, 星野 清, 川崎 聰・他: 胸水穿刺施行115例の臨床的検討. 日胸 49: 135-140, 1990.
 
6) Lueallen EC, Carr DT: Pleural effusion: Astatistical study of 436 patients. N. Engl. J. Med. 252: 79-83, 1955.
 
7) Marel M, Stastny B, Melinova L, et al: Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest 107: 1598-1603, 1995.
PubMed
8) Albain KS, Crawley JJ, LeBlanc M, et al: Determinants of improved outcome in small-cell lung cancer: analysis of the 2580-patient. Southwest Oncology Group data base. J. Clin. Oncol. 8: 1563-1574, 1990.
 
9) Spiegelman D, Maurer LH, Wade JH, et al: Prognostic factor in small-cell carcinoma of the lung; an analysis of 1521 patients. J. Clin. Oncol. 7: 344-354, 1989.
 
10) Livingston RB, McCracken JD, Trauth CJ, et al: Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. Chest 811208-211, 1982.
PubMed
11) Dearing MP, Steinberg SM, Phelps R, et al: Outcome of patients with small-cell lung cancer, effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J. Clin. Oncol. 8: 1042-1049, 1990.
PubMed
12) Sugiyama S, Ando Y, Minami H, et al: Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin. Cancer Res. 3: 47-50, 1997.
 
13) Buhr J, Berghauser KH, Gonner S, et al: The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patients with lung cancer. J. Thorac. Cardiovasc. Surg. 113: 683-690, 1997.
PubMed
14) Kondo H, Asamura H, Suemasu K, et al: Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with Iung cancer. J, Thorac. Cardiovasc. Surg. 106: 1092-1097, 1993.
 
15) Ruckdeschel JC: Management of malignant pleural effusion: an overview. Semin. Oncol. 15(suppl. B) : 24-28, 1988.
 
16) Woodring JH: Recognition of pleural effusion on supine radiographs: How much fluid is required? AJR 142: 59-64, 1984.
PubMed
17) Gryminski J, Krakowka P, Lypacewicz G: The diagnosis of pleural effusion by ultrasonic and radiologic thwehniques. Chest 70: 33-37, 1976.
 
18) Marks WM, Filly RA, Callen PW: Real-time evaluation of pleural lesions: new observations regarding the probability of obtaining free fluid. Radiology 142: 163-164, 1982.
PubMed
19) Grogan DR, Irwin RS, Channick R, et al: Complications associated with thoracentesis. Arch. Intern. Med. 150: 873-877, 1990.
PubMed
20) Lomas DJ, Padley SG, Flower CDR: The sonographic appearances of pleural fluid. Br. J. Radiol. 66: 619-624, 1993.
 
21) McLoud TC, Flower CDR: Imaging the pleura: sonography, CT, and MR imaging. AJR 156: 1145-1153, 1991.
 
22) Bartter T, Santarelli R, Akers SM, et al: The evaluation of pleural effusion, Chest 106: 1209-1214, 1994.
PubMed
23) Rodriguez-Panadero F, Lopez MJ: Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis. Am. Rev. Respir. Dis. 139: 663-667, 1989.
 
24) Ishikawa H, Satoh H, Hasegawa S, et al: Urokinase-type plasminogen activator in carcinomatous pleural fluid. Eur. Respir. J. 10: 1566-1571, 1997.
PubMed
25) Martinez-Vea A, Gatell JM, Segura F, et al: Diagnostic value of tumoral markers in serous effusions: carcinoembryonic antigen, alpha 1-acid glycoprotein, alpha-fetoprotein, phosphohexose isomerase and beta 2-microglobulin. Cancer 50: 1783-1788, 1982.
PubMed
26) Satoh H, Sumi M, Yagyu H, et al: Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology 52: 211-214, 1995.
PubMed
27) Prakash UBS, Reiman HM: Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin. Proc. 60: 158-164, 1985.
 
28) Light RW, Erozan YS, Ball WC: Cells in pleural fluid. Arch. Intern. Med. 132: 854-860, 1973.
PubMed
29) Menzies R, Charbonneneau M: Thoracoscopy for the diagnosis of pleural disease. Ann. Intern. Med. 114: 271-276, 1991.
 
30) Lynch TJ: Management of malignant pleural effusions. Chest 103: 385 S-389 S, 1993.
 
31) Allen MS, Deschamps C, Jones DM, et al: Video-assisted thoracic surgical procedures; the Mayo experience. Mayo Clin. Proc. 71: 351-359, 1996.
PubMed
32) Yim APC, Chung SS, Lee TW, et al: Thoracoscopic management of malignant pleural effusions. Chest lO9: 1234-1238, 1996.
 
33) Rusch VW: The optimal treatment of malignant pleural effusions. A continuing dilemma. Chest 100: 1483-1484, 1991.
PubMed
34) Martini N, Bains MS, Beattie EJ: Indications for pleurectomy in malignant effusion. Cancer 35: 734-738, 1975.
PubMed
35) 宮沢直人, 横井香平, 神谷紀輝・他: 癌性胸膜炎. 日本臨牀(別冊 呼吸器症候群) : 762-765, 1994.
 
36) 原 信之, 萩本直樹, 中西洋一: 癌性胸膜炎, 心膜炎の治療. 医学のあゆみ 180: 331-334, 1997.
Medical*Online
37) Moffett MJ, Ruckdeschel JC: Bleomycin and tetracycline in malignant pleural effusions: A review. Semin. Oncol. 19: 59-63, 1992.
 
38) Ruckdeschel JC, Moores D, Lee JY, et al: Intrapleural therapy for malignant pleural effusions: a comparison of bleomycin and tetracycline. Chest 100: 1528-1535, 1991.
PubMed
39) Zaloznik AJ, Oswald SG, Langin M: Intrapleural tetracycline in malignant pleural effusions. Cancer 51: 752-755, 1983.
PubMed
40) McAlpine LG, Hulks G, Thompson NC: Management of recurrent malignant pleural effusion in the United Kingdom: survey of clinical practice. Thorax 45: 699-701, 1990.
 
41) Millikan JS, Moore EE, Steiner E, et al: Complications of tube thoracostomy for acute trauma. Am. J. Surg. 140: 738-741, 1980.
PubMed
42) Carney M, Ravin CE: Intercostal artery laceration during thoracentesis: increased risk in elderly patients. Chest 75: 520-522, 1979.
 
43) Seneff MG, Corwin W, Gold LH, et al: Complications associated with thoracentesis. Chest 89: 97-100, 1986.
 
44) Collins TR, Sahn SA: Thoracentesis. Chest 91: 817-822, 1987.
 
45) McFadden PM, Jones JW: Tube thoracostomy: anatomical considerations, overview of complications, and a proposed technique to avoid complications. Military Med. 150: 681-685, 1985.
 
46) Miller KS, Sahn SA: Chest tubes. Indications, technique, management and complications. Chest 91: 258-264, 1987.
PubMed
47) Firmin RK, Welch JD: Insertion of a chest drain. Ilospital Update 6: 481-486, 1980.
 
48) Robinson LA, Fleming WH, Galbraith TA: Intrapleural doxycycline control of malignant pleural effusions. Ann. Thorac. Surg. 55: 1115-1122, 1993.
PubMed
49) Morrison MC, Mueller PR, Lee MJ, et al: Sclerotherapy of malignant pleural effusions through sonographically placed small-bore catheters. AJR 158: 41-43, 1992.
PubMed
50) Seaton KG, Patz EF, Goodman PC: Palliative treatment of malignant pleural effusions: value of small-bore catheter thoracostomy and doxycycline sclerotherapy. AJR 164: 589-591, 1995.
PubMed
51) Trapnell DH, Thurston JGB: Unilateral pulmonary oedema after pleural aspiration. Lancet 1: 1367-1369, 1970.
 
52) Sahn SA: Pleural effusion in lung cancer. Clin. Chest Med. 3: 443-452, 1982.
PubMed
53) Walsh FW, Alberts M, Solomon DA, et al: Malignant pleural effusions: pleurodesis using a small-bore percutaneous catheters. South. Med. J. 82.: 963-972, 1989.
 
54) Villanueva AG, Gray AW, Shahian DM, et al: Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 49: 23-25, 1994.
PubMed
55) Dryzer SR, Allen ML, Strange C, et al: A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest lO4: 1763-1766, 1993.
 
56) Sherman S, Grady KJ, Siedman JC: Clinical experience with tetracycline pleurodesis of malignant pleural effusions. South. Med. J. 80: 716-719, 1987.
 
57) Greewald DW, Phillips C, Bennett JM: Management of malignant pleural effusion. J. Surg. Oncol. 10: 361-368, 1978.
 
58) Rubinson RM, Bolooki H: Intrapleural tetracycline for control of malignant pleural effusion: apreliminary report. South. Med. J. 65: 847-849, 1972.
 
59) Wallach HW: Intrapleural tetracycline for control of malignant pleural effusions. Chest 68: 510-512, 1975.
 
60) Antony VB, Rothfuss KJ, Godbey SW, et al: Mechanism of tetracycline hydrochloride-induced plerodesis. Am. Rev. Respir. Dis. 146: 1009-1013, 1992.
 
61) Dryzer SR, Joseph J, Baumann M, et al: Early inflammatory response of minocycline and tetracycline on the rabbit pleura. Chest 104: 1585-1588, 1993.
PubMed
62) Light RW, Wang NS, Sassoon CSH, et al: Comparison of the effectiveness of tetracycline and minocycline as pleural sclerosing agents in rabbits. Chest 106: 577-582, 1994.
 
63) Rodriguez-Panadero F, Antony VB: Pleurodesis: state of the art. Eur. Respir. J. 10: 1648-1654, 1997.
PubMed
64) Milanez RC, Vargas FS, Filomeno LB, et al: Intrapleural talc for the treatment of malignant pleural effusions secondary to breast cancer. Cancer 75: 2688-2692, 1995.
PubMed
65) Kennedy L, Sahn SA: Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest lO6: 1215-1222, 1994.
 
66) Kennedy L, Harley RA, Sahn SA, et al: Talc slurry pleurodesis: pleural fluid and histologic analysis. Chest 107: 1707-1712, 1995.
PubMed
67) Light RW, Wang NS, Sassoon CSH, et al: Talc slurry is an effective pleural sclerosant in rabbits. Chest 107: 1702-1706, 1995.
 
68) LoCicero J III: Thoracoscopic management of malignant pleural effusion. Ann. Thorac. Surg. 56: 641-643, 1993.
 
69) Hickman JA, Jones MC: Treatment of neoplastic pleural effusions with local instillation of quinacrine(metacrine) hydrochloride. Thorax 25: 226-229, 1970.
 
70) Borja ER, Pugh RP: Single dose quinacrine(atabrine) and thoracostomy in the control of pleural effusion in patients with neoplastic diseases. Cancer 31: 899-902, 1973.
PubMed
71) Taylor SA, Hooton NS, MacArthur AM: Quinacrine in the management of malignant pleural effusion. Br. J. Surg. 64: 52-53, 1977.
PubMed
72) Bjorkman S, Elisson LO, Gabrielson J: Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man. J. Pharm. Pharmacol. 41: 160-163, 1989.
 
73) Paladine W, Cunningham TJ, Sponzo R, et al: Intracavitary bleomycin in the management of malignant effusions. Cancer 38: 1903-1908, 1976.
PubMed
74) Albert DS, Chen HS, Mayersohn M, et al: Bleomycin pharmacokinetics in man. Cancer Chemother. Pharmacol. 2: 127-132, 1979.
 
75) Ostrowski MJ: An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin. Cancer 57: 721-727, 1986.
 
76) Bleomycin sulfate. In: AHFS Drug Information 92 (ed by McEvoy GK) . American Society of Hospital Pharmacists, Bethesda, Maryland, 1992, pp. 488-490.
 
77) 山口恵理子, 永井厚志, 坂本匡一・他: ブレオマイシンの胸腔内投与における胸膜の形態変化. 癌と化学療法 18: 971- 975, 1991.
 
78) Sitton DW(ed) : Drug Topics Red Book 1992. Montvale, N 'ew Jersey, Medical Economics Data;1992.
 
79) Walker-Renard PB, Vaughan LM, Sahn SA: Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med. 120: 56-64, 1994.
PubMed
80) Kefford RF, Woods RL, Fox RM, et al: Intracavitary adriamycin, nitrogen mustard and tetracycline in the control of malignant effusions: arandomized study. Med. J. Aust. 2: 447-448, 1980.
 
81) 植田保子, 広田正毅, 朝長昭光・他: Adriamycinを用いた癌性胸膜炎の治療. 癌の臨床 28: 789-793, 1982.
 
82) Masuno T, Kishimoto S, Ogura T, et al: A comparative trial of LC 9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secorldary to lung cancer. Cancer 68: 1495-1500, 1991.
PubMed
83) Luh KT, Yang PC, Kuo SH, et al: Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer: A randomized trial. Cancer 69: 674-679, 1992.
PubMed
84) Markman M, Cleary S, King M, et al: Cisplatin and cytarabine administrated intrapleurally as treatment of malignant pleural effusions. Med. Pediatr. Oncol. 13: 191-193, 1985.
 
85) Rusch VW, Figlin R, Godwin D, et al: Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A Lung Cancer Study Group Trial J. Clin. Oncol. 9: 313-319, 1991.
 
86) Antini E, Cavazzini G, Pasquini E, et al: Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. Acta Oncol. 33: 191-194, 1994.
PubMed
87) Holoye PY, Jeffries DG, Dhingra HM, et al: Intrapleural etoposide for malignant effusion. Cancer Chemother. Pharmacol. 26: 147-150, 1990.
PubMed
88) Markman M: Intracavitary chemotherapy. Curr. Probl. Cancer 10: 402-437, 1986.
 
89) Ostrowsky MJ, Priestman TJ, Houstman RF, et al: A randomized trial of intracavitary bleomycin and Co rynebacte rium parvum in the control of malignant pleural effusions. Radiother. Oncol. 14: 19-26, 1989.
 
90) 長尾啓一, 滝沢弘隆, 椙田 隆・他: OK-432による癌性胸膜炎の治療. チューブドレナージ法について. 癌と化学療法 6: 1161-1166, 1979.
Medical*Online
91) 長尾啓一: 癌性胸膜炎の治療に関する研究. 千葉医誌 58: 345-353, 1982.
 
92) 浦田淳夫, 西村 穣, 太田和雄: OK-432による癌性胸膜炎の治療. 癌と化学療法 13: 1497-1503, 1983.
 
93) 長尾啓一: 癌性胸膜炎に対するOK-432胸腔内投与. Ther. Res. 10: 3857-3864, 1989.
Medical*Online
94) Rosso R, Rimoldi R, Salvati F, et al: Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 45: 253-256, 1988.
PubMed
95) Sone S, Ogura T: Local interleukin-2 therapy for cancer, and its effector induction mechanisms. Oncology 51: 170-176, 1994.
PubMed
96) Monti G, Jaurand MC, Monnet I, et al: Intrapleural production of interleukin 6 during mesothelioma and its modulation by γ-interferon treatment. Cancer Res. 54: 4419-4423, 1994.
 
97) Tsang V, Fernando HC, Goldstraw P: Pleuroperitoneal shunt for recurrent malignant effusions. Thorax 45: 369-372, 1990.
PubMed
98) Kodama K, Doi O, Higashiyama M, et al: Long-term results of postoperative intrathoracic thermochemotherapy for lung cancer with pleural dissemination. Cancer 72: 426-431, 1993.
 
99) Matsuzaki Y, Shibata K, Yoshioka M, et al: Intrapleural perfusion hyperthermo-chemotherapy for management pleural dissemination and effusion. Ann. Thorac. Surg. 59: 127-131, 1995.
 
100) Ichinose Y, Hara N, Ota K, et al: Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer. J. Thorac. Cardiovasc. Surg. 105: 1041-1046, 1993.
 
101) 一瀬幸人, 原 信之, 矢野篤次郎・他: 開胸により発見された癌性胸膜炎および胸腔内再発リスク症例に対する術中胸腔内hypotonic cisplatin treatment. 肺癌 33: 233-238, 1993.
 
102) 厚生省がん研究助成金指定研究「固形がんの集学的治療の研究」班編: 非小細胞肺癌による癌性胸膜炎に対する「ブレオマイシン局所癒着療法」と「OK-432局所癒着療法」と「シスプラチン, エトポシド併用局所化学療法」との Randomized Phase II試験. JCOG集学的治療プロトコール集(第10集) , 1997, pp. 1-38.
 
P.1629 掲載の参考文献
1) McAllister HA, Fenoglio JJ: Tumors of the cardiovascular system-Tumors of the heart and pericardium. In: Atlas of tumor pathology (ed. by Hartmann WH) , Armed Forces Institute of Pathology, Washington, 1978, pp. 111-119.
 
2) Mukai K, Shinkai T, Tominaga K, et al: Incidence of secondary tumors of the heart and pericardium: a l0-year experience of one institution. JPn. J. Clin. Oncol. 18: 195-201, 1988.
 
3) Fincher R-M E: Case report: malignant pericardial effusion as the initial manifestation of malignancy. Am. J. Med. Sci. 305: 106-110, 1993.
 
4) Thurber DL, Edwards JE, Achor RWP: Secondary malignant tumors of the pericardium. Circulation 26: 228-241, 1962.
 
5) Press OW, Livingston R: Management of malignant pericardial effusion and tamponade. JAMA 257: 1088-1092, 1987.
PubMed
6) Vaikus PT, Herrmann HC, LeWinter MM: Treatment of malignant pericardial effusion. JAMA 272: 59-64, 1994.
 
7) Liu G, Crump M, Goss PE, et al: Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J. Clin, Oncol. 14: 3141-3147, 1996.
PubMed
8) Millaire A, Wurtz A, de Groote P, et al: Malignant pericardial effusions: usefulness of pericardioscopy. Am. Heart J. 124: 1030-1034, 1992.
PubMed
9) Smith FE, Lane M, Hudgins PT: Conservative management of malignant pericardial effusion. Cancer 33: 47-57, 1974.
PubMed
10) Krikorian JG, Hancock EW: Pericardiocentesis. Am. J. Med. 65: 808-814, 1978.
PubMed
11) Terry LN, Kligerman MM: Pericardial and myocardial involvement by lymphomas and leukemias: the role of radiotherapy. Cancer 25: 1003-1008, 1970.
PubMed
12) Davis S, Sharma SM, Blumberg ED, et al: Intrapericardial tetracycline for the management of cardiac tamponade secondary to malignant pericardial effusion. N. Engl. J. Med. 299: 1113-1114, 1978.
PubMed
13) Davis S, Ramboti P, Grignani F: Intrapericardial tetracyclin sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three cases. J. Clin. Oncol. 2: 631-636, 1984.
 
14) Shepherd FA, Morgan C, Evans WK, et al: Medical management of malignant pericardial effusion by tetracycline sclerosis. Am. J. Cardiol. 60: 1161-1166, 1987.
PubMed
15) Imamura T, Tamura K, Takenaga M, et al: Intrapericardial OK-432 instilation for the management of malignant pericardial effusion. Cancer 68: 259-263, 1991.
 
16) 新海 哲: 胸水, 心嚢水. 最新内科学体系. 第80巻臨床腫瘍学(関連領域疾患4) (井村裕夫, 尾形悦朗, 高久史麿, 垂井清一郎編, 阿部 薫専門編) . 中山書店, 東京, 1995, pp. 368-373.
 
17) Hankin Jp, Satterfield JR, Aisner J, et al: Pericardial window for malignant pericardial effusion. Ann. Thorac. Surg. 30: 465-471, 1980.
 
18) Shinkai T, Tominaga K, Saijo N, et al: The incidence of cardiac metastasis in primary lung cancer and the management of malignant pericardial effusion. JPn. J. Clin. Oncol. 12: 23-32, 1982.
 
19) Reitknecht F, Regal A-M, Antkowiak JG, et al: Management of cardiac tamponade in patients with malig-nancy. J. Surg. Oncol. 30119-22, 1985.
 
20) Okamoto H, Shinkai T, Yamakido M, et al: Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion. Cancer 71: 93-98, 1993.
PubMed
21) Hill GJ, Cohen BI: Pleural pericardial window for palliation of cardiac tamponade due to cancer. Cancer 26: 81-93, 1970.
PubMed
22) Palacios IF, Tuzcu EM, Ziskind AA, et al: Percutaneous balloon pericardial window for patients with malignant pericardial effusion and tamponade. Catheter Cardiovasc. Diagn. 22: 244-249, 1991.
PubMed
23) Jackson G, Keane D, Mishra B: Percutaneous balloon pericardiotomy in the management of recurrent malignant pericardial effusions. Br. Heart J. 68: 613-615, 1992.
PubMed
24) Ziskind AA, Pearce AC, Lemmon CC, et al: Percutaneous balloon pericardiotomy for the treatment of cardiac tamponade and large pericardial effusions: description of technique and report of the first 50 cases. J. Am. Coll. Cardiol. 21: 1-5, 1993.
 
25) Liu H-P, Chang C-H, Lin PJ, et al: Thoracoscopic management of effusive pericardial disease: indications and technique. Ann. Thorac. Surg. 58: 1695-1697, 1994.
PubMed
26) Wang N, Feikes JR, Mogensen T, et al: Pericardioperitoneal shunt: an alternative treatment for malignant pericardial effusion. Ann. Thorac. Surg. 57: 289-292, 1994.
PubMed
P.1634 掲載の参考文献
1) 近田千尋: 癌の細胞診と癌治療"胸腹水", 癌と化学療法 9: 1716-1720, 1982.
 
2) Lacy JH, Wieman TJ, Shively EH: Management of Malignant Ascites. Surg. Gynecol. Obstet. 159: 397-412, 1984.
PubMed
3) 曽和融生, 加藤保之: 癌性腹膜炎に対する対症療法の実際2) 腹水の対策. 消化器外科 14: 1503-1507, 1991.
 
4) 山本政勝: 癌性腹膜炎. 消化器病学(亀田治男, 武藤輝一編) 第2版, 朝倉書店, 東京, 1981, pp. 655-663.
 
5) 佐々木大輔, 大川正臣, 坂田 優・他: 肝癌, 転移性肝癌および肝硬変の腹水に対するSoldactone (Potassium car-renoate) の使用経験. 新薬と臨床 31: 27-35, 1981.
 
6) 横山正和: 腹膜癌. 化学療法の領域 2: 1757-1766, 1986.
 
7) 小貫 誠, 波多野剛之, 児玉秀文・他: 肝硬変難治腹水症および癌性腹膜炎における濃縮腹水還流装置での治療. 現代医療 11: 1379-1384, 1979.
 
8) 小山善之, 斉藤達雄: 固形がん化学療法の臨床効果判定基準. 日癌治療会誌 21: 929-942, 1986.
 
9) 萩原明於, 高橋俊雄, 李 方行・他: 活性炭吸着マイトマイシンC(MMC-CH) による癌性胸腹膜炎の治療-臨床応用の結果について-. 日癌治療会誌 20: 2144-2153, 1985.
 
10) 清水敬生: 卵巣癌の治療-腹腔内化学療法. KARKINOS 7: 1027-1033, 1994.
 
11) Fukawa T, Kumai K, Kubota T, et al.: Experimental and Clinical Studies on the Peritoneal Administration of Cis-diamminedichloroplatinum(II) for Peritoneal Carcinomatosis Caused by Gastric Cancer. JPn. J. Surg. 23: 298-306, 1993.
 
12) Schilsky R, Choi KE, Grayhack J, et al.: Phase I Clinical and Pharmacological Study of Intraperitoneal Cisplatin and Fluorouracil in Patients with Advanced Intraabdominal Cancer. J. Clin. Oncol. 8: 2054-2061, 1990.
 
13) 小倉 剛, 曽根三郎, 仁井昌彦・他: 転移癌に対する治療戦略-癌性胸, 腹膜炎に対する治療. Oncologia 20(5) : 48- 56, 1987.
 
14) 坂田正毅, 鳥巣要道: 癌性腹膜炎の免疫療法. 消化器外科 6: 1195-1203, 1983.
 
15) 涌井 昭, 斉藤達雄, 中尾 功・他: 消化器癌の癌性腹水に対するRecombinant Interferon-β (GKT-β) の腹腔内投与の効果. BIOTHERAPY 2: 339-347, 1988.
 
16) 漆崎一朗, 新津洋司郎, 高後 裕: 抗腫瘍性サイトカイン. Oncologia 20: 105-121, 1987.
 
17) Gilly FN, Carry PY, Sayag AC, et al.: Regional Chemotherapy (with MitomycinC) and IntraoperativeHyperthermia for Digestive Cancers with Peritoneal Carcinomatosis. Hepatogastroenterology 41: 124-129, 1994.
 
18) 沖永功太, 安達実樹, 並木一信: 癌性腹膜炎に対する対症療法の実際-イレウスの対策. 消化器外科 14: 1497-1501, 1991.
 
19) Link KH, Hepp G, Staib L, et al.: Intraperitoneal regional chemotherapy with mitoxantrone. Cancer Treat. Res. 81: 31-40, 1996.
PubMed
20) Loggie BW, Perini M, Fleming RA. et al.: Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am. Surg. 63: 2, 137-143, 1997.
PubMed
21) Yamaguchi Y, Satoh Y, Miyahara E, et al.: Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res. 15: 5B, 2201-2206, 1995.
PubMed
P.1643 掲載の参考文献
1) Viadana E, Erros IDJ, Pickren WJ: Cascade spread of blood-born metastases in solid and nonsolid cancers of humans. Pulmonary metastasis (ed. by Weiss L, Gilbert HA) , Martinus Nijhoff Medical Division, Hague-Boston, London, 1978, pp. 142-167.
 
2) 末舛恵一, 米山武志, 成毛詔夫・他: がん転移の基礎と臨床. 癌と化学療法 14: 561-566, 1987.
 
3) Paget S: The distribution of secondary growth in cancer of the breast. Lancet 1: 571-573, 1889.
 
4) 森 亘, 足立山夫, 岡辺治男・他: 悪性腫瘍剖検例755例の解析-その転移に関する統計的研究-. 癌の臨床 9: 351-374, 1963.
 
5) Gemma A, Noguchi M, Hirohashi S, et al: Clinicopathologic and immunohistochemical characteristics of goblet cell type adenocarcinoma of the lung. Acta Pathol. Jpn. 41: 737-743, 1991.
PubMed
6) Lore JM, Madden JL, Gerold FP: Pre-existing porta caval shunts. Cancer 11: 24-27, 1958.
 
7) Heitmiller RF, Marasco WJ, Hruban RH, et al: Endobronchial metastasis. J. Thorac. Cardiovasc. Surg. 106: 537-542, 1993.
PubMed
8) Carlin BW, Harrell JH, Olson LK, et al: Endobronchial metastasis due to colorectal carcinoma. Chest 96: 1110-1114, 1989.
 
9) Lote K, Dahl O, Vigander T: Pneumothorax during combination chemotherapy. Cancer 47: 1743-1745, 1981.
PubMed
10) Crow J, Slavin G, Kreel L: Pulmonary metastasis: Apathologic and radiologic study. Cancer 47: 2595-2602, 1981.
PubMed
11) Kaneko M, Eguchi K, Ohmatsu H, et al: Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 201: 798-802, 1996.
PubMed
12) Peuchot M, Libshitz HI: Pulmonary metastatic disease: radiographic-surgical correlation. Radiology 164: 719-722, 1987.
 
13) Cahan WG, Castro EB, Hajdu SI: The significance of a solitary lung shadow in patients with colon carcinoma. Cancer 33: 414-421, 1974.
PubMed
14) Goya T, Miyazawa N, Kondo H, et al: Surgical resection of pulmonary metastases from colorectal cancer: 10-year follow-up. Cancer 64: 1418-1421, 1989.
PubMed
15) Okumura S, Kondo H, Tsuboi M, et al: Pulmonary resection for metastatic colorectal cancer: Experiences with 159 patients. J. Thorac. Cardiovasc. Surg. 112: 867-874, 1996.
PubMed
16) Einhorn LH, Williams SD, Donohue JO, et al: Cancer of the testis. Cancer; Principles & Practices of Oncology (ed. by Devita VT, et al) , (2 nd. ed.) , J. B. Lippincott, Philadelphia, 1985, pp. 979-1011.
 
17) Shimosato Y, Baba K, Oboshi S, et al: Pathological studies on pulmonary cancer treated with bronchial artery infusion of mitomycin C. Jpn. J. Cancer Clin. 14: 945-957, 1968.
 
18) Thomford NR, Woolner LB, Clagett OT, et al: The surgical treatment of metastatic tumors in the lungs. J. Thorac. Cardiovasc. Surg. 49: 357-363, 1965.
PubMed
19) 近藤晴彦: 転移性肺癌の外科治療. 日臨外医会誌 58: 495-501, 1997.
 
20) McCormack PM, Burt ME, Bains MS, et al: Lung resection for colorectal metastases. Arch. Surg. 127: 1403-1406, 1992.
PubMed
21) McAfee MK, Allen MS, Trastek VF, et al: Colorectal lung metastases: Results of surgical excision. Ann. Thorac. Surg. 53: 780-786, 1992.
PubMed
22) Anyanwu E, Krysa S, Buelzebruck, et al: Pulmonary metastatectomy as secondary treatment for testicular tumors. Ann. Thorac. Surg. 57: 1222-1228, 1994.
 
23) Goorin AM, Shuster JJ, Baker A, et al: Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: Results from the multiinstitutional osteosarcoma group. J. Clin. Oncol. 9: 600-605, 1991.
 
24) Skinner KA, Eilber FR, Holmes EC, et al: Surgical treatment and chemotherapy for pulmonary metastases from osteosarcoma. Arch. Surg. 127: 1065-1072, 1992.
PubMed
25) van Geel AN, Pastorino U, Jauch KW, et al: Surgical treatment of lung metastases. The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Study of 255 Patients. Cancer 77: 675-682, 1996.
 
26) Lanza LA, Natarajan G, Roth JA, et al: Long term survival after resection of pulmonary metastases from carcinoma of the breast. Ann. Thorac. Surg. 54: 244-248, 1992.
PubMed
27) McDonald TH, Deschamps C, Ilstrup DM, et al: Pulmonary resection for metastatic breast cancer. Ann. Thorac. Surg. 58: 1599-1602, 1994.
 
28) Cerfolio RJ, Allen MS, Deschamps C, et al: Pulmonary resection of metastatic renal cell carcinoma. Ann. Thorac. Surg. 57: 339-344, 1994.
PubMed
29) Sercarz J, Ellison D, Holmes EC, et al: Isolated pulmonary nodules in head and neck cancer patients. Ann, Otol. Rhinol. Laryngol. 98: 1138, 1989.
 
30) Tafra L, Dale PS, Wanek LA, et al: Resection and immunotherapy for melanoma metastatic to the lung and thorax. J. Thorac. Cardiovasc. Surg. 110: 119-129, 1995.
 
31) Aberg T, Malmberg KA, Nilsson B, et al: The effect of metastatectomy: Fact or fiction? Ann. Thorac. Surg. 30: 378-384, 1980.
PubMed
32) 原 勲, 郷司和男, 荒川創一・他: 腎癌とサイトカイン. Biotherapy 11: 893-899, 1997.
Medical*Online
33) Garbe C: Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res. 3: 291-299, 1993.
PubMed
P.1653 掲載の参考文献
1) Healey JE Jr, Schroy PC: Anatomy of the biliary ducts within the human liver. Analysis of the prevailing pattern of branching and the major variations of the biliary ducts. Arch. Surg. 66: 599-616, 1953.
 
2) Couinaud C, Le Foie: Etudes Antomiques et Chirurgicales. Masson, Paris, 1957.
 
3) Makuuchi M, Hasegawa H, Yamasaki S: Ultrasonically guided subsegmentectomy. Surg. Gynecol. Obstet. 161: 346, 1985.
 
4) Pickren JW, Tsukada Y, Lane WW: Analysis and autopsy data. In: Liver metastasis (eds. by Weiss L, Gilbert HA) . Hall Medical Publishers, Boston, 1982.
 
5) 森岡恭彦, 長尾 桓: 転移性肝腫瘍. 最新内科学大系第50巻, 中山書店, 東京, 1991, pp. 251-274.
 
6) 草野満夫・他: 転移性肝癌の治療. 日消外会誌 57: 1595, 1987.
 
7) Desai AG, Park CH, Schilling JF et al: Streaming in portal vein: Its effect on the spread of metastases to the liver. Clin. Nucl. Med. 10: 556, 1985.
 
8) Weiss L, Grundmann E, Hartveit F, et al: Hematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol. 150: 195-203, 1986.
 
9) Foster JH: Survival after liver resection for cancer. Cancer 26: 493-502, 1970.
PubMed
10) Brasfield RD, Bowden L, McPeak CJ: Major hepatic resection for malignant neoplasms of the liver. Ann. Surg. 176: 171-177, 1972.
PubMed
11) Wilson SM, Adson MA: Surgical treatment of hepatic metastases from colorectal cancers. Arch. Surg. 111: 330, 1976.
PubMed
12) Hanks JB, Meyers WC, Filston HC, et al: Surgical resection for benign and malignant liver disease. Ann. Surg. 191: 584-592, 1980.
PubMed
13) Pestana C, Reitemeier RJ, Moertel CG, et al: The natural history of carcinoma of the colon and rectum. Am. J. Surg. 108: 826-829, 1964.
PubMed
14) Jaffe BM, Donegan W, Watson F, et al: Factors influencing survival in patients with untreated hepatic metastases. Surg. Gynecol. Obstet. 127: 1-11, 1968.
PubMed
15) Bengmark S, Hafstrom L: The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 23: 198-202, 1969.
PubMed
16) Nielsen J, Balslev I, Jensen H: Carcinoma of the colon with liver metastases. Operative indications and prognosis. Acta Chir. Scand. 137: 463-465, 1971.
PubMed
17) Wood CB, Gillis CR, Blumgart LH: A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin. Oncol. 2: 285-288, 1976.
PubMed
18) Bengtsson G, Carlsson G, Hafstrom L, et al: Natural history of patients with untreated liver metastases. Am. J. Surg. 141: 586-589, 1981.
PubMed
19) Goslin R, Steele G, Zamcheck N, et al: Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colorl or rectum. Dis. Colon Rectum 25: 749-754, 1982.
PubMed
20) Wagner JS, Adson MA, Van Heerden J, et al: The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann. Surg. 199: 502-508, 1984.
PubMed
21) Finan PJ, Marshall RJ, Cooper EH, et al: Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br. J. Surg. 72: 373-377, 1985.
PubMed
22) Steele G, Bledy R, Mayer RJ, et al: A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J. Clin. Oncol. 9: 1105-1112, 1991.
 
23) Scheele J, Stangl R, Altendorf-Hoffmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br. J. Surg. 77: 1241, 1990.
 
24) Benhamou G, Marmuse Jp, Johanet H, et al: Should liver metastasis from colorectal cancers be treated surgically? Lancet 335: 482-483, 1990.
PubMed
25) Aberg T, Malmber KA, Nilsson B, et al: The effect of metastasectomy: fact or fiction? Ann. Thorac. Surg. 30: 378-384, 1980.
PubMed
26) Adson MA: The resection of hepatic metastases. another view. Arch. Surg. 124: 1023-1024. 1989.
PubMed
27) Silen W: Hepatic resection for metastases from colorectal carcinoma is of dubious value. Arch. Surg. 124: 1021-1022, 1989.
PubMed
28) Thomford NR, Woolner LB, Clagett OT: The surgical treatment of metastatic tumors in the lungs. J. Thorac. Cardiovasc. Surg. 49: 357-363, 1965.
PubMed
29) Hughes K, Scheele J, Sugarbaker PH: Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg. Clin. North Am. 69: 339-359, 1989.
 
30) Scheele J, Stangl R, Altendorf-Hoffmann A, et al: Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110113-29, 1991.
 
31) Bismuth H, Adam R, Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224: 509-522, 1996.
PubMed
32) Brunschwig A: Hepatic lobectomy for metastatic cancer. Cancer 16: 277-282, 1963.
PubMed
33) Woodington GF, Waugh JM: Results of resection of metastatic tumors of the liver. Am. J. Surg. 105: 24-29, 1963.
PubMed
34) Flanagan L, Foster JH: Hepatic resection for metastatic cancer. Am. J. Surg. 113: 551-557, 1967.
PubMed
35) Attiyeh FF, Wanebo HJ, Stearns MW: Hepatic resection for metastasis from colorectal cancer. Dis. Colon Rectum 21: 160-162, 1978.
PubMed
36) Wanebo HJ, Semoglou C, Attiyeh F, et al: Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am. J. Surg. 135: 81-85, 1978.
PubMed
37) Adson MA, Van Heerden JA: Major hepatic resection for metastatic colorectal cancer. Ann. Surg. 191: 576-583, 1980.
PubMed
38) Foster JH: Survival after liver resection for secondary tumors. Am. J. Surg. 135: 389-394, 1978.
PubMed
39) Morrow CE, Grage TB, Sutherland DER, et al: Hepatic resection for secondary neoplasms. Surgery 92: 610-614, 1982.
 
40) Rajpal S, Dasmahapatra KS, Ledesma E, et al: Extensive resections of isolated metastases from carcinoma of the colon and rectum. Surg. Gynecol. Obstet. 155: 813-816, 1982.
 
41) Logan SE, Meier SJ, Ramming KP, et al: Hepatic resection of metastatic colorectal carcinoma. A ten-year experience. Arch. Surg. 117: 25-28, 1982.
 
42) Thoma-de la Vega JE, Donahue EJ, Doolas A, et al: A ten year experience with hepatic resection. Surg. Gynecol. Obstet. 159: 223-228, 1984.
 
43) Nims TA: Resection of the liver for metastatic cancer. Surg. Gynecol. Obstet. 158: 46-48, 1984.
PubMed
44) Fortner JG, Silva JS, Golbey RB, et al: Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann. Surg. 199: 306-315, 1984.
PubMed
45) Kortz WJ, Meyers WC, Hanks JB, et al: Hepatic resection for metastatic cancer. Ann. Surg. 199: 182-186, 1984.
PubMed
46) Adson MA, Van Heerden JA, Adson MH, et al: Resection of hepatic metastases from colorectal cancer. Arch. Surg. 119: 647-651, 1984.
PubMed
47) August DA, Sugarbaker PH, Ottow RT, et al: Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann. Surg. 201: 210-218, 1985.
PubMed
48) Cady B, McDermott WV: Major hepatic resection for metachronous metastases from colon cancer. Ann. Surg. 201: 204-209, 1985.
PubMed
49) Petrelli NJ, Nambisan RN, Herrera L, et al: Hepatic resection for isolated metastasis from colorectal carcinoma. Am. J. Surg. 149: 205-209, 1985.
PubMed
50) Bozzetti F, Bignami P, Morabito A, et al: Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for multimodal approach. Ann. Surg. 205: 264-270, 1986.
 
51) Gennari L, Doci R, Bozzetti F, et al: Surgical treatment of hepatic metastases from colorectal cancer. Ann. Surg. 203: 49-54, 1986.
PubMed
52) Butler J, Attiyeh FF, Daly JM: Hepatic resection for metastases of the colon and rectum. Surg. Gynecol. Obstet. 162: 109-113, 1986.
PubMed
53) Iwatsuki S, Esquivel CO, Gordon RD, et al: Liver resection for. metastatic colorectal cancer. Surgery 100: 804-809, 1986.
PubMed
54) Ekberg H, Tranberg KG, Andersson R, et al: Determinants of survival in liver resection for colorectal secondaries. Br. J. Surg. 73: 727-731, 1986.
PubMed
55) Bradpiece HA, Benjamin IS, Halevy A, et al: Major hepatic resection for colorectal liver metastases. Br. J. Surg. 74: 324-326, 1987.
PubMed
56) Cobourn CS, Makowka L, Langer B, et al : Examination of patient selection and outcome for hepatic resection for metastatic disease. Surg. Gynecol. Obstet. 165: 239-246, 1987.
PubMed
57) Nordlinger B, Parc R, Delva E, et al: Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrence in 80 patients. Ann. Surg. 205: 256-263, 1987.
PubMed
58) Sesto ME, Vogt DP, Hermann RE: Hepatic resection in 128 patients: a 24-year experience. Surgery 102: 846-851, 1987.
PubMed
59) Attiyeh FF, Wichern WA: Hepatic resection for primary and metastatic tumors. Am. J. Surg. 156: 368-373, 1988.
PubMed
60) Registry of hepatic metastases. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indication for resection. Surgery 103: 278-288, 1988.
 
61) Holm A, Bradley E, Aldrete JS: Hepatic resection of metastasis from colorectal carcinoma. Morbidity, mortality and pattern of recurrence. Ann. Surg. 209: 428-434, 1989.
PubMed
62) Schlag P, Hohenberger P, Herfarth Ch: Resection of liver metastases in colorectal cancer-competitive analysis of treatment results in synchronous versus metachronous metastases. Eur. J. Surg. Oncol. 16: 360-365, 1990.
 
63) Doci R, Gennari L, Bignami P, et al: One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br. J. Surg. 78: 797-801, 1991.
PubMed
64) Rosen CB, Nagorney DM, Taswell HF, et al: Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann. Surg. 216: 493-505, 1992.
PubMed
65) Nakamura S, Yokoi Y, Suzuki S, et al: Results of extensive surgery for liver metastases in colorectal carcinoma. Br. J. Surg. 79135-38, 1992.
 
66) Sugihara K, Hojo K, Moriya Y, et al: Pattern of recurrence after hepatic resection for colorectal metastases. Br. J. Surg. 80: 1032-1035, 1993.
PubMed
67) Gayowski TJ, Iwatsuki S, Madariage JR, et al: Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116: 703-711, 1994.
 
68) Jatzko GR, Losborg PH, Stettner HM, et al: Hepatic resection for metastases from colorectal carcinoma-a survival analysis. Eur. J. Cancer 31 A: 41-46, 1995.
 
69) Jamison RL, Donohue JH, Nagorney DM, et al: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch. Surg. 132: 505-511, 1997.
PubMed
70) Shirabe K, Takenaka K, Gion T, et al: Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin. Br. J. Surg. 84: 1077-1080, 1997.
 
71) Rees M, Plant G, Bygrave S: Late results justify resection for multiple hepatic metastases from colorectal cancer. Br. J. Surg. 84: 1136-1140, 1997,
PubMed
72) Wolf RF, Goodnight JE, Krag DE, et al: Results of resection and proposed guidelines for patient selection in instances of non-colorectal hepatic metastases. Surg. Gynecol. Obstet. 173: 454-60, 1991.
PubMed
73) Yamamoto J, Sugihara K, Kosuge T, et al: Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann. Surg. 221: 4-78, 1995.
 
74) Makuuchi M, et al: Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma. A preliminary report. Surgery 107: 521-527, 1990.
PubMed
75) Kawasaki S, Makuuchi M, Kakazu T, et al: Resection for multiple metastatic liver tumors aftcr portal embolization. 151674, 1994.
 
76) Hughes KS, Simon R, Songhorabodi S, et al: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100: 278-284, 1986.
PubMed
77) Ochiai T, Sasako M, Mizuno S, et al: Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br. J. Surg. 81: 1175-1178, 1994.
PubMed
78) Lange JF, Leese T, Castaing D, et al: Repeat hepatectomy for recurrent malignant tumors of the liver. Surg. Gynecol. Obstet. 169: 119-126, 1989.
PubMed
79) Stone MD, Cady B, Jenkins RL, et al: Surgical therapy for recurrent liver metastases from colorectal cancer. Arch. Surg. 125: 718-722, 1990.
PubMed
80) Huguet C, Bona S, Nordlinger B, et al: Repeat hepatic resection for primary and metastatic carcinoma of the liver. Surg. Gynecol. Obstet. 171: 398-402, 1990.
PubMed
81) Bozzetti F, Bignami P, Montalto F, et al: Repeated hepatic resection for recurrent metastases from colorectal cancer. Br. J. Surg, 79: 146-148, 1992.
PubMed
82) Vaillant JC, Balladur P, Nordlinger B, et al: Repeat liver resection for recurrent colorectal metastases. Br. J. Surg. 80: 340-344, 1993.
PubMed
83) Guillat C, Ducerf C, Partensky C, et al: Repeated hepatic resections for colorectal metastases. Eur. J. Surg. Oncol. 19: 443-447, 1993.
 
84) Elias D, Lasser Ph, Hoang JM, et al: Repeat hepatectomy for cancer. Br. J. Surg. 80: 1557-1562, 1993.
 
85) Nordlinger B, Vaillant JC, Fuiguet M, et al: Survival benefit of repeat liver resections for recurrent colorectal metastases. 143 cases: Association Francaise de Chirurgie. J. Clin. Oncol. 12: 1491-1496, 1994.
 
86) Fong Y, Blumgart LH, Cohen A, et al: Repeat hepatic resections for metastatic colorectal cancer. Ann. Surg. 220: 657-662, 1994.
PubMed
87) Fernandez-Trigo V, Shamsa F, Sugarbaker PH: Repeat Hepatic Metastasis Registry. Repeat liver resections from colorectal metastasis. Surgery 117: 296-304, 1995.
PubMed
88) Quyen DC, Vezeridis MP, Avradopulos KA, et al: Repeat hepatic resection for recurrent colorectal cancer. World J. Surg. 21: 292-296, 1997.
 
89) Adam R, Bismuth H, Castaing D, et al: Repeat hepatectomy for colorectal liver metastases. Ann. Surg. Surg. 225: 51-62, 1997.
PubMed
90) Craig JR, Peters RL, Edmondson HA: Metastatic tumors. In: Tumors of the liver and intrahepatic bile ducts. Armed Forces Institute of Pathology, Washington D. C. 1989, p. 256.
 
91) 高安賢一: 転移性肝癌. 肝臓の画像診断-細小肝癌の発見から治療まで(高安賢一著) . 文光堂, 東京, 1991, p. 262.
 
P.1665 掲載の参考文献
1) 日本整形外科学会骨軟部腫瘍委員会: 全国骨腫瘍患者登録一覧表(平成7年度) . 国立がんセンタ-, 1995.
 
2) Harrington KD: Orthopaedic Management of Metastatic Bone Disease. The CV Mosby, St. Louis, Washington, DC, Toronto, 1988.
 
3) 福間久俊, 館崎新一郎: 骨腫瘍の鑑別診断. 整形外科診断学(辻 陽雄, 高橋栄明編) , 第2版, 金原出版, 東京, 1988, pp. 631-650.
 
4) 明神美弥子: 転移性脊椎腫瘍の放射線治療におけるMRI診断の意義. 厚生省がん研究助成金による研究報告集(平成7年度) , 7-18尾形悦郎班. 1995, pp. 339-342.
 
5) 0 Shimizu K, Shikata T, Iida T, et al: Posterior decompression and stabilization for multiple metastatic tumors of spine. Spine 17: 1400-1404, 1992.
 
6) 志水克時: 転移性腫瘍. 整形外科手術(1) (富田勝郎編) , 第1版, 中山書店, 東京, 1995, pp. 178-182.
 
7) Sonoo H, Shimozuma K, Kurebayashi J, et al: Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis. Gan To Kagaku Ryoho 22(suppl. 1) : 10-15, 1995.
 
8) Shiba E, Kobayashi T, Takeda T, et al: Acase of advanced breast cancer with multiple organ metastases successfully treated by tamoxifen. Gan To Kagaku Ryoho 19(13) : 2255-2258, 1992.
 
9) Nishioka A, Ogawa Y, Hamada N, et al: A case report of bone metastasis diagnosed by MRI and effectively treated with UFT after breast concerving therapy for breast cancer. Gan To Kagaku Ryoho 19(13) : 2251-2254, 1992.
 
10) Kubota Y, Nakada T, Imai K, et al: Chemo-endocrine therapy in patients with stage D-2 prostate cancer. Prostate 26 (1) : 50-54, 1995.
 
11) Sasaki H, Minami Y, Kanetake H, et al: Chemo-endocrine therapy for prostate cancer with bone metastasis. Cancer Chemother. Pharmacol. 35(suppl.) : S23-26, 1994.
 
12) Fujita K, Mathushima H, Nakano M, et al: Ifosfamide in combined hormonochemotherapy on prostate cancer. Gan To Kagaku Ryoho 21(2) : 227-230, 1994.
 
13) Harada Y, Arima S, Futami K, et al: A case of remarkable response of colon cancer with multiple liver and bone metastasis. Gan To Kagaku Ryoho 22(1) : 123-127, 1995.
PubMed
14) Kobayashi T, Sasaki T, Ibuka T, et al: Sequential MTX and 5 FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation. Gan To Kagaku Ryoho 19(1) : 69-74, 1992.
 
15) Tanaka S, Morikawa Y: Complete remission of bone metastasis of bladder cancer treated by cisplatin-etoposide therapy. Gan To Kagaku Ryoho 18(6) : 1039-1041, 1991.
PubMed
16) 山脇慎也, 小林昌幸, 井須和男・他: がんの骨転移の治療. Mebio 4(1) : 11-17, 1987.
 
17) Ratanatharathorn V, Powers WE, Steverson N, et al: Bone metastasis from cervical cancer. Cancer 73(9) : 2372-2379, 1994.
PubMed
18) Honda K, Simizu C: Long term paincontrol in terminal care with homehospice care. Gan To Kagaku Ryoho 21(Suppl. 4) : 489-492, 1994.
 
19) Brescia FJ, Portenoy RK, Ryan M, et al: Pain, opioid use, and survival in hospitalized patients with advanced cancer. J. Clin. Oncol. 10(1) : 149-155, 1992.
 
20) 佐々木和朗, 笠井祐子: 硬膜外ブロック使用による経口モルヒネ鎮痛法とQOLダイヤグラムによる評価. 在宅癌治療 2: 45-51, 1991.
 
21) 笠井祐子, 佐々木和朗: 癌疼痛治療とQOLダイヤグラムによる評価法. 癌治療と宿主 4(1) : 86-93, 1992.
 
22) 笠井祐子: 癌患者のQuality of life(QOL) の新しい評価法. 北海道医誌 69(2) : 282-292, 1994.
 
23) 大川智彦, 赤座英之, 安達 勇・他: 日本癌治療学会 骨転移治療効果判定基準(案) . 日癌治療会誌 32(6) : 883- 888, 1997.
 
P.1673 掲載の参考文献
1) 脳腫瘍全国統計委員会: 脳腫瘍全国集計調査報告9巻(1969-1990) . 1996.
 
2) Galicich JH, Arbit E: Metastatic brain tumors. Nurological surgery(ed by Youmans JR) , WB Saunders, London, Tokyo, 1990, pp. 3204-3222.
 
3) Takakura K, Sano K, Hojo S, et al: Metastatic tumors of the central nervous system. Igakushoin, Tokyo-New York, 1982.
 
4) Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv. Neurol. 19: 575-587, 1978.
 
5) Posner JB: Management of brain metastasis. Rev. Neurol. (Paris) 148: 477-487, 1992.
PubMed
6) Delattre JY, Krol G, Thaler HT, et al: Distribution of brain metastases. Arch. Neurol. 45: 741-744, 1988.
PubMed
7) Alleyne CH, Bakay RA, Costigan D, et al: Intracranial adenoid cystic carcinoma: case report and review of the literature. Surg. Neurol 45: 265-271, 1996.
PubMed
8) Batson OV: The function of the vertebral veins and their role in the spread of metastases. Ann. Surg. 112: 138-149, 1940.
PubMed
9) 生塩之敬: 転移性脳腫瘍. 図説癌シリーズ, 脳腫瘍(末舛惠一, 高倉公朋編) , メジカルビュー社, 東京, 1987, pp. 143- 151.
 
10) Dale AJD, Okazaki H: Meningeal carcinomatosis: Clinical manifestations. Arch. Neurol. 30: 138-143, 1974.
 
11) Mandell L, Hilaris B, Sullivan M, et al: The treatment of single brain metastasis from non-oat cell lung carcinoma. Cancer 58: 641-649, 1986.
PubMed
12) 松谷雅生: 転移性脳腫瘍. 脳神経外科学(太田富雄編) , 第7版, 金芳堂, 1996, pp. 671-680.
 
13) 松谷雅生: New Lecture. 第2版, 篠原出版, 東京, 1996, pp. 333-347.
 
14) Arseni C, Constantinescu AI: Cerebral and cranial metastases from breast cancer. Neurochirurgia 25: 95-99, 1982.
PubMed
15) Wasserstrom WR, Glass Jp, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors. Experience with 90 patients. Cancer 49: 759-777, 1982.
PubMed
16) Ascherl GF Jr, Hilal SK, BrisMan R: Computed tomography of disseminated meningeal and ependymal malignant neoplasms. Neurology 311567-574, 1981.
 
17) Tsuchiya K, Inaoka S, Mizutani Y, et al: Fast fluid-attenuated interversion-recovery MR of intracranial infections. AJNR 18: 909-913, 1997.
 
18) 遠藤啓吾: がんの核医学診断. 核医学 32: 1125-1130, 1995.
Medical*Online
19) 野村和弘, 渡辺 卓: M因子の解析-転移性脳腫瘍とCT診断. 肺癌の画像診断(鈴木 明, 河野通雄, 江口研二編) , 日本肺癌学会, 東京, 1988, pp. 109-115.
 
20) 松谷雅生, 河野 正, 長島 正・他: 肺癌脳転移の手術放射線治療. 日癌治療会誌 18: 1979-1986, 1983.
 
21) Tsukada Y, Fouad A, Pickren JW, et al: Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52: 2349-2354, 1983.
PubMed
22) Chiang MF, Brock M, Patt S: Pituitary metastases. Neurochirurgia 33: 127-131, 1990.
PubMed
23) DiStefano A, Yong YY, Hortobagyi GN, et al: The natural history of breast cancer patients with brain metastases. Cancer 44: 1913-1918, 1979.
 
24) 中村 治, 松谷雅生, 長島 正・他: 乳癌脳転移の治療. 癌の臨床 35: 979-982, 1989.
Medical*Online
25) 高橋 昭, 山本正彦, 祖父江逸郎: 髄膜癌腫症. 臨床成人病 10: 149-158, 1980.
 
26) 山下純宏, 大塚信一, 山崎俊樹・他: 肺癌脳転移116例の臨床的検討-手術および放射線治療の相対的役割. 日癌治療会誌 18: 1124-1134, 1983.
 
27) Gagliardi FM, Mercuri S: Single metastasis in the brain: Late results in 325 cases. Acta Neurochir. (Wien) 68: 253-262, 1983.
PubMed
28) White K, Fleming TR, Laws ER Jr: Single metastasis to the brain. Surgical treatment in 122 consecutive patients. Mayo Clin. Proc. 56: 424-428, 1981.
 
29) Patchell R, Tibbs P, Walsh J, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322: 494-500, 1990.
 
30) Bindal R, Sawaya R, Leavens M, et al: Surgical treatment of multiple brain metastases. J. Neurosurg. 79: 210-216, 1993.
PubMed
31) Bindal R, Sawaya R, Leavens M, et al: Reoperation for recurrent metastatic brain tumors. J. Neurosurg. 83: 600-604, 1995.
PubMed
32) 浅井昭雄, 松谷雅生, 高倉公朋: 脳腫瘍放射線治療後の亜急性障害としての脳萎縮と痴呆. 癌の臨床 33: 753-761, 1987.
 
33) Bindal A, Bindal R, Hess K, et al: Surgery versus radiosurgery in the treatment of brain metastasis. J. Neurosurg. 84: 748-754, 1996.
PubMed
34) Joseph J, Adler J, Cox R, et al: Linear Accelerator-based stereotaxic radiosurgery for brain metastases: the influence of number of lesion on survival. J. Clin. Oncol. 14: 1085-1092, 1992.
 
35) Flickinger J, Kondziolka D, Lunsford L, et al: A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int. J. Radiat. Oncol. Biol. Phys. 28: 797-802, 1994.
PubMed
36) Shaw E, Scott C, Souhami L, et al: Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastasis: initial report of Radiation Therapy Oncology Group protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 34: 647-654, 1996.
PubMed
37) Ushio Y, Arita N, Hayakawa T, et al: Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 28: 201-205, 1991.
PubMed
38) Nakagawa H, Fujita T, Izumimoto S, et al: Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. II: Clinical effects. J. Neurooncol. 16: 69-76, 1993.
PubMed
39) Silber J, Radcliffe J, Peckham V, et al: Whole-brain irradiation and decline in intelligence: The influence of dose and age on IQ score. J. Clin. Oncol. 10: 1390-1396, 1992.
 
40) Halberg F, Kramer J, Moore I, et al: Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int. J. Radiat. Oncol, Biol. Phys. 22: 13-16, 1992.
PubMed
41) Work E, Bentzen S, Nielsen O, et al: Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer: Survival Benefit in Patients with Favourable Characteristics. Eur. J. Cancer 32: 772-778, 1996.
 
42) Nakagawa H, Groothius D, Owen E, et al: Dexamethasone effects on [1251] albumin distribution in experimental RG-2 glioma and adjacent brain. J. Cereb. Blood Flow Metab. 7: 687-701, 1987.
 
P.1678 掲載の参考文献
1) Perez CA, Presant CA, Van Amburg AL III: Management of superior vena cava syndrome. Semin. Oncol. 5: 123-134, 1978.
 
2) 今泉宗久, 渡辺英世, 竹内誠次郎: 上大静脈症候群の診断と治療指針. 外科治療 72: 1-7, 1995.
 
3) 呉屋朝幸: 縦隔腫瘍とクリティカルケア(土屋了介編) , 第1版, 中外医学社, 東京, 1991, pp. 152-160.
 
4) Ehrlich W, Ballon HC, Graham EA: Superior vena caval obstruction with a consideration of the possibl relief of symptoms by mediastinal decopression. J. Thorac. Surg. 3: 352-364, 1934.
 
5) Glover DJ, Grabelsky S, Glick JH: Oncological emergencies and special complications. In Medical Oncology (eds by Calabresi P, Schein PS) , 2nd Ed, McGraw-Hill, New York, 1993, pp. 1021-1072.
 
6) Davenport D, Ferree C, Blake D, et al: Radiation therapy in the treatment of superior vena caval obstruction. Cancer 42: 2600-2603, 1978.
PubMed
7) Schraufnagel DE, Hill R, Leech JA, et al: Superior vena caval obstruction. Is it a medical emergency? Am. J. Med. 70: 1169-1174, 1981.
PubMed
8) Sculier J, Feld R: Superior vena cava obstruction syndrome: recomendation for management. Cancer Treat. Rev. 12: 209-218, 1985.
 
9) Ahmann FR: A reassessment of the clinical implications of the superior vena caval syndrome. (Review) . J Clin. Oncol. 2: 961-969, 1984.
PubMed
10) Armstrong BA, Perez CA, Simpson JR, et al: Role of irradiation in the management of superior ven cava syndrome. Int. J. Radiat. Oncol. Biol. Phys. 13: 531-539, 1987.
 
11) Dake MD, Zemel G, Dolmatch BL, et al: The cause of superior vena cava syndrome: diagnosis with percutaneous atherectomy. Radiology 174: 957-959, 1990.
PubMed
12) Carabell SC, Goodman RL: Oncologic emergencies: Superior vena cava syndrome. In Cancer-Principles and Practice of Oncology (eds by DeVita VT, Hellman S, Rosenverg SA) , 2nd Ed, JB Lippincott, Philadlphia, 1985, pp. 1855-1860.
 
13) Carlson HA: Obstruction of the superior vena cava: An experimental study. Arch. Surg. 29: 669-677, 1934.
 
14) Van der Kogel AJ: Radiation tolerance of the rat spinal cord: Time-dose relationship. Radiology 122: 05-509, 1977.
 
15) Choi NC, Carey RW: Importance of radiation dose in achieving improved locoregional tumor control in limited stage small-cell lung carcinoma: an update. Int. J. Radiat. Oncol. Biol. Phys. 171307-10, 1989.
 
16) Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiatio therapy with total doses of 60. 0 Gy to 79. 2 Gy: possible survival benefit with greater than or equal t 69. 6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cel lung carcinoma: reort Radiation Therapy Oncology Group 83-11. J. Clin. Oncol. 8: 1543-1555, 1990.
 
17) Perez CA, Stanley K, Rubin P, et al: A prospective randomized study of various irradiation doses an fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by Radiation Therapy Oncology Group. Cancer 45: 2744-2753, 1980.
 
18) Urban T, Lebeau B, Chastang C, et al: Superior vena cava syndrome in small-cell lung cancer. Arch. Intern. Med. 153: 384-387, 1993.
PubMed
19) Van Houtte P, De Jagaer R, Lustman-Marechal J, et al: Prognostic value of the superior vena cava syndrome as the presenting sign of small cell anaplastic carcinoma of the lung. Eur. J. Cancer 16: 1447-1450, 1980.
 
20) Abner A: Approach to the patient who presents with superior vena cava obstruction. Chest 103: 394S-397S, 1993.
 
21) Gray BH, Olin JW, Graor RA, et al: Safety and efficiency of thrombolytic therapy for superior vena cava syndrome. Chest 99: 54-59, 1991,
 
22) Baker GL, Barnes HJ: Superior vena cava syndrome: etiology, diagnosis, and tretment. Am. J. Crit. Care 1: 54-64, 1992.
 
23) Charnsangavej C, Carrasco CH, Wallace S, et al: Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents. Radiology 161: 295-298, 1986.
PubMed
24) Rosch J, Bedell JE, Putnam J, et al: Gianturco expandable wire stents in the treatment of superior vena cava syndrome recurring after maximum-tolerance radiation. Cancer 60: 1243-1246, 1987.
PubMed
P.1687 掲載の参考文献
1) 池田恭治: 悪性腫瘍に伴う高カルシウム血症. Annual Review内分泌代謝, p. 1-7, 1996.
 
2) Mondy GR, Ibbottson KJ, D 'Souoza SM, et al: The hypercalcemia of cancer: Clinical implications and pathogenetic mechanisms. N. Engl. J . Med. 310: 1718-1727, 1984.
 
3) Holic MF, Krane SM, Potts JT: Calcium, Phosphorus and Bone metabolism: Calcium regulating hormones. In: Harrison 's Principles of Internal Medicine, McGraw Hill, 1991, pp. 1888-1902.
 
4) Bushinsky DA, Krieger NS: Integration of calcium metabolism in the adult. In: Disorders of Bone and Mineral Metabolism(ed. by Coe FL, Favou MJ) Ravan Press, New York, 1992, pp. 417-432.
 
5) Payne RB, Little AJ, Williams RB, et al: Interpretation of serum calcium in patients with abnormal serum proteins. Br. Med. J. 4: 643, 1973.
PubMed
6) Nussbaum SR, VandePol CJ, Zubler MA, et al: Single-dose intravenous therapy with pamidronate for thetreatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90 mg dosages. Am. J. Med. 95: 297-304, 1993.
 
7) 佐藤幹二: 高カルシウム血症Q&A-悪性腫瘍による高カルシウム血症を中心に-. 医薬ジャーナル社, 大阪, 1996, pp. 20-25, 28, 29.
 
8) Burtis WJ, Brady TG, Orloff JJ, et al: Immunochemical characterization of circulating parathyroid hormonerelated protein in patients with humoral hypercalcemia of cancer. N. Engl. J Med. 322: 1106-1112, 1990.
 
9) Suva LJ, Winslow GA, Wettenhall REH, et al: A parathyroid hormone-related protein implicated in malignant hypercalcemia; cloning and expression. Science 237: 893-896, 1987.
 
10) Juppner H, About-Sammra AB, Freeman M, et al: AGprotein-linked receptor for parathyroid hormone an parathyroid hormone-related peptide. Science 254: 1024-1026, 1991.
 
11) Stewart AF, Vignery A, Silvergate A, et al: Quantitative bone histomorphometry in humoral hypercalcemia of malignancy; uncoupling of bone cell activity. J. Clin. Endocrinol. Metab. 55: 219-227, 1982.
 
12) Senior PV, Heath DA, Beck F: Expression of parathyroid hormone-related protein mRNA in the rat before birth: demonstration by hybridization. J. Mol. Endocrinol. 6: 281-290, 1991.
PubMed
13) Kramer S, Reynords Jr FH, Castillo M, et al: Immunological identification and distribution of parathyroid hormone-like protein polypeptides in normal malignant tissues. Endocrinology 128: 1927-1937, 1991.
 
14) Morendino Jr JJ, Insogna KL, Nilstone LM, et al: A parathyroid hormone-like protein from cultured human keratinocytes. Science 231: 388-390, 1986.
 
15) Ikeda K, Weir EC, Mangin M, et al: Expression of messenger ribonucleic acid encording a parathyroid hormonelike peptide in normal human and animal tissues with abnormal expression in human parathyroid adenomas. Mol. Endocrinol. 2: 1230-1236, 1988.
 
16) Rodda CP, Kubota M, Heath JA, et al: Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein implicated in humoral hypercalcemia of malignancy. J. Endocrinol. 117: 261-271, 1988.
 
17) Asa SL, Henderson J, Goltzman D, et al: Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues. J. Clin. Endocrinol. Metab. 7111112-1118, 1990.
PubMed
18) Kitazawa S, Fukase M, Kitazawa R, et al: Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer 15: 984-989, 1991.
 
19) Southby J, Kissen MW, Danks JA, et al: Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res. 50: 7710-7716, 1990.
 
20) Powell GL, Southby J, Danks JA, et al: Localization of parathyroid hormone-related protein in breast cancer metastases; Increased incidence in bone compared with other sites. Cancer Res. 51: 3059-3061, 1991.
 
21) Kohno N, Kitazawa S, Fukase M, et al: The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surgery Today 241215-220, 1994.
PubMed
22) Guise TA JJ, Yin SD, Taylor Y, et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer mediated osteolysis. J. Clin. Invest. 98: 1544-1549, 1996.
 
23) Tsuchihashi T, Yamaguchi K, Miyake Y, et al: Parathyroid hormone-related protein in tumor tissues obteined from patients with humoral hypercalcemia malignancy. J. Natl. Cancer. Inst. 82: 40-44, 1990.
 
24) Yoneda T, Alsina MA, Chavez JB, et al: Evidence that tumor necrosing factor plays a pathogenetic role in the paraneoplastic syndromes of cahexia, hypercalcernia and leukocytosis in human tumor in nude mice. J. Clin. Invest. 87: 977-985, 1991.
 
25) Bertolini DR, Nedwin GE, Bringman TS, et al: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosing factor. Nature 319: 516-518, 1986.
 
26) Garett IR, Durie BG, Nedwin GE, et al: Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med. 317: 526-532, 1987.
 
27) Kawano M, Yamamoto I, Iwato K: Interleukin-I beta rather than lymphotoxin as a major bone resorbing activity in multiple myeloma. Blood 73: 1646-1649, 1989.
PubMed
28) Mundy GR: Mechanism of osteolytic bone destruction. Bone 12: (suppl. 1) S1-S 6, 1991.
 
29) De La Mata J, Uy HL, Guise TA, et al: Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J. Clin. Invest. 95: 2846-2852, 1995.
PubMed
30) Sato K, Fuj ii Y, Kasano K, et al: Parathyroid hormone-related protein and interleukin 1 alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo. Endocrinology 124: 2172-2178, 1989.
 
31) Engelmann H, Holtmann H, Brakebush C, et al: Antibodies to a soluble form of a tumor necrosis factor(TNF) receptor have TNF-like activity. J. Biol. Chem. 265: 14497-14504, 1990.
 
32) Okuno Y, Takahashi T, Suzuki A, et al: Coproduction of Interleukin-1 and interleukin-6 in tumor cell lines elaborating colony-stimulating factors. Jpn. J. Cancer Res. 82: 890-892, 1991.
 
33) Manolagas SC, Jilka RL, Girasole G, et al: Estrogens, cytokines, and pathophysiology of osteoporosis. In: Current opinion in endocrinology and diabetes(ed by Kohler PO) , Current Science, Philadelphia, 1994, pp. 275-281.
 
34) Singer FR, Sharp Jr CF, Rude PK I Pathogenesis of hypercalcemia in malignancy. Miner. Electrolyte Metab. 2: 161-178, 1979.
 
35) Myers WPL: Hypercalcemia associated with malignant disease. In: Endocrine hormone-producing tumors. Year Book Medical, Chicago, 1973, pp. 147-171.
 
36) 木村 哲, 佐藤 豊, 阿部 薫: 腫瘍随伴高カルシウム血症. 腫瘍随伴症候群(井村裕夫, 高久史磨編) , サイエンスフォーラム, 第1版, 東京, 1987, pp. 85-100.
 
37) Vassilopoulou-Sellin R, Newman BM, Taylor SH, et al: Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 71: 1309-1312, 1993.
PubMed
38) Strewler GJ, Rossenblatt M: Mineral Metabolism. In: Endocrinology and metabolism (3rd ed) . McGraw-Hill, 1995, pp. 1407-1474.
 
39) 木村 哲, 永田直一, 江藤澄哉・他: 癌患者における高カルシウム血症の治療に関する研究. 厚生省がん研究助成金による研究報告集, 昭和61年度, pp. 264-268.
 
40) Ikeda K, Ohno H, Hane M, et al: Development of sensitive two-site immunoradioometric assay for parathyroid hormone-related peptide; evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J. Clin. Endocrinol. Metab. 79: 1322-1327, 1994.
 
41) 福本誠二, 池田恭治, 竹内靖博・他: IRMA法による血漿PTH-related protein(PTHrP) 測定の基礎的および臨床的検討. ホルモンと臨床 40: 1309-1314, 1992.
 
42) Nakayama K, Fukumoto S, Takeda S, et al: Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J. Clin. Endocrinol. Metab. 81: 607-611, 1996.
PubMed
43) Body JJ, Delmas PD: Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J. Clin. Endocrinol. Metab. 74: 471-475, 1992.
PubMed
44) Pecherstorfer M, Hermann Z, Body JJ, et al: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J. Clin. Oncol. 14: 268-276 1996.
 
45) 福永仁夫, 大塚信昭, 小野史磨人・他: 1型コラーゲン・Cross-linked Carboxyterminal Telepeptide(1CTP) の血中濃度の測定. ホルモンと臨床 41: 729-736, 1993.
 
46) Bouillon R, Bex M, Herck EV, et al: Influence of age, sex, and insulin on osteoblast function: Osteoblast dysfunction in diabetes melitus. J. Clin. Endocrinol. Metab. 80: 1194-1202, 1995.
 
47) Vinholes J, Guo C-Y, Purohit OM, et al: Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia malignancy. J. Clin. Oncol. 15: 131-138, 1997.
PubMed
48) Hosking D, Cowley A, Bucknall C, et al: Rehydration in the treatment of severe hypercalcemia. Q. J. Med. 50: 473-481, 1981.
PubMed
49) Suki W, Yium J, Van Mundium M, et al: Acute treatment of hypercalcemia with fluosemide. N. Engl. J. Med. 283: 836-840, 1970.
 
50) 佐藤幹二: 悪性腫瘍と高カルシュウム血症. 医薬ジャーナル33: 133-139, 1997.
 
51) Fleish H: Bisphosphonates: a new class drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res. 116: 1-28, 1989.
 
52) Fitton A, McTavish D: Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41: 289-318, 1991.
PubMed
53) Plosker GL, Goa KL: Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47: 945-982, 1994.
PubMed
54) Jantunen E, Laakso M: Annotation: Bisphosphonates in multiple myeloma: current status; future perspectives. Br. J. Haematol. 93: 501-506, 1996.
 
55) Boonenkamp PM, van der Wee-pals LJA, van Wijk-van Lennep MML, et al: Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1: 27-39, 1986.
 
56) Flanagan AM, Chambers TJ: Dichloromethylenbisphosphonate (C 12 MBP) inhibits bone resorption through injury to osteoclasts that resorb C 12 MBP coated bone. Bone Miner. 6: 33-43, 1989.
 
57) Sato M, Grasser W, Endo N, et al: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast structure. J. Clin. Invest. 88: 2095-2105, 1991.
 
58) 松本俊夫, 藤田拓男, 森井浩世・他: 悪性腫瘍に伴う高カルシウム血症患者におけるPamidoronate disodium(AHPr-BP) の用量設定試験. 臨床医薬 8: 605-629, 1992.
 
59) 江藤澄哉, 服部理男, 富田明夫・他: 悪性腫瘍における高カルシウム血症患者におけるアレンドロネート注射剤の有用性検討Prog. Med. 14: 2869-2882, 1994.
 
60) 佐藤幹二, 服部理男, 富田明夫・他: 悪性腫瘍に伴う高カルシウム血症患者におけるアレンドロネート注射剤の容量設定試験. Prog. Med. 14: 2883-2906, 1994.
 
61) 松本俊夫, 武部和男, 石井 淳・他: 悪性腫瘍に伴う高カルシウム血症患者におけるYM-175の用量設定試験. 臨床と研究 71: 3263-3280, 1994.
 
62) 松本俊夫, 永田直一, 堀越 昇・他: 悪性腫瘍に伴う高カルシウム血症患者におけるYM-175とエルカトニンの比較試験. 臨床成人病 25: 383-396, 1995.
 
63) 池田恭治: 私信による.
 
64) 芝 英一, 井上共生, 赤沢健司・他: オクトレオチドが奏効した進行乳癌に伴う高カルシウム血症の一例. 癌と化学療 法 23: 343-347, 1996.
 
65) Sauty A, Pecherstorfer M, Zimmer-Roth I, et al: Interleukin-6 and tumor necrosis facter-a after bisphos-phonates treatment in vitro and in patients with malignancy. Bone 18: 133-139, 1996.
 
66) Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335: 1785-1791, 1996.
PubMed
67) Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334: 488-493, 1996.
PubMed
P.1693 掲載の参考文献
1) 井形高明: 脊椎・脊髄損傷. 標準整形外科学(第6版) (寺山和雄, 広畑和志監修) , 医学書院, 東京, 1996, pp. 638- 657.
 
2) 日本整形外科学会骨軟部腫瘍委員会: 全国骨腫瘍患者登録一覧表 (平成7年度) . 国立がんセンター, 1997.
 
3) 白井康正: 脊髄損傷の褥創. 今日の整形外科治療指針 (山内裕雄・他編集) , 医学書院, 東京, 1995, pp. 264-265.
 
4) Frankel HL, Hancock DO, et al: The value of postural reduction in the initial management of closed injuries to the spine with paraplegia and tetra plegia. Paraplegia 7: 179, 1969.
 
5) 芝本雄太, 阿部光幸: 骨転移に対する放射線療法. 新図説臨床整形外科講座13, 骨・軟部腫瘍および類似疾患. メジカルビュー社, 東京, 1995, pp. 124-126.
 
6) Kevin D, Haarington MD: Orthopedic Management of Metastatic Bone Disease. C. V. Mosby, st. Louis 1988, pp. 83-94.
 
7) 伊藤淳二, 原田征行: 椎体前方成分の腫瘍, 椎弓(後方成分) の腫瘍. 整形外科手術9(黒川高秀編) , 中山書店, 東京, 1995, pp. 147-154.
 

書評

最近チェックした商品履歴

Loading...